#Chr	Start	End	Ref	Alt	Gene.refGene	Func.refGene	ExonicFunc.refGene	GeneDetail.refGene	AAChange.refGene	MAX_MAF	MAX_MAF_ReportedDatabase	GIV_Indian_HOM-VAR	GIV_CDFD_HOM-VAR	RefinedGenotype	Zygosity	Depth	ReferenceAlleleDepth	AltAlleleDepth	VariantAlleleFrequency	QUAL	FILTER	CADD_phred	MIM_disease.refGene	MIM_id.refGene	InterVar_automated	Orphanet_disorder.refGene	Orphanet_association_type.refGene	Trait_association(GWAS).refGene	HPO_id.refGene	HPO_name.refGene	CLNDN	CLNREVSTAT	CLNSIG	Tissue_specificity(Uniprot).refGene	SIFT_pred	SIFT4G_pred	Polyphen2_HDIV_pred	Polyphen2_HVAR_pred	LRT_pred	MutationTaster_pred	MutationAssessor_pred	FATHMM_pred	PROVEAN_pred	MetaSVM_pred	MetaLR_pred	MetaRNN_pred	M-CAP_pred	PrimateAI_pred	DEOGEN2_pred	BayesDel_addAF_pred	ClinPred_pred	LIST-S2_pred	Aloft_pred	fathmm-MKL_coding_pred	fathmm-XF_coding_pred	Interpro_domain	dbscSNV_ADA_SCORE	dbscSNV_RF_SCORE	Gene damage prediction (all Mendelian disease-causing genes).refGene	Gene damage prediction (Mendelian AD disease-causing genes).refGene	Gene damage prediction (Mendelian AR disease-causing genes).refGene	Expression(egenetics).refGene	Expression(GNF/Atlas).refGene	LoFtool_score.refGene	Essential_gene.refGene	Essential_gene_CRISPR.refGene	Essential_gene_CRISPR2.refGene	Essential_gene_gene-trap.refGene	Gene_indispensability_score.refGene	Gene_indispensability_pred.refGene	MGI_mouse_gene.refGene	MGI_mouse_phenotype.refGene	ZFIN_zebrafish_gene.refGene	ZFIN_zebrafish_structure.refGene	ZFIN_zebrafish_phenotype_quality.refGene	ZFIN_zebrafish_phenotype_tag.refGene	GnomAdExome_AF	GnomAdExome_AF_popmax	GnomAdExome_controls_AF_popmax	GnomAdGenome_AF	GnomAdGenomeAF_popmax	1000g2015aug_all	esp6500siv2_all	Kaviar_AF	abraom_freq	abraom_filter	GME_AF_popmax	GIV_Indian_AAF	GIV_Indian_HET	GIV_CDFD_AAF	GIV_CDFD_HET	#CHROM	POS	ID	REF	ALT	QUAL.1	FILTER.1	INFO	FORMAT	Sample1
chr1	14932	14932	G	T	WASH7P	ncRNA_intronic	NA	NA	NA	0.1819	GnomAdGenome_AF_eas	0		WT/SomaticVariant	het	7	5	2	0.285714285714286	61.64	DP10;MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0662	0.1819	0	0	0.0001153	0		0	0.007246	3			chr1	14932	NA	G	T	61.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=3.68;AS_MQ=23;AS_MQRankSum=-2;AS_QD=8.86;AS_ReadPosRankSum=1;AS_SOR=2.258;BaseQRankSum=-0.712;DP=7;ExcessHet=3.0103;FS=3.68;MLEAC=1;MLEAF=0.5;MQ=24.3;MQRankSum=-1.981;QD=8.81;ReadPosRankSum=1.07;SOR=2.258	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:5,2:7:69:0|1:14932_G_T:69,0,189:14932
chr1	14937	14937	T	C	WASH7P	ncRNA_intronic	NA	NA	NA	0.0752	GnomAdGenome_AF_asj			WT/SomaticVariant	het	7	5	2	0.285714285714286	61.64	DP10;MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0553	0.0752	0	0	0.0000384	0		0					chr1	14937	NA	T	C	61.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.9;AS_FS=3.68;AS_MQ=23;AS_MQRankSum=-2;AS_QD=8.86;AS_ReadPosRankSum=0.8;AS_SOR=2.258;BaseQRankSum=-1.834;DP=7;ExcessHet=3.0103;FS=3.68;MLEAC=1;MLEAF=0.5;MQ=24.3;MQRankSum=-1.981;QD=8.81;ReadPosRankSum=0.842;SOR=2.258	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:5,2:7:69:0|1:14932_G_T:69,0,189:14932
chr1	15015	15015	G	C	WASH7P	ncRNA_exonic	NA	NA	NA	0.1304	GnomAdGenome_AF_fin			HeterozygousVariant	het	6	4	2	0.333333333333333	33.64	DP10;MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.054	0.1304	0	0	0	0		0					chr1	15015	NA	G	C	33.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=3.979;AS_MQ=24.51;AS_MQRankSum=-0.5;AS_QD=5.67;AS_ReadPosRankSum=1.8;AS_SOR=2.225;BaseQRankSum=-0.524;DP=6;ExcessHet=3.0103;FS=3.979;MLEAC=1;MLEAF=0.5;MQ=24.67;MQRankSum=-0.431;QD=5.61;ReadPosRankSum=1.83;SOR=2.225	GT:AD:DP:GQ:PL	0/1:4,2:6:41:41,0,80
chr1	15045	15045	C	T	WASH7P	ncRNA_intronic	NA	NA	NA	0.2334	GnomAdGenome_AF_fin			HeterozygousVariant	het	5	3	2	0.4	35.64	DP10;MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1609	0.2334	0	0	0	0		0					chr1	15045	NA	C	T	35.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=3.979;AS_MQ=24.51;AS_MQRankSum=-0.3;AS_QD=7.2;AS_ReadPosRankSum=1;AS_SOR=2.245;BaseQRankSum=-0.674;DP=5;ExcessHet=3.0103;FS=3.979;MLEAC=1;MLEAF=0.5;MQ=24.6;MQRankSum=-0.253;QD=7.13;ReadPosRankSum=1.04;SOR=2.245	GT:AD:DP:GQ:PL	0/1:3,2:5:43:43,0,73
chr1	15820	15820	G	T	WASH7P	ncRNA_exonic	NA	NA	NA	0.4298	GnomAdGenome_AF_afr	8		HeterozygousVariant	het	62	38	24	0.387096774193548	765.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.2245	0.4298	0.410543	0	0.0869832	0.215909	VQSRTrancheSNP99.00to99.90	0	0.133	22			chr1	15820	NA	G	T	765.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=16.897;AS_MQ=46.1;AS_MQRankSum=2.6;AS_QD=12.08;AS_ReadPosRankSum=-5.1;AS_SOR=1.706;BaseQRankSum=1.28;DP=72;ExcessHet=3.0103;FS=16.897;MLEAC=1;MLEAF=0.5;MQ=47.16;MQRankSum=2.6;QD=12.35;ReadPosRankSum=-5.034;SOR=1.706	GT:AD:DP:GQ:PL	0/1:38,24:62:99:773,0,827
chr1	16949	16949	A	C	WASH7P	ncRNA_exonic	NA	NA	NA	0.3925	GnomAdGenome_AF_asj	0	0	HeterozygousVariant	het	17	8	9	0.529411764705882	165.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.3352	0.3925	0.0139776	0	0.0159444	0.157895	VQSRTrancheSNP99.00to99.90	0	0.215	89	0.15625	5	chr1	16949	NA	A	C	165.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=2.077;AS_MQ=22.23;AS_MQRankSum=-2.3;AS_QD=9.76;AS_ReadPosRankSum=0.6;AS_SOR=0.235;BaseQRankSum=0.674;DP=17;ExcessHet=3.0103;FS=2.077;MLEAC=1;MLEAF=0.5;MQ=22.72;MQRankSum=-2.205;QD=9.74;ReadPosRankSum=0.659;SOR=0.235	GT:AD:DP:GQ:PL	0/1:8,9:17:99:173,0,172
chr1	17020	17020	G	A	WASH7P	ncRNA_exonic	NA	NA	NA	0.2415	GnomAdGenome_AF_asj	0	0	HeterozygousVariant	het	14	7	7	0.5	139.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1822	0.2415	0	0	0.0141002	0.181818	VQSRTrancheSNP99.90to100.00	0	0.172	71	0.15625	5	chr1	17020	NA	G	A	139.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.4;AS_FS=2.276;AS_MQ=22.3;AS_MQRankSum=-0.1;AS_QD=10;AS_ReadPosRankSum=-1.6;AS_SOR=1.535;BaseQRankSum=-2.352;DP=14;ExcessHet=3.0103;FS=2.276;MLEAC=1;MLEAF=0.5;MQ=22.38;MQRankSum=-0.055;QD=9.97;ReadPosRankSum=-1.521;SOR=1.535	GT:AD:DP:GQ:PL	0/1:7,7:14:99:147,0,186
chr1	17385	17385	G	A	MIR6859-1;MIR6859-2;MIR6859-3;MIR6859-4	ncRNA_exonic	NA	NA	NA	0.2596	GnomAdGenome_AF_asj	0	0	WT/SomaticVariant	het	23	20	3	0.130434782608696	37.64	QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.173	0.2215	0.225	0.1934	0.2596	0	0	0.0015912	0.142857	VQSRTrancheSNP99.00to99.90	0	0.224	107	0.25	8	chr1	17385	NA	G	A	37.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=2.793;AS_MQ=40.68;AS_MQRankSum=-0.1;AS_QD=1.65;AS_ReadPosRankSum=-0.2;AS_SOR=1.828;BaseQRankSum=0.439;DP=25;ExcessHet=3.0103;FS=2.793;MLEAC=1;MLEAF=0.5;MQ=40.37;MQRankSum=-0.051;QD=1.64;ReadPosRankSum=-0.137;SOR=1.828	GT:AD:DP:GQ:PL	0/1:20,3:23:45:45,0,572
chr1	17697	17697	G	C	WASH7P	ncRNA_exonic	NA	NA	NA	0.2228	GnomAdGenome_AF_fin	0	0	HeterozygousVariant	het	6	4	2	0.333333333333333	41.64	DP10;MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1534	0.2228	0	0	0.0155602	0.114865	VQSRTrancheSNP99.00to99.90	0	0.1	41	0.03125	1	chr1	17697	NA	G	C	41.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=0;AS_MQ=31.95;AS_MQRankSum=-1;AS_QD=7;AS_ReadPosRankSum=1.2;AS_SOR=0.307;BaseQRankSum=0.524;DP=7;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=37.87;MQRankSum=-0.967;QD=6.94;ReadPosRankSum=1.28;SOR=0.307	GT:AD:DP:GQ:PL	0/1:4,2:6:49:49,0,98
chr1	69270	69270	A	G	OR4F5	exonic	synonymous SNV	NA	OR4F5:NM_001005484:exon1:c.A180G:p.S60S	0.9984	GnomAdExome_AF_eas	360	56	HomozygousVariant	hom	8	0	8	1	224.04	DP10;MQ40;SOR3	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.838	0.9984	0.9986	0.6076	0.9954	0	0	0.10388	0.706897	VQSRTrancheSNP99.90to100.00	0.868852	0.901	24	0.862319	7	chr1	69270	NA	A	G	224.04	DP10;MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=25;AS_MQRankSum=.;AS_QD=28;AS_ReadPosRankSum=.;AS_SOR=4.407;DP=8;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=25;QD=28;SOR=4.407	GT:AD:DP:GQ:PL	1/1:0,8:8:24:238,24,0
chr1	69511	69511	A	G	OR4F5	exonic	nonsynonymous SNV	NA	OR4F5:NM_001005484:exon1:c.A421G:p.T141A	1	GnomAdGenome_AF_eas	478	112	HomozygousVariant	hom	65	0	65	1	1801.06	PASS	2.209	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	GPCR, rhodopsin-like, 7TM;GPCR, rhodopsin-like, 7TM	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.9497	0.9994	0.9994	0.8368	1	0	0.7598	0.54161	0.853175	VQSRTrancheSNP99.00to99.90	0.916667	0.982	4	0.995575	1	chr1	69511	NA	A	G	1801.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=45.23;AS_MQRankSum=.;AS_QD=27.71;AS_ReadPosRankSum=.;AS_SOR=0.787;DP=67;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=45.22;QD=27.71;SOR=0.787	GT:AD:DP:GQ:PL	1/1:0,65:65:99:1815,194,0
chr1	69897	69897	T	C	OR4F5	exonic	synonymous SNV	NA	OR4F5:NM_001005484:exon1:c.T807C:p.S269S	0.964286	GME_CA	151	19	HomozygousVariant	hom	4	0	4	1	107.14	DP10;MQ40	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.7209	0.8438	0.8428	0.4742	0.7002	0.688099	0	0.0914607	0.71	VQSRTrancheSNP99.90to100.00	0.964286	0.589	82	0.618421	9	chr1	69897	NA	T	C	107.14	DP10;MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=25.51;AS_MQRankSum=.;AS_QD=26.75;AS_ReadPosRankSum=.;AS_SOR=1.609;DP=4;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=25.51;QD=26.79;SOR=1.609	GT:AD:DP:GQ:PL	1/1:0,4:4:12:121,12,0
chr1	185336	185336	C	T	LOC102725121	downstream	NA	dist=458	NA	0.3086	GnomAdGenome_AF_eas			HeterozygousVariant	het	53	37	16	0.30188679245283	257.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0705	0.3086	0	0	0	0		0					chr1	185336	NA	C	T	257.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=2.64;AS_MQ=24.75;AS_MQRankSum=-1.3;AS_QD=4.87;AS_ReadPosRankSum=0.9;AS_SOR=1.22;BaseQRankSum=-0.119;DP=54;ExcessHet=3.0103;FS=2.64;MLEAC=1;MLEAF=0.5;MQ=24.85;MQRankSum=-1.296;QD=4.86;ReadPosRankSum=0.932;SOR=1.22	GT:AD:DP:GQ:PL	0/1:37,16:53:99:265,0,830
chr1	185451	185451	A	G	LOC102725121	downstream	NA	dist=573	NA	0.5594	GnomAdGenome_AF_afr			HeterozygousVariant	het	14	5	9	0.642857142857143	219.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.5356	0.5594	0	0	0	0		0					chr1	185451	NA	A	G	219.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.7;AS_FS=4.472;AS_MQ=25;AS_MQRankSum=1.5;AS_QD=15.71;AS_ReadPosRankSum=1.5;AS_SOR=2.833;BaseQRankSum=2.78;DP=14;ExcessHet=3.0103;FS=4.472;MLEAC=1;MLEAF=0.5;MQ=24.86;MQRankSum=1.6;QD=15.69;ReadPosRankSum=1.59;SOR=2.833	GT:AD:DP:GQ:PL	0/1:5,9:14:66:227,0,66
chr1	187210	187210	G	A	MIR6859-1;MIR6859-2;MIR6859-3;MIR6859-4	downstream	NA	dist=681	NA	0.4526	GnomAdGenome_AF_afr			WT/SomaticVariant	het	31	23	8	0.258064516129032	154.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.3869	0.4526	0	0	0	0		0					chr1	187210	NA	G	A	154.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=1.927;AS_MQ=33.97;AS_MQRankSum=-0.9;AS_QD=5;AS_ReadPosRankSum=0.4;AS_SOR=1.23;BaseQRankSum=-1.77;DP=35;ExcessHet=3.0103;FS=1.927;MLEAC=1;MLEAF=0.5;MQ=36.36;MQRankSum=-0.835;QD=4.99;ReadPosRankSum=0.408;SOR=1.23	GT:AD:DP:GQ:PL	0/1:23,8:31:99:162,0,648
chr1	187241	187241	T	A	MIR6859-1;MIR6859-2;MIR6859-3;MIR6859-4	downstream	NA	dist=650	NA	0.4391	GnomAdGenome_AF_afr			HeterozygousVariant	het	9	6	3	0.333333333333333	72.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.3924	0.4391	0	0	0	0		0					chr1	187241	NA	T	A	72.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.1;AS_FS=0;AS_MQ=35.48;AS_MQRankSum=0.8;AS_QD=8.11;AS_ReadPosRankSum=-0.8;AS_SOR=0.283;BaseQRankSum=2.1;DP=10;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=32.72;MQRankSum=0.876;QD=8.07;ReadPosRankSum=-0.732;SOR=0.283	GT:AD:DP:GQ:PL	0/1:6,3:9:80:80,0,163
chr1	873542	873542	G	A	FAM41C	ncRNA_intronic	NA	NA	NA	1	GnomAdGenome_AF_ami	206	15	HomozygousVariant	hom	124	0	124	1	3716.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.988	1	0.982628	0	0.473682	0		0	0.995	2	0.96875	1	chr1	873542	NA	G	A	3716.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=55.72;AS_MQRankSum=.;AS_QD=29.97;AS_ReadPosRankSum=.;AS_SOR=0.981;DP=129;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=55.89;QD=29.97;SOR=0.981	GT:AD:DP:GQ:PL	1/1:0,124:124:99:3730,371,0
chr1	942451	942451	T	C	SAMD11	exonic	nonsynonymous SNV	NA	SAMD11:NM_152486:exon10:c.T1027C:p.W343R	1	GnomAdExome_AF_eas	744	136	HomozygousVariant	hom	79	0	79	1	2241.06	PASS	19.24	NA	616765	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	NA	N	T	T	T	NA	D	T	T	T	T	.;.;.;.;.;.;	N	N	.;.;.;.;.;.	NA	NA	Medium	Medium	Medium	developmental;cochlea;thymus;epididymis;skin;stomach;testis;lens;lymphoreticular;unclassifiable (Anatomical System);choroid;kidney;larynx;uterus;retina;pancreas;muscle;head and neck;mammary gland;islets of Langerhans;visual apparatus;cervix;fovea centralis;liver;endometrium;bone;germinal center;brain;blood;heart;lung;salivary gland;ovary;macula lutea;lymph node;oesophagus;colon;placenta;prostate;optic nerve;gum;	NA	NA	NA	N	N	N	0.187549044243291	N	Samd11	NA	NA	NA	NA	NA	0.9999	1	1	0.9998	1	1	0	0.0001153	1	PASS	1	0.999	1	1	0	chr1	942451	NA	T	C	2241.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.37;AS_ReadPosRankSum=.;AS_SOR=0.77;DP=83;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.37;SOR=0.77	GT:AD:DP:GQ:PL	1/1:0,79:79:99:2255,237,0
chr1	946247	946247	G	A	NOC2L	exonic	synonymous SNV	NA	NOC2L:NM_015658:exon16:c.C1843T:p.L615L	0.6738	GnomAdGenome_AF_eas	173	42	HomozygousVariant	hom	94	0	94	1	2653.06	PASS	NA	NA	610770	Benign	NA	NA	Pancreatic cancer[29422604];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	choroid;larynx;epididymis;colon;head and neck;stomach;prostate;testis;unclassifiable (Anatomical System);	NA	0.887	NA	E	E	N	0.946496023965855	E	Noc2l	endocrine/exocrine gland phenotype; cellular phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; immune system phenotype; 	noc2l	anatomical system	quality	abnormal	0.5696	0.6586	0.6541	0.4737	0.6738	0.441893	0.4748	0.561927	0.507389	PASS	0.6	0.544	291	0.573944	79	chr1	946247	NA	G	A	2653.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.22;AS_ReadPosRankSum=.;AS_SOR=0.78;DP=95;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.22;SOR=0.78	GT:AD:DP:GQ:PL	1/1:0,94:94:99:2667,280,0
chr1	948245	948245	A	G	NOC2L	intronic	NA	NA	NA	1	GnomAdExome_AF	298	142	HomozygousVariant	hom	28	0	28	1	814.06	PASS	NA	NA	610770	NA	NA	NA	Pancreatic cancer[29422604];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	choroid;larynx;epididymis;colon;head and neck;stomach;prostate;testis;unclassifiable (Anatomical System);	NA	0.887	NA	E	E	N	0.946496023965855	E	Noc2l	endocrine/exocrine gland phenotype; cellular phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; immune system phenotype; 	noc2l	anatomical system	quality	abnormal	1	1	1	0.9999	1	1	0.9998	0.0001537	1	PASS	0	1	0	1	0	chr1	948245	NA	A	G	814.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.07;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=30;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.07;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,28:28:84:828,84,0
chr1	952421	952421	A	G	NOC2L	exonic	synonymous SNV	NA	NOC2L:NM_015658:exon10:c.T1182C:p.T394T	1	GME_Israel	504	123	HomozygousVariant	hom	69	0	69	1	2025.06	PASS	NA	NA	610770	Benign	NA	NA	Pancreatic cancer[29422604];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	choroid;larynx;epididymis;colon;head and neck;stomach;prostate;testis;unclassifiable (Anatomical System);	NA	0.887	NA	E	E	N	0.946496023965855	E	Noc2l	endocrine/exocrine gland phenotype; cellular phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; immune system phenotype; 	noc2l	anatomical system	quality	abnormal	0.9378	0.9545	0.9535	0.934	0.9649	0.922324	0.9274	0.0002305	0.944992	PASS	1	0.924	75	0.929577	18	chr1	952421	NA	A	G	2025.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.73;AS_MQRankSum=.;AS_QD=29.35;AS_ReadPosRankSum=.;AS_SOR=1.385;DP=71;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.74;QD=29.35;SOR=1.385	GT:AD:DP:GQ:PL	1/1:0,69:69:99:2039,207,0
chr1	953259	953259	T	C	NOC2L	exonic	synonymous SNV	NA	NOC2L:NM_015658:exon9:c.A918G:p.E306E	1	GME_Israel	504	123	HomozygousVariant	hom	101	1	100	0.99009900990099	2670.06	PASS	NA	NA	610770	Benign	NA	NA	Pancreatic cancer[29422604];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	choroid;larynx;epididymis;colon;head and neck;stomach;prostate;testis;unclassifiable (Anatomical System);	NA	0.887	NA	E	E	N	0.946496023965855	E	Noc2l	endocrine/exocrine gland phenotype; cellular phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; immune system phenotype; 	noc2l	anatomical system	quality	abnormal	0.9378	0.9546	0.9537	0.934	0.9648	0.922724	0.9273	0.0001537	0.944171	PASS	1	0.926	75	0.929577	18	chr1	953259	NA	T	C	2670.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.5;AS_FS=0;AS_MQ=59.3;AS_MQRankSum=-0.3;AS_QD=26.44;AS_ReadPosRankSum=-0.6;AS_SOR=0.275;BaseQRankSum=-1.462;DP=103;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.32;MQRankSum=-0.256;QD=26.44;ReadPosRankSum=-0.549;SOR=0.275	GT:AD:DP:GQ:PL	1/1:1,100:101:99:2684,263,0
chr1	953279	953279	T	C	NOC2L	exonic	nonsynonymous SNV	NA	NOC2L:NM_015658:exon9:c.A898G:p.I300V	1	GME_Israel	504	123	HomozygousVariant	hom	91	2	89	0.978021978021978	2312.06	PASS	3.893	NA	610770	NA	NA	NA	Pancreatic cancer[29422604];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	choroid;larynx;epididymis;colon;head and neck;stomach;prostate;testis;unclassifiable (Anatomical System);	NA	0.887	NA	E	E	N	0.946496023965855	E	Noc2l	endocrine/exocrine gland phenotype; cellular phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; immune system phenotype; 	noc2l	anatomical system	quality	abnormal	0.9378	0.9546	0.9535	0.934	0.9648	0.922724	0.9273	0.92579	0.944171	PASS	1	0.926	75	0.929577	18	chr1	953279	NA	T	C	2312.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.5;AS_FS=0;AS_MQ=59.63;AS_MQRankSum=-0.3;AS_QD=25.41;AS_ReadPosRankSum=-0.6;AS_SOR=0.715;BaseQRankSum=0.516;DP=92;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.64;MQRankSum=-0.267;QD=25.41;ReadPosRankSum=-0.569;SOR=0.715	GT:AD:DP:GQ:PL	1/1:2,89:91:99:2326,222,0
chr1	959193	959193	G	A	NOC2L	intronic	NA	NA	NA	0.9026	GnomAdGenome_AF_fin	442	107	HomozygousVariant	hom	127	0	127	1	3820.06	PASS	NA	NA	610770	NA	NA	NA	Pancreatic cancer[29422604];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	choroid;larynx;epididymis;colon;head and neck;stomach;prostate;testis;unclassifiable (Anatomical System);	NA	0.887	NA	E	E	N	0.946496023965855	E	Noc2l	endocrine/exocrine gland phenotype; cellular phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; immune system phenotype; 	noc2l	anatomical system	quality	abnormal	0.8198	0.8971	0.898	0.6931	0.9026	0.634385	0.6902	0.79682	0.720854	PASS	0	0.872	122	0.873239	34	chr1	959193	NA	G	A	3820.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.08;AS_ReadPosRankSum=.;AS_SOR=0.843;DP=131;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.08;SOR=0.843	GT:AD:DP:GQ:PL	1/1:0,127:127:99:3834,381,0
chr1	961945	961945	G	C	KLHL17	exonic	synonymous SNV	NA	KLHL17:NM_198317:exon4:c.G609C:p.A203A	0.942073	GME_TP	652	123	HomozygousVariant	hom	89	0	89	1	2494.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;cartilage;endometrium;skin;stomach;bone;germinal center;testis;lens;unclassifiable (Anatomical System);cerebellum;lung;salivary gland;choroid;retina;macula lutea;colon;head and neck;hypopharynx;mammary gland;optic nerve;	ciliary ganglion;pons;subthalamic nucleus;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;globus pallidus;	0.386	NA	N	N	N	0.323193869751981	N	Klhl17	NA	NA	NA	NA	NA	0.9127	0.937	0.9349	0.8653	0.9404	0.859225	0.8589	0.8968	0.885057	PASS	0.942073	0.925	95	0.929577	18	chr1	961945	NA	G	C	2494.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.02;AS_ReadPosRankSum=.;AS_SOR=0.761;DP=96;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.02;SOR=0.761	GT:AD:DP:GQ:PL	1/1:0,89:89:99:2508,266,0
chr1	964548	964548	G	C	KLHL17	intronic	NA	NA	NA	0.9279	GnomAdExome_AF_amr	254	72	HomozygousVariant	hom	30	0	30	1	1187.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;cartilage;endometrium;skin;stomach;bone;germinal center;testis;lens;unclassifiable (Anatomical System);cerebellum;lung;salivary gland;choroid;retina;macula lutea;colon;head and neck;hypopharynx;mammary gland;optic nerve;	ciliary ganglion;pons;subthalamic nucleus;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;globus pallidus;	0.386	NA	N	N	N	0.323193869751981	N	Klhl17	NA	NA	NA	NA	NA	0.8984	0.9279	0.9298	0.8064	0.9198	0.828874	0.8736	0.0001153	0.846491	VQSRTrancheSNP99.00to99.90	0	0.897	39	0.862637	13	chr1	964548	NA	G	C	1187.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.2;AS_ReadPosRankSum=.;AS_SOR=2.019;DP=30;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.55;SOR=2.019	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,30:30:90:1|1:964548_G_C:1201,90,0:964548
chr1	973858	973858	G	C	PLEKHN1	exonic	nonsynonymous SNV	NA	PLEKHN1:NM_001160184:exon13:c.G1355C:p.R452P,PLEKHN1:NM_001367552:exon14:c.G1496C:p.R499P,PLEKHN1:NM_032129:exon14:c.G1460C:p.R487P	0.8811	GnomAdGenome_AF_eas	356	104	HeterozygousVariant	het	111	40	71	0.63963963963964	1873.64	PASS	9.265	NA	NA	Benign	NA	NA	'Parkinson''s disease[26227905];'	NA	NA	NA	NA	NA	Ubiquitous (PubMed:18191643). Epressed in several cancer cell lines of differing origin (PubMed:29531808). {ECO:0000269|PubMed:18191643, ECO:0000269|PubMed:29531808}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.926	NA	N	N	N	0.259498654175253	N	Plekhn1	NA	NA	NA	NA	NA	0.6694	0.8778	0.8752	0.6668	0.8811	0.776558	0.6501	0.650186	0.698686	PASS	0.810345	0.843	124	0.855634	35	chr1	973858	NA	G	C	1873.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.8;AS_FS=1.667;AS_MQ=60;AS_MQRankSum=0;AS_QD=16.88;AS_ReadPosRankSum=0.6;AS_SOR=0.498;BaseQRankSum=2.83;DP=114;ExcessHet=3.0103;FS=1.667;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=16.88;ReadPosRankSum=0.691;SOR=0.498	GT:AD:DP:GQ:PL	0/1:40,71:111:99:1881,0,740
chr1	974388	974388	A	G	PLEKHN1	intronic	NA	NA	NA	1	GnomAdExome_AF	576	142	HomozygousVariant	hom	62	0	62	1	1730.06	PASS	NA	NA	NA	NA	NA	NA	'Parkinson''s disease[26227905];'	NA	NA	NA	NA	NA	Ubiquitous (PubMed:18191643). Epressed in several cancer cell lines of differing origin (PubMed:29531808). {ECO:0000269|PubMed:18191643, ECO:0000269|PubMed:29531808}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.926	NA	N	N	N	0.259498654175253	N	Plekhn1	NA	NA	NA	NA	NA	1	1	1	0.9999	1	0.999601	0.9998	0.0001153	1	PASS	0	1	0	1	0	chr1	974388	NA	A	G	1730.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.9;AS_ReadPosRankSum=.;AS_SOR=0.758;DP=64;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.9;SOR=0.758	GT:AD:DP:GQ:PL	1/1:0,62:62:99:1744,186,0
chr1	976215	976215	A	G	PERM1	exonic	nonsynonymous SNV	NA	PERM1:NM_001369898:exon3:c.T2264C:p.V755A,PERM1:NM_001291366:exon4:c.T2330C:p.V777A,PERM1:NM_001369897:exon4:c.T2330C:p.V777A,PERM1:NM_001291367:exon5:c.T1988C:p.V663A	0.9444	GnomAdExome_AF_eas	362	92	HomozygousVariant	hom	38	0	38	1	1070.06	PASS	15.59	NA	615921	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Muscle-specific expression is increased by endurance exercise. {ECO:0000269|PubMed:23836911}.;	D	T	NA	NA	N	P	NA	NA	D	T	T	T	NA	NA	T	T	T	T	.;.;	N	N	.;.	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Perm1	NA	NA	NA	NA	NA	0.7916	0.9444	0.9438	0.7082	0.9429	0.710264	0	0.210282	0.710526	PASS	0	0.782	191	0.809859	46	chr1	976215	NA	A	G	1070.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.16;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=39;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.16;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,38:38:99:1084,114,0
chr1	978953	978953	C	G	PERM1	exonic	nonsynonymous SNV	NA	PERM1:NM_001369898:exon1:c.G2077C:p.E693Q,PERM1:NM_001291366:exon2:c.G2077C:p.E693Q,PERM1:NM_001369897:exon2:c.G2077C:p.E693Q,PERM1:NM_001291367:exon3:c.G1735C:p.E579Q	0.8181	GnomAdGenome_AF_eas	242	66	HomozygousVariant	hom	60	0	60	1	1807.06	PASS	0.844	NA	615921	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Muscle-specific expression is increased by endurance exercise. {ECO:0000269|PubMed:23836911}.;	T	T	NA	NA	N	P	NA	NA	N	T	T	T	NA	NA	T	T	T	T	.;.;	N	N	.;.	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Perm1	NA	NA	NA	NA	NA	0.6169	0.8124	0.8141	0.5234	0.8181	0.55631	0	0.0034282	0.567454	PASS	0	0.637	261	0.685714	60	chr1	978953	NA	C	G	1807.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.12;AS_ReadPosRankSum=.;AS_SOR=0.831;DP=60;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.12;SOR=0.831	GT:AD:DP:GQ:PL	1/1:0,60:60:99:1821,180,0
chr1	979472	979472	G	C	PERM1	exonic	nonsynonymous SNV	NA	PERM1:NM_001369898:exon1:c.C1558G:p.Q520E,PERM1:NM_001291366:exon2:c.C1558G:p.Q520E,PERM1:NM_001369897:exon2:c.C1558G:p.Q520E,PERM1:NM_001291367:exon3:c.C1216G:p.Q406E	0.7238	GnomAdGenome_AF_eas	235	65	HomozygousVariant	hom	38	0	38	1	1194.06	PASS	0.218	NA	615921	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Muscle-specific expression is increased by endurance exercise. {ECO:0000269|PubMed:23836911}.;	T	T	NA	NA	N	P	NA	T	N	T	T	T	NA	NA	T	T	T	T	.;.;	N	N	.;.	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Perm1	NA	NA	NA	NA	NA	0.596	0.7235	0.7195	0.4933	0.7238	0.51258	0	0.162255	0.538651	PASS	0	0.632	269	0.684397	63	chr1	979472	NA	G	C	1194.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=31.42;AS_ReadPosRankSum=.;AS_SOR=0.914;DP=41;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=31.42;SOR=0.914	GT:AD:DP:GQ:PL	1/1:0,38:38:99:1208,114,0
chr1	979496	979496	T	C	PERM1	exonic	nonsynonymous SNV	NA	PERM1:NM_001369898:exon1:c.A1534G:p.S512G,PERM1:NM_001291366:exon2:c.A1534G:p.S512G,PERM1:NM_001369897:exon2:c.A1534G:p.S512G,PERM1:NM_001291367:exon3:c.A1192G:p.S398G	1	GnomAdGenome_AF_eas	556	134	HomozygousVariant	hom	34	0	34	1	987.06	PASS	0.739	NA	615921	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Muscle-specific expression is increased by endurance exercise. {ECO:0000269|PubMed:23836911}.;	T	T	NA	NA	N	P	NA	T	N	T	T	T	NA	NA	T	T	T	T	.;.;	N	N	.;.	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Perm1	NA	NA	NA	NA	NA	0.9721	0.9999	0.9998	0.9661	1	0.966853	0	0.272021	0.963816	PASS	0	0.977	27	0.975177	7	chr1	979496	NA	T	C	987.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.03;AS_ReadPosRankSum=.;AS_SOR=0.811;DP=36;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.03;SOR=0.811	GT:AD:DP:GQ:PL	1/1:0,34:34:99:1001,102,0
chr1	979560	979560	T	C	PERM1	exonic	synonymous SNV	NA	PERM1:NM_001369898:exon1:c.A1470G:p.A490A,PERM1:NM_001291366:exon2:c.A1470G:p.A490A,PERM1:NM_001369897:exon2:c.A1470G:p.A490A,PERM1:NM_001291367:exon3:c.A1128G:p.A376A	0.7245	GnomAdGenome_AF_eas	237	64	HomozygousVariant	hom	43	0	43	1	1230.06	PASS	NA	NA	615921	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Muscle-specific expression is increased by endurance exercise. {ECO:0000269|PubMed:23836911}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Perm1	NA	NA	NA	NA	NA	0.5887	0.7237	0.7203	0.4843	0.7245	0.509585	0	0.16179	0.528783	PASS	0	0.636	268	0.680851	64	chr1	979560	NA	T	C	1230.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.6;AS_ReadPosRankSum=.;AS_SOR=0.739;DP=44;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.61;SOR=0.739	GT:AD:DP:GQ:PL	1/1:0,43:43:99:1244,129,0
chr1	979847	979847	A	G	PERM1	exonic	synonymous SNV	NA	PERM1:NM_001369898:exon1:c.T1183C:p.L395L,PERM1:NM_001291366:exon2:c.T1183C:p.L395L,PERM1:NM_001369897:exon2:c.T1183C:p.L395L,PERM1:NM_001291367:exon3:c.T841C:p.L281L	0.9999	GnomAdExome_AF_eas	557	136	HomozygousVariant	hom	80	0	80	1	2673.06	PASS	NA	NA	615921	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Muscle-specific expression is increased by endurance exercise. {ECO:0000269|PubMed:23836911}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Perm1	NA	NA	NA	NA	NA	0.962	0.9999	0.9998	0.9143	0.9997	0.918131	0	0.278069	0.908867	PASS	0	0.978	26	0.978873	6	chr1	979847	NA	A	G	2673.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=33.41;AS_ReadPosRankSum=.;AS_SOR=1.165;DP=82;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=33.41;SOR=1.165	GT:AD:DP:GQ:PL	1/1:0,80:80:99:2687,240,0
chr1	981169	981169	A	G	PERM1	UTR5	NA	NM_001291367:c.-3T>C;NM_001369897:c.-140T>C;NM_001369898:c.-140T>C	NA	0.8761	GnomAdGenome_AF_eas	413	103	HomozygousVariant	hom	92	0	92	1	2483.06	PASS	NA	NA	615921	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Muscle-specific expression is increased by endurance exercise. {ECO:0000269|PubMed:23836911}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Perm1	NA	NA	NA	NA	NA	0.7735	0.8648	0.866	0.7168	0.8761	0.758586	0	0.216084	0.731107	PASS	0	0.83	147	0.84507	34	chr1	981169	NA	A	G	2483.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.99;AS_ReadPosRankSum=.;AS_SOR=0.737;DP=95;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.99;SOR=0.737	GT:AD:DP:GQ:PL	1/1:0,92:92:99:2497,275,0
chr1	999842	999842	C	A	HES4	exonic	nonsynonymous SNV	NA	HES4:NM_001142467:exon1:c.G132T:p.R44S	0.786	GnomAdExome_AF_eas	271	64	HomozygousVariant	hom	59	0	59	1	1758.06	PASS	6.212	NA	608060	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	NA	T	N	T	T	T	NA	NA	NA	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	endometrium;unclassifiable (Anatomical System);	atrioventricular node;superior cervical ganglion;	NA	NA	N	S	N	0.99544852671045	E	NA	NA	NA	NA	NA	NA	0.6136	0.786	0.7842	0.4451	0.7632	0.49381	0.4367	0.0001537	0.509031	VQSRTrancheSNP99.00to99.90	0.75	0.668	239	0.672535	63	chr1	999842	NA	C	A	1758.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.8;AS_ReadPosRankSum=.;AS_SOR=2.041;DP=63;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.8;SOR=2.041	GT:AD:DP:GQ:PL	1/1:0,59:59:99:1772,177,0
chr1	1013541	1013541	T	C	ISG15	UTR5	NA	NM_005101:c.-33T>C	NA	1	GnomAdGenome_AF_eas	739	133	HomozygousVariant	hom	28	0	28	1	802.06	PASS	NA	[MIM:616126]Immunodeficiency 38, with basal ganglia calcification;	147571	NA	Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency	Disease-causing germline mutation(s) in	Blood protein levels[29875488;30072576];	HP:0001250;HP:0011274;HP:0002721;HP:0000007;HP:0002716;HP:0002135	Seizure;Recurrent mycobacterial infections;Immunodeficiency;Autosomal recessive inheritance;Lymphadenopathy;Basal ganglia calcification	NA	NA	NA	Detected in lymphoid cells, striated and smooth muscle, several epithelia and neurons. Expressed in neutrophils, monocytes and lymphocytes. Enhanced expression seen in pancreatic adenocarcinoma, endometrial cancer, and bladder cancer, as compared to non-cancerous tissue. In bladder cancer, the increase in expression exhibits a striking positive correlation with more advanced stages of the disease. {ECO:0000269|PubMed:22859821, ECO:0000269|PubMed:7490683}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.501	N	N	N	N	0.893955099408202	E	Isg15	skeleton phenotype; 	NA	NA	NA	NA	0.9457	0.9998	0.9998	0.8943	1	0.903155	0.8858	0.932653	0.895731	PASS	0	0.962	56	0.964789	8	chr1	1013541	NA	T	C	802.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.64;AS_ReadPosRankSum=.;AS_SOR=0.836;DP=28;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.65;SOR=0.836	GT:AD:DP:GQ:PL	1/1:0,28:28:84:816,84,0
chr1	1014228	1014228	G	A	ISG15	exonic	nonsynonymous SNV	NA	ISG15:NM_005101:exon2:c.G248A:p.S83N	0.4813	GnomAdGenome_AF_fin	102	19	HeterozygousVariant	het	94	40	54	0.574468085106383	1397.64	PASS	1.515	[MIM:616126]Immunodeficiency 38, with basal ganglia calcification;	147571	Benign	Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency	Disease-causing germline mutation(s) in	Blood protein levels[29875488;30072576];	HP:0001250;HP:0011274;HP:0002721;HP:0000007;HP:0002716;HP:0002135	Seizure;Recurrent mycobacterial infections;Immunodeficiency;Autosomal recessive inheritance;Lymphadenopathy;Basal ganglia calcification	not_specified	criteria_provided,_single_submitter	Benign	Detected in lymphoid cells, striated and smooth muscle, several epithelia and neurons. Expressed in neutrophils, monocytes and lymphocytes. Enhanced expression seen in pancreatic adenocarcinoma, endometrial cancer, and bladder cancer, as compared to non-cancerous tissue. In bladder cancer, the increase in expression exhibits a striking positive correlation with more advanced stages of the disease. {ECO:0000269|PubMed:22859821, ECO:0000269|PubMed:7490683}.;	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	Ubiquitin domain|Ubiquitin domain;Ubiquitin domain|Ubiquitin domain;Ubiquitin domain|Ubiquitin domain;Ubiquitin domain|Ubiquitin domain	NA	NA	Medium	Medium	Medium	NA	NA	0.501	N	N	N	N	0.893955099408202	E	Isg15	skeleton phenotype; 	NA	NA	NA	NA	0.3593	0.4146	0.4063	0.388	0.4813	0.338858	0.4016	0.363631	0.339901	PASS	0.353659	0.345	355	0.359155	64	chr1	1014228	NA	G	A	1397.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=0.779;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.87;AS_ReadPosRankSum=-1.4;AS_SOR=0.581;BaseQRankSum=0.445;DP=96;ExcessHet=3.0103;FS=0.779;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.87;ReadPosRankSum=-1.396;SOR=0.581	GT:AD:DP:GQ:PL	0/1:40,54:94:99:1405,0,929
chr1	1014274	1014274	A	G	ISG15	exonic	synonymous SNV	NA	ISG15:NM_005101:exon2:c.A294G:p.V98V	0.9744	GnomAdGenome_AF_ami	735	129	HomozygousVariant	hom	124	0	124	1	3777.06	PASS	NA	[MIM:616126]Immunodeficiency 38, with basal ganglia calcification;	147571	Benign	Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency	Disease-causing germline mutation(s) in	Blood protein levels[29875488;30072576];	HP:0001250;HP:0011274;HP:0002721;HP:0000007;HP:0002716;HP:0002135	Seizure;Recurrent mycobacterial infections;Immunodeficiency;Autosomal recessive inheritance;Lymphadenopathy;Basal ganglia calcification	NA	NA	NA	Detected in lymphoid cells, striated and smooth muscle, several epithelia and neurons. Expressed in neutrophils, monocytes and lymphocytes. Enhanced expression seen in pancreatic adenocarcinoma, endometrial cancer, and bladder cancer, as compared to non-cancerous tissue. In bladder cancer, the increase in expression exhibits a striking positive correlation with more advanced stages of the disease. {ECO:0000269|PubMed:22859821, ECO:0000269|PubMed:7490683}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.501	N	N	N	N	0.893955099408202	E	Isg15	skeleton phenotype; 	NA	NA	NA	NA	0.9188	0.9495	0.9513	0.8328	0.9744	0.825679	0.8204	0.0001153	0.851396	PASS	0.92803	0.953	72	0.950704	12	chr1	1014274	NA	A	G	3777.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.46;AS_ReadPosRankSum=.;AS_SOR=0.902;DP=130;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.46;SOR=0.902	GT:AD:DP:GQ:PL	1/1:0,124:124:99:3791,372,0
chr1	1020217	1020217	G	T	AGRN	exonic	synonymous SNV	NA	AGRN:NM_198576:exon1:c.G45T:p.P15P	0.5	GME_SD	76	20	HomozygousVariant	het	16	3	13	0.8125	275.64	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	Benign	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.3428	0.3665	0.3716	0.3084	0.4339	0.282548	0	0.0646111	0.316872	PASS	0.5	0.309	306	0.31203	43	chr1	1020217	NA	G	T	275.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=17.25;AS_ReadPosRankSum=-2.4;AS_SOR=0.458;BaseQRankSum=-1.169;DP=17;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=17.23;ReadPosRankSum=-2.302;SOR=0.458	GT:AD:DP:GQ:PL	0/1:3,13:16:42:283,0,42
chr1	1041950	1041950	T	C	AGRN	intronic	NA	NA	NA	1	GnomAdGenome_AF_eas	706	134	HomozygousVariant	hom	48	0	48	1	1394.06	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	NA	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.002	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.9233	0.9998	0.9998	0.8679	1	0.885184	0.8526	0.0317351	0.902299	PASS	0	0.959	52	0.971631	6	chr1	1041950	NA	T	C	1394.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.04;AS_ReadPosRankSum=.;AS_SOR=0.866;DP=48;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.04;SOR=0.866	GT:AD:DP:GQ:PL	1/1:0,48:48:99:1408,144,0
chr1	1044310	1044310	G	A	AGRN	intronic	NA	NA	NA	0.0621	GnomAdExome_AF_afr	0	0	HeterozygousVariant	het	61	28	33	0.540983606557377	734.64	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	NA	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	NA	NA	NA	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.0114	0.0621	0.0644	0.0224	0.0601	0.0299521	0.0215	0.0115781	0.027915	PASS	0	0.007255	12	0.003521	1	chr1	1044310	NA	G	A	734.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=3.495;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.05;AS_ReadPosRankSum=2.4;AS_SOR=1.161;BaseQRankSum=0.286;DP=63;ExcessHet=3.0103;FS=3.495;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.04;ReadPosRankSum=2.48;SOR=1.161	GT:AD:DP:GQ:PL	0/1:28,33:61:99:742,0,601
chr1	1044455	1044455	G	A	AGRN	intronic	NA	NA	NA	0.0635	GnomAdExome_AF_afr	0	0	HeterozygousVariant	het	39	27	12	0.307692307692308	208.64	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	NA	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.0114	0.0635	0.0648	0.023	0.062	0.0305511	0.0217	0.0107243	0.027961	PASS	0	0.006793	10	0.003521	1	chr1	1044455	NA	G	A	208.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.366;AS_MQ=60;AS_MQRankSum=0;AS_QD=5.36;AS_ReadPosRankSum=-1.1;AS_SOR=0.404;BaseQRankSum=0.496;DP=39;ExcessHet=3.0103;FS=1.366;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=5.35;ReadPosRankSum=-1.02;SOR=0.404	GT:AD:DP:GQ:PL	0/1:27,12:39:99:216,0,617
chr1	1045444	1045444	G	C	AGRN	exonic	synonymous SNV	NA	AGRN:NM_198576:exon14:c.G2457C:p.G819G	0.0557	GnomAdGenome_AF_afr	0	0	HeterozygousVariant	het	72	43	29	0.402777777777778	600.64	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	Likely benign	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	Myasthenic_syndrome,_congenital,_8|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.0109	0.0553	0.0556	0.0211	0.0557	0.0273562	0.0181	0.0109507	0.026359	PASS	0	0.007766	13	0.003521	1	chr1	1045444	NA	G	C	600.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=0.904;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.35;AS_ReadPosRankSum=-0.1;AS_SOR=0.854;BaseQRankSum=0.63;DP=77;ExcessHet=3.0103;FS=0.904;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.34;ReadPosRankSum=-0.092;SOR=0.854	GT:AD:DP:GQ:PL	0/1:43,29:72:99:608,0,983
chr1	1045751	1045751	A	G	AGRN	exonic	nonsynonymous SNV	NA	AGRN:NM_198576:exon15:c.A2555G:p.Q852R	0.0733	GnomAdExome_AF_afr	0	0	HeterozygousVariant	het	97	48	49	0.505154639175258	1015.64	PASS	0.673	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	Likely benign	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	Myasthenic_syndrome,_congenital,_8|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	T	T	NA	NA	N	N	N	T	N	T	T	T	NA	T	NA	T	T	T	.;.;	N	N	.;Laminin EGF domain|Laminin EGF domain|Laminin EGF domain	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.0123	0.0733	0.0761	0.0255	0.0702	0.0345447	0.0245	0.0127036	0.028736	PASS	0.02038	0.007766	13	0.003521	1	chr1	1045751	NA	A	G	1015.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.47;AS_ReadPosRankSum=0.8;AS_SOR=0.65;BaseQRankSum=-0.302;DP=101;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.47;ReadPosRankSum=0.892;SOR=0.65	GT:AD:DP:GQ:PL	0/1:48,49:97:99:1023,0,1048
chr1	1046551	1046551	A	G	AGRN	exonic	synonymous SNV	NA	AGRN:NM_198576:exon18:c.A3066G:p.S1022S	0.9866	GnomAdGenome_AF_ami	675	120	HeterozygousVariant	het	152	89	63	0.414473684210526	1414.64	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	Benign	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.8865	0.9677	0.967	0.7939	0.9866	0.797724	0.7802	0.0001153	0.83087	VQSRTrancheSNP99.00to99.90	0.897727	0.898	153	0.919014	21	chr1	1046551	NA	A	G	1414.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=8.6;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.31;AS_ReadPosRankSum=0.1;AS_SOR=1.302;BaseQRankSum=1.65;DP=154;ExcessHet=3.0103;FS=8.6;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.31;ReadPosRankSum=0.14;SOR=1.302	GT:AD:DP:GQ:PL	0/1:89,63:152:99:1422,0,2092
chr1	1047561	1047561	T	C	AGRN	intronic	NA	NA	NA	0.9867	GnomAdGenome_AF_ami	752	134	HeterozygousVariant	het	73	37	36	0.493150684931507	831.64	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	NA	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0.014	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.8963	0.9726	0.9722	0.7841	0.9867	0.79992	0.7666	0.0002305	0.82977	PASS	0	0.952	70	0.96831	7	chr1	1047561	NA	T	C	831.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=1.926;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.4;AS_ReadPosRankSum=0;AS_SOR=0.468;BaseQRankSum=-0.499;DP=76;ExcessHet=3.0103;FS=1.926;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.39;ReadPosRankSum=0.05;SOR=0.468	GT:AD:DP:GQ:PL	0/1:37,36:73:99:839,0,933
chr1	1047614	1047614	T	C	AGRN	exonic	synonymous SNV	NA	AGRN:NM_198576:exon21:c.T3558C:p.F1186F	0.9995	GnomAdExome_AF_eas	774	135	HomozygousVariant	hom	103	0	103	1	2929.06	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	Benign	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.9083	0.9995	0.9997	0.8106	0.999	0.835863	0.7912	0.881082	0.857143	PASS	0.943182	0.959	58	0.971831	6	chr1	1047614	NA	T	C	2929.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.44;AS_ReadPosRankSum=.;AS_SOR=0.712;DP=104;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.44;SOR=0.712	GT:AD:DP:GQ:PL	1/1:0,103:103:99:2943,308,0
chr1	1048922	1048922	T	C	AGRN	exonic	synonymous SNV	NA	AGRN:NM_198576:exon24:c.T4161C:p.T1387T	0.8196	GnomAdExome_AF_eas	254	45	HeterozygousVariant	het	71	39	32	0.450704225352113	718.64	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	Benign	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.5883	0.8196	0.8186	0.4952	0.8127	0.545727	0.4586	0.0001153	0.539933	PASS	0.7	0.56	430	0.560714	67	chr1	1048922	NA	T	C	718.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.13;AS_ReadPosRankSum=-0.2;AS_SOR=0.646;BaseQRankSum=1.23;DP=75;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.12;ReadPosRankSum=-0.15;SOR=0.646	GT:AD:DP:GQ:PL	0/1:39,32:71:99:726,0,855
chr1	1049886	1049886	C	T	AGRN	intronic	NA	NA	NA	0.8103	GnomAdExome_AF_eas	234	39	HeterozygousVariant	het	132	65	67	0.507575757575758	1508.64	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	NA	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.5575	0.8103	0.8039	0.4409	0.8045	0.495208	0.4022	0.52522	0.498358	PASS	0	0.541	425	0.524648	71	chr1	1049886	NA	C	T	1508.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=2.241;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.43;AS_ReadPosRankSum=0.3;AS_SOR=0.515;BaseQRankSum=-0.123;DP=136;ExcessHet=3.0103;FS=2.241;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.43;ReadPosRankSum=0.392;SOR=0.515	GT:AD:DP:GQ:PL	0/1:65,67:132:99:1516,0,1459
chr1	1051063	1051063	C	T	AGRN	intronic	NA	NA	NA	0.9958	GnomAdGenome_AF_eas	484	114	HomozygousVariant	hom	94	0	94	1	2653.06	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	NA	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_provided	criteria_provided,_single_submitter	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.8973	0.9955	0.9957	0.7723	0.9958	0.788538	0	0.360843	0.824013	PASS	0	0.894	106	0.894366	26	chr1	1051063	NA	C	T	2653.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.22;AS_ReadPosRankSum=.;AS_SOR=0.924;DP=94;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.22;SOR=0.924	GT:AD:DP:GQ:PL	1/1:0,94:94:99:2667,280,0
chr1	1051820	1051820	C	T	AGRN	intronic	NA	NA	NA	0.9957	GnomAdExome_AF_eas	646	110	HomozygousVariant	hom	71	0	71	1	2010.06	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	NA	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0002	0.016	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.8871	0.9957	0.9959	0.7778	0.9952	0.788738	0.7569	0.0001153	0.830049	PASS	0	0.883	168	0.883803	31	chr1	1051820	NA	C	T	2010.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.31;AS_ReadPosRankSum=.;AS_SOR=0.779;DP=71;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.31;SOR=0.779	GT:AD:DP:GQ:PL	1/1:0,71:71:99:2024,213,0
chr1	1053552	1053552	G	C	AGRN	intronic	NA	NA	NA	0.9952	GnomAdGenome_AF_eas	231	112	HomozygousVariant	hom	21	0	21	1	669.06	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	NA	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_provided	criteria_provided,_single_submitter	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0	0	0	0.7405	0.9952	0.775359	0	0.0001537	0.804455	PASS	0	0.874	64	0.890845	29	chr1	1053552	NA	G	C	669.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=31.86;AS_ReadPosRankSum=.;AS_SOR=0.784;DP=23;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=31.86;SOR=0.784	GT:AD:DP:GQ:PL	1/1:0,21:21:63:683,63,0
chr1	1054900	1054900	C	T	AGRN	exonic	synonymous SNV	NA	AGRN:NM_198576:exon36:c.C6057T:p.D2019D	0.9	GME_Israel	291	53	HeterozygousVariant	het	88	52	36	0.409090909090909	676.64	PASS	NA	[MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?];	103320	Benign	Presynaptic congenital myasthenic syndromes;Postsynaptic congenital myasthenic syndromes	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0003202;HP:0000961;HP:0005659;HP:0000218;HP:0001315;HP:0003388;HP:0002878;HP:0003458;HP:0002091;HP:0031374;HP:0030199;HP:0009005;HP:0003443;HP:0003722;HP:0000597;HP:0002792;HP:0030196;HP:0002875;HP:0002329;HP:0410011;HP:0003547;HP:0003803;HP:0031108;HP:0009077;HP:0000508;HP:0003402;HP:0010628;HP:0003403;HP:0002194;HP:0000651;HP:0012515;HP:0012764;HP:0001558;HP:0011469;HP:0001265;HP:0012801;HP:0000651;HP:0100285;HP:0001374;HP:0004885;HP:0008443;HP:0000508;HP:0000961;HP:0003325;HP:0001388;HP:0002392;HP:0004661;HP:0040083;HP:0025401;HP:0011398;HP:0002421;HP:0002882;HP:0003701;HP:0001618;HP:0001250;HP:0002015;HP:0001251;HP:0001270;HP:0000768;HP:0000308;HP:0001249;HP:0030842;HP:0003473;HP:0002870;HP:0002515;HP:0002033;HP:0002804;HP:0001284;HP:0000602;HP:0000218;HP:0009053;HP:0000639;HP:0001612;HP:0000565;HP:0000407;HP:0003458;HP:0002205;HP:0003324;HP:0007178;HP:0001761;HP:0010536;HP:0000369;HP:0001561;HP:0100295;HP:0010307;HP:0002020;HP:0002872;HP:0001283;HP:0005943;HP:0002355;HP:0003693;HP:0003388;HP:0001611;HP:0000467;HP:0003306;HP:0000276;HP:0002751;HP:0004889;HP:0003701;HP:0000218;HP:0003388;HP:0003828;HP:0000007;HP:0002093;HP:0010628;HP:0000774;HP:0000508	Skeletal muscle atrophy;Cyanosis;Thoracic kyphoscoliosis;High palate;Reduced tendon reflexes;Easy fatigability;Respiratory failure;EMG: myopathic abnormalities;Restrictive ventilatory defect;Ankle weakness;Fatigable weakness of neck muscles;Weakness of the intrinsic hand muscles;Decreased size of nerve terminals;Neck flexor weakness;Ophthalmoparesis;Reduced vital capacity;Fatigable weakness of respiratory muscles;Exertional dyspnea;Drowsiness;Abnormality of masticatory muscle;Shoulder girdle muscle weakness;Type 1 muscle fiber predominance;Triceps weakness;Weakness of long finger extensor muscles;Ptosis;Decreased miniature endplate potentials;Facial palsy;EMG: decremental response of compound muscle action potential to repetitive nerve stimulation;Delayed gross motor development;Diplopia;Hip flexor weakness;Orthopnea;Decreased fetal movement;Nasal regurgitation;Hyporeflexia;Narrow jaw;Diplopia;EMG: impaired neuromuscular transmission;Congenital hip dislocation;Episodic respiratory distress;Spinal deformities;Ptosis;Cyanosis;Limb-girdle muscle weakness;Joint laxity;EEG with polyspike wave complexes;Frontalis muscle weakness;Toe walking;Staring gaze;Central hypotonia;Poor head control;Sudden episodic apnea;Proximal muscle weakness;Dysphonia;Seizure;Dysphagia;Ataxia;Motor delay;Pectus carinatum;Microretrognathia;Intellectual disability;Choking episodes;Fatigable weakness;Obstructive sleep apnea;Waddling gait;Poor suck;Arthrogryposis multiplex congenita;Areflexia;Ophthalmoplegia;High palate;Distal lower limb muscle weakness;Nystagmus;Weak cry;Esotropia;Sensorineural hearing impairment;EMG: myopathic abnormalities;Recurrent respiratory infections;Generalized muscle weakness;Motor polyneuropathy;Pes cavus;Central sleep apnea;Low-set ears;Polyhydramnios;Muscle fiber atrophy;Stridor;Gastroesophageal reflux;Apneic episodes precipitated by illness, fatigue, stress;Bulbar palsy;Respiratory arrest;Difficulty walking;Distal amyotrophy;Easy fatigability;Nasal speech;Neck muscle weakness;Spinal rigidity;Long face;Kyphoscoliosis;Intermittent episodes of respiratory insufficiency due to muscle weakness;Proximal muscle weakness;High palate;Easy fatigability;Variable expressivity;Autosomal recessive inheritance;Respiratory insufficiency;Facial palsy;Narrow chest;Ptosis	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380, ECO:0000269|PubMed:9652404}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.421	E	N	N	N	0.88298741376669	E	Agrn	growth/size/body region phenotype; homeostasis/metabolism phenotype; muscle phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	agrn	CaP motoneuron	decreased length	abnormal	0.6764	0.8138	0.8097	0.5834	0.8075	0.585264	0.5792	0.466301	0.622483	PASS	0.9	0.592	409	0.598592	64	chr1	1054900	NA	C	T	676.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0.81;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.69;AS_ReadPosRankSum=-1.4;AS_SOR=0.582;BaseQRankSum=-0.638;DP=90;ExcessHet=3.0103;FS=0.81;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.69;ReadPosRankSum=-1.392;SOR=0.582	GT:AD:DP:GQ:PL	0/1:52,36:88:99:684,0,1167
chr1	1071823	1071823	A	G	RNF223	exonic	synonymous SNV	NA	RNF223:NM_001205252:exon2:c.T744C:p.D248D	0.9078	GnomAdExome_AF_eas	321	92	HeterozygousVariant	het	60	29	31	0.516666666666667	737.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.11437135981131	N	Rnf223	NA	NA	NA	NA	NA	0.816	0.9078	0.9082	0.8131	0.8971	0.841254	0	0.0001537	0.798291	PASS	0.875	0.775	158	0.822222	38	chr1	1071823	NA	A	G	737.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.3;AS_ReadPosRankSum=1;AS_SOR=0.784;BaseQRankSum=-0.446;DP=60;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.29;ReadPosRankSum=1.04;SOR=0.784	GT:AD:DP:GQ:PL	0/1:29,31:60:99:745,0,715
chr1	1072052	1072052	G	A	RNF223	exonic	nonsynonymous SNV	NA	RNF223:NM_001205252:exon2:c.C515T:p.A172V	0.8456	GnomAdExome_AF_eas	180	42	HeterozygousVariant	het	88	41	47	0.534090909090909	1098.64	PASS	0.018	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	NA	NA	NA	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.11437135981131	N	Rnf223	NA	NA	NA	NA	NA	0.6458	0.8456	0.8523	0.4909	0.7766	0.532149	0	0.0002689	0.547826	PASS	0.78125	0.551	285	0.540146	64	chr1	1072052	NA	G	A	1098.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=6.965;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.49;AS_ReadPosRankSum=1.7;AS_SOR=0.362;BaseQRankSum=-0.329;DP=95;ExcessHet=3.0103;FS=6.965;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.48;ReadPosRankSum=1.72;SOR=0.362	GT:AD:DP:GQ:PL	0/1:41,47:88:99:1106,0,908
chr1	1197405	1197405	C	T	TTLL10	intronic	NA	NA	NA	0.6002	GnomAdExome_AF_eas	24	16	HeterozygousVariant	het	6	2	4	0.666666666666667	123.64	DP10	NA	NA	NA	NA	Cone rod dystrophy	Disease-causing germline mutation(s) (loss of function) in	Large artery stroke[24262325];Lead levels[26025379];Height[21998595];	HP:0000613;HP:0000505;HP:0000551;HP:0007703;HP:0000662;HP:0000548;HP:0000556;HP:0000007	Photophobia;Visual impairment;Color vision defect;Abnormality of retinal pigmentation;Nyctalopia;Cone/cone-rod dystrophy;Retinal dystrophy;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.95	NA	N	N	N	0.0884618892570334	N	Ttll10	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.2386	0.6002	0.601	0.1246	0.578	0.263978	0	0.0001153	0.167544	PASS	0	0.272	64	0.288889	46	chr1	1197405	NA	C	T	123.64	DP10	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=3.979;AS_MQ=60;AS_MQRankSum=0;AS_QD=20.67;AS_ReadPosRankSum=-1.9;AS_SOR=1.414;BaseQRankSum=-0.253;DP=9;ExcessHet=3.0103;FS=3.979;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=20.61;ReadPosRankSum=-1.834;SOR=1.414	GT:AD:DP:GQ:PL	0/1:2,4:6:58:131,0,58
chr1	1197558	1197558	G	A	TTLL10	exonic	nonsynonymous SNV	NA	TTLL10:NM_001130045:exon16:c.G1733A:p.G578D	0.6042	GnomAdExome_AF_eas	63	11	HeterozygousVariant	het	72	36	36	0.5	875.64	PASS	15.14	NA	NA	Benign	Cone rod dystrophy	Disease-causing germline mutation(s) (loss of function) in	Large artery stroke[24262325];Lead levels[26025379];Height[21998595];	HP:0000613;HP:0000505;HP:0000551;HP:0007703;HP:0000662;HP:0000548;HP:0000556;HP:0000007	Photophobia;Visual impairment;Color vision defect;Abnormality of retinal pigmentation;Nyctalopia;Cone/cone-rod dystrophy;Retinal dystrophy;Autosomal recessive inheritance	NA	NA	NA	NA	D	D	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.95	NA	N	N	N	0.0884618892570334	N	Ttll10	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.2326	0.6042	0.5998	0.1169	0.586	0.248203	0	0.0002689	0.141541	PASS	0.285714	0.301	226	0.269504	54	chr1	1197558	NA	G	A	875.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.17;AS_ReadPosRankSum=1.6;AS_SOR=0.592;BaseQRankSum=0.888;DP=83;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.16;ReadPosRankSum=1.63;SOR=0.592	GT:AD:DP:GQ:PL	0/1:36,36:72:99:883,0,827
chr1	1197586	1197586	C	A	TTLL10	exonic	synonymous SNV	NA	TTLL10:NM_001130045:exon16:c.C1761A:p.P587P	0.6101	GnomAdExome_AF_eas	63	12	HeterozygousVariant	het	79	46	33	0.417721518987342	737.64	PASS	NA	NA	NA	Benign	Cone rod dystrophy	Disease-causing germline mutation(s) (loss of function) in	Large artery stroke[24262325];Lead levels[26025379];Height[21998595];	HP:0000613;HP:0000505;HP:0000551;HP:0007703;HP:0000662;HP:0000548;HP:0000556;HP:0000007	Photophobia;Visual impairment;Color vision defect;Abnormality of retinal pigmentation;Nyctalopia;Cone/cone-rod dystrophy;Retinal dystrophy;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.95	NA	N	N	N	0.0884618892570334	N	Ttll10	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.2405	0.6101	0.6053	0.1292	0.5853	0.263778	0	0.0001153	0.153266	PASS	0.285714	0.301	226	0.275	53	chr1	1197586	NA	C	A	737.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.34;AS_ReadPosRankSum=1.9;AS_SOR=0.73;BaseQRankSum=-0.102;DP=84;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.34;ReadPosRankSum=1.95;SOR=0.73	GT:AD:DP:GQ:PL	0/1:46,33:79:99:745,0,1117
chr1	1197697	1197697	A	G	TTLL10	exonic	synonymous SNV	NA	TTLL10:NM_001130045:exon16:c.A1872G:p.P624P	0.8401	GnomAdGenome_AF_eas	163	37	HomozygousVariant	hom	78	0	78	1	2243.06	PASS	NA	NA	NA	Benign	Cone rod dystrophy	Disease-causing germline mutation(s) (loss of function) in	Large artery stroke[24262325];Lead levels[26025379];Height[21998595];	HP:0000613;HP:0000505;HP:0000551;HP:0007703;HP:0000662;HP:0000548;HP:0000556;HP:0000007	Photophobia;Visual impairment;Color vision defect;Abnormality of retinal pigmentation;Nyctalopia;Cone/cone-rod dystrophy;Retinal dystrophy;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.95	NA	N	N	N	0.0884618892570334	N	Ttll10	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.37	0.8337	0.843	0.3805	0.8401	0.546526	0	0.0882912	0.363712	PASS	0.416667	0.497	255	0.503623	65	chr1	1197697	NA	A	G	2243.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.76;AS_ReadPosRankSum=.;AS_SOR=0.744;DP=81;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.76;SOR=0.744	GT:AD:DP:GQ:PL	1/1:0,78:78:99:2257,234,0
chr1	1197874	1197874	G	A	TTLL10	UTR3	NA	NM_001130045:c.*27G>A	NA	0.6592	GnomAdExome_AF_eas	18	15	HeterozygousVariant	het	65	31	34	0.523076923076923	700.64	PASS	NA	NA	NA	NA	Cone rod dystrophy	Disease-causing germline mutation(s) (loss of function) in	Large artery stroke[24262325];Lead levels[26025379];Height[21998595];	HP:0000613;HP:0000505;HP:0000551;HP:0007703;HP:0000662;HP:0000548;HP:0000556;HP:0000007	Photophobia;Visual impairment;Color vision defect;Abnormality of retinal pigmentation;Nyctalopia;Cone/cone-rod dystrophy;Retinal dystrophy;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.95	NA	N	N	N	0.0884618892570334	N	Ttll10	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.2451	0.6592	0.6637	0.1224	0.5847	0.255391	0	0.0030736	0.141156	PASS	0	0.271	76	0.276119	44	chr1	1197874	NA	G	A	700.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=3.459;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.78;AS_ReadPosRankSum=-0.9;AS_SOR=0.342;BaseQRankSum=-1.28;DP=70;ExcessHet=3.0103;FS=3.459;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.78;ReadPosRankSum=-0.854;SOR=0.342	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:31,34:65:99:0|1:1197874_G_A:708,0,707:1197874
chr1	1211863	1211863	A	C	TNFRSF4	intronic	NA	NA	NA	0.1512	GnomAdGenome_AF_eas	13	0	HeterozygousVariant	het	66	34	32	0.484848484848485	820.64	PASS	NA	[MIM:615593]Immunodeficiency 16 [recessive?];	600315	NA	Combined immunodeficiency due to OX40 deficiency	Disease-causing germline mutation(s) (loss of function) in	Inflammatory bowel disease[23128233];	HP:0000007;HP:0001744;HP:0001876;HP:0003621;HP:0004844;HP:0100726;HP:0002721	'Autosomal recessive inheritance;Splenomegaly;Pancytopenia;Juvenile onset;Coombs-positive hemolytic anemia;Kaposi''s sarcoma;Immunodeficiency'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	N	N	N	N	0.604344439678925	E	Tnfrsf4	homeostasis/metabolism phenotype; cellular phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); immune system phenotype; digestive/alimentary phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; respiratory system phenotype; liver/biliary system phenotype; 	NA	NA	NA	NA	0.0808	0.1425	0.1469	0.0819	0.1512	0.0872604	0.0545	0.0487833	0.068482	PASS	0	0.095	131	0.092857	26	chr1	1211863	NA	A	C	820.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1;AS_FS=4.86;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.44;AS_ReadPosRankSum=0.5;AS_SOR=1.306;BaseQRankSum=1.09;DP=67;ExcessHet=3.0103;FS=4.86;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.43;ReadPosRankSum=0.591;SOR=1.306	GT:AD:DP:GQ:PL	0/1:34,32:66:99:828,0,853
chr1	1212042	1212042	C	T	TNFRSF4	exonic	synonymous SNV	NA	TNFRSF4:NM_003327:exon5:c.G534A:p.E178E	0.7415	GnomAdExome_AF_eas	313	56	HeterozygousVariant	het	136	75	61	0.448529411764706	1369.64	PASS	NA	[MIM:615593]Immunodeficiency 16 [recessive?];	600315	Benign	Combined immunodeficiency due to OX40 deficiency	Disease-causing germline mutation(s) (loss of function) in	Inflammatory bowel disease[23128233];	HP:0000007;HP:0001744;HP:0001876;HP:0003621;HP:0004844;HP:0100726;HP:0002721	'Autosomal recessive inheritance;Splenomegaly;Pancytopenia;Juvenile onset;Coombs-positive hemolytic anemia;Kaposi''s sarcoma;Immunodeficiency'	not_specified	criteria_provided,_single_submitter	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	N	N	N	N	0.604344439678925	E	Tnfrsf4	homeostasis/metabolism phenotype; cellular phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); immune system phenotype; digestive/alimentary phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; respiratory system phenotype; liver/biliary system phenotype; 	NA	NA	NA	NA	0.3671	0.7415	0.7379	0.309	0.7346	0.498403	0.2642	0.334058	0.305419	PASS	0.424242	0.599	364	0.613475	61	chr1	1212042	NA	C	T	1369.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=2.18;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.07;AS_ReadPosRankSum=0.3;AS_SOR=0.565;BaseQRankSum=0.476;DP=142;ExcessHet=3.0103;FS=2.18;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.07;ReadPosRankSum=0.311;SOR=0.565	GT:AD:DP:GQ:PL	0/1:75,61:136:99:1377,0,1734
chr1	1213709	1213709	G	A	TNFRSF4	exonic	synonymous SNV	NA	TNFRSF4:NM_003327:exon2:c.C222T:p.D74D	0.0023	GnomAdExome_AF_sas	0	0	HeterozygousVariant	het	46	27	19	0.41304347826087	307.64	PASS	NA	[MIM:615593]Immunodeficiency 16 [recessive?];	600315	Likely benign	Combined immunodeficiency due to OX40 deficiency	Disease-causing germline mutation(s) (loss of function) in	Inflammatory bowel disease[23128233];	HP:0000007;HP:0001744;HP:0001876;HP:0003621;HP:0004844;HP:0100726;HP:0002721	'Autosomal recessive inheritance;Splenomegaly;Pancytopenia;Juvenile onset;Coombs-positive hemolytic anemia;Kaposi''s sarcoma;Immunodeficiency'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	N	N	N	N	0.604344439678925	E	Tnfrsf4	homeostasis/metabolism phenotype; cellular phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); immune system phenotype; digestive/alimentary phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; respiratory system phenotype; liver/biliary system phenotype; 	NA	NA	NA	NA	0.0003	0.0023	0.0021	0.00003489	0.0016	0.000998403	0	0.0002911	0		0	0.003597	6	0.003521	1	chr1	1213709	NA	G	A	307.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.9;AS_FS=1.162;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.7;AS_ReadPosRankSum=-0.9;AS_SOR=0.626;BaseQRankSum=-1.825;DP=47;ExcessHet=3.0103;FS=1.162;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.69;ReadPosRankSum=-0.86;SOR=0.626	GT:AD:DP:GQ:PL	0/1:27,19:46:99:315,0,583
chr1	1223251	1223251	A	G	SDF4	exonic	synonymous SNV	NA	SDF4:NM_016176:exon4:c.T570C:p.D190D,SDF4:NM_016547:exon4:c.T570C:p.D190D	0.9998	GnomAdExome_AF_eas	544	132	HomozygousVariant	hom	54	0	54	1	1392.06	PASS	NA	NA	614282	NA	NA	NA	'Chronic inflammatory diseases (ankylosing spondylitis, Crohn''s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)[26974007];'	NA	NA	NA	NA	NA	Ubiquitous. Isoform 5 is expressed in pancreas. {ECO:0000269|PubMed:17442889}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;spinal ganglion;alveolus;ganglion;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;muscle;urinary;mammary gland;trophoblast;islets of Langerhans;visual apparatus;cervix;fovea centralis;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;macula lutea;lymph node;oesophagus;colon;placenta;prostate;aorta;optic nerve;medulla oblongata;	thyroid;liver;placenta;prostate;testis;	0.585	NA	N	N	N	0.92867963348666	E	Sdf4	NA	sdf4	dorsal longitudinal anastomotic vessel	aplastic	abnormal	0.9144	0.9998	0.9999	0.9185	0.9997	0.953275	0.92	0.906172	0.889984	PASS	0.931818	0.963	43	0.964789	10	chr1	1223251	NA	A	G	1392.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=25.78;AS_ReadPosRankSum=.;AS_SOR=0.931;DP=58;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=25.78;SOR=0.931	GT:AD:DP:GQ:PL	1/1:0,54:54:99:1406,161,0
chr1	1281201	1281201	G	C	SCNN1D	intronic	NA	NA	NA	0.1306	GnomAdGenome_AF_sas	8	3	HeterozygousVariant	het	105	54	51	0.485714285714286	1228.64	PASS	NA	NA	601328	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;bone;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;ovary;retina;macula lutea;placenta;optic nerve;islets of Langerhans;medulla oblongata;	pons;temporal lobe;superior cervical ganglion;trigeminal ganglion;medulla oblongata;	0.84	NA	N	N	N	0.82478239090071	E	NA	NA	NA	NA	NA	NA	0.0493	0.1172	0.1147	0.0402	0.1306	0.0656949	0	0.0135251	0.037205	PASS	0	0.125	84	0.137324	33	chr1	1281201	NA	G	C	1228.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=0.741;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.7;AS_ReadPosRankSum=0.9;AS_SOR=0.608;BaseQRankSum=-0.752;DP=106;ExcessHet=3.0103;FS=0.741;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.7;ReadPosRankSum=0.956;SOR=0.608	GT:AD:DP:GQ:PL	0/1:54,51:105:99:1236,0,1344
chr1	1281631	1281631	A	C	SCNN1D	intronic	NA	NA	NA	0.4057	GnomAdExome_AF_afr	18	5	HeterozygousVariant	het	45	28	17	0.377777777777778	560.64	PASS	NA	NA	601328	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;bone;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;ovary;retina;macula lutea;placenta;optic nerve;islets of Langerhans;medulla oblongata;	pons;temporal lobe;superior cervical ganglion;trigeminal ganglion;medulla oblongata;	0.84	NA	N	N	N	0.82478239090071	E	NA	NA	NA	NA	NA	NA	0.1163	0.4057	0.4123	0.1753	0.3878	0.209665	0	0.0350707	0.157068	PASS	0	0.176	146	0.195035	45	chr1	1281631	NA	A	C	560.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=1.237;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.47;AS_ReadPosRankSum=-1.5;AS_SOR=0.945;BaseQRankSum=0.175;DP=45;ExcessHet=3.0103;FS=1.237;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.46;ReadPosRankSum=-1.476;SOR=0.945	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:28,17:45:99:0|1:1281631_A_C:568,0,1081:1281631
chr1	1285574	1285574	G	A	SCNN1D	exonic	synonymous SNV	NA	SCNN1D:NM_001130413:exon6:c.G468A:p.S156S	0.636	GnomAdExome_AF_afr	119	21	HeterozygousVariant	het	74	40	34	0.45945945945946	763.64	PASS	NA	NA	601328	Benign	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;bone;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;ovary;retina;macula lutea;placenta;optic nerve;islets of Langerhans;medulla oblongata;	pons;temporal lobe;superior cervical ganglion;trigeminal ganglion;medulla oblongata;	0.84	NA	N	N	N	0.82478239090071	E	NA	NA	NA	NA	NA	NA	0.2163	0.636	0.6501	0.2556	0.6194	0.442692	0.2107	0.0653743	0.26398	PASS	0.244565	0.359	340	0.359155	60	chr1	1285574	NA	G	A	763.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=3.16;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.32;AS_ReadPosRankSum=-0.4;AS_SOR=0.38;BaseQRankSum=-0.479;DP=75;ExcessHet=3.0103;FS=3.16;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.32;ReadPosRankSum=-0.38;SOR=0.38	GT:AD:DP:GQ:PL	0/1:40,34:74:99:771,0,995
chr1	1287315	1287315	G	C	SCNN1D	intronic	NA	NA	NA	0.617	GnomAdExome_AF_eas	42	24	HeterozygousVariant	het	26	14	12	0.461538461538462	294.64	PASS	NA	NA	601328	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;bone;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;ovary;retina;macula lutea;placenta;optic nerve;islets of Langerhans;medulla oblongata;	pons;temporal lobe;superior cervical ganglion;trigeminal ganglion;medulla oblongata;	0.84	NA	N	N	N	0.82478239090071	E	NA	NA	NA	NA	NA	NA	0.1986	0.617	0.6124	0.1715	0.6071	0.354832	0.1269	0.151305	0.186371	PASS	0	0.4	83	0.363309	53	chr1	1287315	NA	G	C	294.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=1.58;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.35;AS_ReadPosRankSum=0;AS_SOR=0.868;BaseQRankSum=0.867;DP=28;ExcessHet=3.0103;FS=1.58;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.33;ReadPosRankSum=0.052;SOR=0.868	GT:AD:DP:GQ:PL	0/1:14,12:26:99:302,0,335
chr1	1290261	1290261	C	A	SCNN1D	intronic	NA	NA	NA	0.8463	GnomAdGenome_AF_eas	34	9	HeterozygousVariant	het	31	10	21	0.67741935483871	487.64	PASS	NA	NA	601328	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0005	0.064	Medium	Medium	Medium	fovea centralis;bone;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;ovary;retina;macula lutea;placenta;optic nerve;islets of Langerhans;medulla oblongata;	pons;temporal lobe;superior cervical ganglion;trigeminal ganglion;medulla oblongata;	0.84	NA	N	N	N	0.82478239090071	E	NA	NA	NA	NA	NA	NA	0.271	0.8457	0.8447	0.2708	0.8463	0.490815	0.2929	0.0445855	0.268473	PASS	0	0.238	169	0.187023	31	chr1	1290261	NA	C	A	487.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.74;AS_ReadPosRankSum=0.5;AS_SOR=1.027;BaseQRankSum=-0.972;DP=31;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.73;ReadPosRankSum=0.55;SOR=1.027	GT:AD:DP:GQ:PL	0/1:10,21:31:99:495,0,196
chr1	1290519	1290519	G	A	SCNN1D	exonic	nonsynonymous SNV	NA	SCNN1D:NM_001130413:exon14:c.G1823A:p.R608Q	0.0744	GnomAdGenome_AF_ami	0		HeterozygousVariant	het	99	57	42	0.424242424242424	869.64	PASS	3.264	NA	601328	Likely benign	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	T	T	NA	NA	N	N	L	T	N	T	T	T	D	T	NA	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	fovea centralis;bone;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;ovary;retina;macula lutea;placenta;optic nerve;islets of Langerhans;medulla oblongata;	pons;temporal lobe;superior cervical ganglion;trigeminal ganglion;medulla oblongata;	0.84	NA	N	N	N	0.82478239090071	E	NA	NA	NA	NA	NA	NA	0.0052	0.0078	0.0075	0.0058	0.0744	0.00339457	0.0054	0.0049611	0.007389	PASS	0.007576	0.003759	6			chr1	1290519	NA	G	A	869.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=6.403;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.79;AS_ReadPosRankSum=-0.5;AS_SOR=0.683;BaseQRankSum=-0.231;DP=104;ExcessHet=3.0103;FS=6.403;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.78;ReadPosRankSum=-0.411;SOR=0.683	GT:AD:DP:GQ:PL	0/1:57,42:99:99:877,0,1310
chr1	1290968	1290968	C	G	SCNN1D	intronic	NA	NA	NA	0.7992	GnomAdExome_AF_eas	126	29	HeterozygousVariant	het	84	33	51	0.607142857142857	1158.64	PASS	NA	NA	601328	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;bone;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;ovary;retina;macula lutea;placenta;optic nerve;islets of Langerhans;medulla oblongata;	pons;temporal lobe;superior cervical ganglion;trigeminal ganglion;medulla oblongata;	0.84	NA	N	N	N	0.82478239090071	E	NA	NA	NA	NA	NA	NA	0.2886	0.7992	0.7968	0.3274	0.7919	0.504193	0.3024	0.00011	0.292282	VQSRTrancheSNP99.00to99.90	0	0.376	348	0.408451	58	chr1	1290968	NA	C	G	1158.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=1.827;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.8;AS_ReadPosRankSum=-0.2;AS_SOR=0.5;BaseQRankSum=-0.251;DP=84;ExcessHet=3.0103;FS=1.827;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.79;ReadPosRankSum=-0.133;SOR=0.5	GT:AD:DP:GQ:PL	0/1:33,51:84:99:1166,0,709
chr1	1291377	1291377	G	A	SCNN1D	exonic	nonsynonymous SNV	NA	SCNN1D:NM_001130413:exon18:c.G2176A:p.G726S	0.1782	GnomAdGenome_AF_eas	22	2	HeterozygousVariant	het	89	55	34	0.382022471910112	752.64	PASS	5.932	NA	601328	Benign	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	T	T	NA	NA	NA	P	N	T	N	T	T	T	NA	T	NA	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	fovea centralis;bone;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;ovary;retina;macula lutea;placenta;optic nerve;islets of Langerhans;medulla oblongata;	pons;temporal lobe;superior cervical ganglion;trigeminal ganglion;medulla oblongata;	0.84	NA	N	N	N	0.82478239090071	E	NA	NA	NA	NA	NA	NA	0.084	0.1645	0.1642	0.0721	0.1782	0.109625	0.0569	0.0726511	0.069901	PASS	0.127976	0.118	147	0.130282	33	chr1	1291377	NA	G	A	752.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=0.815;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.46;AS_ReadPosRankSum=0.3;AS_SOR=0.818;BaseQRankSum=0.368;DP=92;ExcessHet=3.0103;FS=0.815;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.46;ReadPosRankSum=0.376;SOR=0.818	GT:AD:DP:GQ:PL	0/1:55,34:89:99:760,0,1400
chr1	1291509	1291509	G	A	SCNN1D	exonic	nonsynonymous SNV	NA	SCNN1D:NM_001130413:exon18:c.G2308A:p.G770R	0.1817	GnomAdGenome_AF_eas	22	3	HeterozygousVariant	het	80	36	44	0.55	998.64	PASS	0.37	NA	601328	Benign	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	T	D	NA	NA	N	P	N	T	N	T	T	T	NA	T	NA	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	fovea centralis;bone;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;ovary;retina;macula lutea;placenta;optic nerve;islets of Langerhans;medulla oblongata;	pons;temporal lobe;superior cervical ganglion;trigeminal ganglion;medulla oblongata;	0.84	NA	N	N	N	0.82478239090071	E	NA	NA	NA	NA	NA	NA	0.0792	0.1696	0.1706	0.0681	0.1817	0.109824	0.053	0.0684985	0.068144	PASS	0.138235	0.118	146	0.140845	34	chr1	1291509	NA	G	A	998.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0.85;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.49;AS_ReadPosRankSum=0.9;AS_SOR=0.862;BaseQRankSum=-0.551;DP=86;ExcessHet=3.0103;FS=0.85;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.48;ReadPosRankSum=0.905;SOR=0.862	GT:AD:DP:GQ:PL	0/1:36,44:80:99:1006,0,784
chr1	1298561	1298561	T	C	ACAP3	intronic	NA	NA	NA	0.7739	GnomAdGenome_AF_eas	100	24	HeterozygousVariant	het	44	28	16	0.363636363636364	357.64	PASS	NA	NA	NA	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.002	Medium	Medium	Medium	alveolus;skin;stomach;testis;pituitary gland;lens;unclassifiable (Anatomical System);lymphoreticular;choroid;kidney;uterus;retina;pancreas;muscle;urinary;mammary gland;islets of Langerhans;visual apparatus;cervix;fovea centralis;peripheral nerve;spleen;liver;cartilage;bone;brain;blood;heart;bone marrow;lung;ovary;macula lutea;bladder;frontal lobe;colon;placenta;breast;optic nerve;hypothalamus;	NA	0.471	NA	N	N	N	0.78140813875094	E	Acap3	growth/size/body region phenotype; 	NA	NA	NA	NA	0.2495	0.7704	0.7669	0.3476	0.7739	0.496805	0.2902	0.234706	0.2578	PASS	0	0.389	248	0.386525	61	chr1	1298561	NA	T	C	357.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=8.758;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.14;AS_ReadPosRankSum=-1.4;AS_SOR=0.094;BaseQRankSum=0.509;DP=45;ExcessHet=3.0103;FS=8.758;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.13;ReadPosRankSum=-1.343;SOR=0.094	GT:AD:DP:GQ:PL	0/1:28,16:44:99:365,0,654
chr1	1299383	1299383	G	-	ACAP3	intronic	NA	NA	NA	0.1931	GnomAdGenome_AF_eas	17	3	HeterozygousVariant	het	91	39	52	0.571428571428571	1427.6	PASS	NA	NA	NA	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	alveolus;skin;stomach;testis;pituitary gland;lens;unclassifiable (Anatomical System);lymphoreticular;choroid;kidney;uterus;retina;pancreas;muscle;urinary;mammary gland;islets of Langerhans;visual apparatus;cervix;fovea centralis;peripheral nerve;spleen;liver;cartilage;bone;brain;blood;heart;bone marrow;lung;ovary;macula lutea;bladder;frontal lobe;colon;placenta;breast;optic nerve;hypothalamus;	NA	0.471	NA	N	N	N	0.78140813875094	E	Acap3	growth/size/body region phenotype; 	NA	NA	NA	NA	0.084	0.1673	0.1713	0.0833	0.1931	0.119409	0.074	0.0144844	0.089109	PASS	0	0.109	90	0.131206	31	chr1	1299382	NA	AG	A	1427.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.69;AS_ReadPosRankSum=0.3;AS_SOR=0.623;BaseQRankSum=-0.062;DP=97;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.69;ReadPosRankSum=0.337;SOR=0.623	GT:AD:DP:GQ:PL	0/1:39,52:91:99:1435,0,993
chr1	1310624	1310624	A	G	PUSL1	intronic	NA	NA	NA	0.9883	GnomAdExome_AF_amr	465	103	HomozygousVariant	hom	83	0	83	1	2409.06	PASS	NA	NA	NA	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0.002	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.92979242613757	E	Pusl1	NA	NA	NA	NA	NA	0.9616	0.9883	0.9886	0.9719	0.9881	0.951877	0.9769	0.0001153	0.977011	PASS	0	0.907	53	0.885827	19	chr1	1310624	NA	A	G	2409.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.02;AS_ReadPosRankSum=.;AS_SOR=0.928;DP=84;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.02;SOR=0.928	GT:AD:DP:GQ:PL	1/1:0,83:83:99:2423,249,0
chr1	1312114	1312114	T	C	INTS11	exonic	synonymous SNV	NA	INTS11:NM_001256462:exon14:c.A1347G:p.P449P,INTS11:NM_001256463:exon14:c.A1338G:p.P446P,INTS11:NM_017871:exon16:c.A1641G:p.P547P,INTS11:NM_001256460:exon17:c.A1554G:p.P518P,INTS11:NM_001256456:exon18:c.A1659G:p.P553P	0.8212	GnomAdExome_AF_asj	73	19	HeterozygousVariant	het	30	13	17	0.566666666666667	431.64	PASS	NA	NA	611354	NA	NA	NA	Inflammatory bowel disease[28067908];Systolic blood pressure[28135244];Systemic lupus erythematosus[28714469];Pulse pressure[28135244;28135244];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	H	NA	NA	Ints11	NA	ints11	hemopoiesis	disrupted	abnormal	0.558	0.7968	0.7958	0.587	0.817	0.319289	0.6009	0.0001537	0.596535	VQSRTrancheSNP99.00to99.90	0.8	0.313	220	0.327465	55	chr1	1312114	NA	T	C	431.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=5.486;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.4;AS_ReadPosRankSum=0.5;AS_SOR=0.395;BaseQRankSum=-0.645;DP=34;ExcessHet=3.0103;FS=5.486;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.39;ReadPosRankSum=0.503;SOR=0.395	GT:AD:DP:GQ:PL	0/1:13,17:30:99:439,0,336
chr1	1312198	1312198	-	GG	INTS11	intronic	NA	NA	NA	0.7249	GnomAdGenome_AF_eas	67	22	WT/SomaticVariant	het	14	11	3	0.214285714285714	51.6	PASS	NA	NA	611354	NA	NA	NA	Inflammatory bowel disease[28067908];Systolic blood pressure[28135244];Systemic lupus erythematosus[28714469];Pulse pressure[28135244;28135244];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	H	NA	NA	Ints11	NA	ints11	hemopoiesis	disrupted	abnormal	0	0	0	0.2724	0.7249	0	0	0.0001153	0.254545	VQSRTrancheINDEL99.00to99.90	0	0.432	106	0.383333	25	chr1	1312198	NA	T	TGG	51.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=3.71;AS_ReadPosRankSum=-0.4;AS_SOR=0.105;BaseQRankSum=-0.872;DP=17;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=3.69;ReadPosRankSum=-0.389;SOR=0.105	GT:AD:DP:GQ:PL	0/1:11,3:14:59:59,0,357
chr1	1313807	1313807	G	A	INTS11	exonic	synonymous SNV	NA	INTS11:NM_001256462:exon7:c.C588T:p.F196F,INTS11:NM_001256463:exon7:c.C579T:p.F193F,INTS11:NM_017871:exon9:c.C882T:p.F294F,INTS11:NM_001256460:exon10:c.C795T:p.F265F,INTS11:NM_001256456:exon11:c.C900T:p.F300F	0.8173	GnomAdExome_AF_asj	72	20	HeterozygousVariant	het	107	52	55	0.514018691588785	1283.64	PASS	NA	NA	611354	Benign	NA	NA	Inflammatory bowel disease[28067908];Systolic blood pressure[28135244];Systemic lupus erythematosus[28714469];Pulse pressure[28135244;28135244];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	H	NA	NA	Ints11	NA	ints11	hemopoiesis	disrupted	abnormal	0.5768	0.7983	0.8001	0.55	0.81	0.310104	0.5864	0.587017	0.590312	PASS	0.8	0.313	224	0.34507	58	chr1	1313807	NA	G	A	1283.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.7;AS_FS=0.719;AS_MQ=60;AS_MQRankSum=0;AS_QD=12;AS_ReadPosRankSum=0.1;AS_SOR=0.66;BaseQRankSum=1.75;DP=107;ExcessHet=3.0103;FS=0.719;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12;ReadPosRankSum=0.112;SOR=0.66	GT:AD:DP:GQ:PL	0/1:52,55:107:99:1291,0,1097
chr1	1318875	1318875	G	A	INTS11	intronic	NA	NA	NA	0.1362	GnomAdExome_AF_amr	5	3	HeterozygousVariant	het	89	51	38	0.426966292134831	893.64	PASS	3.01	NA	611354	NA	NA	NA	Inflammatory bowel disease[28067908];Systolic blood pressure[28135244];Systemic lupus erythematosus[28714469];Pulse pressure[28135244;28135244];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	P	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	.;	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	H	NA	NA	Ints11	NA	ints11	hemopoiesis	disrupted	abnormal	0.0459	0.1362	0.1396	0.0399	0.1042	0.0626997	0	0.0098834	0		0	0.039	35	0.046429	7	chr1	1318875	NA	G	A	893.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.04;AS_ReadPosRankSum=-1.6;AS_SOR=0.648;BaseQRankSum=-0.891;DP=90;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.04;ReadPosRankSum=-1.51;SOR=0.648	GT:AD:DP:GQ:PL	0/1:51,38:89:99:901,0,1357
chr1	1319056	1319056	A	G	INTS11	intronic	NA	NA	NA	0.9641	GnomAdGenome_AF_nfe	452	104	HeterozygousVariant	het	157	91	66	0.420382165605096	2362.64	PASS	NA	NA	611354	NA	NA	NA	Inflammatory bowel disease[28067908];Systolic blood pressure[28135244];Systemic lupus erythematosus[28714469];Pulse pressure[28135244;28135244];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	H	NA	NA	Ints11	NA	ints11	hemopoiesis	disrupted	abnormal	0.9082	0.9638	0.9654	0.9166	0.9641	0.873403	0	0.655904	0.914614	PASS	0	0.869	100	0.852113	34	chr1	1319056	NA	A	G	2362.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.7;AS_FS=4.761;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.05;AS_ReadPosRankSum=-1.2;AS_SOR=0.772;BaseQRankSum=1.79;DP=159;ExcessHet=3.0103;FS=4.761;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.05;ReadPosRankSum=-1.12;SOR=0.772	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:91,66:157:99:0|1:1319056_A_G:2370,0,3499:1319056
chr1	1319063	1319063	G	A	INTS11	intronic	NA	NA	NA	0.9478	GnomAdGenome_AF_ami	423	98	HeterozygousVariant	het	157	90	67	0.426751592356688	2422.64	PASS	0.152	NA	611354	NA	NA	NA	Inflammatory bowel disease[28067908];Systolic blood pressure[28135244];Systemic lupus erythematosus[28714469];Pulse pressure[28135244;28135244];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	P	NA	NA	NA	NA	NA	T	NA	NA	NA	T	NA	T	.;	N	NA	Metallo-beta-lactamase	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	H	NA	NA	Ints11	NA	ints11	hemopoiesis	disrupted	abnormal	0.8549	0.9324	0.9342	0.7513	0.9478	0.713458	0	0.613472	0.788177	PASS	0	0.838	121	0.833333	39	chr1	1319063	NA	G	A	2422.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.2;AS_FS=4.761;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.43;AS_ReadPosRankSum=-2.4;AS_SOR=0.821;BaseQRankSum=2.26;DP=158;ExcessHet=3.0103;FS=4.761;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.43;ReadPosRankSum=-2.385;SOR=0.821	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:90,67:157:99:0|1:1319056_A_G:2430,0,3466:1319056
chr1	1319461	1319461	C	G	INTS11	exonic	synonymous SNV	NA	INTS11:NM_017871:exon4:c.G264C:p.G88G,INTS11:NM_001256460:exon5:c.G177C:p.G59G,INTS11:NM_001256456:exon6:c.G282C:p.G94G	0.9478	GnomAdGenome_AF_ami	430	99	HeterozygousVariant	het	131	64	67	0.511450381679389	1643.64	PASS	NA	NA	611354	Benign	NA	NA	Inflammatory bowel disease[28067908];Systolic blood pressure[28135244];Systemic lupus erythematosus[28714469];Pulse pressure[28135244;28135244];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	H	NA	NA	Ints11	NA	ints11	hemopoiesis	disrupted	abnormal	0.8519	0.9317	0.9315	0.7518	0.9478	0.713658	0.7513	0.834776	0.788998	PASS	0.881098	0.842	125	0.830986	38	chr1	1319461	NA	C	G	1643.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=0.665;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.55;AS_ReadPosRankSum=-2.1;AS_SOR=0.766;BaseQRankSum=0.841;DP=136;ExcessHet=3.0103;FS=0.665;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.55;ReadPosRankSum=-2.078;SOR=0.766	GT:AD:DP:GQ:PL	0/1:64,67:131:99:1651,0,1445
chr1	1320445	1320445	C	G	INTS11	intronic	NA	NA	NA	0.0057	GnomAdExome_AF_sas	1	1	HeterozygousVariant	het	64	37	27	0.421875	587.64	PASS	NA	NA	611354	NA	NA	NA	Inflammatory bowel disease[28067908];Systolic blood pressure[28135244];Systemic lupus erythematosus[28714469];Pulse pressure[28135244;28135244];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	H	NA	NA	Ints11	NA	ints11	hemopoiesis	disrupted	abnormal	0.0007	0.0057	0.0055	0.00006977	0.003	0.00159744	0.000077	0.0007568	0		0	0.007114	5	0.014085	2	chr1	1320445	NA	C	G	587.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.19;AS_ReadPosRankSum=0.5;AS_SOR=0.718;BaseQRankSum=0.987;DP=65;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.18;ReadPosRankSum=0.531;SOR=0.718	GT:AD:DP:GQ:PL	0/1:37,27:64:99:595,0,821
chr1	1327021	1327021	G	A	CPTP	exonic	synonymous SNV	NA	CPTP:NM_001029885:exon2:c.G111A:p.K37K	0.0005	GnomAdGenome_AF_oth			HeterozygousVariant	het	64	33	31	0.484375	623.64	PASS	NA	NA	615467	Likely benign	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	Ubiquitous. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes. {ECO:0000269|PubMed:23863933}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Cptp	NA	NA	NA	NA	NA	0	0	0	0.00001395	0.0005	0	0	0	0		0					chr1	1327021	NA	G	A	623.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.75;AS_ReadPosRankSum=1.9;AS_SOR=0.598;BaseQRankSum=-2.314;DP=65;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.74;ReadPosRankSum=1.92;SOR=0.598	GT:AD:DP:GQ:PL	0/1:33,31:64:99:631,0,804
chr1	1327211	1327211	C	T	CPTP	intronic	NA	NA	NA	0.9533	GnomAdGenome_AF_ami	228	99	WT/SomaticVariant	het	23	18	5	0.217391304347826	100.64	SOR3	NA	NA	615467	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	Ubiquitous. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes. {ECO:0000269|PubMed:23863933}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Cptp	NA	NA	NA	NA	NA	0.8538	0.933	0.9325	0.7585	0.9533	0.719848	0.7598	0.830481	0.791391	PASS	0	0.866	60	0.834507	39	chr1	1327211	NA	C	T	100.64	SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.8;AS_FS=9.132;AS_MQ=60;AS_MQRankSum=0;AS_QD=4.39;AS_ReadPosRankSum=0.7;AS_SOR=3.223;BaseQRankSum=1.87;DP=26;ExcessHet=3.0103;FS=9.132;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=4.38;ReadPosRankSum=0.71;SOR=3.223	GT:AD:DP:GQ:PL	0/1:18,5:23:99:108,0,437
chr1	1327586	1327586	C	T	CPTP	exonic	synonymous SNV	NA	CPTP:NM_001029885:exon3:c.C468T:p.R156R	0.9444	GnomAdGenome_AF_ami	430	100	HeterozygousVariant	het	111	48	63	0.567567567567568	1463.64	PASS	NA	NA	615467	Benign	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	Ubiquitous. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes. {ECO:0000269|PubMed:23863933}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Cptp	NA	NA	NA	NA	NA	0.8646	0.9305	0.93	0.8038	0.9444	0.76258	0.8131	0.836723	0.832512	PASS	0.885965	0.844	126	0.841549	39	chr1	1327586	NA	C	T	1463.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.19;AS_ReadPosRankSum=-0.2;AS_SOR=0.65;BaseQRankSum=-1.39;DP=113;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.19;ReadPosRankSum=-0.182;SOR=0.65	GT:AD:DP:GQ:PL	0/1:48,63:111:99:1471,0,1136
chr1	1327764	1327764	G	A	CPTP	UTR3	NA	NM_001029885:c.*1G>A	NA	0.9533	GnomAdGenome_AF_ami	358	100	HeterozygousVariant	het	76	31	45	0.592105263157895	1148.64	PASS	NA	NA	615467	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	Ubiquitous. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes. {ECO:0000269|PubMed:23863933}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Cptp	NA	NA	NA	NA	NA	0.8869	0.9341	0.9338	0.8899	0.9533	0.84984	0.9083	0.867738	0.89491	PASS	0	0.844	108	0.834507	37	chr1	1327764	NA	G	A	1148.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=3.276;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.12;AS_ReadPosRankSum=1.4;AS_SOR=0.399;BaseQRankSum=-1.31;DP=76;ExcessHet=3.0103;FS=3.276;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.11;ReadPosRankSum=1.43;SOR=0.399	GT:AD:DP:GQ:PL	0/1:31,45:76:99:1156,0,723
chr1	1331945	1331945	-	C	TAS1R3	intronic	NA	NA	NA	0.4248	GnomAdExome_AF_afr	4	2	HeterozygousVariant	het	39	16	23	0.58974358974359	549.6	PASS	NA	NA	605865	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lens;	ciliary ganglion;pons;occipital lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;	NA	N	N	N	N	0.91825220373292	E	Tas1r3	taste/olfaction phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0972	0.4248	0.4342	0.1632	0.4206	0.189497	0.1654	0.0001153	0.146141	PASS	0	0.063	58	0.056338	12	chr1	1331945	NA	G	GC	549.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=3.819;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.1;AS_ReadPosRankSum=-2;AS_SOR=1.625;BaseQRankSum=0.192;DP=55;ExcessHet=3.0103;FS=3.819;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.09;ReadPosRankSum=-1.959;SOR=1.625	GT:AD:DP:GQ:PL	0/1:16,23:39:99:557,0,375
chr1	1332686	1332686	A	G	TAS1R3	exonic	synonymous SNV	NA	TAS1R3:NM_152228:exon3:c.A1155G:p.L385L	0.0011	GnomAdExome_AF_sas	0	0	HeterozygousVariant	het	89	36	53	0.595505617977528	1399.64	PASS	NA	NA	605865	Likely benign	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lens;	ciliary ganglion;pons;occipital lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;	NA	N	N	N	N	0.91825220373292	E	Tas1r3	taste/olfaction phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0001	0.0011	0.0014	0.0000279	0.001	0.000199681	0	0.0000906	0		0	0.001796	3	0.003521	1	chr1	1332686	NA	A	G	1399.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1;AS_FS=1.748;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.73;AS_ReadPosRankSum=-1.8;AS_SOR=0.72;BaseQRankSum=1.06;DP=92;ExcessHet=3.0103;FS=1.748;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.73;ReadPosRankSum=-1.723;SOR=0.72	GT:AD:DP:GQ:PL	0/1:36,53:89:99:1407,0,839
chr1	1332779	1332779	C	T	TAS1R3	exonic	synonymous SNV	NA	TAS1R3:NM_152228:exon3:c.C1248T:p.P416P	0.2824	GnomAdExome_AF_afr	7	2	HeterozygousVariant	het	100	56	44	0.44	915.64	PASS	NA	NA	605865	Benign	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lens;	ciliary ganglion;pons;occipital lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;	NA	N	N	N	N	0.91825220373292	E	Tas1r3	taste/olfaction phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0884	0.2824	0.2869	0.1216	0.2746	0.140575	0.1167	0.0818101	0.116585	PASS	0.170103	0.068	98	0.057971	12	chr1	1332779	NA	C	T	915.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=2.659;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.16;AS_ReadPosRankSum=-0.3;AS_SOR=1.042;BaseQRankSum=0.233;DP=103;ExcessHet=3.0103;FS=2.659;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.16;ReadPosRankSum=-0.271;SOR=1.042	GT:AD:DP:GQ:PL	0/1:56,44:100:99:923,0,1209
chr1	1332815	1332815	G	A	TAS1R3	intronic	NA	NA	NA	0.2901	GnomAdExome_AF_afr	4	2	HeterozygousVariant	het	73	46	27	0.36986301369863	605.64	PASS	NA	NA	605865	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lens;	ciliary ganglion;pons;occipital lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;	NA	N	N	N	N	0.91825220373292	E	Tas1r3	taste/olfaction phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0742	0.2901	0.2938	0.1106	0.2804	0.136581	0.108	0.0679681	0.107553	PASS	0	0.054	48	0.047445	9	chr1	1332815	NA	G	A	605.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=2.046;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.3;AS_ReadPosRankSum=1.3;AS_SOR=1.071;BaseQRankSum=0.796;DP=73;ExcessHet=3.0103;FS=2.046;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.3;ReadPosRankSum=1.33;SOR=1.071	GT:AD:DP:GQ:PL	0/1:46,27:73:99:613,0,1113
chr1	1334174	1334174	T	C	TAS1R3	exonic	nonsynonymous SNV	NA	TAS1R3:NM_152228:exon6:c.T2269C:p.C757R	0.9883	GnomAdGenome_AF_afr	702	115	HomozygousVariant	hom	141	0	141	1	3963.06	PASS	6.166	NA	605865	Benign	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	GPCR family 3, C-terminal|GPCR family 3, C-terminal	NA	NA	Medium	Medium	Medium	lens;	ciliary ganglion;pons;occipital lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;	NA	N	N	N	N	0.91825220373292	E	Tas1r3	taste/olfaction phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.9607	0.9882	0.9879	0.9721	0.9883	0.951877	0.9774	0.9031	0.977011	PASS	0.974138	0.913	120	0.901409	26	chr1	1334174	NA	T	C	3963.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.11;AS_ReadPosRankSum=.;AS_SOR=0.827;DP=145;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.11;SOR=0.827	GT:AD:DP:GQ:PL	1/1:0,141:141:99:3977,422,0
chr1	1340336	1340336	T	A	DVL1	intronic	NA	NA	NA	0.1573	GnomAdExome_AF_amr	4	2	HeterozygousVariant	het	72	39	33	0.458333333333333	945.64	PASS	NA	[MIM:616331]Robinow syndrome, autosomal dominant 2 [dominant?];	601365	NA	Autosomal dominant Robinow syndrome	Disease-causing germline mutation(s) in	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	HP:0002937;HP:0002812;HP:0000637;HP:0000463;HP:0008736;HP:0000508;HP:0005280;HP:0000592;HP:0001263;HP:0000668;HP:0008402;HP:0000674;HP:0001328;HP:0001385;HP:0011800;HP:0000064;HP:0000286;HP:0001249;HP:0007665;HP:0003196;HP:0040036;HP:0006101;HP:0000960;HP:0002673;HP:0003510;HP:0002007;HP:0000445;HP:0004279;HP:0100541;HP:0000278;HP:0000365;HP:0002705;HP:0000212;HP:0000347;HP:0000494;HP:0000256;HP:0000677;HP:0002714;HP:0000322;HP:0000047;HP:0011069;HP:0011220;HP:0000060;HP:0000527;HP:0000028;HP:0002827;HP:0000059;HP:0100490;HP:0000767;HP:0000768;HP:0005743;HP:0002650;HP:0100798;HP:0010733;HP:0005306;HP:0008501;HP:0000358;HP:0004209;HP:0001596;HP:0002983;HP:0000316;HP:0001537;HP:0000520;HP:0000582;HP:0000369;HP:0000023;HP:0000470;HP:0001156;HP:0010297;HP:0000343;HP:0000431;HP:0003042;HP:0012905;HP:0000039;HP:0010807;HP:0000486;HP:0000059;HP:0002007;HP:0001537;HP:0000684;HP:0004279;HP:0000520;HP:0000219;HP:0000126;HP:0000767;HP:0000207;HP:0000347;HP:0000189;HP:0000202;HP:0001263;HP:0000678;HP:0001837;HP:0000286;HP:0009883;HP:0012368;HP:0000256;HP:0000316;HP:0001156;HP:0000023;HP:0001249;HP:0000431;HP:0000158;HP:0011800;HP:0000582;HP:0000637;HP:0000369;HP:0002750;HP:0009466;HP:0000272;HP:0000212;HP:0001853;HP:0000060;HP:0000358;HP:0002714;HP:0010297;HP:0003027;HP:0000028;HP:0005280;HP:0011304;HP:0000463;HP:0000527;HP:0001052;HP:0008905;HP:0000463;HP:0000075;HP:0010290;HP:0000494;HP:0000054;HP:0000343;HP:0004220;HP:0000006;HP:0002164;HP:0000470;HP:0200055;HP:0000260;HP:0030084;HP:0000278;HP:0001705;HP:0003196;HP:0000218;HP:0000054;HP:0000212;HP:0000006;HP:0003577;HP:0000028;HP:0000520;HP:0001156;HP:0011304;HP:0000678;HP:0000207;HP:0000348;HP:0004322;HP:0000347;HP:0000463;HP:0009882;HP:0011001;HP:0002007;HP:0003027;HP:0000405;HP:0011800;HP:0000407;HP:0030084;HP:0000219;HP:0000316;HP:0000343;HP:0000256;HP:0003196;HP:0000689;HP:0001537;HP:0002684	Hemivertebrae;Coxa vara;Long palpebral fissure;Anteverted nares;Hypoplasia of penis;Ptosis;Depressed nasal bridge;Blue sclerae;Global developmental delay;Hypodontia;Ridged fingernail;Anodontia;Specific learning disability;Hip dysplasia;Midface retrusion;Hypoplastic labia minora;Epicanthus;Intellectual disability;Curly eyelashes;Short nose;Onychogryposis of fingernail;Finger syndactyly;Sacral dimple;Coxa valga;Severe short stature;Frontal bossing;Wide nose;Short palm;Femoral hernia;Retrognathia;Hearing impairment;High, narrow palate;Gingival overgrowth;Micrognathia;Downslanted palpebral fissures;Macrocephaly;Oligodontia;Downturned corners of mouth;Short philtrum;Hypospadias;Increased number of teeth;Prominent forehead;Clitoral hypoplasia;Long eyelashes;Cryptorchidism;Hip dislocation;Hypoplastic labia majora;Camptodactyly of finger;Pectus excavatum;Pectus carinatum;Avascular necrosis of the capital femoral epiphysis;Scoliosis;Fingernail dysplasia;Naevus flammeus of the eyelid;Capillary hemangioma;Median cleft lip and palate;Posteriorly rotated ears;Clinodactyly of the 5th finger;Alopecia;Micromelia;Hypertelorism;Umbilical hernia;Proptosis;Upslanted palpebral fissure;Low-set ears;Inguinal hernia;Short neck;Brachydactyly;Bifid tongue;Long philtrum;Wide nasal bridge;Elbow dislocation;Euryblepharon;Epispadias;Open bite;Strabismus;Hypoplastic labia majora;Frontal bossing;Umbilical hernia;Delayed eruption of teeth;Short palm;Proptosis;Thin upper lip vermilion;Hydronephrosis;Pectus excavatum;Triangular mouth;Micrognathia;Narrow palate;Oral cleft;Global developmental delay;Dental crowding;Broad toe;Epicanthus;Duplication of the distal phalanx of hand;Flat face;Macrocephaly;Hypertelorism;Brachydactyly;Inguinal hernia;Intellectual disability;Wide nasal bridge;Macroglossia;Midface retrusion;Upslanted palpebral fissure;Long palpebral fissure;Low-set ears;Delayed skeletal maturation;Radial deviation of finger;Malar flattening;Gingival overgrowth;Bifid distal phalanx of toe;Clitoral hypoplasia;Posteriorly rotated ears;Downturned corners of mouth;Bifid tongue;Mesomelia;Cryptorchidism;Depressed nasal bridge;Broad thumb;Anteverted nares;Long eyelashes;Nevus flammeus;Rhizomelia;Anteverted nares;Renal duplication;Short hard palate;Downslanted palpebral fissures;Micropenis;Long philtrum;Short middle phalanx of the 5th finger;Autosomal dominant inheritance;Nail dysplasia;Short neck;Small hand;Wide anterior fontanel;Clinodactyly;Retrognathia;Right ventricular outlet tract obstruction;Short nose;High palate;Micropenis;Gingival overgrowth;Autosomal dominant inheritance;Congenital onset;Cryptorchidism;Proptosis;Brachydactyly;Broad thumb;Dental crowding;Triangular mouth;High forehead;Short stature;Micrognathia;Anteverted nares;Short distal phalanx of finger;Increased bone mineral density;Frontal bossing;Mesomelia;Conductive hearing impairment;Midface retrusion;Sensorineural hearing impairment;Clinodactyly;Thin upper lip vermilion;Hypertelorism;Long philtrum;Macrocephaly;Short nose;Dental malocclusion;Umbilical hernia;Thickened calvaria	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;stomach;testis;lens;pituitary gland;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;muscle;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;liver;cartilage;endometrium;bone;germinal center;brain;bone marrow;lung;salivary gland;ovary;thyroid;macula lutea;colon;placenta;prostate;optic nerve;hypothalamus;medulla oblongata;	prefrontal cortex;skeletal muscle;	0.43	N	N	S	N	0.987808131388244	E	Dvl1	hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0607	0.1573	0.1571	0.064	0.1321	0.0888578	0.0575	0.0090943	0.067323	PASS	0	0.055	49	0.052817	11	chr1	1340336	NA	T	A	945.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=4.7;AS_FS=1.961;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.14;AS_ReadPosRankSum=-1.4;AS_SOR=0.985;BaseQRankSum=4.79;DP=77;ExcessHet=3.0103;FS=1.961;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.13;ReadPosRankSum=-1.396;SOR=0.985	GT:AD:DP:GQ:PL	0/1:39,33:72:99:953,0,951
chr1	1342153	1342153	T	C	DVL1	exonic	synonymous SNV	NA	DVL1:NM_001330311:exon4:c.A366G:p.P122P,DVL1:NM_004421:exon4:c.A366G:p.P122P	1	GnomAdGenome_AF_ami	806	142	HomozygousVariant	hom	83	0	83	1	2278.06	PASS	NA	[MIM:616331]Robinow syndrome, autosomal dominant 2 [dominant?];	601365	Benign	Autosomal dominant Robinow syndrome	Disease-causing germline mutation(s) in	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];	HP:0002937;HP:0002812;HP:0000637;HP:0000463;HP:0008736;HP:0000508;HP:0005280;HP:0000592;HP:0001263;HP:0000668;HP:0008402;HP:0000674;HP:0001328;HP:0001385;HP:0011800;HP:0000064;HP:0000286;HP:0001249;HP:0007665;HP:0003196;HP:0040036;HP:0006101;HP:0000960;HP:0002673;HP:0003510;HP:0002007;HP:0000445;HP:0004279;HP:0100541;HP:0000278;HP:0000365;HP:0002705;HP:0000212;HP:0000347;HP:0000494;HP:0000256;HP:0000677;HP:0002714;HP:0000322;HP:0000047;HP:0011069;HP:0011220;HP:0000060;HP:0000527;HP:0000028;HP:0002827;HP:0000059;HP:0100490;HP:0000767;HP:0000768;HP:0005743;HP:0002650;HP:0100798;HP:0010733;HP:0005306;HP:0008501;HP:0000358;HP:0004209;HP:0001596;HP:0002983;HP:0000316;HP:0001537;HP:0000520;HP:0000582;HP:0000369;HP:0000023;HP:0000470;HP:0001156;HP:0010297;HP:0000343;HP:0000431;HP:0003042;HP:0012905;HP:0000039;HP:0010807;HP:0000486;HP:0000059;HP:0002007;HP:0001537;HP:0000684;HP:0004279;HP:0000520;HP:0000219;HP:0000126;HP:0000767;HP:0000207;HP:0000347;HP:0000189;HP:0000202;HP:0001263;HP:0000678;HP:0001837;HP:0000286;HP:0009883;HP:0012368;HP:0000256;HP:0000316;HP:0001156;HP:0000023;HP:0001249;HP:0000431;HP:0000158;HP:0011800;HP:0000582;HP:0000637;HP:0000369;HP:0002750;HP:0009466;HP:0000272;HP:0000212;HP:0001853;HP:0000060;HP:0000358;HP:0002714;HP:0010297;HP:0003027;HP:0000028;HP:0005280;HP:0011304;HP:0000463;HP:0000527;HP:0001052;HP:0008905;HP:0000463;HP:0000075;HP:0010290;HP:0000494;HP:0000054;HP:0000343;HP:0004220;HP:0000006;HP:0002164;HP:0000470;HP:0200055;HP:0000260;HP:0030084;HP:0000278;HP:0001705;HP:0003196;HP:0000218;HP:0000054;HP:0000212;HP:0000006;HP:0003577;HP:0000028;HP:0000520;HP:0001156;HP:0011304;HP:0000678;HP:0000207;HP:0000348;HP:0004322;HP:0000347;HP:0000463;HP:0009882;HP:0011001;HP:0002007;HP:0003027;HP:0000405;HP:0011800;HP:0000407;HP:0030084;HP:0000219;HP:0000316;HP:0000343;HP:0000256;HP:0003196;HP:0000689;HP:0001537;HP:0002684	Hemivertebrae;Coxa vara;Long palpebral fissure;Anteverted nares;Hypoplasia of penis;Ptosis;Depressed nasal bridge;Blue sclerae;Global developmental delay;Hypodontia;Ridged fingernail;Anodontia;Specific learning disability;Hip dysplasia;Midface retrusion;Hypoplastic labia minora;Epicanthus;Intellectual disability;Curly eyelashes;Short nose;Onychogryposis of fingernail;Finger syndactyly;Sacral dimple;Coxa valga;Severe short stature;Frontal bossing;Wide nose;Short palm;Femoral hernia;Retrognathia;Hearing impairment;High, narrow palate;Gingival overgrowth;Micrognathia;Downslanted palpebral fissures;Macrocephaly;Oligodontia;Downturned corners of mouth;Short philtrum;Hypospadias;Increased number of teeth;Prominent forehead;Clitoral hypoplasia;Long eyelashes;Cryptorchidism;Hip dislocation;Hypoplastic labia majora;Camptodactyly of finger;Pectus excavatum;Pectus carinatum;Avascular necrosis of the capital femoral epiphysis;Scoliosis;Fingernail dysplasia;Naevus flammeus of the eyelid;Capillary hemangioma;Median cleft lip and palate;Posteriorly rotated ears;Clinodactyly of the 5th finger;Alopecia;Micromelia;Hypertelorism;Umbilical hernia;Proptosis;Upslanted palpebral fissure;Low-set ears;Inguinal hernia;Short neck;Brachydactyly;Bifid tongue;Long philtrum;Wide nasal bridge;Elbow dislocation;Euryblepharon;Epispadias;Open bite;Strabismus;Hypoplastic labia majora;Frontal bossing;Umbilical hernia;Delayed eruption of teeth;Short palm;Proptosis;Thin upper lip vermilion;Hydronephrosis;Pectus excavatum;Triangular mouth;Micrognathia;Narrow palate;Oral cleft;Global developmental delay;Dental crowding;Broad toe;Epicanthus;Duplication of the distal phalanx of hand;Flat face;Macrocephaly;Hypertelorism;Brachydactyly;Inguinal hernia;Intellectual disability;Wide nasal bridge;Macroglossia;Midface retrusion;Upslanted palpebral fissure;Long palpebral fissure;Low-set ears;Delayed skeletal maturation;Radial deviation of finger;Malar flattening;Gingival overgrowth;Bifid distal phalanx of toe;Clitoral hypoplasia;Posteriorly rotated ears;Downturned corners of mouth;Bifid tongue;Mesomelia;Cryptorchidism;Depressed nasal bridge;Broad thumb;Anteverted nares;Long eyelashes;Nevus flammeus;Rhizomelia;Anteverted nares;Renal duplication;Short hard palate;Downslanted palpebral fissures;Micropenis;Long philtrum;Short middle phalanx of the 5th finger;Autosomal dominant inheritance;Nail dysplasia;Short neck;Small hand;Wide anterior fontanel;Clinodactyly;Retrognathia;Right ventricular outlet tract obstruction;Short nose;High palate;Micropenis;Gingival overgrowth;Autosomal dominant inheritance;Congenital onset;Cryptorchidism;Proptosis;Brachydactyly;Broad thumb;Dental crowding;Triangular mouth;High forehead;Short stature;Micrognathia;Anteverted nares;Short distal phalanx of finger;Increased bone mineral density;Frontal bossing;Mesomelia;Conductive hearing impairment;Midface retrusion;Sensorineural hearing impairment;Clinodactyly;Thin upper lip vermilion;Hypertelorism;Long philtrum;Macrocephaly;Short nose;Dental malocclusion;Umbilical hernia;Thickened calvaria	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;stomach;testis;lens;pituitary gland;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;muscle;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;liver;cartilage;endometrium;bone;germinal center;brain;bone marrow;lung;salivary gland;ovary;thyroid;macula lutea;colon;placenta;prostate;optic nerve;hypothalamus;medulla oblongata;	prefrontal cortex;skeletal muscle;	0.43	N	N	S	N	0.987808131388244	E	Dvl1	hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	NA	NA	NA	NA	0.9961	0.9998	1	0.9966	1	0.998003	0.9991	0.0001153	1	PASS	1	0.999	1	1	0	chr1	1342153	NA	T	C	2278.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.45;AS_ReadPosRankSum=.;AS_SOR=0.717;DP=83;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.45;SOR=0.717	GT:AD:DP:GQ:PL	1/1:0,83:83:99:2292,248,0
chr1	1355780	1355780	A	-	MXRA8	intronic	NA	NA	NA	1	GnomAdExome_AF	203	70	HomozygousVariant	hom	14	0	14	1	503.03	PASS	NA	NA	617293	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];Intraocular pressure[29617998;29617998];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;substantia nigra;iris;liver;cartilage;endometrium;bone;parathyroid;brain;heart;lung;ovary;thyroid;macula lutea;colon;placenta;prostate;nasopharynx;optic nerve;	ciliary ganglion;dorsal root ganglion;adipose tissue;atrioventricular node;trigeminal ganglion;superior cervical ganglion;skeletal muscle;	NA	NA	N	N	N	0.11437135981131	N	Mxra8	normal phenotype; 	NA	NA	NA	NA	1	1	1	0.9953	0.9979	1	0.9954	0.0580523	1	PASS	0	0.993	1	0.886076	0	chr1	1355779	NA	GA	G	503.03	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=31.67;AS_ReadPosRankSum=.;AS_SOR=1.329;DP=19;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.53;SOR=1.329	GT:AD:DP:GQ:PL	1/1:0,14:14:42:517,42,0
chr1	1361311	1361311	C	G	MXRA8	UTR5	NA	NM_001282583:c.-48G>C	NA	0.9896	GnomAdExome_AF_afr	186	115	HomozygousVariant	hom	59	0	59	1	1630.06	PASS	NA	NA	617293	NA	NA	NA	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];Intraocular pressure[29617998;29617998];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;substantia nigra;iris;liver;cartilage;endometrium;bone;parathyroid;brain;heart;lung;ovary;thyroid;macula lutea;colon;placenta;prostate;nasopharynx;optic nerve;	ciliary ganglion;dorsal root ganglion;adipose tissue;atrioventricular node;trigeminal ganglion;superior cervical ganglion;skeletal muscle;	NA	NA	N	N	N	0.11437135981131	N	Mxra8	normal phenotype; 	NA	NA	NA	NA	0.961	0.9896	0.9883	0.9721	0.9883	0.951478	0	0.284731	0		0	0.942	20	0.901409	26	chr1	1361311	NA	C	G	1630.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.63;AS_ReadPosRankSum=.;AS_SOR=1.217;DP=62;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.63;SOR=1.217	GT:AD:DP:GQ:PL	1/1:0,59:59:99:1644,176,0
chr1	1374694	1374694	C	G	AURKAIP1	intronic	NA	NA	NA	0.9675	GnomAdExome_AF_asj	486	113	HomozygousVariant	hom	110	0	110	1	3297.06	PASS	NA	NA	609183	NA	Acromegaly;Prolactinoma;Familial isolated pituitary adenoma;Silent pituitary adenoma;Null pituitary adenoma	Major susceptibility factor in;Major susceptibility factor in;Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in	Inflammatory bowel disease[28067908];Ulcerative colitis[28067908];Intraocular pressure[29617998;29617998];	HP:0040278;HP:0000822;HP:0000845;HP:0000870;HP:0006767;HP:0000006;HP:0001428;HP:0002893;HP:0000858;HP:0011760;HP:0030269;HP:0001638;HP:0000280;HP:0001712;HP:0100829;HP:0000876;HP:0001065;HP:0002808;HP:0001058;HP:0001575;HP:0040270;HP:0001007;HP:0000939;HP:0001948;HP:0031364;HP:0003154;HP:0012743;HP:0000007;HP:0001513;HP:0000969;HP:0000822;HP:0001345;HP:0100852;HP:0002953;HP:0003202;HP:0000006;HP:0000787;HP:0000978;HP:0002893;HP:0004586;HP:0000963;HP:0001041;HP:0002900;HP:0000975;HP:0001653;HP:0100021;HP:0001386;HP:0000445;HP:0004099;HP:0030265;HP:0000716;HP:0000158;HP:0000822;HP:0003416;HP:0008388;HP:0001639;HP:0002007;HP:0001061;HP:0010535;HP:0011760;HP:0000956;HP:0000337;HP:0000280;HP:0002076;HP:0100786;HP:0001231;HP:0000664;HP:0000303;HP:0002758;HP:0012378;HP:0001176;HP:0000040;HP:0100540;HP:0100518;HP:0000802;HP:0001182;HP:0003859;HP:0007440;HP:0000293;HP:0003401;HP:0002808;HP:0000098;HP:0000845;HP:0001869;HP:0000830;HP:0000819;HP:0000044;HP:0000179;HP:0002829;HP:0006191;HP:0000400;HP:0001769;HP:0000687;HP:0000739;HP:0002230;HP:0012802;HP:0100607;HP:0100829;HP:0006767;HP:0000276;HP:0001609;HP:0000618;HP:0000044;HP:0000141;HP:0007942;HP:0000858;HP:0003388;HP:0006897;HP:0030016;HP:0001117;HP:0002920;HP:0000845;HP:0002321;HP:0030521;HP:0100829;HP:0002315;HP:0002615;HP:0030018;HP:0008240;HP:0012246;HP:0000980;HP:0000134;HP:0000802;HP:0000868;HP:0008245;HP:0000938;HP:0000823;HP:0001250;HP:0000529;HP:0011735;HP:0011362;HP:0012378;HP:0007011;HP:0000939;HP:0012041;HP:0000026;HP:0000508;HP:0000771;HP:0002013;HP:0011748;HP:0000651;HP:0000141;HP:0030269;HP:0000280;HP:0000870;HP:0001712;HP:0001833;HP:0000975;HP:0001639;HP:0005978;HP:0011760;HP:0000845;HP:0000303;HP:0005616;HP:0006767;HP:0001176;HP:0012411;HP:0002007;HP:0100829;HP:0011407	Prolactinoma;Hypertension;Growth hormone excess;Increased circulating prolactin concentration;Pituitary prolactin cell adenoma;Autosomal dominant inheritance;Somatic mutation;Pituitary adenoma;Irregular menstruation;Pituitary growth hormone cell adenoma;Increased serum insulin-like growth factor 1;Cardiomyopathy;Coarse facial features;Left ventricular hypertrophy;Galactorrhea;Oligomenorrhea;Striae distensae;Kyphosis;Poor wound healing;Mood changes;Impaired glucose tolerance;Hirsutism;Osteoporosis;Alkalosis;Ecchymosis;Increased circulating ACTH level;Abdominal obesity;Autosomal recessive inheritance;Obesity;Edema;Hypertension;Psychotic mentation;Abnormal fear/anxiety-related behavior;Vertebral compression fractures;Skeletal muscle atrophy;Autosomal dominant inheritance;Nephrolithiasis;Bruising susceptibility;Pituitary adenoma;Biconcave vertebral bodies;Thin skin;Facial erythema;Hypokalemia;Hyperhidrosis;Mitral regurgitation;Cerebral palsy;Joint swelling;Wide nose;Macrodactyly;Wide penis;Depressivity;Macroglossia;Hypertension;Spinal canal stenosis;Abnormal toenail morphology;Hypertrophic cardiomyopathy;Frontal bossing;Acne;Sleep apnea;Pituitary growth hormone cell adenoma;Acanthosis nigricans;Broad forehead;Coarse facial features;Migraine;Hypersomnia;Abnormal fingernail morphology;Synophrys;Mandibular prognathia;Osteoarthritis;Fatigue;Large hands;Long penis;Palpebral edema;Dysuria;Impotence;Tapered finger;Cortical diaphyseal thickening of the upper limbs;Generalized hyperpigmentation;Full cheeks;Paresthesia;Kyphosis;Tall stature;Growth hormone excess;Deep plantar creases;Anterior hypopituitarism;Diabetes mellitus;Hypogonadotropic hypogonadism;Thick lower lip vermilion;Arthralgia;Deep palmar crease;Macrotia;Broad foot;Widely spaced teeth;Anxiety;Generalized hirsutism;Broad jaw;Dysmenorrhea;Galactorrhea;Pituitary prolactin cell adenoma;Long face;Hoarse voice;Blindness;Hypogonadotropic hypogonadism;Amenorrhea;Internal ophthalmoplegia;Irregular menstruation;Easy fatigability;Cranial nerve VI palsy;Dyspareunia;Sudden loss of visual acuity;Decreased circulating ACTH level;Growth hormone excess;Vertigo;Bitemporal hemianopia;Galactorrhea;Headache;Hypotension;Decreased female libido;Secondary growth hormone deficiency;Oculomotor nerve palsy;Pallor;Female hypogonadism;Impotence;Decreased fertility in females;Pituitary hypothyroidism;Osteopenia;Delayed puberty;Seizure;Progressive visual loss;Adrenocorticotropin deficient adrenal insufficiency;Abnormal hair quantity;Fatigue;Fourth cranial nerve palsy;Osteoporosis;Decreased fertility in males;Male hypogonadism;Ptosis;Gynecomastia;Vomiting;Adrenocorticotropic hormone deficiency;Diplopia;Amenorrhea;Increased serum insulin-like growth factor 1;Coarse facial features;Increased circulating prolactin concentration;Left ventricular hypertrophy;Long foot;Hyperhidrosis;Hypertrophic cardiomyopathy;Type II diabetes mellitus;Pituitary growth hormone cell adenoma;Growth hormone excess;Mandibular prognathia;Accelerated skeletal maturation;Pituitary prolactin cell adenoma;Large hands;Premature pubarche;Frontal bossing;Galactorrhea;Proportionate tall stature	NA	NA	NA	Ubiquitously expressed and especially highly expressed in heart, skeletal muscle and testis.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;pharynx;cornea;stomach;testis;choroid;kidney;uterus;pancreas;bile duct;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;liver;spleen;germinal center;heart;lung;salivary gland;synovium;placenta;optic nerve;thymus;intestine;skin;myocardium;lens;unclassifiable (Anatomical System);lymphoreticular;retina;muscle;mammary gland;umbilical cord;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;ovary;macula lutea;lymph node;frontal lobe;colon;prostate;breast;	liver;testis - seminiferous tubule;testis - interstitial;whole brain;testis;heart;	0.788	NA	E	E	N	0.852290266619608	E	Aurkaip1	NA	NA	NA	NA	NA	0.9113	0.9519	0.9519	0.8522	0.9657	0.829073	0.8594	0.0053492	0.892027	PASS	0	0.912	81	0.894366	28	chr1	1374694	NA	C	G	3297.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.97;AS_ReadPosRankSum=.;AS_SOR=0.73;DP=113;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.97;SOR=0.73	GT:AD:DP:GQ:PL	1/1:0,110:110:99:3311,330,0
chr1	1419135	1419135	C	G	ANKRD65	exonic	nonsynonymous SNV	NA	ANKRD65:NM_001145210:exon4:c.G1165C:p.E389Q	0.7647	GnomAdExome_AF_afr	23	5	HeterozygousVariant	het	92	51	39	0.423913043478261	903.64	PASS	0.299	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	NA	0.11437135981131	N	Ankrd65	NA	NA	NA	NA	NA	0.1679	0.7647	0.78	0.2931	0.7354	0.322883	0	0.0475479	0.234513	PASS	0.3	0.151	129	0.136691	28	chr1	1419135	NA	C	G	903.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=2.825;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.04;AS_ReadPosRankSum=0.2;AS_SOR=1.017;BaseQRankSum=-0.271;DP=95;ExcessHet=3.0103;FS=1.745;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.04;ReadPosRankSum=0.279;SOR=0.983	GT:AD:DP:GQ:PL	0/1:51,39:92:99:911,0,1276
chr1	1419214	1419214	A	G	ANKRD65	exonic	synonymous SNV	NA	ANKRD65:NM_001145210:exon4:c.T1086C:p.T362T	0.5162	GnomAdExome_AF_afr	23	4	HeterozygousVariant	het	109	54	55	0.504587155963303	1370.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	NA	0.11437135981131	N	Ankrd65	NA	NA	NA	NA	NA	0.1503	0.5162	0.5348	0.218	0.4941	0.249601	0	0.0426838	0.162522	PASS	0.197368	0.158	139	0.15493	36	chr1	1419214	NA	A	G	1370.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=4.764;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.58;AS_ReadPosRankSum=0.1;AS_SOR=1.165;BaseQRankSum=1.39;DP=113;ExcessHet=3.0103;FS=4.764;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.57;ReadPosRankSum=0.118;SOR=1.165	GT:AD:DP:GQ:PL	0/1:54,55:109:99:1378,0,1261
chr1	1420203	1420203	C	A	ANKRD65	exonic	nonsynonymous SNV	NA	ANKRD65:NM_001145210:exon3:c.G599T:p.G200V	0.5	GnomAdExome_AF_sas	31	10	HeterozygousVariant	het	17	9	8	0.470588235294118	155.64	PASS	21.2	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	D	D	P	NA	P	H	T	D	T	T	T	NA	D	T	T	T	T	.;.;	N	N	Ankyrin repeat-containing domain;Ankyrin repeat-containing domain	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	NA	0.11437135981131	N	Ankrd65	NA	NA	NA	NA	NA	0.1897	0.5	0.5	0.2102	0.4667	0.232228	0	0.0001153	0.153944	PASS	0.274194	0.18	36	0.163265	12	chr1	1420203	NA	C	A	155.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=4.752;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.18;AS_ReadPosRankSum=0.2;AS_SOR=1.815;BaseQRankSum=-0.233;DP=18;ExcessHet=3.0103;FS=4.752;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.16;ReadPosRankSum=0.234;SOR=1.815	GT:AD:DP:GQ:PL	0/1:9,8:17:99:163,0,205
chr1	1420416	1420416	C	T	ANKRD65	exonic	nonsynonymous SNV	NA	ANKRD65:NM_001145210:exon3:c.G386A:p.R129H	0.1156	GnomAdGenome_AF_ami	15	7	HeterozygousVariant	het	17	7	10	0.588235294117647	188.64	PASS	14.19	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	P	B	NA	N	N	T	N	T	T	T	NA	D	T	T	T	D	.;.;	N	N	Ankyrin repeat-containing domain|Ankyrin repeat-containing domain|Ankyrin repeat-containing domain;Ankyrin repeat-containing domain|Ankyrin repeat-containing domain|Ankyrin repeat-containing domain	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	NA	0.11437135981131	N	Ankrd65	NA	NA	NA	NA	NA	0.0554	0.1026	0.0987	0.0347	0.1156	0.0535144	0	0.0096765	0.022777	PASS	0.11	0.101	87	0.127907	19	chr1	1420416	NA	C	T	188.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.12;AS_ReadPosRankSum=-0.2;AS_SOR=0.495;BaseQRankSum=-2.127;DP=17;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.1;ReadPosRankSum=-0.196;SOR=0.495	GT:AD:DP:GQ:PL	0/1:7,10:17:99:196,0,148
chr1	1426253	1426253	G	A	TMEM88B	exonic	synonymous SNV	NA	TMEM88B:NM_001146685:exon1:c.G126A:p.S42S	0.9006	GnomAdExome_AF_eas	154	37	HeterozygousVariant	het	79	29	50	0.632911392405063	1955.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.11437135981131	N	Tmem88b	NA	NA	NA	NA	NA	0.3112	0.9006	0.8967	0.1893	0.8657	0.39996	0	0.0001153	0.185811	PASS	0.314516	0.492	267	0.482143	61	chr1	1426253	NA	G	A	1955.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=7.898;AS_MQ=60;AS_MQRankSum=0;AS_QD=24.76;AS_ReadPosRankSum=3.4;AS_SOR=0.235;BaseQRankSum=-0.082;DP=81;ExcessHet=3.0103;FS=7.898;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=24.75;ReadPosRankSum=3.46;SOR=0.235	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:29,50:79:99:0|1:1426253_G_A:1963,0,963:1426253
chr1	1439454	1439454	A	G	VWA1	exonic	synonymous SNV	NA	VWA1:NM_022834:exon3:c.A1005G:p.P335P	0.9971	GnomAdGenome_AF_eas	282	62	HeterozygousVariant	het	48	25	23	0.479166666666667	608.64	PASS	NA	NA	611901	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;stomach;testis;brain;lens;unclassifiable (Anatomical System);lung;choroid;kidney;uterus;retina;macula lutea;colon;placenta;optic nerve;islets of Langerhans;	NA	NA	N	N	N	N	0.0208174400685481	N	Vwa1	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	NA	NA	NA	NA	0.316	0.9966	0.9969	0.4275	0.9971	0.669728	0	0.0001153	0.379397	PASS	0.409091	0.679	225	0.656934	56	chr1	1439454	NA	A	G	608.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.1;AS_FS=2.379;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.69;AS_ReadPosRankSum=1.6;AS_SOR=0.909;BaseQRankSum=2.1;DP=50;ExcessHet=3.0103;FS=2.379;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.68;ReadPosRankSum=1.69;SOR=0.909	GT:AD:DP:GQ:PL	0/1:25,23:48:99:616,0,550
chr1	1439805	1439805	G	C	VWA1	UTR3	NA	NM_022834:c.*18G>C;NM_199121:c.*766G>C	NA	0.8408	GnomAdGenome_AF_eas	53	35	HeterozygousVariant	het	15	7	8	0.533333333333333	177.64	PASS	NA	NA	611901	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;stomach;testis;brain;lens;unclassifiable (Anatomical System);lung;choroid;kidney;uterus;retina;macula lutea;colon;placenta;optic nerve;islets of Langerhans;	NA	NA	N	N	N	N	0.0208174400685481	N	Vwa1	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	NA	NA	NA	NA	0.1138	0.5	0	0.2553	0.8408	0.46266	0	0.0001153	0.248188	PASS	0	0.47	33	0.494318	17	chr1	1439805	NA	G	C	177.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.87;AS_ReadPosRankSum=-0.2;AS_SOR=0.495;BaseQRankSum=-0.633;DP=15;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.84;ReadPosRankSum=-0.112;SOR=0.495	GT:AD:DP:GQ:PL	0/1:7,8:15:99:185,0,217
chr1	1450636	1450636	A	G	ATAD3C	UTR5	NA	NM_001039211:c.-48A>G	NA	0.4311	GnomAdExome_AF_amr	46	22	HeterozygousVariant	het	24	11	13	0.541666666666667	272.64	PASS	NA	NA	617227	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.441	NA	N	N	N	0.0728655507034106	N	Atad3a	muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.2386	0.4311	0.4355	0.1792	0.3768	0.272564	0	0.185903	0.166949	VQSRTrancheSNP99.00to99.90	0	0.385	140	0.394366	68	chr1	1450636	NA	A	G	272.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=0;AS_MQ=57.9;AS_MQRankSum=-1.3;AS_QD=11.38;AS_ReadPosRankSum=0.1;AS_SOR=0.941;BaseQRankSum=-1.27;DP=27;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=59;MQRankSum=-1.268;QD=11.36;ReadPosRankSum=0.145;SOR=0.941	GT:AD:DP:GQ:PL	0/1:11,13:24:99:280,0,262
chr1	1452346	1452346	A	G	ATAD3C	intronic	NA	NA	NA	0.4942	GnomAdExome_AF_amr	45	19	HeterozygousVariant	het	82	51	31	0.378048780487805	611.64	PASS	NA	NA	617227	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.441	NA	N	N	N	0.0728655507034106	N	Atad3a	muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.2534	0.4942	0.4911	0.1942	0.3884	0.290535	0.1671	0.230767	0.197865	VQSRTrancheSNP99.00to99.90	0	0.384	141	0.387324	72	chr1	1452346	NA	A	G	611.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=0.852;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.46;AS_ReadPosRankSum=-1.8;AS_SOR=0.816;BaseQRankSum=0.94;DP=84;ExcessHet=3.0103;FS=0.852;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.46;ReadPosRankSum=-1.732;SOR=0.816	GT:AD:DP:GQ:PL	0/1:51,31:82:99:619,0,1130
chr1	1452384	1452384	G	A	ATAD3C	exonic	nonsynonymous SNV	NA	ATAD3C:NM_001039211:exon3:c.G172A:p.G58R	0.38	GnomAdGenome_AF_eas	77	18	HeterozygousVariant	het	116	70	46	0.396551724137931	929.64	PASS	29.8	NA	617227	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	D	D	D	D	D	P	M	D	D	T	T	T	NA	T	T	T	T	D	.;.;	D	D	ATPase family AAA domain-containing protein 3, domain of unknown function DUF3523;ATPase family AAA domain-containing protein 3, domain of unknown function DUF3523	NA	NA	Medium	Medium	Medium	NA	NA	0.441	NA	N	N	N	0.0728655507034106	N	Atad3a	muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.2345	0.373	0.3702	0.1869	0.38	0.279952	0.1649	0.217022	0.184729	VQSRTrancheSNP99.00to99.90	0.276515	0.382	227	0.383803	73	chr1	1452384	NA	G	A	929.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=0.707;AS_MQ=59.05;AS_MQRankSum=-0.7;AS_QD=8.02;AS_ReadPosRankSum=0.2;AS_SOR=0.811;BaseQRankSum=-0.098;DP=118;ExcessHet=3.0103;FS=0.707;MLEAC=1;MLEAF=0.5;MQ=59.2;MQRankSum=-0.615;QD=8.01;ReadPosRankSum=0.2;SOR=0.811	GT:AD:DP:GQ:PL	0/1:70,46:116:99:937,0,1656
chr1	1455495	1455495	C	T	ATAD3C	exonic	synonymous SNV	NA	ATAD3C:NM_001039211:exon5:c.C414T:p.D138D	0.5216	GnomAdExome_AF_amr	128	27	HeterozygousVariant	het	109	54	55	0.504587155963303	1153.64	PASS	NA	NA	617227	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.441	NA	N	N	N	0.0728655507034106	N	Atad3a	muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.3092	0.5216	0.5193	0.3085	0.5174	0.42512	0.2788	0.287079	0.289649	PASS	0.323077	0.452	277	0.454225	75	chr1	1455495	NA	C	T	1153.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=0.713;AS_MQ=56.77;AS_MQRankSum=-0.3;AS_QD=10.59;AS_ReadPosRankSum=0.2;AS_SOR=0.591;BaseQRankSum=0.246;DP=112;ExcessHet=3.0103;FS=0.713;MLEAC=1;MLEAF=0.5;MQ=56.91;MQRankSum=-0.209;QD=10.58;ReadPosRankSum=0.224;SOR=0.591	GT:AD:DP:GQ:PL	0/1:54,55:109:99:1161,0,1116
chr1	1471992	1471992	T	C	ATAD3B	exonic	synonymous SNV	NA	ATAD3B:NM_031921:exon1:c.T108C:p.G36G	0.9905	GnomAdGenome_AF_eas	188	43	HeterozygousVariant	het	79	41	38	0.481012658227848	800.64	PASS	NA	NA	612317	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Tends to be down-regulated in differentiated cells and re-expressed in pluripotent stem cells or cancer cells (at protein level). {ECO:0000269|PubMed:16909202, ECO:0000269|PubMed:22664726}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;tongue;skin;myocardium;stomach;testis;pituitary gland;lens;unclassifiable (Anatomical System);kidney;uterus;whole body;pancreas;muscle;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;brain;duodenum;lung;thyroid;lymph node;frontal lobe;colon;placenta;optic nerve;	NA	0.167	NA	N	N	N	0.935577982016194	E	Atad3a	muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.2289	0.65	1	0.4537	0.9905	0.6877	0	0.0001153	0.286127	VQSRTrancheSNP99.00to99.90	0.428571	0.544	128	0.518349	27	chr1	1471992	NA	T	C	800.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=0;AS_MQ=36.87;AS_MQRankSum=-7;AS_QD=10.14;AS_ReadPosRankSum=-0.2;AS_SOR=0.648;BaseQRankSum=-0.947;DP=82;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=46.55;MQRankSum=-6.962;QD=10.13;ReadPosRankSum=-0.162;SOR=0.648	GT:AD:DP:GQ:PL	0/1:41,38:79:99:808,0,965
chr1	1486536	1486536	T	C	ATAD3B	intronic	NA	NA	NA	0.3324	GnomAdExome_AF_afr	0	0	WT/SomaticVariant	het	133	107	26	0.195488721804511	256.64	QD2	NA	NA	612317	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Tends to be down-regulated in differentiated cells and re-expressed in pluripotent stem cells or cancer cells (at protein level). {ECO:0000269|PubMed:16909202, ECO:0000269|PubMed:22664726}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	High	High	High	thymus;tongue;skin;myocardium;stomach;testis;pituitary gland;lens;unclassifiable (Anatomical System);kidney;uterus;whole body;pancreas;muscle;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;brain;duodenum;lung;thyroid;lymph node;frontal lobe;colon;placenta;optic nerve;	NA	0.167	NA	N	N	N	0.935577982016194	E	Atad3a	muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.1891	0.3324	0.3372	0.0127	0.0407	0	0	0.0076066	0.135135	VQSRTrancheSNP99.00to99.90	0	0.311	187	0.31338	89	chr1	1486536	NA	T	C	256.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=0;AS_MQ=43.27;AS_MQRankSum=-3.8;AS_QD=1.93;AS_ReadPosRankSum=1.6;AS_SOR=0.635;BaseQRankSum=-1.137;DP=135;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=49.78;MQRankSum=-3.749;QD=1.93;ReadPosRankSum=1.67;SOR=0.635	GT:AD:DP:GQ:PL	0/1:107,26:133:99:264,0,2620
chr1	1512376	1512376	G	C	ATAD3A	exonic	synonymous SNV	NA	ATAD3A:NM_001170535:exon1:c.G108C:p.G36G,ATAD3A:NM_018188:exon1:c.G108C:p.G36G	0.7365	GnomAdGenome_AF_afr	67	16	HeterozygousVariant	het	84	54	30	0.357142857142857	645.64	PASS	NA	[MIM:617183]Harel-Yoon syndrome [dominant?] [recessive?];	612316	Benign	Optic atrophy-peripheral neuropathy-developmental delay syndrome	Disease-causing germline mutation(s) in	Body mass index[26426971];	HP:0001250;HP:0000303;HP:0000347;HP:0001249;HP:0000276;HP:0008936;HP:0003535;HP:0005656;HP:0000582;HP:0000348;HP:0000823;HP:0000648;HP:0001272;HP:0007957;HP:0007210;HP:0002360;HP:0003196;HP:0002151;HP:0002465;HP:0000609;HP:0000545;HP:0000518;HP:0000028;HP:0000768;HP:0002066;HP:0000490;HP:0000565;HP:0001263;HP:0001639;HP:0001385;HP:0002064;HP:0003477;HP:0000639;HP:0002650;HP:0011968;HP:0001249;HP:0000006;HP:0008936;HP:0000750;HP:0000648;HP:0000276;HP:0000347;HP:0000545;HP:0002121;HP:0011968;HP:0000768;HP:0002007;HP:0000303;HP:0000348;HP:0001290;HP:0002650;HP:0000565;HP:0001385;HP:0000639;HP:0003593;HP:0001263;HP:0000582;HP:0003477;HP:0003196;HP:0002540;HP:0001272;HP:0001639;HP:0001257;HP:0001760;HP:0000007;HP:0001251;HP:0000490;HP:0003693	Seizure;Mandibular prognathia;Micrognathia;Intellectual disability;Long face;Muscular hypotonia of the trunk;3-Methylglutaconic aciduria;Positional foot deformity;Upslanted palpebral fissure;High forehead;Delayed puberty;Optic atrophy;Cerebellar atrophy;Corneal opacity;Lower limb amyotrophy;Sleep disturbance;Short nose;Increased serum lactate;Poor speech;Optic nerve hypoplasia;Myopia;Cataract;Cryptorchidism;Pectus carinatum;Gait ataxia;Deeply set eye;Esotropia;Global developmental delay;Hypertrophic cardiomyopathy;Hip dysplasia;Spastic gait;Peripheral axonal neuropathy;Nystagmus;Scoliosis;Feeding difficulties;Intellectual disability;Autosomal dominant inheritance;Muscular hypotonia of the trunk;Delayed speech and language development;Optic atrophy;Long face;Micrognathia;Myopia;Generalized non-motor (absence) seizure;Feeding difficulties;Pectus carinatum;Frontal bossing;Mandibular prognathia;High forehead;Generalized hypotonia;Scoliosis;Esotropia;Hip dysplasia;Nystagmus;Infantile onset;Global developmental delay;Upslanted palpebral fissure;Peripheral axonal neuropathy;Short nose;Inability to walk;Cerebellar atrophy;Hypertrophic cardiomyopathy;Spasticity;Abnormality of the foot;Autosomal recessive inheritance;Ataxia;Deeply set eye;Distal amyotrophy	NA	NA	NA	Overexpressed in lung adenocarcinomas (at protein level). {ECO:0000269|PubMed:20332122}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;head and neck;germinal center;mammary gland;	superior cervical ganglion;skeletal muscle;	0.095	NA	N	N	N	0.735489525488829	E	Atad3a	muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.1265	0.7059	0.8333	0.3427	0.7365	0.46226	0	0.0001153	0.215686	VQSRTrancheSNP99.00to99.90	0.214286	0.238	195	0.252	31	chr1	1512376	NA	G	C	645.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=0;AS_MQ=39.17;AS_MQRankSum=-6.6;AS_QD=7.69;AS_ReadPosRankSum=-0.9;AS_SOR=0.624;BaseQRankSum=1.67;DP=86;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=48.68;MQRankSum=-6.505;QD=7.69;ReadPosRankSum=-0.803;SOR=0.624	GT:AD:DP:GQ:PL	0/1:54,30:84:99:653,0,1234
chr1	1512498	1512501	GCGG	-	ATAD3A	intronic	NA	NA	NA	0.0013	GnomAdGenome_AF_asj	1		WT/SomaticVariant	het	21	17	4	0.19047619047619	96.6	PASS	NA	[MIM:617183]Harel-Yoon syndrome [dominant?] [recessive?];	612316	NA	Optic atrophy-peripheral neuropathy-developmental delay syndrome	Disease-causing germline mutation(s) in	Body mass index[26426971];	HP:0001250;HP:0000303;HP:0000347;HP:0001249;HP:0000276;HP:0008936;HP:0003535;HP:0005656;HP:0000582;HP:0000348;HP:0000823;HP:0000648;HP:0001272;HP:0007957;HP:0007210;HP:0002360;HP:0003196;HP:0002151;HP:0002465;HP:0000609;HP:0000545;HP:0000518;HP:0000028;HP:0000768;HP:0002066;HP:0000490;HP:0000565;HP:0001263;HP:0001639;HP:0001385;HP:0002064;HP:0003477;HP:0000639;HP:0002650;HP:0011968;HP:0001249;HP:0000006;HP:0008936;HP:0000750;HP:0000648;HP:0000276;HP:0000347;HP:0000545;HP:0002121;HP:0011968;HP:0000768;HP:0002007;HP:0000303;HP:0000348;HP:0001290;HP:0002650;HP:0000565;HP:0001385;HP:0000639;HP:0003593;HP:0001263;HP:0000582;HP:0003477;HP:0003196;HP:0002540;HP:0001272;HP:0001639;HP:0001257;HP:0001760;HP:0000007;HP:0001251;HP:0000490;HP:0003693	Seizure;Mandibular prognathia;Micrognathia;Intellectual disability;Long face;Muscular hypotonia of the trunk;3-Methylglutaconic aciduria;Positional foot deformity;Upslanted palpebral fissure;High forehead;Delayed puberty;Optic atrophy;Cerebellar atrophy;Corneal opacity;Lower limb amyotrophy;Sleep disturbance;Short nose;Increased serum lactate;Poor speech;Optic nerve hypoplasia;Myopia;Cataract;Cryptorchidism;Pectus carinatum;Gait ataxia;Deeply set eye;Esotropia;Global developmental delay;Hypertrophic cardiomyopathy;Hip dysplasia;Spastic gait;Peripheral axonal neuropathy;Nystagmus;Scoliosis;Feeding difficulties;Intellectual disability;Autosomal dominant inheritance;Muscular hypotonia of the trunk;Delayed speech and language development;Optic atrophy;Long face;Micrognathia;Myopia;Generalized non-motor (absence) seizure;Feeding difficulties;Pectus carinatum;Frontal bossing;Mandibular prognathia;High forehead;Generalized hypotonia;Scoliosis;Esotropia;Hip dysplasia;Nystagmus;Infantile onset;Global developmental delay;Upslanted palpebral fissure;Peripheral axonal neuropathy;Short nose;Inability to walk;Cerebellar atrophy;Hypertrophic cardiomyopathy;Spasticity;Abnormality of the foot;Autosomal recessive inheritance;Ataxia;Deeply set eye;Distal amyotrophy	NA	NA	NA	Overexpressed in lung adenocarcinomas (at protein level). {ECO:0000269|PubMed:20332122}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;head and neck;germinal center;mammary gland;	superior cervical ganglion;skeletal muscle;	0.095	NA	N	N	N	0.735489525488829	E	Atad3a	muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0	0	0	0.00008164	0.0013	0	0	0	0		0	0.009109	7			chr1	1512497	NA	CGCGG	C	96.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=5.651;AS_MQ=57.88;AS_MQRankSum=2;AS_QD=4.62;AS_ReadPosRankSum=-0.5;AS_SOR=1.468;BaseQRankSum=-0.292;DP=32;ExcessHet=3.0103;FS=5.651;MLEAC=1;MLEAF=0.5;MQ=49.43;MQRankSum=2.07;QD=4.6;ReadPosRankSum=-0.426;SOR=1.468	GT:AD:DP:GQ:PL	0/1:17,4:21:99:104,0,664
chr1	1516000	1516000	T	C	ATAD3A	intronic	NA	NA	NA	0.7618	GnomAdExome_AF_afr	51	21	HeterozygousVariant	het	67	31	36	0.537313432835821	787.64	PASS	NA	[MIM:617183]Harel-Yoon syndrome [dominant?] [recessive?];	612316	NA	Optic atrophy-peripheral neuropathy-developmental delay syndrome	Disease-causing germline mutation(s) in	Body mass index[26426971];	HP:0001250;HP:0000303;HP:0000347;HP:0001249;HP:0000276;HP:0008936;HP:0003535;HP:0005656;HP:0000582;HP:0000348;HP:0000823;HP:0000648;HP:0001272;HP:0007957;HP:0007210;HP:0002360;HP:0003196;HP:0002151;HP:0002465;HP:0000609;HP:0000545;HP:0000518;HP:0000028;HP:0000768;HP:0002066;HP:0000490;HP:0000565;HP:0001263;HP:0001639;HP:0001385;HP:0002064;HP:0003477;HP:0000639;HP:0002650;HP:0011968;HP:0001249;HP:0000006;HP:0008936;HP:0000750;HP:0000648;HP:0000276;HP:0000347;HP:0000545;HP:0002121;HP:0011968;HP:0000768;HP:0002007;HP:0000303;HP:0000348;HP:0001290;HP:0002650;HP:0000565;HP:0001385;HP:0000639;HP:0003593;HP:0001263;HP:0000582;HP:0003477;HP:0003196;HP:0002540;HP:0001272;HP:0001639;HP:0001257;HP:0001760;HP:0000007;HP:0001251;HP:0000490;HP:0003693	Seizure;Mandibular prognathia;Micrognathia;Intellectual disability;Long face;Muscular hypotonia of the trunk;3-Methylglutaconic aciduria;Positional foot deformity;Upslanted palpebral fissure;High forehead;Delayed puberty;Optic atrophy;Cerebellar atrophy;Corneal opacity;Lower limb amyotrophy;Sleep disturbance;Short nose;Increased serum lactate;Poor speech;Optic nerve hypoplasia;Myopia;Cataract;Cryptorchidism;Pectus carinatum;Gait ataxia;Deeply set eye;Esotropia;Global developmental delay;Hypertrophic cardiomyopathy;Hip dysplasia;Spastic gait;Peripheral axonal neuropathy;Nystagmus;Scoliosis;Feeding difficulties;Intellectual disability;Autosomal dominant inheritance;Muscular hypotonia of the trunk;Delayed speech and language development;Optic atrophy;Long face;Micrognathia;Myopia;Generalized non-motor (absence) seizure;Feeding difficulties;Pectus carinatum;Frontal bossing;Mandibular prognathia;High forehead;Generalized hypotonia;Scoliosis;Esotropia;Hip dysplasia;Nystagmus;Infantile onset;Global developmental delay;Upslanted palpebral fissure;Peripheral axonal neuropathy;Short nose;Inability to walk;Cerebellar atrophy;Hypertrophic cardiomyopathy;Spasticity;Abnormality of the foot;Autosomal recessive inheritance;Ataxia;Deeply set eye;Distal amyotrophy	NA	NA	NA	Overexpressed in lung adenocarcinomas (at protein level). {ECO:0000269|PubMed:20332122}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0.004	Medium	Medium	Medium	tongue;head and neck;germinal center;mammary gland;	superior cervical ganglion;skeletal muscle;	0.095	NA	N	N	N	0.735489525488829	E	Atad3a	muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.276	0.7618	0.7657	0.3574	0.7406	0.470847	0.3385	0.262733	0.314784	PASS	0	0.308	190	0.387324	68	chr1	1516000	NA	T	C	787.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0.941;AS_MQ=59.07;AS_MQRankSum=0.1;AS_QD=11.76;AS_ReadPosRankSum=0.3;AS_SOR=0.57;BaseQRankSum=-0.436;DP=69;ExcessHet=3.0103;FS=0.941;MLEAC=1;MLEAF=0.5;MQ=59.32;MQRankSum=0.107;QD=11.76;ReadPosRankSum=0.39;SOR=0.57	GT:AD:DP:GQ:PL	0/1:31,36:67:99:795,0,687
chr1	1543953	1543953	A	G	SSU72	exonic	synonymous SNV	NA	SSU72:NM_014188:exon4:c.T399C:p.P133P	0.881	GnomAdExome_AF_eas	308	66	HeterozygousVariant	het	60	33	27	0.45	543.64	PASS	NA	NA	617680	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Low	Low	Low	pharynx;stomach;testis;choroid;kidney;uterus;whole body;pancreas;adrenal gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;iris;spleen;liver;peripheral nerve;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;thymus;intestine;epididymis;tongue;alveolus;spinal ganglion;skin;myocardium;lens;pituitary gland;unclassifiable (Anatomical System);cerebellum;retina;muscle;head and neck;mammary gland;cervix;pineal body;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;ovary;macula lutea;lymph node;bladder;colon;aorta;prostate;breast;hypothalamus;	amygdala;whole brain;atrioventricular node;	0.508	NA	E	E	E	0.964462658328966	E	Ssu72	NA	NA	NA	NA	NA	0.4596	0.881	0.8843	0.4917	0.8728	0.69369	0.4718	0.444289	0.455665	PASS	0.606061	0.713	220	0.672535	59	chr1	1543953	NA	A	G	543.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=0.996;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.07;AS_ReadPosRankSum=-0.1;AS_SOR=0.498;BaseQRankSum=-0.899;DP=60;ExcessHet=3.0103;FS=0.996;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.06;ReadPosRankSum=-0.037;SOR=0.498	GT:AD:DP:GQ:PL	0/1:33,27:60:99:551,0,781
chr1	1574445	1574445	A	G	SSU72	intronic	NA	NA	NA	0.881	GnomAdExome_AF_eas	304	69	HomozygousVariant	hom	56	0	56	1	1547.06	PASS	NA	NA	617680	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Low	Low	Low	pharynx;stomach;testis;choroid;kidney;uterus;whole body;pancreas;adrenal gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;iris;spleen;liver;peripheral nerve;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;thymus;intestine;epididymis;tongue;alveolus;spinal ganglion;skin;myocardium;lens;pituitary gland;unclassifiable (Anatomical System);cerebellum;retina;muscle;head and neck;mammary gland;cervix;pineal body;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;ovary;macula lutea;lymph node;bladder;colon;aorta;prostate;breast;hypothalamus;	amygdala;whole brain;atrioventricular node;	0.508	NA	E	E	E	0.964462658328966	E	Ssu72	NA	NA	NA	NA	NA	0.4541	0.881	0.882	0.5046	0.874	0.701278	0.481	0.419503	0.47708	PASS	0	0.711	213	0.697183	60	chr1	1574445	NA	A	G	1547.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.63;AS_ReadPosRankSum=.;AS_SOR=0.922;DP=59;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.63;SOR=0.922	GT:AD:DP:GQ:PL	1/1:0,56:56:99:1561,168,0
chr1	1623412	1623412	T	C	MIB2	exonic	nonsynonymous SNV	NA	MIB2:NM_001170686:exon3:c.T134C:p.M45T,MIB2:NM_001170688:exon3:c.T305C:p.M102T,MIB2:NM_080875:exon3:c.T134C:p.M45T	0.9807	GnomAdGenome_AF_asj	351	92	HeterozygousVariant	het	64	39	25	0.390625	512.64	PASS	0.488	NA	611141	Benign	Left ventricular noncompaction	Major susceptibility factor in	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed in skeletal muscle, and to a lesser extent in heart, brain and kidney. {ECO:0000269|PubMed:14507647}.;	T	T	NA	NA	U	P	NA	T	N	T	T	T	NA	T	NA	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	cervix;hippocampus;spleen;endometrium;skin;stomach;bone;testis;parathyroid;brain;unclassifiable (Anatomical System);lung;kidney;uterus;thyroid;pancreas;colon;prostate;breast;islets of Langerhans;visual apparatus;	NA	0.153	N	N	N	N	0.990583330011819	E	Mib2	homeostasis/metabolism phenotype; growth/size/body region phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	NA	NA	NA	NA	0.8671	0.9378	0.9383	0.8638	0.9807	0.773562	0.8856	0.813735	0.898829	PASS	0.95	0.845	131	0.812057	45	chr1	1623412	NA	T	C	512.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0.996;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.02;AS_ReadPosRankSum=-0.5;AS_SOR=0.495;BaseQRankSum=0.082;DP=64;ExcessHet=3.0103;FS=0.996;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.01;ReadPosRankSum=-0.427;SOR=0.495	GT:AD:DP:GQ:PL	0/1:39,25:64:99:520,0,974
chr1	1634663	1634663	C	G	CDK11B;MMP23A;MMP23B	downstream	NA	dist=562	NA	0.4898	GnomAdGenome_AF_asj			HeterozygousVariant	het	3	1	2	0.666666666666667	32.64	DP10;MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4004	0.4898	0	0	0.0255042	0		0					chr1	1634663	NA	C	G	32.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=0;AS_MQ=27;AS_MQRankSum=0;AS_QD=11;AS_ReadPosRankSum=0;AS_SOR=0.223;BaseQRankSum=-0.967;DP=3;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=27;MQRankSum=0;QD=10.88;ReadPosRankSum=0;SOR=0.223	GT:AD:DP:GQ:PL	0/1:1,2:3:23:40,0,23
chr1	1640475	1640475	C	G	CDK11B	intronic	NA	NA	NA	0.4274	GnomAdExome_AF_asj	0	0	HeterozygousVariant	het	128	86	42	0.328125	654.64	PASS	NA	NA	176873	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;epididymis;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;pancreas;head and neck;mammary gland;skeletal muscle;islets of Langerhans;epidermis;foreskin;tonsil;cervix;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	E	NA	NA	NA	0.781199836008485	E	Cdk11b	embryo phenotype; neoplasm; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cellular phenotype; 	NA	NA	NA	NA	0.3922	0.3998	0.3994	0.3485	0.389	0	0	0.0109766	0.331218	VQSRTrancheSNP99.00to99.90	0	0.384	399	0.420863	117	chr1	1640475	NA	C	G	654.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.7;AS_FS=10.541;AS_MQ=40.62;AS_MQRankSum=-0.6;AS_QD=5.12;AS_ReadPosRankSum=-1.5;AS_SOR=0.423;BaseQRankSum=-2.68;DP=130;ExcessHet=3.0103;FS=10.541;MLEAC=1;MLEAF=0.5;MQ=41.14;MQRankSum=-0.565;QD=5.11;ReadPosRankSum=-1.454;SOR=0.423	GT:AD:DP:GQ:PL	0/1:86,42:128:99:662,0,1954
chr1	1645163	1645163	T	C	CDK11B	exonic	synonymous SNV	NA	CDK11B:NM_001291345:exon6:c.A564G:p.A188A,CDK11B:NM_001787:exon6:c.A594G:p.A198A,CDK11B:NM_033486:exon6:c.A594G:p.A198A,CDK11B:NM_033489:exon7:c.A492G:p.A164A	0.1897	GnomAdGenome_AF_asj			HomozygousVariant	hom	2	0	2	1	56.32	DP10;MQ40	NA	NA	176873	Likely benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;epididymis;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;pancreas;head and neck;mammary gland;skeletal muscle;islets of Langerhans;epidermis;foreskin;tonsil;cervix;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	E	NA	NA	NA	0.781199836008485	E	Cdk11b	embryo phenotype; neoplasm; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cellular phenotype; 	NA	NA	NA	NA	0	0	0	0.1109	0.1897	0	0	0.0248962	0		0					chr1	1645163	NA	T	C	56.32	DP10;MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=39;AS_MQRankSum=.;AS_QD=28;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=2;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=39;QD=28.16;SOR=2.303	GT:AD:DP:GQ:PL	1/1:0,2:2:6:68,6,0
chr1	1657220	1657220	G	A	CDK11B	intronic	NA	NA	NA	0.4949	GnomAdGenome_AF_nfe	0	0	WT/SomaticVariant	het	50	44	6	0.12	59.64	QD2	NA	NA	176873	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;epididymis;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;pancreas;head and neck;mammary gland;skeletal muscle;islets of Langerhans;epidermis;foreskin;tonsil;cervix;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	E	NA	NA	NA	0.781199836008485	E	Cdk11b	embryo phenotype; neoplasm; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cellular phenotype; 	NA	NA	NA	NA	0.4124	0.456	0.4589	0.4596	0.4949	0	0	0.1712	0		0	0.13	47	0.411765	56	chr1	1657220	NA	G	A	59.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=4.959;AS_MQ=53.24;AS_MQRankSum=-3.9;AS_QD=1.2;AS_ReadPosRankSum=-0.3;AS_SOR=2.34;BaseQRankSum=0.582;DP=51;ExcessHet=3.0103;FS=4.959;MLEAC=1;MLEAF=0.5;MQ=59.25;MQRankSum=-3.825;QD=1.19;ReadPosRankSum=-0.209;SOR=2.34	GT:AD:DP:GQ:PL	0/1:44,6:50:67:67,0,1275
chr1	1668373	1668373	C	T	SLC35E2B	exonic	nonsynonymous SNV	NA	SLC35E2B:NM_001110781:exon8:c.G934A:p.V312I,SLC35E2B:NM_001290264:exon9:c.G934A:p.V312I	0.6204	GnomAdGenome_AF_amr	30	11	WT/SomaticVariant	het	119	106	13	0.109243697478992	87.64	QD2	15.15	NA	NA	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	T	B	B	D	P	NA	NA	NA	T	T	T	NA	T	T	T	T	T	.;.;	D	N	Sugar phosphate transporter domain;Sugar phosphate transporter domain	NA	NA	Medium	Medium	Medium	thymus;endometrium;skin;stomach;germinal center;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;kidney;ovary;uterus;synovium;thyroid;muscle;colon;placenta;skeletal muscle;islets of Langerhans;	NA	NA	NA	N	N	N	0.11437135981131	N	Slc35e2	NA	NA	NA	NA	NA	0.4646	0.4976	0.499	0.5449	0.6204	0	0	0.0520821	0.454023	VQSRTrancheSNP99.90to100.00	0.482456	0.418	429	0.435252	99	chr1	1668373	NA	C	T	87.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.9;AS_FS=14.232;AS_MQ=38.29;AS_MQRankSum=-1.4;AS_QD=0.74;AS_ReadPosRankSum=-0.4;AS_SOR=2.625;BaseQRankSum=3.99;DP=120;ExcessHet=3.0103;FS=14.232;MLEAC=1;MLEAF=0.5;MQ=41.17;MQRankSum=-1.39;QD=0.74;ReadPosRankSum=-0.388;SOR=2.625	GT:AD:DP:GQ:PL	0/1:106,13:119:95:95,0,2518
chr1	1668449	1668449	A	G	SLC35E2B	exonic	synonymous SNV	NA	SLC35E2B:NM_001110781:exon8:c.T858C:p.S286S,SLC35E2B:NM_001290264:exon9:c.T858C:p.S286S	0.897	GnomAdGenome_AF_afr	60	20	WT/SomaticVariant	het	156	132	24	0.153846153846154	187.64	QD2	0.238	NA	NA	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	P	NA	NA	NA	NA	NA	T	NA	NA	NA	T	NA	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	thymus;endometrium;skin;stomach;germinal center;testis;brain;lens;blood;unclassifiable (Anatomical System);lung;choroid;kidney;ovary;uterus;synovium;thyroid;muscle;colon;placenta;skeletal muscle;islets of Langerhans;	NA	NA	NA	N	N	N	0.11437135981131	N	Slc35e2	NA	NA	NA	NA	NA	0.5293	0.7908	0.8138	0.7914	0.897	0	0	0.0001153	0.546798	VQSRTrancheSNP99.90to100.00	0.59596	0.532	502	0.545775	115	chr1	1668449	NA	A	G	187.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=4.262;AS_MQ=50.02;AS_MQRankSum=0.3;AS_QD=1.21;AS_ReadPosRankSum=2.4;AS_SOR=0.956;BaseQRankSum=1.62;DP=163;ExcessHet=3.0103;FS=4.262;MLEAC=1;MLEAF=0.5;MQ=47.54;MQRankSum=0.382;QD=1.2;ReadPosRankSum=2.43;SOR=0.956	GT:AD:DP:GQ:PL	0/1:132,24:156:99:195,0,2862
chr1	1701565	1701565	G	-	MMP23A	ncRNA_intronic	NA	NA	NA	0.1702	GnomAdGenome_AF_eas			HeterozygousVariant	het	39	16	23	0.58974358974359	546.6	PASS	NA	NA	603320	NA	Situs ambiguus;Situs inversus totalis	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in	Body mass index[26426971];	HP:0002566;HP:0030853;HP:0004935;HP:0005160;HP:0011671;HP:0012020;HP:0004762;HP:0001696;HP:0001646;HP:0001669;HP:0011611;HP:0001748;HP:0006695;HP:0004971;HP:0011565;HP:0001631;HP:0011560;HP:0000961;HP:0001702;HP:0000007	Intestinal malrotation;Heterotaxy;Pulmonary artery atresia;Total anomalous pulmonary venous return;Interrupted inferior vena cava with azygous continuation;Right aortic arch;Hypoplasia of right ventricle;Situs inversus totalis;Abnormal aortic valve morphology;Transposition of the great arteries;Interrupted aortic arch;Polysplenia;Atrioventricular canal defect;Pulmonary artery hypoplasia;Common atrium;Atrial septal defect;Mitral atresia;Cyanosis;Abnormal tricuspid valve morphology;Autosomal recessive inheritance	NA	NA	NA	Predominantly expressed in ovary, testis and prostate. {ECO:0000269|PubMed:9988691}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	lung;kidney;uterus;whole body;colon;myocardium;prostate;testis;heart;medulla oblongata;	NA	NA	NA	NA	NA	NA	NA	NA	Mmp21	craniofacial phenotype; growth/size/body region phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); digestive/alimentary phenotype; skeleton phenotype; liver/biliary system phenotype; respiratory system phenotype; 	NA	NA	NA	NA	0	0	0	0.1151	0.1702	0	0	0.0004226	0		0					chr1	1701564	NA	CG	C	546.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=2.747;AS_MQ=29.28;AS_MQRankSum=-4.8;AS_QD=14.03;AS_ReadPosRankSum=-0.8;AS_SOR=1.179;BaseQRankSum=-0.352;DP=45;ExcessHet=3.0103;FS=2.747;MLEAC=1;MLEAF=0.5;MQ=36.73;MQRankSum=-4.727;QD=14.02;ReadPosRankSum=-0.705;SOR=1.179	GT:AD:DP:GQ:PL	0/1:16,23:39:99:554,0,339
chr1	1703565	1703565	T	C	CDK11A	exonic	synonymous SNV	NA	CDK11A:NM_001313896:exon18:c.A1980G:p.K660K,CDK11A:NM_001313982:exon18:c.A1968G:p.K656K,CDK11A:NM_024011:exon18:c.A1971G:p.K657K,CDK11A:NM_033529:exon18:c.A1941G:p.K647K	0.8791	GnomAdGenome_AF_afr	276	46	HeterozygousVariant	het	127	71	56	0.440944881889764	1208.64	PASS	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.5539	0.842	0.8491	0.652	0.8791	0.592252	0.6241	0.0154065	0.58595	VQSRTrancheSNP99.00to99.90	0.666667	0.51	295	0.536232	56	chr1	1703565	NA	T	C	1208.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=0;AS_MQ=54.34;AS_MQRankSum=-4.1;AS_QD=9.52;AS_ReadPosRankSum=2.5;AS_SOR=0.666;BaseQRankSum=1.32;DP=128;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=57;MQRankSum=-4.101;QD=9.52;ReadPosRankSum=2.56;SOR=0.666	GT:AD:DP:GQ:PL	0/1:71,56:127:99:1216,0,1594
chr1	1704180	1704180	T	C	CDK11A	intronic	NA	NA	NA	0.8985	GnomAdExome_AF_afr	184	51	HeterozygousVariant	het	88	36	52	0.590909090909091	1164.64	PASS	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.6011	0.8985	0.9017	0.6743	0.8882	0.646965	0.688	0.0003842	0.621087	PASS	0	0.574	229	0.609929	70	chr1	1704180	NA	T	C	1164.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=4.146;AS_MQ=58.77;AS_MQRankSum=-1.7;AS_QD=13.24;AS_ReadPosRankSum=-0.5;AS_SOR=0.354;BaseQRankSum=-1.306;DP=93;ExcessHet=3.0103;FS=4.146;MLEAC=1;MLEAF=0.5;MQ=59.05;MQRankSum=-1.643;QD=13.23;ReadPosRankSum=-0.45;SOR=0.354	GT:AD:DP:GQ:PL	0/1:36,52:88:99:1172,0,801
chr1	1704310	1704310	C	A	CDK11A	exonic	synonymous SNV	NA	CDK11A:NM_001313896:exon15:c.G1608T:p.R536R,CDK11A:NM_001313982:exon15:c.G1596T:p.R532R,CDK11A:NM_024011:exon15:c.G1599T:p.R533R,CDK11A:NM_033529:exon15:c.G1569T:p.R523R	0.57716	GME_TP	97	14	HeterozygousVariant	het	92	44	48	0.521739130434783	1002.64	PASS	NA	NA	116951	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.4722	0.54	0.5401	0.4847	0.5631	0.397564	0.4715	0.417905	0.481878	VQSRTrancheSNP99.00to99.90	0.57716	0.329	354	0.304965	58	chr1	1704310	NA	C	A	1002.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.5;AS_FS=2.72;AS_MQ=51.84;AS_MQRankSum=-3.3;AS_QD=10.9;AS_ReadPosRankSum=-0.7;AS_SOR=0.458;BaseQRankSum=-1.498;DP=100;ExcessHet=3.0103;FS=2.72;MLEAC=1;MLEAF=0.5;MQ=54.77;MQRankSum=-3.282;QD=10.9;ReadPosRankSum=-0.641;SOR=0.458	GT:AD:DP:GQ:PL	0/1:44,48:92:99:1010,0,990
chr1	1704605	1704605	G	A	CDK11A	exonic	synonymous SNV	NA	CDK11A:NM_001313896:exon14:c.C1518T:p.Y506Y,CDK11A:NM_001313982:exon14:c.C1506T:p.Y502Y,CDK11A:NM_024011:exon14:c.C1509T:p.Y503Y,CDK11A:NM_033529:exon14:c.C1479T:p.Y493Y	0.9024	GnomAdExome_AF_afr	292	53	HeterozygousVariant	het	111	63	48	0.432432432432432	997.64	PASS	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.5819	0.9024	0.8995	0.6748	0.8966	0.647963	0.6633	0.516119	0.595197	VQSRTrancheSNP99.00to99.90	0.675	0.572	372	0.620567	69	chr1	1704605	NA	G	A	997.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.528;AS_MQ=47.97;AS_MQRankSum=-5;AS_QD=8.99;AS_ReadPosRankSum=0.3;AS_SOR=0.696;BaseQRankSum=0.441;DP=118;ExcessHet=3.0103;FS=1.528;MLEAC=1;MLEAF=0.5;MQ=53.37;MQRankSum=-4.943;QD=8.99;ReadPosRankSum=0.351;SOR=0.696	GT:AD:DP:GQ:PL	0/1:63,48:111:99:1005,0,1433
chr1	1708856	1708864	TCCTCCTCC	-	CDK11A	exonic	nonframeshift deletion	NA	CDK11A:NM_001313896:exon9:c.942_950del:p.E322_E324del,CDK11A:NM_001313982:exon9:c.930_938del:p.E318_E320del,CDK11A:NM_024011:exon9:c.933_941del:p.E319_E321del,CDK11A:NM_033529:exon9:c.903_911del:p.E309_E311del	0.4609	GnomAdGenome_AF_asj			HeterozygousVariant	het	102	56	44	0.431372549019608	1642.6	PASS	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.0006	0.0018	0.0018	0.3138	0.4609	0	0	0.0000384	0		0					chr1	1708855	NA	TTCCTCCTCC	T	1642.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=2.74;AS_MQ=35.98;AS_MQRankSum=-2.4;AS_QD=16.43;AS_ReadPosRankSum=-0.9;AS_SOR=0.454;BaseQRankSum=-0.764;DP=116;ExcessHet=3.0103;FS=2.722;MLEAC=1;MLEAF=0.5;MQ=38.68;MQRankSum=-2.244;QD=16.43;ReadPosRankSum=-0.582;SOR=0.44	GT:AD:DP:GQ:PL	0/1:56,44:102:99:1650,0,2261
chr1	1708951	1708951	C	T	CDK11A	exonic	synonymous SNV	NA	CDK11A:NM_001313896:exon9:c.G855A:p.A285A,CDK11A:NM_001313982:exon9:c.G843A:p.A281A,CDK11A:NM_024011:exon9:c.G846A:p.A282A,CDK11A:NM_033529:exon9:c.G816A:p.A272A	0.3981	GnomAdGenome_AF_asj	1		HeterozygousVariant	het	23	9	14	0.608695652173913	366.64	MQ40	NA	NA	116951	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.0578	0.3033	0.2993	0.3332	0.3981	0.0882588	0	0.0182496	0		0.2	0.036	0			chr1	1708951	NA	C	T	366.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.1;AS_FS=0;AS_MQ=27;AS_MQRankSum=0;AS_QD=15.96;AS_ReadPosRankSum=-0.7;AS_SOR=1.179;BaseQRankSum=3.18;DP=24;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=27;MQRankSum=0;QD=15.94;ReadPosRankSum=-0.63;SOR=1.179	GT:AD:DP:GQ:PL	0/1:9,14:23:99:374,0,214
chr1	1716489	1716489	A	G	CDK11A	intronic	NA	NA	NA	0.5233	GnomAdGenome_AF_eas	0	0	HeterozygousVariant	het	65	33	32	0.492307692307692	718.64	PASS	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0056	0.084	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.3129	0.4146	0.4144	0.3155	0.5233	0.347444	0	0.0380137	0.289819	VQSRTrancheSNP99.00to99.90	0	0.313	325	0.302817	86	chr1	1716489	NA	A	G	718.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.06;AS_ReadPosRankSum=-1.3;AS_SOR=0.776;BaseQRankSum=0.597;DP=66;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=59.97;MQRankSum=0;QD=11.06;ReadPosRankSum=-1.267;SOR=0.776	GT:AD:DP:GQ:PL	0/1:33,32:65:99:726,0,734
chr1	1719368	1719368	T	C	CDK11A	exonic	synonymous SNV	NA	CDK11A:NM_001313896:exon4:c.A315G:p.R105R,CDK11A:NM_001313982:exon4:c.A315G:p.R105R,CDK11A:NM_024011:exon4:c.A315G:p.R105R,CDK11A:NM_033529:exon4:c.A315G:p.R105R	0.9279	GnomAdGenome_AF_nfe	1	0	HomozygousVariant	hom	14	0	14	1	373.06	PASS	NA	NA	116951	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.4801	0.4965	0.4968	0.8014	0.9279	0.747404	0	0.0109497	0.481938	VQSRTrancheSNP99.00to99.90	0.5	0.45	742	0.419014	119	chr1	1719368	NA	T	C	373.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.64;AS_ReadPosRankSum=.;AS_SOR=0.976;DP=14;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.65;SOR=0.976	GT:AD:DP:GQ:PL	1/1:0,14:14:41:387,41,0
chr1	1719406	1719406	G	A	CDK11A	exonic	nonsynonymous SNV	NA	CDK11A:NM_001313896:exon4:c.C277T:p.R93W,CDK11A:NM_001313982:exon4:c.C277T:p.R93W,CDK11A:NM_024011:exon4:c.C277T:p.R93W,CDK11A:NM_033529:exon4:c.C277T:p.R93W	0.9283	GnomAdGenome_AF_nfe	2	0	HomozygousVariant	hom	14	0	14	1	354.06	PASS	29.1	NA	116951	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	T	D	D	D	U	D	M	T	N	T	T	T	NA	D	T	T	T	D	.;.;.;.;.;.;.;	D	D	.;.;.;.;.;.;.	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.4797	0.4963	0.497	0.802	0.9283	0.747404	0.4496	0.0562735	0.481938	VQSRTrancheSNP99.90to100.00	0.5	0.449	745	0.419014	119	chr1	1719406	NA	G	A	354.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=25.29;AS_ReadPosRankSum=.;AS_SOR=0.976;DP=14;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=25.29;SOR=0.976	GT:AD:DP:GQ:PL	1/1:0,14:14:42:368,42,0
chr1	1721589	1721589	C	T	CDK11A	intronic	NA	NA	NA	0.9299	GnomAdExome_AF_nfe	294	68	HomozygousVariant	hom	59	0	59	1	1673.06	PASS	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.8583	0.9299	0.9328	0.8017	0.928	0.747404	0.8128	0.837214	0.807263	PASS	0	0.74	179	0.666667	52	chr1	1721589	NA	C	T	1673.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=55.61;AS_MQRankSum=.;AS_QD=28.36;AS_ReadPosRankSum=.;AS_SOR=0.95;DP=59;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=55.61;QD=28.36;SOR=0.95	GT:AD:DP:GQ:PL	1/1:0,59:59:99:1687,177,0
chr1	1722599	1722599	G	A	CDK11A	intronic	NA	NA	NA	0.7635	GnomAdExome_AF_fin	319	47	HomozygousVariant	hom	4	0	4	1	130.14	DP10;SOR3	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.4604	0.6159	0.45	0.3385	0.6643	0	0	0.331813	0.728995	VQSRTrancheSNP99.90to100.00	0	0.574	189	0.53937	43	chr1	1722599	NA	G	A	130.14	DP10;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=47.7;AS_MQRankSum=.;AS_QD=32.5;AS_ReadPosRankSum=.;AS_SOR=3.258;DP=4;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=47.7;QD=32.54;SOR=3.258	GT:AD:DP:GQ:PL	1/1:0,4:4:12:144,12,0
chr1	1722619	1722619	C	T	CDK11A	intronic	NA	NA	NA	0.8102	GnomAdExome_AF_fin	330	51	HomozygousVariant	hom	6	0	6	1	255.97	DP10;SOR3	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.5619	0.7002	0.5736	0.5629	0.7792	0	0	0.400849	0.785008	VQSRTrancheSNP99.90to100.00	0	0.617	255	0.564394	47	chr1	1722619	NA	C	T	255.97	DP10;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=49.14;AS_MQRankSum=.;AS_QD=35.18;AS_ReadPosRankSum=.;AS_SOR=3.912;DP=6;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=49.14;QD=29.59;SOR=3.912	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,6:6:18:1|1:1722619_C_T:270,18,0:1722619
chr1	1722625	1722625	A	T	CDK11A	intronic	NA	NA	NA	0.8322	GnomAdExome_AF_fin	335	53	HomozygousVariant	hom	6	0	6	1	255.97	DP10;SOR3	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.6573	0.7678	0.7078	0.591	0.7904	0.667133	0	0.434503	0.724876	VQSRTrancheSNP99.90to100.00	0	0.604	250	0.567669	45	chr1	1722625	NA	A	T	255.97	DP10;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=49.14;AS_MQRankSum=.;AS_QD=32.25;AS_ReadPosRankSum=.;AS_SOR=3.912;DP=6;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=49.14;QD=34.86;SOR=3.912	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,6:6:18:1|1:1722619_C_T:270,18,0:1722619
chr1	1722627	1722629	GCG	-	CDK11A	intronic	NA	NA	NA	0.8268	GnomAdExome_AF_fin	335	53	HomozygousVariant	hom	6	0	6	1	255.93	DP10	NA	NA	116951	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed ubiquitously. Some evidence of isoform-specific tissue distribution. {ECO:0000269|PubMed:8195233, ECO:0000269|PubMed:9750192}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	thymus;epididymis;tongue;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);kidney;larynx;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;islets of Langerhans;epidermis;foreskin;cervix;tonsil;spleen;liver;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;nasopharynx;breast;amnion;	white blood cells;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;trigeminal ganglion;parietal lobe;testis;skeletal muscle;heart;	NA	NA	N	S	N	0.781199836008485	E	NA	NA	NA	NA	NA	NA	0.6515	0.76	0.7015	0.5945	0.7902	0.667133	0.6389	0.17316	0.791941	VQSRTrancheINDEL99.90to100.00	0	0.603	250	0.567669	45	chr1	1722626	NA	AGCG	A	255.93	DP10	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=49.14;AS_MQRankSum=.;AS_QD=32.49;AS_ReadPosRankSum=.;AS_SOR=3.912;DP=6;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=49.14;QD=29.05;SOR=3.912	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,6:6:18:1|1:1722619_C_T:270,18,0:1722619
chr1	1734736	1734736	C	T	SLC35E2A	exonic	nonsynonymous SNV	NA	SLC35E2A:NM_182838:exon5:c.G686A:p.R229H,SLC35E2A:NM_001199787:exon6:c.G686A:p.R229H	0.427	GnomAdExome_AF_fin	16	5	HomozygousVariant	het	40	10	30	0.75	622.64	MQ40	22.5	NA	NA	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	T	T	D	P	U	N	L	NA	N	T	T	T	NA	T	T	T	T	T	.;.;	D	N	.;.	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Slc35e2	NA	NA	NA	NA	NA	0.3059	0.3552	0.354	0.0397	0.0616	0	0	0.0076002	0.396552	VQSRTrancheSNP99.90to100.00	0.426901	0.427	468	0.432624	112	chr1	1734736	NA	C	T	622.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-5.3;AS_FS=0;AS_MQ=41.88;AS_MQRankSum=3.2;AS_QD=15.58;AS_ReadPosRankSum=0.8;AS_SOR=0.826;BaseQRankSum=-5.298;DP=42;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=38.41;MQRankSum=3.23;QD=15.57;ReadPosRankSum=0.86;SOR=0.826	GT:AD:DP:GQ:PL	0/1:10,30:40:99:630,0,200
chr1	1734812	1734812	G	A	SLC35E2A	exonic	nonsynonymous SNV	NA	SLC35E2A:NM_182838:exon5:c.C610T:p.R204W,SLC35E2A:NM_001199787:exon6:c.C610T:p.R204W	0.7683	GnomAdGenome_AF_ami	4	0	WT/SomaticVariant	het	57	43	14	0.245614035087719	258.64	PASS	0.562	NA	NA	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	D	T	B	B	U	P	N	NA	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Slc35e2	NA	NA	NA	NA	NA	0.3486	0.4603	0.4615	0.5288	0.7683	0	0	0.166475	0.381773	VQSRTrancheSNP99.90to100.00	0.4	0.291	333	0.258865	73	chr1	1734812	NA	G	A	258.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=4.6;AS_FS=8.805;AS_MQ=37.26;AS_MQRankSum=-2.5;AS_QD=4.54;AS_ReadPosRankSum=3.3;AS_SOR=1.724;BaseQRankSum=4.63;DP=57;ExcessHet=3.0103;FS=8.805;MLEAC=1;MLEAF=0.5;MQ=41.49;MQRankSum=-2.476;QD=4.54;ReadPosRankSum=3.36;SOR=1.724	GT:AD:DP:GQ:PL	0/1:43,14:57:99:266,0,913
chr1	1738295	1738295	G	T	SLC35E2A	intronic	NA	NA	NA	0.5791	GnomAdExome_AF_asj	39	19	HeterozygousVariant	het	108	62	46	0.425925925925926	890.64	PASS	NA	NA	NA	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Slc35e2	NA	NA	NA	NA	NA	0.42	0.5179	0.5187	0.361	0.5732	0.288339	0.3852	0.0001153	0.382208	VQSRTrancheSNP99.00to99.90	0	0.331	120	0.302817	48	chr1	1738295	NA	G	T	890.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=59.11;AS_MQRankSum=8;AS_QD=8.25;AS_ReadPosRankSum=0.8;AS_SOR=0.737;BaseQRankSum=-1.719;DP=110;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=55.49;MQRankSum=8;QD=8.25;ReadPosRankSum=0.823;SOR=0.737	GT:AD:DP:GQ:PL	0/1:62,46:108:99:898,0,2358
chr1	1738309	1738309	A	G	SLC35E2A	intronic	NA	NA	NA	0.5556	GnomAdExome_AF_amr	39	16	HeterozygousVariant	het	118	55	63	0.533898305084746	1404.64	PASS	NA	NA	NA	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Slc35e2	NA	NA	NA	NA	NA	0.3867	0.5556	0.5587	0.3285	0.5092	0.304712	0.2983	0.0001153	0.378089	VQSRTrancheSNP99.00to99.90	0	0.351	132	0.274648	46	chr1	1738309	NA	A	G	1404.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=2.401;AS_MQ=52.52;AS_MQRankSum=-7.5;AS_QD=11.91;AS_ReadPosRankSum=-0.3;AS_SOR=0.476;BaseQRankSum=0.155;DP=122;ExcessHet=3.0103;FS=2.401;MLEAC=1;MLEAF=0.5;MQ=54.71;MQRankSum=-7.453;QD=11.9;ReadPosRankSum=-0.265;SOR=0.476	GT:AD:DP:GQ:PL	0/1:55,63:118:99:1412,0,1926
chr1	1739519	1739519	C	G	SLC35E2A	exonic	synonymous SNV	NA	SLC35E2A:NM_182838:exon2:c.G39C:p.L13L,SLC35E2A:NM_001199787:exon3:c.G39C:p.L13L	0.878788	GME_SD	211	41	HomozygousVariant	hom	4	0	4	1	113.14	DP10;MQ40;SOR3	NA	NA	NA	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Slc35e2	NA	NA	NA	NA	NA	0.5604	0.6253	0.6246	0.5834	0.725	0	0	0.0670431	0.794737	VQSRTrancheSNP99.00to99.90	0.878788	0.592	247	0.530534	57	chr1	1739519	NA	C	G	113.14	DP10;MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=27;AS_MQRankSum=.;AS_QD=28.25;AS_ReadPosRankSum=.;AS_SOR=3.258;DP=4;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=27;QD=28.29;SOR=3.258	GT:AD:DP:GQ:PL	1/1:0,4:4:12:127,12,0
chr1	1752908	1752908	-	CCTCCTCCT	NADK	exonic	nonframeshift insertion	NA	NADK:NM_001198995:exon10:c.1240_1241insAGGAGGAGG:p.E413_G414insEEE,NADK:NM_001198993:exon12:c.1336_1337insAGGAGGAGG:p.E445_G446insEEE,NADK:NM_001353641:exon12:c.1336_1337insAGGAGGAGG:p.E445_G446insEEE,NADK:NM_001353642:exon12:c.1075_1076insAGGAGGAGG:p.E358_G359insEEE,NADK:NM_023018:exon12:c.1336_1337insAGGAGGAGG:p.E445_G446insEEE,NADK:NM_001198994:exon14:c.1771_1772insAGGAGGAGG:p.E590_G591insEEE	0.005587	abraom_freq	0		WT/SomaticVariant	het	82	50	20	0.24390243902439	794.6	PASS	NA	NA	611616	NA	NA	NA	Systolic blood pressure[28135244];Body mass index[26426971;28892062];Pulse pressure[28135244;28135244];Blood protein levels[30072576];	NA	NA	NA	NA	NA	Widely expressed but not detected in skeletal muscle. {ECO:0000269|PubMed:11594753}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;testis;adrenal cortex;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;adrenal gland;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;tonsil;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;macula lutea;lymph node;frontal lobe;colon;placenta;prostate;breast;optic nerve;hypothalamus;amnion;	ciliary ganglion;superior cervical ganglion;cingulate cortex;whole blood;adrenal gland;testis;	0.501	NA	E	S	K	0.98164969096622	E	Nadk	NA	NA	NA	NA	NA	0.0001	0.0002	0.0001	0.0002	0.0003	0	0	0.0000259	0.005587	VQSRTrancheINDEL99.00to99.90	0	0.0006614	1			chr1	1752908	NA	C	CCCTCCTCCT	794.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=2.264;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.76;AS_ReadPosRankSum=2.2;AS_SOR=0.378;BaseQRankSum=0.363;DP=94;ExcessHet=3.0103;FS=1.883;MLEAC=1;MLEAF=0.5;MQ=59.74;MQRankSum=0;QD=11.35;ReadPosRankSum=1.33;SOR=0.458	GT:AD:DP:GQ:PL	0/1:50,20:82:99:802,0,1976
chr1	1753033	1753033	C	T	NADK	exonic	synonymous SNV	NA	NADK:NM_001198995:exon10:c.G1116A:p.P372P,NADK:NM_001198993:exon12:c.G1212A:p.P404P,NADK:NM_001353641:exon12:c.G1212A:p.P404P,NADK:NM_001353642:exon12:c.G951A:p.P317P,NADK:NM_023018:exon12:c.G1212A:p.P404P,NADK:NM_001198994:exon14:c.G1647A:p.P549P	0.5899	GnomAdExome_AF_amr	105	18	HeterozygousVariant	het	82	53	29	0.353658536585366	472.64	PASS	NA	NA	611616	NA	NA	NA	Systolic blood pressure[28135244];Body mass index[26426971;28892062];Pulse pressure[28135244;28135244];Blood protein levels[30072576];	NA	NA	NA	NA	NA	Widely expressed but not detected in skeletal muscle. {ECO:0000269|PubMed:11594753}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;testis;adrenal cortex;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;adrenal gland;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;tonsil;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;macula lutea;lymph node;frontal lobe;colon;placenta;prostate;breast;optic nerve;hypothalamus;amnion;	ciliary ganglion;superior cervical ganglion;cingulate cortex;whole blood;adrenal gland;testis;	0.501	NA	E	S	K	0.98164969096622	E	Nadk	NA	NA	NA	NA	NA	0.4572	0.5899	0.5923	0.3959	0.5592	0.339657	0.3812	0.422284	0.446458	PASS	0.45	0.382	371	0.321429	54	chr1	1753033	NA	C	T	472.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=1.912;AS_MQ=60;AS_MQRankSum=0;AS_QD=5.77;AS_ReadPosRankSum=0.4;AS_SOR=1.023;BaseQRankSum=-1.743;DP=95;ExcessHet=3.0103;FS=1.912;MLEAC=1;MLEAF=0.5;MQ=59.74;MQRankSum=0;QD=5.76;ReadPosRankSum=0.427;SOR=1.023	GT:AD:DP:GQ:PL	0/1:53,29:82:99:480,0,1244
chr1	1754601	1754601	G	T	NADK	exonic	nonsynonymous SNV	NA	NADK:NM_001198995:exon6:c.C690A:p.N230K,NADK:NM_001198993:exon8:c.C786A:p.N262K,NADK:NM_001353641:exon8:c.C786A:p.N262K,NADK:NM_001353642:exon8:c.C525A:p.N175K,NADK:NM_023018:exon8:c.C786A:p.N262K,NADK:NM_001198994:exon10:c.C1221A:p.N407K	0.527439	GME_TP	78	17	HeterozygousVariant	het	123	61	62	0.504065040650406	1263.64	PASS	0.153	NA	611616	Benign	NA	NA	Systolic blood pressure[28135244];Body mass index[26426971;28892062];Pulse pressure[28135244;28135244];Blood protein levels[30072576];	NA	NA	NA	NA	NA	Widely expressed but not detected in skeletal muscle. {ECO:0000269|PubMed:11594753}.;	T	T	B	B	D	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;testis;adrenal cortex;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;adrenal gland;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;tonsil;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;macula lutea;lymph node;frontal lobe;colon;placenta;prostate;breast;optic nerve;hypothalamus;amnion;	ciliary ganglion;superior cervical ganglion;cingulate cortex;whole blood;adrenal gland;testis;	0.501	NA	E	S	K	0.98164969096622	E	Nadk	NA	NA	NA	NA	NA	0.354	0.4243	0.4253	0.3024	0.4825	0.249401	0.3175	0.350248	0.32266	VQSRTrancheSNP99.90to100.00	0.527439	0.306	313	0.295775	50	chr1	1754601	NA	G	T	1263.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=3.268;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.28;AS_ReadPosRankSum=-1.1;AS_SOR=1.016;BaseQRankSum=-0.411;DP=128;ExcessHet=3.0103;FS=3.268;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.27;ReadPosRankSum=-1.058;SOR=1.016	GT:AD:DP:GQ:PL	0/1:61,62:123:99:1271,0,1288
chr1	1755504	1755504	T	C	NADK	intronic	NA	NA	NA	0.5517	GnomAdExome_AF_asj	47	22	HeterozygousVariant	het	74	33	41	0.554054054054054	1312.64	PASS	NA	NA	611616	NA	NA	NA	Systolic blood pressure[28135244];Body mass index[26426971;28892062];Pulse pressure[28135244;28135244];Blood protein levels[30072576];	NA	NA	NA	NA	NA	Widely expressed but not detected in skeletal muscle. {ECO:0000269|PubMed:11594753}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;testis;adrenal cortex;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;adrenal gland;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;tonsil;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;macula lutea;lymph node;frontal lobe;colon;placenta;prostate;breast;optic nerve;hypothalamus;amnion;	ciliary ganglion;superior cervical ganglion;cingulate cortex;whole blood;adrenal gland;testis;	0.501	NA	E	S	K	0.98164969096622	E	Nadk	NA	NA	NA	NA	NA	0.4288	0.4849	0.486	0.4042	0.5458	0.353235	0.4192	0.422336	0.3867	PASS	0	0.332	164	0.352113	56	chr1	1755504	NA	T	C	1312.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=17.74;AS_ReadPosRankSum=-1.4;AS_SOR=0.619;BaseQRankSum=-0.338;DP=76;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=17.74;ReadPosRankSum=-1.357;SOR=0.619	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:33,41:74:99:0|1:1755504_T_C:1320,0,1077:1755504
chr1	1765220	1765220	A	G	NADK	intronic	NA	NA	NA	0.9446	GnomAdGenome_AF_nfe	174	57	HomozygousVariant	hom	40	0	40	1	1121.06	PASS	NA	NA	611616	NA	NA	NA	Systolic blood pressure[28135244];Body mass index[26426971;28892062];Pulse pressure[28135244;28135244];Blood protein levels[30072576];	NA	NA	NA	NA	NA	Widely expressed but not detected in skeletal muscle. {ECO:0000269|PubMed:11594753}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	Medium	Medium	Medium	epididymis;skin;stomach;testis;adrenal cortex;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;adrenal gland;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;tonsil;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;macula lutea;lymph node;frontal lobe;colon;placenta;prostate;breast;optic nerve;hypothalamus;amnion;	ciliary ganglion;superior cervical ganglion;cingulate cortex;whole blood;adrenal gland;testis;	0.501	NA	E	S	K	0.98164969096622	E	Nadk	NA	NA	NA	NA	NA	0.8694	0.944	0.9468	0.8204	0.9446	0.741214	0.8272	0.0001537	0.853859	PASS	0	0.704	145	0.644366	69	chr1	1765220	NA	A	G	1121.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.03;AS_ReadPosRankSum=.;AS_SOR=0.793;DP=41;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.03;SOR=0.793	GT:AD:DP:GQ:PL	1/1:0,40:40:99:1135,120,0
chr1	1915326	1915326	G	A	CALML6	intronic	NA	NA	NA	0.5596	GnomAdExome_AF_amr	78	21	HeterozygousVariant	het	78	24	54	0.692307692307692	1235.64	PASS	NA	NA	610171	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	Expressed in prostate, thymus, heart, skeleton muscle, bone marrow and ovary. {ECO:0000269|PubMed:15621662}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	choroid;fovea centralis;whole body;retina;macula lutea;stomach;lens;optic nerve;	NA	0.538	NA	N	S	N	0.33284315994001	N	NA	NA	NA	NA	NA	NA	0.4551	0.5596	0.5656	0.3846	0.5265	0.356629	0.3657	0.28964	0.416252	PASS	0	0.367	266	0.341549	55	chr1	1915326	NA	G	A	1235.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=2.037;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.85;AS_ReadPosRankSum=0.4;AS_SOR=0.726;BaseQRankSum=-1.588;DP=79;ExcessHet=3.0103;FS=2.037;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.84;ReadPosRankSum=0.493;SOR=0.726	GT:AD:DP:GQ:PL	0/1:24,54:78:99:1243,0,472
chr1	1918090	1918090	A	G	TMEM52	exonic	nonsynonymous SNV	NA	TMEM52:NM_178545:exon5:c.T422C:p.M141T	0.5641	GnomAdExome_AF_amr	80	21	HeterozygousVariant	het	139	70	69	0.496402877697842	1490.64	PASS	9.675	NA	NA	Benign	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	L	T	D	T	T	T	NA	T	T	T	T	T	.;.;	N	NA	.;.	NA	NA	High	High	High	spleen;stomach;testis;unclassifiable (Anatomical System);lung;kidney;whole body;pancreas;muscle;colon;skeletal muscle;islets of Langerhans;medulla oblongata;	NA	0.409	NA	N	S	N	0.110443664027722	N	Tmem52	NA	NA	NA	NA	NA	0.4541	0.5641	0.5674	0.3821	0.5265	0.352037	0.3706	0.43936	0.417077	PASS	0.5	0.366	268	0.341549	55	chr1	1918090	NA	A	G	1490.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.7;AS_FS=1.335;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.73;AS_ReadPosRankSum=-0.7;AS_SOR=0.732;BaseQRankSum=-1.691;DP=144;ExcessHet=3.0103;FS=1.335;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.72;ReadPosRankSum=-0.603;SOR=0.732	GT:AD:DP:GQ:PL	0/1:70,69:139:99:1498,0,1646
chr1	1919189	1919197	AGCGGCAGG	-	TMEM52	exonic	nonframeshift deletion	NA	TMEM52:NM_178545:exon1:c.69_77del:p.L24_L26del	0.5211	GnomAdGenome_AF_amr	77	16	HeterozygousVariant	het	20	13	7	0.35	193.6	PASS	NA	NA	NA	NA	NA	NA	Body mass index[26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	spleen;stomach;testis;unclassifiable (Anatomical System);lung;kidney;whole body;pancreas;muscle;colon;skeletal muscle;islets of Langerhans;medulla oblongata;	NA	0.409	NA	N	S	N	0.110443664027722	N	Tmem52	NA	NA	NA	NA	NA	0.0252	0.0602	0.0704	0.382	0.5211	0.359026	0.281	0.0391501	0.371457	PASS	0	0.33	228	0.268382	41	chr1	1919188	NA	CAGCGGCAGG	C	193.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.7;AS_ReadPosRankSum=-0.7;AS_SOR=0.787;BaseQRankSum=-0.664;DP=35;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.68;ReadPosRankSum=-0.678;SOR=0.787	GT:AD:DP:GQ:PL	0/1:13,7:20:99:201,0,524
chr1	1922670	1922670	A	G	CFAP74	exonic	synonymous SNV	NA	CFAP74:NM_001304360:exon38:c.T4737C:p.S1579S	0.6645	GnomAdExome_AF_amr	265	71	HeterozygousVariant	het	50	25	25	0.5	590.64	PASS	NA	NA	NA	Benign	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.5726	0.6645	0.6642	0.5505	0.664	0.598842	0.5319	0.558596	0		0	0.664	247	0.679577	51	chr1	1922670	NA	A	G	590.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.82;AS_ReadPosRankSum=2.4;AS_SOR=0.853;BaseQRankSum=0.886;DP=50;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.81;ReadPosRankSum=2.48;SOR=0.853	GT:AD:DP:GQ:PL	0/1:25,25:50:99:598,0,568
chr1	1930143	1930143	C	T	CFAP74	exonic	nonsynonymous SNV	NA	CFAP74:NM_001304360:exon26:c.G3205A:p.G1069R	0.5618	GnomAdExome_AF_amr	81	20	HeterozygousVariant	het	73	39	34	0.465753424657534	741.64	PASS	24.9	NA	NA	Benign	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	D	NA	NA	NA	NA	NA	NA	NA	T	T	T	NA	NA	T	T	T	D	.;	D	D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.4559	0.5618	0.5676	0.3842	0.5271	0.355831	0	0.115581	0		0	0.367	267	0.334507	55	chr1	1930143	NA	C	T	741.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=0.88;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.16;AS_ReadPosRankSum=2.9;AS_SOR=0.568;BaseQRankSum=0.891;DP=74;ExcessHet=3.0103;FS=0.88;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.16;ReadPosRankSum=2.92;SOR=0.568	GT:AD:DP:GQ:PL	0/1:39,34:73:99:749,0,847
chr1	1942014	1942014	G	A	CFAP74	intronic	NA	NA	NA	0.6628	GnomAdGenome_AF_eas	94	69	HeterozygousVariant	het	43	30	13	0.302325581395349	287.64	PASS	NA	NA	NA	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.4752	0.5613	0.5771	0.5417	0.6628	0.592452	0	0.146065	0		0	0.663	88	0.661871	46	chr1	1942014	NA	G	A	287.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.6;AS_FS=1.338;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.7;AS_ReadPosRankSum=-2.2;AS_SOR=1.055;BaseQRankSum=2.6;DP=45;ExcessHet=3.0103;FS=1.338;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.69;ReadPosRankSum=-2.183;SOR=1.055	GT:AD:DP:GQ:PL	0/1:30,13:43:99:295,0,698
chr1	1942075	1942075	A	G	CFAP74	exonic	synonymous SNV	NA	CFAP74:NM_001304360:exon22:c.T2568C:p.Y856Y	0.6639	GnomAdGenome_AF_eas	269	73	HeterozygousVariant	het	58	39	19	0.327586206896552	374.64	PASS	NA	NA	NA	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.5703	0.6554	0.6571	0.5418	0.6639	0.592452	0	0.148996	0		0	0.668	246	0.690141	50	chr1	1942075	NA	A	G	374.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=2.345;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.47;AS_ReadPosRankSum=2.5;AS_SOR=0.988;BaseQRankSum=0.501;DP=60;ExcessHet=3.0103;FS=2.345;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.46;ReadPosRankSum=2.54;SOR=0.988	GT:AD:DP:GQ:PL	0/1:39,19:58:99:382,0,920
chr1	1942086	1942086	T	C	CFAP74	exonic	nonsynonymous SNV	NA	CFAP74:NM_001304360:exon22:c.A2557G:p.K853E	0.663	GnomAdGenome_AF_eas	269	73	HeterozygousVariant	het	60	37	23	0.383333333333333	433.64	PASS	15.94	NA	NA	Benign	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.5714	0.6567	0.6592	0.5418	0.663	0.592452	0	0.148976	0		0	0.668	246	0.690141	50	chr1	1942086	NA	T	C	433.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=1.017;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.23;AS_ReadPosRankSum=1.3;AS_SOR=0.646;BaseQRankSum=-0.679;DP=63;ExcessHet=3.0103;FS=1.017;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.23;ReadPosRankSum=1.3;SOR=0.646	GT:AD:DP:GQ:PL	0/1:37,23:60:99:441,0,865
chr1	1944419	1944419	C	G	CFAP74	exonic	nonsynonymous SNV	NA	CFAP74:NM_001304360:exon21:c.G2398C:p.V800L	0.5705	GnomAdExome_AF_amr	90	22	HeterozygousVariant	het	56	24	32	0.571428571428571	1257.64	PASS	21.9	NA	NA	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	T	D	NA	NA	NA	NA	NA	T	N	T	T	T	NA	NA	T	T	T	T	.;	D	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.4634	0.5705	0.5756	0.4012	0.5337	0.384984	0	0.0663445	0		0	0.387	274	0.348592	55	chr1	1944419	NA	C	G	1257.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=22.46;AS_ReadPosRankSum=-0.1;AS_SOR=0.657;BaseQRankSum=-1.067;DP=56;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=22.46;ReadPosRankSum=-0.033;SOR=0.657	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:24,32:56:99:0|1:1944419_C_G:1265,0,901:1944419
chr1	1944420	1944420	A	G	CFAP74	exonic	synonymous SNV	NA	CFAP74:NM_001304360:exon21:c.T2397C:p.D799D	0.5728	GnomAdExome_AF_amr	90	22	HeterozygousVariant	het	56	24	32	0.571428571428571	1257.64	PASS	NA	NA	NA	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.4659	0.5728	0.578	0.4139	0.5391	0.397764	0	0.0003074	0		0	0.387	274	0.348592	55	chr1	1944420	NA	A	G	1257.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=22.46;AS_ReadPosRankSum=0;AS_SOR=0.657;BaseQRankSum=-0.686;DP=56;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=22.46;ReadPosRankSum=0.017;SOR=0.657	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:24,32:56:99:0|1:1944419_C_G:1265,0,901:1944419
chr1	1960038	1960038	A	G	CFAP74	intronic	NA	NA	NA	0.296	GnomAdExome_AF_afr	4	0	HeterozygousVariant	het	55	34	21	0.381818181818182	398.64	PASS	NA	NA	NA	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.0986	0.296	0.3002	0.1537	0.2948	0.132188	0.1606	0.103104	0.155172	PASS	0	0.082	87	0.06338	18	chr1	1960038	NA	A	G	398.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.25;AS_ReadPosRankSum=0.3;AS_SOR=0.566;BaseQRankSum=0.408;DP=55;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.25;ReadPosRankSum=0.347;SOR=0.566	GT:AD:DP:GQ:PL	0/1:34,21:55:99:406,0,739
chr1	1968747	1968747	T	C	CFAP74	exonic	nonsynonymous SNV	NA	CFAP74:NM_001304360:exon11:c.A1133G:p.K378R	0.336257	GME_AP	23	5	HeterozygousVariant	het	54	29	25	0.462962962962963	463.64	PASS	0.747	NA	NA	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	T	B	B	N	P	NA	NA	NA	T	T	T	NA	T	T	T	T	T	.;	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.1882	0.2183	0.2188	0.1562	0.2691	0.153954	0.1632	0.182152	0.191297	PASS	0.336257	0.189	177	0.193662	45	chr1	1968747	NA	T	C	463.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=1.05;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.59;AS_ReadPosRankSum=1.4;AS_SOR=0.609;BaseQRankSum=-1.343;DP=59;ExcessHet=3.0103;FS=1.05;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.59;ReadPosRankSum=1.46;SOR=0.609	GT:AD:DP:GQ:PL	0/1:29,25:54:99:471,0,659
chr1	1968793	1968793	T	C	CFAP74	exonic	nonsynonymous SNV	NA	CFAP74:NM_001304360:exon11:c.A1087G:p.I363V	0.529	GnomAdExome_AF_asj	67	16	HeterozygousVariant	het	45	21	24	0.533333333333333	490.64	PASS	0.132	NA	NA	Benign	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	T	B	B	N	P	NA	NA	NA	T	T	T	NA	T	T	T	T	T	.;	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.4221	0.4466	0.4443	0.4245	0.5193	0.38778	0.4351	0.0860403	0.434319	PASS	0.512195	0.328	252	0.34507	66	chr1	1968793	NA	T	C	490.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2;AS_FS=4.485;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.91;AS_ReadPosRankSum=-1.8;AS_SOR=0.232;BaseQRankSum=-1.93;DP=46;ExcessHet=3.0103;FS=4.485;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.9;ReadPosRankSum=-1.709;SOR=0.232	GT:AD:DP:GQ:PL	0/1:21,24:45:99:498,0,492
chr1	1985451	1985451	C	T	CFAP74	exonic	synonymous SNV	NA	CFAP74:NM_001304360:exon6:c.G435A:p.L145L	0.6246	GnomAdExome_AF_afr	101	22	HeterozygousVariant	het	67	38	29	0.432835820895522	564.64	PASS	NA	NA	NA	Benign	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.3643	0.6246	0.6279	0.4242	0.6126	0.438498	0.4104	0.365571	0.375205	PASS	0.404891	0.4	268	0.401408	70	chr1	1985451	NA	C	T	564.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.43;AS_ReadPosRankSum=-0.4;AS_SOR=0.687;BaseQRankSum=0.579;DP=69;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.43;ReadPosRankSum=-0.399;SOR=0.687	GT:AD:DP:GQ:PL	0/1:38,29:67:99:572,0,818
chr1	1987049	1987049	A	G	CFAP74	intronic	NA	NA	NA	0.8859	GnomAdExome_AF_afr	107	51	HomozygousVariant	hom	60	0	60	1	1709.06	PASS	NA	NA	NA	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.5522	0.8859	0.8936	0.6227	0.8764	0.630591	0.6404	0.541022	0.58867	PASS	0	0.595	143	0.577465	62	chr1	1987049	NA	A	G	1709.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.48;AS_ReadPosRankSum=.;AS_SOR=1.071;DP=62;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.48;SOR=1.071	GT:AD:DP:GQ:PL	1/1:0,60:60:99:1723,180,0
chr1	1988996	1988996	A	-	CFAP74	intronic	NA	NA	NA	0.4626	GnomAdExome_AF_eas	10	1	HeterozygousVariant	het	23	15	8	0.347826086956522	117.6	PASS	NA	NA	NA	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.3954	0.4626	0.4656	0.0813	0.1827	0	0	0.0001537	0.300403	PASS	0	0.283	148	0.346429	95	chr1	1988995	NA	TA	T	117.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=1.76;AS_MQ=60;AS_MQRankSum=0;AS_QD=5.13;AS_ReadPosRankSum=-0.5;AS_SOR=1.112;BaseQRankSum=1.3;DP=32;ExcessHet=3.0103;FS=1.76;MLEAC=1;MLEAF=0.5;MQ=59.66;MQRankSum=0;QD=5.11;ReadPosRankSum=-0.484;SOR=1.112	GT:AD:DP:GQ:PL	0/1:15,8:23:99:125,0,323
chr1	1990864	1990864	C	T	CFAP74	intronic	NA	NA	NA	0.8741	GnomAdExome_AF_afr	112	54	HeterozygousVariant	het	22	8	14	0.636363636363636	295.64	PASS	NA	NA	NA	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Cfap74	NA	NA	NA	NA	NA	0.5674	0.8741	0.8812	0.633	0.8699	0.649561	0.6424	0.564048	0.598522	PASS	0	0.615	144	0.59507	61	chr1	1990864	NA	C	T	295.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.45;AS_ReadPosRankSum=-1;AS_SOR=0.976;BaseQRankSum=-1.232;DP=23;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.44;ReadPosRankSum=-0.922;SOR=0.976	GT:AD:DP:GQ:PL	0/1:8,14:22:99:303,0,167
chr1	2024923	2024923	G	A	GABRD	intronic	NA	NA	NA	0.9332	GnomAdGenome_AF_ami	307	89	HomozygousVariant	hom	113	0	113	1	3512.06	PASS	NA	[MIM:613060]Generalized epilepsy with febrile seizures plus 5 [dominant?];[MIM:613060]Epilepsy, idiopathic generalized 10;[MIM:613060]Juvenile myoclonic epilepsy 7;	137163	NA	Juvenile myoclonic epilepsy;1p36 deletion syndrome;Generalized epilepsy with febrile seizures-plus	Major susceptibility factor in;Role in the phenotype of;Candidate gene tested in	Body mass index[26426971;26426971];	HP:0002373;HP:0000006;HP:0002123;HP:0002121;HP:0007359;HP:0002069;HP:0000496;HP:0002373;HP:0002121;HP:0002133;HP:0000718;HP:0007207;HP:0000153;HP:0007000;HP:0002392;HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733;HP:0002123;HP:0001763;HP:0001252;HP:0000739;HP:0003066;HP:0004684;HP:0008770;HP:0002384;HP:0007058;HP:0010819;HP:0001337;HP:0002539;HP:0002121;HP:0002373;HP:0002311;HP:0000729;HP:0001251;HP:0011151;HP:0010850;HP:0100543;HP:0002069;HP:0007010;HP:0002376;HP:0002067;HP:0100694	Febrile seizure (within the age range of 3 months to 6 years);Autosomal dominant inheritance;Generalized myoclonic seizure;Generalized non-motor (absence) seizure;Focal-onset seizure;Bilateral tonic-clonic seizure;Abnormality of eye movement;Febrile seizure (within the age range of 3 months to 6 years);Generalized non-motor (absence) seizure;Status epilepticus;Aggressive behavior;Photosensitive tonic-clonic seizure;Abnormality of the mouth;Morning myoclonic jerks;EEG with polyspike wave complexes;Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule;Generalized myoclonic seizure;Pes planus;Muscular hypotonia;Anxiety;Limited knee extension;Talipes valgus;Obsessive-compulsive trait;Focal impaired awareness seizure;Generalized cerebral atrophy/hypoplasia;Atonic seizure;Tremor;Cortical dysplasia;Generalized non-motor (absence) seizure;Febrile seizure (within the age range of 3 months to 6 years);Incoordination;Autistic behavior;Ataxia;Atypical absence status epilepticus;EEG with spike-wave complexes;Cognitive impairment;Bilateral tonic-clonic seizure;Poor fine motor coordination;Developmental regression;Bradykinesia;Tibial torsion	not_specified	criteria_provided,_single_submitter	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0118	E	N	S	N	0.896286527779523	E	Gabrd	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.8032	0.8311	0.833	0.814	0.9332	0.775559	0.8197	0.788567	0.826765	PASS	0	0.765	183	0.797872	47	chr1	2024923	NA	G	A	3512.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=31.08;AS_ReadPosRankSum=.;AS_SOR=0.946;DP=119;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=31.08;SOR=0.946	GT:AD:DP:GQ:PL	1/1:0,113:113:99:3526,338,0
chr1	2025598	2025598	T	C	GABRD	exonic	synonymous SNV	NA	GABRD:NM_000815:exon4:c.T330C:p.G110G	0.8	GME_Israel	167	25	HeterozygousVariant	het	92	40	52	0.565217391304348	1235.64	PASS	12.6	[MIM:613060]Generalized epilepsy with febrile seizures plus 5 [dominant?];[MIM:613060]Epilepsy, idiopathic generalized 10;[MIM:613060]Juvenile myoclonic epilepsy 7;	137163	Benign	Juvenile myoclonic epilepsy;1p36 deletion syndrome;Generalized epilepsy with febrile seizures-plus	Major susceptibility factor in;Role in the phenotype of;Candidate gene tested in	Body mass index[26426971;26426971];	HP:0002373;HP:0000006;HP:0002123;HP:0002121;HP:0007359;HP:0002069;HP:0000496;HP:0002373;HP:0002121;HP:0002133;HP:0000718;HP:0007207;HP:0000153;HP:0007000;HP:0002392;HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733;HP:0002123;HP:0001763;HP:0001252;HP:0000739;HP:0003066;HP:0004684;HP:0008770;HP:0002384;HP:0007058;HP:0010819;HP:0001337;HP:0002539;HP:0002121;HP:0002373;HP:0002311;HP:0000729;HP:0001251;HP:0011151;HP:0010850;HP:0100543;HP:0002069;HP:0007010;HP:0002376;HP:0002067;HP:0100694	Febrile seizure (within the age range of 3 months to 6 years);Autosomal dominant inheritance;Generalized myoclonic seizure;Generalized non-motor (absence) seizure;Focal-onset seizure;Bilateral tonic-clonic seizure;Abnormality of eye movement;Febrile seizure (within the age range of 3 months to 6 years);Generalized non-motor (absence) seizure;Status epilepticus;Aggressive behavior;Photosensitive tonic-clonic seizure;Abnormality of the mouth;Morning myoclonic jerks;EEG with polyspike wave complexes;Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule;Generalized myoclonic seizure;Pes planus;Muscular hypotonia;Anxiety;Limited knee extension;Talipes valgus;Obsessive-compulsive trait;Focal impaired awareness seizure;Generalized cerebral atrophy/hypoplasia;Atonic seizure;Tremor;Cortical dysplasia;Generalized non-motor (absence) seizure;Febrile seizure (within the age range of 3 months to 6 years);Incoordination;Autistic behavior;Ataxia;Atypical absence status epilepticus;EEG with spike-wave complexes;Cognitive impairment;Bilateral tonic-clonic seizure;Poor fine motor coordination;Developmental regression;Bradykinesia;Tibial torsion	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	P	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0118	E	N	S	N	0.896286527779523	E	Gabrd	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.588	0.7305	0.7293	0.6611	0.7878	0.561302	0.6843	0.575885	0.665846	PASS	0.8	0.447	413	0.426056	71	chr1	2025598	NA	T	C	1235.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=0.79;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.43;AS_ReadPosRankSum=-0.6;AS_SOR=0.686;BaseQRankSum=1.62;DP=99;ExcessHet=3.0103;FS=0.79;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.43;ReadPosRankSum=-0.548;SOR=0.686	GT:AD:DP:GQ:PL	0/1:40,52:92:99:1243,0,787
chr1	2029235	2029235	C	T	GABRD	exonic	synonymous SNV	NA	GABRD:NM_000815:exon7:c.C816T:p.S272S	0.4717	GnomAdExome_AF_eas	57	7	HeterozygousVariant	het	105	57	48	0.457142857142857	980.64	PASS	3.352	[MIM:613060]Generalized epilepsy with febrile seizures plus 5 [dominant?];[MIM:613060]Epilepsy, idiopathic generalized 10;[MIM:613060]Juvenile myoclonic epilepsy 7;	137163	Benign	Juvenile myoclonic epilepsy;1p36 deletion syndrome;Generalized epilepsy with febrile seizures-plus	Major susceptibility factor in;Role in the phenotype of;Candidate gene tested in	Body mass index[26426971;26426971];	HP:0002373;HP:0000006;HP:0002123;HP:0002121;HP:0007359;HP:0002069;HP:0000496;HP:0002373;HP:0002121;HP:0002133;HP:0000718;HP:0007207;HP:0000153;HP:0007000;HP:0002392;HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733;HP:0002123;HP:0001763;HP:0001252;HP:0000739;HP:0003066;HP:0004684;HP:0008770;HP:0002384;HP:0007058;HP:0010819;HP:0001337;HP:0002539;HP:0002121;HP:0002373;HP:0002311;HP:0000729;HP:0001251;HP:0011151;HP:0010850;HP:0100543;HP:0002069;HP:0007010;HP:0002376;HP:0002067;HP:0100694	Febrile seizure (within the age range of 3 months to 6 years);Autosomal dominant inheritance;Generalized myoclonic seizure;Generalized non-motor (absence) seizure;Focal-onset seizure;Bilateral tonic-clonic seizure;Abnormality of eye movement;Febrile seizure (within the age range of 3 months to 6 years);Generalized non-motor (absence) seizure;Status epilepticus;Aggressive behavior;Photosensitive tonic-clonic seizure;Abnormality of the mouth;Morning myoclonic jerks;EEG with polyspike wave complexes;Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule;Generalized myoclonic seizure;Pes planus;Muscular hypotonia;Anxiety;Limited knee extension;Talipes valgus;Obsessive-compulsive trait;Focal impaired awareness seizure;Generalized cerebral atrophy/hypoplasia;Atonic seizure;Tremor;Cortical dysplasia;Generalized non-motor (absence) seizure;Febrile seizure (within the age range of 3 months to 6 years);Incoordination;Autistic behavior;Ataxia;Atypical absence status epilepticus;EEG with spike-wave complexes;Cognitive impairment;Bilateral tonic-clonic seizure;Poor fine motor coordination;Developmental regression;Bradykinesia;Tibial torsion	not_specified	criteria_provided,_single_submitter	Benign	NA	NA	NA	NA	NA	NA	P	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0118	E	N	S	N	0.896286527779523	E	Gabrd	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.1918	0.4717	0.4681	0.1199	0.4472	0.198283	0.0978	0.147139	0.130148	PASS	0.167939	0.257	315	0.292254	69	chr1	2029235	NA	C	T	980.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=0.738;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.34;AS_ReadPosRankSum=0.2;AS_SOR=0.557;BaseQRankSum=-0.848;DP=109;ExcessHet=3.0103;FS=0.738;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.34;ReadPosRankSum=0.286;SOR=0.557	GT:AD:DP:GQ:PL	0/1:57,48:105:99:988,0,1314
chr1	2056554	2056554	T	C	PRKCZ	exonic	synonymous SNV	NA	PRKCZ:NM_002744:exon3:c.T264C:p.D88D	0.9622	GnomAdGenome_AF_eas	288	55	HeterozygousVariant	het	74	49	25	0.337837837837838	437.64	PASS	NA	NA	176982	Benign	NA	NA	Body mass index[26426971;26426971];Response to antipsychotic treatment in schizophrenia (reasoning)[21107309];Height[20881960];	NA	NA	NA	NA	NA	Expressed in brain, and to a lesser extent in lung, kidney and testis.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.375	N	N	S	N	0.97172769797035	E	Prkcz	vision/eye phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); pigmentation phenotype; hematopoietic system phenotype; homeostasis/metabolism phenotype; 	prkcz	dorsal longitudinal anastomotic vessel	aplastic	abnormal	0.4571	0.9519	0.9503	0.506	0.9622	0.669928	0.5047	0.447911	0.464696	PASS	0.576023	0.592	379	0.620567	65	chr1	2056554	NA	T	C	437.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=4.863;AS_MQ=60;AS_MQRankSum=0;AS_QD=5.92;AS_ReadPosRankSum=-1.1;AS_SOR=0.455;BaseQRankSum=0.051;DP=74;ExcessHet=3.0103;FS=4.863;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=5.91;ReadPosRankSum=-1.092;SOR=0.455	GT:AD:DP:GQ:PL	0/1:49,25:74:99:445,0,1087
chr1	2059575	2059575	A	G	PRKCZ	exonic	synonymous SNV	NA	PRKCZ:NM_002744:exon4:c.A318G:p.P106P	0.4891	GnomAdGenome_AF_eas	58	11	HeterozygousVariant	het	108	56	52	0.481481481481481	1155.64	PASS	NA	NA	176982	Benign	NA	NA	Body mass index[26426971;26426971];Response to antipsychotic treatment in schizophrenia (reasoning)[21107309];Height[20881960];	NA	NA	NA	NA	NA	Expressed in brain, and to a lesser extent in lung, kidney and testis.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.375	N	N	S	N	0.97172769797035	E	Prkcz	vision/eye phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); pigmentation phenotype; hematopoietic system phenotype; homeostasis/metabolism phenotype; 	prkcz	dorsal longitudinal anastomotic vessel	aplastic	abnormal	0.2114	0.4796	0.4835	0.1634	0.4891	0.23762	0.1531	0.202003	0.182266	PASS	0.265244	0.267	314	0.288732	60	chr1	2059575	NA	A	G	1155.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.4;AS_FS=0.72;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.7;AS_ReadPosRankSum=1.3;AS_SOR=0.565;BaseQRankSum=1.46;DP=111;ExcessHet=3.0103;FS=0.72;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.7;ReadPosRankSum=1.39;SOR=0.565	GT:AD:DP:GQ:PL	0/1:56,52:108:99:1163,0,1189
chr1	2074301	2074301	T	C	PRKCZ	intronic	NA	NA	NA	0.999	GnomAdExome_AF_eas	708	128	HomozygousVariant	hom	152	0	152	1	4016.06	PASS	NA	NA	176982	NA	NA	NA	Body mass index[26426971;26426971];Response to antipsychotic treatment in schizophrenia (reasoning)[21107309];Height[20881960];	NA	NA	NA	NA	NA	Expressed in brain, and to a lesser extent in lung, kidney and testis.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.375	N	N	S	N	0.97172769797035	E	Prkcz	vision/eye phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); pigmentation phenotype; hematopoietic system phenotype; homeostasis/metabolism phenotype; 	prkcz	dorsal longitudinal anastomotic vessel	aplastic	abnormal	0.8706	0.999	0.9993	0.8875	0.9984	0.932508	0	0.287001	0.897942	PASS	0	0.945	88	0.957143	12	chr1	2074301	NA	T	C	4016.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.42;AS_ReadPosRankSum=.;AS_SOR=0.803;DP=159;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.42;SOR=0.803	GT:AD:DP:GQ:PL	1/1:0,152:152:99:4030,452,0
chr1	2194700	2194700	C	G	FAAP20	exonic	nonsynonymous SNV	NA	FAAP20:NM_001256945:exon1:c.G50C:p.R17P,FAAP20:NM_001256946:exon1:c.G50C:p.R17P,FAAP20:NM_001256947:exon1:c.G50C:p.R17P,FAAP20:NM_001282673:exon1:c.G50C:p.R17P,FAAP20:NM_182533:exon1:c.G50C:p.R17P	1	GnomAdExome_AF_afr	297	79	HomozygousVariant	hom	9	0	9	1	224.05	PASS	14.29	NA	615183	Benign	NA	NA	Body mass index[26426971;26426971];	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	N	T	N	T	T	T	NA	NA	T	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Faap20	endocrine/exocrine gland phenotype; cellular phenotype; reproductive system phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.9961	1	1	1	1	0	0	0.0159442	1	PASS	0	0.127	0	1	0	chr1	2194700	NA	C	G	224.05	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=24.89;AS_ReadPosRankSum=.;AS_SOR=0.892;DP=11;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=24.89;SOR=0.892	GT:AD:DP:GQ:PL	1/1:0,9:9:27:238,27,0
chr1	2355481	2355481	C	T	MORN1	intronic	NA	NA	NA	0.3319	GnomAdExome_AF_afr	11	1	HeterozygousVariant	het	70	35	35	0.5	763.64	PASS	NA	NA	NA	NA	NA	NA	Body mass index[26426971;26426971];Serum folate levels[29953918];Coronary artery disease[29212778;29212778;29212778];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.788	NA	N	N	N	0.866389995007417	E	Morn1	NA	NA	NA	NA	NA	0.0465	0.3319	0.3317	0.1098	0.3206	0.157149	0	0.0177811	0		0	0.112	107	0.123239	33	chr1	2355481	NA	C	T	763.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.91;AS_ReadPosRankSum=-0.2;AS_SOR=0.81;BaseQRankSum=0.251;DP=70;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.91;ReadPosRankSum=-0.123;SOR=0.81	GT:AD:DP:GQ:PL	0/1:35,35:70:99:771,0,741
chr1	2355508	2355508	A	G	MORN1	intronic	NA	NA	NA	0.9514	GnomAdExome_AF_afr	252	126	HomozygousVariant	hom	57	0	57	1	1618.06	PASS	NA	NA	NA	NA	NA	NA	Body mass index[26426971;26426971];Serum folate levels[29953918];Coronary artery disease[29212778;29212778;29212778];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.788	NA	N	N	N	0.866389995007417	E	Morn1	NA	NA	NA	NA	NA	0.8289	0.9514	0.9534	0.8374	0.9424	0.882987	0	0.0001537	0		0	0.918	43	0.940141	15	chr1	2355508	NA	A	G	1618.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.39;AS_ReadPosRankSum=.;AS_SOR=1.238;DP=59;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.39;SOR=1.238	GT:AD:DP:GQ:PL	1/1:0,57:57:99:1632,171,0
chr1	2400952	2400952	C	T	RER1	intronic	NA	NA	NA	0.5367	GnomAdGenome_AF_fin	28	18	HeterozygousVariant	het	40	26	14	0.35	290.64	PASS	NA	NA	NA	NA	NA	NA	Body mass index[26426971;26426971];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Low	pharynx;cornea;stomach;testis;pineal gland;choroid;kidney;uterus;whole body;pancreas;bile duct;adrenal gland;skeletal muscle;islets of Langerhans;visual apparatus;vein;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;optic nerve;intestine;tongue;alveolus;skin;lymphoreticular;unclassifiable (Anatomical System);retina;head and neck;mammary gland;umbilical cord;cervix;pineal body;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;ovary;lymph node;colon;aorta;prostate;	thyroid;liver;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;placenta;prostate;testis;globus pallidus;	0.0535	N	N	S	NA	0.862984749831986	E	Rer1	muscle phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	rer1	retinal rod cell	decreased amount	abnormal	0.4128	0.4506	0.457	0.3977	0.5367	0.340256	0.3945	0.404212	0.396552	PASS	0	0.314	131	0.327465	57	chr1	2400952	NA	C	T	290.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.28;AS_ReadPosRankSum=-1.8;AS_SOR=0.807;BaseQRankSum=1.64;DP=42;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.27;ReadPosRankSum=-1.746;SOR=0.807	GT:AD:DP:GQ:PL	0/1:26,14:40:99:298,0,561
chr1	2405755	2405755	C	T	PEX10	UTR3	NA	NM_002617:c.*11G>A;NM_153818:c.*11G>A	NA	0.0767	GnomAdGenome_AF_sas	9	3	HeterozygousVariant	het	77	35	42	0.545454545454545	993.64	PASS	NA	[MIM:614870]Peroxisome biogenesis disorder complementation group 7;[MIM:614870]Peroxisome biogenesis disorder 6A;[MIM:614871]Peroxisome biogenesis disorder 6B;	602859	NA	Zellweger syndrome;Neonatal adrenoleukodystrophy;Autosomal recessive ataxia due to PEX10 deficiency;Infantile Refsum disease	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Body mass index[26426971;26426971];Non-obstructive azoospermia[22197933];	HP:0001392;HP:0000505;HP:0000486;HP:0008207;HP:0000518;HP:0000174;HP:0000348;HP:0000368;HP:0000463;HP:0000508;HP:0007703;HP:0011344;HP:0000256;HP:0000407;HP:0001250;HP:0002269;HP:0002353;HP:0000648;HP:0001252;HP:0007598;HP:0000260;HP:0001347;HP:0004322;HP:0000639;HP:0000431;HP:0000268;HP:0001939;HP:0002376;HP:0000007;HP:0001290;HP:0001410;HP:0011344;HP:0001302;HP:0002240;HP:0003678;HP:0000369;HP:0008872;HP:0000431;HP:0010655;HP:0030048;HP:0001250;HP:0000107;HP:0008935;HP:0001256;HP:0007256;HP:0007772;HP:0002078;HP:0007002;HP:0011499;HP:0002070;HP:0001347;HP:0002457;HP:0007240;HP:0008167;HP:0005978;HP:0100275;HP:0001260;HP:0001761;HP:0002073;HP:0010965;HP:0001260;HP:0002080;HP:0000556;HP:0000639;HP:0001272;HP:0007772;HP:0001761;HP:0002500;HP:0003693;HP:0000007;HP:0001410;HP:0001263;HP:0003677;HP:0001319;HP:0000407;HP:0000505;HP:0001290;HP:0001251;HP:0001265;HP:0000641;HP:0002936;HP:0003828;HP:0000286;HP:0000003;HP:0000474;HP:0000407;HP:0001622;HP:0009891;HP:0000639;HP:0000952;HP:0001399;HP:0002021;HP:0005280;HP:0000582;HP:0000347;HP:0000256;HP:0002240;HP:0006829;HP:0100543;HP:0001315;HP:0008872;HP:0000532;HP:0002353;HP:0000218;HP:0012736;HP:0001629;HP:0008167;HP:0000627;HP:0002126;HP:0007957;HP:0000028;HP:0002652;HP:0000260;HP:0000431;HP:0000505;HP:0000126;HP:0004322;HP:0008572;HP:0000348;HP:0000252;HP:0001522;HP:0000047;HP:0001508;HP:0000518;HP:0001928;HP:0010655;HP:0008665;HP:0000648;HP:0001088;HP:0008207;HP:0012368;HP:0005469;HP:0000501;HP:0000157;HP:0001250;HP:0002024;HP:0002093;HP:0002240;HP:0008064;HP:0011675;HP:0000518;HP:0001263;HP:0000407;HP:0005930;HP:0000639;HP:0000662;HP:0001257;HP:0001250;HP:0001508;HP:0000708;HP:0000510;HP:0001638;HP:0001133;HP:0004322;HP:0008167;HP:0010571;HP:0003323;HP:0010628;HP:0000648;HP:0001251;HP:0001252	Abnormality of the liver;Visual impairment;Strabismus;Primary adrenal insufficiency;Cataract;Abnormal palate morphology;High forehead;Low-set, posteriorly rotated ears;Anteverted nares;Ptosis;Abnormality of retinal pigmentation;Severe global developmental delay;Macrocephaly;Sensorineural hearing impairment;Seizure;Abnormality of neuronal migration;EEG abnormality;Optic atrophy;Muscular hypotonia;Bilateral single transverse palmar creases;Wide anterior fontanel;Hyperreflexia;Short stature;Nystagmus;Wide nasal bridge;Dolichocephaly;Abnormality of metabolism/homeostasis;Developmental regression;Autosomal recessive inheritance;Generalized hypotonia;Decreased liver function;Severe global developmental delay;Pachygyria;Hepatomegaly;Rapidly progressive;Low-set ears;Feeding difficulties in infancy;Wide nasal bridge;Epiphyseal stippling;Colpocephaly;Seizure;Renal cyst;Generalized neonatal hypotonia;Intellectual disability, mild;Abnormal pyramidal sign;Impaired smooth pursuit;Truncal ataxia;Motor axonal neuropathy;Mydriasis;Limb ataxia;Hyperreflexia;Abnormal head movements;Progressive gait ataxia;Very long chain fatty acid accumulation;Type II diabetes mellitus;Diffuse cerebellar atrophy;Dysarthria;Pes cavus;Progressive cerebellar ataxia;Abnormal circulating phytanic acid level;Dysarthria;Intention tremor;Retinal dystrophy;Nystagmus;Cerebellar atrophy;Impaired smooth pursuit;Pes cavus;Abnormality of the cerebral white matter;Distal amyotrophy;Autosomal recessive inheritance;Decreased liver function;Global developmental delay;Slow progression;Neonatal hypotonia;Sensorineural hearing impairment;Visual impairment;Generalized hypotonia;Ataxia;Hyporeflexia;Dysmetric saccades;Distal sensory impairment;Variable expressivity;Epicanthus;Multicystic kidney dysplasia;Thickened nuchal skin fold;Sensorineural hearing impairment;Premature birth;Underdeveloped supraorbital ridges;Nystagmus;Jaundice;Hepatic failure;Pyloric stenosis;Depressed nasal bridge;Upslanted palpebral fissure;Micrognathia;Macrocephaly;Hepatomegaly;Severe muscular hypotonia;Cognitive impairment;Reduced tendon reflexes;Feeding difficulties in infancy;Abnormal chorioretinal morphology;EEG abnormality;High palate;Profound global developmental delay;Ventricular septal defect;Very long chain fatty acid accumulation;Posterior embryotoxon;Polymicrogyria;Corneal opacity;Cryptorchidism;Skeletal dysplasia;Wide anterior fontanel;Wide nasal bridge;Visual impairment;Hydronephrosis;Short stature;External ear malformation;High forehead;Microcephaly;Death in infancy;Hypospadias;Failure to thrive;Cataract;Abnormality of coagulation;Epiphyseal stippling;Clitoral hypertrophy;Optic atrophy;Brushfield spots;Primary adrenal insufficiency;Flat face;Flat occiput;Glaucoma;Abnormality of the tongue;Seizure;Malabsorption;Respiratory insufficiency;Hepatomegaly;Ichthyosis;Arrhythmia;Cataract;Global developmental delay;Sensorineural hearing impairment;Abnormality of epiphysis morphology;Nystagmus;Nyctalopia;Spasticity;Seizure;Failure to thrive;Behavioral abnormality;Rod-cone dystrophy;Cardiomyopathy;Constriction of peripheral visual field;Short stature;Very long chain fatty acid accumulation;Elevated levels of phytanic acid;Progressive muscle weakness;Facial palsy;Optic atrophy;Ataxia;Muscular hypotonia	Peroxisome_biogenesis_disorder_6A|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;bile duct;mammary gland;islets of Langerhans;visual apparatus;cervix;fovea centralis;pineal body;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;macula lutea;oesophagus;colon;placenta;prostate;optic nerve;hypothalamus;	NA	0.234	NA	E	S	N	0.87577753265438	E	Pex10	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; 	NA	NA	NA	NA	0.0281	0.0722	0.072	0.0352	0.0767	0.0617013	0.0344	0.0275352	0.023849	PASS	0	0.081	116	0.102113	23	chr1	2405755	NA	C	T	993.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=1.854;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.91;AS_ReadPosRankSum=-1.4;AS_SOR=0.919;BaseQRankSum=-0.623;DP=80;ExcessHet=3.0103;FS=1.854;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.9;ReadPosRankSum=-1.315;SOR=0.919	GT:AD:DP:GQ:PL	0/1:35,42:77:99:1001,0,817
chr1	2408761	2408761	T	C	PEX10	exonic	synonymous SNV	NA	PEX10:NM_002617:exon3:c.A291G:p.T97T,PEX10:NM_153818:exon3:c.A291G:p.T97T	0.8638	GnomAdGenome_AF_ami	428	66	HomozygousVariant	hom	117	0	117	1	3255.06	PASS	NA	[MIM:614870]Peroxisome biogenesis disorder complementation group 7;[MIM:614870]Peroxisome biogenesis disorder 6A;[MIM:614871]Peroxisome biogenesis disorder 6B;	602859	Benign	Zellweger syndrome;Neonatal adrenoleukodystrophy;Autosomal recessive ataxia due to PEX10 deficiency;Infantile Refsum disease	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Body mass index[26426971;26426971];Non-obstructive azoospermia[22197933];	HP:0001392;HP:0000505;HP:0000486;HP:0008207;HP:0000518;HP:0000174;HP:0000348;HP:0000368;HP:0000463;HP:0000508;HP:0007703;HP:0011344;HP:0000256;HP:0000407;HP:0001250;HP:0002269;HP:0002353;HP:0000648;HP:0001252;HP:0007598;HP:0000260;HP:0001347;HP:0004322;HP:0000639;HP:0000431;HP:0000268;HP:0001939;HP:0002376;HP:0000007;HP:0001290;HP:0001410;HP:0011344;HP:0001302;HP:0002240;HP:0003678;HP:0000369;HP:0008872;HP:0000431;HP:0010655;HP:0030048;HP:0001250;HP:0000107;HP:0008935;HP:0001256;HP:0007256;HP:0007772;HP:0002078;HP:0007002;HP:0011499;HP:0002070;HP:0001347;HP:0002457;HP:0007240;HP:0008167;HP:0005978;HP:0100275;HP:0001260;HP:0001761;HP:0002073;HP:0010965;HP:0001260;HP:0002080;HP:0000556;HP:0000639;HP:0001272;HP:0007772;HP:0001761;HP:0002500;HP:0003693;HP:0000007;HP:0001410;HP:0001263;HP:0003677;HP:0001319;HP:0000407;HP:0000505;HP:0001290;HP:0001251;HP:0001265;HP:0000641;HP:0002936;HP:0003828;HP:0000286;HP:0000003;HP:0000474;HP:0000407;HP:0001622;HP:0009891;HP:0000639;HP:0000952;HP:0001399;HP:0002021;HP:0005280;HP:0000582;HP:0000347;HP:0000256;HP:0002240;HP:0006829;HP:0100543;HP:0001315;HP:0008872;HP:0000532;HP:0002353;HP:0000218;HP:0012736;HP:0001629;HP:0008167;HP:0000627;HP:0002126;HP:0007957;HP:0000028;HP:0002652;HP:0000260;HP:0000431;HP:0000505;HP:0000126;HP:0004322;HP:0008572;HP:0000348;HP:0000252;HP:0001522;HP:0000047;HP:0001508;HP:0000518;HP:0001928;HP:0010655;HP:0008665;HP:0000648;HP:0001088;HP:0008207;HP:0012368;HP:0005469;HP:0000501;HP:0000157;HP:0001250;HP:0002024;HP:0002093;HP:0002240;HP:0008064;HP:0011675;HP:0000518;HP:0001263;HP:0000407;HP:0005930;HP:0000639;HP:0000662;HP:0001257;HP:0001250;HP:0001508;HP:0000708;HP:0000510;HP:0001638;HP:0001133;HP:0004322;HP:0008167;HP:0010571;HP:0003323;HP:0010628;HP:0000648;HP:0001251;HP:0001252	Abnormality of the liver;Visual impairment;Strabismus;Primary adrenal insufficiency;Cataract;Abnormal palate morphology;High forehead;Low-set, posteriorly rotated ears;Anteverted nares;Ptosis;Abnormality of retinal pigmentation;Severe global developmental delay;Macrocephaly;Sensorineural hearing impairment;Seizure;Abnormality of neuronal migration;EEG abnormality;Optic atrophy;Muscular hypotonia;Bilateral single transverse palmar creases;Wide anterior fontanel;Hyperreflexia;Short stature;Nystagmus;Wide nasal bridge;Dolichocephaly;Abnormality of metabolism/homeostasis;Developmental regression;Autosomal recessive inheritance;Generalized hypotonia;Decreased liver function;Severe global developmental delay;Pachygyria;Hepatomegaly;Rapidly progressive;Low-set ears;Feeding difficulties in infancy;Wide nasal bridge;Epiphyseal stippling;Colpocephaly;Seizure;Renal cyst;Generalized neonatal hypotonia;Intellectual disability, mild;Abnormal pyramidal sign;Impaired smooth pursuit;Truncal ataxia;Motor axonal neuropathy;Mydriasis;Limb ataxia;Hyperreflexia;Abnormal head movements;Progressive gait ataxia;Very long chain fatty acid accumulation;Type II diabetes mellitus;Diffuse cerebellar atrophy;Dysarthria;Pes cavus;Progressive cerebellar ataxia;Abnormal circulating phytanic acid level;Dysarthria;Intention tremor;Retinal dystrophy;Nystagmus;Cerebellar atrophy;Impaired smooth pursuit;Pes cavus;Abnormality of the cerebral white matter;Distal amyotrophy;Autosomal recessive inheritance;Decreased liver function;Global developmental delay;Slow progression;Neonatal hypotonia;Sensorineural hearing impairment;Visual impairment;Generalized hypotonia;Ataxia;Hyporeflexia;Dysmetric saccades;Distal sensory impairment;Variable expressivity;Epicanthus;Multicystic kidney dysplasia;Thickened nuchal skin fold;Sensorineural hearing impairment;Premature birth;Underdeveloped supraorbital ridges;Nystagmus;Jaundice;Hepatic failure;Pyloric stenosis;Depressed nasal bridge;Upslanted palpebral fissure;Micrognathia;Macrocephaly;Hepatomegaly;Severe muscular hypotonia;Cognitive impairment;Reduced tendon reflexes;Feeding difficulties in infancy;Abnormal chorioretinal morphology;EEG abnormality;High palate;Profound global developmental delay;Ventricular septal defect;Very long chain fatty acid accumulation;Posterior embryotoxon;Polymicrogyria;Corneal opacity;Cryptorchidism;Skeletal dysplasia;Wide anterior fontanel;Wide nasal bridge;Visual impairment;Hydronephrosis;Short stature;External ear malformation;High forehead;Microcephaly;Death in infancy;Hypospadias;Failure to thrive;Cataract;Abnormality of coagulation;Epiphyseal stippling;Clitoral hypertrophy;Optic atrophy;Brushfield spots;Primary adrenal insufficiency;Flat face;Flat occiput;Glaucoma;Abnormality of the tongue;Seizure;Malabsorption;Respiratory insufficiency;Hepatomegaly;Ichthyosis;Arrhythmia;Cataract;Global developmental delay;Sensorineural hearing impairment;Abnormality of epiphysis morphology;Nystagmus;Nyctalopia;Spasticity;Seizure;Failure to thrive;Behavioral abnormality;Rod-cone dystrophy;Cardiomyopathy;Constriction of peripheral visual field;Short stature;Very long chain fatty acid accumulation;Elevated levels of phytanic acid;Progressive muscle weakness;Facial palsy;Optic atrophy;Ataxia;Muscular hypotonia	Peroxisome_biogenesis_disorder_6A|Zellweger_syndrome|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;bile duct;mammary gland;islets of Langerhans;visual apparatus;cervix;fovea centralis;pineal body;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;macula lutea;oesophagus;colon;placenta;prostate;optic nerve;hypothalamus;	NA	0.234	NA	E	S	N	0.87577753265438	E	Pex10	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; 	NA	NA	NA	NA	0.7735	0.8112	0.812	0.7415	0.8638	0.698882	0.7438	0.0001153	0.761084	PASS	0.77439	0.717	343	0.679577	61	chr1	2408761	NA	T	C	3255.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.82;AS_ReadPosRankSum=.;AS_SOR=0.745;DP=122;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.82;SOR=0.745	GT:AD:DP:GQ:PL	1/1:0,117:117:99:3269,351,0
chr1	2467680	2467680	A	G	PLCH2	intronic	NA	NA	NA	0.8756	GnomAdGenome_AF_eas	233	54	HeterozygousVariant	het	66	38	28	0.424242424242424	999.64	PASS	NA	NA	612836	NA	NA	NA	Body mass index[26426971];Schizophrenia[25056061];Ulcerative colitis[21297633;23128233];	NA	NA	NA	NA	NA	Expressed in retina and kidney. {ECO:0000269|PubMed:16107206}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;amygdala;substantia nigra;germinal center;brain;lens;pineal gland;unclassifiable (Anatomical System);lung;choroid;kidney;retina;macula lutea;whole body;lymph node;pancreas;colon;mammary gland;optic nerve;islets of Langerhans;visual apparatus;	ciliary ganglion;temporal lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;cingulate cortex;skeletal muscle;cerebellum;	NA	N	NA	N	N	0.394096840921037	N	Plch2	normal phenotype; 	NA	NA	NA	NA	0.4981	0.8421	0.7857	0.6162	0.8756	0.720048	0	0.11474	0		0	0.624	190	0.639831	43	chr1	2467680	NA	A	G	999.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.5;AS_FS=2.051;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.15;AS_ReadPosRankSum=2.6;AS_SOR=0.997;BaseQRankSum=1.53;DP=67;ExcessHet=3.0103;FS=2.051;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.15;ReadPosRankSum=2.61;SOR=0.997	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:38,28:66:99:0|1:2467680_A_G:1007,0,1208:2467680
chr1	2467710	2467710	A	G	PLCH2	intronic	NA	NA	NA	0.8746	GnomAdGenome_AF_eas	116	58	HeterozygousVariant	het	49	24	25	0.510204081632653	955.64	PASS	NA	NA	612836	NA	NA	NA	Body mass index[26426971];Schizophrenia[25056061];Ulcerative colitis[21297633;23128233];	NA	NA	NA	NA	NA	Expressed in retina and kidney. {ECO:0000269|PubMed:16107206}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;amygdala;substantia nigra;germinal center;brain;lens;pineal gland;unclassifiable (Anatomical System);lung;choroid;kidney;retina;macula lutea;whole body;lymph node;pancreas;colon;mammary gland;optic nerve;islets of Langerhans;visual apparatus;	ciliary ganglion;temporal lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;cingulate cortex;skeletal muscle;cerebellum;	NA	N	NA	N	N	0.394096840921037	N	Plch2	normal phenotype; 	NA	NA	NA	NA	0.4409	0.75	0.75	0.5858	0.8746	0.698682	0	0.106118	0		0	0.622	130	0.641667	38	chr1	2467710	NA	A	G	955.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=19.51;AS_ReadPosRankSum=-1;AS_SOR=0.76;BaseQRankSum=-0.086;DP=50;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=19.5;ReadPosRankSum=-0.981;SOR=0.76	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:24,25:49:99:0|1:2467680_A_G:963,0,888:2467680
chr1	2499178	2499178	C	T	PLCH2	exonic	synonymous SNV	NA	PLCH2:NM_001303012:exon19:c.C2448T:p.I816I,PLCH2:NM_001303013:exon19:c.C2589T:p.I863I,PLCH2:NM_014638:exon19:c.C2529T:p.I843I	0.6711	GnomAdGenome_AF_ami	61	15	HeterozygousVariant	het	162	75	87	0.537037037037037	1959.64	PASS	NA	NA	612836	Benign	NA	NA	Body mass index[26426971];Schizophrenia[25056061];Ulcerative colitis[21297633;23128233];	NA	NA	NA	NA	NA	Expressed in retina and kidney. {ECO:0000269|PubMed:16107206}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;amygdala;substantia nigra;germinal center;brain;lens;pineal gland;unclassifiable (Anatomical System);lung;choroid;kidney;retina;macula lutea;whole body;lymph node;pancreas;colon;mammary gland;optic nerve;islets of Langerhans;visual apparatus;	ciliary ganglion;temporal lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;cingulate cortex;skeletal muscle;cerebellum;	NA	N	NA	N	N	0.394096840921037	N	Plch2	normal phenotype; 	NA	NA	NA	NA	0.4337	0.5178	0.518	0.3853	0.6711	0.366613	0.3866	0.42632	0.460591	PASS	0.5	0.314	247	0.338028	66	chr1	2499178	NA	C	T	1959.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.246;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.1;AS_ReadPosRankSum=-0.2;AS_SOR=0.565;BaseQRankSum=0.423;DP=167;ExcessHet=3.0103;FS=1.246;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.1;ReadPosRankSum=-0.109;SOR=0.565	GT:AD:DP:GQ:PL	0/1:75,87:162:99:1967,0,1560
chr1	2502461	2502461	C	T	PLCH2	exonic	nonsynonymous SNV	NA	PLCH2:NM_001303012:exon21:c.C2930T:p.P977L	0.7322	GnomAdGenome_AF_ami	62	15	HeterozygousVariant	het	50	33	17	0.34	383.64	PASS	1.489	NA	612836	Benign	NA	NA	Body mass index[26426971];Schizophrenia[25056061];Ulcerative colitis[21297633;23128233];	NA	NA	NA	NA	NA	Expressed in retina and kidney. {ECO:0000269|PubMed:16107206}.;	T	T	B	B	NA	P	NA	T	N	T	T	T	NA	NA	NA	T	T	NA	.;	N	N	NA	NA	NA	Medium	Medium	Medium	fovea centralis;amygdala;substantia nigra;germinal center;brain;lens;pineal gland;unclassifiable (Anatomical System);lung;choroid;kidney;retina;macula lutea;whole body;lymph node;pancreas;colon;mammary gland;optic nerve;islets of Langerhans;visual apparatus;	ciliary ganglion;temporal lobe;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;cingulate cortex;skeletal muscle;cerebellum;	NA	N	NA	N	N	0.394096840921037	N	Plch2	normal phenotype; 	NA	NA	NA	NA	0.4623	0.5212	0.5237	0.4181	0.7322	0.379792	0	0.0001153	0.502513	PASS	0	0.324	252	0.343972	67	chr1	2502461	NA	C	T	383.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.3;AS_FS=2.678;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.68;AS_ReadPosRankSum=1.5;AS_SOR=1.292;BaseQRankSum=2.39;DP=53;ExcessHet=3.0103;FS=2.678;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.67;ReadPosRankSum=1.57;SOR=1.292	GT:AD:DP:GQ:PL	0/1:33,17:50:99:391,0,773
chr1	2512975	2512975	G	A	PANK4	exonic	nonsynonymous SNV	NA	PANK4:NM_018216:exon13:c.C1640T:p.A547V	0.5022	GnomAdGenome_AF_ami	26	5	HeterozygousVariant	het	204	84	120	0.588235294117647	2534.64	PASS	19.04	NA	606162	Benign	NA	NA	Obesity-related traits[23251661];	NA	NA	NA	NA	NA	Ubiquitously expressed with higher expression in the muscle. {ECO:0000269|PubMed:11479594}.;	NA	T	NA	NA	N	P	NA	NA	NA	T	T	T	NA	T	NA	T	T	T	.;.;	D	N	.;Domain of unknown function DUF89	NA	NA	Medium	Medium	Medium	NA	NA	0.0792	NA	N	N	N	0.957315720354982	E	Pank4	NA	NA	NA	NA	NA	0.315	0.375	0.3736	0.2714	0.5022	0.225639	0.2721	0.31268	0.324302	PASS	0.45	0.213	198	0.21831	52	chr1	2512975	NA	G	A	2534.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.43;AS_ReadPosRankSum=0.7;AS_SOR=0.693;BaseQRankSum=-0.28;DP=207;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.42;ReadPosRankSum=0.733;SOR=0.693	GT:AD:DP:GQ:PL	0/1:84,120:204:99:2542,0,1648
chr1	2521130	2521130	T	C	PANK4	exonic	synonymous SNV	NA	PANK4:NM_018216:exon3:c.A393G:p.K131K	0.965	GnomAdExome_AF_eas	313	97	HeterozygousVariant	het	171	91	80	0.467836257309942	1789.64	PASS	NA	NA	606162	Benign	NA	NA	Obesity-related traits[23251661];	NA	NA	NA	NA	NA	Ubiquitously expressed with higher expression in the muscle. {ECO:0000269|PubMed:11479594}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0792	NA	N	N	N	0.957315720354982	E	Pank4	NA	NA	NA	NA	NA	0.7805	0.965	0.9665	0.7975	0.962	0.846046	0.7952	0.768593	0.833333	PASS	0.787879	0.792	161	0.823944	40	chr1	2521130	NA	T	C	1789.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=1.218;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.47;AS_ReadPosRankSum=0.7;AS_SOR=0.821;BaseQRankSum=1.22;DP=176;ExcessHet=3.0103;FS=1.218;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.47;ReadPosRankSum=0.728;SOR=0.821	GT:AD:DP:GQ:PL	0/1:91,80:171:99:1797,0,1996
chr1	2556714	2556714	A	G	TNFRSF14	exonic	nonsynonymous SNV	NA	TNFRSF14:NM_001297605:exon1:c.A50G:p.K17R,TNFRSF14:NM_003820:exon1:c.A50G:p.K17R	0.7267	GnomAdExome_AF_afr	370	66	HeterozygousVariant	het	127	66	61	0.480314960629921	1291.64	PASS	5.987	NA	602746	Benign	NA	NA	'Inflammatory bowel disease[28067908];Celiac disease[20190752];Body mass index[26426971];Multiple sclerosis[28445677];Allergic disease (asthma, hay fever or eczema)[29083406];Rheumatoid arthritis[18794853;24390342;24390342;24390342;20453842;24449572];Chronic inflammatory diseases (ankylosing spondylitis, Crohn''s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)[26974007];Ulcerative colitis[21297633;23128233;28067908];'	NA	NA	not_specified	no_assertion_provided	not_provided	Widely expressed, with the highest expression in lung, spleen and thymus.;	T	T	B	B	NA	P	L	D	N	T	T	T	NA	T	T	T	T	NA	.;.;.;.;.;.;	N	N	.;.;.;.;.;.	NA	NA	Medium	Medium	Medium	alveolus;smooth muscle;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;head and neck;mammary gland;skeletal muscle;visual apparatus;iris;spleen;liver;cartilage;endometrium;germinal center;parathyroid;brain;blood;heart;lung;ovary;thyroid;lymph node;oesophagus;frontal lobe;sympathetic chain;colon;placenta;prostate;hypothalamus;	superior cervical ganglion;skeletal muscle;	0.186	N	N	N	N	0.860306174112817	E	Tnfrsf14	hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; digestive/alimentary phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.5136	0.7267	0.7319	0.5561	0.7166	0.614816	0.558	0.490459	0.516474	PASS	0.675258	0.671	345	0.680851	60	chr1	2556714	NA	A	G	1291.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0.657;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.17;AS_ReadPosRankSum=1.5;AS_SOR=0.793;BaseQRankSum=0.013;DP=128;ExcessHet=3.0103;FS=0.657;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.17;ReadPosRankSum=1.51;SOR=0.793	GT:AD:DP:GQ:PL	0/1:66,61:127:99:1299,0,1452
chr1	2559867	2559867	G	A	TNFRSF14	exonic	nonsynonymous SNV	NA	TNFRSF14:NM_001297605:exon4:c.G349A:p.A117T,TNFRSF14:NM_003820:exon4:c.G349A:p.A117T	0.0435	GnomAdGenome_AF_eas	0	0	HeterozygousVariant	het	210	108	102	0.485714285714286	2252.64	PASS	0.034	NA	602746	Likely benign	NA	NA	'Inflammatory bowel disease[28067908];Celiac disease[20190752];Body mass index[26426971];Multiple sclerosis[28445677];Allergic disease (asthma, hay fever or eczema)[29083406];Rheumatoid arthritis[18794853;24390342;24390342;24390342;20453842;24449572];Chronic inflammatory diseases (ankylosing spondylitis, Crohn''s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)[26974007];Ulcerative colitis[21297633;23128233;28067908];'	NA	NA	not_specified	no_assertion_provided	not_provided	Widely expressed, with the highest expression in lung, spleen and thymus.;	T	T	P	B	NA	N	N	D	N	T	T	T	NA	T	T	T	T	NA	.;.;.;.;.;.;	N	N	TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|Tumor necrosis factor receptor 14/UL144, N-terminal;TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|Tumor necrosis factor receptor 14/UL144, N-terminal;TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|Tumor necrosis factor receptor 14/UL144, N-terminal;TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|Tumor necrosis factor receptor 14/UL144, N-terminal;TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|Tumor necrosis factor receptor 14/UL144, N-terminal;TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|TNFR/NGFR cysteine-rich region|Tumor necrosis factor receptor 14/UL144, N-terminal	NA	NA	Medium	Medium	Medium	alveolus;smooth muscle;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;head and neck;mammary gland;skeletal muscle;visual apparatus;iris;spleen;liver;cartilage;endometrium;germinal center;parathyroid;brain;blood;heart;lung;ovary;thyroid;lymph node;oesophagus;frontal lobe;sympathetic chain;colon;placenta;prostate;hypothalamus;	superior cervical ganglion;skeletal muscle;	0.186	N	N	N	N	0.860306174112817	E	Tnfrsf14	hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; digestive/alimentary phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.0107	0.0383	0.0387	0.0153	0.0435	0.0211661	0.0157	0.0100646	0.016474	PASS	0.015432	0.028	45	0.010563	3	chr1	2559867	NA	G	A	2252.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=0.506;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.73;AS_ReadPosRankSum=-1.4;AS_SOR=0.627;BaseQRankSum=-0.86;DP=211;ExcessHet=3.0103;FS=0.506;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.73;ReadPosRankSum=-1.317;SOR=0.627	GT:AD:DP:GQ:PL	0/1:108,102:210:99:2260,0,2582
chr1	2562891	2562891	G	A	TNFRSF14	exonic	nonsynonymous SNV	NA	TNFRSF14:NM_003820:exon7:c.G721A:p.V241I	0.237805	GME_TP	28	2	HeterozygousVariant	het	263	151	112	0.425855513307985	2228.64	PASS	0.037	NA	602746	Benign	NA	NA	'Inflammatory bowel disease[28067908];Celiac disease[20190752];Body mass index[26426971];Multiple sclerosis[28445677];Allergic disease (asthma, hay fever or eczema)[29083406];Rheumatoid arthritis[18794853;24390342;24390342;24390342;20453842;24449572];Chronic inflammatory diseases (ankylosing spondylitis, Crohn''s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)[26974007];Ulcerative colitis[21297633;23128233;28067908];'	NA	NA	not_specified	no_assertion_provided	not_provided	Widely expressed, with the highest expression in lung, spleen and thymus.;	T	T	B	B	NA	P	N	D	N	T	T	T	NA	T	T	T	T	NA	.;	N	N	NA	NA	NA	Medium	Medium	Medium	alveolus;smooth muscle;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;head and neck;mammary gland;skeletal muscle;visual apparatus;iris;spleen;liver;cartilage;endometrium;germinal center;parathyroid;brain;blood;heart;lung;ovary;thyroid;lymph node;oesophagus;frontal lobe;sympathetic chain;colon;placenta;prostate;hypothalamus;	superior cervical ganglion;skeletal muscle;	0.186	N	N	N	N	0.860306174112817	E	Tnfrsf14	hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; digestive/alimentary phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.1275	0.18	0.1776	0.1201	0.1741	0.113818	0.1233	0.127534	0.118227	PASS	0.237805	0.17	219	0.144366	37	chr1	2562891	NA	G	A	2228.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0.951;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.48;AS_ReadPosRankSum=2.1;AS_SOR=0.771;BaseQRankSum=-0.547;DP=271;ExcessHet=3.0103;FS=0.951;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.47;ReadPosRankSum=2.14;SOR=0.771	GT:AD:DP:GQ:PL	0/1:151,112:263:99:2236,0,3314
chr1	2586747	2586747	A	G	PRXL2B	upstream	NA	dist=30	NA	1	GnomAdExome_AF_afr	282	89	HomozygousVariant	hom	29	0	29	1	790.06	PASS	NA	NA	NA	NA	NA	NA	Celiac disease[22057235];Ulcerative colitis[21297633];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Fam213b	NA	NA	NA	NA	NA	0.9985	1	1	0.9996	1	1	0	0.0001153	1	PASS	0	0.021	0	1	0	chr1	2586747	NA	A	G	790.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.24;AS_ReadPosRankSum=.;AS_SOR=1.942;DP=29;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.24;SOR=1.942	GT:AD:DP:GQ:PL	1/1:0,29:29:87:804,87,0
chr1	2596694	2596694	T	C	MMEL1	intronic	NA	NA	NA	0.8474	GnomAdGenome_AF_ami	114	22	HomozygousVariant	hom	88	0	88	1	2353.06	PASS	NA	NA	618104	NA	Primary biliary cholangitis	Major susceptibility factor in	'Inflammatory bowel disease[28067908];Celiac disease[20190752;22057235];Body mass index[26426971];Multiple sclerosis[21833088;24076602;27386562];Rheumatoid arthritis (ACPA-positive)[24532676;23143596];Graves'' disease[22922229];Rheumatoid arthritis[18794853;24390342;24390342;24390342;23143596];Autoimmune thyroid diseases (Graves disease or Hashimoto''s thyroiditis)[22922229];Primary sclerosing cholangitis[27992413];Non-obstructive azoospermia[22197933];Ulcerative colitis[21297633;23128233;28067908];'	HP:0000953;HP:0003496;HP:0003155;HP:0012203;HP:0003493;HP:0004386;HP:0000820;HP:0012378;HP:0001409;HP:0000939;HP:0001541;HP:0001278;HP:0003119;HP:0003270;HP:0002908;HP:0003261;HP:0001395;HP:0001402;HP:0001394;HP:0002608;HP:0011040;HP:0003073;HP:0002613;HP:0012115;HP:0001399;HP:0011971;HP:0000989;HP:0000952;HP:0001262	Hyperpigmentation of the skin;Increased circulating IgM level;Elevated alkaline phosphatase;Onychomycosis;Antinuclear antibody positivity;Gastrointestinal inflammation;Abnormality of the thyroid gland;Fatigue;Portal hypertension;Osteoporosis;Ascites;Orthostatic hypotension;Abnormal circulating lipid concentration;Abdominal distention;Conjugated hyperbilirubinemia;Increased circulating IgA level;Hepatic fibrosis;Hepatocellular carcinoma;Cirrhosis;Celiac disease;Abnormality of the intrahepatic bile duct;Hypoalbuminemia;Biliary cirrhosis;Hepatitis;Hepatic failure;Dermatographic urticaria;Pruritus;Jaundice;Excessive daytime somnolence	NA	NA	NA	Predominantly expressed in testis. Weakly expressed in brain, kidney and heart. {ECO:0000269|PubMed:11560781}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.004	Medium	Medium	Medium	developmental;iris;cartilage;stomach;bone;testis;brain;blood;unclassifiable (Anatomical System);lung;ovary;uterus;colon;mammary gland;breast;islets of Langerhans;	NA	0.224	N	N	N	N	0.137321032144049	N	Mmel1	reproductive system phenotype; 	NA	NA	NA	NA	0.6097	0.682	0.684	0.5874	0.8474	0.501597	0.5939	0.0235131	0.606732	PASS	0	0.447	237	0.411972	73	chr1	2596694	NA	T	C	2353.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.74;AS_ReadPosRankSum=.;AS_SOR=1.055;DP=90;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.74;SOR=1.055	GT:AD:DP:GQ:PL	1/1:0,88:88:99:2367,263,0
chr1	2629443	2629443	G	A	MMEL1	exonic	synonymous SNV	NA	MMEL1:NM_033467:exon2:c.C42T:p.A14A	0.846	GnomAdGenome_AF_ami	182	27	HomozygousVariant	hom	148	0	148	1	6188.06	PASS	NA	NA	618104	Benign	Primary biliary cholangitis	Major susceptibility factor in	'Inflammatory bowel disease[28067908];Celiac disease[20190752;22057235];Body mass index[26426971];Multiple sclerosis[21833088;24076602;27386562];Rheumatoid arthritis (ACPA-positive)[24532676;23143596];Graves'' disease[22922229];Rheumatoid arthritis[18794853;24390342;24390342;24390342;23143596];Autoimmune thyroid diseases (Graves disease or Hashimoto''s thyroiditis)[22922229];Primary sclerosing cholangitis[27992413];Non-obstructive azoospermia[22197933];Ulcerative colitis[21297633;23128233;28067908];'	HP:0000953;HP:0003496;HP:0003155;HP:0012203;HP:0003493;HP:0004386;HP:0000820;HP:0012378;HP:0001409;HP:0000939;HP:0001541;HP:0001278;HP:0003119;HP:0003270;HP:0002908;HP:0003261;HP:0001395;HP:0001402;HP:0001394;HP:0002608;HP:0011040;HP:0003073;HP:0002613;HP:0012115;HP:0001399;HP:0011971;HP:0000989;HP:0000952;HP:0001262	Hyperpigmentation of the skin;Increased circulating IgM level;Elevated alkaline phosphatase;Onychomycosis;Antinuclear antibody positivity;Gastrointestinal inflammation;Abnormality of the thyroid gland;Fatigue;Portal hypertension;Osteoporosis;Ascites;Orthostatic hypotension;Abnormal circulating lipid concentration;Abdominal distention;Conjugated hyperbilirubinemia;Increased circulating IgA level;Hepatic fibrosis;Hepatocellular carcinoma;Cirrhosis;Celiac disease;Abnormality of the intrahepatic bile duct;Hypoalbuminemia;Biliary cirrhosis;Hepatitis;Hepatic failure;Dermatographic urticaria;Pruritus;Jaundice;Excessive daytime somnolence	NA	NA	NA	Predominantly expressed in testis. Weakly expressed in brain, kidney and heart. {ECO:0000269|PubMed:11560781}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;iris;cartilage;stomach;bone;testis;brain;blood;unclassifiable (Anatomical System);lung;ovary;uterus;colon;mammary gland;breast;islets of Langerhans;	NA	0.224	N	N	N	N	0.137321032144049	N	Mmel1	reproductive system phenotype; 	NA	NA	NA	NA	0.583	0.6634	0.6627	0.5396	0.846	0.461462	0.5905	0.0001153	0.575658	PASS	0.75	0.454	386	0.450355	73	chr1	2629443	NA	G	A	6188.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=32.7;AS_ReadPosRankSum=.;AS_SOR=0.748;DP=155;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.94;SOR=0.748	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,148:148:99:1|1:2629443_G_A:6202,445,0:2629443
chr1	2629464	2629464	T	G	MMEL1	exonic	synonymous SNV	NA	MMEL1:NM_033467:exon2:c.A21C:p.P7P	0.8474	GnomAdGenome_AF_ami	185	27	HomozygousVariant	hom	140	0	140	1	5957.06	PASS	NA	NA	618104	Benign	Primary biliary cholangitis	Major susceptibility factor in	'Inflammatory bowel disease[28067908];Celiac disease[20190752;22057235];Body mass index[26426971];Multiple sclerosis[21833088;24076602;27386562];Rheumatoid arthritis (ACPA-positive)[24532676;23143596];Graves'' disease[22922229];Rheumatoid arthritis[18794853;24390342;24390342;24390342;23143596];Autoimmune thyroid diseases (Graves disease or Hashimoto''s thyroiditis)[22922229];Primary sclerosing cholangitis[27992413];Non-obstructive azoospermia[22197933];Ulcerative colitis[21297633;23128233;28067908];'	HP:0000953;HP:0003496;HP:0003155;HP:0012203;HP:0003493;HP:0004386;HP:0000820;HP:0012378;HP:0001409;HP:0000939;HP:0001541;HP:0001278;HP:0003119;HP:0003270;HP:0002908;HP:0003261;HP:0001395;HP:0001402;HP:0001394;HP:0002608;HP:0011040;HP:0003073;HP:0002613;HP:0012115;HP:0001399;HP:0011971;HP:0000989;HP:0000952;HP:0001262	Hyperpigmentation of the skin;Increased circulating IgM level;Elevated alkaline phosphatase;Onychomycosis;Antinuclear antibody positivity;Gastrointestinal inflammation;Abnormality of the thyroid gland;Fatigue;Portal hypertension;Osteoporosis;Ascites;Orthostatic hypotension;Abnormal circulating lipid concentration;Abdominal distention;Conjugated hyperbilirubinemia;Increased circulating IgA level;Hepatic fibrosis;Hepatocellular carcinoma;Cirrhosis;Celiac disease;Abnormality of the intrahepatic bile duct;Hypoalbuminemia;Biliary cirrhosis;Hepatitis;Hepatic failure;Dermatographic urticaria;Pruritus;Jaundice;Excessive daytime somnolence	NA	NA	NA	Predominantly expressed in testis. Weakly expressed in brain, kidney and heart. {ECO:0000269|PubMed:11560781}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;iris;cartilage;stomach;bone;testis;brain;blood;unclassifiable (Anatomical System);lung;ovary;uterus;colon;mammary gland;breast;islets of Langerhans;	NA	0.224	N	N	N	N	0.137321032144049	N	Mmel1	reproductive system phenotype; 	NA	NA	NA	NA	0.6005	0.6753	0.6742	0.5993	0.8474	0.515775	0.6404	0.0220916	0.62603	PASS	0.722222	0.454	388	0.446429	71	chr1	2629464	NA	T	G	5957.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.96;AS_ReadPosRankSum=.;AS_SOR=0.751;DP=143;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.28;SOR=0.751	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,140:140:99:1|1:2629443_G_A:5971,421,0:2629443
chr1	2641760	2641760	A	G	TTC34	exonic	synonymous SNV	NA	TTC34:NM_001242672:exon8:c.T2848C:p.L950L	0.9985	GnomAdExome_AF_eas	509	129	HomozygousVariant	hom	111	0	111	1	3420.06	PASS	NA	NA	NA	Benign	NA	NA	Body mass index[26426971];Celiac disease[22057235];Lung cancer in ever smokers[28604730];Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)[29310926];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	NA	0.191889623350618	N	Ttc34	NA	NA	NA	NA	NA	0.8944	0.9985	0.9995	0.8947	0.9981	0.934704	0	0.0001153	0.900329	PASS	0.988764	0.934	73	0.947183	11	chr1	2641760	NA	A	G	3420.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.81;AS_ReadPosRankSum=.;AS_SOR=0.748;DP=113;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.81;SOR=0.748	GT:AD:DP:GQ:PL	1/1:0,111:111:99:3434,333,0
chr1	2645580	2645580	C	G	TTC34	intronic	NA	NA	NA	0.4833	GnomAdExome_AF_eas	0	0	WT/SomaticVariant	het	51	41	10	0.196078431372549	71.64	QD2;SOR3	NA	NA	NA	NA	NA	NA	Body mass index[26426971];Celiac disease[22057235];Lung cancer in ever smokers[28604730];Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)[29310926];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	NA	0.191889623350618	N	Ttc34	NA	NA	NA	NA	NA	0.1693	0.4833	0.5	0.0668	0.1298	0	0	0.0000384	0.160112	VQSRTrancheSNP99.00to99.90	0	0.003676	2	0.005263	1	chr1	2645580	NA	C	G	71.64	QD2;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=48.399;AS_MQ=60;AS_MQRankSum=0;AS_QD=1.41;AS_ReadPosRankSum=-2.4;AS_SOR=4.797;BaseQRankSum=-1.144;DP=56;ExcessHet=3.0103;FS=48.399;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=1.4;ReadPosRankSum=-2.318;SOR=4.797	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:41,10:51:79:0|1:2645580_C_G:79,0,1010:2645580
chr1	2645584	2645584	C	G	TTC34	intronic	NA	NA	NA	0.4714	GnomAdExome_AF_eas	0	0	WT/SomaticVariant	het	48	38	10	0.208333333333333	81.64	QD2;SOR3	NA	NA	NA	NA	NA	NA	Body mass index[26426971];Celiac disease[22057235];Lung cancer in ever smokers[28604730];Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)[29310926];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	NA	0.191889623350618	N	Ttc34	NA	NA	NA	NA	NA	0.3108	0.4714	0.4857	0.0497	0.0833	0	0	0.0000384	0.221875	VQSRTrancheSNP99.00to99.90	0	0.004016	2	0.011494	2	chr1	2645584	NA	C	G	81.64	QD2;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=55.268;AS_MQ=60;AS_MQRankSum=0;AS_QD=1.71;AS_ReadPosRankSum=-2.2;AS_SOR=4.796;BaseQRankSum=-0.726;DP=49;ExcessHet=3.0103;FS=55.268;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=1.7;ReadPosRankSum=-2.162;SOR=4.796	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:38,10:48:89:0|1:2645580_C_G:89,0,919:2645580
chr1	2800342	2800342	G	C	TTC34	exonic	synonymous SNV	NA	TTC34:NM_001242672:exon1:c.C486G:p.L162L	0.4892	GnomAdGenome_AF_asj			HeterozygousVariant	het	76	40	36	0.473684210526316	879.64	PASS	NA	NA	NA	NA	NA	NA	Body mass index[26426971];Celiac disease[22057235];Lung cancer in ever smokers[28604730];Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)[29310926];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	NA	0.191889623350618	N	Ttc34	NA	NA	NA	NA	NA	0	0	0	0.354	0.4892	0.297524	0	0.392385	0		0					chr1	2800342	NA	G	C	879.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.58;AS_ReadPosRankSum=0;AS_SOR=0.611;BaseQRankSum=-0.446;DP=78;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.57;ReadPosRankSum=0.005;SOR=0.611	GT:AD:DP:GQ:PL	0/1:40,36:76:99:887,0,1012
chr1	3069321	3069321	C	G	PRDM16	intronic	NA	NA	NA	0.6106	GnomAdExome_AF_amr	74	17	HeterozygousVariant	het	38	16	22	0.578947368421053	515.64	PASS	NA	[MIM:615373]Cardiomyopathy, dilated 1LL;	605557	NA	Familial isolated dilated cardiomyopathy;1p36 deletion syndrome;Left ventricular noncompaction	Disease-causing germline mutation(s) in;Role in the phenotype of;Disease-causing germline mutation(s) in	Systolic blood pressure[27618448];Headache[29397368];Mean corpuscular volume[27863252];Mean corpuscular hemoglobin[27863252];Migraine[23793025;21666692;27322543;27322543;27182965];Diastolic blood pressure[27618448];Hematocrit[27863252];Platelet distribution width[27863252];Plateletcrit[27863252];Response to statin therapy[20339536];Red blood cell count[27863252];Mean arterial pressure[27618448];Nose morphology[29921221];Coronary artery disease[29212778;29212778;29212778];Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)[29310926];Mean platelet volume[27863252];Allergic rhinitis[25085501];Motion sickness[25628336];QRS duration[25035420];Cognitive decline (age-related)[28078323];Post bronchodilator FEV1/FVC ratio in COPD[26634245];	HP:0001711;HP:0011675;HP:0001644;HP:0001635;HP:0005162;HP:0000006;HP:0001653;HP:0030682;HP:0000982;HP:0003457;HP:0100578;HP:0001644;HP:0003236;HP:0001874;HP:0000407;HP:0003198;HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733	Abnormal left ventricle morphology;Arrhythmia;Dilated cardiomyopathy;Congestive heart failure;Left ventricular dysfunction;Autosomal dominant inheritance;Mitral regurgitation;Left ventricular noncompaction;Palmoplantar keratoderma;EMG abnormality;Lipoatrophy;Dilated cardiomyopathy;Elevated serum creatine kinase;Abnormality of neutrophils;Sensorineural hearing impairment;Myopathy;Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule	not_provided	criteria_provided,_single_submitter	Benign	Expressed in uterus and kidney. Expressed in both cardiomyocytes and interstitial cells. {ECO:0000269|PubMed:11050005, ECO:0000269|PubMed:12816872, ECO:0000269|PubMed:23768516}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;whole body;liver;lymph node;colon;testis;brain;unclassifiable (Anatomical System);	trigeminal ganglion;	0.101	E	N	S	N	0.593595300928883	E	Prdm16	adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; craniofacial phenotype; cellular phenotype; immune system phenotype; homeostasis/metabolism phenotype; respiratory system phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; skeleton phenotype; 	prdm16	cardiac muscle cell	decreased amount	abnormal	0.459	0.6106	0.6122	0.3497	0.5657	0.360224	0.3045	0.0001153	0.339465	PASS	0	0.355	194	0.328571	58	chr1	3069321	NA	C	G	515.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.58;AS_ReadPosRankSum=1.6;AS_SOR=0.754;BaseQRankSum=0.172;DP=39;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.57;ReadPosRankSum=1.66;SOR=0.754	GT:AD:DP:GQ:PL	0/1:16,22:38:99:523,0,343
chr1	3385157	3385157	C	T	PRDM16	exonic	synonymous SNV	NA	PRDM16:NM_022114:exon4:c.C444T:p.S148S,PRDM16:NM_199454:exon4:c.C444T:p.S148S	0.6059	GnomAdGenome_AF_eas	216	50	HomozygousVariant	hom	159	0	159	1	4579.06	PASS	NA	[MIM:615373]Cardiomyopathy, dilated 1LL;	605557	Benign	Familial isolated dilated cardiomyopathy;1p36 deletion syndrome;Left ventricular noncompaction	Disease-causing germline mutation(s) in;Role in the phenotype of;Disease-causing germline mutation(s) in	Systolic blood pressure[27618448];Headache[29397368];Mean corpuscular volume[27863252];Mean corpuscular hemoglobin[27863252];Migraine[23793025;21666692;27322543;27322543;27182965];Diastolic blood pressure[27618448];Hematocrit[27863252];Platelet distribution width[27863252];Plateletcrit[27863252];Response to statin therapy[20339536];Red blood cell count[27863252];Mean arterial pressure[27618448];Nose morphology[29921221];Coronary artery disease[29212778;29212778;29212778];Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)[29310926];Mean platelet volume[27863252];Allergic rhinitis[25085501];Motion sickness[25628336];QRS duration[25035420];Cognitive decline (age-related)[28078323];Post bronchodilator FEV1/FVC ratio in COPD[26634245];	HP:0001711;HP:0011675;HP:0001644;HP:0001635;HP:0005162;HP:0000006;HP:0001653;HP:0030682;HP:0000982;HP:0003457;HP:0100578;HP:0001644;HP:0003236;HP:0001874;HP:0000407;HP:0003198;HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733	Abnormal left ventricle morphology;Arrhythmia;Dilated cardiomyopathy;Congestive heart failure;Left ventricular dysfunction;Autosomal dominant inheritance;Mitral regurgitation;Left ventricular noncompaction;Palmoplantar keratoderma;EMG abnormality;Lipoatrophy;Dilated cardiomyopathy;Elevated serum creatine kinase;Abnormality of neutrophils;Sensorineural hearing impairment;Myopathy;Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in uterus and kidney. Expressed in both cardiomyocytes and interstitial cells. {ECO:0000269|PubMed:11050005, ECO:0000269|PubMed:12816872, ECO:0000269|PubMed:23768516}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;whole body;liver;lymph node;colon;testis;brain;unclassifiable (Anatomical System);	trigeminal ganglion;	0.101	E	N	S	N	0.593595300928883	E	Prdm16	adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; craniofacial phenotype; cellular phenotype; immune system phenotype; homeostasis/metabolism phenotype; respiratory system phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; skeleton phenotype; 	prdm16	cardiac muscle cell	decreased amount	abnormal	0.3336	0.5993	0.5904	0.2357	0.6059	0.340455	0.2049	0.316684	0.214286	PASS	0.375	0.536	337	0.542254	54	chr1	3385157	NA	C	T	4579.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.8;AS_ReadPosRankSum=.;AS_SOR=0.927;DP=167;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.8;SOR=0.927	GT:AD:DP:GQ:PL	1/1:0,159:159:99:4593,477,0
chr1	3411794	3411794	T	C	PRDM16	exonic	nonsynonymous SNV	NA	PRDM16:NM_022114:exon9:c.T1597C:p.S533P,PRDM16:NM_199454:exon9:c.T1597C:p.S533P	0.9997	GnomAdExome_AF_eas	739	120	HeterozygousVariant	het	232	129	103	0.443965517241379	2311.64	PASS	13.09	[MIM:615373]Cardiomyopathy, dilated 1LL;	605557	Benign	Familial isolated dilated cardiomyopathy;1p36 deletion syndrome;Left ventricular noncompaction	Disease-causing germline mutation(s) in;Role in the phenotype of;Disease-causing germline mutation(s) in	Systolic blood pressure[27618448];Headache[29397368];Mean corpuscular volume[27863252];Mean corpuscular hemoglobin[27863252];Migraine[23793025;21666692;27322543;27322543;27182965];Diastolic blood pressure[27618448];Hematocrit[27863252];Platelet distribution width[27863252];Plateletcrit[27863252];Response to statin therapy[20339536];Red blood cell count[27863252];Mean arterial pressure[27618448];Nose morphology[29921221];Coronary artery disease[29212778;29212778;29212778];Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)[29310926];Mean platelet volume[27863252];Allergic rhinitis[25085501];Motion sickness[25628336];QRS duration[25035420];Cognitive decline (age-related)[28078323];Post bronchodilator FEV1/FVC ratio in COPD[26634245];	HP:0001711;HP:0011675;HP:0001644;HP:0001635;HP:0005162;HP:0000006;HP:0001653;HP:0030682;HP:0000982;HP:0003457;HP:0100578;HP:0001644;HP:0003236;HP:0001874;HP:0000407;HP:0003198;HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733	Abnormal left ventricle morphology;Arrhythmia;Dilated cardiomyopathy;Congestive heart failure;Left ventricular dysfunction;Autosomal dominant inheritance;Mitral regurgitation;Left ventricular noncompaction;Palmoplantar keratoderma;EMG abnormality;Lipoatrophy;Dilated cardiomyopathy;Elevated serum creatine kinase;Abnormality of neutrophils;Sensorineural hearing impairment;Myopathy;Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule	Left_ventricular_noncompaction_8|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in uterus and kidney. Expressed in both cardiomyocytes and interstitial cells. {ECO:0000269|PubMed:11050005, ECO:0000269|PubMed:12816872, ECO:0000269|PubMed:23768516}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;.;	N	N	.;.;.;.;.	NA	NA	Medium	Medium	Medium	lung;whole body;liver;lymph node;colon;testis;brain;unclassifiable (Anatomical System);	trigeminal ganglion;	0.101	E	N	S	N	0.593595300928883	E	Prdm16	adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; craniofacial phenotype; cellular phenotype; immune system phenotype; homeostasis/metabolism phenotype; respiratory system phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; skeleton phenotype; 	prdm16	cardiac muscle cell	decreased amount	abnormal	0.8896	0.9997	0.9998	0.892	0.9994	0.945088	0.8777	0.871858	0.866995	PASS	0.95	0.954	66	0.915493	20	chr1	3411794	NA	T	C	2311.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=1.015;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.97;AS_ReadPosRankSum=0.2;AS_SOR=0.71;BaseQRankSum=0.754;DP=252;ExcessHet=3.0103;FS=1.015;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.96;ReadPosRankSum=0.278;SOR=0.71	GT:AD:DP:GQ:PL	0/1:129,103:232:99:2319,0,2996
chr1	3467334	3467334	A	G	ARHGEF16	exonic	synonymous SNV	NA	ARHGEF16:NM_014448:exon4:c.A801G:p.P267P	1	GME_Israel	390	111	HeterozygousVariant	het	77	29	48	0.623376623376623	1088.64	PASS	NA	NA	NA	Benign	NA	NA	Response to statin therapy[20339536];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.808	NA	N	N	N	0.754870526372456	E	Arhgef16	NA	NA	NA	NA	NA	0.8741	0.9084	0.9046	0.8894	0.9756	0.860024	0.8974	0.0001153	0.897035	PASS	1	0.885	96	0.869718	25	chr1	3467334	NA	A	G	1088.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.7;AS_FS=3.225;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.14;AS_ReadPosRankSum=-0.7;AS_SOR=0.412;BaseQRankSum=-1.609;DP=80;ExcessHet=3.0103;FS=3.225;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.14;ReadPosRankSum=-0.652;SOR=0.412	GT:AD:DP:GQ:PL	0/1:29,48:77:99:1096,0,664
chr1	3473163	3473163	C	T	ARHGEF16	exonic	nonsynonymous SNV	NA	ARHGEF16:NM_014448:exon7:c.C1108T:p.H370Y	0.9689	GnomAdGenome_AF_ami	424	104	HeterozygousVariant	het	121	66	55	0.454545454545455	1047.64	PASS	15.26	NA	NA	Benign	NA	NA	Response to statin therapy[20339536];	NA	NA	NA	NA	NA	NA	T	T	B	B	D	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;.;	D	N	Dbl homology (DH) domain|Dbl homology (DH) domain|Dbl homology (DH) domain|Dbl homology (DH) domain;.;.;Dbl homology (DH) domain|Dbl homology (DH) domain|Dbl homology (DH) domain|Dbl homology (DH) domain;Dbl homology (DH) domain|Dbl homology (DH) domain|Dbl homology (DH) domain|Dbl homology (DH) domain	NA	NA	Medium	Medium	Medium	NA	NA	0.808	NA	N	N	N	0.754870526372456	E	Arhgef16	NA	NA	NA	NA	NA	0.8037	0.8748	0.8721	0.7332	0.9689	0.684505	0.7354	0.797073	0.772578	PASS	0.896552	0.853	147	0.841549	31	chr1	3473163	NA	C	T	1047.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0.676;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.66;AS_ReadPosRankSum=0.8;AS_SOR=0.674;BaseQRankSum=-0.46;DP=121;ExcessHet=3.0103;FS=0.676;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.66;ReadPosRankSum=0.844;SOR=0.674	GT:AD:DP:GQ:PL	0/1:66,55:121:99:1055,0,1460
chr1	3477892	3477892	T	C	ARHGEF16	exonic	synonymous SNV	NA	ARHGEF16:NM_014448:exon11:c.T1491C:p.S497S	1	GnomAdExome_AF_eas	521	141	HomozygousVariant	hom	86	0	86	1	2393.06	PASS	NA	NA	NA	Benign	NA	NA	Response to statin therapy[20339536];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.808	NA	N	N	N	0.754870526372456	E	Arhgef16	NA	NA	NA	NA	NA	0.9919	1	1	0.9707	1	0.970647	0.9684	0.0001153	0.977011	PASS	1	0.999	1	0.996479	1	chr1	3477892	NA	T	C	2393.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.83;AS_ReadPosRankSum=.;AS_SOR=0.839;DP=88;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.83;SOR=0.839	GT:AD:DP:GQ:PL	1/1:0,86:86:99:2407,257,0
chr1	3478475	3478475	G	A	ARHGEF16	exonic	synonymous SNV	NA	ARHGEF16:NM_014448:exon12:c.G1677A:p.V559V	0.9689	GnomAdGenome_AF_ami	424	103	HeterozygousVariant	het	138	78	60	0.434782608695652	1231.64	PASS	NA	NA	NA	Benign	NA	NA	Response to statin therapy[20339536];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.808	NA	N	N	N	0.754870526372456	E	Arhgef16	NA	NA	NA	NA	NA	0.8021	0.8735	0.8707	0.7334	0.9689	0.686102	0.7342	0.791633	0.770936	PASS	0.887195	0.851	148	0.838028	32	chr1	3478475	NA	G	A	1231.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=2.152;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.93;AS_ReadPosRankSum=0.3;AS_SOR=0.884;BaseQRankSum=-1.577;DP=145;ExcessHet=3.0103;FS=2.152;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.92;ReadPosRankSum=0.316;SOR=0.884	GT:AD:DP:GQ:PL	0/1:78,60:138:99:1239,0,1906
chr1	3478610	3478610	C	A	ARHGEF16	exonic	synonymous SNV	NA	ARHGEF16:NM_014448:exon12:c.C1812A:p.S604S	0.2412	GnomAdExome_AF_amr	4	3	HeterozygousVariant	het	59	29	30	0.508474576271186	743.64	PASS	NA	NA	NA	Benign	NA	NA	Response to statin therapy[20339536];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.008	Medium	Medium	Medium	NA	NA	0.808	NA	N	N	N	0.754870526372456	E	Arhgef16	NA	NA	NA	NA	NA	0.1007	0.2412	0.2402	0.0639	0.215	0.091254	0.052	0.088136	0.059934	PASS	0	0.093	84	0.102113	23	chr1	3478610	NA	C	A	743.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.8;AS_FS=2.369;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.61;AS_ReadPosRankSum=-1.3;AS_SOR=1.09;BaseQRankSum=1.8;DP=60;ExcessHet=3.0103;FS=2.369;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.6;ReadPosRankSum=-1.244;SOR=1.09	GT:AD:DP:GQ:PL	0/1:29,30:59:99:751,0,623
chr1	3499885	3499885	C	A	MEGF6	exonic	nonsynonymous SNV	NA	MEGF6:NM_001409:exon22:c.G2747T:p.R916L	0.832031	GME_CA	337	73	HomozygousVariant	hom	55	0	55	1	1518.06	PASS	6.147	NA	604266	NA	NA	NA	Chronic central serous retinopathy[30073298];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	L	T	D	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;Laminin EGF domain|EGF-like domain|EGF-like domain	NA	NA	High	High	High	fovea centralis;skin;myocardium;testis;parathyroid;brain;lens;unclassifiable (Anatomical System);heart;lung;choroid;kidney;ovary;retina;macula lutea;colon;placenta;urinary;prostate;optic nerve;	NA	0.187	NA	N	N	N	0.627416316732691	E	Megf6	NA	NA	NA	NA	NA	0.6723	0.7772	0.7812	0.6151	0.7797	0.568291	0.6374	0.542102	0.660626	PASS	0.832031	0.76	215	0.707746	55	chr1	3499885	NA	C	A	1518.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.6;AS_ReadPosRankSum=.;AS_SOR=0.804;DP=60;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.6;SOR=0.804	GT:AD:DP:GQ:PL	1/1:0,55:55:99:1532,165,0
chr1	3501827	3501827	C	T	MEGF6	exonic	synonymous SNV	NA	MEGF6:NM_001409:exon18:c.G2283A:p.P761P	0.416667	GME_CA	71	11	HeterozygousVariant	het	97	45	52	0.536082474226804	1086.64	PASS	NA	NA	604266	Benign	NA	NA	Chronic central serous retinopathy[30073298];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	fovea centralis;skin;myocardium;testis;parathyroid;brain;lens;unclassifiable (Anatomical System);heart;lung;choroid;kidney;ovary;retina;macula lutea;colon;placenta;urinary;prostate;optic nerve;	NA	0.187	NA	N	N	N	0.627416316732691	E	Megf6	NA	NA	NA	NA	NA	0.3057	0.3313	0.332	0.2813	0.343	0.286142	0.2708	0.286232	0.328947	VQSRTrancheSNP99.00to99.90	0.416667	0.331	245	0.306338	65	chr1	3501827	NA	C	T	1086.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.21;AS_ReadPosRankSum=2.5;AS_SOR=0.714;BaseQRankSum=-1.193;DP=99;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.2;ReadPosRankSum=2.52;SOR=0.714	GT:AD:DP:GQ:PL	0/1:45,52:97:99:1094,0,989
chr1	3505333	3505333	A	G	MEGF6	exonic	nonsynonymous SNV	NA	MEGF6:NM_001409:exon17:c.T2063C:p.L688P	0.3921	GnomAdExome_AF_afr	14	4	HeterozygousVariant	het	105	55	50	0.476190476190476	1062.64	PASS	7.617	NA	604266	Benign	NA	NA	Chronic central serous retinopathy[30073298];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;Laminin EGF domain|EGF-like domain	NA	NA	High	High	High	fovea centralis;skin;myocardium;testis;parathyroid;brain;lens;unclassifiable (Anatomical System);heart;lung;choroid;kidney;ovary;retina;macula lutea;colon;placenta;urinary;prostate;optic nerve;	NA	0.187	NA	N	N	N	0.627416316732691	E	Megf6	NA	NA	NA	NA	NA	0.2012	0.3921	0.3872	0.2411	0.3829	0.259185	0.2234	0.190916	0.214638	PASS	0.173469	0.142	139	0.198582	48	chr1	3505333	NA	A	G	1062.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.12;AS_ReadPosRankSum=1.4;AS_SOR=0.672;BaseQRankSum=-1.459;DP=108;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.12;ReadPosRankSum=1.41;SOR=0.672	GT:AD:DP:GQ:PL	0/1:55,50:105:99:1070,0,1306
chr1	3507944	3507944	G	A	MEGF6	intronic	NA	NA	NA	0.1212	GnomAdExome_AF_eas	4	1	HeterozygousVariant	het	42	18	24	0.571428571428571	554.64	PASS	NA	NA	604266	NA	NA	NA	Chronic central serous retinopathy[30073298];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	fovea centralis;skin;myocardium;testis;parathyroid;brain;lens;unclassifiable (Anatomical System);heart;lung;choroid;kidney;ovary;retina;macula lutea;colon;placenta;urinary;prostate;optic nerve;	NA	0.187	NA	N	N	N	0.627416316732691	E	Megf6	NA	NA	NA	NA	NA	0.0596	0.1212	0.1189	0.0442	0.1192	0.0593051	0.0435	0.0585245	0.041872	PASS	0	0.076	37	0.066901	17	chr1	3507944	NA	G	A	554.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.21;AS_ReadPosRankSum=0.4;AS_SOR=0.657;BaseQRankSum=-1.241;DP=43;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.21;ReadPosRankSum=0.446;SOR=0.657	GT:AD:DP:GQ:PL	0/1:18,24:42:99:562,0,443
chr1	3508619	3508619	G	A	MEGF6	exonic	synonymous SNV	NA	MEGF6:NM_001409:exon13:c.C1599T:p.C533C	0.1215	GnomAdExome_AF_eas	7	1	HeterozygousVariant	het	107	56	51	0.476635514018692	1104.64	PASS	NA	NA	604266	NA	NA	NA	Chronic central serous retinopathy[30073298];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	fovea centralis;skin;myocardium;testis;parathyroid;brain;lens;unclassifiable (Anatomical System);heart;lung;choroid;kidney;ovary;retina;macula lutea;colon;placenta;urinary;prostate;optic nerve;	NA	0.187	NA	N	N	N	0.627416316732691	E	Megf6	NA	NA	NA	NA	NA	0.0614	0.1215	0.1188	0.0513	0.1195	0.0648962	0.0514	0.0611441	0.043514	PASS	0.112805	0.072	71	0.066901	17	chr1	3508619	NA	G	A	1104.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=0.719;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.33;AS_ReadPosRankSum=-0.6;AS_SOR=0.668;BaseQRankSum=0.768;DP=108;ExcessHet=3.0103;FS=0.719;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.32;ReadPosRankSum=-0.54;SOR=0.668	GT:AD:DP:GQ:PL	0/1:56,51:107:99:1112,0,1227
chr1	3511596	3511596	T	G	MEGF6	exonic	synonymous SNV	NA	MEGF6:NM_001409:exon9:c.A1068C:p.T356T	0.7069	GnomAdExome_AF_afr	55	16	HeterozygousVariant	het	88	31	57	0.647727272727273	1290.64	PASS	NA	NA	604266	Benign	NA	NA	Chronic central serous retinopathy[30073298];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	fovea centralis;skin;myocardium;testis;parathyroid;brain;lens;unclassifiable (Anatomical System);heart;lung;choroid;kidney;ovary;retina;macula lutea;colon;placenta;urinary;prostate;optic nerve;	NA	0.187	NA	N	N	N	0.627416316732691	E	Megf6	NA	NA	NA	NA	NA	0.3708	0.7069	0.7057	0.4358	0.6975	0.5	0.4212	0.361451	0.392447	PASS	0.372449	0.307	251	0.348592	67	chr1	3511596	NA	T	G	1290.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=1.804;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.67;AS_ReadPosRankSum=1.8;AS_SOR=0.51;BaseQRankSum=0.056;DP=90;ExcessHet=3.0103;FS=1.804;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.67;ReadPosRankSum=1.84;SOR=0.51	GT:AD:DP:GQ:PL	0/1:31,57:88:99:1298,0,581
chr1	3579915	3579915	T	C	MEGF6	exonic	nonsynonymous SNV	NA	MEGF6:NM_001409:exon4:c.A391G:p.S131G	0.95	GME_Israel	442	109	HomozygousVariant	hom	74	0	74	1	2031.06	PASS	1.491	NA	604266	NA	NA	NA	Chronic central serous retinopathy[30073298];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	EGF-like domain|EGF-like calcium-binding domain|EGF-like domain	NA	NA	High	High	High	fovea centralis;skin;myocardium;testis;parathyroid;brain;lens;unclassifiable (Anatomical System);heart;lung;choroid;kidney;ovary;retina;macula lutea;colon;placenta;urinary;prostate;optic nerve;	NA	0.187	NA	N	N	N	0.627416316732691	E	Megf6	NA	NA	NA	NA	NA	0.8841	0.9102	0.9094	0.8947	0.9356	0.852835	0.9042	0.0001153	0.890805	PASS	0.95	0.871	128	0.876761	31	chr1	3579915	NA	T	C	2031.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.45;AS_ReadPosRankSum=.;AS_SOR=1.061;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.45;SOR=1.061	GT:AD:DP:GQ:PL	1/1:0,74:74:99:2045,221,0
chr1	3595370	3595370	A	G	MEGF6	exonic	nonsynonymous SNV	NA	MEGF6:NM_001409:exon3:c.T344C:p.M115T	0.3723	GnomAdExome_AF_eas	39	5	HeterozygousVariant	het	67	39	28	0.417910447761194	545.64	PASS	10.07	NA	604266	Benign	NA	NA	Chronic central serous retinopathy[30073298];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	EMI domain	NA	NA	High	High	High	fovea centralis;skin;myocardium;testis;parathyroid;brain;lens;unclassifiable (Anatomical System);heart;lung;choroid;kidney;ovary;retina;macula lutea;colon;placenta;urinary;prostate;optic nerve;	NA	0.187	NA	N	N	N	0.627416316732691	E	Megf6	NA	NA	NA	NA	NA	0.1882	0.3723	0.3706	0.1727	0.3697	0.227236	0.1569	0.176317	0.188013	PASS	0.255102	0.222	182	0.200704	47	chr1	3595370	NA	A	G	545.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.15;AS_ReadPosRankSum=1.4;AS_SOR=0.781;BaseQRankSum=-0.248;DP=69;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.14;ReadPosRankSum=1.49;SOR=0.781	GT:AD:DP:GQ:PL	0/1:39,28:67:99:553,0,889
chr1	3628612	3628630	TTCTGGGAGCTCCTCCCCC	-	TPRG1L	UTR3	NA	NM_182752:c.*9_*27delTTCTGGGAGCTCCTCCCCC	NA	0.9671	GnomAdExome_AF_eas	161	113	HomozygousVariant	hom	41	0	41	1	1828.03	PASS	NA	NA	611460	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	cochlea;tongue;skin;myocardium;stomach;testis;unclassifiable (Anatomical System);kidney;uterus;whole body;retina;pancreas;head and neck;adrenal gland;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;parathyroid;brain;blood;heart;bone marrow;lung;cerebral cortex;ovary;synovium;thyroid;macula lutea;bladder;frontal lobe;colon;placenta;prostate;breast;	NA	0.447	NA	N	N	N	0.601472074800569	E	Tprgl	NA	NA	NA	NA	NA	0.86	0.9671	0.965	0.8603	0.9616	0	0.8315	0.0001153	0.862069	PASS	0	0.947	19	0.884058	18	chr1	3628611	NA	GTTCTGGGAGCTCCTCCCCC	G	1828.03	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=25.4;AS_ReadPosRankSum=.;AS_SOR=1.501;DP=69;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.98;SOR=1.501	GT:AD:DP:GQ:PL	1/1:0,41:41:99:1842,128,0
chr1	3631572	3631572	T	C	WRAP73	exonic	synonymous SNV	NA	WRAP73:NM_017818:exon11:c.A1134G:p.A378A	0.9964	GnomAdExome_AF_eas	517	124	HomozygousVariant	hom	127	0	127	1	3660.06	PASS	NA	NA	606040	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Ubiquitous. Predominant expression in heart, brain, liver, thymus, prostate, and testis, and barely detectable expression in lung.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	pharynx;stomach;testis;choroid;kidney;uterus;whole body;pancreas;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;germinal center;heart;lung;salivary gland;synovium;placenta;optic nerve;thymus;intestine;epididymis;alveolus;smooth muscle;skin;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;mammary gland;cervix;cartilage;endometrium;bone;brain;blood;bone marrow;ovary;macula lutea;lymph node;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	white blood cells;	NA	NA	N	N	H	0.11437135981131	N	Wrap73	NA	NA	NA	NA	NA	0.8703	0.9964	0.9961	0.8596	0.9955	0.90615	0.8505	0.0001537	0.86289	PASS	0.912879	0.941	63	0.933099	17	chr1	3631572	NA	T	C	3660.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.82;AS_ReadPosRankSum=.;AS_SOR=0.843;DP=133;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.82;SOR=0.843	GT:AD:DP:GQ:PL	1/1:0,127:127:99:3674,380,0
chr1	3637131	3637131	C	A	WRAP73	intronic	NA	NA	NA	0.0002	GnomAdExome_AF_oth	0		HeterozygousVariant	het	15	5	10	0.666666666666667	238.64	PASS	NA	NA	606040	NA	NA	NA	NA	NA	NA	NA	NA	NA	Ubiquitous. Predominant expression in heart, brain, liver, thymus, prostate, and testis, and barely detectable expression in lung.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	pharynx;stomach;testis;choroid;kidney;uterus;whole body;pancreas;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;germinal center;heart;lung;salivary gland;synovium;placenta;optic nerve;thymus;intestine;epididymis;alveolus;smooth muscle;skin;lens;lymphoreticular;unclassifiable (Anatomical System);retina;muscle;mammary gland;cervix;cartilage;endometrium;bone;brain;blood;bone marrow;ovary;macula lutea;lymph node;bladder;colon;aorta;prostate;breast;hypothalamus;medulla oblongata;	white blood cells;	NA	NA	N	N	H	0.11437135981131	N	Wrap73	NA	NA	NA	NA	NA	0.00001564	0.00007927	0	0	0	0	0	0.0000129	0		0	0.002793	1			chr1	3637131	NA	C	A	238.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.93;AS_ReadPosRankSum=0.3;AS_SOR=0.892;BaseQRankSum=-1.053;DP=18;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.91;ReadPosRankSum=0.368;SOR=0.892	GT:AD:DP:GQ:PL	0/1:5,10:15:99:246,0,128
chr1	3682336	3682336	G	A	TP73	UTR5	NA	NM_001204184:c.-30G>A;NM_005427:c.-30G>A;NM_001204186:c.-30G>A;NM_001204185:c.-30G>A;NM_001204187:c.-30G>A;NM_001204188:c.-30G>A	NA	0.2794	GnomAdExome_AF_amr	11	8	HeterozygousVariant	het	32	16	16	0.5	595.64	PASS	NA	NA	601990	NA	Small cell lung cancer	Disease-causing somatic mutation(s) in	Visceral fat[22589738;22589738];Visceral adipose tissue adjusted for BMI[22589738];Visceral adipose tissue/subcutaneous adipose tissue ratio[22589738];	NA	NA	NA	NA	NA	Expressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue. {ECO:0000269|PubMed:11753569, ECO:0000269|PubMed:16461361}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;muscle;colon;placenta;germinal center;unclassifiable (Anatomical System);	ciliary ganglion;atrioventricular node;trigeminal ganglion;skeletal muscle;adrenal cortex;	0.0179	E	N	N	N	0.908594912125606	E	Trp73	skeleton phenotype; immune system phenotype; vision/eye phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; embryo phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; 	tp73	ceratobranchial cartilage	decreased size	abnormal	0.2032	0.2794	0.2867	0.1853	0.2758	0.177516	0.1757	0.142197	0.20398	PASS	0	0.116	98	0.169014	32	chr1	3682336	NA	G	A	595.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=18.63;AS_ReadPosRankSum=-1.6;AS_SOR=0.693;BaseQRankSum=-0.309;DP=32;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=18.61;ReadPosRankSum=-1.584;SOR=0.693	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:16,16:32:99:0|1:3682336_G_A:603,0,613:3682336
chr1	3682346	3682346	C	T	TP73	UTR5	NA	NM_001204184:c.-20C>T;NM_005427:c.-20C>T;NM_001204186:c.-20C>T;NM_001204185:c.-20C>T;NM_001204187:c.-20C>T;NM_001204188:c.-20C>T	NA	0.2781	GnomAdExome_AF_amr	12	8	HeterozygousVariant	het	34	18	16	0.470588235294118	589.64	PASS	NA	NA	601990	NA	Small cell lung cancer	Disease-causing somatic mutation(s) in	Visceral fat[22589738;22589738];Visceral adipose tissue adjusted for BMI[22589738];Visceral adipose tissue/subcutaneous adipose tissue ratio[22589738];	NA	NA	NA	NA	NA	Expressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue. {ECO:0000269|PubMed:11753569, ECO:0000269|PubMed:16461361}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;muscle;colon;placenta;germinal center;unclassifiable (Anatomical System);	ciliary ganglion;atrioventricular node;trigeminal ganglion;skeletal muscle;adrenal cortex;	0.0179	E	N	N	N	0.908594912125606	E	Trp73	skeleton phenotype; immune system phenotype; vision/eye phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; embryo phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; 	tp73	ceratobranchial cartilage	decreased size	abnormal	0.2018	0.2781	0.2854	0.185	0.2754	0.177915	0.1764	0.144177	0.205785	PASS	0	0.117	97	0.169014	32	chr1	3682346	NA	C	T	589.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=17.35;AS_ReadPosRankSum=-1.2;AS_SOR=0.693;BaseQRankSum=0.249;DP=36;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=17.34;ReadPosRankSum=-1.122;SOR=0.693	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:18,16:34:99:0|1:3682336_G_A:597,0,673:3682336
chr1	3722110	3722110	C	T	TP73	exonic	synonymous SNV	NA	TP73:NM_001126240:exon3:c.C372T:p.T124T,TP73:NM_001126241:exon3:c.C372T:p.T124T,TP73:NM_001126242:exon3:c.C372T:p.T124T,TP73:NM_001204189:exon3:c.C372T:p.T124T,TP73:NM_001204190:exon3:c.C372T:p.T124T,TP73:NM_001204191:exon3:c.C372T:p.T124T,TP73:NM_001204192:exon3:c.C306T:p.T102T,TP73:NM_001204184:exon5:c.C519T:p.T173T,TP73:NM_001204185:exon5:c.C519T:p.T173T,TP73:NM_001204186:exon5:c.C519T:p.T173T,TP73:NM_001204187:exon5:c.C519T:p.T173T,TP73:NM_001204188:exon5:c.C519T:p.T173T,TP73:NM_005427:exon5:c.C519T:p.T173T	0.9756	GnomAdGenome_AF_ami	478	76	HeterozygousVariant	het	95	57	38	0.4	813.64	PASS	NA	NA	601990	Benign	Small cell lung cancer	Disease-causing somatic mutation(s) in	Visceral fat[22589738;22589738];Visceral adipose tissue adjusted for BMI[22589738];Visceral adipose tissue/subcutaneous adipose tissue ratio[22589738];	NA	NA	NA	NA	NA	Expressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue. {ECO:0000269|PubMed:11753569, ECO:0000269|PubMed:16461361}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;muscle;colon;placenta;germinal center;unclassifiable (Anatomical System);	ciliary ganglion;atrioventricular node;trigeminal ganglion;skeletal muscle;adrenal cortex;	0.0179	E	N	N	N	0.908594912125606	E	Trp73	skeleton phenotype; immune system phenotype; vision/eye phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; embryo phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; 	tp73	ceratobranchial cartilage	decreased size	abnormal	0.8038	0.8972	0.8986	0.8293	0.9756	0.736022	0.8495	0.805391	0.848933	PASS	0.95	0.747	291	0.71831	52	chr1	3722110	NA	C	T	813.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.5;AS_FS=0.784;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.57;AS_ReadPosRankSum=0.9;AS_SOR=0.768;BaseQRankSum=2.57;DP=98;ExcessHet=3.0103;FS=0.784;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.56;ReadPosRankSum=0.904;SOR=0.768	GT:AD:DP:GQ:PL	0/1:57,38:95:99:821,0,1230
chr1	3727785	3727785	A	G	TP73	intronic	NA	NA	NA	0.8103	GnomAdGenome_AF_ami	174	54	HeterozygousVariant	het	104	50	54	0.519230769230769	1161.64	PASS	NA	NA	601990	NA	Small cell lung cancer	Disease-causing somatic mutation(s) in	Visceral fat[22589738;22589738];Visceral adipose tissue adjusted for BMI[22589738];Visceral adipose tissue/subcutaneous adipose tissue ratio[22589738];	NA	NA	NA	NA	NA	Expressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue. {ECO:0000269|PubMed:11753569, ECO:0000269|PubMed:16461361}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;muscle;colon;placenta;germinal center;unclassifiable (Anatomical System);	ciliary ganglion;atrioventricular node;trigeminal ganglion;skeletal muscle;adrenal cortex;	0.0179	E	N	N	N	0.908594912125606	E	Trp73	skeleton phenotype; immune system phenotype; vision/eye phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; embryo phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; 	tp73	ceratobranchial cartilage	decreased size	abnormal	0.6895	0.79	0.7913	0.7518	0.8103	0.64996	0.7878	0.432536	0.7675	PASS	0	0.63	190	0.598592	62	chr1	3727785	NA	A	G	1161.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=7.897;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.17;AS_ReadPosRankSum=0;AS_SOR=0.273;BaseQRankSum=-1.326;DP=107;ExcessHet=3.0103;FS=7.897;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.17;ReadPosRankSum=0.085;SOR=0.273	GT:AD:DP:GQ:PL	0/1:50,54:104:99:1169,0,1176
chr1	3761369	3761369	T	C	CCDC27	exonic	nonsynonymous SNV	NA	CCDC27:NM_152492:exon5:c.T800C:p.M267T	0.6383	GnomAdExome_AF_afr	113	26	HeterozygousVariant	het	106	53	53	0.5	1184.64	PASS	0.442	NA	NA	Benign	NA	NA	Visceral fat[22589738;22589738];Visceral adipose tissue/subcutaneous adipose tissue ratio[22589738];Obesity-related traits[23251661];Hemoglobin concentration[27863252];Blood trace element (Cu levels)[23720494];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	testis;	NA	0.969	NA	N	N	N	0.000820672031338782	N	Ccdc27	NA	NA	NA	NA	NA	0.4161	0.6383	0.6452	0.4663	0.6255	0.476038	0.4684	0.409704	0.486043	PASS	0.565657	0.427	275	0.408451	64	chr1	3761369	NA	T	C	1184.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0.726;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.18;AS_ReadPosRankSum=-2.9;AS_SOR=0.777;BaseQRankSum=0.02;DP=109;ExcessHet=3.0103;FS=0.726;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.18;ReadPosRankSum=-2.877;SOR=0.777	GT:AD:DP:GQ:PL	0/1:53,53:106:99:1192,0,1160
chr1	3815539	3815539	T	C	CEP104	intronic	NA	NA	NA	0.8676	GnomAdExome_AF_afr	244	66	HomozygousVariant	hom	64	0	64	1	1682.06	PASS	NA	[MIM:616781]Joubert syndrome 25 [recessive?];	616690	NA	Joubert syndrome	Disease-causing germline mutation(s) in	Mean corpuscular volume[27863252];	HP:0001263;HP:0001251;HP:0003593;HP:0000007;HP:0000657;HP:0002419;HP:0001321;HP:0000512;HP:0001290;HP:0000864;HP:0002251;HP:0002104;HP:0000463;HP:0002126;HP:0001320;HP:0001249;HP:0001263;HP:0004422;HP:0002084;HP:0008872;HP:0000202;HP:0000369;HP:0001161;HP:0001829;HP:0002553;HP:0001337;HP:0000612;HP:0001251;HP:0003312;HP:0000238;HP:0001252;HP:0000426;HP:0000639;HP:0001696;HP:0007370;HP:0002876;HP:0001250;HP:0001288;HP:0000486;HP:0000657;HP:0002650;HP:0000276;HP:0000508	Global developmental delay;Ataxia;Infantile onset;Autosomal recessive inheritance;Oculomotor apraxia;Molar tooth sign on MRI;Cerebellar hypoplasia;Abnormal electroretinogram;Generalized hypotonia;Abnormality of the hypothalamus-pituitary axis;Aganglionic megacolon;Apnea;Anteverted nares;Polymicrogyria;Cerebellar vermis hypoplasia;Intellectual disability;Global developmental delay;Biparietal narrowing;Encephalocele;Feeding difficulties in infancy;Oral cleft;Low-set ears;Hand polydactyly;Foot polydactyly;Highly arched eyebrow;Tremor;Iris coloboma;Ataxia;Abnormal form of the vertebral bodies;Hydrocephalus;Muscular hypotonia;Prominent nasal bridge;Nystagmus;Situs inversus totalis;Aplasia/Hypoplasia of the corpus callosum;Episodic tachypnea;Seizure;Gait disturbance;Strabismus;Oculomotor apraxia;Scoliosis;Long face;Ptosis	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.11437135981131	N	Cep104	NA	NA	NA	NA	NA	0.5929	0.8676	0.8713	0.6511	0.8588	0.656749	0.6527	0.554475	0.607553	PASS	0	0.703	176	0.685714	60	chr1	3815539	NA	T	C	1682.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.28;AS_ReadPosRankSum=.;AS_SOR=1.214;DP=67;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.28;SOR=1.214	GT:AD:DP:GQ:PL	1/1:0,64:64:99:1696,191,0
chr1	3826755	3826755	G	A	CEP104	intronic	NA	NA	NA	0.5787	GnomAdGenome_AF_eas	225	40	HomozygousVariant	hom	82	2	80	0.975609756097561	2207.06	PASS	NA	[MIM:616781]Joubert syndrome 25 [recessive?];	616690	NA	Joubert syndrome	Disease-causing germline mutation(s) in	Mean corpuscular volume[27863252];	HP:0001263;HP:0001251;HP:0003593;HP:0000007;HP:0000657;HP:0002419;HP:0001321;HP:0000512;HP:0001290;HP:0000864;HP:0002251;HP:0002104;HP:0000463;HP:0002126;HP:0001320;HP:0001249;HP:0001263;HP:0004422;HP:0002084;HP:0008872;HP:0000202;HP:0000369;HP:0001161;HP:0001829;HP:0002553;HP:0001337;HP:0000612;HP:0001251;HP:0003312;HP:0000238;HP:0001252;HP:0000426;HP:0000639;HP:0001696;HP:0007370;HP:0002876;HP:0001250;HP:0001288;HP:0000486;HP:0000657;HP:0002650;HP:0000276;HP:0000508	Global developmental delay;Ataxia;Infantile onset;Autosomal recessive inheritance;Oculomotor apraxia;Molar tooth sign on MRI;Cerebellar hypoplasia;Abnormal electroretinogram;Generalized hypotonia;Abnormality of the hypothalamus-pituitary axis;Aganglionic megacolon;Apnea;Anteverted nares;Polymicrogyria;Cerebellar vermis hypoplasia;Intellectual disability;Global developmental delay;Biparietal narrowing;Encephalocele;Feeding difficulties in infancy;Oral cleft;Low-set ears;Hand polydactyly;Foot polydactyly;Highly arched eyebrow;Tremor;Iris coloboma;Ataxia;Abnormal form of the vertebral bodies;Hydrocephalus;Muscular hypotonia;Prominent nasal bridge;Nystagmus;Situs inversus totalis;Aplasia/Hypoplasia of the corpus callosum;Episodic tachypnea;Seizure;Gait disturbance;Strabismus;Oculomotor apraxia;Scoliosis;Long face;Ptosis	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.11437135981131	N	Cep104	NA	NA	NA	NA	NA	0.3809	0.5574	0.5585	0.3916	0.5787	0.473442	0.3805	0.374303	0.367816	PASS	0	0.522	335	0.538732	73	chr1	3826755	NA	G	A	2207.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=26.91;AS_ReadPosRankSum=-0.2;AS_SOR=0.968;BaseQRankSum=0.844;DP=82;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=26.92;ReadPosRankSum=-0.12;SOR=0.968	GT:AD:DP:GQ:PL	1/1:2,80:82:99:2221,196,0
chr1	3829360	3829360	G	A	CEP104	exonic	nonsynonymous SNV	NA	CEP104:NM_014704:exon15:c.C2057T:p.A686V	0.5292	GnomAdGenome_AF_eas	81	15	HomozygousVariant	hom	80	0	80	1	2159.06	PASS	22.9	[MIM:616781]Joubert syndrome 25 [recessive?];	616690	NA	Joubert syndrome	Disease-causing germline mutation(s) in	Mean corpuscular volume[27863252];	HP:0001263;HP:0001251;HP:0003593;HP:0000007;HP:0000657;HP:0002419;HP:0001321;HP:0000512;HP:0001290;HP:0000864;HP:0002251;HP:0002104;HP:0000463;HP:0002126;HP:0001320;HP:0001249;HP:0001263;HP:0004422;HP:0002084;HP:0008872;HP:0000202;HP:0000369;HP:0001161;HP:0001829;HP:0002553;HP:0001337;HP:0000612;HP:0001251;HP:0003312;HP:0000238;HP:0001252;HP:0000426;HP:0000639;HP:0001696;HP:0007370;HP:0002876;HP:0001250;HP:0001288;HP:0000486;HP:0000657;HP:0002650;HP:0000276;HP:0000508	Global developmental delay;Ataxia;Infantile onset;Autosomal recessive inheritance;Oculomotor apraxia;Molar tooth sign on MRI;Cerebellar hypoplasia;Abnormal electroretinogram;Generalized hypotonia;Abnormality of the hypothalamus-pituitary axis;Aganglionic megacolon;Apnea;Anteverted nares;Polymicrogyria;Cerebellar vermis hypoplasia;Intellectual disability;Global developmental delay;Biparietal narrowing;Encephalocele;Feeding difficulties in infancy;Oral cleft;Low-set ears;Hand polydactyly;Foot polydactyly;Highly arched eyebrow;Tremor;Iris coloboma;Ataxia;Abnormal form of the vertebral bodies;Hydrocephalus;Muscular hypotonia;Prominent nasal bridge;Nystagmus;Situs inversus totalis;Aplasia/Hypoplasia of the corpus callosum;Episodic tachypnea;Seizure;Gait disturbance;Strabismus;Oculomotor apraxia;Scoliosis;Long face;Ptosis	NA	NA	NA	NA	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;	D	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.11437135981131	N	Cep104	NA	NA	NA	NA	NA	0.139	0.5037	0.5089	0.0888	0.5292	0.210463	0.0604	0.131467	0.084565	PASS	0.170455	0.31	309	0.359155	72	chr1	3829360	NA	G	A	2159.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.99;AS_ReadPosRankSum=.;AS_SOR=1.096;DP=82;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.99;SOR=1.096	GT:AD:DP:GQ:PL	1/1:0,80:80:99:2173,240,0
chr1	3883678	3883678	A	G	DFFB	exonic	synonymous SNV	NA	DFFB:NM_001282669:exon7:c.A1026G:p.P342P,DFFB:NM_001320132:exon7:c.A807G:p.P269P,DFFB:NM_001320136:exon7:c.A762G:p.P254P,DFFB:NM_004402:exon7:c.A954G:p.P318P	0.5056	GnomAdGenome_AF_ami	106	18	HeterozygousVariant	het	156	69	87	0.557692307692308	2140.64	PASS	NA	NA	601883	Benign	CAD-CDG	Disease-causing germline mutation(s) in	Blood trace element (Cu levels)[23720494];	HP:0002136;HP:0001981;HP:0003593;HP:0004823;HP:0200134;HP:0001947;HP:0012345;HP:0001263;HP:0001290;HP:0001927;HP:0000007;HP:0002133;HP:0001987;HP:0002465;HP:0001903;HP:0003676;HP:0012444;HP:0002376	Broad-based gait;Schistocytosis;Infantile onset;Anisopoikilocytosis;Epileptic encephalopathy;Renal tubular acidosis;Abnormal glycosylation;Global developmental delay;Generalized hypotonia;Acanthocytosis;Autosomal recessive inheritance;Status epilepticus;Hyperammonemia;Poor speech;Anemia;Progressive;Brain atrophy;Developmental regression	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;skeletal muscle;unclassifiable (Anatomical System);	white blood cells;dorsal root ganglion;cingulate cortex;superior cervical ganglion;globus pallidus;	0.718	N	N	N	N	0.94521045461494	E	Dffb	hematopoietic system phenotype; immune system phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; cellular phenotype; 	NA	NA	NA	NA	0.3866	0.4499	0.4554	0.3908	0.5056	0.355831	0.4129	0.392718	0.366995	PASS	0.474747	0.389	243	0.366197	68	chr1	3883678	NA	A	G	2140.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=1.285;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.72;AS_ReadPosRankSum=-0.6;AS_SOR=0.567;BaseQRankSum=-1.002;DP=161;ExcessHet=3.0103;FS=1.285;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.72;ReadPosRankSum=-0.559;SOR=0.567	GT:AD:DP:GQ:PL	0/1:69,87:156:99:2148,0,1747
chr1	3890079	3890079	T	A	C1orf174	intronic	NA	NA	NA	0.5405	GnomAdExome_AF_afr	38	16	HeterozygousVariant	het	63	36	27	0.428571428571429	594.64	PASS	NA	NA	NA	NA	NA	NA	Verbal declarative memory[25648963;25648963;25648963];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	Medium	Medium	Medium	cervix;liver;cartilage;skin;stomach;bone;testis;brain;unclassifiable (Anatomical System);heart;amniotic fluid;lung;kidney;cerebral cortex;uterus;pancreas;colon;placenta;prostate;nasopharynx;skeletal muscle;breast;visual apparatus;	ciliary ganglion;trigeminal ganglion;atrioventricular node;	0.876	NA	N	N	N	NA	NA	A430005L14Rik	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.3503	0.5405	0.5485	0.3886	0.525	0.421526	0.3794	0.347408	0.409688	PASS	0	0.327	119	0.31338	57	chr1	3890079	NA	T	A	594.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=5.261;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.44;AS_ReadPosRankSum=-2.3;AS_SOR=1.444;BaseQRankSum=0.991;DP=70;ExcessHet=3.0103;FS=5.261;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.44;ReadPosRankSum=-2.211;SOR=1.444	GT:AD:DP:GQ:PL	0/1:36,27:63:99:602,0,836
chr1	3891029	3891029	G	C	C1orf174	exonic	nonsynonymous SNV	NA	C1orf174:NM_207356:exon3:c.C158G:p.T53R	1	GnomAdGenome_AF_eas	581	142	HomozygousVariant	hom	36	0	36	1	1178.06	PASS	4.555	NA	NA	Benign	NA	NA	Verbal declarative memory[25648963;25648963;25648963];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	cervix;liver;cartilage;skin;stomach;bone;testis;brain;unclassifiable (Anatomical System);heart;amniotic fluid;lung;kidney;cerebral cortex;uterus;pancreas;colon;placenta;prostate;nasopharynx;skeletal muscle;breast;visual apparatus;	ciliary ganglion;trigeminal ganglion;atrioventricular node;	0.876	NA	N	N	N	NA	NA	A430005L14Rik	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.9944	0.9998	1	0.9941	1	0.997804	0.9941	0.983823	0.997537	PASS	1	0.998	2	1	0	chr1	3891029	NA	G	C	1178.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=32.72;AS_ReadPosRankSum=.;AS_SOR=1.949;DP=38;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=32.72;SOR=1.949	GT:AD:DP:GQ:PL	1/1:0,36:36:99:1192,108,0
chr1	3892859	3892859	G	A	C1orf174	intronic	NA	NA	NA	0.2238	GnomAdGenome_AF_eas	11	3	HeterozygousVariant	het	82	33	49	0.597560975609756	1275.64	PASS	NA	NA	NA	NA	NA	NA	Verbal declarative memory[25648963;25648963;25648963];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	cervix;liver;cartilage;skin;stomach;bone;testis;brain;unclassifiable (Anatomical System);heart;amniotic fluid;lung;kidney;cerebral cortex;uterus;pancreas;colon;placenta;prostate;nasopharynx;skeletal muscle;breast;visual apparatus;	ciliary ganglion;trigeminal ganglion;atrioventricular node;	0.876	NA	N	N	N	NA	NA	A430005L14Rik	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.14	0.2151	0.2137	0.125	0.2238	0.145567	0.1164	0.137747	0.125616	PASS	0	0.137	62	0.15493	38	chr1	3892859	NA	G	A	1275.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=3.011;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.56;AS_ReadPosRankSum=0.8;AS_SOR=0.784;BaseQRankSum=0.01;DP=83;ExcessHet=3.0103;FS=3.011;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.56;ReadPosRankSum=0.814;SOR=0.784	GT:AD:DP:GQ:PL	0/1:33,49:82:99:1283,0,769
chr1	4711990	4711990	C	A	AJAP1	exonic	synonymous SNV	NA	AJAP1:NM_001042478:exon2:c.C120A:p.A40A,AJAP1:NM_018836:exon2:c.C120A:p.A40A	0.030488	GME_TP	0	0	HeterozygousVariant	het	107	62	45	0.420560747663551	945.64	PASS	NA	NA	610972	Likely benign	NA	NA	Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)[29455858];Dental caries[23064961];Nickel levels[26025379];QT interval[29213071];Verbal declarative memory[25648963;25648963;25648963];Smooth-surface caries[24556642];Carotid plaque burden[28282560];Adolescent idiopathic scoliosis[26394188];Systemic juvenile idiopathic arthritis[27927641];Migraine - clinic-based[23793025];Response to haloperidol in schizophrenia[29503163];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858];	NA	NA	NA	NA	NA	Expressed in uterus and pancreas (at protein level). {ECO:0000269|PubMed:14595118}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	S	N	0.649785072240633	E	Ajap1	skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0035	0.0209	0.0219	0.0012	0.0223	0.00479233	0.0009	0.0032212	0.003284	PASS	0.030488	0.021	25	0.024648	7	chr1	4711990	NA	C	A	945.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=0.742;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.84;AS_ReadPosRankSum=-0.8;AS_SOR=0.839;BaseQRankSum=0.725;DP=111;ExcessHet=3.0103;FS=0.742;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.84;ReadPosRankSum=-0.755;SOR=0.839	GT:AD:DP:GQ:PL	0/1:62,45:107:99:953,0,1400
chr1	4712657	4712657	G	A	AJAP1	exonic	nonsynonymous SNV	NA	AJAP1:NM_001042478:exon2:c.G787A:p.G263R,AJAP1:NM_018836:exon2:c.G787A:p.G263R	0.7	GME_Israel	116	22	HomozygousVariant	hom	93	0	93	1	2886.06	PASS	20.7	NA	610972	Benign	NA	NA	Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)[29455858];Dental caries[23064961];Nickel levels[26025379];QT interval[29213071];Verbal declarative memory[25648963;25648963;25648963];Smooth-surface caries[24556642];Carotid plaque burden[28282560];Adolescent idiopathic scoliosis[26394188];Systemic juvenile idiopathic arthritis[27927641];Migraine - clinic-based[23793025];Response to haloperidol in schizophrenia[29503163];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858];	NA	NA	NA	NA	NA	Expressed in uterus and pancreas (at protein level). {ECO:0000269|PubMed:14595118}.;	T	T	D	P	N	P	L	T	D	T	T	T	NA	T	T	T	T	T	.;.;	D	N	AJAP1/PANP, C-terminal;AJAP1/PANP, C-terminal	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	S	N	0.649785072240633	E	Ajap1	skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); 	NA	NA	NA	NA	0.5218	0.6672	0.6683	0.4908	0.6628	0.360823	0.5241	0.524062	0.521346	PASS	0.7	0.404	233	0.363971	55	chr1	4712657	NA	G	A	2886.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=31.03;AS_ReadPosRankSum=.;AS_SOR=1.511;DP=100;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=31.03;SOR=1.511	GT:AD:DP:GQ:PL	1/1:0,93:93:99:2900,279,0
chr1	5864537	5864537	G	A	NPHP4	intronic	NA	NA	NA	0.0059	GnomAdExome_AF_sas	0		HeterozygousVariant	het	43	20	23	0.534883720930232	629.64	PASS	NA	[MIM:606996]Senior-Loken syndrome 4;	607215	NA	Senior-Loken syndrome;Juvenile nephronophthisis	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	QT interval[19305408];Dimensional psychopathology (Positive)[29496196];Response to taxane treatment (placlitaxel)[23006423];	HP:0005576;HP:0000007;HP:0000108;HP:0003774;HP:0000090;HP:0001510;HP:0001959;HP:0000103;HP:0000092;HP:0001903;HP:0000510;HP:0000007;HP:0000090;HP:0001959;HP:0001425;HP:0001903;HP:0001141;HP:0003774;HP:0001583;HP:0000646;HP:0000103;HP:0000529;HP:0008209;HP:0000090;HP:0000822;HP:0004322;HP:0001263;HP:0010579;HP:0007703;HP:0000556;HP:0000518;HP:0004348;HP:0001251;HP:0002612;HP:0003774	Tubulointerstitial fibrosis;Autosomal recessive inheritance;Renal corticomedullary cysts;Stage 5 chronic kidney disease;Nephronophthisis;Growth delay;Polydipsia;Polyuria;Renal tubular atrophy;Anemia;Rod-cone dystrophy;Autosomal recessive inheritance;Nephronophthisis;Polydipsia;Heterogeneous;Anemia;Severely reduced visual acuity;Stage 5 chronic kidney disease;Rotary nystagmus;Amblyopia;Polyuria;Progressive visual loss;Premature ovarian insufficiency;Nephronophthisis;Hypertension;Short stature;Global developmental delay;Cone-shaped epiphysis;Abnormality of retinal pigmentation;Retinal dystrophy;Cataract;Abnormality of bone mineral density;Ataxia;Congenital hepatic fibrosis;Stage 5 chronic kidney disease	NA	NA	NA	Expressed in kidney, skeletal muscle, heart and liver, and to a lesser extent in brain and lung. {ECO:0000269|PubMed:12244321}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.021	N	N	N	N	0.915706938849517	E	Nphp4	cellular phenotype; pigmentation phenotype; reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	nphp4	posterior pronephric duct	bent	abnormal	0.0009	0.0059	0.0062	0.0002	0.0029	0.000599042	0	0.0004592	0		0	0.001163	1			chr1	5864537	NA	G	A	629.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.65;AS_ReadPosRankSum=-1.2;AS_SOR=0.892;BaseQRankSum=0.911;DP=46;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.64;ReadPosRankSum=-1.121;SOR=0.892	GT:AD:DP:GQ:PL	0/1:20,23:43:99:637,0,453
chr1	5875102	5875102	T	A	NPHP4	splicing	NA	NM_001291593:exon18:c.1279-2A>T;NM_001291594:exon17:c.1282-2A>T;NM_015102:exon21:c.2818-2A>T	NA	0.2535	GnomAdGenome_AF_asj			HeterozygousVariant	het	59	25	34	0.576271186440678	831.64	PASS	24.4	[MIM:606996]Senior-Loken syndrome 4;	607215	NA	Senior-Loken syndrome;Juvenile nephronophthisis	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	QT interval[19305408];Dimensional psychopathology (Positive)[29496196];Response to taxane treatment (placlitaxel)[23006423];	HP:0005576;HP:0000007;HP:0000108;HP:0003774;HP:0000090;HP:0001510;HP:0001959;HP:0000103;HP:0000092;HP:0001903;HP:0000510;HP:0000007;HP:0000090;HP:0001959;HP:0001425;HP:0001903;HP:0001141;HP:0003774;HP:0001583;HP:0000646;HP:0000103;HP:0000529;HP:0008209;HP:0000090;HP:0000822;HP:0004322;HP:0001263;HP:0010579;HP:0007703;HP:0000556;HP:0000518;HP:0004348;HP:0001251;HP:0002612;HP:0003774	Tubulointerstitial fibrosis;Autosomal recessive inheritance;Renal corticomedullary cysts;Stage 5 chronic kidney disease;Nephronophthisis;Growth delay;Polydipsia;Polyuria;Renal tubular atrophy;Anemia;Rod-cone dystrophy;Autosomal recessive inheritance;Nephronophthisis;Polydipsia;Heterogeneous;Anemia;Severely reduced visual acuity;Stage 5 chronic kidney disease;Rotary nystagmus;Amblyopia;Polyuria;Progressive visual loss;Premature ovarian insufficiency;Nephronophthisis;Hypertension;Short stature;Global developmental delay;Cone-shaped epiphysis;Abnormality of retinal pigmentation;Retinal dystrophy;Cataract;Abnormality of bone mineral density;Ataxia;Congenital hepatic fibrosis;Stage 5 chronic kidney disease	NA	NA	NA	Expressed in kidney, skeletal muscle, heart and liver, and to a lesser extent in brain and lung. {ECO:0000269|PubMed:12244321}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.021	N	N	N	N	0.915706938849517	E	Nphp4	cellular phenotype; pigmentation phenotype; reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	nphp4	posterior pronephric duct	bent	abnormal	0	0	0	0.152	0.2535	0	0	0.0039586	0		0					chr1	5875102	NA	T	A	831.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=2.315;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.1;AS_ReadPosRankSum=-0.6;AS_SOR=0.441;BaseQRankSum=0.509;DP=60;ExcessHet=3.0103;FS=2.315;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.1;ReadPosRankSum=-0.554;SOR=0.441	GT:AD:DP:GQ:PL	0/1:25,34:59:99:839,0,566
chr1	5877267	5877267	C	T	NPHP4	exonic	synonymous SNV	NA	NPHP4:NM_001291594:exon16:c.G1107A:p.A369A,NPHP4:NM_001291593:exon17:c.G1104A:p.A368A,NPHP4:NM_015102:exon20:c.G2643A:p.A881A	0.2277	GnomAdGenome_AF_asj	16	0	HeterozygousVariant	het	84	47	37	0.44047619047619	745.64	PASS	NA	[MIM:606996]Senior-Loken syndrome 4;	607215	Benign	Senior-Loken syndrome;Juvenile nephronophthisis	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	QT interval[19305408];Dimensional psychopathology (Positive)[29496196];Response to taxane treatment (placlitaxel)[23006423];	HP:0005576;HP:0000007;HP:0000108;HP:0003774;HP:0000090;HP:0001510;HP:0001959;HP:0000103;HP:0000092;HP:0001903;HP:0000510;HP:0000007;HP:0000090;HP:0001959;HP:0001425;HP:0001903;HP:0001141;HP:0003774;HP:0001583;HP:0000646;HP:0000103;HP:0000529;HP:0008209;HP:0000090;HP:0000822;HP:0004322;HP:0001263;HP:0010579;HP:0007703;HP:0000556;HP:0000518;HP:0004348;HP:0001251;HP:0002612;HP:0003774	Tubulointerstitial fibrosis;Autosomal recessive inheritance;Renal corticomedullary cysts;Stage 5 chronic kidney disease;Nephronophthisis;Growth delay;Polydipsia;Polyuria;Renal tubular atrophy;Anemia;Rod-cone dystrophy;Autosomal recessive inheritance;Nephronophthisis;Polydipsia;Heterogeneous;Anemia;Severely reduced visual acuity;Stage 5 chronic kidney disease;Rotary nystagmus;Amblyopia;Polyuria;Progressive visual loss;Premature ovarian insufficiency;Nephronophthisis;Hypertension;Short stature;Global developmental delay;Cone-shaped epiphysis;Abnormality of retinal pigmentation;Retinal dystrophy;Cataract;Abnormality of bone mineral density;Ataxia;Congenital hepatic fibrosis;Stage 5 chronic kidney disease	Nephronophthisis|Nephronophthisis_4|Senior-Loken_syndrome_4|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in kidney, skeletal muscle, heart and liver, and to a lesser extent in brain and lung. {ECO:0000269|PubMed:12244321}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.021	N	N	N	N	0.915706938849517	E	Nphp4	cellular phenotype; pigmentation phenotype; reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	nphp4	posterior pronephric duct	bent	abnormal	0.1314	0.1633	0.1607	0.1182	0.2277	0.0894569	0.1255	0.131234	0.146141	PASS	0.125	0.118	165	0.084507	24	chr1	5877267	NA	C	T	745.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=0.828;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.88;AS_ReadPosRankSum=0.8;AS_SOR=0.569;BaseQRankSum=-0.272;DP=84;ExcessHet=3.0103;FS=0.828;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.88;ReadPosRankSum=0.852;SOR=0.569	GT:AD:DP:GQ:PL	0/1:47,37:84:99:753,0,1014
chr1	5887335	5887335	G	A	NPHP4	exonic	synonymous SNV	NA	NPHP4:NM_001291594:exon14:c.C900T:p.G300G,NPHP4:NM_001291593:exon15:c.C897T:p.G299G,NPHP4:NM_015102:exon18:c.C2436T:p.G812G	0.000821	abraom_freq	0		HeterozygousVariant	het	93	46	47	0.505376344086022	953.64	PASS	NA	[MIM:606996]Senior-Loken syndrome 4;	607215	NA	Senior-Loken syndrome;Juvenile nephronophthisis	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	QT interval[19305408];Dimensional psychopathology (Positive)[29496196];Response to taxane treatment (placlitaxel)[23006423];	HP:0005576;HP:0000007;HP:0000108;HP:0003774;HP:0000090;HP:0001510;HP:0001959;HP:0000103;HP:0000092;HP:0001903;HP:0000510;HP:0000007;HP:0000090;HP:0001959;HP:0001425;HP:0001903;HP:0001141;HP:0003774;HP:0001583;HP:0000646;HP:0000103;HP:0000529;HP:0008209;HP:0000090;HP:0000822;HP:0004322;HP:0001263;HP:0010579;HP:0007703;HP:0000556;HP:0000518;HP:0004348;HP:0001251;HP:0002612;HP:0003774	Tubulointerstitial fibrosis;Autosomal recessive inheritance;Renal corticomedullary cysts;Stage 5 chronic kidney disease;Nephronophthisis;Growth delay;Polydipsia;Polyuria;Renal tubular atrophy;Anemia;Rod-cone dystrophy;Autosomal recessive inheritance;Nephronophthisis;Polydipsia;Heterogeneous;Anemia;Severely reduced visual acuity;Stage 5 chronic kidney disease;Rotary nystagmus;Amblyopia;Polyuria;Progressive visual loss;Premature ovarian insufficiency;Nephronophthisis;Hypertension;Short stature;Global developmental delay;Cone-shaped epiphysis;Abnormality of retinal pigmentation;Retinal dystrophy;Cataract;Abnormality of bone mineral density;Ataxia;Congenital hepatic fibrosis;Stage 5 chronic kidney disease	not_provided	criteria_provided,_single_submitter	Uncertain_significance	Expressed in kidney, skeletal muscle, heart and liver, and to a lesser extent in brain and lung. {ECO:0000269|PubMed:12244321}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.021	N	N	N	N	0.915706938849517	E	Nphp4	cellular phenotype; pigmentation phenotype; reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	nphp4	posterior pronephric duct	bent	abnormal	0.00009675	0.0007	0.0008	0.0002	0.0007	0.000199681	0.0002	0.000097	0.000821	PASS	0	0.0005981	1			chr1	5887335	NA	G	A	953.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.26;AS_ReadPosRankSum=0.7;AS_SOR=0.735;BaseQRankSum=0.39;DP=93;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.25;ReadPosRankSum=0.75;SOR=0.735	GT:AD:DP:GQ:PL	0/1:46,47:93:99:961,0,924
chr1	5927636	5927636	T	C	NPHP4	intronic	NA	NA	NA	0.2223	GnomAdGenome_AF_asj	9	0	HeterozygousVariant	het	94	44	50	0.531914893617021	1190.64	PASS	NA	[MIM:606996]Senior-Loken syndrome 4;	607215	NA	Senior-Loken syndrome;Juvenile nephronophthisis	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	QT interval[19305408];Dimensional psychopathology (Positive)[29496196];Response to taxane treatment (placlitaxel)[23006423];	HP:0005576;HP:0000007;HP:0000108;HP:0003774;HP:0000090;HP:0001510;HP:0001959;HP:0000103;HP:0000092;HP:0001903;HP:0000510;HP:0000007;HP:0000090;HP:0001959;HP:0001425;HP:0001903;HP:0001141;HP:0003774;HP:0001583;HP:0000646;HP:0000103;HP:0000529;HP:0008209;HP:0000090;HP:0000822;HP:0004322;HP:0001263;HP:0010579;HP:0007703;HP:0000556;HP:0000518;HP:0004348;HP:0001251;HP:0002612;HP:0003774	Tubulointerstitial fibrosis;Autosomal recessive inheritance;Renal corticomedullary cysts;Stage 5 chronic kidney disease;Nephronophthisis;Growth delay;Polydipsia;Polyuria;Renal tubular atrophy;Anemia;Rod-cone dystrophy;Autosomal recessive inheritance;Nephronophthisis;Polydipsia;Heterogeneous;Anemia;Severely reduced visual acuity;Stage 5 chronic kidney disease;Rotary nystagmus;Amblyopia;Polyuria;Progressive visual loss;Premature ovarian insufficiency;Nephronophthisis;Hypertension;Short stature;Global developmental delay;Cone-shaped epiphysis;Abnormality of retinal pigmentation;Retinal dystrophy;Cataract;Abnormality of bone mineral density;Ataxia;Congenital hepatic fibrosis;Stage 5 chronic kidney disease	Nephronophthisis_4|Senior-Loken_syndrome_4|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in kidney, skeletal muscle, heart and liver, and to a lesser extent in brain and lung. {ECO:0000269|PubMed:12244321}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.021	N	N	N	N	0.915706938849517	E	Nphp4	cellular phenotype; pigmentation phenotype; reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	nphp4	posterior pronephric duct	bent	abnormal	0.1455	0.2101	0.2151	0.1737	0.2223	0.141174	0.1838	0.147993	0.184729	PASS	0	0.106	92	0.073944	21	chr1	5927636	NA	T	C	1190.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.67;AS_ReadPosRankSum=-0.9;AS_SOR=0.732;BaseQRankSum=-0.765;DP=103;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.67;ReadPosRankSum=-0.887;SOR=0.732	GT:AD:DP:GQ:PL	0/1:44,50:94:99:1198,0,1022
chr1	6124032	6124032	A	G	CHD5	exonic	nonsynonymous SNV	NA	CHD5:NM_015557:exon31:c.T4615C:p.S1539P	0.9968	GnomAdGenome_AF_eas	549	100	HomozygousVariant	hom	76	0	76	1	2123.06	PASS	17.96	NA	610771	NA	NA	NA	Zinc levels[26025379];	NA	NA	NA	NA	NA	Preferentially expressed in total brain, fetal brain, and cerebellum. It is also moderately expressed in the adrenal gland and detected in testis. {ECO:0000269|PubMed:12592387, ECO:0000269|PubMed:21931736}.;	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	fovea centralis;testis;brain;lens;unclassifiable (Anatomical System);lung;choroid;retina;macula lutea;frontal lobe;colon;placenta;skeletal muscle;optic nerve;hypothalamus;	temporal lobe;amygdala;testis - seminiferous tubule;prefrontal cortex;cingulate cortex;superior cervical ganglion;testis;pons;fetal brain;occipital lobe;testis - interstitial;subthalamic nucleus;whole brain;atrioventricular node;parietal lobe;globus pallidus;medulla oblongata;	0.0144	NA	E	N	N	0.256035855399172	N	Chd5	cellular phenotype; reproductive system phenotype; 	chd5	splanchnocranium	absent	abnormal	0.6511	0.9964	0.9962	0.6072	0.9968	0.727636	0.588	0.634921	0.587849	PASS	0.698276	0.815	219	0.834507	37	chr1	6124032	NA	A	G	2123.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.93;AS_ReadPosRankSum=.;AS_SOR=0.984;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.94;SOR=0.984	GT:AD:DP:GQ:PL	1/1:0,76:76:99:2137,227,0
chr1	6128486	6128486	G	A	CHD5	intronic	NA	NA	NA	0.428	GnomAdExome_AF_asj	68	27	HeterozygousVariant	het	60	24	36	0.6	807.64	PASS	NA	NA	610771	NA	NA	NA	Zinc levels[26025379];	NA	NA	NA	NA	NA	Preferentially expressed in total brain, fetal brain, and cerebellum. It is also moderately expressed in the adrenal gland and detected in testis. {ECO:0000269|PubMed:12592387, ECO:0000269|PubMed:21931736}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;testis;brain;lens;unclassifiable (Anatomical System);lung;choroid;retina;macula lutea;frontal lobe;colon;placenta;skeletal muscle;optic nerve;hypothalamus;	temporal lobe;amygdala;testis - seminiferous tubule;prefrontal cortex;cingulate cortex;superior cervical ganglion;testis;pons;fetal brain;occipital lobe;testis - interstitial;subthalamic nucleus;whole brain;atrioventricular node;parietal lobe;globus pallidus;medulla oblongata;	0.0144	NA	E	N	N	0.256035855399172	N	Chd5	cellular phenotype; reproductive system phenotype; 	chd5	splanchnocranium	absent	abnormal	0.2902	0.4019	0.4029	0.2294	0.4213	0.2502	0.2237	0.270663	0.256979	PASS	0	0.414	219	0.43662	70	chr1	6128486	NA	G	A	807.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=2.2;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.47;AS_ReadPosRankSum=-1.1;AS_SOR=0.43;BaseQRankSum=0.175;DP=62;ExcessHet=3.0103;FS=2.2;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.46;ReadPosRankSum=-1.042;SOR=0.43	GT:AD:DP:GQ:PL	0/1:24,36:60:99:815,0,474
chr1	6218354	6218354	A	G	RNF207	exonic	nonsynonymous SNV	NA	RNF207:NM_207396:exon17:c.A1718G:p.N573S	0.7162	GnomAdExome_AF_afr	151	34	HomozygousVariant	hom	68	0	68	1	1959.06	PASS	1.879	NA	616923	Benign	NA	NA	Systolic blood pressure[28135244];QT interval[19305408;19305409;24952745;24952745;29213071];Resting heart rate[27798624];Pulse pressure[27618447];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.769	NA	N	N	N	0.216580111939887	N	Rnf207	NA	rnf207b	ventricular myocardium	increased duration	abnormal	0.349	0.7162	0.7183	0.4434	0.7071	0.437101	0.4512	0.0001153	0.42775	PASS	0.65	0.42	375	0.450704	60	chr1	6218354	NA	A	G	1959.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.81;AS_ReadPosRankSum=.;AS_SOR=0.949;DP=68;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.81;SOR=0.949	GT:AD:DP:GQ:PL	1/1:0,68:68:99:1973,204,0
chr1	6219310	6219310	G	C	RNF207	exonic	nonsynonymous SNV	NA	RNF207:NM_207396:exon18:c.G1808C:p.G603A	0.4	GME_Israel	71	19	HeterozygousVariant	het	105	66	39	0.371428571428571	818.64	PASS	1.524	NA	616923	Benign	NA	NA	Systolic blood pressure[28135244];QT interval[19305408;19305409;24952745;24952745;29213071];Resting heart rate[27798624];Pulse pressure[27618447];	NA	NA	NA	NA	NA	NA	T	T	B	B	U	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.769	NA	N	N	N	0.216580111939887	N	Rnf207	NA	rnf207b	ventricular myocardium	increased duration	abnormal	0.2352	0.2958	0.2913	0.1963	0.3486	0.172524	0.1994	0.234298	0.201149	PASS	0.4	0.289	324	0.309859	50	chr1	6219310	NA	G	C	818.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=1.623;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.8;AS_ReadPosRankSum=-1.8;AS_SOR=0.897;BaseQRankSum=1.38;DP=106;ExcessHet=3.0103;FS=1.623;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.8;ReadPosRankSum=-1.755;SOR=0.897	GT:AD:DP:GQ:PL	0/1:66,39:105:99:826,0,1470
chr1	6245141	6245141	A	C	HES3	exonic	nonsynonymous SNV	NA	HES3:NM_001024598:exon4:c.A195C:p.Q65H	0.081395	GME_CA	6	1	HeterozygousVariant	het	48	21	27	0.5625	669.64	PASS	17.84	NA	609971	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	N	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	N	N	S	N	0.110825582013905	N	Hes3	cellular phenotype; growth/size/body region phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; embryo phenotype; 	her3	rhombomere 4	mislocalised	abnormal	0.0213	0.0673	0.0682	0.0305	0.0777	0.0441294	0.0167	0.0113388	0.020725	PASS	0.081395	0.082	84	0.088028	23	chr1	6245141	NA	A	C	669.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=2.643;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.96;AS_ReadPosRankSum=-0.7;AS_SOR=0.325;BaseQRankSum=0.196;DP=52;ExcessHet=3.0103;FS=2.643;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.95;ReadPosRankSum=-0.687;SOR=0.325	GT:AD:DP:GQ:PL	0/1:21,27:48:99:677,0,470
chr1	6253878	6253878	C	T	GPR153	exonic	nonsynonymous SNV	NA	GPR153:NM_207370:exon3:c.G626A:p.R209H	0.8113	GnomAdExome_AF_amr	300	69	HeterozygousVariant	het	50	27	23	0.46	446.64	PASS	2.974	NA	614269	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	D	N	GPCR, rhodopsin-like, 7TM	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.354866594519884	N	Gpr153	NA	NA	NA	NA	NA	0.7065	0.8113	0.812	0.7043	0.754	0.699081	0	0.680994	0.732348	PASS	0.767241	0.71	228	0.703571	59	chr1	6253878	NA	C	T	446.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=2.448;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.94;AS_ReadPosRankSum=-0.5;AS_SOR=1.127;BaseQRankSum=-1.001;DP=55;ExcessHet=3.0103;FS=2.448;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.93;ReadPosRankSum=-0.467;SOR=1.127	GT:AD:DP:GQ:PL	0/1:27,23:50:99:454,0,633
chr1	6254762	6254762	T	C	GPR153	exonic	synonymous SNV	NA	GPR153:NM_207370:exon2:c.A144G:p.T48T	0.8151	GnomAdExome_AF_amr	310	76	HeterozygousVariant	het	99	55	44	0.444444444444444	931.64	PASS	NA	NA	614269	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.354866594519884	N	Gpr153	NA	NA	NA	NA	NA	0.712	0.8151	0.814	0.7281	0.7881	0.73143	0.7318	0.0001153	0.744663	PASS	0.784483	0.723	225	0.728873	55	chr1	6254762	NA	T	C	931.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.41;AS_ReadPosRankSum=0.5;AS_SOR=0.709;BaseQRankSum=-0.884;DP=102;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.41;ReadPosRankSum=0.507;SOR=0.709	GT:AD:DP:GQ:PL	0/1:55,44:99:99:939,0,1331
chr1	6413234	6413234	A	G	ACOT7;HES2	intergenic	NA	dist=19468;dist=2000	NA	0.614	GnomAdExome_AF_afr	25	7	HeterozygousVariant	het	137	70	67	0.489051094890511	1549.64	PASS	5.939	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	NA	NA	N	T	T	T	NA	NA	NA	T	T	T	.;.;	N	N	.;.	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.1635	0.614	0.6216	0.2777	0.6006	0.290735	0	0.0582334	0		0	0.176	154	0.169014	34	chr1	6413234	NA	A	G	1549.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1;AS_FS=1.348;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.31;AS_ReadPosRankSum=1.1;AS_SOR=0.566;BaseQRankSum=1.04;DP=141;ExcessHet=3.0103;FS=1.348;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.31;ReadPosRankSum=1.14;SOR=0.566	GT:AD:DP:GQ:PL	0/1:70,67:137:99:1557,0,1550
chr1	6418980	6418980	G	A	HES2	exonic	nonsynonymous SNV	NA	HES2:NM_019089:exon4:c.C415T:p.P139S	0.1265	GnomAdGenome_AF_eas	3	1	WT/SomaticVariant	het	57	43	14	0.245614035087719	222.64	PASS	6.599	NA	609970	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in placenta, pancreatic cancer, colon cancer with RER, cervical cancer, and in head and neck tumors. {ECO:0000269|PubMed:15254753}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.230912229909725	N	Hes2	NA	NA	NA	NA	NA	0.0359	0.1222	0.0897	0.0569	0.1265	0.0780751	0	0.0081047	0.051174	VQSRTrancheSNP99.00to99.90	0.119205	0.028	27	0.037594	8	chr1	6418980	NA	G	A	222.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=1.169;AS_MQ=60;AS_MQRankSum=0;AS_QD=3.91;AS_ReadPosRankSum=-0.7;AS_SOR=0.495;BaseQRankSum=-1.27;DP=59;ExcessHet=3.0103;FS=1.169;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=3.91;ReadPosRankSum=-0.603;SOR=0.495	GT:AD:DP:GQ:PL	0/1:43,14:57:99:230,0,1175
chr1	6419878	6419878	A	G	HES2	UTR5	NA	NM_019089:c.-58T>C	NA	0.2281	GnomAdGenome_AF_afr	9	2	HeterozygousVariant	het	22	8	14	0.636363636363636	357.64	PASS	NA	NA	609970	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in placenta, pancreatic cancer, colon cancer with RER, cervical cancer, and in head and neck tumors. {ECO:0000269|PubMed:15254753}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.230912229909725	N	Hes2	NA	NA	NA	NA	NA	0	0	0	0.142	0.2281	0.159545	0.074	0.0201485	0.130148	PASS	0	0.145	34	0.101449	24	chr1	6419878	NA	A	G	357.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=16.27;AS_ReadPosRankSum=-0.5;AS_SOR=0.551;BaseQRankSum=0.95;DP=23;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=16.26;ReadPosRankSum=-0.446;SOR=0.551	GT:AD:DP:GQ:PL	0/1:8,14:22:99:365,0,160
chr1	6440984	6440984	C	G	ESPN	exonic	synonymous SNV	NA	ESPN:NM_001367473:exon5:c.C909G:p.R303R,ESPN:NM_001367474:exon5:c.C909G:p.R303R,ESPN:NM_031475:exon5:c.C909G:p.R303R	0.254386	GME_AP	35	6	HeterozygousVariant	het	81	45	36	0.444444444444444	828.64	PASS	NA	[MIM:609006]Deafness, autosomal recessive, 36, with or without vestibular involvement [recessive?];	606351	Benign	Autosomal recessive non-syndromic sensorineural deafness type DFNB	Disease-causing germline mutation(s) in	Male-pattern baldness[29146897];	HP:0000738;HP:0000739;HP:0000375;HP:0007360;HP:0007730;HP:0100753;HP:0000512;HP:0012157;HP:0002120;HP:0000682;HP:0001263;HP:0008499;HP:0000572;HP:0000407;HP:0000575;HP:0000716;HP:0001249;HP:0012377;HP:0000662;HP:0001756;HP:0000518;HP:0001251;HP:0000007;HP:0000407;HP:0008568	Hallucinations;Anxiety;Abnormal cochlea morphology;Aplasia/Hypoplasia of the cerebellum;Iris hypopigmentation;Schizophrenia;Abnormal electroretinogram;Subcortical cerebral atrophy;Cerebral cortical atrophy;Abnormality of dental enamel;Global developmental delay;High hypermetropia;Visual loss;Sensorineural hearing impairment;Scotoma;Depressivity;Intellectual disability;Hemianopia;Nyctalopia;Vestibular hypofunction;Cataract;Ataxia;Autosomal recessive inheritance;Sensorineural hearing impairment;Vestibular areflexia	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	N	N	N	N	0.370466227400857	N	Espn	hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; 	NA	NA	NA	NA	0.1361	0.2433	0.2465	0.1658	0.2489	0.182109	0.1585	0.12822	0.165025	PASS	0.254386	0.19	247	0.18662	41	chr1	6440984	NA	C	G	828.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=0.84;AS_MQ=60;AS_MQRankSum=1.5;AS_QD=10.23;AS_ReadPosRankSum=0.4;AS_SOR=0.767;BaseQRankSum=0.636;DP=82;ExcessHet=3.0103;FS=0.84;MLEAC=1;MLEAF=0.5;MQ=59.64;MQRankSum=1.58;QD=10.23;ReadPosRankSum=0.442;SOR=0.767	GT:AD:DP:GQ:PL	0/1:45,36:81:99:836,0,1031
chr1	6466123	6466123	G	A	TNFRSF25;PLEKHG5	UTR5;UTR3	NA	NM_003790:c.-16C>T;NM_148970:c.-16C>T;NM_148967:c.-16C>T;NM_148966:c.-16C>T;NM_148965:c.-16C>T;NM_001039664:c.-16C>T;NM_001265593:c.*1440C>T;NM_001042665:c.*1440C>T;NM_001042664:c.*1440C>T;NM_001265592:c.*1440C>T;NM_198681:c.*1440C>T;NM_001265594:c.*1468C>T;NM_020631:c.*1440C>T;NM_001042663:c.*1440C>T	NA	0.502	GnomAdExome_AF_afr	6	2	HeterozygousVariant	het	50	32	18	0.36	522.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	Distal_spinal_muscular_atrophy,_autosomal_recessive_4	criteria_provided,_single_submitter	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0781	0.502	0.5116	0.1963	0.4886	0.202276	0.1659	0.0768166	0.178869	VQSRTrancheSNP99.00to99.90	0	0.038	47	0.073944	17	chr1	6466123	NA	G	A	522.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=2.584;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.46;AS_ReadPosRankSum=-2.3;AS_SOR=0.368;BaseQRankSum=-1.195;DP=51;ExcessHet=3.0103;FS=2.584;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.45;ReadPosRankSum=-2.226;SOR=0.368	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:32,18:50:99:0|1:6466123_G_A:530,0,1182:6466123
chr1	6466143	6466150	CGTGCTCT	-	TNFRSF25;PLEKHG5	UTR5;UTR3	NA	NM_003790:c.-36_-43delAGAGCACG;NM_148970:c.-36_-43delAGAGCACG;NM_148967:c.-36_-43delAGAGCACG;NM_148966:c.-36_-43delAGAGCACG;NM_148965:c.-36_-43delAGAGCACG;NM_001039664:c.-36_-43delAGAGCACG;NM_001265593:c.*1420_*1413delAGAGCACG;NM_001042665:c.*1420_*1413delAGAGCACG;NM_001042664:c.*1420_*1413delAGAGCACG;NM_001265592:c.*1420_*1413delAGAGCACG;NM_198681:c.*1420_*1413delAGAGCACG;NM_001265594:c.*1448_*1441delAGAGCACG;NM_020631:c.*1420_*1413delAGAGCACG;NM_001042663:c.*1420_*1413delAGAGCACG	NA	0.4888	GnomAdGenome_AF_afr	6	2	HeterozygousVariant	het	45	30	15	0.333333333333333	477.6	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	Distal_spinal_muscular_atrophy	criteria_provided,_single_submitter	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0613	0.4251	0.4412	0.1965	0.4888	0.202676	0.1632	0.0179806	0.177311	PASS	0	0.123	41	0.074468	17	chr1	6466142	NA	CCGTGCTCT	C	477.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=2.822;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.62;AS_ReadPosRankSum=-1.2;AS_SOR=0.352;BaseQRankSum=0.141;DP=46;ExcessHet=3.0103;FS=2.822;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.61;ReadPosRankSum=-1.109;SOR=0.352	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:30,15:45:99:0|1:6466123_G_A:485,0,1168:6466123
chr1	6469179	6469179	C	T	PLEKHG5	exonic	synonymous SNV	NA	PLEKHG5:NM_001042664:exon19:c.G2112A:p.L704L,PLEKHG5:NM_001042665:exon19:c.G2112A:p.L704L,PLEKHG5:NM_001265593:exon19:c.G2319A:p.L773L,PLEKHG5:NM_001265594:exon19:c.G2112A:p.L704L,PLEKHG5:NM_020631:exon19:c.G2112A:p.L704L,PLEKHG5:NM_001042663:exon20:c.G2280A:p.L760L,PLEKHG5:NM_001265592:exon20:c.G2349A:p.L783L,PLEKHG5:NM_198681:exon20:c.G2343A:p.L781L	0.0008	GnomAdExome_AF_sas	0		HeterozygousVariant	het	155	85	70	0.451612903225806	1432.64	PASS	NA	[MIM:615376]Charcot-Marie-Tooth disease, recessive, intermediate type, C;	611101	NA	Autosomal recessive lower motor neuron disease with childhood onset;Autosomal recessive intermediate Charcot-Marie-Tooth disease type C	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	QT interval[19305408];Multiple sclerosis[24076602];	HP:0002747;HP:0001762;HP:0009473;HP:0000007;HP:0001284;HP:0002650;HP:0003307;HP:0007269;HP:0002460;HP:0003701;HP:0011463;HP:0003551;HP:0002515;HP:0003693;HP:0003445;HP:0002355;HP:0003678;HP:0002366;HP:0003697;HP:0002460;HP:0001765;HP:0002936;HP:0003431;HP:0001761;HP:0001284;HP:0008180;HP:0000007;HP:0003387	Respiratory insufficiency due to muscle weakness;Talipes equinovarus;Joint contracture of the hand;Autosomal recessive inheritance;Areflexia;Scoliosis;Hyperlordosis;Spinal muscular atrophy;Distal muscle weakness;Proximal muscle weakness;Childhood onset;Difficulty climbing stairs;Waddling gait;Distal amyotrophy;EMG: neuropathic changes;Difficulty walking;Rapidly progressive;Abnormal lower motor neuron morphology;Scapuloperoneal amyotrophy;Distal muscle weakness;Hammertoe;Distal sensory impairment;Decreased motor nerve conduction velocity;Pes cavus;Areflexia;Mildly elevated creatine kinase;Autosomal recessive inheritance;Decreased number of large peripheral myelinated nerve fibers	NA	NA	NA	Predominantly expressed in the peripheral nervous system and brain. Highest expression is observed in heart, lung, kidney, testis and moderate expression is present in spleen, pancreas, skeletal muscle, ovary and liver. Weakly expressed in glioblastoma (GBM) cell lines. {ECO:0000269|PubMed:11704860, ECO:0000269|PubMed:16467373, ECO:0000269|PubMed:9872452}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;whole body;retina;head and neck;mammary gland;skeletal muscle;visual apparatus;fovea centralis;liver;cartilage;endometrium;bone;brain;heart;lung;thyroid;macula lutea;frontal lobe;colon;placenta;prostate;optic nerve;hypothalamus;	ciliary ganglion;pons;kidney;subthalamic nucleus;dorsal root ganglion;atrioventricular node;trigeminal ganglion;skin;superior cervical ganglion;skeletal muscle;globus pallidus;	0.803	N	N	N	N	0.375009372441274	N	Plekhg5	muscle phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); renal/urinary system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	plekhg5b	dorsal longitudinal anastomotic vessel	aplastic	abnormal	0.0001	0.0008	0.0008	0.000006977	0.0003	0.000399361	0	0.0000768	0		0	0.002013	3			chr1	6469179	NA	C	T	1432.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=1.253;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.25;AS_ReadPosRankSum=-0.2;AS_SOR=0.593;BaseQRankSum=-0.717;DP=160;ExcessHet=3.0103;FS=1.253;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.24;ReadPosRankSum=-0.142;SOR=0.593	GT:AD:DP:GQ:PL	0/1:85,70:155:99:1440,0,1925
chr1	6469383	6469383	A	G	PLEKHG5	exonic	synonymous SNV	NA	PLEKHG5:NM_001042664:exon18:c.T2001C:p.S667S,PLEKHG5:NM_001042665:exon18:c.T2001C:p.S667S,PLEKHG5:NM_001265593:exon18:c.T2208C:p.S736S,PLEKHG5:NM_001265594:exon18:c.T2001C:p.S667S,PLEKHG5:NM_020631:exon18:c.T2001C:p.S667S,PLEKHG5:NM_001042663:exon19:c.T2169C:p.S723S,PLEKHG5:NM_001265592:exon19:c.T2238C:p.S746S,PLEKHG5:NM_198681:exon19:c.T2232C:p.S744S	0.5922	GnomAdExome_AF_afr	35	3	HeterozygousVariant	het	42	25	17	0.404761904761905	446.64	PASS	NA	[MIM:615376]Charcot-Marie-Tooth disease, recessive, intermediate type, C;	611101	Benign	Autosomal recessive lower motor neuron disease with childhood onset;Autosomal recessive intermediate Charcot-Marie-Tooth disease type C	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	QT interval[19305408];Multiple sclerosis[24076602];	HP:0002747;HP:0001762;HP:0009473;HP:0000007;HP:0001284;HP:0002650;HP:0003307;HP:0007269;HP:0002460;HP:0003701;HP:0011463;HP:0003551;HP:0002515;HP:0003693;HP:0003445;HP:0002355;HP:0003678;HP:0002366;HP:0003697;HP:0002460;HP:0001765;HP:0002936;HP:0003431;HP:0001761;HP:0001284;HP:0008180;HP:0000007;HP:0003387	Respiratory insufficiency due to muscle weakness;Talipes equinovarus;Joint contracture of the hand;Autosomal recessive inheritance;Areflexia;Scoliosis;Hyperlordosis;Spinal muscular atrophy;Distal muscle weakness;Proximal muscle weakness;Childhood onset;Difficulty climbing stairs;Waddling gait;Distal amyotrophy;EMG: neuropathic changes;Difficulty walking;Rapidly progressive;Abnormal lower motor neuron morphology;Scapuloperoneal amyotrophy;Distal muscle weakness;Hammertoe;Distal sensory impairment;Decreased motor nerve conduction velocity;Pes cavus;Areflexia;Mildly elevated creatine kinase;Autosomal recessive inheritance;Decreased number of large peripheral myelinated nerve fibers	Distal_spinal_muscular_atrophy,_autosomal_recessive_4|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Predominantly expressed in the peripheral nervous system and brain. Highest expression is observed in heart, lung, kidney, testis and moderate expression is present in spleen, pancreas, skeletal muscle, ovary and liver. Weakly expressed in glioblastoma (GBM) cell lines. {ECO:0000269|PubMed:11704860, ECO:0000269|PubMed:16467373, ECO:0000269|PubMed:9872452}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;whole body;retina;head and neck;mammary gland;skeletal muscle;visual apparatus;fovea centralis;liver;cartilage;endometrium;bone;brain;heart;lung;thyroid;macula lutea;frontal lobe;colon;placenta;prostate;optic nerve;hypothalamus;	ciliary ganglion;pons;kidney;subthalamic nucleus;dorsal root ganglion;atrioventricular node;trigeminal ganglion;skin;superior cervical ganglion;skeletal muscle;globus pallidus;	0.803	N	N	N	N	0.375009372441274	N	Plekhg5	muscle phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); renal/urinary system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	plekhg5b	dorsal longitudinal anastomotic vessel	aplastic	abnormal	0.1612	0.5922	0.599	0.271	0.5757	0.269569	0.2872	0.168969	0.252053	PASS	0.324561	0.196	258	0.158451	39	chr1	6469383	NA	A	G	446.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.1;AS_FS=4.519;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.64;AS_ReadPosRankSum=0;AS_SOR=1.335;BaseQRankSum=1.15;DP=44;ExcessHet=3.0103;FS=4.519;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.63;ReadPosRankSum=0.051;SOR=1.335	GT:AD:DP:GQ:PL	0/1:25,17:42:99:454,0,618
chr1	6485330	6485330	A	T	PLEKHG5	exonic	nonsynonymous SNV	NA	PLEKHG5:NM_001265593:exon1:c.T114A:p.D38E	0.54	GnomAdGenome_AF_afr	48	9	HeterozygousVariant	het	40	21	19	0.475	384.64	PASS	5.677	[MIM:615376]Charcot-Marie-Tooth disease, recessive, intermediate type, C;	611101	Benign	Autosomal recessive lower motor neuron disease with childhood onset;Autosomal recessive intermediate Charcot-Marie-Tooth disease type C	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	QT interval[19305408];Multiple sclerosis[24076602];	HP:0002747;HP:0001762;HP:0009473;HP:0000007;HP:0001284;HP:0002650;HP:0003307;HP:0007269;HP:0002460;HP:0003701;HP:0011463;HP:0003551;HP:0002515;HP:0003693;HP:0003445;HP:0002355;HP:0003678;HP:0002366;HP:0003697;HP:0002460;HP:0001765;HP:0002936;HP:0003431;HP:0001761;HP:0001284;HP:0008180;HP:0000007;HP:0003387	Respiratory insufficiency due to muscle weakness;Talipes equinovarus;Joint contracture of the hand;Autosomal recessive inheritance;Areflexia;Scoliosis;Hyperlordosis;Spinal muscular atrophy;Distal muscle weakness;Proximal muscle weakness;Childhood onset;Difficulty climbing stairs;Waddling gait;Distal amyotrophy;EMG: neuropathic changes;Difficulty walking;Rapidly progressive;Abnormal lower motor neuron morphology;Scapuloperoneal amyotrophy;Distal muscle weakness;Hammertoe;Distal sensory impairment;Decreased motor nerve conduction velocity;Pes cavus;Areflexia;Mildly elevated creatine kinase;Autosomal recessive inheritance;Decreased number of large peripheral myelinated nerve fibers	not_specified	criteria_provided,_single_submitter	Benign	Predominantly expressed in the peripheral nervous system and brain. Highest expression is observed in heart, lung, kidney, testis and moderate expression is present in spleen, pancreas, skeletal muscle, ovary and liver. Weakly expressed in glioblastoma (GBM) cell lines. {ECO:0000269|PubMed:11704860, ECO:0000269|PubMed:16467373, ECO:0000269|PubMed:9872452}.;	T	T	NA	NA	NA	P	NA	T	N	T	T	T	NA	T	NA	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;whole body;retina;head and neck;mammary gland;skeletal muscle;visual apparatus;fovea centralis;liver;cartilage;endometrium;bone;brain;heart;lung;thyroid;macula lutea;frontal lobe;colon;placenta;prostate;optic nerve;hypothalamus;	ciliary ganglion;pons;kidney;subthalamic nucleus;dorsal root ganglion;atrioventricular node;trigeminal ganglion;skin;superior cervical ganglion;skeletal muscle;globus pallidus;	0.803	N	N	N	N	0.375009372441274	N	Plekhg5	muscle phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); renal/urinary system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	plekhg5b	dorsal longitudinal anastomotic vessel	aplastic	abnormal	0.1209	0.4622	0.4811	0.2565	0.54	0.292133	0	0.0389387	0.221326	PASS	0	0.207	236	0.202899	38	chr1	6485330	NA	A	T	384.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.63;AS_ReadPosRankSum=0.9;AS_SOR=0.718;BaseQRankSum=-0.326;DP=42;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.62;ReadPosRankSum=0.908;SOR=0.718	GT:AD:DP:GQ:PL	0/1:21,19:40:99:392,0,454
chr1	6496949	6496949	A	C	PLEKHG5	intronic	NA	NA	NA	0.6303	GnomAdExome_AF_afr	42	6	HomozygousVariant	hom	102	0	102	1	2888.06	PASS	NA	[MIM:615376]Charcot-Marie-Tooth disease, recessive, intermediate type, C;	611101	NA	Autosomal recessive lower motor neuron disease with childhood onset;Autosomal recessive intermediate Charcot-Marie-Tooth disease type C	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	QT interval[19305408];Multiple sclerosis[24076602];	HP:0002747;HP:0001762;HP:0009473;HP:0000007;HP:0001284;HP:0002650;HP:0003307;HP:0007269;HP:0002460;HP:0003701;HP:0011463;HP:0003551;HP:0002515;HP:0003693;HP:0003445;HP:0002355;HP:0003678;HP:0002366;HP:0003697;HP:0002460;HP:0001765;HP:0002936;HP:0003431;HP:0001761;HP:0001284;HP:0008180;HP:0000007;HP:0003387	Respiratory insufficiency due to muscle weakness;Talipes equinovarus;Joint contracture of the hand;Autosomal recessive inheritance;Areflexia;Scoliosis;Hyperlordosis;Spinal muscular atrophy;Distal muscle weakness;Proximal muscle weakness;Childhood onset;Difficulty climbing stairs;Waddling gait;Distal amyotrophy;EMG: neuropathic changes;Difficulty walking;Rapidly progressive;Abnormal lower motor neuron morphology;Scapuloperoneal amyotrophy;Distal muscle weakness;Hammertoe;Distal sensory impairment;Decreased motor nerve conduction velocity;Pes cavus;Areflexia;Mildly elevated creatine kinase;Autosomal recessive inheritance;Decreased number of large peripheral myelinated nerve fibers	not_specified	criteria_provided,_single_submitter	Benign	Predominantly expressed in the peripheral nervous system and brain. Highest expression is observed in heart, lung, kidney, testis and moderate expression is present in spleen, pancreas, skeletal muscle, ovary and liver. Weakly expressed in glioblastoma (GBM) cell lines. {ECO:0000269|PubMed:11704860, ECO:0000269|PubMed:16467373, ECO:0000269|PubMed:9872452}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;whole body;retina;head and neck;mammary gland;skeletal muscle;visual apparatus;fovea centralis;liver;cartilage;endometrium;bone;brain;heart;lung;thyroid;macula lutea;frontal lobe;colon;placenta;prostate;optic nerve;hypothalamus;	ciliary ganglion;pons;kidney;subthalamic nucleus;dorsal root ganglion;atrioventricular node;trigeminal ganglion;skin;superior cervical ganglion;skeletal muscle;globus pallidus;	0.803	N	N	N	N	0.375009372441274	N	Plekhg5	muscle phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); renal/urinary system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	plekhg5b	dorsal longitudinal anastomotic vessel	aplastic	abnormal	0.1695	0.6303	0.6333	0.275	0.5995	0.324481	0	0.0440098	0.25	PASS	0	0.204	250	0.188406	40	chr1	6496949	NA	A	C	2888.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.31;AS_ReadPosRankSum=.;AS_SOR=1.27;DP=102;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.31;SOR=1.27	GT:AD:DP:GQ:PL	1/1:0,102:102:99:2902,305,0
chr1	6526003	6526003	G	A	NOL9	exonic	nonsynonymous SNV	NA	NOL9:NM_024654:exon12:c.C1960T:p.R654C	0.000821	abraom_freq			WT/SomaticVariant	het	59	42	17	0.288135593220339	278.64	PASS	16.76	NA	NA	NA	NA	NA	Body mass index[25673413];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	N	N	T	N	T	T	T	T	T	T	T	T	T	.;	D	N	NA	0	0.008	Medium	Medium	Medium	NA	NA	0.576	NA	E	E	E	0.767522461596202	E	Nol9	NA	nol9	hematopoietic multipotent progenitor cell	decreased amount	abnormal	0.00002006	0.0002	0.0001	0.00001397	0.00002383	0	0	0	0.000821	PASS	0					chr1	6526003	NA	G	A	278.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.104;AS_MQ=60;AS_MQRankSum=0;AS_QD=4.73;AS_ReadPosRankSum=-0.6;AS_SOR=0.879;BaseQRankSum=0.486;DP=60;ExcessHet=3.0103;FS=1.104;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=4.72;ReadPosRankSum=-0.578;SOR=0.879	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:42,17:59:99:0|1:6526003_G_A:286,0,972:6526003
chr1	6526010	6526010	C	T	NOL9	intronic	NA	NA	NA	1	GnomAdExome_AF_eas	298	142	HomozygousVariant	hom	55	0	55	1	1800.06	PASS	NA	NA	NA	NA	NA	NA	Body mass index[25673413];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0	Medium	Medium	Medium	NA	NA	0.576	NA	E	E	E	0.767522461596202	E	Nol9	NA	nol9	hematopoietic multipotent progenitor cell	decreased amount	abnormal	0.9946	1	1	0.9776	1	0.979433	0.9755	0.951909	0.984401	PASS	0	1	0	1	0	chr1	6526010	NA	C	T	1800.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=32.73;AS_ReadPosRankSum=.;AS_SOR=1.371;DP=56;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=32.73;SOR=1.371	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,55:55:99:1|1:6526003_G_A:1814,165,0:6526003
chr1	6554170	6554170	G	A	NOL9	exonic	synonymous SNV	NA	NOL9:NM_024654:exon1:c.C333T:p.L111L	0.2596	GnomAdGenome_AF_afr	20	6	HeterozygousVariant	het	140	74	66	0.471428571428571	1401.64	PASS	NA	NA	NA	NA	NA	NA	Body mass index[25673413];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.576	NA	E	E	E	0.767522461596202	E	Nol9	NA	nol9	hematopoietic multipotent progenitor cell	decreased amount	abnormal	0.1299	0.244	0.2588	0.1641	0.2596	0.188099	0.1262	0.0470887	0.170918	PASS	0.244186	0.172	162	0.166667	35	chr1	6554170	NA	G	A	1401.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=2.998;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.01;AS_ReadPosRankSum=0;AS_SOR=0.957;BaseQRankSum=0.693;DP=141;ExcessHet=3.0103;FS=2.998;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.01;ReadPosRankSum=0.027;SOR=0.957	GT:AD:DP:GQ:PL	0/1:74,66:140:99:1409,0,1613
chr1	6554331	6554331	A	C	NOL9	exonic	nonsynonymous SNV	NA	NOL9:NM_024654:exon1:c.T172G:p.S58A	1	GME_Israel	581	137	HomozygousVariant	hom	75	0	75	1	3077.06	PASS	13.73	NA	NA	NA	NA	NA	Body mass index[25673413];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	D	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.576	NA	E	E	E	0.767522461596202	E	Nol9	NA	nol9	hematopoietic multipotent progenitor cell	decreased amount	abnormal	0.9887	0.9948	0.9937	0.9607	0.9985	0.95627	0.9613	0.0001537	0.978512	PASS	1	0.995	6	0.992806	2	chr1	6554331	NA	A	C	3077.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=32.16;AS_ReadPosRankSum=.;AS_SOR=0.719;DP=80;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.67;SOR=0.719	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,75:75:99:1|1:6554331_A_C:3091,226,0:6554331
chr1	6554355	6554355	A	G	NOL9	exonic	nonsynonymous SNV	NA	NOL9:NM_024654:exon1:c.T148C:p.W50R	1	GnomAdExome_AF_eas	585	138	HomozygousVariant	hom	70	0	70	1	2900.06	PASS	15	NA	NA	NA	NA	NA	Body mass index[25673413];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	D	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.576	NA	E	E	E	0.767522461596202	E	Nol9	NA	nol9	hematopoietic multipotent progenitor cell	decreased amount	abnormal	0.9953	1	1	0.9776	1	0.979832	0.973	0.0001153	0.984349	PASS	1	1	0	1	0	chr1	6554355	NA	A	G	2900.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=32.18;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=72;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.65;SOR=0.693	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,70:70:99:1|1:6554331_A_C:2914,211,0:6554331
chr1	6554475	6554475	G	A	NOL9	exonic	nonsynonymous SNV	NA	NOL9:NM_024654:exon1:c.C28T:p.R10W	0.9174	GnomAdExome_AF_amr	395	94	HeterozygousVariant	het	76	47	29	0.381578947368421	584.64	PASS	23.2	NA	NA	Benign	NA	NA	Body mass index[25673413];	NA	NA	NA	NA	NA	NA	D	D	D	D	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.576	NA	E	E	E	0.767522461596202	E	Nol9	NA	nol9	hematopoietic multipotent progenitor cell	decreased amount	abnormal	0.8461	0.9174	0.9162	0.7595	0.9088	0.722244	0.7868	0.0001153	0.777504	PASS	0.822086	0.821	167	0.810714	39	chr1	6554475	NA	G	A	584.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=3.229;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.7;AS_ReadPosRankSum=3;AS_SOR=0.376;BaseQRankSum=-1.157;DP=79;ExcessHet=3.0103;FS=3.229;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.69;ReadPosRankSum=3.04;SOR=0.376	GT:AD:DP:GQ:PL	0/1:47,29:76:99:592,0,1188
chr1	6575171	6575171	A	G	TAS1R1	exonic	nonsynonymous SNV	NA	TAS1R1:NM_138697:exon3:c.A1039G:p.K347E	1	GnomAdExome_AF_eas	835	142	HomozygousVariant	hom	104	0	104	1	3211.06	PASS	3.35	NA	606225	Benign	NA	NA	White blood cell types[21738478];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Receptor, ligand binding region	NA	NA	Medium	Medium	Medium	cervix;spleen;bone;parathyroid;testis;brain;unclassifiable (Anatomical System);lung;ovary;uterus;placenta;skeletal muscle;visual apparatus;	pons;ciliary ganglion;skin;atrioventricular node;superior cervical ganglion;trigeminal ganglion;globus pallidus;	0.0502	N	N	N	N	0.758457623259474	E	Tas1r1	taste/olfaction phenotype; endocrine/exocrine gland phenotype; cellular phenotype; reproductive system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.9806	1	1	0.9258	1	0.923323	0.9197	0.961708	0.953202	PASS	1	1	0	1	0	chr1	6575171	NA	A	G	3211.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.88;AS_ReadPosRankSum=.;AS_SOR=0.9;DP=106;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.88;SOR=0.9	GT:AD:DP:GQ:PL	1/1:0,104:104:99:3225,312,0
chr1	6575246	6575246	G	A	TAS1R1	exonic	nonsynonymous SNV	NA	TAS1R1:NM_138697:exon3:c.G1114A:p.A372T	0.3128	GnomAdExome_AF_eas	10	0	HeterozygousVariant	het	86	43	43	0.5	976.64	PASS	2.141	NA	606225	Benign	NA	NA	White blood cell types[21738478];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Receptor, ligand binding region	NA	NA	Medium	Medium	Medium	cervix;spleen;bone;parathyroid;testis;brain;unclassifiable (Anatomical System);lung;ovary;uterus;placenta;skeletal muscle;visual apparatus;	pons;ciliary ganglion;skin;atrioventricular node;superior cervical ganglion;trigeminal ganglion;globus pallidus;	0.0502	N	N	N	N	0.758457623259474	E	Tas1r1	taste/olfaction phenotype; endocrine/exocrine gland phenotype; cellular phenotype; reproductive system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.1314	0.3128	0.3149	0.1186	0.2983	0.135383	0.1064	0.0045336	0.099343	PASS	0.070122	0.104	154	0.080986	23	chr1	6575246	NA	G	A	976.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.36;AS_ReadPosRankSum=1.5;AS_SOR=0.608;BaseQRankSum=-2.886;DP=95;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.36;ReadPosRankSum=1.55;SOR=0.608	GT:AD:DP:GQ:PL	0/1:43,43:86:99:984,0,1148
chr1	6579104	6579105	TG	-	TAS1R1	exonic	frameshift deletion	NA	TAS1R1:NM_177540:exon5:c.1284_1285del:p.V429Dfs*24,TAS1R1:NM_138697:exon6:c.2046_2047del:p.V683Dfs*24	0.011364	GME_CA	1		HeterozygousVariant	het	112	58	54	0.482142857142857	2071.6	PASS	NA	NA	606225	NA	NA	NA	White blood cell types[21738478];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	cervix;spleen;bone;parathyroid;testis;brain;unclassifiable (Anatomical System);lung;ovary;uterus;placenta;skeletal muscle;visual apparatus;	pons;ciliary ganglion;skin;atrioventricular node;superior cervical ganglion;trigeminal ganglion;globus pallidus;	0.0502	N	N	N	N	0.758457623259474	E	Tas1r1	taste/olfaction phenotype; endocrine/exocrine gland phenotype; cellular phenotype; reproductive system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0011	0.0092	0.0085	0.0002	0.0095	0.00219649	0	0.0010673	0		0.011364	0.013	19			chr1	6579103	NA	TTG	T	2071.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=1.521;AS_MQ=60;AS_MQRankSum=0;AS_QD=18.5;AS_ReadPosRankSum=2.9;AS_SOR=0.516;BaseQRankSum=0.329;DP=119;ExcessHet=3.0103;FS=1.521;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=18.5;ReadPosRankSum=2.99;SOR=0.516	GT:AD:DP:GQ:PL	0/1:58,54:112:99:2079,0,2214
chr1	6619788	6619788	C	T	PHF13	intronic	NA	NA	NA	0.3733	GnomAdGenome_AF_ami	21	11	HeterozygousVariant	het	25	14	11	0.44	253.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.646638689617467	E	Phf13	mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; endocrine/exocrine gland phenotype; cellular phenotype; 	NA	NA	NA	NA	0.2752	0.3459	0.3472	0.2542	0.3733	0.217652	0.2658	0.276335	0.263158	PASS	0	0.27	85	0.271429	54	chr1	6619788	NA	C	T	253.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=1.697;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.16;AS_ReadPosRankSum=-0.2;AS_SOR=1.402;BaseQRankSum=0.766;DP=26;ExcessHet=3.0103;FS=1.697;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.15;ReadPosRankSum=-0.192;SOR=1.402	GT:AD:DP:GQ:PL	0/1:14,11:25:99:261,0,323
chr1	6635742	6635742	A	G	DNAJC11	intronic	NA	NA	NA	0.7592	GnomAdGenome_AF_sas	185	99	HeterozygousVariant	het	79	42	37	0.468354430379747	735.64	PASS	NA	NA	614827	NA	NA	NA	Rosacea symptom severity[29771307];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	cornea;skin;myocardium;stomach;testis;lymphoreticular;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;muscle;bile duct;mammary gland;skeletal muscle;mesenchyma;islets of Langerhans;visual apparatus;cervix;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;lung;ovary;synovium;thyroid;colon;placenta;prostate;nasopharynx;	caudate nucleus;amygdala;prefrontal cortex;whole brain;globus pallidus;	0.422	NA	N	E	E	0.805451248859072	E	Dnajc11	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; cellular phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; muscle phenotype; 	NA	NA	NA	NA	0.6626	0.7451	0.7444	0.6849	0.7592	0.702476	0.7039	0.0001153	0.69376	PASS	0	0.782	96	0.816901	34	chr1	6635742	NA	A	G	735.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=0.844;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.32;AS_ReadPosRankSum=-1;AS_SOR=0.571;BaseQRankSum=-0.068;DP=79;ExcessHet=3.0103;FS=0.844;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.31;ReadPosRankSum=-0.968;SOR=0.571	GT:AD:DP:GQ:PL	0/1:42,37:79:99:743,0,883
chr1	6644575	6644575	A	G	DNAJC11	exonic	synonymous SNV	NA	DNAJC11:NM_018198:exon10:c.T1080C:p.G360G	1	GME_Israel	449	111	HeterozygousVariant	het	73	45	28	0.383561643835616	524.64	PASS	NA	NA	614827	Benign	NA	NA	Rosacea symptom severity[29771307];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	cornea;skin;myocardium;stomach;testis;lymphoreticular;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;muscle;bile duct;mammary gland;skeletal muscle;mesenchyma;islets of Langerhans;visual apparatus;cervix;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;lung;ovary;synovium;thyroid;colon;placenta;prostate;nasopharynx;	caudate nucleus;amygdala;prefrontal cortex;whole brain;globus pallidus;	0.422	NA	N	E	E	0.805451248859072	E	Dnajc11	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; cellular phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; muscle phenotype; 	NA	NA	NA	NA	0.8852	0.9644	0.9632	0.892	0.95	0.833067	0.9	0.876457	0.918719	PASS	1	0.87	122	0.880282	28	chr1	6644575	NA	A	G	524.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=6.499;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.19;AS_ReadPosRankSum=0.3;AS_SOR=1.542;BaseQRankSum=0.985;DP=75;ExcessHet=3.0103;FS=6.499;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.19;ReadPosRankSum=0.358;SOR=1.542	GT:AD:DP:GQ:PL	0/1:45,28:73:99:532,0,948
chr1	7091419	7091419	T	C	CAMTA1	intronic	NA	NA	NA	0.3989	GnomAdGenome_AF_ami	12	3	HeterozygousVariant	het	25	10	15	0.6	391.64	PASS	NA	[MIM:614756]Cerebellar ataxia, non-progressive, with mental retardation;	611501	NA	Epithelioid hemangioendothelioma;Non-progressive cerebellar ataxia with intellectual disability	Part of a fusion gene in;Disease-causing germline mutation(s) (loss of function) in	'Puberty onset (breast development)[24770850];Survival in sporadic amyotrophic lateral sclerosis[27244217];Platelet distribution width[27863252];Alcohol dependence[26365420];Periodontal microbiota[22699663];Crohn''s disease[28067908];Photic sneeze reflex[27182965];Inflammatory bowel disease[28067908];Mean platelet volume[27863252];Rosacea symptom severity[29771307];Stearic acid (18:0) levels[23362303];Puberty onset[24770850];Tourette''s syndrome or obsessive-compulsive disorder[25158072];Ulcerative colitis[28067908];Post bronchodilator FEV1[26634245];'	HP:0000750;HP:0000160;HP:0000463;HP:0001321;HP:0002354;HP:0000486;HP:0000490;HP:0000414;HP:0002003;HP:0100540;HP:0002080;HP:0002120;HP:0000307;HP:0002470;HP:0001319;HP:0000445;HP:0002536;HP:0001256;HP:0000729;HP:0001263;HP:0012433;HP:0000256;HP:0011166;HP:0000276;HP:0025517;HP:0002019;HP:0001310;HP:0011067;HP:0000179;HP:0007256;HP:0400005;HP:0001348;HP:0001260;HP:0000343;HP:0002317;HP:0000718;HP:0000494;HP:0000752;HP:0410170;HP:0000006;HP:0000369;HP:0002003;HP:0002317;HP:0000750;HP:0001319;HP:0000160;HP:0001263;HP:0000414;HP:0000337;HP:0000316;HP:0002020;HP:0000463;HP:0000486;HP:0001310;HP:0000276;HP:0001321;HP:0000718;HP:0001250;HP:0001256;HP:0002120;HP:0002275;HP:0000343;HP:0002019;HP:0000411;HP:0400005;HP:0000307;HP:0000179;HP:0100540;HP:0001260	Delayed speech and language development;Narrow mouth;Anteverted nares;Cerebellar hypoplasia;Memory impairment;Strabismus;Deeply set eye;Bulbous nose;Large forehead;Palpebral edema;Intention tremor;Cerebral cortical atrophy;Pointed chin;Nonprogressive cerebellar ataxia;Neonatal hypotonia;Wide nose;Abnormal cortical gyration;Intellectual disability, mild;Autistic behavior;Global developmental delay;Abnormal social behavior;Macrocephaly;Focal myoclonic seizure;Long face;Hypoplastic hippocampus;Constipation;Dysmetria;Mesiodens;Thick lower lip vermilion;Abnormal pyramidal sign;Short ear;Brisk reflexes;Dysarthria;Long philtrum;Unsteady gait;Aggressive behavior;Downslanted palpebral fissures;Hyperactivity;Hippocampal atrophy;Autosomal dominant inheritance;Low-set ears;Large forehead;Unsteady gait;Delayed speech and language development;Neonatal hypotonia;Narrow mouth;Global developmental delay;Bulbous nose;Broad forehead;Hypertelorism;Gastroesophageal reflux;Anteverted nares;Strabismus;Dysmetria;Long face;Cerebellar hypoplasia;Aggressive behavior;Seizure;Intellectual disability, mild;Cerebral cortical atrophy;Poor motor coordination;Long philtrum;Constipation;Protruding ear;Short ear;Pointed chin;Thick lower lip vermilion;Palpebral edema;Dysarthria	NA	NA	NA	Normally expressed in non-neoplastic adult central nervous system tissues: detected in whole brain, cerebellum, brain cortex, occipital lobe, frontal lobe, temporal lobe, putamen. Expression levels are low in oligodendroglial tumors, and are reduced by half in oligodendroglioma and astrocytoma cases with 1p loss of heterozygosity. Detected in neuroblastic-type cultured neuroblastoma cells. Expressed in heart and kidney. {ECO:0000269|PubMed:11925432, ECO:0000269|PubMed:15138581, ECO:0000269|PubMed:15709179}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;iris;hippocampus;brain;pineal gland;unclassifiable (Anatomical System);heart;lung;kidney;whole body;retina;macula lutea;frontal lobe;sympathetic chain;skeletal muscle;hypothalamus;	caudate nucleus;amygdala;temporal lobe;liver;prefrontal cortex;superior cervical ganglion;cingulate cortex;trigeminal ganglion;testis;cerebellum peduncles;cerebellum;pons;kidney;fetal brain;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;globus pallidus;medulla oblongata;hypothalamus;thalamus;	0.00455	NA	N	N	N	0.704890543786866	E	Camta1	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; 	NA	NA	NA	NA	0.1452	0.1751	0.1703	0.1279	0.3989	0.107428	0.1312	0.139746	0.146962	PASS	0	0.146	64	0.102837	23	chr1	7091419	NA	T	C	391.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=1.76;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.68;AS_ReadPosRankSum=0.4;AS_SOR=1.371;BaseQRankSum=0.39;DP=25;ExcessHet=3.0103;FS=1.76;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.67;ReadPosRankSum=0.446;SOR=1.371	GT:AD:DP:GQ:PL	0/1:10,15:25:99:399,0,240
chr1	7467936	7467936	T	C	CAMTA1	intronic	NA	NA	NA	0.6579	GnomAdGenome_AF_afr	65	23	HeterozygousVariant	het	56	22	34	0.607142857142857	719.64	PASS	NA	[MIM:614756]Cerebellar ataxia, non-progressive, with mental retardation;	611501	NA	Epithelioid hemangioendothelioma;Non-progressive cerebellar ataxia with intellectual disability	Part of a fusion gene in;Disease-causing germline mutation(s) (loss of function) in	'Puberty onset (breast development)[24770850];Survival in sporadic amyotrophic lateral sclerosis[27244217];Platelet distribution width[27863252];Alcohol dependence[26365420];Periodontal microbiota[22699663];Crohn''s disease[28067908];Photic sneeze reflex[27182965];Inflammatory bowel disease[28067908];Mean platelet volume[27863252];Rosacea symptom severity[29771307];Stearic acid (18:0) levels[23362303];Puberty onset[24770850];Tourette''s syndrome or obsessive-compulsive disorder[25158072];Ulcerative colitis[28067908];Post bronchodilator FEV1[26634245];'	HP:0000750;HP:0000160;HP:0000463;HP:0001321;HP:0002354;HP:0000486;HP:0000490;HP:0000414;HP:0002003;HP:0100540;HP:0002080;HP:0002120;HP:0000307;HP:0002470;HP:0001319;HP:0000445;HP:0002536;HP:0001256;HP:0000729;HP:0001263;HP:0012433;HP:0000256;HP:0011166;HP:0000276;HP:0025517;HP:0002019;HP:0001310;HP:0011067;HP:0000179;HP:0007256;HP:0400005;HP:0001348;HP:0001260;HP:0000343;HP:0002317;HP:0000718;HP:0000494;HP:0000752;HP:0410170;HP:0000006;HP:0000369;HP:0002003;HP:0002317;HP:0000750;HP:0001319;HP:0000160;HP:0001263;HP:0000414;HP:0000337;HP:0000316;HP:0002020;HP:0000463;HP:0000486;HP:0001310;HP:0000276;HP:0001321;HP:0000718;HP:0001250;HP:0001256;HP:0002120;HP:0002275;HP:0000343;HP:0002019;HP:0000411;HP:0400005;HP:0000307;HP:0000179;HP:0100540;HP:0001260	Delayed speech and language development;Narrow mouth;Anteverted nares;Cerebellar hypoplasia;Memory impairment;Strabismus;Deeply set eye;Bulbous nose;Large forehead;Palpebral edema;Intention tremor;Cerebral cortical atrophy;Pointed chin;Nonprogressive cerebellar ataxia;Neonatal hypotonia;Wide nose;Abnormal cortical gyration;Intellectual disability, mild;Autistic behavior;Global developmental delay;Abnormal social behavior;Macrocephaly;Focal myoclonic seizure;Long face;Hypoplastic hippocampus;Constipation;Dysmetria;Mesiodens;Thick lower lip vermilion;Abnormal pyramidal sign;Short ear;Brisk reflexes;Dysarthria;Long philtrum;Unsteady gait;Aggressive behavior;Downslanted palpebral fissures;Hyperactivity;Hippocampal atrophy;Autosomal dominant inheritance;Low-set ears;Large forehead;Unsteady gait;Delayed speech and language development;Neonatal hypotonia;Narrow mouth;Global developmental delay;Bulbous nose;Broad forehead;Hypertelorism;Gastroesophageal reflux;Anteverted nares;Strabismus;Dysmetria;Long face;Cerebellar hypoplasia;Aggressive behavior;Seizure;Intellectual disability, mild;Cerebral cortical atrophy;Poor motor coordination;Long philtrum;Constipation;Protruding ear;Short ear;Pointed chin;Thick lower lip vermilion;Palpebral edema;Dysarthria	NA	NA	NA	Normally expressed in non-neoplastic adult central nervous system tissues: detected in whole brain, cerebellum, brain cortex, occipital lobe, frontal lobe, temporal lobe, putamen. Expression levels are low in oligodendroglial tumors, and are reduced by half in oligodendroglioma and astrocytoma cases with 1p loss of heterozygosity. Detected in neuroblastic-type cultured neuroblastoma cells. Expressed in heart and kidney. {ECO:0000269|PubMed:11925432, ECO:0000269|PubMed:15138581, ECO:0000269|PubMed:15709179}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;iris;hippocampus;brain;pineal gland;unclassifiable (Anatomical System);heart;lung;kidney;whole body;retina;macula lutea;frontal lobe;sympathetic chain;skeletal muscle;hypothalamus;	caudate nucleus;amygdala;temporal lobe;liver;prefrontal cortex;superior cervical ganglion;cingulate cortex;trigeminal ganglion;testis;cerebellum peduncles;cerebellum;pons;kidney;fetal brain;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;globus pallidus;medulla oblongata;hypothalamus;thalamus;	0.00455	NA	N	N	N	0.704890543786866	E	Camta1	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; 	NA	NA	NA	NA	0.488	0.6553	0.6572	0.5639	0.6579	0.464058	0.6066	0.492976	0.581281	PASS	0	0.364	183	0.382979	62	chr1	7467936	NA	T	C	719.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=1.071;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.86;AS_ReadPosRankSum=0.2;AS_SOR=1.018;BaseQRankSum=-0.828;DP=58;ExcessHet=3.0103;FS=1.071;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.85;ReadPosRankSum=0.26;SOR=1.018	GT:AD:DP:GQ:PL	0/1:22,34:56:99:727,0,452
chr1	7663897	7663897	G	A	CAMTA1	exonic	synonymous SNV	NA	CAMTA1:NM_001349608:exon8:c.G1260A:p.S420S,CAMTA1:NM_001349612:exon8:c.G1260A:p.S420S,CAMTA1:NM_001349609:exon9:c.G1350A:p.S450S,CAMTA1:NM_001349610:exon9:c.G1350A:p.S450S,CAMTA1:NM_015215:exon9:c.G1350A:p.S450S	0.5144	GnomAdGenome_AF_fin	150	28	HeterozygousVariant	het	130	59	71	0.546153846153846	1755.64	PASS	NA	[MIM:614756]Cerebellar ataxia, non-progressive, with mental retardation;	611501	Benign	Epithelioid hemangioendothelioma;Non-progressive cerebellar ataxia with intellectual disability	Part of a fusion gene in;Disease-causing germline mutation(s) (loss of function) in	'Puberty onset (breast development)[24770850];Survival in sporadic amyotrophic lateral sclerosis[27244217];Platelet distribution width[27863252];Alcohol dependence[26365420];Periodontal microbiota[22699663];Crohn''s disease[28067908];Photic sneeze reflex[27182965];Inflammatory bowel disease[28067908];Mean platelet volume[27863252];Rosacea symptom severity[29771307];Stearic acid (18:0) levels[23362303];Puberty onset[24770850];Tourette''s syndrome or obsessive-compulsive disorder[25158072];Ulcerative colitis[28067908];Post bronchodilator FEV1[26634245];'	HP:0000750;HP:0000160;HP:0000463;HP:0001321;HP:0002354;HP:0000486;HP:0000490;HP:0000414;HP:0002003;HP:0100540;HP:0002080;HP:0002120;HP:0000307;HP:0002470;HP:0001319;HP:0000445;HP:0002536;HP:0001256;HP:0000729;HP:0001263;HP:0012433;HP:0000256;HP:0011166;HP:0000276;HP:0025517;HP:0002019;HP:0001310;HP:0011067;HP:0000179;HP:0007256;HP:0400005;HP:0001348;HP:0001260;HP:0000343;HP:0002317;HP:0000718;HP:0000494;HP:0000752;HP:0410170;HP:0000006;HP:0000369;HP:0002003;HP:0002317;HP:0000750;HP:0001319;HP:0000160;HP:0001263;HP:0000414;HP:0000337;HP:0000316;HP:0002020;HP:0000463;HP:0000486;HP:0001310;HP:0000276;HP:0001321;HP:0000718;HP:0001250;HP:0001256;HP:0002120;HP:0002275;HP:0000343;HP:0002019;HP:0000411;HP:0400005;HP:0000307;HP:0000179;HP:0100540;HP:0001260	Delayed speech and language development;Narrow mouth;Anteverted nares;Cerebellar hypoplasia;Memory impairment;Strabismus;Deeply set eye;Bulbous nose;Large forehead;Palpebral edema;Intention tremor;Cerebral cortical atrophy;Pointed chin;Nonprogressive cerebellar ataxia;Neonatal hypotonia;Wide nose;Abnormal cortical gyration;Intellectual disability, mild;Autistic behavior;Global developmental delay;Abnormal social behavior;Macrocephaly;Focal myoclonic seizure;Long face;Hypoplastic hippocampus;Constipation;Dysmetria;Mesiodens;Thick lower lip vermilion;Abnormal pyramidal sign;Short ear;Brisk reflexes;Dysarthria;Long philtrum;Unsteady gait;Aggressive behavior;Downslanted palpebral fissures;Hyperactivity;Hippocampal atrophy;Autosomal dominant inheritance;Low-set ears;Large forehead;Unsteady gait;Delayed speech and language development;Neonatal hypotonia;Narrow mouth;Global developmental delay;Bulbous nose;Broad forehead;Hypertelorism;Gastroesophageal reflux;Anteverted nares;Strabismus;Dysmetria;Long face;Cerebellar hypoplasia;Aggressive behavior;Seizure;Intellectual disability, mild;Cerebral cortical atrophy;Poor motor coordination;Long philtrum;Constipation;Protruding ear;Short ear;Pointed chin;Thick lower lip vermilion;Palpebral edema;Dysarthria	not_specified	no_assertion_criteria_provided	Likely_benign	Normally expressed in non-neoplastic adult central nervous system tissues: detected in whole brain, cerebellum, brain cortex, occipital lobe, frontal lobe, temporal lobe, putamen. Expression levels are low in oligodendroglial tumors, and are reduced by half in oligodendroglioma and astrocytoma cases with 1p loss of heterozygosity. Detected in neuroblastic-type cultured neuroblastoma cells. Expressed in heart and kidney. {ECO:0000269|PubMed:11925432, ECO:0000269|PubMed:15138581, ECO:0000269|PubMed:15709179}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;iris;hippocampus;brain;pineal gland;unclassifiable (Anatomical System);heart;lung;kidney;whole body;retina;macula lutea;frontal lobe;sympathetic chain;skeletal muscle;hypothalamus;	caudate nucleus;amygdala;temporal lobe;liver;prefrontal cortex;superior cervical ganglion;cingulate cortex;trigeminal ganglion;testis;cerebellum peduncles;cerebellum;pons;kidney;fetal brain;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;globus pallidus;medulla oblongata;hypothalamus;thalamus;	0.00455	NA	N	N	N	0.704890543786866	E	Camta1	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; 	NA	NA	NA	NA	0.4462	0.504	0.5042	0.4332	0.5144	0.40016	0.43	0.440596	0.449097	PASS	0.45	0.418	399	0.408451	60	chr1	7663897	NA	G	A	1755.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.51;AS_ReadPosRankSum=1.3;AS_SOR=0.69;BaseQRankSum=1.25;DP=138;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.5;ReadPosRankSum=1.33;SOR=0.69	GT:AD:DP:GQ:PL	0/1:59,71:130:99:1763,0,1333
chr1	7665224	7665224	C	A	CAMTA1	intronic	NA	NA	NA	0.452	GnomAdGenome_AF_fin	57	22	HeterozygousVariant	het	26	18	8	0.307692307692308	184.64	PASS	NA	[MIM:614756]Cerebellar ataxia, non-progressive, with mental retardation;	611501	NA	Epithelioid hemangioendothelioma;Non-progressive cerebellar ataxia with intellectual disability	Part of a fusion gene in;Disease-causing germline mutation(s) (loss of function) in	'Puberty onset (breast development)[24770850];Survival in sporadic amyotrophic lateral sclerosis[27244217];Platelet distribution width[27863252];Alcohol dependence[26365420];Periodontal microbiota[22699663];Crohn''s disease[28067908];Photic sneeze reflex[27182965];Inflammatory bowel disease[28067908];Mean platelet volume[27863252];Rosacea symptom severity[29771307];Stearic acid (18:0) levels[23362303];Puberty onset[24770850];Tourette''s syndrome or obsessive-compulsive disorder[25158072];Ulcerative colitis[28067908];Post bronchodilator FEV1[26634245];'	HP:0000750;HP:0000160;HP:0000463;HP:0001321;HP:0002354;HP:0000486;HP:0000490;HP:0000414;HP:0002003;HP:0100540;HP:0002080;HP:0002120;HP:0000307;HP:0002470;HP:0001319;HP:0000445;HP:0002536;HP:0001256;HP:0000729;HP:0001263;HP:0012433;HP:0000256;HP:0011166;HP:0000276;HP:0025517;HP:0002019;HP:0001310;HP:0011067;HP:0000179;HP:0007256;HP:0400005;HP:0001348;HP:0001260;HP:0000343;HP:0002317;HP:0000718;HP:0000494;HP:0000752;HP:0410170;HP:0000006;HP:0000369;HP:0002003;HP:0002317;HP:0000750;HP:0001319;HP:0000160;HP:0001263;HP:0000414;HP:0000337;HP:0000316;HP:0002020;HP:0000463;HP:0000486;HP:0001310;HP:0000276;HP:0001321;HP:0000718;HP:0001250;HP:0001256;HP:0002120;HP:0002275;HP:0000343;HP:0002019;HP:0000411;HP:0400005;HP:0000307;HP:0000179;HP:0100540;HP:0001260	Delayed speech and language development;Narrow mouth;Anteverted nares;Cerebellar hypoplasia;Memory impairment;Strabismus;Deeply set eye;Bulbous nose;Large forehead;Palpebral edema;Intention tremor;Cerebral cortical atrophy;Pointed chin;Nonprogressive cerebellar ataxia;Neonatal hypotonia;Wide nose;Abnormal cortical gyration;Intellectual disability, mild;Autistic behavior;Global developmental delay;Abnormal social behavior;Macrocephaly;Focal myoclonic seizure;Long face;Hypoplastic hippocampus;Constipation;Dysmetria;Mesiodens;Thick lower lip vermilion;Abnormal pyramidal sign;Short ear;Brisk reflexes;Dysarthria;Long philtrum;Unsteady gait;Aggressive behavior;Downslanted palpebral fissures;Hyperactivity;Hippocampal atrophy;Autosomal dominant inheritance;Low-set ears;Large forehead;Unsteady gait;Delayed speech and language development;Neonatal hypotonia;Narrow mouth;Global developmental delay;Bulbous nose;Broad forehead;Hypertelorism;Gastroesophageal reflux;Anteverted nares;Strabismus;Dysmetria;Long face;Cerebellar hypoplasia;Aggressive behavior;Seizure;Intellectual disability, mild;Cerebral cortical atrophy;Poor motor coordination;Long philtrum;Constipation;Protruding ear;Short ear;Pointed chin;Thick lower lip vermilion;Palpebral edema;Dysarthria	NA	NA	NA	Normally expressed in non-neoplastic adult central nervous system tissues: detected in whole brain, cerebellum, brain cortex, occipital lobe, frontal lobe, temporal lobe, putamen. Expression levels are low in oligodendroglial tumors, and are reduced by half in oligodendroglioma and astrocytoma cases with 1p loss of heterozygosity. Detected in neuroblastic-type cultured neuroblastoma cells. Expressed in heart and kidney. {ECO:0000269|PubMed:11925432, ECO:0000269|PubMed:15138581, ECO:0000269|PubMed:15709179}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;iris;hippocampus;brain;pineal gland;unclassifiable (Anatomical System);heart;lung;kidney;whole body;retina;macula lutea;frontal lobe;sympathetic chain;skeletal muscle;hypothalamus;	caudate nucleus;amygdala;temporal lobe;liver;prefrontal cortex;superior cervical ganglion;cingulate cortex;trigeminal ganglion;testis;cerebellum peduncles;cerebellum;pons;kidney;fetal brain;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;globus pallidus;medulla oblongata;hypothalamus;thalamus;	0.00455	NA	N	N	N	0.704890543786866	E	Camta1	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; 	NA	NA	NA	NA	0.3108	0.3926	0.3953	0.3008	0.452	0.228235	0.2908	0.272778	0.307061	PASS	0	0.385	201	0.373832	36	chr1	7665224	NA	C	A	184.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=4.262;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.12;AS_ReadPosRankSum=0;AS_SOR=1.73;BaseQRankSum=0.088;DP=28;ExcessHet=3.0103;FS=4.262;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.1;ReadPosRankSum=0.083;SOR=1.73	GT:AD:DP:GQ:PL	0/1:18,8:26:99:192,0,494
chr1	7778203	7778203	T	C	VAMP3	intronic	NA	NA	NA	0.1404	GnomAdExome_AF_sas	14	3	HeterozygousVariant	het	56	39	17	0.303571428571429	352.64	PASS	NA	NA	603657	NA	NA	NA	'Inflammatory bowel disease[28067908];Morning vs. evening chronotype[26835600];Crohn''s disease[21102463;28067908];Periodontal microbiota[22699663];Ulcerative colitis[28067908];'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Low	lung;testis;unclassifiable (Anatomical System);bone marrow;amnion;	occipital lobe;superior cervical ganglion;trigeminal ganglion;spinal cord;hypothalamus;	0.526	N	N	N	N	0.780049075115073	E	Vamp3	immune system phenotype; homeostasis/metabolism phenotype; normal phenotype; hematopoietic system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0511	0.1404	0.1372	0.0374	0.1302	0.043131	0.0311	0.0498571	0.035304	PASS	0	0.184	82	0.151408	37	chr1	7778203	NA	T	C	352.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.2;AS_FS=1.125;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.3;AS_ReadPosRankSum=-0.5;AS_SOR=0.906;BaseQRankSum=2.28;DP=57;ExcessHet=3.0103;FS=1.125;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.3;ReadPosRankSum=-0.412;SOR=0.906	GT:AD:DP:GQ:PL	0/1:39,17:56:99:360,0,889
chr1	7801098	7801098	T	G	PER3	intronic	NA	NA	NA	0.157	GnomAdExome_AF_asj	10	2	HeterozygousVariant	het	8	4	4	0.5	65.64	DP10	NA	[MIM:616882]Advanced sleep phase syndrome, familial, 3;	603427	NA	Familial advanced sleep-phase syndrome	Disease-causing germline mutation(s) in	'Inflammatory bowel disease[28067908];Morning vs. evening chronotype[26835600];Crohn''s disease[28067908];Ulcerative colitis[28067908];'	HP:0000006;HP:0000716;HP:0031873	Autosomal dominant inheritance;Depressivity;Early chronotype	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;pineal body;hippocampus;spleen;liver;cartilage;endometrium;bone;artery;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;frontal lobe;placenta;aorta;prostate;breast;optic nerve;	ciliary ganglion;superior cervical ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.978	N	N	N	N	0.957079964545495	E	Per3	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); vision/eye phenotype; 	per3	circadian regulation of gene expression	process quality	abnormal	0.0927	0.1078	0.109	0.075	0.1408	0.0626997	0.0049	0.073686	0.037767	VQSRTrancheSNP99.00to99.90	0	0.09	89	0.105634	26	chr1	7801098	NA	T	G	65.64	DP10	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.25;AS_ReadPosRankSum=0;AS_SOR=0.223;BaseQRankSum=-0.674;DP=8;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.2;ReadPosRankSum=0;SOR=0.223	GT:AD:DP:GQ:PL	0/1:4,4:8:73:73,0,87
chr1	7809988	7809988	T	C	PER3	exonic	synonymous SNV	NA	PER3:NM_001289861:exon12:c.T1338C:p.S446S,PER3:NM_001289862:exon12:c.T1338C:p.S446S,PER3:NM_001289863:exon12:c.T1338C:p.S446S,PER3:NM_001289864:exon12:c.T381C:p.S127S,PER3:NM_016831:exon12:c.T1335C:p.S445S	0.9657	GnomAdExome_AF_afr	739	122	HomozygousVariant	hom	61	0	61	1	1661.06	PASS	NA	[MIM:616882]Advanced sleep phase syndrome, familial, 3;	603427	Benign	Familial advanced sleep-phase syndrome	Disease-causing germline mutation(s) in	'Inflammatory bowel disease[28067908];Morning vs. evening chronotype[26835600];Crohn''s disease[28067908];Ulcerative colitis[28067908];'	HP:0000006;HP:0000716;HP:0031873	Autosomal dominant inheritance;Depressivity;Early chronotype	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;pineal body;hippocampus;spleen;liver;cartilage;endometrium;bone;artery;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;frontal lobe;placenta;aorta;prostate;breast;optic nerve;	ciliary ganglion;superior cervical ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.978	N	N	N	N	0.957079964545495	E	Per3	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); vision/eye phenotype; 	per3	circadian regulation of gene expression	process quality	abnormal	0.8804	0.9657	0.9682	0.9214	0.9639	0.878994	0.9374	0.882764	0.882594	PASS	0.959596	0.938	86	0.926056	19	chr1	7809988	NA	T	C	1661.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.23;AS_ReadPosRankSum=.;AS_SOR=0.725;DP=61;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.23;SOR=0.725	GT:AD:DP:GQ:PL	1/1:0,61:61:99:1675,182,0
chr1	7827433	7827433	T	C	PER3	exonic	nonsynonymous SNV	NA	PER3:NM_001289861:exon18:c.T2504C:p.L835P,PER3:NM_001289862:exon18:c.T2504C:p.L835P,PER3:NM_001289863:exon18:c.T2483C:p.L828P,PER3:NM_001289864:exon18:c.T1547C:p.L516P,PER3:NM_016831:exon18:c.T2480C:p.L827P	1	GnomAdGenome_AF_eas	791	136	HomozygousVariant	hom	162	0	162	1	4767.06	PASS	6.605	[MIM:616882]Advanced sleep phase syndrome, familial, 3;	603427	Benign	Familial advanced sleep-phase syndrome	Disease-causing germline mutation(s) in	'Inflammatory bowel disease[28067908];Morning vs. evening chronotype[26835600];Crohn''s disease[28067908];Ulcerative colitis[28067908];'	HP:0000006;HP:0000716;HP:0031873	Autosomal dominant inheritance;Depressivity;Early chronotype	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;pineal body;hippocampus;spleen;liver;cartilage;endometrium;bone;artery;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;frontal lobe;placenta;aorta;prostate;breast;optic nerve;	ciliary ganglion;superior cervical ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.978	N	N	N	N	0.957079964545495	E	Per3	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); vision/eye phenotype; 	per3	circadian regulation of gene expression	process quality	abnormal	0.9697	0.9995	0.9994	0.9652	1	0.97524	0.961	0.957006	0.960591	PASS	1	0.974	41	0.978873	6	chr1	7827433	NA	T	C	4767.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.43;AS_ReadPosRankSum=.;AS_SOR=0.718;DP=166;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.43;SOR=0.718	GT:AD:DP:GQ:PL	1/1:0,162:162:99:4781,485,0
chr1	7827519	7827519	C	G	PER3	exonic	nonsynonymous SNV	NA	PER3:NM_001289861:exon18:c.C2590G:p.P864A,PER3:NM_001289862:exon18:c.C2590G:p.P864A,PER3:NM_001289863:exon18:c.C2569G:p.P857A,PER3:NM_001289864:exon18:c.C1633G:p.P545A,PER3:NM_016831:exon18:c.C2566G:p.P856A	0.25	GME_Israel	14	2	HeterozygousVariant	het	172	100	72	0.418604651162791	1628.64	PASS	0.786	[MIM:616882]Advanced sleep phase syndrome, familial, 3;	603427	Benign	Familial advanced sleep-phase syndrome	Disease-causing germline mutation(s) in	'Inflammatory bowel disease[28067908];Morning vs. evening chronotype[26835600];Crohn''s disease[28067908];Ulcerative colitis[28067908];'	HP:0000006;HP:0000716;HP:0031873	Autosomal dominant inheritance;Depressivity;Early chronotype	NA	NA	NA	NA	T	D	B	B	N	P	M	T	D	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;pineal body;hippocampus;spleen;liver;cartilage;endometrium;bone;artery;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;frontal lobe;placenta;aorta;prostate;breast;optic nerve;	ciliary ganglion;superior cervical ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.978	N	N	N	N	0.957079964545495	E	Per3	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); vision/eye phenotype; 	per3	circadian regulation of gene expression	process quality	abnormal	0.0866	0.1036	0.1058	0.0728	0.1393	0.0603035	0.0768	0.0163646	0.076355	PASS	0.25	0.092	126	0.105634	26	chr1	7827519	NA	C	G	1628.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=0.564;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.47;AS_ReadPosRankSum=0.5;AS_SOR=0.749;BaseQRankSum=-1.332;DP=172;ExcessHet=3.0103;FS=0.564;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.47;ReadPosRankSum=0.523;SOR=0.749	GT:AD:DP:GQ:PL	0/1:100,72:172:99:1636,0,2696
chr1	7830004	7830004	A	G	PER3;PER3	exonic;splicing	synonymous SNV	NM_001289863:exon20:c.2981-2A>G;NM_001289861:exon20:c.3002-2A>G	PER3:NM_001289862:exon19:c.A3057G:p.T1019T,PER3:NM_001289864:exon19:c.A2097G:p.T699T,PER3:NM_016831:exon19:c.A3030G:p.T1010T	0.5783	GnomAdGenome_AF_asj	118	11	HeterozygousVariant	het	211	69	142	0.672985781990521	3231.64	PASS	7.649	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	P	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	.;	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.1466	0.1568	0.1494	0.529	0.5783	0.244808	0	0.112845	0.307882	VQSRTrancheSNP99.00to99.90	0.510101	0.346	314	0.293233	56	chr1	7830004	NA	A	G	3231.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.8;AS_FS=1.134;AS_MQ=59.97;AS_MQRankSum=3;AS_QD=15.32;AS_ReadPosRankSum=-2.1;AS_SOR=0.609;BaseQRankSum=-3.752;DP=218;ExcessHet=3.0103;FS=1.134;MLEAC=1;MLEAF=0.5;MQ=59.61;MQRankSum=3.05;QD=15.32;ReadPosRankSum=-2.087;SOR=0.609	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:69,142:211:99:0|1:7830004_A_G:3239,0,2210:7830004
chr1	7830057	7830057	T	C	PER3	exonic	nonsynonymous SNV	NA	PER3:NM_001289862:exon19:c.T3110C:p.M1037T,PER3:NM_001289864:exon19:c.T2150C:p.M717T,PER3:NM_016831:exon19:c.T3083C:p.M1028T,PER3:NM_001289861:exon20:c.T3053C:p.M1018T,PER3:NM_001289863:exon20:c.T3032C:p.M1011T	0.3153	GnomAdGenome_AF_fin	60	10	HeterozygousVariant	het	308	185	123	0.399350649350649	2680.64	PASS	0.161	[MIM:616882]Advanced sleep phase syndrome, familial, 3;	603427	Benign	Familial advanced sleep-phase syndrome	Disease-causing germline mutation(s) in	'Inflammatory bowel disease[28067908];Morning vs. evening chronotype[26835600];Crohn''s disease[28067908];Ulcerative colitis[28067908];'	HP:0000006;HP:0000716;HP:0031873	Autosomal dominant inheritance;Depressivity;Early chronotype	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;pineal body;hippocampus;spleen;liver;cartilage;endometrium;bone;artery;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;frontal lobe;placenta;aorta;prostate;breast;optic nerve;	ciliary ganglion;superior cervical ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.978	N	N	N	N	0.957079964545495	E	Per3	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); vision/eye phenotype; 	per3	circadian regulation of gene expression	process quality	abnormal	0.1391	0.1613	0.1408	0.2324	0.3153	0.185304	0.2383	0.250074	0.216749	VQSRTrancheSNP99.00to99.90	0.310606	0.251	294	0.228571	44	chr1	7830057	NA	T	C	2680.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=4.6;AS_FS=2.504;AS_MQ=59.35;AS_MQRankSum=-2.6;AS_QD=8.7;AS_ReadPosRankSum=-1.4;AS_SOR=0.784;BaseQRankSum=4.62;DP=319;ExcessHet=3.0103;FS=2.504;MLEAC=1;MLEAF=0.5;MQ=59.73;MQRankSum=-2.505;QD=8.7;ReadPosRankSum=-1.32;SOR=0.784	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:185,123:308:99:1|0:7830004_A_G:2688,0,5943:7830004
chr1	7853370	7853370	G	A	UTS2	exonic	nonsynonymous SNV	NA	UTS2:NM_021995:exon1:c.C62T:p.T21M	0.75	GME_Israel	326	51	HomozygousVariant	hom	55	2	53	0.963636363636364	1363.06	PASS	1.127	NA	604097	Benign	NA	NA	'Inflammatory bowel disease[28067908];Crohn''s disease[28067908];Ulcerative colitis[21297633;28067908];'	NA	NA	NA	NA	NA	Brain specific.;	D	D	B	B	NA	P	NA	T	N	T	T	T	NA	T	NA	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	spleen;pancreas;colon;	superior cervical ganglion;trigeminal ganglion;	0.851	NA	N	N	N	0.426590863056365	N	Uts2	homeostasis/metabolism phenotype; liver/biliary system phenotype; 	NA	NA	NA	NA	0.5129	0.6309	0.6321	0.5191	0.6626	0.478435	0.537	0.520213	0.518062	PASS	0.75	0.615	372	0.584507	64	chr1	7853370	NA	G	A	1363.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=24.78;AS_ReadPosRankSum=1.5;AS_SOR=0.981;BaseQRankSum=0.665;DP=57;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=24.78;ReadPosRankSum=1.51;SOR=0.981	GT:AD:DP:GQ:PL	1/1:2,53:55:99:1377,115,0
chr1	8004518	8004518	A	G	PARK7;ERRFI1	intergenic	NA	dist=19013;dist=7209	NA	1	GnomAdExome_AF_asj	26	0	HeterozygousVariant	het	116	56	60	0.517241379310345	1311.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.3167	0.3571	0.2857	0.2889	0.5546	0.169529	0	0.0584016	0		0	0.222	140	0.125	4	chr1	8004518	NA	A	G	1311.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=2.349;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.31;AS_ReadPosRankSum=0.4;AS_SOR=0.507;BaseQRankSum=0.096;DP=118;ExcessHet=3.0103;FS=2.349;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.31;ReadPosRankSum=0.428;SOR=0.507	GT:AD:DP:GQ:PL	0/1:56,60:116:99:1319,0,1197
chr1	8330435	8330435	A	G	SLC45A1	exonic	synonymous SNV	NA	SLC45A1:NM_001080397:exon5:c.A1044G:p.P348P	0.8619	GnomAdGenome_AF_fin	359	89	HeterozygousVariant	het	97	57	40	0.412371134020619	851.64	PASS	NA	NA	605763	Benign	Autosomal recessive non-syndromic intellectual disability	Disease-causing germline mutation(s) in	Psoriasis[25903422;23143594];Autism spectrum disorder or schizophrenia[28540026];Schizophrenia[28991256];Depression[29700475];Breast cancer[23468962];Inflammatory skin disease[25574825];Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)[28521775];Strep throat[28928442];Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)[24823311];Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)[23453885];Allergic rhinitis[30013184];Hair shape[29220522];Hair color[29662168];	HP:0001332;HP:0002059;HP:0100704;HP:0000729;HP:0001256;HP:0001290;HP:0002079;HP:0002465;HP:0010841;HP:0007048;HP:0000733;HP:0002521;HP:0000252;HP:0001270;HP:0000752;HP:0001331;HP:0000750;HP:0002342;HP:0002072;HP:0040288;HP:0100710;HP:0002360;HP:0011097;HP:0000736;HP:0001263;HP:0000716;HP:0010864;HP:0002539;HP:0002126;HP:0001999;HP:0002197;HP:0100660;HP:0007359;HP:0001257;HP:0000007;HP:0000319;HP:0001290;HP:0000494;HP:0008770;HP:0005280;HP:0000233;HP:0002553;HP:0000739;HP:0001250;HP:0002342;HP:0001263;HP:0000316;HP:0000325	Dystonia;Cerebral atrophy;Cerebral visual impairment;Autistic behavior;Intellectual disability, mild;Generalized hypotonia;Hypoplasia of the corpus callosum;Poor speech;Multifocal epileptiform discharges;Large basal ganglia;Stereotypy;Hypsarrhythmia;Microcephaly;Motor delay;Hyperactivity;Absent septum pellucidum;Delayed speech and language development;Intellectual disability, moderate;Chorea;Nasogastric tube feeding;Impulsivity;Sleep disturbance;Epileptic spasm;Short attention span;Global developmental delay;Depressivity;Intellectual disability, severe;Cortical dysplasia;Polymicrogyria;Abnormal facial shape;Generalized-onset seizure;Dyskinesia;Focal-onset seizure;Spasticity;Autosomal recessive inheritance;Smooth philtrum;Generalized hypotonia;Downslanted palpebral fissures;Obsessive-compulsive trait;Depressed nasal bridge;Thin vermilion border;Highly arched eyebrow;Anxiety;Seizure;Intellectual disability, moderate;Global developmental delay;Hypertelorism;Triangular face	NA	NA	NA	Expressed in adult heart, brain, muscle and kidney, with very strong expression in brain. Also expressed in fetal brain, kidney and lung. {ECO:0000269|PubMed:10729226}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;iris;stomach;brain;lens;blood;unclassifiable (Anatomical System);choroid;ovary;retina;macula lutea;frontal lobe;breast;optic nerve;	pons;cingulate cortex;cerebellum;	0.184	NA	N	N	NA	0.2537002656718	N	Slc45a1	NA	NA	NA	NA	NA	0.7688	0.8546	0.858	0.761	0.8619	0.776358	0.7436	0.728483	0.710181	PASS	0.746212	0.779	194	0.796429	45	chr1	8330435	NA	A	G	851.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.78;AS_ReadPosRankSum=0.5;AS_SOR=0.621;BaseQRankSum=-0.261;DP=103;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.78;ReadPosRankSum=0.532;SOR=0.621	GT:AD:DP:GQ:PL	0/1:57,40:97:99:859,0,1339
chr1	8330828	8330828	G	A	SLC45A1	exonic	synonymous SNV	NA	SLC45A1:NM_001080397:exon5:c.G1437A:p.P479P	0.6	GME_Israel	56	9	HeterozygousVariant	het	85	46	39	0.458823529411765	995.64	PASS	NA	NA	605763	Benign	Autosomal recessive non-syndromic intellectual disability	Disease-causing germline mutation(s) in	Psoriasis[25903422;23143594];Autism spectrum disorder or schizophrenia[28540026];Schizophrenia[28991256];Depression[29700475];Breast cancer[23468962];Inflammatory skin disease[25574825];Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)[28521775];Strep throat[28928442];Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)[24823311];Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)[23453885];Allergic rhinitis[30013184];Hair shape[29220522];Hair color[29662168];	HP:0001332;HP:0002059;HP:0100704;HP:0000729;HP:0001256;HP:0001290;HP:0002079;HP:0002465;HP:0010841;HP:0007048;HP:0000733;HP:0002521;HP:0000252;HP:0001270;HP:0000752;HP:0001331;HP:0000750;HP:0002342;HP:0002072;HP:0040288;HP:0100710;HP:0002360;HP:0011097;HP:0000736;HP:0001263;HP:0000716;HP:0010864;HP:0002539;HP:0002126;HP:0001999;HP:0002197;HP:0100660;HP:0007359;HP:0001257;HP:0000007;HP:0000319;HP:0001290;HP:0000494;HP:0008770;HP:0005280;HP:0000233;HP:0002553;HP:0000739;HP:0001250;HP:0002342;HP:0001263;HP:0000316;HP:0000325	Dystonia;Cerebral atrophy;Cerebral visual impairment;Autistic behavior;Intellectual disability, mild;Generalized hypotonia;Hypoplasia of the corpus callosum;Poor speech;Multifocal epileptiform discharges;Large basal ganglia;Stereotypy;Hypsarrhythmia;Microcephaly;Motor delay;Hyperactivity;Absent septum pellucidum;Delayed speech and language development;Intellectual disability, moderate;Chorea;Nasogastric tube feeding;Impulsivity;Sleep disturbance;Epileptic spasm;Short attention span;Global developmental delay;Depressivity;Intellectual disability, severe;Cortical dysplasia;Polymicrogyria;Abnormal facial shape;Generalized-onset seizure;Dyskinesia;Focal-onset seizure;Spasticity;Autosomal recessive inheritance;Smooth philtrum;Generalized hypotonia;Downslanted palpebral fissures;Obsessive-compulsive trait;Depressed nasal bridge;Thin vermilion border;Highly arched eyebrow;Anxiety;Seizure;Intellectual disability, moderate;Global developmental delay;Hypertelorism;Triangular face	NA	NA	NA	Expressed in adult heart, brain, muscle and kidney, with very strong expression in brain. Also expressed in fetal brain, kidney and lung. {ECO:0000269|PubMed:10729226}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;iris;stomach;brain;lens;blood;unclassifiable (Anatomical System);choroid;ovary;retina;macula lutea;frontal lobe;breast;optic nerve;	pons;cingulate cortex;cerebellum;	0.184	NA	N	N	NA	0.2537002656718	N	Slc45a1	NA	NA	NA	NA	NA	0.3059	0.5138	0.5129	0.3616	0.5132	0.340455	0.3879	0.311658	0.388342	PASS	0.6	0.305	246	0.28169	62	chr1	8330828	NA	G	A	995.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=2.92;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.72;AS_ReadPosRankSum=1.3;AS_SOR=1.121;BaseQRankSum=1.69;DP=91;ExcessHet=3.0103;FS=2.92;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.71;ReadPosRankSum=1.39;SOR=1.121	GT:AD:DP:GQ:PL	0/1:46,39:85:99:1003,0,1066
chr1	8358584	8358584	C	A	RERE	exonic	synonymous SNV	NA	RERE:NM_001042682:exon10:c.G2289T:p.R763R,RERE:NM_001042681:exon20:c.G3951T:p.R1317R,RERE:NM_012102:exon21:c.G3951T:p.R1317R	0.9076	GnomAdGenome_AF_eas	472	93	HomozygousVariant	hom	122	0	122	1	5389.06	PASS	NA	[MIM:616975]Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart [dominant?];	605226	Benign	1p36 deletion syndrome;RERE-related neurodevelopmental syndrome	Role in the phenotype of;Disease-causing germline mutation(s) (loss of function) in	Allergy[27182965];Optic cup area[28073927;28073927;25631615;25631615];Autism spectrum disorder or schizophrenia[28540026];Lymphocyte counts[27863252];Heel bone mineral density[28869591;28869591;28869591];Schizophrenia[28991256];Depression[29700475];Vertical cup-disc ratio[25241763;20548946];Eosinophil counts[27863252];Upper eyelid morphology[29921221;29921221];Major depressive disorder[27479909];Sum eosinophil basophil counts[27863252];Vitiligo[20410501;27723757];Eosinophil percentage of granulocytes[27863252];Total body bone mineral density[29304378];Allergic disease (asthma, hay fever or eczema)[29083406];Tonsillectomy[27182965;28928442];Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)[23453885];White blood cell count[27863252];Allergic rhinitis[30013184];Bone mineral density[22504420];Neutrophil percentage of granulocytes[27863252];Eosinophil percentage of white cells[27863252];	HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733;HP:0007018;HP:0000006;HP:0011968;HP:0000729;HP:0004209;HP:0410030;HP:0000659;HP:0000252;HP:0001734;HP:0001629;HP:0000589;HP:0003593;HP:0000319;HP:0000107;HP:0000369;HP:0001263;HP:0001643;HP:0000648;HP:0000349;HP:0001655;HP:0000486;HP:0030303;HP:0001159;HP:0000377;HP:0001252;HP:0001511;HP:0000028;HP:0000453;HP:0004322;HP:0000316;HP:0002079;HP:0000047;HP:0002007;HP:0002119;HP:0000568;HP:0001285;HP:0000407;HP:0000490;HP:0000325;HP:0000463;HP:0000601;HP:0000414;HP:0001320;HP:0001250;HP:0000187;HP:0001385;HP:0002020;HP:0002188;HP:0000098;HP:0001260;HP:0001792;HP:0001290;HP:0000076;HP:0000218;HP:0000221;HP:0000286;HP:0002247;HP:0011229;HP:0000581;HP:0003186;HP:0000256;HP:0007565;HP:0002938;HP:0000494;HP:0000347;HP:0012110;HP:0000582;HP:0000358;HP:0010535;HP:0002650;HP:0001320;HP:0002007;HP:0000368;HP:0002020;HP:0000508;HP:0000659;HP:0008897;HP:0000047;HP:0002650;HP:0031910;HP:0000568;HP:0000453;HP:0001263;HP:0001385;HP:0012803;HP:0000347;HP:0002015;HP:0000648;HP:0002119;HP:0000365;HP:0000565;HP:0000483;HP:0100704;HP:0000028;HP:0001511;HP:0000286;HP:0000581;HP:0001249;HP:0001252;HP:0002079;HP:0410263;HP:0007018;HP:0000076;HP:0000612;HP:0000545;HP:0001999;HP:0000463;HP:0007305;HP:0001629;HP:0000577;HP:0100716;HP:0002033;HP:0001250;HP:0011229;HP:0000729;HP:0000567	'Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule;Attention deficit hyperactivity disorder;Autosomal dominant inheritance;Feeding difficulties;Autistic behavior;Clinodactyly of the 5th finger;Cleft lip;Peters anomaly;Microcephaly;Annular pancreas;Ventricular septal defect;Coloboma;Infantile onset;Smooth philtrum;Renal cyst;Low-set ears;Global developmental delay;Patent ductus arteriosus;Optic atrophy;Widow''s peak;Patent foramen ovale;Strabismus;Hypoplastic anterior commissure;Syndactyly;Abnormality of the pinna;Muscular hypotonia;Intrauterine growth retardation;Cryptorchidism;Choanal atresia;Short stature;Hypertelorism;Hypoplasia of the corpus callosum;Hypospadias;Frontal bossing;Ventriculomegaly;Microphthalmia;Spastic tetraparesis;Sensorineural hearing impairment;Deeply set eye;Triangular face;Anteverted nares;Hypotelorism;Bulbous nose;Cerebellar vermis hypoplasia;Seizure;Broad alveolar ridges;Hip dysplasia;Gastroesophageal reflux;Delayed CNS myelination;Tall stature;Dysarthria;Small nail;Generalized hypotonia;Vesicoureteral reflux;High palate;Furrowed tongue;Epicanthus;Duodenal atresia;Broad eyebrow;Blepharophimosis;Inverted nipples;Macrocephaly;Multiple cafe-au-lait spots;Lumbar hyperlordosis;Downslanted palpebral fissures;Micrognathia;Hypoplasia of the pons;Upslanted palpebral fissure;Posteriorly rotated ears;Sleep apnea;Scoliosis;Cerebellar vermis hypoplasia;Frontal bossing;Low-set, posteriorly rotated ears;Gastroesophageal reflux;Ptosis;Peters anomaly;Postnatal growth retardation;Hypospadias;Scoliosis;Abnormal cranial nerve physiology;Microphthalmia;Choanal atresia;Global developmental delay;Hip dysplasia;Anisometropia;Micrognathia;Dysphagia;Optic atrophy;Ventriculomegaly;Hearing impairment;Esotropia;Astigmatism;Cerebral visual impairment;Cryptorchidism;Intrauterine growth retardation;Epicanthus;Blepharophimosis;Intellectual disability;Muscular hypotonia;Hypoplasia of the corpus callosum;Brain imaging abnormality;Attention deficit hyperactivity disorder;Vesicoureteral reflux;Iris coloboma;Myopia;Abnormal facial shape;Anteverted nares;CNS demyelination;Ventricular septal defect;Exotropia;Self-injurious behavior;Poor suck;Seizure;Broad eyebrow;Autistic behavior;Chorioretinal coloboma'	NA	NA	NA	Widely expressed. Expressed in tumor cell lines. {ECO:0000269|PubMed:10729226, ECO:0000269|PubMed:10814707, ECO:0000269|PubMed:11331249}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;cerebellum cortex;stomach;lacrimal gland;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;whole body;retina;pancreas;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;tonsil;cervix;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;trabecular meshwork;lung;salivary gland;ovary;lymph node;frontal lobe;sympathetic chain;colon;placenta;aorta;prostate;nasopharynx;optic nerve;	ciliary ganglion;temporal lobe;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;cerebellum;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;spinal cord;skeletal muscle;globus pallidus;	0.0674	E	N	N	N	0.717445692295276	E	Rere	growth/size/body region phenotype; craniofacial phenotype; renal/urinary system phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; vision/eye phenotype; 	rerea	hair cell	quality	abnormal	0.719	0.8932	0.8929	0.733	0.9076	0.797524	0.7308	0.703865	0.772578	PASS	0.827586	0.765	292	0.792254	39	chr1	8358584	NA	C	A	5389.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.22;AS_ReadPosRankSum=.;AS_SOR=0.868;DP=125;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.25;SOR=0.868	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,122:122:99:1|1:8358584_C_A:5403,367,0:8358584
chr1	8358590	8358590	T	C	RERE	exonic	synonymous SNV	NA	RERE:NM_001042682:exon10:c.A2283G:p.R761R,RERE:NM_001042681:exon20:c.A3945G:p.R1315R,RERE:NM_012102:exon21:c.A3945G:p.R1315R	0.9086	GnomAdGenome_AF_eas	474	94	HomozygousVariant	hom	124	0	124	1	5465.06	PASS	NA	[MIM:616975]Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart [dominant?];	605226	Benign	1p36 deletion syndrome;RERE-related neurodevelopmental syndrome	Role in the phenotype of;Disease-causing germline mutation(s) (loss of function) in	Allergy[27182965];Optic cup area[28073927;28073927;25631615;25631615];Autism spectrum disorder or schizophrenia[28540026];Lymphocyte counts[27863252];Heel bone mineral density[28869591;28869591;28869591];Schizophrenia[28991256];Depression[29700475];Vertical cup-disc ratio[25241763;20548946];Eosinophil counts[27863252];Upper eyelid morphology[29921221;29921221];Major depressive disorder[27479909];Sum eosinophil basophil counts[27863252];Vitiligo[20410501;27723757];Eosinophil percentage of granulocytes[27863252];Total body bone mineral density[29304378];Allergic disease (asthma, hay fever or eczema)[29083406];Tonsillectomy[27182965;28928442];Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)[23453885];White blood cell count[27863252];Allergic rhinitis[30013184];Bone mineral density[22504420];Neutrophil percentage of granulocytes[27863252];Eosinophil percentage of white cells[27863252];	HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733;HP:0007018;HP:0000006;HP:0011968;HP:0000729;HP:0004209;HP:0410030;HP:0000659;HP:0000252;HP:0001734;HP:0001629;HP:0000589;HP:0003593;HP:0000319;HP:0000107;HP:0000369;HP:0001263;HP:0001643;HP:0000648;HP:0000349;HP:0001655;HP:0000486;HP:0030303;HP:0001159;HP:0000377;HP:0001252;HP:0001511;HP:0000028;HP:0000453;HP:0004322;HP:0000316;HP:0002079;HP:0000047;HP:0002007;HP:0002119;HP:0000568;HP:0001285;HP:0000407;HP:0000490;HP:0000325;HP:0000463;HP:0000601;HP:0000414;HP:0001320;HP:0001250;HP:0000187;HP:0001385;HP:0002020;HP:0002188;HP:0000098;HP:0001260;HP:0001792;HP:0001290;HP:0000076;HP:0000218;HP:0000221;HP:0000286;HP:0002247;HP:0011229;HP:0000581;HP:0003186;HP:0000256;HP:0007565;HP:0002938;HP:0000494;HP:0000347;HP:0012110;HP:0000582;HP:0000358;HP:0010535;HP:0002650;HP:0001320;HP:0002007;HP:0000368;HP:0002020;HP:0000508;HP:0000659;HP:0008897;HP:0000047;HP:0002650;HP:0031910;HP:0000568;HP:0000453;HP:0001263;HP:0001385;HP:0012803;HP:0000347;HP:0002015;HP:0000648;HP:0002119;HP:0000365;HP:0000565;HP:0000483;HP:0100704;HP:0000028;HP:0001511;HP:0000286;HP:0000581;HP:0001249;HP:0001252;HP:0002079;HP:0410263;HP:0007018;HP:0000076;HP:0000612;HP:0000545;HP:0001999;HP:0000463;HP:0007305;HP:0001629;HP:0000577;HP:0100716;HP:0002033;HP:0001250;HP:0011229;HP:0000729;HP:0000567	'Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule;Attention deficit hyperactivity disorder;Autosomal dominant inheritance;Feeding difficulties;Autistic behavior;Clinodactyly of the 5th finger;Cleft lip;Peters anomaly;Microcephaly;Annular pancreas;Ventricular septal defect;Coloboma;Infantile onset;Smooth philtrum;Renal cyst;Low-set ears;Global developmental delay;Patent ductus arteriosus;Optic atrophy;Widow''s peak;Patent foramen ovale;Strabismus;Hypoplastic anterior commissure;Syndactyly;Abnormality of the pinna;Muscular hypotonia;Intrauterine growth retardation;Cryptorchidism;Choanal atresia;Short stature;Hypertelorism;Hypoplasia of the corpus callosum;Hypospadias;Frontal bossing;Ventriculomegaly;Microphthalmia;Spastic tetraparesis;Sensorineural hearing impairment;Deeply set eye;Triangular face;Anteverted nares;Hypotelorism;Bulbous nose;Cerebellar vermis hypoplasia;Seizure;Broad alveolar ridges;Hip dysplasia;Gastroesophageal reflux;Delayed CNS myelination;Tall stature;Dysarthria;Small nail;Generalized hypotonia;Vesicoureteral reflux;High palate;Furrowed tongue;Epicanthus;Duodenal atresia;Broad eyebrow;Blepharophimosis;Inverted nipples;Macrocephaly;Multiple cafe-au-lait spots;Lumbar hyperlordosis;Downslanted palpebral fissures;Micrognathia;Hypoplasia of the pons;Upslanted palpebral fissure;Posteriorly rotated ears;Sleep apnea;Scoliosis;Cerebellar vermis hypoplasia;Frontal bossing;Low-set, posteriorly rotated ears;Gastroesophageal reflux;Ptosis;Peters anomaly;Postnatal growth retardation;Hypospadias;Scoliosis;Abnormal cranial nerve physiology;Microphthalmia;Choanal atresia;Global developmental delay;Hip dysplasia;Anisometropia;Micrognathia;Dysphagia;Optic atrophy;Ventriculomegaly;Hearing impairment;Esotropia;Astigmatism;Cerebral visual impairment;Cryptorchidism;Intrauterine growth retardation;Epicanthus;Blepharophimosis;Intellectual disability;Muscular hypotonia;Hypoplasia of the corpus callosum;Brain imaging abnormality;Attention deficit hyperactivity disorder;Vesicoureteral reflux;Iris coloboma;Myopia;Abnormal facial shape;Anteverted nares;CNS demyelination;Ventricular septal defect;Exotropia;Self-injurious behavior;Poor suck;Seizure;Broad eyebrow;Autistic behavior;Chorioretinal coloboma'	NA	NA	NA	Widely expressed. Expressed in tumor cell lines. {ECO:0000269|PubMed:10729226, ECO:0000269|PubMed:10814707, ECO:0000269|PubMed:11331249}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;cerebellum cortex;stomach;lacrimal gland;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;whole body;retina;pancreas;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;tonsil;cervix;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;trabecular meshwork;lung;salivary gland;ovary;lymph node;frontal lobe;sympathetic chain;colon;placenta;aorta;prostate;nasopharynx;optic nerve;	ciliary ganglion;temporal lobe;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;cerebellum;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;spinal cord;skeletal muscle;globus pallidus;	0.0674	E	N	N	N	0.717445692295276	E	Rere	growth/size/body region phenotype; craniofacial phenotype; renal/urinary system phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; vision/eye phenotype; 	rerea	hair cell	quality	abnormal	0.7198	0.8941	0.8932	0.7343	0.9086	0.80012	0.7339	0.699926	0.773399	PASS	0.827586	0.767	291	0.799296	39	chr1	8358590	NA	T	C	5465.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.9;AS_ReadPosRankSum=.;AS_SOR=0.941;DP=127;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=34.67;SOR=0.941	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,124:124:99:1|1:8358584_C_A:5479,373,0:8358584
chr1	8361032	8361032	C	T	RERE	exonic	synonymous SNV	NA	RERE:NM_001042682:exon8:c.G813A:p.P271P,RERE:NM_001042681:exon18:c.G2475A:p.P825P,RERE:NM_012102:exon19:c.G2475A:p.P825P	0.843	GnomAdGenome_AF_eas	143	26	HomozygousVariant	hom	184	0	184	1	4964.06	PASS	NA	[MIM:616975]Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart [dominant?];	605226	Benign	1p36 deletion syndrome;RERE-related neurodevelopmental syndrome	Role in the phenotype of;Disease-causing germline mutation(s) (loss of function) in	Allergy[27182965];Optic cup area[28073927;28073927;25631615;25631615];Autism spectrum disorder or schizophrenia[28540026];Lymphocyte counts[27863252];Heel bone mineral density[28869591;28869591;28869591];Schizophrenia[28991256];Depression[29700475];Vertical cup-disc ratio[25241763;20548946];Eosinophil counts[27863252];Upper eyelid morphology[29921221;29921221];Major depressive disorder[27479909];Sum eosinophil basophil counts[27863252];Vitiligo[20410501;27723757];Eosinophil percentage of granulocytes[27863252];Total body bone mineral density[29304378];Allergic disease (asthma, hay fever or eczema)[29083406];Tonsillectomy[27182965;28928442];Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)[23453885];White blood cell count[27863252];Allergic rhinitis[30013184];Bone mineral density[22504420];Neutrophil percentage of granulocytes[27863252];Eosinophil percentage of white cells[27863252];	HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733;HP:0007018;HP:0000006;HP:0011968;HP:0000729;HP:0004209;HP:0410030;HP:0000659;HP:0000252;HP:0001734;HP:0001629;HP:0000589;HP:0003593;HP:0000319;HP:0000107;HP:0000369;HP:0001263;HP:0001643;HP:0000648;HP:0000349;HP:0001655;HP:0000486;HP:0030303;HP:0001159;HP:0000377;HP:0001252;HP:0001511;HP:0000028;HP:0000453;HP:0004322;HP:0000316;HP:0002079;HP:0000047;HP:0002007;HP:0002119;HP:0000568;HP:0001285;HP:0000407;HP:0000490;HP:0000325;HP:0000463;HP:0000601;HP:0000414;HP:0001320;HP:0001250;HP:0000187;HP:0001385;HP:0002020;HP:0002188;HP:0000098;HP:0001260;HP:0001792;HP:0001290;HP:0000076;HP:0000218;HP:0000221;HP:0000286;HP:0002247;HP:0011229;HP:0000581;HP:0003186;HP:0000256;HP:0007565;HP:0002938;HP:0000494;HP:0000347;HP:0012110;HP:0000582;HP:0000358;HP:0010535;HP:0002650;HP:0001320;HP:0002007;HP:0000368;HP:0002020;HP:0000508;HP:0000659;HP:0008897;HP:0000047;HP:0002650;HP:0031910;HP:0000568;HP:0000453;HP:0001263;HP:0001385;HP:0012803;HP:0000347;HP:0002015;HP:0000648;HP:0002119;HP:0000365;HP:0000565;HP:0000483;HP:0100704;HP:0000028;HP:0001511;HP:0000286;HP:0000581;HP:0001249;HP:0001252;HP:0002079;HP:0410263;HP:0007018;HP:0000076;HP:0000612;HP:0000545;HP:0001999;HP:0000463;HP:0007305;HP:0001629;HP:0000577;HP:0100716;HP:0002033;HP:0001250;HP:0011229;HP:0000729;HP:0000567	'Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule;Attention deficit hyperactivity disorder;Autosomal dominant inheritance;Feeding difficulties;Autistic behavior;Clinodactyly of the 5th finger;Cleft lip;Peters anomaly;Microcephaly;Annular pancreas;Ventricular septal defect;Coloboma;Infantile onset;Smooth philtrum;Renal cyst;Low-set ears;Global developmental delay;Patent ductus arteriosus;Optic atrophy;Widow''s peak;Patent foramen ovale;Strabismus;Hypoplastic anterior commissure;Syndactyly;Abnormality of the pinna;Muscular hypotonia;Intrauterine growth retardation;Cryptorchidism;Choanal atresia;Short stature;Hypertelorism;Hypoplasia of the corpus callosum;Hypospadias;Frontal bossing;Ventriculomegaly;Microphthalmia;Spastic tetraparesis;Sensorineural hearing impairment;Deeply set eye;Triangular face;Anteverted nares;Hypotelorism;Bulbous nose;Cerebellar vermis hypoplasia;Seizure;Broad alveolar ridges;Hip dysplasia;Gastroesophageal reflux;Delayed CNS myelination;Tall stature;Dysarthria;Small nail;Generalized hypotonia;Vesicoureteral reflux;High palate;Furrowed tongue;Epicanthus;Duodenal atresia;Broad eyebrow;Blepharophimosis;Inverted nipples;Macrocephaly;Multiple cafe-au-lait spots;Lumbar hyperlordosis;Downslanted palpebral fissures;Micrognathia;Hypoplasia of the pons;Upslanted palpebral fissure;Posteriorly rotated ears;Sleep apnea;Scoliosis;Cerebellar vermis hypoplasia;Frontal bossing;Low-set, posteriorly rotated ears;Gastroesophageal reflux;Ptosis;Peters anomaly;Postnatal growth retardation;Hypospadias;Scoliosis;Abnormal cranial nerve physiology;Microphthalmia;Choanal atresia;Global developmental delay;Hip dysplasia;Anisometropia;Micrognathia;Dysphagia;Optic atrophy;Ventriculomegaly;Hearing impairment;Esotropia;Astigmatism;Cerebral visual impairment;Cryptorchidism;Intrauterine growth retardation;Epicanthus;Blepharophimosis;Intellectual disability;Muscular hypotonia;Hypoplasia of the corpus callosum;Brain imaging abnormality;Attention deficit hyperactivity disorder;Vesicoureteral reflux;Iris coloboma;Myopia;Abnormal facial shape;Anteverted nares;CNS demyelination;Ventricular septal defect;Exotropia;Self-injurious behavior;Poor suck;Seizure;Broad eyebrow;Autistic behavior;Chorioretinal coloboma'	NA	NA	NA	Widely expressed. Expressed in tumor cell lines. {ECO:0000269|PubMed:10729226, ECO:0000269|PubMed:10814707, ECO:0000269|PubMed:11331249}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;cerebellum cortex;stomach;lacrimal gland;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;whole body;retina;pancreas;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;tonsil;cervix;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;trabecular meshwork;lung;salivary gland;ovary;lymph node;frontal lobe;sympathetic chain;colon;placenta;aorta;prostate;nasopharynx;optic nerve;	ciliary ganglion;temporal lobe;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;cerebellum;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;spinal cord;skeletal muscle;globus pallidus;	0.0674	E	N	N	N	0.717445692295276	E	Rere	growth/size/body region phenotype; craniofacial phenotype; renal/urinary system phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; vision/eye phenotype; 	rerea	hair cell	quality	abnormal	0.5019	0.8413	0.8403	0.4021	0.843	0.457867	0.3275	0.156182	0.44062	PASS	0.666667	0.389	281	0.387097	44	chr1	8361032	NA	C	T	4964.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.98;AS_ReadPosRankSum=.;AS_SOR=1.014;DP=199;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.98;SOR=1.014	GT:AD:DP:GQ:PL	1/1:0,184:184:99:4978,546,0
chr1	8361143	8361143	T	C	RERE	exonic	synonymous SNV	NA	RERE:NM_001042682:exon8:c.A702G:p.P234P,RERE:NM_001042681:exon18:c.A2364G:p.P788P,RERE:NM_012102:exon19:c.A2364G:p.P788P	0.9226	GnomAdGenome_AF_eas	428	84	HomozygousVariant	hom	159	0	159	1	4696.06	PASS	NA	[MIM:616975]Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart [dominant?];	605226	NA	1p36 deletion syndrome;RERE-related neurodevelopmental syndrome	Role in the phenotype of;Disease-causing germline mutation(s) (loss of function) in	Allergy[27182965];Optic cup area[28073927;28073927;25631615;25631615];Autism spectrum disorder or schizophrenia[28540026];Lymphocyte counts[27863252];Heel bone mineral density[28869591;28869591;28869591];Schizophrenia[28991256];Depression[29700475];Vertical cup-disc ratio[25241763;20548946];Eosinophil counts[27863252];Upper eyelid morphology[29921221;29921221];Major depressive disorder[27479909];Sum eosinophil basophil counts[27863252];Vitiligo[20410501;27723757];Eosinophil percentage of granulocytes[27863252];Total body bone mineral density[29304378];Allergic disease (asthma, hay fever or eczema)[29083406];Tonsillectomy[27182965;28928442];Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)[23453885];White blood cell count[27863252];Allergic rhinitis[30013184];Bone mineral density[22504420];Neutrophil percentage of granulocytes[27863252];Eosinophil percentage of white cells[27863252];	HP:0002242;HP:0000160;HP:0000518;HP:0000733;HP:0000286;HP:0004322;HP:0004374;HP:0000639;HP:0003416;HP:0000902;HP:0001156;HP:0000343;HP:0000486;HP:0000878;HP:0002591;HP:0000368;HP:0000431;HP:0003198;HP:0001734;HP:0000047;HP:0100490;HP:0000307;HP:0000648;HP:0001009;HP:0001385;HP:0002020;HP:0005113;HP:0011228;HP:0000248;HP:0002650;HP:0002007;HP:0008872;HP:0002808;HP:0008066;HP:0100559;HP:0000107;HP:0000892;HP:0001643;HP:0001252;HP:0001508;HP:0001513;HP:0000407;HP:0001387;HP:0002465;HP:0100716;HP:0000457;HP:0008551;HP:0001644;HP:0005280;HP:0008499;HP:0001250;HP:0001274;HP:0002021;HP:0000252;HP:0001344;HP:0001773;HP:0000270;HP:0000464;HP:0004378;HP:0006824;HP:0001654;HP:0000505;HP:0000717;HP:0001397;HP:0001671;HP:0000135;HP:0008736;HP:0001249;HP:0000055;HP:0000126;HP:0000821;HP:0001743;HP:0002230;HP:0003006;HP:0004209;HP:0001288;HP:0002353;HP:0001829;HP:0002019;HP:0002119;HP:0000490;HP:0002120;HP:0001263;HP:0000028;HP:0000405;HP:0011800;HP:0001107;HP:0002015;HP:0001636;HP:0012733;HP:0007018;HP:0000006;HP:0011968;HP:0000729;HP:0004209;HP:0410030;HP:0000659;HP:0000252;HP:0001734;HP:0001629;HP:0000589;HP:0003593;HP:0000319;HP:0000107;HP:0000369;HP:0001263;HP:0001643;HP:0000648;HP:0000349;HP:0001655;HP:0000486;HP:0030303;HP:0001159;HP:0000377;HP:0001252;HP:0001511;HP:0000028;HP:0000453;HP:0004322;HP:0000316;HP:0002079;HP:0000047;HP:0002007;HP:0002119;HP:0000568;HP:0001285;HP:0000407;HP:0000490;HP:0000325;HP:0000463;HP:0000601;HP:0000414;HP:0001320;HP:0001250;HP:0000187;HP:0001385;HP:0002020;HP:0002188;HP:0000098;HP:0001260;HP:0001792;HP:0001290;HP:0000076;HP:0000218;HP:0000221;HP:0000286;HP:0002247;HP:0011229;HP:0000581;HP:0003186;HP:0000256;HP:0007565;HP:0002938;HP:0000494;HP:0000347;HP:0012110;HP:0000582;HP:0000358;HP:0010535;HP:0002650;HP:0001320;HP:0002007;HP:0000368;HP:0002020;HP:0000508;HP:0000659;HP:0008897;HP:0000047;HP:0002650;HP:0031910;HP:0000568;HP:0000453;HP:0001263;HP:0001385;HP:0012803;HP:0000347;HP:0002015;HP:0000648;HP:0002119;HP:0000365;HP:0000565;HP:0000483;HP:0100704;HP:0000028;HP:0001511;HP:0000286;HP:0000581;HP:0001249;HP:0001252;HP:0002079;HP:0410263;HP:0007018;HP:0000076;HP:0000612;HP:0000545;HP:0001999;HP:0000463;HP:0007305;HP:0001629;HP:0000577;HP:0100716;HP:0002033;HP:0001250;HP:0011229;HP:0000729;HP:0000567	'Abnormal intestine morphology;Narrow mouth;Cataract;Stereotypy;Epicanthus;Short stature;Hemiplegia/hemiparesis;Nystagmus;Spinal canal stenosis;Rib fusion;Brachydactyly;Long philtrum;Strabismus;11 pairs of ribs;Polyphagia;Low-set, posteriorly rotated ears;Wide nasal bridge;Myopathy;Annular pancreas;Hypospadias;Camptodactyly of finger;Pointed chin;Optic atrophy;Telangiectasia;Hip dysplasia;Gastroesophageal reflux;Aortic arch aneurysm;Horizontal eyebrow;Brachycephaly;Scoliosis;Frontal bossing;Feeding difficulties in infancy;Kyphosis;Abnormal blistering of the skin;Lower limb asymmetry;Renal cyst;Bifid ribs;Patent ductus arteriosus;Muscular hypotonia;Failure to thrive;Obesity;Sensorineural hearing impairment;Joint stiffness;Poor speech;Self-injurious behavior;Depressed nasal ridge;Microtia;Dilated cardiomyopathy;Depressed nasal bridge;High hypermetropia;Seizure;Agenesis of corpus callosum;Pyloric stenosis;Microcephaly;Absent speech;Short foot;Delayed cranial suture closure;Abnormality of the neck;Abnormality of the anus;Cranial nerve paralysis;Abnormal heart valve morphology;Visual impairment;Autism;Hepatic steatosis;Abnormal cardiac septum morphology;Hypogonadism;Hypoplasia of penis;Intellectual disability;Abnormality of female external genitalia;Hydronephrosis;Hypothyroidism;Abnormality of the spleen;Generalized hirsutism;Neuroblastoma;Clinodactyly of the 5th finger;Gait disturbance;EEG abnormality;Foot polydactyly;Constipation;Ventriculomegaly;Deeply set eye;Cerebral cortical atrophy;Global developmental delay;Cryptorchidism;Conductive hearing impairment;Midface retrusion;Ocular albinism;Dysphagia;Tetralogy of Fallot;Macule;Attention deficit hyperactivity disorder;Autosomal dominant inheritance;Feeding difficulties;Autistic behavior;Clinodactyly of the 5th finger;Cleft lip;Peters anomaly;Microcephaly;Annular pancreas;Ventricular septal defect;Coloboma;Infantile onset;Smooth philtrum;Renal cyst;Low-set ears;Global developmental delay;Patent ductus arteriosus;Optic atrophy;Widow''s peak;Patent foramen ovale;Strabismus;Hypoplastic anterior commissure;Syndactyly;Abnormality of the pinna;Muscular hypotonia;Intrauterine growth retardation;Cryptorchidism;Choanal atresia;Short stature;Hypertelorism;Hypoplasia of the corpus callosum;Hypospadias;Frontal bossing;Ventriculomegaly;Microphthalmia;Spastic tetraparesis;Sensorineural hearing impairment;Deeply set eye;Triangular face;Anteverted nares;Hypotelorism;Bulbous nose;Cerebellar vermis hypoplasia;Seizure;Broad alveolar ridges;Hip dysplasia;Gastroesophageal reflux;Delayed CNS myelination;Tall stature;Dysarthria;Small nail;Generalized hypotonia;Vesicoureteral reflux;High palate;Furrowed tongue;Epicanthus;Duodenal atresia;Broad eyebrow;Blepharophimosis;Inverted nipples;Macrocephaly;Multiple cafe-au-lait spots;Lumbar hyperlordosis;Downslanted palpebral fissures;Micrognathia;Hypoplasia of the pons;Upslanted palpebral fissure;Posteriorly rotated ears;Sleep apnea;Scoliosis;Cerebellar vermis hypoplasia;Frontal bossing;Low-set, posteriorly rotated ears;Gastroesophageal reflux;Ptosis;Peters anomaly;Postnatal growth retardation;Hypospadias;Scoliosis;Abnormal cranial nerve physiology;Microphthalmia;Choanal atresia;Global developmental delay;Hip dysplasia;Anisometropia;Micrognathia;Dysphagia;Optic atrophy;Ventriculomegaly;Hearing impairment;Esotropia;Astigmatism;Cerebral visual impairment;Cryptorchidism;Intrauterine growth retardation;Epicanthus;Blepharophimosis;Intellectual disability;Muscular hypotonia;Hypoplasia of the corpus callosum;Brain imaging abnormality;Attention deficit hyperactivity disorder;Vesicoureteral reflux;Iris coloboma;Myopia;Abnormal facial shape;Anteverted nares;CNS demyelination;Ventricular septal defect;Exotropia;Self-injurious behavior;Poor suck;Seizure;Broad eyebrow;Autistic behavior;Chorioretinal coloboma'	NA	NA	NA	Widely expressed. Expressed in tumor cell lines. {ECO:0000269|PubMed:10729226, ECO:0000269|PubMed:10814707, ECO:0000269|PubMed:11331249}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;cerebellum cortex;stomach;lacrimal gland;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;whole body;retina;pancreas;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;tonsil;cervix;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;trabecular meshwork;lung;salivary gland;ovary;lymph node;frontal lobe;sympathetic chain;colon;placenta;aorta;prostate;nasopharynx;optic nerve;	ciliary ganglion;temporal lobe;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;cerebellum;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;spinal cord;skeletal muscle;globus pallidus;	0.0674	E	N	N	N	0.717445692295276	E	Rere	growth/size/body region phenotype; craniofacial phenotype; renal/urinary system phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; vision/eye phenotype; 	rerea	hair cell	quality	abnormal	0.7381	0.9138	0.9105	0.7236	0.9226	0.79992	0.7292	0.0003458	0.75793	PASS	0.848214	0.742	226	0.774194	24	chr1	8361143	NA	T	C	4696.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.53;AS_ReadPosRankSum=.;AS_SOR=0.784;DP=168;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.53;SOR=0.784	GT:AD:DP:GQ:PL	1/1:0,159:159:99:4710,476,0
chr1	8868066	8868066	G	T	ENO1	intronic	NA	NA	NA	0.7473	GnomAdGenome_AF_eas	87	17	HeterozygousVariant	het	55	21	34	0.618181818181818	729.64	PASS	NA	NA	172430	NA	NA	NA	White blood cell count (basophil)[27863252];Tonsillectomy[27182965;28928442];Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)[23453885];Plateletcrit[27863252];Blood protein levels[30072576];	NA	NA	NA	NA	NA	The alpha/alpha homodimer is expressed in embryo and in most adult tissues. The alpha/beta heterodimer and the beta/beta homodimer are found in striated muscle, and the alpha/gamma heterodimer and the gamma/gamma homodimer in neurons.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0045	0.202	Medium	Medium	Medium	intestine;pharynx;tongue;cornea;alveolus;skin;stomach;testis;adrenal cortex;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;muscle;head and neck;adrenal gland;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;bone marrow;lung;salivary gland;ovary;lymph node;bladder;colon;placenta;prostate;gum;	lung;liver;tumor;whole brain;smooth muscle;heart;	0.774	E	E	E	E	0.999944786827537	E	Eno1	growth/size/body region phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.3286	0.747	0.7465	0.2568	0.7473	0.34345	0.2277	0.305468	0.271757	PASS	0	0.299	319	0.292254	49	chr1	8868066	NA	G	T	729.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.27;AS_ReadPosRankSum=-0.7;AS_SOR=0.593;BaseQRankSum=-1.121;DP=55;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.27;ReadPosRankSum=-0.668;SOR=0.593	GT:AD:DP:GQ:PL	0/1:21,34:55:99:737,0,446
chr1	8951527	8951527	T	G	CA6	intronic	NA	NA	NA	0.7093	GnomAdExome_AF_afr	302	50	HomozygousVariant	hom	85	0	85	1	2357.06	PASS	0.489	NA	114780	NA	NA	NA	Blood protein levels[28240269;28240269;29875488;30072576];Post bronchodilator FEV1[26634245];	NA	NA	NA	NA	NA	Major constituent of saliva.;	T	T	NA	NA	NA	P	NA	T	N	T	T	T	NA	NA	T	T	T	T	.;	N	N	Alpha carbonic anhydrase domain|Alpha carbonic anhydrase domain	NA	NA	High	High	High	unclassifiable (Anatomical System);	salivary gland;superior cervical ganglion;	0.759	N	N	N	N	0.78246210387518	E	Car6	immune system phenotype; 	ca6	swim bladder	uninflated	abnormal	0.618	0.7093	0.7123	0.6439	0.7066	0.650359	0.6594	0.0001153	0		0	0.615	368	0.584507	66	chr1	8951527	NA	T	G	2357.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.73;AS_ReadPosRankSum=.;AS_SOR=0.815;DP=85;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.73;SOR=0.815	GT:AD:DP:GQ:PL	1/1:0,85:85:99:2371,255,0
chr1	8951663	8951663	G	T	CA6	intronic	NA	NA	NA	0.8075	GnomAdExome_AF_eas	321	61	HomozygousVariant	hom	70	0	70	1	1958.06	PASS	0.755	NA	114780	NA	NA	NA	Blood protein levels[28240269;28240269;29875488;30072576];Post bronchodilator FEV1[26634245];	NA	NA	NA	NA	NA	Major constituent of saliva.;	D	T	NA	NA	NA	P	NA	T	N	T	T	T	NA	NA	T	T	T	T	.;	N	N	Alpha carbonic anhydrase domain|Alpha carbonic anhydrase domain	NA	NA	High	High	High	unclassifiable (Anatomical System);	salivary gland;superior cervical ganglion;	0.759	N	N	N	N	0.78246210387518	E	Car6	immune system phenotype; 	ca6	swim bladder	uninflated	abnormal	0.6533	0.8075	0.8058	0.6883	0.8019	0.723243	0.704	0.607858	0		0	0.65	316	0.637324	59	chr1	8951663	NA	G	T	1958.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.97;AS_ReadPosRankSum=.;AS_SOR=1.011;DP=72;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.97;SOR=1.011	GT:AD:DP:GQ:PL	1/1:0,70:70:99:1972,210,0
chr1	8957145	8957145	A	G	CA6	exonic	nonsynonymous SNV	NA	CA6:NM_001270501:exon2:c.A88G:p.S30G,CA6:NM_001215:exon3:c.A268G:p.S90G,CA6:NM_001270500:exon3:c.A268G:p.S90G	0.5635	GnomAdGenome_AF_eas	149	29	HeterozygousVariant	het	89	51	38	0.426966292134831	784.64	PASS	17.22	NA	114780	Benign	NA	NA	Blood protein levels[28240269;28240269;29875488;30072576];Post bronchodilator FEV1[26634245];	NA	NA	NA	NA	NA	Major constituent of saliva.;	T	T	D	P	N	P	M	T	D	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	Alpha carbonic anhydrase domain|Alpha carbonic anhydrase domain|Alpha carbonic anhydrase domain;Alpha carbonic anhydrase domain|Alpha carbonic anhydrase domain|Alpha carbonic anhydrase domain;.;.	NA	NA	High	High	High	unclassifiable (Anatomical System);	salivary gland;superior cervical ganglion;	0.759	N	N	N	N	0.78246210387518	E	Car6	immune system phenotype; 	ca6	swim bladder	uninflated	abnormal	0.3359	0.5572	0.5679	0.2677	0.5635	0.34385	0.2498	0.320701	0.300493	PASS	0.435673	0.421	403	0.446809	68	chr1	8957145	NA	A	G	784.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0.812;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.82;AS_ReadPosRankSum=-2.9;AS_SOR=0.561;BaseQRankSum=-0.493;DP=95;ExcessHet=3.0103;FS=0.812;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.82;ReadPosRankSum=-2.863;SOR=0.561	GT:AD:DP:GQ:PL	0/1:51,38:89:99:792,0,1167
chr1	8970905	8970905	C	T	CA6	exonic	synonymous SNV	NA	CA6:NM_001270502:exon5:c.C384T:p.N128N,CA6:NM_001270501:exon6:c.C588T:p.N196N,CA6:NM_001215:exon7:c.C768T:p.N256N,CA6:NM_001270500:exon7:c.C768T:p.N256N	0.553	GnomAdGenome_AF_eas	88	19	HeterozygousVariant	het	90	61	29	0.322222222222222	556.64	PASS	NA	NA	114780	Benign	NA	NA	Blood protein levels[28240269;28240269;29875488;30072576];Post bronchodilator FEV1[26634245];	NA	NA	NA	NA	NA	Major constituent of saliva.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	unclassifiable (Anatomical System);	salivary gland;superior cervical ganglion;	0.759	N	N	N	N	0.78246210387518	E	Car6	immune system phenotype; 	ca6	swim bladder	uninflated	abnormal	0.2562	0.5451	0.5578	0.209	0.553	0.288538	0.1908	0.241834	0.244663	PASS	0.383041	0.319	355	0.366197	66	chr1	8970905	NA	C	T	556.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=0.856;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.19;AS_ReadPosRankSum=-1;AS_SOR=0.873;BaseQRankSum=0.372;DP=91;ExcessHet=3.0103;FS=0.856;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.18;ReadPosRankSum=-0.929;SOR=0.873	GT:AD:DP:GQ:PL	0/1:61,29:90:99:564,0,1457
chr1	8974362	8974362	G	A	CA6	exonic	nonsynonymous SNV	NA	CA6:NM_001270500:exon8:c.G860A:p.G287E	0.6788	GnomAdGenome_AF_eas	232	51	HomozygousVariant	hom	102	0	102	1	2968.06	PASS	4.484	NA	114780	Benign	NA	NA	Blood protein levels[28240269;28240269;29875488;30072576];Post bronchodilator FEV1[26634245];	NA	NA	NA	NA	NA	Major constituent of saliva.;	D	T	NA	NA	N	P	NA	T	N	T	T	T	NA	T	NA	T	T	T	.;	N	N	NA	NA	NA	High	High	High	unclassifiable (Anatomical System);	salivary gland;superior cervical ganglion;	0.759	N	N	N	N	0.78246210387518	E	Car6	immune system phenotype; 	ca6	swim bladder	uninflated	abnormal	0.4148	0.6602	0.665	0.3788	0.6788	0.460064	0.3484	0.302182	0.407225	PASS	0	0.498	364	0.591549	66	chr1	8974362	NA	G	A	2968.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.1;AS_ReadPosRankSum=.;AS_SOR=1;DP=105;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.1;SOR=1	GT:AD:DP:GQ:PL	1/1:0,102:102:99:2982,306,0
chr1	9014802	9014802	C	T	SLC2A7	exonic	nonsynonymous SNV	NA	SLC2A7:NM_207420:exon7:c.G782A:p.R261Q	0.1649	GnomAdExome_AF_amr	6	1	HeterozygousVariant	het	96	51	45	0.46875	1010.64	PASS	0.033	NA	610371	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in small intestine and colon. Weakly expressed in testis and prostate. {ECO:0000269|PubMed:15033637}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Major facilitator superfamily domain|Major facilitator superfamily domain	NA	NA	Medium	Medium	Medium	NA	NA	0.748	NA	N	N	N	0.42378333720555	N	Slc2a7	NA	NA	NA	NA	NA	0.1041	0.1649	0.1662	0.0847	0.1585	0.0950479	0.075	0.0912343	0.112664	PASS	0.083333	0.077	79	0.056338	14	chr1	9014802	NA	C	T	1010.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.53;AS_ReadPosRankSum=-1.6;AS_SOR=0.642;BaseQRankSum=1.17;DP=96;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.53;ReadPosRankSum=-1.598;SOR=0.642	GT:AD:DP:GQ:PL	0/1:51,45:96:99:1018,0,1097
chr1	9014873	9014873	G	A	SLC2A7	intronic	NA	NA	NA	0.5944	GnomAdExome_AF_amr	30	29	HeterozygousVariant	het	45	25	20	0.444444444444444	440.64	PASS	NA	NA	610371	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in small intestine and colon. Weakly expressed in testis and prostate. {ECO:0000269|PubMed:15033637}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	Medium	Medium	Medium	NA	NA	0.748	NA	N	N	N	0.42378333720555	N	Slc2a7	NA	NA	NA	NA	NA	0.4085	0.5944	0.5922	0.416	0.5205	0.446486	0.4011	0.365008	0.43514	PASS	0	0.365	92	0.406475	55	chr1	9014873	NA	G	A	440.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=2.78;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.8;AS_ReadPosRankSum=2;AS_SOR=0.315;BaseQRankSum=-1.109;DP=46;ExcessHet=3.0103;FS=2.78;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.79;ReadPosRankSum=2.09;SOR=0.315	GT:AD:DP:GQ:PL	0/1:25,20:45:99:448,0,637
chr1	9246974	9246974	G	A	H6PD	exonic	synonymous SNV	NA	H6PD:NM_001282587:exon3:c.G669A:p.A223A,H6PD:NM_004285:exon3:c.G636A:p.A212A	0.4379	GnomAdGenome_AF_eas	27	8	HeterozygousVariant	het	61	31	30	0.491803278688525	644.64	PASS	NA	NA	138090	Benign	Hyperandrogenism due to cortisone reductase deficiency	Disease-causing germline mutation(s) (loss of function) in	Height[23563607;25282103];Blood protein levels[29875488;30072576];	HP:0000826;HP:0001061;HP:0000876;HP:0000789;HP:0000007;HP:0001513;HP:0001007	Precocious puberty;Acne;Oligomenorrhea;Infertility;Autosomal recessive inheritance;Obesity;Hirsutism	NA	NA	NA	Present in most tissues examined, strongest in liver.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0874	N	N	N	N	0.733120737826362	E	H6pd	endocrine/exocrine gland phenotype; growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.2265	0.4282	0.4284	0.2069	0.4379	0.222644	0.2116	0.225657	0.232348	PASS	0.3	0.147	192	0.18662	37	chr1	9246974	NA	G	A	644.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.57;AS_ReadPosRankSum=-0.4;AS_SOR=0.641;BaseQRankSum=0.789;DP=62;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.57;ReadPosRankSum=-0.375;SOR=0.641	GT:AD:DP:GQ:PL	0/1:31,30:61:99:652,0,670
chr1	9247079	9247079	T	C	H6PD	exonic	synonymous SNV	NA	H6PD:NM_001282587:exon3:c.T774C:p.A258A,H6PD:NM_004285:exon3:c.T741C:p.A247A	0.4503	GnomAdGenome_AF_eas	27	8	HeterozygousVariant	het	69	30	39	0.565217391304348	868.64	PASS	NA	NA	138090	Benign	Hyperandrogenism due to cortisone reductase deficiency	Disease-causing germline mutation(s) (loss of function) in	Height[23563607;25282103];Blood protein levels[29875488;30072576];	HP:0000826;HP:0001061;HP:0000876;HP:0000789;HP:0000007;HP:0001513;HP:0001007	Precocious puberty;Acne;Oligomenorrhea;Infertility;Autosomal recessive inheritance;Obesity;Hirsutism	NA	NA	NA	Present in most tissues examined, strongest in liver.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0874	N	N	N	N	0.733120737826362	E	H6pd	endocrine/exocrine gland phenotype; growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.2392	0.4467	0.4465	0.2527	0.4503	0.275759	0.261	0.240663	0.26601	PASS	0.3	0.149	195	0.18662	37	chr1	9247079	NA	T	C	868.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.59;AS_ReadPosRankSum=0;AS_SOR=0.687;BaseQRankSum=-0.826;DP=73;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.59;ReadPosRankSum=0.061;SOR=0.687	GT:AD:DP:GQ:PL	0/1:30,39:69:99:876,0,673
chr1	9262329	9262329	G	T	H6PD	splicing	NA	NM_004285:exon4:c.1015+1G>T;NM_001282587:exon4:c.1048+1G>T	NA	0	GnomAdExome_AF			HeterozygousVariant	het	59	34	25	0.423728813559322	535.64	PASS	35	NA	138090	NA	Hyperandrogenism due to cortisone reductase deficiency	Disease-causing germline mutation(s) (loss of function) in	Height[23563607;25282103];Blood protein levels[29875488;30072576];	HP:0000826;HP:0001061;HP:0000876;HP:0000789;HP:0000007;HP:0001513;HP:0001007	Precocious puberty;Acne;Oligomenorrhea;Infertility;Autosomal recessive inheritance;Obesity;Hirsutism	NA	NA	NA	Present in most tissues examined, strongest in liver.;	NA	NA	NA	NA	NA	D	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	NA	NA	.;.;	D	NA	.;.	1	0.95	Medium	Medium	Medium	NA	NA	0.0874	N	N	N	N	0.733120737826362	E	H6pd	endocrine/exocrine gland phenotype; growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0	0	0	0	0	0	0	0	0		0					chr1	9262329	NA	G	T	535.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.08;AS_ReadPosRankSum=0.2;AS_SOR=0.732;BaseQRankSum=0.028;DP=59;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.08;ReadPosRankSum=0.207;SOR=0.732	GT:AD:DP:GQ:PL	0/1:34,25:59:99:543,0,810
chr1	9263851	9263851	G	A	H6PD	exonic	nonsynonymous SNV	NA	H6PD:NM_001282587:exon5:c.G1391A:p.R464Q,H6PD:NM_004285:exon5:c.G1358A:p.R453Q	0.477	GnomAdGenome_AF_eas	106	25	HomozygousVariant	hom	118	1	117	0.991525423728814	3635.06	PASS	4.715	NA	138090	Benign	Hyperandrogenism due to cortisone reductase deficiency	Disease-causing germline mutation(s) (loss of function) in	Height[23563607;25282103];Blood protein levels[29875488;30072576];	HP:0000826;HP:0001061;HP:0000876;HP:0000789;HP:0000007;HP:0001513;HP:0001007	Precocious puberty;Acne;Oligomenorrhea;Infertility;Autosomal recessive inheritance;Obesity;Hirsutism	Cortisone_reductase_deficiency_1	no_assertion_criteria_provided	Uncertain_significance	Present in most tissues examined, strongest in liver.;	T	T	B	B	N	P	L	D	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	Glucose-6-phosphate dehydrogenase, C-terminal;Glucose-6-phosphate dehydrogenase, C-terminal	NA	NA	Medium	Medium	Medium	NA	NA	0.0874	N	N	N	N	0.733120737826362	E	H6pd	endocrine/exocrine gland phenotype; growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.2845	0.4725	0.4716	0.312	0.477	0.389577	0.3066	0.280068	0.321018	PASS	0.298913	0.331	340	0.380282	58	chr1	9263851	NA	G	A	3635.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0;AS_FS=3.085;AS_MQ=60;AS_MQRankSum=0;AS_QD=30.81;AS_ReadPosRankSum=-0.5;AS_SOR=0.305;BaseQRankSum=0.093;DP=123;ExcessHet=3.0103;FS=3.085;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=30.81;ReadPosRankSum=-0.499;SOR=0.305	GT:AD:DP:GQ:PL	1/1:1,117:118:99:3649,320,0
chr1	9539764	9539764	A	G	SLC25A33	intronic	NA	NA	NA	0.469	GnomAdGenome_AF_afr	29	7	HeterozygousVariant	het	56	37	19	0.339285714285714	312.64	PASS	NA	NA	610816	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in the central nervous system. Also expressed in testis and skeletal muscle. Weakly expressed in heart, liver, kidney, prostate, colon and peripheral blood leukocytes. {ECO:0000269|PubMed:14715278}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;stomach;testis;unclassifiable (Anatomical System);kidney;uterus;pancreas;bile duct;head and neck;mammary gland;visual apparatus;fovea centralis;spleen;liver;cartilage;bone;germinal center;brain;blood;heart;lung;salivary gland;cerebral cortex;ovary;thyroid;macula lutea;lymph node;bladder;colon;placenta;prostate;breast;hypothalamus;medulla oblongata;	NA	0.424	NA	N	N	N	0.122883935188963	N	Slc25a33	NA	NA	NA	NA	NA	0.1712	0.4433	0.4375	0.2603	0.469	0.298722	0	0.0001537	0.21755	PASS	0	0.134	112	0.213636	33	chr1	9539764	NA	A	G	312.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=1.085;AS_MQ=60;AS_MQRankSum=0;AS_QD=5.59;AS_ReadPosRankSum=-0.3;AS_SOR=0.957;BaseQRankSum=-1.148;DP=60;ExcessHet=3.0103;FS=1.085;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=5.58;ReadPosRankSum=-0.294;SOR=0.957	GT:AD:DP:GQ:PL	0/1:37,19:56:99:320,0,880
chr1	9582271	9582271	C	T	SLC25A33	intronic	NA	NA	NA	0.2921	GnomAdGenome_AF_eas	6	8	HeterozygousVariant	het	48	27	21	0.4375	484.64	PASS	NA	NA	610816	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in the central nervous system. Also expressed in testis and skeletal muscle. Weakly expressed in heart, liver, kidney, prostate, colon and peripheral blood leukocytes. {ECO:0000269|PubMed:14715278}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;stomach;testis;unclassifiable (Anatomical System);kidney;uterus;pancreas;bile duct;head and neck;mammary gland;visual apparatus;fovea centralis;spleen;liver;cartilage;bone;germinal center;brain;blood;heart;lung;salivary gland;cerebral cortex;ovary;thyroid;macula lutea;lymph node;bladder;colon;placenta;prostate;breast;hypothalamus;medulla oblongata;	NA	0.424	NA	N	N	N	0.122883935188963	N	Slc25a33	NA	NA	NA	NA	NA	0.1592	0.2852	0.284	0.1476	0.2921	0.172125	0.1452	0.0316813	0.170139	PASS	0	0.137	117	0.207746	43	chr1	9582271	NA	C	T	484.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.1;AS_ReadPosRankSum=1.2;AS_SOR=0.632;BaseQRankSum=-1.672;DP=50;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.1;ReadPosRankSum=1.26;SOR=0.632	GT:AD:DP:GQ:PL	0/1:27,21:48:99:492,0,790
chr1	9598649	9598649	G	A	TMEM201	intronic	NA	NA	NA	0.8237	GnomAdExome_AF_nfe	281	77	HeterozygousVariant	het	31	17	14	0.451612903225806	325.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	cervix;fovea centralis;epididymis;spleen;liver;endometrium;skin;stomach;testis;brain;lens;unclassifiable (Anatomical System);blood;lung;choroid;kidney;ovary;retina;macula lutea;lymph node;pancreas;colon;optic nerve;	ciliary ganglion;superior cervical ganglion;	0.0119	NA	N	N	N	0.47306578943448	N	Tmem201	NA	NA	NA	NA	NA	0.7939	0.8237	0.8276	0.7778	0.8179	0.746406	0.7887	0.779175	0.787022	PASS	0	0.844	110	0.730216	49	chr1	9598649	NA	G	A	325.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.52;AS_ReadPosRankSum=0.2;AS_SOR=0.665;BaseQRankSum=-0.451;DP=31;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.5;ReadPosRankSum=0.238;SOR=0.665	GT:AD:DP:GQ:PL	0/1:17,14:31:99:333,0,441
chr1	9610776	9610776	C	T	TMEM201	exonic	nonsynonymous SNV	NA	TMEM201:NM_001130924:exon9:c.C1736T:p.P579L	0.8107	GnomAdGenome_AF_nfe	430	69	HeterozygousVariant	het	110	55	55	0.5	1279.64	PASS	0.316	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	NA	NA	N	P	N	NA	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	cervix;fovea centralis;epididymis;spleen;liver;endometrium;skin;stomach;testis;brain;lens;unclassifiable (Anatomical System);blood;lung;choroid;kidney;ovary;retina;macula lutea;lymph node;pancreas;colon;optic nerve;	ciliary ganglion;superior cervical ganglion;	0.0119	NA	N	N	N	0.47306578943448	N	Tmem201	NA	NA	NA	NA	NA	0.7636	0.8099	0.8135	0.7217	0.8107	0.671126	0.7308	0.0001921	0.737105	PASS	0.785714	0.759	269	0.683099	56	chr1	9610776	NA	C	T	1279.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.64;AS_ReadPosRankSum=0.6;AS_SOR=0.623;BaseQRankSum=1.58;DP=111;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.63;ReadPosRankSum=0.649;SOR=0.623	GT:AD:DP:GQ:PL	0/1:55,55:110:99:1287,0,1167
chr1	9724365	9724365	C	T	PIK3CD	exonic	synonymous SNV	NA	PIK3CD:NM_001350235:exon21:c.C2721T:p.Y907Y,PIK3CD:NM_001350234:exon22:c.C2805T:p.Y935Y,PIK3CD:NM_005026:exon22:c.C2808T:p.Y936Y	0.5384	GnomAdExome_AF_afr	119	17	HeterozygousVariant	het	96	61	35	0.364583333333333	711.64	PASS	NA	[MIM:615513]Activated PI3K-delta syndrome;	602839	Benign	Combined immunodeficiency with faciooculoskeletal anomalies;Activated PI3K-delta syndrome	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (gain of function) in	Diisocyanate-induced asthma[25918132];Irritable bowel syndrome[29626450];Monocyte count[27863252];Testicular germ cell tumor[28604728];	HP:0005425;HP:0005403;HP:0012476;HP:0100658;HP:0008348;HP:0030388;HP:0002721;HP:0002716;HP:0000006;HP:0001744;HP:0002110;HP:0003496;HP:0030381;HP:0410018	Recurrent sinopulmonary infections;Decrease in T cell count;Decreased specific pneumococcal antibody level;Cellulitis;Decreased circulating IgG2 level;Decreased proportion of class-switched memory B cells;Immunodeficiency;Lymphadenopathy;Autosomal dominant inheritance;Splenomegaly;Bronchiectasis;Increased circulating IgM level;Increased proportion of transitional B cells;Recurrent ear infections	Immunodeficiency_14	criteria_provided,_single_submitter	Benign	Isoform 2 is expressed in normal thymus, lung and spleen tissues, and is detected at low levels in normal lysates from colon and ovarian biopsies, at elevated levels in lysates from colorectal tumors and is abundantly expressed in some ovarian tumors (at protein level). Both isoform 1 and isoform 2 are widely expressed. Isoform 1 is expressed predominantly in leukocytes. {ECO:0000269|PubMed:22020336}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	spleen;liver;endometrium;skin;germinal center;testis;blood;lymphoreticular;unclassifiable (Anatomical System);bone marrow;lung;uterus;lymph node;prostate;skeletal muscle;breast;visual apparatus;	pons;ciliary ganglion;white blood cells;subthalamic nucleus;dorsal root ganglion;superior cervical ganglion;atrioventricular node;trigeminal ganglion;whole blood;bone marrow;	0.183	N	N	N	H	0.99522805203928	E	Pik3cd	hematopoietic system phenotype; immune system phenotype; skeleton phenotype; digestive/alimentary phenotype; endocrine/exocrine gland phenotype; cellular phenotype; homeostasis/metabolism phenotype; 	pik3cd	retinal ganglion cell	decreased branchiness	abnormal	0.1661	0.5384	0.5441	0.2291	0.529	0.305911	0.2305	0.164823	0.197044	PASS	0.25	0.365	372	0.373239	72	chr1	9724365	NA	C	T	711.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.1;AS_FS=4.039;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.42;AS_ReadPosRankSum=1.4;AS_SOR=1.173;BaseQRankSum=2.11;DP=96;ExcessHet=3.0103;FS=4.039;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.41;ReadPosRankSum=1.4;SOR=1.173	GT:AD:DP:GQ:PL	0/1:61,35:96:99:719,0,1295
chr1	9744635	9744635	C	T	CLSTN1	exonic	nonsynonymous SNV	NA	CLSTN1:NM_014944:exon7:c.G964A:p.A322T,CLSTN1:NM_001009566:exon8:c.G994A:p.A332T,CLSTN1:NM_001302883:exon8:c.G994A:p.A332T	0.2894	GnomAdGenome_AF_sas	81	11	HeterozygousVariant	het	127	66	61	0.480314960629921	1197.64	PASS	0.144	NA	611321	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in the brain and, a lower level, in the heart, skeletal muscle, kidney and placenta. Accumulates in dystrophic neurites around the amyloid core of Alzheimer disease senile plaques (at protein level). {ECO:0000269|PubMed:12498782, ECO:0000269|PubMed:12972431}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	cochlea;pharynx;stomach;testis;pineal gland;choroid;larynx;kidney;uterus;whole body;pancreas;bile duct;adrenal gland;skeletal muscle;islets of Langerhans;visual apparatus;meninges;fovea centralis;vein;pia mater;spleen;liver;germinal center;heart;dura mater;lung;salivary gland;thyroid;sympathetic chain;placenta;optic nerve;thymus;amygdala;intestine;skin;pituitary gland;lens;lymphoreticular;unclassifiable (Anatomical System);cerebellum;retina;muscle;head and neck;mammary gland;cartilage;endometrium;bone;parathyroid;brain;blood;cerebral cortex;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;prostate;breast;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;cerebellum peduncles;cerebellum;pons;occipital lobe;subthalamic nucleus;whole brain;parietal lobe;globus pallidus;medulla oblongata;thalamus;	0.289	NA	N	N	N	0.813511346533686	E	Clstn1	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	clstn1	Rohon-Beard neuron	decreased occurrence	abnormal	0.1178	0.2805	0.281	0.1225	0.2894	0.198083	0.1126	0.110076	0.105911	PASS	0.170455	0.308	279	0.299296	63	chr1	9744635	NA	C	T	1197.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2;AS_FS=1.406;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.43;AS_ReadPosRankSum=-1.2;AS_SOR=0.565;BaseQRankSum=-1.912;DP=130;ExcessHet=3.0103;FS=1.406;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.43;ReadPosRankSum=-1.173;SOR=0.565	GT:AD:DP:GQ:PL	0/1:66,61:127:99:1205,0,1446
chr1	9751483	9751483	A	G	CLSTN1	exonic	synonymous SNV	NA	CLSTN1:NM_014944:exon4:c.T609C:p.V203V,CLSTN1:NM_001009566:exon5:c.T639C:p.V213V,CLSTN1:NM_001302883:exon5:c.T639C:p.V213V	0.5448	GnomAdExome_AF_afr	92	12	HeterozygousVariant	het	37	20	17	0.45945945945946	361.64	PASS	NA	NA	611321	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in the brain and, a lower level, in the heart, skeletal muscle, kidney and placenta. Accumulates in dystrophic neurites around the amyloid core of Alzheimer disease senile plaques (at protein level). {ECO:0000269|PubMed:12498782, ECO:0000269|PubMed:12972431}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	cochlea;pharynx;stomach;testis;pineal gland;choroid;larynx;kidney;uterus;whole body;pancreas;bile duct;adrenal gland;skeletal muscle;islets of Langerhans;visual apparatus;meninges;fovea centralis;vein;pia mater;spleen;liver;germinal center;heart;dura mater;lung;salivary gland;thyroid;sympathetic chain;placenta;optic nerve;thymus;amygdala;intestine;skin;pituitary gland;lens;lymphoreticular;unclassifiable (Anatomical System);cerebellum;retina;muscle;head and neck;mammary gland;cartilage;endometrium;bone;parathyroid;brain;blood;cerebral cortex;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;prostate;breast;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;cerebellum peduncles;cerebellum;pons;occipital lobe;subthalamic nucleus;whole brain;parietal lobe;globus pallidus;medulla oblongata;thalamus;	0.289	NA	N	N	N	0.813511346533686	E	Clstn1	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	clstn1	Rohon-Beard neuron	decreased occurrence	abnormal	0.1698	0.5448	0.5476	0.2354	0.5356	0.309505	0.2329	0.168911	0.197865	PASS	0.217172	0.327	284	0.306338	63	chr1	9751483	NA	A	G	361.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.78;AS_ReadPosRankSum=1.2;AS_SOR=0.507;BaseQRankSum=-2.168;DP=37;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.77;ReadPosRankSum=1.27;SOR=0.507	GT:AD:DP:GQ:PL	0/1:20,17:37:99:369,0,526
chr1	9756562	9756562	T	C	CLSTN1	intronic	NA	NA	NA	0.9987	GnomAdGenome_AF_eas	284	137	HeterozygousVariant	het	26	12	14	0.538461538461538	300.64	PASS	NA	NA	611321	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in the brain and, a lower level, in the heart, skeletal muscle, kidney and placenta. Accumulates in dystrophic neurites around the amyloid core of Alzheimer disease senile plaques (at protein level). {ECO:0000269|PubMed:12498782, ECO:0000269|PubMed:12972431}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	cochlea;pharynx;stomach;testis;pineal gland;choroid;larynx;kidney;uterus;whole body;pancreas;bile duct;adrenal gland;skeletal muscle;islets of Langerhans;visual apparatus;meninges;fovea centralis;vein;pia mater;spleen;liver;germinal center;heart;dura mater;lung;salivary gland;thyroid;sympathetic chain;placenta;optic nerve;thymus;amygdala;intestine;skin;pituitary gland;lens;lymphoreticular;unclassifiable (Anatomical System);cerebellum;retina;muscle;head and neck;mammary gland;cartilage;endometrium;bone;parathyroid;brain;blood;cerebral cortex;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;prostate;breast;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;cerebellum peduncles;cerebellum;pons;occipital lobe;subthalamic nucleus;whole brain;parietal lobe;globus pallidus;medulla oblongata;thalamus;	0.289	NA	N	N	N	0.813511346533686	E	Clstn1	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	clstn1	Rohon-Beard neuron	decreased occurrence	abnormal	0.9674	0.9984	0.9986	0.9692	0.9987	0.982228	0.9673	0.948164	0.966338	PASS	0	0.975	15	0.978873	4	chr1	9756562	NA	T	C	300.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=1.54;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.58;AS_ReadPosRankSum=-0.9;AS_SOR=0.412;BaseQRankSum=-0.589;DP=28;ExcessHet=3.0103;FS=1.54;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.56;ReadPosRankSum=-0.876;SOR=0.412	GT:AD:DP:GQ:PL	0/1:12,14:26:99:308,0,261
chr1	10261933	10261933	A	G	KIF1B	exonic	nonsynonymous SNV	NA	KIF1B:NM_001365951:exon5:c.A392G:p.N131S,KIF1B:NM_001365952:exon5:c.A392G:p.N131S,KIF1B:NM_001365953:exon5:c.A392G:p.N131S,KIF1B:NM_015074:exon5:c.A392G:p.N131S,KIF1B:NM_183416:exon5:c.A392G:p.N131S	0.0007	GnomAdGenome_AF_sas			HeterozygousVariant	het	43	24	19	0.441860465116279	335.64	PASS	21.7	[MIM:256700]Neuroblastoma 1;[MIM:171300]Pheochromocytoma;	605995	Uncertain significance	Hereditary pheochromocytoma-paraganglioma;Autosomal dominant Charcot-Marie-Tooth disease type 2A1	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in	Mean platelet volume[22139419;27863252];Virologic severity in Herpes simplex virus type 2 infection[29535370];Multiple sclerosis[18997785];Waist circumference adjusted for BMI in non-smokers[28443625];Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)[28443625];Hematocrit[27863252];Hand grip strength[29691431];Hepatocellular carcinoma[20676096];Waist circumference adjusted for BMI (adjusted for smoking behaviour)[28443625];Hepatitis B virus-related hepatocellular carcinoma[29246937];	HP:0011979;HP:0000822;HP:0001336;HP:0000765;HP:0011977;HP:0001945;HP:0001508;HP:0031500;HP:0003005;HP:0011978;HP:0000006;HP:0002653;HP:0002277;HP:0200036;HP:0002014;HP:0002027;HP:0001251;HP:0002176;HP:0003006;HP:0001824;HP:0010543;HP:0001428;HP:0006747;HP:0001425;HP:0001903;HP:0003829;HP:0003745;HP:0003674;HP:0003380;HP:0003677;HP:0003431;HP:0003693;HP:0001765;HP:0003383;HP:0003384;HP:0003376;HP:0000006;HP:0003378;HP:0001761;HP:0002460;HP:0001284;HP:0001265;HP:0003690;HP:0003693;HP:0009027;HP:0009830;HP:0001425;HP:0002936;HP:0002664;HP:0003345;HP:0001649;HP:0003574;HP:0001635;HP:0001028;HP:0000093;HP:0002666;HP:0003072;HP:0000006;HP:0001095;HP:0001920;HP:0000957;HP:0000519;HP:0001342;HP:0000875;HP:0000975;HP:0003345;HP:0031284;HP:0002864;HP:0006748;HP:0002018;HP:0002331;HP:0001824;HP:0000790;HP:0000096;HP:0011979;HP:0001342;HP:0001095;HP:0000980;HP:0011703;HP:0001635;HP:0000740;HP:0008629;HP:0001618;HP:0001069;HP:0003072;HP:0005584;HP:0003528;HP:0000405;HP:0003574;HP:0100749;HP:0001962;HP:0025269;HP:0010532;HP:0001337;HP:0006737;HP:0002574;HP:0001293;HP:0012222;HP:0003639;HP:0000526;HP:0009711;HP:0012378;HP:0000093;HP:0001605	Elevated urinary dopamine;Hypertension;Myoclonus;Abnormality of the thorax;Elevated urinary homovanillic acid;Fever;Failure to thrive;Abdominal mass;Ganglioneuroma;Elevated urinary vanillylmandelic acid;Autosomal dominant inheritance;Bone pain;Horner syndrome;Skin nodule;Diarrhea;Abdominal pain;Ataxia;Spinal cord compression;Neuroblastoma;Weight loss;Opsoclonus;Somatic mutation;Ganglioneuroblastoma;Heterogeneous;Anemia;Incomplete penetrance;Sporadic;Onset;Decreased number of peripheral myelinated nerve fibers;Slow progression;Decreased motor nerve conduction velocity;Distal amyotrophy;Hammertoe;Onion bulb formation;Peripheral axonal atrophy;Steppage gait;Autosomal dominant inheritance;Axonal degeneration/regeneration;Pes cavus;Distal muscle weakness;Areflexia;Hyporeflexia;Limb muscle weakness;Distal amyotrophy;Foot dorsiflexor weakness;Peripheral neuropathy;Heterogeneous;Distal sensory impairment;Neoplasm;Elevated urinary norepinephrine;Tachycardia;Positive regitine blocking test;Congestive heart failure;Hemangioma;Proteinuria;Pheochromocytoma;Hypercalcemia;Autosomal dominant inheritance;Hypertensive retinopathy;Renal artery stenosis;Cafe-au-lait spot;Developmental cataract;Cerebral hemorrhage;Episodic hypertension;Hyperhidrosis;Elevated urinary norepinephrine;Flushing;Paraganglioma of head and neck;Adrenal pheochromocytoma;Nausea;Recurrent paroxysmal headache;Weight loss;Hematuria;Glomerulosclerosis;Elevated urinary dopamine;Cerebral hemorrhage;Hypertensive retinopathy;Pallor;Sinus tachycardia;Congestive heart failure;Episodic paroxysmal anxiety;Pulsatile tinnitus;Dysphonia;Episodic hyperhidrosis;Hypercalcemia;Renal cell carcinoma;Elevated calcitonin;Conductive hearing impairment;Positive regitine blocking test;Chest pain;Palpitations;Panic attack;Paroxysmal vertigo;Tremor;Extraadrenal pheochromocytoma;Episodic abdominal pain;Cranial nerve compression;Arachnoid hemangiomatosis;Elevated urinary epinephrine;Aniridia;Retinal capillary hemangioma;Fatigue;Proteinuria;Vocal cord paralysis	Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_single_submitter	Uncertain_significance	Isoform 3 is abundant in the skeletal muscle. It is also expressed in fetal brain, lung and kidney, and adult heart, placenta, testis, ovary and small intestine. Isoform 2 is abundant in the brain and also expressed in fetal heart, lung, liver and kidney, and adult skeletal muscle, placenta, liver, kidney, heart, spleen, thymus, prostate, testis, ovary, small intestine, colon and pancreas. {ECO:0000269|PubMed:10762626, ECO:0000269|PubMed:11526494, ECO:0000269|PubMed:12888911}.;	T	T	B	B	D	D	N	D	D	T	T	T	D	T	T	T	T	D	.;.;.;.;.;.;.;	D	D	.;.;Kinesin motor domain|Kinesin motor domain|Kinesin motor domain;.;.;Kinesin motor domain|Kinesin motor domain|Kinesin motor domain;Kinesin motor domain|Kinesin motor domain|Kinesin motor domain	NA	NA	Medium	Medium	Medium	amygdala;spinal ganglion;skin;cerebellum cortex;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);cerebellum;amniotic fluid;larynx;kidney;uterus;whole body;retina;head and neck;mammary gland;spinal cord;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;hippocampus;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;frontal lobe;colon;placenta;prostate;breast;optic nerve;gum;hypothalamus;	caudate nucleus;amygdala;temporal lobe;prefrontal cortex;cingulate cortex;cerebellum peduncles;cerebellum;pons;occipital lobe;fetal brain;subthalamic nucleus;whole brain;spinal cord;parietal lobe;globus pallidus;hypothalamus;medulla oblongata;thalamus;	0.206	E	N	N	N	0.958396729723497	E	Kif1b	homeostasis/metabolism phenotype; craniofacial phenotype; muscle phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); embryo phenotype; skeleton phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	kif1b	thrombocyte	decreased amount	abnormal	0.00003183	0.0002	0.0002	0.00002094	0.0007	0	0	0.0000323	0		0					chr1	10261933	NA	A	G	335.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.81;AS_ReadPosRankSum=0.7;AS_SOR=0.636;BaseQRankSum=-1.82;DP=43;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.81;ReadPosRankSum=0.796;SOR=0.636	GT:AD:DP:GQ:PL	0/1:24,19:43:99:343,0,586
chr1	10442251	10442251	T	-	CENPS;CENPS-CORT	intronic	NA	NA	NA	0.9807	GnomAdExome_AF_asj	332	101	HomozygousVariant	hom	31	0	31	1	879.03	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.8877	0.9303	0.929	0.8776	0.978	0.840855	0.8925	0.0003458	0.88796	PASS	0	0.82	131	0.841549	37	chr1	10442250	NA	AT	A	879.03	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.35;AS_ReadPosRankSum=.;AS_SOR=1.609;DP=31;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.36;SOR=1.609	GT:AD:DP:GQ:PL	1/1:0,31:31:93:893,93,0
chr1	10451487	10451487	C	T	CENPS-CORT;CORT	exonic	synonymous SNV	NA	CORT:NM_001302:exon2:c.C210T:p.A70A,CENPS-CORT:NM_001243768:exon4:c.C324T:p.A108A,CENPS-CORT:NM_198544:exon5:c.C387T:p.A129A	0.4891	GnomAdGenome_AF_eas	63	12	HomozygousVariant	hom	105	0	105	1	2898.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.3695	0.4874	0.492	0.2976	0.4891	0.28754	0.2897	0.362356	0.36289	PASS	0.417683	0.307	233	0.338028	72	chr1	10451487	NA	C	T	2898.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.6;AS_ReadPosRankSum=.;AS_SOR=0.833;DP=110;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.6;SOR=0.833	GT:AD:DP:GQ:PL	1/1:0,105:105:99:2912,313,0
chr1	10451532	10451532	T	C	CENPS-CORT;CORT	exonic	synonymous SNV	NA	CORT:NM_001302:exon2:c.T255C:p.S85S,CENPS-CORT:NM_001243768:exon4:c.T369C:p.S123S,CENPS-CORT:NM_198544:exon5:c.T432C:p.S144S	0.9888	GnomAdExome_AF_asj	410	103	HomozygousVariant	hom	80	0	80	1	2186.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.8921	0.939	0.937	0.909	0.9844	0.867612	0.9269	0.888759	0.918719	PASS	0.979021	0.832	152	0.848592	35	chr1	10451532	NA	T	C	2186.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.33;AS_ReadPosRankSum=.;AS_SOR=0.968;DP=83;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.33;SOR=0.968	GT:AD:DP:GQ:PL	1/1:0,80:80:99:2200,239,0
chr1	10629885	10629885	G	T	PEX14	exonic	synonymous SNV	NA	PEX14:NM_004565:exon9:c.G1032T:p.G344G	0.22561	GME_TP	28	4	HomozygousVariant	hom	150	0	150	1	4137.06	PASS	NA	[MIM:614887]Peroxisome biogenesis disorder complementation group K;[MIM:614887]Peroxisome biogenesis disorder 13A;	601791	Benign	Zellweger syndrome;Neonatal adrenoleukodystrophy;Infantile Refsum disease	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Optic nerve measurement (rim area)[20395239];Breast size[27182965];Self-reported allergy[23817569];Hand grip strength[29313844];Breast cancer[23535733;27117709;23535729;29059683];Breast cancer (estrogen-receptor negative)[27117709];Prostate cancer[25217961];Asthma[27182965];	HP:0001392;HP:0000505;HP:0000486;HP:0008207;HP:0000518;HP:0000174;HP:0000348;HP:0000368;HP:0000463;HP:0000508;HP:0007703;HP:0011344;HP:0000256;HP:0000407;HP:0001250;HP:0002269;HP:0002353;HP:0000648;HP:0001252;HP:0007598;HP:0000260;HP:0001347;HP:0004322;HP:0000639;HP:0000431;HP:0000268;HP:0001939;HP:0002376;HP:0000348;HP:0011968;HP:0000347;HP:0000007;HP:0000268;HP:0000952;HP:0000478;HP:0000422;HP:0001476;HP:0002269;HP:0011398;HP:0000325;HP:0001250;HP:0002240;HP:0005469;HP:0000239;HP:0001290;HP:0000286;HP:0000003;HP:0000474;HP:0000407;HP:0001622;HP:0009891;HP:0000639;HP:0000952;HP:0001399;HP:0002021;HP:0005280;HP:0000582;HP:0000347;HP:0000256;HP:0002240;HP:0006829;HP:0100543;HP:0001315;HP:0008872;HP:0000532;HP:0002353;HP:0000218;HP:0012736;HP:0001629;HP:0008167;HP:0000627;HP:0002126;HP:0007957;HP:0000028;HP:0002652;HP:0000260;HP:0000431;HP:0000505;HP:0000126;HP:0004322;HP:0008572;HP:0000348;HP:0000252;HP:0001522;HP:0000047;HP:0001508;HP:0000518;HP:0001928;HP:0010655;HP:0008665;HP:0000648;HP:0001088;HP:0008207;HP:0012368;HP:0005469;HP:0000501;HP:0000157;HP:0001250;HP:0002024;HP:0002093;HP:0002240;HP:0008064;HP:0011675;HP:0000518;HP:0001263;HP:0000407;HP:0005930;HP:0000639;HP:0000662;HP:0001257;HP:0001250;HP:0001508;HP:0000708;HP:0000510;HP:0001638;HP:0001133;HP:0004322;HP:0008167;HP:0010571;HP:0003323;HP:0010628;HP:0000648;HP:0001251;HP:0001252	Abnormality of the liver;Visual impairment;Strabismus;Primary adrenal insufficiency;Cataract;Abnormal palate morphology;High forehead;Low-set, posteriorly rotated ears;Anteverted nares;Ptosis;Abnormality of retinal pigmentation;Severe global developmental delay;Macrocephaly;Sensorineural hearing impairment;Seizure;Abnormality of neuronal migration;EEG abnormality;Optic atrophy;Muscular hypotonia;Bilateral single transverse palmar creases;Wide anterior fontanel;Hyperreflexia;Short stature;Nystagmus;Wide nasal bridge;Dolichocephaly;Abnormality of metabolism/homeostasis;Developmental regression;High forehead;Feeding difficulties;Micrognathia;Autosomal recessive inheritance;Dolichocephaly;Jaundice;Abnormality of the eye;Abnormality of the nasal bridge;Delayed closure of the anterior fontanelle;Abnormality of neuronal migration;Central hypotonia;Triangular face;Seizure;Hepatomegaly;Flat occiput;Large fontanelles;Generalized hypotonia;Epicanthus;Multicystic kidney dysplasia;Thickened nuchal skin fold;Sensorineural hearing impairment;Premature birth;Underdeveloped supraorbital ridges;Nystagmus;Jaundice;Hepatic failure;Pyloric stenosis;Depressed nasal bridge;Upslanted palpebral fissure;Micrognathia;Macrocephaly;Hepatomegaly;Severe muscular hypotonia;Cognitive impairment;Reduced tendon reflexes;Feeding difficulties in infancy;Abnormal chorioretinal morphology;EEG abnormality;High palate;Profound global developmental delay;Ventricular septal defect;Very long chain fatty acid accumulation;Posterior embryotoxon;Polymicrogyria;Corneal opacity;Cryptorchidism;Skeletal dysplasia;Wide anterior fontanel;Wide nasal bridge;Visual impairment;Hydronephrosis;Short stature;External ear malformation;High forehead;Microcephaly;Death in infancy;Hypospadias;Failure to thrive;Cataract;Abnormality of coagulation;Epiphyseal stippling;Clitoral hypertrophy;Optic atrophy;Brushfield spots;Primary adrenal insufficiency;Flat face;Flat occiput;Glaucoma;Abnormality of the tongue;Seizure;Malabsorption;Respiratory insufficiency;Hepatomegaly;Ichthyosis;Arrhythmia;Cataract;Global developmental delay;Sensorineural hearing impairment;Abnormality of epiphysis morphology;Nystagmus;Nyctalopia;Spasticity;Seizure;Failure to thrive;Behavioral abnormality;Rod-cone dystrophy;Cardiomyopathy;Constriction of peripheral visual field;Short stature;Very long chain fatty acid accumulation;Elevated levels of phytanic acid;Progressive muscle weakness;Facial palsy;Optic atrophy;Ataxia;Muscular hypotonia	Peroxisome_biogenesis_disorder_13A|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.372	E	E	N	K	0.932699583237108	E	Pex14	mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.1537	0.1958	0.1995	0.134	0.202	0.103634	0.1408	0.147741	0.154351	PASS	0.22561	0.153	199	0.165493	39	chr1	10629885	NA	G	T	4137.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.58;AS_ReadPosRankSum=.;AS_SOR=0.804;DP=157;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.58;SOR=0.804	GT:AD:DP:GQ:PL	1/1:0,150:150:99:4151,448,0
chr1	11013925	11013925	T	C	TARDBP	exonic	synonymous SNV	NA	TARDBP:NM_007375:exon2:c.T198C:p.A66A	0.15	GME_Israel	0	0	HeterozygousVariant	het	45	30	15	0.333333333333333	287.64	PASS	NA	[MIM:612069]Amyotrophic lateral sclerosis 10;	605078	Likely benign	Amyotrophic lateral sclerosis;Frontotemporal dementia with motor neuron disease	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Ewing sarcoma[22327514];Male-pattern baldness[22693459];Beard thickness[26926045];	HP:0025425;HP:0002017;HP:0002094;HP:0000739;HP:0012531;HP:0003470;HP:0000713;HP:0003324;HP:0000716;HP:0007354;HP:0000217;HP:0030196;HP:0003394;HP:0030195;HP:0003202;HP:0002180;HP:0000712;HP:0001257;HP:0002878;HP:0012378;HP:0001257;HP:0000733;HP:0002145;HP:0000006;HP:0000734;HP:0030223;HP:0000741;HP:0003202;HP:0003678;HP:0001260;HP:0007354;HP:0002747;HP:0000712;HP:0002015;HP:0003487;HP:0002442;HP:0002314;HP:0002300;HP:0003700;HP:0002366;HP:0000716;HP:0000734;HP:0003701;HP:0008619;HP:0002283;HP:0001283;HP:0001265;HP:0002127;HP:0000508;HP:0000605;HP:0001260;HP:0001300;HP:0003487;HP:0000738;HP:0030223;HP:0000741;HP:0002015;HP:0002385;HP:0002380;HP:0008322;HP:0002171;HP:0002186;HP:0002145;HP:0002273;HP:0002460;HP:0007190;HP:0002073	Laryngospasm;Nausea and vomiting;Dyspnea;Anxiety;Pain;Paralysis;Agitation;Generalized muscle weakness;Depressivity;Amyotrophic lateral sclerosis;Xerostomia;Fatigable weakness of respiratory muscles;Muscle spasm;Fatigable weakness of swallowing muscles;Skeletal muscle atrophy;Neurodegeneration;Emotional lability;Spasticity;Respiratory failure;Fatigue;Spasticity;Stereotypy;Frontotemporal dementia;Autosomal dominant inheritance;Disinhibition;Perseveration;Apathy;Skeletal muscle atrophy;Rapidly progressive;Dysarthria;Amyotrophic lateral sclerosis;Respiratory insufficiency due to muscle weakness;Emotional lability;Dysphagia;Babinski sign;Dyscalculia;Degeneration of the lateral corticospinal tracts;Mutism;Generalized amyotrophy;Abnormal lower motor neuron morphology;Depressivity;Disinhibition;Proximal muscle weakness;Bilateral sensorineural hearing impairment;Global brain atrophy;Bulbar palsy;Hyporeflexia;Abnormal upper motor neuron morphology;Ptosis;Supranuclear gaze palsy;Dysarthria;Parkinsonism;Babinski sign;Hallucinations;Perseveration;Apathy;Dysphagia;Paraparesis;Fasciculations;Abnormal mitochondrial morphology;Gliosis;Apraxia;Frontotemporal dementia;Tetraparesis;Distal muscle weakness;Neuronal loss in the cerebral cortex;Progressive cerebellar ataxia	Amyotrophic_lateral_sclerosis_type_10|TARDBP-related_frontotemporal_dementia|not_specified|none_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	Ubiquitously expressed. In particular, expression is high in pancreas, placenta, lung, genital tract and spleen.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Low	Low	Low	cochlea;pharynx;cornea;stomach;testis;choroid;larynx;kidney;uterus;whole body;pancreas;hypopharynx;skeletal muscle;mesenchyma;islets of Langerhans;visual apparatus;fovea centralis;iris;vein;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;placenta;small intestine;nasopharynx;optic nerve;thymus;intestine;smooth muscle;skin;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;mammary gland;cervix;endometrium;bone;brain;blood;bone marrow;ovary;macula lutea;lymph node;bladder;colon;prostate;breast;hypothalamus;medulla oblongata;	cingulate cortex;parietal lobe;testis;skeletal muscle;	NA	E	N	NA	E	0.895314001363746	E	Tardbp	muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; hematopoietic system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; 	tardbp	CaP motoneuron	decreased length	abnormal	0.0067	0.0191	0.0194	0.0033	0.0509	0.00519169	0.0044	0.0056338	0.004926	PASS	0.15	0.017	29	0.014085	4	chr1	11013925	NA	T	C	287.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.4;AS_ReadPosRankSum=-0.2;AS_SOR=0.776;BaseQRankSum=-2.134;DP=48;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.39;ReadPosRankSum=-0.169;SOR=0.776	GT:AD:DP:GQ:PL	0/1:30,15:45:99:295,0,820
chr1	11027467	11027467	G	A	MASP2	exonic	synonymous SNV	NA	MASP2:NM_006610:exon11:c.C1479T:p.S493S	0.9	GME_Israel	521	85	HomozygousVariant	hom	69	0	69	1	2103.06	PASS	NA	[MIM:613791]MASP2 deficiency;	605102	Benign	Immunodeficiency due to MASP-2 deficiency	Disease-causing germline mutation(s) in	Beard thickness[26926045];	HP:0002725;HP:0004431;HP:0000006;HP:0006532;HP:0100279;HP:0000007	Systemic lupus erythematosus;Complement deficiency;Autosomal dominant inheritance;Recurrent pneumonia;Ulcerative colitis;Autosomal recessive inheritance	Frontotemporal_dementia|MASP2_deficiency|not_specified|Amyotrophic_Lateral_Sclerosis,_Dominant	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Plasma.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.273	N	N	N	N	0.296230416421892	N	Masp2	immune system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.7934	0.8674	0.8676	0.6799	0.8911	0.6875	0.6732	0.779751	0.732348	PASS	0.9	0.786	270	0.753521	44	chr1	11027467	NA	G	A	2103.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.48;AS_ReadPosRankSum=.;AS_SOR=0.844;DP=71;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.48;SOR=0.844	GT:AD:DP:GQ:PL	1/1:0,69:69:99:2117,206,0
chr1	11030859	11030859	C	A	MASP2	exonic	nonsynonymous SNV	NA	MASP2:NM_006610:exon9:c.G1111T:p.D371Y	0.8689	GnomAdGenome_AF_ami	362	54	HomozygousVariant	hom	59	0	59	1	1560.06	PASS	22.7	[MIM:613791]MASP2 deficiency;	605102	Benign	Immunodeficiency due to MASP-2 deficiency	Disease-causing germline mutation(s) in	Beard thickness[26926045];	HP:0002725;HP:0004431;HP:0000006;HP:0006532;HP:0100279;HP:0000007	Systemic lupus erythematosus;Complement deficiency;Autosomal dominant inheritance;Recurrent pneumonia;Ulcerative colitis;Autosomal recessive inheritance	MASP2_deficiency|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Plasma.;	T	D	P	P	N	P	M	T	D	T	T	T	NA	T	T	T	T	T	.;	N	N	Sushi/SCR/CCP domain|Sushi/SCR/CCP domain|Sushi/SCR/CCP domain|Sushi/SCR/CCP domain	NA	NA	Medium	Medium	Medium	NA	NA	0.273	N	N	N	N	0.296230416421892	N	Masp2	immune system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.7449	0.816	0.8162	0.6295	0.8689	0.58127	0.6298	0.724357	0.696223	PASS	0.85	0.656	372	0.619718	68	chr1	11030859	NA	C	A	1560.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.44;AS_ReadPosRankSum=.;AS_SOR=1.123;DP=59;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.44;SOR=1.123	GT:AD:DP:GQ:PL	1/1:0,59:59:99:1574,176,0
chr1	11059842	11059842	T	C	SRM	exonic	synonymous SNV	NA	SRM:NM_003132:exon1:c.A102G:p.S34S	1	GnomAdExome_AF	583	142	HomozygousVariant	hom	34	0	34	1	960.06	PASS	NA	NA	182891	NA	NA	NA	Beard thickness[26926045];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.268	NA	E	N	N	0.992785162826927	E	Srm	NA	srm	melanophore stripe	patchy	abnormal	1	1	1	1	1	1	0	0.0001153	1	PASS	1	1	0	1	0	chr1	11059842	NA	T	C	960.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.24;AS_ReadPosRankSum=.;AS_SOR=1.085;DP=37;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.24;SOR=1.085	GT:AD:DP:GQ:PL	1/1:0,34:34:99:974,102,0
chr1	11072160	11072160	G	A	EXOSC10	exonic	synonymous SNV	NA	EXOSC10:NM_002685:exon19:c.C2094T:p.R698R,EXOSC10:NM_001001998:exon20:c.C2169T:p.R723R	0.7989	GnomAdExome_AF_amr	285	67	HeterozygousVariant	het	57	31	26	0.456140350877193	577.64	PASS	NA	NA	605960	Benign	NA	NA	Beard thickness[26926045];Intraocular pressure[29617998];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;stomach;lacrimal gland;testis;choroid;kidney;uterus;whole body;pancreas;bile duct;adrenal gland;trophoblast;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;iris;spleen;liver;germinal center;heart;lung;thyroid;sympathetic chain;placenta;nasopharynx;optic nerve;skin;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;mammary gland;spinal cord;cervix;cartilage;endometrium;bone;brain;blood;bone marrow;trabecular meshwork;cerebral cortex;ovary;macula lutea;lymph node;colon;prostate;breast;hypothalamus;medulla oblongata;	testis - seminiferous tubule;subthalamic nucleus;testis - interstitial;prefrontal cortex;cingulate cortex;testis;hypothalamus;	0.0801	NA	E	E	E	0.963225594369206	E	Exosc10	normal phenotype; 	NA	NA	NA	NA	0.7098	0.7989	0.7976	0.5948	0.7891	0.60623	0.5859	0.697882	0.652709	PASS	0.75	0.691	237	0.697183	64	chr1	11072160	NA	G	A	577.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=7.215;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.14;AS_ReadPosRankSum=-0.9;AS_SOR=0.506;BaseQRankSum=-0.783;DP=61;ExcessHet=3.0103;FS=7.215;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.13;ReadPosRankSum=-0.85;SOR=0.506	GT:AD:DP:GQ:PL	0/1:31,26:57:99:585,0,767
chr1	11073899	11073899	-	AAG	EXOSC10	intronic	NA	NA	NA	0.6489	GnomAdGenome_AF_ami	35	10	HeterozygousVariant	het	21	11	10	0.476190476190476	250.6	PASS	NA	NA	605960	NA	NA	NA	Beard thickness[26926045];Intraocular pressure[29617998];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;stomach;lacrimal gland;testis;choroid;kidney;uterus;whole body;pancreas;bile duct;adrenal gland;trophoblast;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;iris;spleen;liver;germinal center;heart;lung;thyroid;sympathetic chain;placenta;nasopharynx;optic nerve;skin;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;mammary gland;spinal cord;cervix;cartilage;endometrium;bone;brain;blood;bone marrow;trabecular meshwork;cerebral cortex;ovary;macula lutea;lymph node;colon;prostate;breast;hypothalamus;medulla oblongata;	testis - seminiferous tubule;subthalamic nucleus;testis - interstitial;prefrontal cortex;cingulate cortex;testis;hypothalamus;	0.0801	NA	E	E	E	0.963225594369206	E	Exosc10	normal phenotype; 	NA	NA	NA	NA	0.0521	0.1063	0.112	0.4515	0.6489	0	0	0.0001488	0		0	0.244	56	0.184211	22	chr1	11073899	NA	A	AAAG	250.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.95;AS_ReadPosRankSum=-1.6;AS_SOR=0.569;BaseQRankSum=-0.278;DP=22;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.93;ReadPosRankSum=-1.586;SOR=0.569	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:11,10:21:99:1|0:11073877_CA_C:258,0,347:11073877
chr1	11081130	11081130	C	G	EXOSC10	exonic	synonymous SNV	NA	EXOSC10:NM_001001998:exon11:c.G1389C:p.P463P,EXOSC10:NM_002685:exon11:c.G1389C:p.P463P	0.9392	GnomAdExome_AF_eas	411	98	HeterozygousVariant	het	56	21	35	0.625	784.64	PASS	NA	NA	605960	Benign	NA	NA	Beard thickness[26926045];Intraocular pressure[29617998];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;stomach;lacrimal gland;testis;choroid;kidney;uterus;whole body;pancreas;bile duct;adrenal gland;trophoblast;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;iris;spleen;liver;germinal center;heart;lung;thyroid;sympathetic chain;placenta;nasopharynx;optic nerve;skin;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;mammary gland;spinal cord;cervix;cartilage;endometrium;bone;brain;blood;bone marrow;trabecular meshwork;cerebral cortex;ovary;macula lutea;lymph node;colon;prostate;breast;hypothalamus;medulla oblongata;	testis - seminiferous tubule;subthalamic nucleus;testis - interstitial;prefrontal cortex;cingulate cortex;testis;hypothalamus;	0.0801	NA	E	E	E	0.963225594369206	E	Exosc10	normal phenotype; 	NA	NA	NA	NA	0.7841	0.9392	0.9394	0.7093	0.9342	0.772364	0.6926	0.0001153	0.748768	PASS	0.85	0.831	150	0.830986	40	chr1	11081130	NA	C	G	784.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.02;AS_ReadPosRankSum=-0.2;AS_SOR=0.636;BaseQRankSum=-0.503;DP=59;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.01;ReadPosRankSum=-0.119;SOR=0.636	GT:AD:DP:GQ:PL	0/1:21,35:56:99:792,0,430
chr1	11121400	11121400	G	T	MTOR	intronic	NA	NA	NA	0.117	GnomAdGenome_AF_sas	11	3	HeterozygousVariant	het	51	35	16	0.313725490196078	309.64	PASS	NA	[MIM:616638]Smith-Kingsmore syndrome [dominant?];[MIM:607341]Focal cortical dysplasia 2;	601231	NA	Isolated focal cortical dysplasia type IIb;Isolated focal cortical dysplasia type IIa;Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome	Disease-causing somatic mutation(s) in;Disease-causing somatic mutation(s) in;Disease-causing germline mutation(s) (gain of function) in	Body mass index[25673413;25673413];Corneal curvature[24963161];Heel bone mineral density[28869591;28869591];Beard thickness[26926045];	HP:0011968;HP:0000256;HP:0000260;HP:0000331;HP:0009882;HP:0000006;HP:0000316;HP:0000348;HP:0000154;HP:0000957;HP:0001290;HP:0000028;HP:0000194;HP:0000219;HP:0006191;HP:0001249;HP:0001537;HP:0001520;HP:0003196;HP:0005280;HP:0012650;HP:0001250;HP:0002720;HP:0007206;HP:0002007;HP:0010241;HP:0001869;HP:0008905;HP:0000343;HP:0000319;HP:0000486;HP:0011800;HP:0000494;HP:0002212;HP:0005257;HP:0001943;HP:0001873;HP:0001540;HP:0002384;HP:0001249;HP:0003745;HP:0100543;HP:0003581;HP:0007042;HP:0032051;HP:0003593;HP:0002446;HP:0001428;HP:0001269;HP:0002539;HP:0007206;HP:0001763;HP:0002197;HP:0005280;HP:0001328;HP:0002007;HP:0001540;HP:0005257;HP:0001998;HP:0000028;HP:0000316;HP:0000486;HP:0000729;HP:0002099;HP:0000331;HP:0000154;HP:0040168;HP:0004789;HP:0002119;HP:0005266;HP:0002167;HP:0000256;HP:0001263;HP:0001273;HP:0001053;HP:0001288;HP:0025104;HP:0001538;HP:0012393;HP:0002212;HP:0000752;HP:0002720;HP:0000343;HP:0001249;HP:0001028;HP:0001520;HP:0000957;HP:0000194;HP:0001355;HP:0001999;HP:0000047;HP:0011220;HP:0000494;HP:0001252;HP:0002126	Feeding difficulties;Macrocephaly;Wide anterior fontanel;Short chin;Short distal phalanx of finger;Autosomal dominant inheritance;Hypertelorism;High forehead;Wide mouth;Cafe-au-lait spot;Generalized hypotonia;Cryptorchidism;Open mouth;Thin upper lip vermilion;Deep palmar crease;Intellectual disability;Umbilical hernia;Large for gestational age;Short nose;Depressed nasal bridge;Perisylvian polymicrogyria;Seizure;Decreased circulating IgA level;Hemimegalencephaly;Frontal bossing;Short proximal phalanx of finger;Deep plantar creases;Rhizomelia;Long philtrum;Smooth philtrum;Strabismus;Midface retrusion;Downslanted palpebral fissures;Curly hair;Thoracic hypoplasia;Hypoglycemia;Thrombocytopenia;Diastasis recti;Focal impaired awareness seizure;Intellectual disability;Sporadic;Cognitive impairment;Adult onset;Focal white matter lesions;Focal cortical dysplasia type II;Infantile onset;Astrocytosis;Somatic mutation;Hemiparesis;Cortical dysplasia;Hemimegalencephaly;Pes planus;Generalized-onset seizure;Depressed nasal bridge;Specific learning disability;Frontal bossing;Diastasis recti;Thoracic hypoplasia;Neonatal hypoglycemia;Cryptorchidism;Hypertelorism;Strabismus;Autistic behavior;Asthma;Short chin;Wide mouth;Focal seizures, afebril;Lactose intolerance;Ventriculomegaly;Intestinal polyp;Neurological speech impairment;Macrocephaly;Global developmental delay;Abnormal corpus callosum morphology;Hypopigmented skin patches;Gait disturbance;Capillary malformation;Protuberant abdomen;Allergy;Curly hair;Hyperactivity;Decreased circulating IgA level;Long philtrum;Intellectual disability;Hemangioma;Large for gestational age;Cafe-au-lait spot;Open mouth;Megalencephaly;Abnormal facial shape;Hypospadias;Prominent forehead;Downslanted palpebral fissures;Muscular hypotonia;Polymicrogyria	NA	NA	NA	Expressed in numerous tissues, with highest levels in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;epididymis;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;macula lutea;lymph node;bladder;colon;placenta;aorta;prostate;nasopharynx;breast;optic nerve;	testis - seminiferous tubule;occipital lobe;testis - interstitial;parietal lobe;testis;skeletal muscle;bone marrow;	0.246	E	E	E	E	0.802053821315338	E	Mtor	respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; 	mtor	cardiac muscle cell	decreased size	abnormal	0.0567	0.1141	0.1143	0.0581	0.117	0.0970447	0.051	0.0534599	0.063218	PASS	0	0.152	136	0.14539	35	chr1	11121400	NA	G	T	309.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=1.189;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.08;AS_ReadPosRankSum=1.3;AS_SOR=0.909;BaseQRankSum=-0.768;DP=52;ExcessHet=3.0103;FS=1.189;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.07;ReadPosRankSum=1.3;SOR=0.909	GT:AD:DP:GQ:PL	0/1:35,16:51:99:317,0,988
chr1	11127836	11127836	T	C	MTOR	intronic	NA	NA	NA	1	GnomAdExome_AF_sas	400	142	HomozygousVariant	hom	38	0	38	1	1363.06	PASS	NA	[MIM:616638]Smith-Kingsmore syndrome [dominant?];[MIM:607341]Focal cortical dysplasia 2;	601231	NA	Isolated focal cortical dysplasia type IIb;Isolated focal cortical dysplasia type IIa;Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome	Disease-causing somatic mutation(s) in;Disease-causing somatic mutation(s) in;Disease-causing germline mutation(s) (gain of function) in	Body mass index[25673413;25673413];Corneal curvature[24963161];Heel bone mineral density[28869591;28869591];Beard thickness[26926045];	HP:0011968;HP:0000256;HP:0000260;HP:0000331;HP:0009882;HP:0000006;HP:0000316;HP:0000348;HP:0000154;HP:0000957;HP:0001290;HP:0000028;HP:0000194;HP:0000219;HP:0006191;HP:0001249;HP:0001537;HP:0001520;HP:0003196;HP:0005280;HP:0012650;HP:0001250;HP:0002720;HP:0007206;HP:0002007;HP:0010241;HP:0001869;HP:0008905;HP:0000343;HP:0000319;HP:0000486;HP:0011800;HP:0000494;HP:0002212;HP:0005257;HP:0001943;HP:0001873;HP:0001540;HP:0002384;HP:0001249;HP:0003745;HP:0100543;HP:0003581;HP:0007042;HP:0032051;HP:0003593;HP:0002446;HP:0001428;HP:0001269;HP:0002539;HP:0007206;HP:0001763;HP:0002197;HP:0005280;HP:0001328;HP:0002007;HP:0001540;HP:0005257;HP:0001998;HP:0000028;HP:0000316;HP:0000486;HP:0000729;HP:0002099;HP:0000331;HP:0000154;HP:0040168;HP:0004789;HP:0002119;HP:0005266;HP:0002167;HP:0000256;HP:0001263;HP:0001273;HP:0001053;HP:0001288;HP:0025104;HP:0001538;HP:0012393;HP:0002212;HP:0000752;HP:0002720;HP:0000343;HP:0001249;HP:0001028;HP:0001520;HP:0000957;HP:0000194;HP:0001355;HP:0001999;HP:0000047;HP:0011220;HP:0000494;HP:0001252;HP:0002126	Feeding difficulties;Macrocephaly;Wide anterior fontanel;Short chin;Short distal phalanx of finger;Autosomal dominant inheritance;Hypertelorism;High forehead;Wide mouth;Cafe-au-lait spot;Generalized hypotonia;Cryptorchidism;Open mouth;Thin upper lip vermilion;Deep palmar crease;Intellectual disability;Umbilical hernia;Large for gestational age;Short nose;Depressed nasal bridge;Perisylvian polymicrogyria;Seizure;Decreased circulating IgA level;Hemimegalencephaly;Frontal bossing;Short proximal phalanx of finger;Deep plantar creases;Rhizomelia;Long philtrum;Smooth philtrum;Strabismus;Midface retrusion;Downslanted palpebral fissures;Curly hair;Thoracic hypoplasia;Hypoglycemia;Thrombocytopenia;Diastasis recti;Focal impaired awareness seizure;Intellectual disability;Sporadic;Cognitive impairment;Adult onset;Focal white matter lesions;Focal cortical dysplasia type II;Infantile onset;Astrocytosis;Somatic mutation;Hemiparesis;Cortical dysplasia;Hemimegalencephaly;Pes planus;Generalized-onset seizure;Depressed nasal bridge;Specific learning disability;Frontal bossing;Diastasis recti;Thoracic hypoplasia;Neonatal hypoglycemia;Cryptorchidism;Hypertelorism;Strabismus;Autistic behavior;Asthma;Short chin;Wide mouth;Focal seizures, afebril;Lactose intolerance;Ventriculomegaly;Intestinal polyp;Neurological speech impairment;Macrocephaly;Global developmental delay;Abnormal corpus callosum morphology;Hypopigmented skin patches;Gait disturbance;Capillary malformation;Protuberant abdomen;Allergy;Curly hair;Hyperactivity;Decreased circulating IgA level;Long philtrum;Intellectual disability;Hemangioma;Large for gestational age;Cafe-au-lait spot;Open mouth;Megalencephaly;Abnormal facial shape;Hypospadias;Prominent forehead;Downslanted palpebral fissures;Muscular hypotonia;Polymicrogyria	NA	NA	NA	Expressed in numerous tissues, with highest levels in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;epididymis;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;macula lutea;lymph node;bladder;colon;placenta;aorta;prostate;nasopharynx;breast;optic nerve;	testis - seminiferous tubule;occipital lobe;testis - interstitial;parietal lobe;testis;skeletal muscle;bone marrow;	0.246	E	E	E	E	0.802053821315338	E	Mtor	respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; 	mtor	cardiac muscle cell	decreased size	abnormal	0.9984	1	1	0.9942	1	0.990016	0.9948	0.944166	0.993432	PASS	0	1	0	1	0	chr1	11127836	NA	T	C	1363.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=33.52;AS_ReadPosRankSum=.;AS_SOR=2.073;DP=38;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.36;SOR=2.073	GT:AD:DP:GQ:PL	1/1:0,38:38:99:1377,114,0
chr1	11145001	11145001	C	T	MTOR	exonic	synonymous SNV	NA	MTOR:NM_004958:exon33:c.G4731A:p.A1577A	0.8135	GnomAdExome_AF_eas	314	56	HeterozygousVariant	het	92	45	47	0.510869565217391	1217.64	PASS	NA	[MIM:616638]Smith-Kingsmore syndrome [dominant?];[MIM:607341]Focal cortical dysplasia 2;	601231	Benign	Isolated focal cortical dysplasia type IIb;Isolated focal cortical dysplasia type IIa;Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome	Disease-causing somatic mutation(s) in;Disease-causing somatic mutation(s) in;Disease-causing germline mutation(s) (gain of function) in	Body mass index[25673413;25673413];Corneal curvature[24963161];Heel bone mineral density[28869591;28869591];Beard thickness[26926045];	HP:0011968;HP:0000256;HP:0000260;HP:0000331;HP:0009882;HP:0000006;HP:0000316;HP:0000348;HP:0000154;HP:0000957;HP:0001290;HP:0000028;HP:0000194;HP:0000219;HP:0006191;HP:0001249;HP:0001537;HP:0001520;HP:0003196;HP:0005280;HP:0012650;HP:0001250;HP:0002720;HP:0007206;HP:0002007;HP:0010241;HP:0001869;HP:0008905;HP:0000343;HP:0000319;HP:0000486;HP:0011800;HP:0000494;HP:0002212;HP:0005257;HP:0001943;HP:0001873;HP:0001540;HP:0002384;HP:0001249;HP:0003745;HP:0100543;HP:0003581;HP:0007042;HP:0032051;HP:0003593;HP:0002446;HP:0001428;HP:0001269;HP:0002539;HP:0007206;HP:0001763;HP:0002197;HP:0005280;HP:0001328;HP:0002007;HP:0001540;HP:0005257;HP:0001998;HP:0000028;HP:0000316;HP:0000486;HP:0000729;HP:0002099;HP:0000331;HP:0000154;HP:0040168;HP:0004789;HP:0002119;HP:0005266;HP:0002167;HP:0000256;HP:0001263;HP:0001273;HP:0001053;HP:0001288;HP:0025104;HP:0001538;HP:0012393;HP:0002212;HP:0000752;HP:0002720;HP:0000343;HP:0001249;HP:0001028;HP:0001520;HP:0000957;HP:0000194;HP:0001355;HP:0001999;HP:0000047;HP:0011220;HP:0000494;HP:0001252;HP:0002126	Feeding difficulties;Macrocephaly;Wide anterior fontanel;Short chin;Short distal phalanx of finger;Autosomal dominant inheritance;Hypertelorism;High forehead;Wide mouth;Cafe-au-lait spot;Generalized hypotonia;Cryptorchidism;Open mouth;Thin upper lip vermilion;Deep palmar crease;Intellectual disability;Umbilical hernia;Large for gestational age;Short nose;Depressed nasal bridge;Perisylvian polymicrogyria;Seizure;Decreased circulating IgA level;Hemimegalencephaly;Frontal bossing;Short proximal phalanx of finger;Deep plantar creases;Rhizomelia;Long philtrum;Smooth philtrum;Strabismus;Midface retrusion;Downslanted palpebral fissures;Curly hair;Thoracic hypoplasia;Hypoglycemia;Thrombocytopenia;Diastasis recti;Focal impaired awareness seizure;Intellectual disability;Sporadic;Cognitive impairment;Adult onset;Focal white matter lesions;Focal cortical dysplasia type II;Infantile onset;Astrocytosis;Somatic mutation;Hemiparesis;Cortical dysplasia;Hemimegalencephaly;Pes planus;Generalized-onset seizure;Depressed nasal bridge;Specific learning disability;Frontal bossing;Diastasis recti;Thoracic hypoplasia;Neonatal hypoglycemia;Cryptorchidism;Hypertelorism;Strabismus;Autistic behavior;Asthma;Short chin;Wide mouth;Focal seizures, afebril;Lactose intolerance;Ventriculomegaly;Intestinal polyp;Neurological speech impairment;Macrocephaly;Global developmental delay;Abnormal corpus callosum morphology;Hypopigmented skin patches;Gait disturbance;Capillary malformation;Protuberant abdomen;Allergy;Curly hair;Hyperactivity;Decreased circulating IgA level;Long philtrum;Intellectual disability;Hemangioma;Large for gestational age;Cafe-au-lait spot;Open mouth;Megalencephaly;Abnormal facial shape;Hypospadias;Prominent forehead;Downslanted palpebral fissures;Muscular hypotonia;Polymicrogyria	not_specified	criteria_provided,_single_submitter	Benign	Expressed in numerous tissues, with highest levels in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;epididymis;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;macula lutea;lymph node;bladder;colon;placenta;aorta;prostate;nasopharynx;breast;optic nerve;	testis - seminiferous tubule;occipital lobe;testis - interstitial;parietal lobe;testis;skeletal muscle;bone marrow;	0.246	E	E	E	E	0.802053821315338	E	Mtor	respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; 	mtor	cardiac muscle cell	decreased size	abnormal	0.6859	0.8135	0.8158	0.5537	0.7989	0.547524	0.5459	0.667553	0.614122	PASS	0.75	0.614	365	0.609155	61	chr1	11145001	NA	C	T	1217.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3;AS_FS=1.704;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.24;AS_ReadPosRankSum=1.2;AS_SOR=0.522;BaseQRankSum=3.05;DP=94;ExcessHet=3.0103;FS=1.704;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.24;ReadPosRankSum=1.2;SOR=0.522	GT:AD:DP:GQ:PL	0/1:45,47:92:99:1225,0,990
chr1	11193787	11193787	C	T	ANGPTL7;MTOR	intronic	NA	NA	NA	0.1169	GnomAdGenome_AF_sas	7	3	WT/SomaticVariant	het	59	43	16	0.271186440677966	285.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0567	0.1134	0.1137	0.0578	0.1169	0.096845	0.0507	0.0530718	0.064039	PASS	0	0.197	57	0.144366	35	chr1	11193787	NA	C	T	285.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=4.85;AS_ReadPosRankSum=0.8;AS_SOR=0.507;BaseQRankSum=-1.916;DP=61;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=4.84;ReadPosRankSum=0.819;SOR=0.507	GT:AD:DP:GQ:PL	0/1:43,16:59:99:293,0,1231
chr1	11194951	11194951	T	C	ANGPTL7	exonic	synonymous SNV	NA	ANGPTL7:NM_021146:exon5:c.T969C:p.Y323Y	0.1268	GnomAdGenome_AF_sas	15	3	HeterozygousVariant	het	142	84	58	0.408450704225352	1060.64	PASS	NA	NA	NA	Benign	NA	NA	Beard thickness[26926045];Intraocular pressure[29617998];	NA	NA	NA	NA	NA	Highly and specifically expressed in the cornea where is confined to the stromal layer. {ECO:0000269|PubMed:9727400}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.54	NA	N	N	N	0.186632194206013	N	Angptl7	NA	NA	NA	NA	NA	0.0575	0.1206	0.1212	0.0584	0.1268	0.0984425	0.0511	0.0543848	0.064039	PASS	0.090909	0.16	158	0.144366	35	chr1	11194951	NA	T	C	1060.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=1.35;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.47;AS_ReadPosRankSum=-0.3;AS_SOR=0.859;BaseQRankSum=-1.34;DP=144;ExcessHet=3.0103;FS=1.35;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.47;ReadPosRankSum=-0.262;SOR=0.859	GT:AD:DP:GQ:PL	0/1:84,58:142:99:1068,0,1885
chr1	11228701	11228701	G	A	MTOR	exonic	synonymous SNV	NA	MTOR:NM_004958:exon19:c.C2997T:p.N999N	0.9191	GnomAdExome_AF_eas	574	99	HomozygousVariant	hom	77	0	77	1	2272.06	PASS	NA	[MIM:616638]Smith-Kingsmore syndrome [dominant?];[MIM:607341]Focal cortical dysplasia 2;	601231	Benign	Isolated focal cortical dysplasia type IIb;Isolated focal cortical dysplasia type IIa;Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome	Disease-causing somatic mutation(s) in;Disease-causing somatic mutation(s) in;Disease-causing germline mutation(s) (gain of function) in	Body mass index[25673413;25673413];Corneal curvature[24963161];Heel bone mineral density[28869591;28869591];Beard thickness[26926045];	HP:0011968;HP:0000256;HP:0000260;HP:0000331;HP:0009882;HP:0000006;HP:0000316;HP:0000348;HP:0000154;HP:0000957;HP:0001290;HP:0000028;HP:0000194;HP:0000219;HP:0006191;HP:0001249;HP:0001537;HP:0001520;HP:0003196;HP:0005280;HP:0012650;HP:0001250;HP:0002720;HP:0007206;HP:0002007;HP:0010241;HP:0001869;HP:0008905;HP:0000343;HP:0000319;HP:0000486;HP:0011800;HP:0000494;HP:0002212;HP:0005257;HP:0001943;HP:0001873;HP:0001540;HP:0002384;HP:0001249;HP:0003745;HP:0100543;HP:0003581;HP:0007042;HP:0032051;HP:0003593;HP:0002446;HP:0001428;HP:0001269;HP:0002539;HP:0007206;HP:0001763;HP:0002197;HP:0005280;HP:0001328;HP:0002007;HP:0001540;HP:0005257;HP:0001998;HP:0000028;HP:0000316;HP:0000486;HP:0000729;HP:0002099;HP:0000331;HP:0000154;HP:0040168;HP:0004789;HP:0002119;HP:0005266;HP:0002167;HP:0000256;HP:0001263;HP:0001273;HP:0001053;HP:0001288;HP:0025104;HP:0001538;HP:0012393;HP:0002212;HP:0000752;HP:0002720;HP:0000343;HP:0001249;HP:0001028;HP:0001520;HP:0000957;HP:0000194;HP:0001355;HP:0001999;HP:0000047;HP:0011220;HP:0000494;HP:0001252;HP:0002126	Feeding difficulties;Macrocephaly;Wide anterior fontanel;Short chin;Short distal phalanx of finger;Autosomal dominant inheritance;Hypertelorism;High forehead;Wide mouth;Cafe-au-lait spot;Generalized hypotonia;Cryptorchidism;Open mouth;Thin upper lip vermilion;Deep palmar crease;Intellectual disability;Umbilical hernia;Large for gestational age;Short nose;Depressed nasal bridge;Perisylvian polymicrogyria;Seizure;Decreased circulating IgA level;Hemimegalencephaly;Frontal bossing;Short proximal phalanx of finger;Deep plantar creases;Rhizomelia;Long philtrum;Smooth philtrum;Strabismus;Midface retrusion;Downslanted palpebral fissures;Curly hair;Thoracic hypoplasia;Hypoglycemia;Thrombocytopenia;Diastasis recti;Focal impaired awareness seizure;Intellectual disability;Sporadic;Cognitive impairment;Adult onset;Focal white matter lesions;Focal cortical dysplasia type II;Infantile onset;Astrocytosis;Somatic mutation;Hemiparesis;Cortical dysplasia;Hemimegalencephaly;Pes planus;Generalized-onset seizure;Depressed nasal bridge;Specific learning disability;Frontal bossing;Diastasis recti;Thoracic hypoplasia;Neonatal hypoglycemia;Cryptorchidism;Hypertelorism;Strabismus;Autistic behavior;Asthma;Short chin;Wide mouth;Focal seizures, afebril;Lactose intolerance;Ventriculomegaly;Intestinal polyp;Neurological speech impairment;Macrocephaly;Global developmental delay;Abnormal corpus callosum morphology;Hypopigmented skin patches;Gait disturbance;Capillary malformation;Protuberant abdomen;Allergy;Curly hair;Hyperactivity;Decreased circulating IgA level;Long philtrum;Intellectual disability;Hemangioma;Large for gestational age;Cafe-au-lait spot;Open mouth;Megalencephaly;Abnormal facial shape;Hypospadias;Prominent forehead;Downslanted palpebral fissures;Muscular hypotonia;Polymicrogyria	NA	NA	NA	Expressed in numerous tissues, with highest levels in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;epididymis;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;macula lutea;lymph node;bladder;colon;placenta;aorta;prostate;nasopharynx;breast;optic nerve;	testis - seminiferous tubule;occipital lobe;testis - interstitial;parietal lobe;testis;skeletal muscle;bone marrow;	0.246	E	E	E	E	0.802053821315338	E	Mtor	respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; 	mtor	cardiac muscle cell	decreased size	abnormal	0.7512	0.9191	0.9195	0.6391	0.9161	0.700479	0.6176	0.733134	0.692118	PASS	0.8	0.84	207	0.834507	39	chr1	11228701	NA	G	A	2272.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.51;AS_ReadPosRankSum=.;AS_SOR=1.463;DP=78;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.51;SOR=1.463	GT:AD:DP:GQ:PL	1/1:0,77:77:99:2286,231,0
chr1	11241657	11241657	A	G	MTOR	exonic	synonymous SNV	NA	MTOR:NM_004958:exon10:c.T1437C:p.D479D	0.8789	GnomAdExome_AF_eas	482	82	HomozygousVariant	hom	60	0	60	1	1659.06	PASS	NA	[MIM:616638]Smith-Kingsmore syndrome [dominant?];[MIM:607341]Focal cortical dysplasia 2;	601231	Benign	Isolated focal cortical dysplasia type IIb;Isolated focal cortical dysplasia type IIa;Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome	Disease-causing somatic mutation(s) in;Disease-causing somatic mutation(s) in;Disease-causing germline mutation(s) (gain of function) in	Body mass index[25673413;25673413];Corneal curvature[24963161];Heel bone mineral density[28869591;28869591];Beard thickness[26926045];	HP:0011968;HP:0000256;HP:0000260;HP:0000331;HP:0009882;HP:0000006;HP:0000316;HP:0000348;HP:0000154;HP:0000957;HP:0001290;HP:0000028;HP:0000194;HP:0000219;HP:0006191;HP:0001249;HP:0001537;HP:0001520;HP:0003196;HP:0005280;HP:0012650;HP:0001250;HP:0002720;HP:0007206;HP:0002007;HP:0010241;HP:0001869;HP:0008905;HP:0000343;HP:0000319;HP:0000486;HP:0011800;HP:0000494;HP:0002212;HP:0005257;HP:0001943;HP:0001873;HP:0001540;HP:0002384;HP:0001249;HP:0003745;HP:0100543;HP:0003581;HP:0007042;HP:0032051;HP:0003593;HP:0002446;HP:0001428;HP:0001269;HP:0002539;HP:0007206;HP:0001763;HP:0002197;HP:0005280;HP:0001328;HP:0002007;HP:0001540;HP:0005257;HP:0001998;HP:0000028;HP:0000316;HP:0000486;HP:0000729;HP:0002099;HP:0000331;HP:0000154;HP:0040168;HP:0004789;HP:0002119;HP:0005266;HP:0002167;HP:0000256;HP:0001263;HP:0001273;HP:0001053;HP:0001288;HP:0025104;HP:0001538;HP:0012393;HP:0002212;HP:0000752;HP:0002720;HP:0000343;HP:0001249;HP:0001028;HP:0001520;HP:0000957;HP:0000194;HP:0001355;HP:0001999;HP:0000047;HP:0011220;HP:0000494;HP:0001252;HP:0002126	Feeding difficulties;Macrocephaly;Wide anterior fontanel;Short chin;Short distal phalanx of finger;Autosomal dominant inheritance;Hypertelorism;High forehead;Wide mouth;Cafe-au-lait spot;Generalized hypotonia;Cryptorchidism;Open mouth;Thin upper lip vermilion;Deep palmar crease;Intellectual disability;Umbilical hernia;Large for gestational age;Short nose;Depressed nasal bridge;Perisylvian polymicrogyria;Seizure;Decreased circulating IgA level;Hemimegalencephaly;Frontal bossing;Short proximal phalanx of finger;Deep plantar creases;Rhizomelia;Long philtrum;Smooth philtrum;Strabismus;Midface retrusion;Downslanted palpebral fissures;Curly hair;Thoracic hypoplasia;Hypoglycemia;Thrombocytopenia;Diastasis recti;Focal impaired awareness seizure;Intellectual disability;Sporadic;Cognitive impairment;Adult onset;Focal white matter lesions;Focal cortical dysplasia type II;Infantile onset;Astrocytosis;Somatic mutation;Hemiparesis;Cortical dysplasia;Hemimegalencephaly;Pes planus;Generalized-onset seizure;Depressed nasal bridge;Specific learning disability;Frontal bossing;Diastasis recti;Thoracic hypoplasia;Neonatal hypoglycemia;Cryptorchidism;Hypertelorism;Strabismus;Autistic behavior;Asthma;Short chin;Wide mouth;Focal seizures, afebril;Lactose intolerance;Ventriculomegaly;Intestinal polyp;Neurological speech impairment;Macrocephaly;Global developmental delay;Abnormal corpus callosum morphology;Hypopigmented skin patches;Gait disturbance;Capillary malformation;Protuberant abdomen;Allergy;Curly hair;Hyperactivity;Decreased circulating IgA level;Long philtrum;Intellectual disability;Hemangioma;Large for gestational age;Cafe-au-lait spot;Open mouth;Megalencephaly;Abnormal facial shape;Hypospadias;Prominent forehead;Downslanted palpebral fissures;Muscular hypotonia;Polymicrogyria	not_specified	criteria_provided,_single_submitter	Benign	Expressed in numerous tissues, with highest levels in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;epididymis;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;macula lutea;lymph node;bladder;colon;placenta;aorta;prostate;nasopharynx;breast;optic nerve;	testis - seminiferous tubule;occipital lobe;testis - interstitial;parietal lobe;testis;skeletal muscle;bone marrow;	0.246	E	E	E	E	0.802053821315338	E	Mtor	respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; 	mtor	cardiac muscle cell	decreased size	abnormal	0.7251	0.8789	0.88	0.6011	0.8704	0.639577	0.5853	0.709512	0.661741	PASS	0.8	0.766	274	0.75	49	chr1	11241657	NA	A	G	1659.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.65;AS_ReadPosRankSum=.;AS_SOR=0.831;DP=64;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.65;SOR=0.831	GT:AD:DP:GQ:PL	1/1:0,60:60:99:1673,180,0
chr1	11243096	11243096	C	A	MTOR	intronic	NA	NA	NA	0.1172	GnomAdGenome_AF_sas	10	3	HeterozygousVariant	het	50	26	24	0.48	559.64	PASS	NA	[MIM:616638]Smith-Kingsmore syndrome [dominant?];[MIM:607341]Focal cortical dysplasia 2;	601231	NA	Isolated focal cortical dysplasia type IIb;Isolated focal cortical dysplasia type IIa;Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome	Disease-causing somatic mutation(s) in;Disease-causing somatic mutation(s) in;Disease-causing germline mutation(s) (gain of function) in	Body mass index[25673413;25673413];Corneal curvature[24963161];Heel bone mineral density[28869591;28869591];Beard thickness[26926045];	HP:0011968;HP:0000256;HP:0000260;HP:0000331;HP:0009882;HP:0000006;HP:0000316;HP:0000348;HP:0000154;HP:0000957;HP:0001290;HP:0000028;HP:0000194;HP:0000219;HP:0006191;HP:0001249;HP:0001537;HP:0001520;HP:0003196;HP:0005280;HP:0012650;HP:0001250;HP:0002720;HP:0007206;HP:0002007;HP:0010241;HP:0001869;HP:0008905;HP:0000343;HP:0000319;HP:0000486;HP:0011800;HP:0000494;HP:0002212;HP:0005257;HP:0001943;HP:0001873;HP:0001540;HP:0002384;HP:0001249;HP:0003745;HP:0100543;HP:0003581;HP:0007042;HP:0032051;HP:0003593;HP:0002446;HP:0001428;HP:0001269;HP:0002539;HP:0007206;HP:0001763;HP:0002197;HP:0005280;HP:0001328;HP:0002007;HP:0001540;HP:0005257;HP:0001998;HP:0000028;HP:0000316;HP:0000486;HP:0000729;HP:0002099;HP:0000331;HP:0000154;HP:0040168;HP:0004789;HP:0002119;HP:0005266;HP:0002167;HP:0000256;HP:0001263;HP:0001273;HP:0001053;HP:0001288;HP:0025104;HP:0001538;HP:0012393;HP:0002212;HP:0000752;HP:0002720;HP:0000343;HP:0001249;HP:0001028;HP:0001520;HP:0000957;HP:0000194;HP:0001355;HP:0001999;HP:0000047;HP:0011220;HP:0000494;HP:0001252;HP:0002126	Feeding difficulties;Macrocephaly;Wide anterior fontanel;Short chin;Short distal phalanx of finger;Autosomal dominant inheritance;Hypertelorism;High forehead;Wide mouth;Cafe-au-lait spot;Generalized hypotonia;Cryptorchidism;Open mouth;Thin upper lip vermilion;Deep palmar crease;Intellectual disability;Umbilical hernia;Large for gestational age;Short nose;Depressed nasal bridge;Perisylvian polymicrogyria;Seizure;Decreased circulating IgA level;Hemimegalencephaly;Frontal bossing;Short proximal phalanx of finger;Deep plantar creases;Rhizomelia;Long philtrum;Smooth philtrum;Strabismus;Midface retrusion;Downslanted palpebral fissures;Curly hair;Thoracic hypoplasia;Hypoglycemia;Thrombocytopenia;Diastasis recti;Focal impaired awareness seizure;Intellectual disability;Sporadic;Cognitive impairment;Adult onset;Focal white matter lesions;Focal cortical dysplasia type II;Infantile onset;Astrocytosis;Somatic mutation;Hemiparesis;Cortical dysplasia;Hemimegalencephaly;Pes planus;Generalized-onset seizure;Depressed nasal bridge;Specific learning disability;Frontal bossing;Diastasis recti;Thoracic hypoplasia;Neonatal hypoglycemia;Cryptorchidism;Hypertelorism;Strabismus;Autistic behavior;Asthma;Short chin;Wide mouth;Focal seizures, afebril;Lactose intolerance;Ventriculomegaly;Intestinal polyp;Neurological speech impairment;Macrocephaly;Global developmental delay;Abnormal corpus callosum morphology;Hypopigmented skin patches;Gait disturbance;Capillary malformation;Protuberant abdomen;Allergy;Curly hair;Hyperactivity;Decreased circulating IgA level;Long philtrum;Intellectual disability;Hemangioma;Large for gestational age;Cafe-au-lait spot;Open mouth;Megalencephaly;Abnormal facial shape;Hypospadias;Prominent forehead;Downslanted palpebral fissures;Muscular hypotonia;Polymicrogyria	NA	NA	NA	Expressed in numerous tissues, with highest levels in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;epididymis;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;bile duct;head and neck;mammary gland;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;macula lutea;lymph node;bladder;colon;placenta;aorta;prostate;nasopharynx;breast;optic nerve;	testis - seminiferous tubule;occipital lobe;testis - interstitial;parietal lobe;testis;skeletal muscle;bone marrow;	0.246	E	E	E	E	0.802053821315338	E	Mtor	respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; 	mtor	cardiac muscle cell	decreased size	abnormal	0.0566	0.1137	0.1141	0.0583	0.1172	0.0970447	0.0512	0.0534081	0.06486	PASS	0	0.157	116	0.140845	34	chr1	11243096	NA	C	A	559.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.2;AS_ReadPosRankSum=0.7;AS_SOR=0.728;BaseQRankSum=-0.045;DP=51;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.19;ReadPosRankSum=0.74;SOR=0.728	GT:AD:DP:GQ:PL	0/1:26,24:50:99:567,0,628
chr1	11501536	11501536	G	A	DISP3	exonic	nonsynonymous SNV	NA	DISP3:NM_020780:exon2:c.G544A:p.G182S	0.6711	GnomAdGenome_AF_ami	75	14	HeterozygousVariant	het	109	54	55	0.504587155963303	1373.64	PASS	4.156	NA	611251	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in brain and testis (PubMed:15645143). {ECO:0000269|PubMed:15645143}.;	T	T	B	B	NA	P	NA	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Disp3	NA	NA	NA	NA	NA	0.5487	0.6643	0.661	0.4946	0.6711	0.371805	0.513	0.532393	0.561576	PASS	0.65	0.323	227	0.299296	57	chr1	11501536	NA	G	A	1373.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.61;AS_ReadPosRankSum=1.3;AS_SOR=0.657;BaseQRankSum=0.019;DP=109;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.6;ReadPosRankSum=1.33;SOR=0.657	GT:AD:DP:GQ:PL	0/1:54,55:109:99:1381,0,1321
chr1	11535146	11535146	A	G	DISP3	intronic	NA	NA	NA	0.2391	GnomAdExome_AF_eas	9	6	HomozygousVariant	hom	63	0	63	1	1847.06	PASS	NA	NA	611251	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in brain and testis (PubMed:15645143). {ECO:0000269|PubMed:15645143}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Disp3	NA	NA	NA	NA	NA	0.1409	0.2391	0.2404	0.1373	0.2372	0.175919	0.1262	0.113239	0.138752	PASS	0	0.205	68	0.193662	43	chr1	11535146	NA	A	G	1847.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.32;AS_ReadPosRankSum=.;AS_SOR=1.27;DP=68;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.32;SOR=1.27	GT:AD:DP:GQ:PL	1/1:0,63:63:99:1861,189,0
chr1	11648679	11648679	T	C	FBXO2	UTR3	NA	NM_012168:c.*15A>G	NA	0.8278	GnomAdGenome_AF_ami	123	35	HeterozygousVariant	het	68	35	33	0.485294117647059	784.64	PASS	NA	NA	607112	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;lacrimal gland;testis;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;pancreas;islets of Langerhans;visual apparatus;cervix;hippocampus;spleen;liver;bone;germinal center;parathyroid;brain;blood;heart;lung;ovary;frontal lobe;colon;placenta;prostate;optic nerve;hypothalamus;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;cerebellum peduncles;pons;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;hypothalamus;medulla oblongata;thalamus;	NA	N	N	S	N	0.805446806468139	E	Fbxo2	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	NA	NA	NA	NA	0.6492	0.7551	0.7543	0.623	0.8278	0.504992	0.6284	0.0001537	0.627258	PASS	0	0.467	240	0.471631	63	chr1	11648679	NA	T	C	784.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.54;AS_ReadPosRankSum=-0.1;AS_SOR=0.61;BaseQRankSum=0.724;DP=72;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.54;ReadPosRankSum=-0.068;SOR=0.61	GT:AD:DP:GQ:PL	0/1:35,33:68:99:792,0,752
chr1	11650504	11650504	T	G	FBXO2	exonic	nonsynonymous SNV	NA	FBXO2:NM_012168:exon2:c.A353C:p.K118T	0.4722	GnomAdExome_AF_eas	47	14	HeterozygousVariant	het	60	29	31	0.516666666666667	687.64	PASS	25.7	NA	607112	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	D	D	N	P	M	T	N	T	T	T	NA	D	T	T	T	D	.;	N	N	F-box associated (FBA) domain|F-box associated (FBA) domain|F-box associated (FBA) domain	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;lacrimal gland;testis;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;pancreas;islets of Langerhans;visual apparatus;cervix;hippocampus;spleen;liver;bone;germinal center;parathyroid;brain;blood;heart;lung;ovary;frontal lobe;colon;placenta;prostate;optic nerve;hypothalamus;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;cerebellum peduncles;pons;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;hypothalamus;medulla oblongata;thalamus;	NA	N	N	S	N	0.805446806468139	E	Fbxo2	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	NA	NA	NA	NA	0.2211	0.4722	0.4724	0.1952	0.4683	0.24361	0.1834	0.202643	0.214286	PASS	0.261364	0.217	257	0.253521	44	chr1	11650504	NA	T	G	687.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.47;AS_ReadPosRankSum=-0.4;AS_SOR=0.673;BaseQRankSum=-0.719;DP=62;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.46;ReadPosRankSum=-0.333;SOR=0.673	GT:AD:DP:GQ:PL	0/1:29,31:60:99:695,0,674
chr1	11654311	11654311	T	G	FBXO2	intronic	NA	NA	NA	0.9019	GnomAdExome_AF_amr	474	85	HomozygousVariant	hom	23	0	23	1	642.06	PASS	NA	NA	607112	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0002	0.004	Medium	Medium	Medium	epididymis;skin;stomach;lacrimal gland;testis;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;pancreas;islets of Langerhans;visual apparatus;cervix;hippocampus;spleen;liver;bone;germinal center;parathyroid;brain;blood;heart;lung;ovary;frontal lobe;colon;placenta;prostate;optic nerve;hypothalamus;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;cerebellum peduncles;pons;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;hypothalamus;medulla oblongata;thalamus;	NA	N	N	S	N	0.805446806468139	E	Fbxo2	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	NA	NA	NA	NA	0.8093	0.9019	0.9018	0.8003	0.8442	0.799121	0.8139	0.218387	0.810185	PASS	0	0.768	261	0.767606	48	chr1	11654311	NA	T	G	642.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.91;AS_ReadPosRankSum=.;AS_SOR=0.776;DP=23;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.92;SOR=0.776	GT:AD:DP:GQ:PL	1/1:0,23:23:69:656,69,0
chr1	11668928	11668928	C	T	FBXO6	exonic	synonymous SNV	NA	FBXO6:NM_018438:exon2:c.C270T:p.R90R	0.0007	GnomAdExome_AF_afr			HeterozygousVariant	het	71	37	34	0.47887323943662	770.64	PASS	NA	NA	605647	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.862	NA	N	N	N	0.654455012647457	E	Fbxo6	NA	NA	NA	NA	NA	0.00005186	0.0007	0.0008	0.0002	0.0006	0	0.000077	0.0000388	0		0					chr1	11668928	NA	C	T	770.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0.931;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.86;AS_ReadPosRankSum=1.2;AS_SOR=0.922;BaseQRankSum=-0.534;DP=75;ExcessHet=3.0103;FS=0.931;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.85;ReadPosRankSum=1.28;SOR=0.922	GT:AD:DP:GQ:PL	0/1:37,34:71:99:778,0,918
chr1	11767247	11767247	A	G	C1orf167	exonic	synonymous SNV	NA	C1orf167:NM_001010881:exon4:c.A1326G:p.P442P	1	GnomAdExome_AF_eas	585	142	HomozygousVariant	hom	110	0	110	1	2956.06	PASS	NA	NA	NA	Benign	NA	NA	Pulse pressure x alcohol consumption interaction (2df test)[29912962];Schizophrenia[27922604];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Midregional pro atrial natriuretic peptide levels[29237677];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	Medium	lung;choroid;larynx;ovary;placenta;prostate;germinal center;testis;brain;unclassifiable (Anatomical System);visual apparatus;	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.9937	1	1	0.9697	1	0.968051	0	0.305526	0		0	1	0	1	0	chr1	11767247	NA	A	G	2956.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.87;AS_ReadPosRankSum=.;AS_SOR=0.767;DP=112;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.87;SOR=0.767	GT:AD:DP:GQ:PL	1/1:0,110:110:99:2970,329,0
chr1	11771538	11771538	G	A	C1orf167	exonic	nonsynonymous SNV	NA	C1orf167:NM_001010881:exon7:c.G1712A:p.R571K	0.1065	GnomAdExome_AF_sas	6	2	HeterozygousVariant	het	61	27	34	0.557377049180328	770.64	PASS	2.391	NA	NA	Benign	NA	NA	Pulse pressure x alcohol consumption interaction (2df test)[29912962];Schizophrenia[27922604];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Midregional pro atrial natriuretic peptide levels[29237677];	NA	NA	NA	NA	NA	NA	T	T	NA	NA	NA	N	L	T	N	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	lung;choroid;larynx;ovary;placenta;prostate;germinal center;testis;brain;unclassifiable (Anatomical System);visual apparatus;	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.066	0.1065	0.1081	0.0659	0.0947	0.0579073	0	0.0201744	0		0	0.086	89	0.091549	22	chr1	11771538	NA	G	A	770.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=3.494;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.64;AS_ReadPosRankSum=0.4;AS_SOR=1.041;BaseQRankSum=-0.618;DP=63;ExcessHet=3.0103;FS=3.494;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.63;ReadPosRankSum=0.472;SOR=1.041	GT:AD:DP:GQ:PL	0/1:27,34:61:99:778,0,619
chr1	11772232	11772232	C	A	C1orf167	exonic	nonsynonymous SNV	NA	C1orf167:NM_001010881:exon8:c.C1961A:p.P654H	0.2439	GnomAdExome_AF_sas	28	7	HeterozygousVariant	het	42	21	21	0.5	417.64	PASS	13.78	NA	NA	Benign	NA	NA	Pulse pressure x alcohol consumption interaction (2df test)[29912962];Schizophrenia[27922604];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Midregional pro atrial natriuretic peptide levels[29237677];	NA	NA	NA	NA	NA	NA	D	D	NA	NA	NA	P	L	T	D	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	lung;choroid;larynx;ovary;placenta;prostate;germinal center;testis;brain;unclassifiable (Anatomical System);visual apparatus;	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.1583	0.2439	0.2435	0.122	0.2407	0.122005	0	0.049262	0		0	0.223	166	0.225352	50	chr1	11772232	NA	C	A	417.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.95;AS_ReadPosRankSum=2;AS_SOR=0.884;BaseQRankSum=-1.753;DP=43;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.94;ReadPosRankSum=2.02;SOR=0.884	GT:AD:DP:GQ:PL	0/1:21,21:42:99:425,0,503
chr1	11779794	11779794	T	-	C1orf167	intronic	NA	NA	NA	0.2458	GnomAdExome_AF_sas	18	6	HeterozygousVariant	het	50	26	24	0.48	695.6	PASS	NA	NA	NA	NA	NA	NA	Pulse pressure x alcohol consumption interaction (2df test)[29912962];Schizophrenia[27922604];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Midregional pro atrial natriuretic peptide levels[29237677];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	Medium	lung;choroid;larynx;ovary;placenta;prostate;germinal center;testis;brain;unclassifiable (Anatomical System);visual apparatus;	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.1578	0.2458	0.2467	0.1222	0.2407	0.120807	0	0.0040103	0		0	0.248	113	0.215827	48	chr1	11779793	NA	CT	C	695.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=4.291;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.92;AS_ReadPosRankSum=-1.9;AS_SOR=1.407;BaseQRankSum=0.272;DP=52;ExcessHet=3.0103;FS=4.291;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.91;ReadPosRankSum=-1.837;SOR=1.407	GT:AD:DP:GQ:PL	0/1:26,24:50:99:703,0,753
chr1	11779914	11779914	C	T	C1orf167	exonic	nonsynonymous SNV	NA	C1orf167:NM_001010881:exon13:c.C2764T:p.R922W	0.0947	GnomAdGenome_AF_ami	8	2	HeterozygousVariant	het	93	52	41	0.440860215053763	889.64	PASS	21	NA	NA	Benign	NA	NA	Pulse pressure x alcohol consumption interaction (2df test)[29912962];Schizophrenia[27922604];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Midregional pro atrial natriuretic peptide levels[29237677];	NA	NA	NA	NA	NA	NA	D	D	P	B	N	N	L	T	D	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	lung;choroid;larynx;ovary;placenta;prostate;germinal center;testis;brain;unclassifiable (Anatomical System);visual apparatus;	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0651	0.0944	0.0963	0.0688	0.0947	0.0563099	0	0.0026894	0		0	0.086	85	0.084507	20	chr1	11779914	NA	C	T	889.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.57;AS_ReadPosRankSum=3.2;AS_SOR=0.685;BaseQRankSum=0.146;DP=96;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.57;ReadPosRankSum=3.21;SOR=0.685	GT:AD:DP:GQ:PL	0/1:52,41:93:99:897,0,2029
chr1	11779915	11779915	G	A	C1orf167	exonic	nonsynonymous SNV	NA	C1orf167:NM_001010881:exon13:c.G2765A:p.R922Q	0.2512	GnomAdExome_AF_sas	34	8	HeterozygousVariant	het	93	42	51	0.548387096774194	1141.64	PASS	12.5	NA	NA	Benign	NA	NA	Pulse pressure x alcohol consumption interaction (2df test)[29912962];Schizophrenia[27922604];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Midregional pro atrial natriuretic peptide levels[29237677];	NA	NA	NA	NA	NA	NA	D	D	P	B	N	P	L	T	N	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	lung;choroid;larynx;ovary;placenta;prostate;germinal center;testis;brain;unclassifiable (Anatomical System);visual apparatus;	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.161	0.2512	0.2516	0.1318	0.2407	0.135184	0	0.0001153	0		0	0.237	211	0.232394	50	chr1	11779915	NA	G	A	1141.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.28;AS_ReadPosRankSum=-3;AS_SOR=0.7;BaseQRankSum=-1.252;DP=95;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.28;ReadPosRankSum=-2.99;SOR=0.7	GT:AD:DP:GQ:PL	0/1:42,51:93:99:1149,0,1596
chr1	11779941	11779941	T	C	C1orf167	exonic	nonsynonymous SNV	NA	C1orf167:NM_001010881:exon13:c.T2791C:p.W931R	0.9978	GnomAdGenome_AF_eas	551	134	HomozygousVariant	hom	83	0	83	1	2363.06	PASS	0.232	NA	NA	Benign	NA	NA	Pulse pressure x alcohol consumption interaction (2df test)[29912962];Schizophrenia[27922604];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Midregional pro atrial natriuretic peptide levels[29237677];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	lung;choroid;larynx;ovary;placenta;prostate;germinal center;testis;brain;unclassifiable (Anatomical System);visual apparatus;	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.9524	0.9972	0.9964	0.8669	0.9978	0.879792	0	0.0001153	0		0	0.968	33	0.975177	7	chr1	11779941	NA	T	C	2363.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.47;AS_ReadPosRankSum=.;AS_SOR=1.048;DP=85;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.47;SOR=1.048	GT:AD:DP:GQ:PL	1/1:0,83:83:99:2377,248,0
chr1	11784397	11784397	A	C	C1orf167	exonic	nonsynonymous SNV	NA	C1orf167:NM_001010881:exon15:c.A3229C:p.K1077Q	0.1002	GnomAdExome_AF_sas	5	2	HeterozygousVariant	het	26	16	10	0.384615384615385	229.64	PASS	0.303	NA	NA	Benign	NA	NA	Pulse pressure x alcohol consumption interaction (2df test)[29912962];Schizophrenia[27922604];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Midregional pro atrial natriuretic peptide levels[29237677];	NA	NA	NA	NA	NA	NA	D	T	B	B	NA	N	N	T	N	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	lung;choroid;larynx;ovary;placenta;prostate;germinal center;testis;brain;unclassifiable (Anatomical System);visual apparatus;	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0702	0.1002	0.1016	0.0754	0.0956	0.0595048	0	0.0220372	0		0	0.082	86	0.088652	21	chr1	11784397	NA	A	C	229.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.85;AS_ReadPosRankSum=-1.6;AS_SOR=0.495;BaseQRankSum=-0.248;DP=28;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.83;ReadPosRankSum=-1.582;SOR=0.495	GT:AD:DP:GQ:PL	0/1:16,10:26:99:237,0,445
chr1	11787379	11787379	T	C	MTHFR	UTR3	NA	NM_005957:c.*3301A>G;NM_001330358:c.*3301A>G	NA	0.095	GnomAdExome_AF_sas	2	2	HeterozygousVariant	het	45	22	23	0.511111111111111	508.64	PASS	NA	[MIM:236250]Methylenetetrahydrofolate reductase deficiency;[MIM:601367]Ischemic stroke;[MIM:601634]Neural tube defects, folate-sensitive;[MIM:181500]Schizophrenia;	607093	NA	Homocystinuria due to methylene tetrahydrofolate reductase deficiency;Upper thoracic spina bifida cystica;Cervicothoracic spina bifida cystica;Cervical spina bifida cystica;Lumbosacral spina bifida cystica;Thoracolumbosacral spina bifida cystica;Total spina bifida cystica;Upper thoracic spina bifida aperta;Thoracolumbosacral spina bifida aperta;Lumbosacral spina bifida aperta;Cervical spina bifida aperta;Cervicothoracic spina bifida aperta;Total spina bifida aperta;Isolated anencephaly/exencephaly;Methotrexate toxicity or dose selection	Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Biomarker tested in	Systolic blood pressure[19430483;27618452;28739976;27618447];Diastolic blood pressure (cigarette smoking interaction)[29455858;29455858];Moyamoya disease[29273593];Serum folate levels[29953918];Atrial fibrillation[19597492];Diastolic blood pressure[29615537;27618452;28739976];High altitude adaptation[28373541];Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Mean arterial pressure[27618448];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Midregional pro atrial natriuretic peptide levels[29237677];Coronary artery disease[29212778];Homocysteine levels[23824729;23824729;20031578];Systolic blood pressure (cigarette smoking interaction)[29455858;29455858];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Tuberculosis[29036319];Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Blood pressure[21909110];Folate pathway vitamin levels[19744961];	HP:0000006;HP:0007086;HP:0000738;HP:0001425;HP:0100753;HP:0000746;HP:0410291;HP:0002353;HP:0001907;HP:0002204;HP:0011463;HP:0002625;HP:0004419;HP:0005305;HP:0000006;HP:0002160;HP:0000007;HP:0000708;HP:0001263;HP:0001288;HP:0001324;HP:0002156;HP:0003401;HP:0001250;HP:0001297;HP:0000252;HP:0002311;HP:0001939;HP:0010301;HP:0000007	Autosomal dominant inheritance;Social and occupational deterioration;Hallucinations;Heterogeneous;Schizophrenia;Delusions;Negativism;EEG abnormality;Thromboembolism;Pulmonary embolism;Childhood onset;Deep venous thrombosis;Recurrent thrombophlebitis;Cerebral venous thrombosis;Autosomal dominant inheritance;Hyperhomocystinemia;Autosomal recessive inheritance;Behavioral abnormality;Global developmental delay;Gait disturbance;Muscle weakness;Homocystinuria;Paresthesia;Seizure;Stroke;Microcephaly;Incoordination;Abnormality of metabolism/homeostasis;Spinal dysraphism;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0	High	Medium	Medium	NA	NA	0.21	N	N	N	N	0.999914092685434	E	Mthfr	liver/biliary system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; skeleton phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; 	NA	NA	NA	NA	0.0649	0.095	0.0964	0.0716	0.0944	0.0597045	0	0.0214616	0.060855	PASS	0	0.079	43	0.084507	20	chr1	11787379	NA	T	C	508.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=2.597;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.31;AS_ReadPosRankSum=-0.1;AS_SOR=0.352;BaseQRankSum=-0.572;DP=45;ExcessHet=3.0103;FS=2.597;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.3;ReadPosRankSum=-0.091;SOR=0.352	GT:AD:DP:GQ:PL	0/1:22,23:45:99:516,0,529
chr1	11788082	11788082	G	A	MTHFR	UTR3	NA	NM_005957:c.*2598C>T;NM_001330358:c.*2598C>T	NA	0.2669	GnomAdExome_AF_sas	20	6	HeterozygousVariant	het	58	21	37	0.637931034482759	942.64	PASS	NA	[MIM:236250]Methylenetetrahydrofolate reductase deficiency;[MIM:601367]Ischemic stroke;[MIM:601634]Neural tube defects, folate-sensitive;[MIM:181500]Schizophrenia;	607093	NA	Homocystinuria due to methylene tetrahydrofolate reductase deficiency;Upper thoracic spina bifida cystica;Cervicothoracic spina bifida cystica;Cervical spina bifida cystica;Lumbosacral spina bifida cystica;Thoracolumbosacral spina bifida cystica;Total spina bifida cystica;Upper thoracic spina bifida aperta;Thoracolumbosacral spina bifida aperta;Lumbosacral spina bifida aperta;Cervical spina bifida aperta;Cervicothoracic spina bifida aperta;Total spina bifida aperta;Isolated anencephaly/exencephaly;Methotrexate toxicity or dose selection	Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Biomarker tested in	Systolic blood pressure[19430483;27618452;28739976;27618447];Diastolic blood pressure (cigarette smoking interaction)[29455858;29455858];Moyamoya disease[29273593];Serum folate levels[29953918];Atrial fibrillation[19597492];Diastolic blood pressure[29615537;27618452;28739976];High altitude adaptation[28373541];Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Mean arterial pressure[27618448];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Midregional pro atrial natriuretic peptide levels[29237677];Coronary artery disease[29212778];Homocysteine levels[23824729;23824729;20031578];Systolic blood pressure (cigarette smoking interaction)[29455858;29455858];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Tuberculosis[29036319];Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Blood pressure[21909110];Folate pathway vitamin levels[19744961];	HP:0000006;HP:0007086;HP:0000738;HP:0001425;HP:0100753;HP:0000746;HP:0410291;HP:0002353;HP:0001907;HP:0002204;HP:0011463;HP:0002625;HP:0004419;HP:0005305;HP:0000006;HP:0002160;HP:0000007;HP:0000708;HP:0001263;HP:0001288;HP:0001324;HP:0002156;HP:0003401;HP:0001250;HP:0001297;HP:0000252;HP:0002311;HP:0001939;HP:0010301;HP:0000007	Autosomal dominant inheritance;Social and occupational deterioration;Hallucinations;Heterogeneous;Schizophrenia;Delusions;Negativism;EEG abnormality;Thromboembolism;Pulmonary embolism;Childhood onset;Deep venous thrombosis;Recurrent thrombophlebitis;Cerebral venous thrombosis;Autosomal dominant inheritance;Hyperhomocystinemia;Autosomal recessive inheritance;Behavioral abnormality;Global developmental delay;Gait disturbance;Muscle weakness;Homocystinuria;Paresthesia;Seizure;Stroke;Microcephaly;Incoordination;Abnormality of metabolism/homeostasis;Spinal dysraphism;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	Medium	Medium	NA	NA	0.21	N	N	N	N	0.999914092685434	E	Mthfr	liver/biliary system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; skeleton phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; 	NA	NA	NA	NA	0.1685	0.2669	0.2673	0.1329	0.2347	0.126797	0	0.0512283	0.141215	PASS	0	0.258	114	0.223404	51	chr1	11788082	NA	G	A	942.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=2.37;AS_MQ=60;AS_MQRankSum=0;AS_QD=16.26;AS_ReadPosRankSum=-1.1;AS_SOR=0.39;BaseQRankSum=-1.326;DP=62;ExcessHet=3.0103;FS=2.37;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=16.25;ReadPosRankSum=-1.085;SOR=0.39	GT:AD:DP:GQ:PL	0/1:21,37:58:99:950,0,508
chr1	11789390	11789390	A	G	C1orf167	exonic	nonsynonymous SNV	NA	C1orf167:NM_001010881:exon21:c.A4294G:p.R1432G	1	GnomAdExome_AF_eas	583	142	HomozygousVariant	hom	56	0	56	1	1545.06	PASS	0.014	NA	NA	Benign	NA	NA	Pulse pressure x alcohol consumption interaction (2df test)[29912962];Schizophrenia[27922604];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Midregional pro atrial natriuretic peptide levels[29237677];	NA	NA	NA	NA	NA	NA	NA	D	B	B	NA	P	N	NA	NA	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	lung;choroid;larynx;ovary;placenta;prostate;germinal center;testis;brain;unclassifiable (Anatomical System);visual apparatus;	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.9874	1	1	0.9361	1	0.932907	0	0.0001153	0.947368	PASS	0	1	0	1	0	chr1	11789390	NA	A	G	1545.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.59;AS_ReadPosRankSum=.;AS_SOR=0.922;DP=59;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.59;SOR=0.922	GT:AD:DP:GQ:PL	1/1:0,56:56:99:1559,168,0
chr1	11792243	11792243	C	T	MTHFR	intronic	NA	NA	NA	0.4203	GnomAdExome_AF_sas	135	21	HeterozygousVariant	het	44	24	20	0.454545454545455	412.64	PASS	NA	[MIM:236250]Methylenetetrahydrofolate reductase deficiency;[MIM:601367]Ischemic stroke;[MIM:601634]Neural tube defects, folate-sensitive;[MIM:181500]Schizophrenia;	607093	NA	Homocystinuria due to methylene tetrahydrofolate reductase deficiency;Upper thoracic spina bifida cystica;Cervicothoracic spina bifida cystica;Cervical spina bifida cystica;Lumbosacral spina bifida cystica;Thoracolumbosacral spina bifida cystica;Total spina bifida cystica;Upper thoracic spina bifida aperta;Thoracolumbosacral spina bifida aperta;Lumbosacral spina bifida aperta;Cervical spina bifida aperta;Cervicothoracic spina bifida aperta;Total spina bifida aperta;Isolated anencephaly/exencephaly;Methotrexate toxicity or dose selection	Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Biomarker tested in	Systolic blood pressure[19430483;27618452;28739976;27618447];Diastolic blood pressure (cigarette smoking interaction)[29455858;29455858];Moyamoya disease[29273593];Serum folate levels[29953918];Atrial fibrillation[19597492];Diastolic blood pressure[29615537;27618452;28739976];High altitude adaptation[28373541];Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Mean arterial pressure[27618448];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Midregional pro atrial natriuretic peptide levels[29237677];Coronary artery disease[29212778];Homocysteine levels[23824729;23824729;20031578];Systolic blood pressure (cigarette smoking interaction)[29455858;29455858];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Tuberculosis[29036319];Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Blood pressure[21909110];Folate pathway vitamin levels[19744961];	HP:0000006;HP:0007086;HP:0000738;HP:0001425;HP:0100753;HP:0000746;HP:0410291;HP:0002353;HP:0001907;HP:0002204;HP:0011463;HP:0002625;HP:0004419;HP:0005305;HP:0000006;HP:0002160;HP:0000007;HP:0000708;HP:0001263;HP:0001288;HP:0001324;HP:0002156;HP:0003401;HP:0001250;HP:0001297;HP:0000252;HP:0002311;HP:0001939;HP:0010301;HP:0000007	Autosomal dominant inheritance;Social and occupational deterioration;Hallucinations;Heterogeneous;Schizophrenia;Delusions;Negativism;EEG abnormality;Thromboembolism;Pulmonary embolism;Childhood onset;Deep venous thrombosis;Recurrent thrombophlebitis;Cerebral venous thrombosis;Autosomal dominant inheritance;Hyperhomocystinemia;Autosomal recessive inheritance;Behavioral abnormality;Global developmental delay;Gait disturbance;Muscle weakness;Homocystinuria;Paresthesia;Seizure;Stroke;Microcephaly;Incoordination;Abnormality of metabolism/homeostasis;Spinal dysraphism;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	Medium	Medium	NA	NA	0.21	N	N	N	N	0.999914092685434	E	Mthfr	liver/biliary system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; skeleton phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; 	NA	NA	NA	NA	0.2614	0.4203	0.4201	0.2318	0.4068	0.251198	0.2229	0.262668	0.207718	PASS	0	0.457	284	0.387324	68	chr1	11792243	NA	C	T	412.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=2.688;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.39;AS_ReadPosRankSum=1.7;AS_SOR=0.339;BaseQRankSum=-1.129;DP=46;ExcessHet=3.0103;FS=2.688;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.38;ReadPosRankSum=1.76;SOR=0.339	GT:AD:DP:GQ:PL	0/1:24,20:44:99:420,0,579
chr1	11794400	11794400	G	A	MTHFR	exonic	synonymous SNV	NA	MTHFR:NM_001330358:exon8:c.C1428T:p.F476F,MTHFR:NM_005957:exon8:c.C1305T:p.F435F	1	GnomAdExome_AF_fin	834	142	HomozygousVariant	hom	147	0	147	1	5278.06	PASS	NA	[MIM:236250]Methylenetetrahydrofolate reductase deficiency;[MIM:601367]Ischemic stroke;[MIM:601634]Neural tube defects, folate-sensitive;[MIM:181500]Schizophrenia;	607093	Benign	Homocystinuria due to methylene tetrahydrofolate reductase deficiency;Upper thoracic spina bifida cystica;Cervicothoracic spina bifida cystica;Cervical spina bifida cystica;Lumbosacral spina bifida cystica;Thoracolumbosacral spina bifida cystica;Total spina bifida cystica;Upper thoracic spina bifida aperta;Thoracolumbosacral spina bifida aperta;Lumbosacral spina bifida aperta;Cervical spina bifida aperta;Cervicothoracic spina bifida aperta;Total spina bifida aperta;Isolated anencephaly/exencephaly;Methotrexate toxicity or dose selection	Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Biomarker tested in	Systolic blood pressure[19430483;27618452;28739976;27618447];Diastolic blood pressure (cigarette smoking interaction)[29455858;29455858];Moyamoya disease[29273593];Serum folate levels[29953918];Atrial fibrillation[19597492];Diastolic blood pressure[29615537;27618452;28739976];High altitude adaptation[28373541];Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Mean arterial pressure[27618448];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Midregional pro atrial natriuretic peptide levels[29237677];Coronary artery disease[29212778];Homocysteine levels[23824729;23824729;20031578];Systolic blood pressure (cigarette smoking interaction)[29455858;29455858];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Tuberculosis[29036319];Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Blood pressure[21909110];Folate pathway vitamin levels[19744961];	HP:0000006;HP:0007086;HP:0000738;HP:0001425;HP:0100753;HP:0000746;HP:0410291;HP:0002353;HP:0001907;HP:0002204;HP:0011463;HP:0002625;HP:0004419;HP:0005305;HP:0000006;HP:0002160;HP:0000007;HP:0000708;HP:0001263;HP:0001288;HP:0001324;HP:0002156;HP:0003401;HP:0001250;HP:0001297;HP:0000252;HP:0002311;HP:0001939;HP:0010301;HP:0000007	Autosomal dominant inheritance;Social and occupational deterioration;Hallucinations;Heterogeneous;Schizophrenia;Delusions;Negativism;EEG abnormality;Thromboembolism;Pulmonary embolism;Childhood onset;Deep venous thrombosis;Recurrent thrombophlebitis;Cerebral venous thrombosis;Autosomal dominant inheritance;Hyperhomocystinemia;Autosomal recessive inheritance;Behavioral abnormality;Global developmental delay;Gait disturbance;Muscle weakness;Homocystinuria;Paresthesia;Seizure;Stroke;Microcephaly;Incoordination;Abnormality of metabolism/homeostasis;Spinal dysraphism;Autosomal recessive inheritance	Homocystinuria_due_to_MTHFR_deficiency|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	Medium	Medium	NA	NA	0.21	N	N	N	N	0.999914092685434	E	Mthfr	liver/biliary system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; skeleton phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; 	NA	NA	NA	NA	0.9748	0.9993	0.9994	0.9037	1	0.902955	0.8905	0.952245	0.921182	PASS	1	0.999	2	1	0	chr1	11794400	NA	G	A	5278.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=35.35;AS_ReadPosRankSum=.;AS_SOR=1.052;DP=147;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.61;SOR=1.052	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,147:147:99:1|1:11794400_G_A:5292,441,0:11794400
chr1	11794419	11794419	T	G	MTHFR	exonic	nonsynonymous SNV	NA	MTHFR:NM_001330358:exon8:c.A1409C:p.E470A,MTHFR:NM_005957:exon8:c.A1286C:p.E429A	0.4116	GnomAdExome_AF_sas	166	19	HeterozygousVariant	het	173	76	97	0.560693641618497	2127.64	PASS	20.9	[MIM:236250]Methylenetetrahydrofolate reductase deficiency;[MIM:601367]Ischemic stroke;[MIM:601634]Neural tube defects, folate-sensitive;[MIM:181500]Schizophrenia;	607093	Benign	Homocystinuria due to methylene tetrahydrofolate reductase deficiency;Upper thoracic spina bifida cystica;Cervicothoracic spina bifida cystica;Cervical spina bifida cystica;Lumbosacral spina bifida cystica;Thoracolumbosacral spina bifida cystica;Total spina bifida cystica;Upper thoracic spina bifida aperta;Thoracolumbosacral spina bifida aperta;Lumbosacral spina bifida aperta;Cervical spina bifida aperta;Cervicothoracic spina bifida aperta;Total spina bifida aperta;Isolated anencephaly/exencephaly;Methotrexate toxicity or dose selection	Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Biomarker tested in	Systolic blood pressure[19430483;27618452;28739976;27618447];Diastolic blood pressure (cigarette smoking interaction)[29455858;29455858];Moyamoya disease[29273593];Serum folate levels[29953918];Atrial fibrillation[19597492];Diastolic blood pressure[29615537;27618452;28739976];High altitude adaptation[28373541];Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Mean arterial pressure[27618448];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Midregional pro atrial natriuretic peptide levels[29237677];Coronary artery disease[29212778];Homocysteine levels[23824729;23824729;20031578];Systolic blood pressure (cigarette smoking interaction)[29455858;29455858];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Tuberculosis[29036319];Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858];Blood pressure[21909110];Folate pathway vitamin levels[19744961];	HP:0000006;HP:0007086;HP:0000738;HP:0001425;HP:0100753;HP:0000746;HP:0410291;HP:0002353;HP:0001907;HP:0002204;HP:0011463;HP:0002625;HP:0004419;HP:0005305;HP:0000006;HP:0002160;HP:0000007;HP:0000708;HP:0001263;HP:0001288;HP:0001324;HP:0002156;HP:0003401;HP:0001250;HP:0001297;HP:0000252;HP:0002311;HP:0001939;HP:0010301;HP:0000007	Autosomal dominant inheritance;Social and occupational deterioration;Hallucinations;Heterogeneous;Schizophrenia;Delusions;Negativism;EEG abnormality;Thromboembolism;Pulmonary embolism;Childhood onset;Deep venous thrombosis;Recurrent thrombophlebitis;Cerebral venous thrombosis;Autosomal dominant inheritance;Hyperhomocystinemia;Autosomal recessive inheritance;Behavioral abnormality;Global developmental delay;Gait disturbance;Muscle weakness;Homocystinuria;Paresthesia;Seizure;Stroke;Microcephaly;Incoordination;Abnormality of metabolism/homeostasis;Spinal dysraphism;Autosomal recessive inheritance	Schizophrenia,_susceptibility_to|Gastrointestinal_stromal_tumor|Homocystinuria_due_to_methylene_tetrahydrofolate_reductase_deficiency|Neural_tube_defects,_folate-sensitive|MTHFR_deficiency,_thermolabile_type|Homocystinuria_due_to_MTHFR_deficiency|not_specified|none_provided|not_provided	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity,_other	NA	T	T	B	B	D	P	L	T	D	T	T	T	NA	T	D	T	T	T	.;.;.;.;.;.;.;	D	N	.;.;.;.;.;.;.	NA	NA	High	Medium	Medium	NA	NA	0.21	N	N	N	N	0.999914092685434	E	Mthfr	liver/biliary system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; skeleton phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; 	NA	NA	NA	NA	0.289	0.4116	0.4119	0.2614	0.4031	0.249401	0.2596	0.290967	0.238916	PASS	0.396341	0.432	391	0.376761	69	chr1	11794419	NA	T	G	2127.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=2.679;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.3;AS_ReadPosRankSum=0.1;AS_SOR=0.916;BaseQRankSum=0.343;DP=175;ExcessHet=3.0103;FS=2.679;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.3;ReadPosRankSum=0.181;SOR=0.916	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:76,97:173:99:0|1:11794400_G_A:2135,0,1516:11794400
chr1	11824498	11824498	A	G	CLCN6	exonic	nonsynonymous SNV	NA	CLCN6:NM_001256959:exon7:c.A527G:p.E176G,CLCN6:NM_001286:exon8:c.A593G:p.E198G	1	GnomAdExome_AF_eas	808	142	HomozygousVariant	hom	144	0	144	1	4178.06	PASS	23	NA	602726	Benign	NA	NA	Systolic blood pressure[19430483;29615537];Diastolic blood pressure (cigarette smoking interaction)[29455858;29455858];Mean corpuscular volume[27863252];Mean corpuscular hemoglobin[27863252];Diastolic blood pressure[29615537];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Testicular germ cell tumor[28604728];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Coronary artery disease[29212778];Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962;29912962];Systolic blood pressure (cigarette smoking interaction)[29455858;29455858];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Tuberculosis[29036319];Pulse pressure x alcohol consumption interaction (2df test)[29912962];Natriuretic peptide levels[21273288];Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962;29912962];Mean arterial pressure x alcohol consumption interaction (2df test)[29912962];	NA	NA	NA	NA	NA	Testis, ovary, small intestine, brain and skeletal muscle. Low level expression in aortic and coronary vascular smooth muscle cells, and aortic endothelial cells. Isoform 3 is only detected in kidney. {ECO:0000269|PubMed:10198195, ECO:0000269|PubMed:8543009, ECO:0000269|PubMed:9224655}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	D	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	thymus;smooth muscle;skin;stomach;adrenal cortex;lens;unclassifiable (Anatomical System);choroid;uterus;whole body;retina;pancreas;muscle;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;cartilage;endometrium;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;cerebral cortex;ovary;macula lutea;frontal lobe;sympathetic chain;colon;placenta;prostate;optic nerve;hypothalamus;	caudate nucleus;amygdala;prefrontal cortex;cingulate cortex;cerebellum;pons;subthalamic nucleus;whole brain;spinal cord;globus pallidus;medulla oblongata;hypothalamus;thalamus;	0.0974	N	N	N	N	0.963731370952422	E	Clcn6	cellular phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	NA	NA	NA	NA	0.9994	1	1	0.9996	1	0.9998	0.9992	0.989735	0.998358	PASS	1	0.999	1	1	0	chr1	11824498	NA	A	G	4178.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.01;AS_ReadPosRankSum=.;AS_SOR=0.971;DP=148;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.01;SOR=0.971	GT:AD:DP:GQ:PL	1/1:0,144:144:99:4192,431,0
chr1	11838792	11838792	T	G	CLCN6	intronic	NA	NA	NA	0.3761	GnomAdExome_AF_afr	19	5	HeterozygousVariant	het	148	80	68	0.45945945945946	1498.64	PASS	NA	NA	602726	NA	NA	NA	Systolic blood pressure[19430483;29615537];Diastolic blood pressure (cigarette smoking interaction)[29455858;29455858];Mean corpuscular volume[27863252];Mean corpuscular hemoglobin[27863252];Diastolic blood pressure[29615537];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Testicular germ cell tumor[28604728];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Coronary artery disease[29212778];Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962;29912962];Systolic blood pressure (cigarette smoking interaction)[29455858;29455858];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Tuberculosis[29036319];Pulse pressure x alcohol consumption interaction (2df test)[29912962];Natriuretic peptide levels[21273288];Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962;29912962];Mean arterial pressure x alcohol consumption interaction (2df test)[29912962];	NA	NA	NA	NA	NA	Testis, ovary, small intestine, brain and skeletal muscle. Low level expression in aortic and coronary vascular smooth muscle cells, and aortic endothelial cells. Isoform 3 is only detected in kidney. {ECO:0000269|PubMed:10198195, ECO:0000269|PubMed:8543009, ECO:0000269|PubMed:9224655}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;smooth muscle;skin;stomach;adrenal cortex;lens;unclassifiable (Anatomical System);choroid;uterus;whole body;retina;pancreas;muscle;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;cartilage;endometrium;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;cerebral cortex;ovary;macula lutea;frontal lobe;sympathetic chain;colon;placenta;prostate;optic nerve;hypothalamus;	caudate nucleus;amygdala;prefrontal cortex;cingulate cortex;cerebellum;pons;subthalamic nucleus;whole brain;spinal cord;globus pallidus;medulla oblongata;hypothalamus;thalamus;	0.0974	N	N	N	N	0.963731370952422	E	Clcn6	cellular phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	NA	NA	NA	NA	0.1293	0.3761	0.3761	0.1968	0.3641	0.161941	0	0.13036	0.163383	PASS	0	0.137	181	0.123239	25	chr1	11838792	NA	T	G	1498.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.13;AS_ReadPosRankSum=-0.4;AS_SOR=0.646;BaseQRankSum=-0.115;DP=156;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.13;ReadPosRankSum=-0.36;SOR=0.646	GT:AD:DP:GQ:PL	0/1:80,68:148:99:1506,0,1895
chr1	11838976	11838976	G	T	CLCN6	intronic	NA	NA	NA	0.3705	GnomAdExome_AF_sas	131	15	HeterozygousVariant	het	55	25	30	0.545454545454545	754.64	PASS	0.268	NA	602726	NA	NA	NA	Systolic blood pressure[19430483;29615537];Diastolic blood pressure (cigarette smoking interaction)[29455858;29455858];Mean corpuscular volume[27863252];Mean corpuscular hemoglobin[27863252];Diastolic blood pressure[29615537];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Testicular germ cell tumor[28604728];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Coronary artery disease[29212778];Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962;29912962];Systolic blood pressure (cigarette smoking interaction)[29455858;29455858];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Tuberculosis[29036319];Pulse pressure x alcohol consumption interaction (2df test)[29912962];Natriuretic peptide levels[21273288];Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858];Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962;29912962];Mean arterial pressure x alcohol consumption interaction (2df test)[29912962];	NA	NA	NA	NA	NA	Testis, ovary, small intestine, brain and skeletal muscle. Low level expression in aortic and coronary vascular smooth muscle cells, and aortic endothelial cells. Isoform 3 is only detected in kidney. {ECO:0000269|PubMed:10198195, ECO:0000269|PubMed:8543009, ECO:0000269|PubMed:9224655}.;	D	NA	NA	NA	U	P	NA	D	N	T	T	T	NA	NA	NA	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	thymus;smooth muscle;skin;stomach;adrenal cortex;lens;unclassifiable (Anatomical System);choroid;uterus;whole body;retina;pancreas;muscle;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;cartilage;endometrium;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;cerebral cortex;ovary;macula lutea;frontal lobe;sympathetic chain;colon;placenta;prostate;optic nerve;hypothalamus;	caudate nucleus;amygdala;prefrontal cortex;cingulate cortex;cerebellum;pons;subthalamic nucleus;whole brain;spinal cord;globus pallidus;medulla oblongata;hypothalamus;thalamus;	0.0974	N	N	N	N	0.963731370952422	E	Clcn6	cellular phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	NA	NA	NA	NA	0.256	0.3705	0.3708	0.2336	0.3623	0.238419	0	0.0854517	0		0	0.392	363	0.340426	66	chr1	11838976	NA	G	T	754.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=2.436;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.73;AS_ReadPosRankSum=0.1;AS_SOR=1.19;BaseQRankSum=0.733;DP=57;ExcessHet=3.0103;FS=2.436;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.72;ReadPosRankSum=0.11;SOR=1.19	GT:AD:DP:GQ:PL	0/1:25,30:55:99:762,0,561
chr1	11846011	11846011	A	G	NPPA	exonic	stoploss	NA	NPPA:NM_006172:exon3:c.T454C:p.X152R	0.4128	GnomAdExome_AF_afr	22	6	HeterozygousVariant	het	118	51	67	0.567796610169492	1511.64	PASS	11.75	[MIM:615745]Atrial standstill 2;[MIM:612201]Atrial fibrillation, familial, 6;	108780	Benign	Atrial standstill;Familial atrial fibrillation	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Systolic blood pressure[19430483];Tuberculosis[29036319];Atrial fibrillation[19597492];Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858;29455858;29455858];Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858;29455858;29455858];Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)[29455858;29455858;29455858;29455858;29455858;29455858;29455858];Midregional pro atrial natriuretic peptide levels[29237677;29237677];	HP:0000006;HP:0005110;HP:0001638;HP:0100699;HP:0200127;HP:0006698;HP:0003238;HP:0000007;HP:0001297;HP:0001692;HP:0001662;HP:0002094;HP:0025478;HP:0001962	Autosomal dominant inheritance;Atrial fibrillation;Cardiomyopathy;Scarring;Atrial cardiomyopathy;Dilatation of the ventricular cavity;Hyperpepsinogenemia I;Autosomal recessive inheritance;Stroke;Atrial arrhythmia;Bradycardia;Dyspnea;Atrial standstill;Palpitations	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	P	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	.;.;	N	NA	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.64	N	N	S	N	0.800905186959344	E	Nppa	renal/urinary system phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); muscle phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.1375	0.4128	0.4123	0.2128	0.402	0.179113	0.241	0.142514	0.175698	PASS	0.257576	0.141	192	0.126761	24	chr1	11846011	NA	A	G	1511.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.484;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.81;AS_ReadPosRankSum=-1.4;AS_SOR=0.817;BaseQRankSum=0.482;DP=120;ExcessHet=3.0103;FS=1.484;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.81;ReadPosRankSum=-1.386;SOR=0.817	GT:AD:DP:GQ:PL	0/1:51,67:118:99:1519,0,1062
chr1	11922523	11922523	G	A	KIAA2013	intronic	NA	NA	NA	0.1331	GnomAdExome_AF_sas	28	2	HeterozygousVariant	het	81	46	35	0.432098765432099	732.64	PASS	8.435	NA	NA	NA	NA	NA	Tuberculosis[29036319];Serum folate levels[29953918];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Blood protein levels[30072576];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Mean arterial pressure x alcohol consumption interaction (2df test)[29912962];	NA	NA	NA	NA	NA	NA	D	NA	D	D	NA	P	NA	NA	N	T	T	T	NA	NA	NA	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.276361486583742	N	2510039O18Rik	NA	NA	NA	NA	NA	0.0651	0.1331	0.1334	0.0662	0.13	0.0854633	0	0.0421728	0.060132	PASS	0	0.16	131	0.123239	31	chr1	11922523	NA	G	A	732.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0.889;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.05;AS_ReadPosRankSum=0.2;AS_SOR=0.835;BaseQRankSum=-0.496;DP=81;ExcessHet=3.0103;FS=0.889;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.04;ReadPosRankSum=0.2;SOR=0.835	GT:AD:DP:GQ:PL	0/1:46,35:81:99:740,0,1083
chr1	11923149	11923149	A	G	KIAA2013	exonic	synonymous SNV	NA	KIAA2013:NM_138346:exon2:c.T1374C:p.F458F	0.7993	GnomAdExome_AF_afr	287	68	HomozygousVariant	hom	111	2	109	0.981981981981982	3084.06	PASS	NA	NA	NA	Benign	NA	NA	Tuberculosis[29036319];Serum folate levels[29953918];Systolic blood pressure x alcohol consumption interaction (2df test)[29912962;29912962];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Blood protein levels[30072576];Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)[29912962];Mean arterial pressure x alcohol consumption interaction (2df test)[29912962];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.276361486583742	N	2510039O18Rik	NA	NA	NA	NA	NA	0.5915	0.7993	0.7981	0.6369	0.7957	0.675319	0.5933	0.544495	0.55666	VQSRTrancheSNP99.00to99.90	0.636	0.679	222	0.679577	57	chr1	11923149	NA	A	G	3084.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.9;AS_FS=0;AS_MQ=49.23;AS_MQRankSum=-2;AS_QD=27.78;AS_ReadPosRankSum=0.3;AS_SOR=0.787;BaseQRankSum=0.957;DP=113;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=49.65;MQRankSum=-1.98;QD=27.78;ReadPosRankSum=0.388;SOR=0.787	GT:AD:DP:GQ:PL	1/1:2,109:111:99:3098,282,0
chr1	11949898	11949898	C	T	PLOD1	exonic	synonymous SNV	NA	PLOD1:NM_000302:exon3:c.C294T:p.F98F,PLOD1:NM_001316320:exon4:c.C435T:p.F145F	0.446	GnomAdExome_AF_fin	170	35	HeterozygousVariant	het	71	37	34	0.47887323943662	737.64	PASS	NA	[MIM:225400]Ehlers-Danlos syndrome, kyphoscoliotic type, 1 [recessive?];	153454	Benign	Ehlers-Danlos syndrome, kyphoscoliotic type	Disease-causing germline mutation(s) in	Moyamoya disease[29273593];Tuberculosis[29036319];Plateletcrit[27863252];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Platelet count[27863252];	HP:0000977;HP:0006532;HP:0001763;HP:0000963;HP:0001290;HP:0000286;HP:0001166;HP:0001939;HP:0005952;HP:0008458;HP:0001388;HP:0005280;HP:0001270;HP:0001373;HP:0002093;HP:0025019;HP:0000541;HP:0000978;HP:0001519;HP:0000592;HP:0002239;HP:0000545;HP:0001635;HP:0001762;HP:0000098;HP:0000007;HP:0000501;HP:0000015;HP:0000939;HP:0001788;HP:0007517;HP:0000563;HP:0000678;HP:0000974;HP:0001252;HP:0001558;HP:0000482;HP:0000023;HP:0000993;HP:0002808;HP:0000618;HP:0001939;HP:0002647;HP:0001762;HP:0002650;HP:0002808;HP:0000541;HP:0000023;HP:0000974;HP:0000501;HP:0005294;HP:0000563;HP:0000482;HP:0002761;HP:0001634;HP:0010727;HP:0000488;HP:0003272;HP:0001933;HP:0000545;HP:0005692;HP:0001319;HP:0000505;HP:0001131;HP:0000987;HP:0001288	Soft skin;Recurrent pneumonia;Pes planus;Thin skin;Generalized hypotonia;Epicanthus;Arachnodactyly;Abnormality of metabolism/homeostasis;Decreased pulmonary function;Progressive congenital scoliosis;Joint laxity;Depressed nasal bridge;Motor delay;Joint dislocation;Respiratory insufficiency;Arterial rupture;Retinal detachment;Bruising susceptibility;Disproportionate tall stature;Blue sclerae;Gastrointestinal hemorrhage;Myopia;Congestive heart failure;Talipes equinovarus;Tall stature;Autosomal recessive inheritance;Glaucoma;Bladder diverticulum;Osteoporosis;Premature rupture of membranes;Palmoplantar cutis laxa;Keratoconus;Dental crowding;Hyperextensible skin;Muscular hypotonia;Decreased fetal movement;Microcornea;Inguinal hernia;Molluscoid pseudotumors;Kyphosis;Blindness;Abnormality of metabolism/homeostasis;Aortic dissection;Talipes equinovarus;Scoliosis;Kyphosis;Retinal detachment;Inguinal hernia;Hyperextensible skin;Glaucoma;Arterial dissection;Keratoconus;Microcornea;Generalized joint laxity;Mitral valve prolapse;Spontaneous rupture of the globe;Retinopathy;Abnormality of the hip bone;Subcutaneous hemorrhage;Myopia;Joint hyperflexibility;Neonatal hypotonia;Visual impairment;Corneal dystrophy;Atypical scarring of skin;Gait disturbance	Ehlers-Danlos_syndrome,_hydroxylysine-deficient|not_specified|Cardiovascular_phenotype	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	pharynx;stomach;testis;choroid;larynx;kidney;uterus;whole body;pancreas;bile duct;hypopharynx;skeletal muscle;mesenchyma;islets of Langerhans;visual apparatus;fovea centralis;iris;spleen;liver;peripheral nerve;germinal center;heart;lung;salivary gland;synovium;thyroid;sympathetic chain;placenta;nasopharynx;optic nerve;intestine;epididymis;tongue;alveolus;spinal ganglion;skin;lens;unclassifiable (Anatomical System);lymphoreticular;cerebellum;amniotic fluid;retina;muscle;head and neck;mammary gland;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;duodenum;cerebral cortex;ovary;macula lutea;bladder;frontal lobe;colon;aorta;prostate;breast;hypothalamus;	trigeminal ganglion;smooth muscle;skeletal muscle;heart;	0.378	N	N	S	N	0.665788551222402	E	Plod1	muscle phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); limbs/digits/tail phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	plod1a	actinotrichium	absent	abnormal	0.3295	0.4236	0.4178	0.2484	0.4359	0.267772	0.2293	0.316833	0.240558	PASS	0.42803	0.427	373	0.496479	71	chr1	11949898	NA	C	T	737.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.39;AS_ReadPosRankSum=-0.3;AS_SOR=0.651;BaseQRankSum=-0.414;DP=74;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.39;ReadPosRankSum=-0.265;SOR=0.651	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:37,34:71:99:0|1:11949898_C_T:745,0,1452:11949898
chr1	11949899	11949899	G	A	PLOD1	exonic	nonsynonymous SNV	NA	PLOD1:NM_000302:exon3:c.G295A:p.A99T,PLOD1:NM_001316320:exon4:c.G436A:p.A146T	0.5503	GnomAdExome_AF_afr	54	5	HeterozygousVariant	het	71	34	37	0.52112676056338	809.64	PASS	15.53	[MIM:225400]Ehlers-Danlos syndrome, kyphoscoliotic type, 1 [recessive?];	153454	Benign	Ehlers-Danlos syndrome, kyphoscoliotic type	Disease-causing germline mutation(s) in	Moyamoya disease[29273593];Tuberculosis[29036319];Plateletcrit[27863252];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Platelet count[27863252];	HP:0000977;HP:0006532;HP:0001763;HP:0000963;HP:0001290;HP:0000286;HP:0001166;HP:0001939;HP:0005952;HP:0008458;HP:0001388;HP:0005280;HP:0001270;HP:0001373;HP:0002093;HP:0025019;HP:0000541;HP:0000978;HP:0001519;HP:0000592;HP:0002239;HP:0000545;HP:0001635;HP:0001762;HP:0000098;HP:0000007;HP:0000501;HP:0000015;HP:0000939;HP:0001788;HP:0007517;HP:0000563;HP:0000678;HP:0000974;HP:0001252;HP:0001558;HP:0000482;HP:0000023;HP:0000993;HP:0002808;HP:0000618;HP:0001939;HP:0002647;HP:0001762;HP:0002650;HP:0002808;HP:0000541;HP:0000023;HP:0000974;HP:0000501;HP:0005294;HP:0000563;HP:0000482;HP:0002761;HP:0001634;HP:0010727;HP:0000488;HP:0003272;HP:0001933;HP:0000545;HP:0005692;HP:0001319;HP:0000505;HP:0001131;HP:0000987;HP:0001288	Soft skin;Recurrent pneumonia;Pes planus;Thin skin;Generalized hypotonia;Epicanthus;Arachnodactyly;Abnormality of metabolism/homeostasis;Decreased pulmonary function;Progressive congenital scoliosis;Joint laxity;Depressed nasal bridge;Motor delay;Joint dislocation;Respiratory insufficiency;Arterial rupture;Retinal detachment;Bruising susceptibility;Disproportionate tall stature;Blue sclerae;Gastrointestinal hemorrhage;Myopia;Congestive heart failure;Talipes equinovarus;Tall stature;Autosomal recessive inheritance;Glaucoma;Bladder diverticulum;Osteoporosis;Premature rupture of membranes;Palmoplantar cutis laxa;Keratoconus;Dental crowding;Hyperextensible skin;Muscular hypotonia;Decreased fetal movement;Microcornea;Inguinal hernia;Molluscoid pseudotumors;Kyphosis;Blindness;Abnormality of metabolism/homeostasis;Aortic dissection;Talipes equinovarus;Scoliosis;Kyphosis;Retinal detachment;Inguinal hernia;Hyperextensible skin;Glaucoma;Arterial dissection;Keratoconus;Microcornea;Generalized joint laxity;Mitral valve prolapse;Spontaneous rupture of the globe;Retinopathy;Abnormality of the hip bone;Subcutaneous hemorrhage;Myopia;Joint hyperflexibility;Neonatal hypotonia;Visual impairment;Corneal dystrophy;Atypical scarring of skin;Gait disturbance	Ehlers-Danlos_syndrome,_hydroxylysine-deficient|not_specified|Cardiovascular_phenotype	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	pharynx;stomach;testis;choroid;larynx;kidney;uterus;whole body;pancreas;bile duct;hypopharynx;skeletal muscle;mesenchyma;islets of Langerhans;visual apparatus;fovea centralis;iris;spleen;liver;peripheral nerve;germinal center;heart;lung;salivary gland;synovium;thyroid;sympathetic chain;placenta;nasopharynx;optic nerve;intestine;epididymis;tongue;alveolus;spinal ganglion;skin;lens;unclassifiable (Anatomical System);lymphoreticular;cerebellum;amniotic fluid;retina;muscle;head and neck;mammary gland;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;duodenum;cerebral cortex;ovary;macula lutea;bladder;frontal lobe;colon;aorta;prostate;breast;hypothalamus;	trigeminal ganglion;smooth muscle;skeletal muscle;heart;	0.378	N	N	S	N	0.665788551222402	E	Plod1	muscle phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); limbs/digits/tail phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	plod1a	actinotrichium	absent	abnormal	0.181	0.5503	0.5508	0.2643	0.5383	0.299521	0.2806	0.187941	0.219212	PASS	0.20202	0.234	283	0.176056	40	chr1	11949899	NA	G	A	809.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.41;AS_ReadPosRankSum=-0.2;AS_SOR=0.737;BaseQRankSum=-0.955;DP=73;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.4;ReadPosRankSum=-0.102;SOR=0.737	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:34,37:71:99:1|0:11949898_C_T:817,0,1276:11949898
chr1	11964178	11964178	C	T	PLOD1	exonic	synonymous SNV	NA	PLOD1:NM_000302:exon12:c.C1206T:p.N402N,PLOD1:NM_001316320:exon13:c.C1347T:p.N449N	0.5011	GnomAdExome_AF_fin	186	39	HomozygousVariant	hom	94	0	94	1	2559.06	PASS	NA	[MIM:225400]Ehlers-Danlos syndrome, kyphoscoliotic type, 1 [recessive?];	153454	Benign	Ehlers-Danlos syndrome, kyphoscoliotic type	Disease-causing germline mutation(s) in	Moyamoya disease[29273593];Tuberculosis[29036319];Plateletcrit[27863252];Diastolic blood pressure x alcohol consumption interaction (2df test)[29912962];Platelet count[27863252];	HP:0000977;HP:0006532;HP:0001763;HP:0000963;HP:0001290;HP:0000286;HP:0001166;HP:0001939;HP:0005952;HP:0008458;HP:0001388;HP:0005280;HP:0001270;HP:0001373;HP:0002093;HP:0025019;HP:0000541;HP:0000978;HP:0001519;HP:0000592;HP:0002239;HP:0000545;HP:0001635;HP:0001762;HP:0000098;HP:0000007;HP:0000501;HP:0000015;HP:0000939;HP:0001788;HP:0007517;HP:0000563;HP:0000678;HP:0000974;HP:0001252;HP:0001558;HP:0000482;HP:0000023;HP:0000993;HP:0002808;HP:0000618;HP:0001939;HP:0002647;HP:0001762;HP:0002650;HP:0002808;HP:0000541;HP:0000023;HP:0000974;HP:0000501;HP:0005294;HP:0000563;HP:0000482;HP:0002761;HP:0001634;HP:0010727;HP:0000488;HP:0003272;HP:0001933;HP:0000545;HP:0005692;HP:0001319;HP:0000505;HP:0001131;HP:0000987;HP:0001288	Soft skin;Recurrent pneumonia;Pes planus;Thin skin;Generalized hypotonia;Epicanthus;Arachnodactyly;Abnormality of metabolism/homeostasis;Decreased pulmonary function;Progressive congenital scoliosis;Joint laxity;Depressed nasal bridge;Motor delay;Joint dislocation;Respiratory insufficiency;Arterial rupture;Retinal detachment;Bruising susceptibility;Disproportionate tall stature;Blue sclerae;Gastrointestinal hemorrhage;Myopia;Congestive heart failure;Talipes equinovarus;Tall stature;Autosomal recessive inheritance;Glaucoma;Bladder diverticulum;Osteoporosis;Premature rupture of membranes;Palmoplantar cutis laxa;Keratoconus;Dental crowding;Hyperextensible skin;Muscular hypotonia;Decreased fetal movement;Microcornea;Inguinal hernia;Molluscoid pseudotumors;Kyphosis;Blindness;Abnormality of metabolism/homeostasis;Aortic dissection;Talipes equinovarus;Scoliosis;Kyphosis;Retinal detachment;Inguinal hernia;Hyperextensible skin;Glaucoma;Arterial dissection;Keratoconus;Microcornea;Generalized joint laxity;Mitral valve prolapse;Spontaneous rupture of the globe;Retinopathy;Abnormality of the hip bone;Subcutaneous hemorrhage;Myopia;Joint hyperflexibility;Neonatal hypotonia;Visual impairment;Corneal dystrophy;Atypical scarring of skin;Gait disturbance	Ehlers-Danlos_syndrome,_hydroxylysine-deficient|not_specified|Cardiovascular_phenotype	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	pharynx;stomach;testis;choroid;larynx;kidney;uterus;whole body;pancreas;bile duct;hypopharynx;skeletal muscle;mesenchyma;islets of Langerhans;visual apparatus;fovea centralis;iris;spleen;liver;peripheral nerve;germinal center;heart;lung;salivary gland;synovium;thyroid;sympathetic chain;placenta;nasopharynx;optic nerve;intestine;epididymis;tongue;alveolus;spinal ganglion;skin;lens;unclassifiable (Anatomical System);lymphoreticular;cerebellum;amniotic fluid;retina;muscle;head and neck;mammary gland;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;duodenum;cerebral cortex;ovary;macula lutea;bladder;frontal lobe;colon;aorta;prostate;breast;hypothalamus;	trigeminal ganglion;smooth muscle;skeletal muscle;heart;	0.378	N	N	S	N	0.665788551222402	E	Plod1	muscle phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); limbs/digits/tail phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	plod1a	actinotrichium	absent	abnormal	0.3609	0.4443	0.4409	0.33	0.4967	0.348442	0.3108	0.352195	0.302956	PASS	0.42803	0.449	377	0.510563	67	chr1	11964178	NA	C	T	2559.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.22;AS_ReadPosRankSum=.;AS_SOR=0.78;DP=96;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.22;SOR=0.78	GT:AD:DP:GQ:PL	1/1:0,94:94:99:2573,281,0
chr1	12022869	12022869	A	G	MIIP	exonic	nonsynonymous SNV	NA	MIIP:NM_021933:exon4:c.A499G:p.K167E	0.8261	GnomAdGenome_AF_fin	330	57	HomozygousVariant	hom	70	0	70	1	1983.06	PASS	13.8	NA	608772	Benign	NA	NA	Tuberculosis[29036319];	NA	NA	NA	NA	NA	Ubiquitous. Isoform 1 is expressed in brain but underexpressed in glioma tissues, at protein level. Isoform 2 is not detected in normal organs, but is expressed in gliomas with increasing levels with glioma progression. On the contrary, at protein level, isoform 2 is not detected in gliomas, suggesting that this isoform is unstable in glioma cells. {ECO:0000269|PubMed:14617774}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;cartilage;endometrium;brain;blood;heart;trabecular meshwork;lung;ovary;macula lutea;colon;placenta;prostate;breast;optic nerve;medulla oblongata;	ciliary ganglion;pons;dorsal root ganglion;atrioventricular node;trigeminal ganglion;superior cervical ganglion;parietal lobe;skeletal muscle;	0.953	NA	N	N	N	0.706772781962826	E	Miip	NA	NA	NA	NA	NA	0.6821	0.7915	0.7863	0.7269	0.8261	0.669329	0.7383	0.671874	0.669951	PASS	0.75731	0.616	367	0.626761	64	chr1	12022869	NA	A	G	1983.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.33;AS_ReadPosRankSum=.;AS_SOR=0.75;DP=74;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.33;SOR=0.75	GT:AD:DP:GQ:PL	1/1:0,70:70:99:1997,209,0
chr1	12104380	12104380	C	T	TNFRSF8	exonic	synonymous SNV	NA	TNFRSF8:NM_001243:exon4:c.C270T:p.D90D	0.4126	GnomAdExome_AF_amr	86	21	HomozygousVariant	hom	76	0	76	1	2158.06	PASS	NA	NA	153243	Benign	NA	NA	Sum eosinophil basophil counts[27863252];Eosinophil percentage of granulocytes[27863252];Tuberculosis[29036319];Mosquito bite size[28199695];Eosinophil counts[27863252];Neutrophil percentage of granulocytes[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.01	Medium	Medium	Medium	intestine;pharynx;liver;brain;blood;unclassifiable (Anatomical System);lung;salivary gland;kidney;ovary;uterus;bladder;colon;prostate;visual apparatus;	ciliary ganglion;atrioventricular node;superior cervical ganglion;skeletal muscle;	0.237	N	N	N	N	0.894939277556302	E	Tnfrsf8	endocrine/exocrine gland phenotype; immune system phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.2878	0.4126	0.4134	0.2457	0.3832	0.292732	0.2336	0.273114	0.247126	PASS	0.352273	0.391	215	0.394366	70	chr1	12104380	NA	C	T	2158.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.39;AS_ReadPosRankSum=.;AS_SOR=1.349;DP=81;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.4;SOR=1.349	GT:AD:DP:GQ:PL	1/1:0,76:76:99:2172,227,0
chr1	12188885	12188885	A	G	TNFRSF1B	exonic	synonymous SNV	NA	TNFRSF1B:NM_001066:exon2:c.A168G:p.K56K	0.301724	GME_SD	56	4	HeterozygousVariant	het	24	16	8	0.333333333333333	149.64	PASS	NA	NA	191191	Benign	Classic mycosis fungoides;S�zary syndrome	Disease-causing somatic mutation(s) in;Disease-causing somatic mutation(s) in	Tuberculosis[29036319];Blood protein levels[29875488;30072576];Urate levels (BMI interaction)[25811787];	HP:0001029;HP:0000958;HP:0001744;HP:0002716;HP:0000989;HP:0010783;HP:0200042;HP:0000492;HP:0001053;HP:0005561;HP:0007400;HP:0000962;HP:0002240;HP:0200035;HP:0000969;HP:0000964;HP:0001597;HP:0000988;HP:0001596;HP:0008069;HP:0004332;HP:0012192;HP:0000982;HP:0002716;HP:0000969;HP:0001999;HP:0008069;HP:0000989;HP:0008404;HP:0001337;HP:0002240;HP:0001596;HP:0003202;HP:0012192;HP:0000656;HP:0100725;HP:0001744;HP:0004332;HP:0010701;HP:0009830;HP:0000958;HP:0007400;HP:0002721;HP:0100758;HP:0001019;HP:0002103	Poikiloderma;Dry skin;Splenomegaly;Lymphadenopathy;Pruritus;Erythema;Skin ulcer;Abnormal eyelid morphology;Hypopigmented skin patches;Abnormality of bone marrow cell morphology;Irregular hyperpigmentation;Hyperkeratosis;Hepatomegaly;Skin plaque;Edema;Eczema;Abnormality of the nail;Skin rash;Alopecia;Neoplasm of the skin;Abnormal lymphocyte morphology;Cutaneous T-cell lymphoma;Palmoplantar keratoderma;Lymphadenopathy;Edema;Abnormal facial shape;Neoplasm of the skin;Pruritus;Nail dystrophy;Tremor;Hepatomegaly;Alopecia;Skeletal muscle atrophy;Cutaneous T-cell lymphoma;Ectropion;Lichenification;Splenomegaly;Abnormal lymphocyte morphology;Abnormal immunoglobulin level;Peripheral neuropathy;Dry skin;Irregular hyperpigmentation;Immunodeficiency;Gangrene;Erythroderma;Abnormal pleura morphology	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0807	N	N	S	N	0.842217408829783	E	Tnfrsf1b	neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); liver/biliary system phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; immune system phenotype; vision/eye phenotype; muscle phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; craniofacial phenotype; 	tnfrsf1b	nucleate erythrocyte	increased accumulation	abnormal	0.2154	0.2631	0.265	0.2186	0.2669	0.199281	0.2351	0.221381	0.215107	PASS	0.301724	0.24	289	0.232394	58	chr1	12188885	NA	A	G	149.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=4.084;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.25;AS_ReadPosRankSum=-0.3;AS_SOR=0.976;BaseQRankSum=-0.943;DP=24;ExcessHet=3.0103;FS=4.084;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.23;ReadPosRankSum=-0.245;SOR=0.976	GT:AD:DP:GQ:PL	0/1:16,8:24:99:157,0,473
chr1	12192835	12192835	C	T	TNFRSF1B	intronic	NA	NA	NA	0.2669	GnomAdGenome_AF_asj	15	5	HeterozygousVariant	het	45	21	24	0.533333333333333	575.64	PASS	NA	NA	191191	NA	Classic mycosis fungoides;S�zary syndrome	Disease-causing somatic mutation(s) in;Disease-causing somatic mutation(s) in	Tuberculosis[29036319];Blood protein levels[29875488;30072576];Urate levels (BMI interaction)[25811787];	HP:0001029;HP:0000958;HP:0001744;HP:0002716;HP:0000989;HP:0010783;HP:0200042;HP:0000492;HP:0001053;HP:0005561;HP:0007400;HP:0000962;HP:0002240;HP:0200035;HP:0000969;HP:0000964;HP:0001597;HP:0000988;HP:0001596;HP:0008069;HP:0004332;HP:0012192;HP:0000982;HP:0002716;HP:0000969;HP:0001999;HP:0008069;HP:0000989;HP:0008404;HP:0001337;HP:0002240;HP:0001596;HP:0003202;HP:0012192;HP:0000656;HP:0100725;HP:0001744;HP:0004332;HP:0010701;HP:0009830;HP:0000958;HP:0007400;HP:0002721;HP:0100758;HP:0001019;HP:0002103	Poikiloderma;Dry skin;Splenomegaly;Lymphadenopathy;Pruritus;Erythema;Skin ulcer;Abnormal eyelid morphology;Hypopigmented skin patches;Abnormality of bone marrow cell morphology;Irregular hyperpigmentation;Hyperkeratosis;Hepatomegaly;Skin plaque;Edema;Eczema;Abnormality of the nail;Skin rash;Alopecia;Neoplasm of the skin;Abnormal lymphocyte morphology;Cutaneous T-cell lymphoma;Palmoplantar keratoderma;Lymphadenopathy;Edema;Abnormal facial shape;Neoplasm of the skin;Pruritus;Nail dystrophy;Tremor;Hepatomegaly;Alopecia;Skeletal muscle atrophy;Cutaneous T-cell lymphoma;Ectropion;Lichenification;Splenomegaly;Abnormal lymphocyte morphology;Abnormal immunoglobulin level;Peripheral neuropathy;Dry skin;Irregular hyperpigmentation;Immunodeficiency;Gangrene;Erythroderma;Abnormal pleura morphology	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0807	N	N	S	N	0.842217408829783	E	Tnfrsf1b	neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); liver/biliary system phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; immune system phenotype; vision/eye phenotype; muscle phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; craniofacial phenotype; 	tnfrsf1b	nucleate erythrocyte	increased accumulation	abnormal	0.2072	0.2551	0.2562	0.2104	0.2669	0.190895	0.2172	0.204849	0.192939	PASS	0	0.232	66	0.22695	54	chr1	12192835	NA	C	T	575.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=1.272;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.8;AS_ReadPosRankSum=-0.2;AS_SOR=0.489;BaseQRankSum=-1.166;DP=50;ExcessHet=3.0103;FS=1.272;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.79;ReadPosRankSum=-0.137;SOR=0.489	GT:AD:DP:GQ:PL	0/1:21,24:45:99:583,0,539
chr1	12192898	12192898	T	G	TNFRSF1B	exonic	nonsynonymous SNV	NA	TNFRSF1B:NM_001066:exon6:c.T587G:p.M196R	0.301724	GME_SD	56	4	HeterozygousVariant	het	128	63	65	0.5078125	1447.64	PASS	6.446	NA	191191	Benign	Classic mycosis fungoides;S�zary syndrome	Disease-causing somatic mutation(s) in;Disease-causing somatic mutation(s) in	Tuberculosis[29036319];Blood protein levels[29875488;30072576];Urate levels (BMI interaction)[25811787];	HP:0001029;HP:0000958;HP:0001744;HP:0002716;HP:0000989;HP:0010783;HP:0200042;HP:0000492;HP:0001053;HP:0005561;HP:0007400;HP:0000962;HP:0002240;HP:0200035;HP:0000969;HP:0000964;HP:0001597;HP:0000988;HP:0001596;HP:0008069;HP:0004332;HP:0012192;HP:0000982;HP:0002716;HP:0000969;HP:0001999;HP:0008069;HP:0000989;HP:0008404;HP:0001337;HP:0002240;HP:0001596;HP:0003202;HP:0012192;HP:0000656;HP:0100725;HP:0001744;HP:0004332;HP:0010701;HP:0009830;HP:0000958;HP:0007400;HP:0002721;HP:0100758;HP:0001019;HP:0002103	Poikiloderma;Dry skin;Splenomegaly;Lymphadenopathy;Pruritus;Erythema;Skin ulcer;Abnormal eyelid morphology;Hypopigmented skin patches;Abnormality of bone marrow cell morphology;Irregular hyperpigmentation;Hyperkeratosis;Hepatomegaly;Skin plaque;Edema;Eczema;Abnormality of the nail;Skin rash;Alopecia;Neoplasm of the skin;Abnormal lymphocyte morphology;Cutaneous T-cell lymphoma;Palmoplantar keratoderma;Lymphadenopathy;Edema;Abnormal facial shape;Neoplasm of the skin;Pruritus;Nail dystrophy;Tremor;Hepatomegaly;Alopecia;Skeletal muscle atrophy;Cutaneous T-cell lymphoma;Ectropion;Lichenification;Splenomegaly;Abnormal lymphocyte morphology;Abnormal immunoglobulin level;Peripheral neuropathy;Dry skin;Irregular hyperpigmentation;Immunodeficiency;Gangrene;Erythroderma;Abnormal pleura morphology	Susceptibility_to_severe_coronavirus_disease_(COVID-19)	no_assertion_criteria_provided	Uncertain_significance	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	TNFR/NGFR cysteine-rich region|Tumor necrosis factor receptor 1B, N-terminal	NA	NA	Medium	Medium	Medium	NA	NA	0.0807	N	N	S	N	0.842217408829783	E	Tnfrsf1b	neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); liver/biliary system phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; renal/urinary system phenotype; immune system phenotype; vision/eye phenotype; muscle phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; craniofacial phenotype; 	tnfrsf1b	nucleate erythrocyte	increased accumulation	abnormal	0.2163	0.2622	0.2644	0.217	0.2663	0.194688	0.2305	0.220599	0.208539	PASS	0.301724	0.241	290	0.239437	60	chr1	12192898	NA	T	G	1447.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=3.302;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.31;AS_ReadPosRankSum=1.2;AS_SOR=0.454;BaseQRankSum=-0.867;DP=133;ExcessHet=3.0103;FS=3.302;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.31;ReadPosRankSum=1.28;SOR=0.454	GT:AD:DP:GQ:PL	0/1:63,65:128:99:1455,0,1498
chr1	12268870	12268870	A	G	VPS13D	exonic	nonsynonymous SNV	NA	VPS13D:NM_015378:exon16:c.A1966G:p.T656A,VPS13D:NM_018156:exon16:c.A1966G:p.T656A	0	GnomAdExome_AF			HeterozygousVariant	het	28	12	16	0.571428571428571	402.64	PASS	22.6	NA	608877	Uncertain significance	NA	NA	Cytokine-stimulated IL-6 production[25896417];Cytokine and corticosteroid-stimulated IL-6 production[25896417];	HP:0002500;HP:0001761;HP:0003487;HP:0032105;HP:0001260;HP:0003477;HP:0000639;HP:0001257;HP:0001347;HP:0000252;HP:0001337;HP:0002359;HP:0003828;HP:0000007;HP:0003693;HP:0001256;HP:0001336;HP:0003581;HP:0008936;HP:0002066;HP:0001251;HP:0001332;HP:0007338;HP:0002380;HP:0002460;HP:0001270	Abnormality of the cerebral white matter;Pes cavus;Babinski sign;Macrosaccadic oscillations;Dysarthria;Peripheral axonal neuropathy;Nystagmus;Spasticity;Hyperreflexia;Microcephaly;Tremor;Frequent falls;Variable expressivity;Autosomal recessive inheritance;Distal amyotrophy;Intellectual disability, mild;Myoclonus;Adult onset;Muscular hypotonia of the trunk;Gait ataxia;Ataxia;Dystonia;Hypermetric saccades;Fasciculations;Distal muscle weakness;Motor delay	NA	NA	NA	Widely expressed. {ECO:0000269|PubMed:15498460}.;	NA	D	B	B	D	D	M	NA	NA	T	T	T	T	T	T	T	D	T	.;.;	D	D	VPS13, repeated coiled region;.	NA	NA	Medium	Medium	Medium	amygdala;alveolus;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;head and neck;hypopharynx;mammary gland;atrium;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;oesophagus;nervous;frontal lobe;colon;placenta;prostate;nasopharynx;breast;optic nerve;hypothalamus;	ciliary ganglion;amygdala;prefrontal cortex;subthalamic nucleus;superior cervical ganglion;atrioventricular node;trigeminal ganglion;parietal lobe;skeletal muscle;globus pallidus;	0.655	E	E	E	E	0.582221207941028	E	Vps13d	mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0	0	0	0	0	0	0	0	0		0					chr1	12268870	NA	A	G	402.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.39;AS_ReadPosRankSum=0.1;AS_SOR=0.941;BaseQRankSum=0.895;DP=34;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.38;ReadPosRankSum=0.116;SOR=0.941	GT:AD:DP:GQ:PL	0/1:12,16:28:99:410,0,254
chr1	12341811	12341811	A	C	VPS13D	exonic	synonymous SNV	NA	VPS13D:NM_018156:exon40:c.A8583C:p.P2861P,VPS13D:NM_015378:exon41:c.A8658C:p.P2886P	0.9189	GnomAdGenome_AF_ami	527	81	HomozygousVariant	hom	115	0	115	1	3219.06	PASS	NA	NA	608877	Benign	NA	NA	Cytokine-stimulated IL-6 production[25896417];Cytokine and corticosteroid-stimulated IL-6 production[25896417];	HP:0002500;HP:0001761;HP:0003487;HP:0032105;HP:0001260;HP:0003477;HP:0000639;HP:0001257;HP:0001347;HP:0000252;HP:0001337;HP:0002359;HP:0003828;HP:0000007;HP:0003693;HP:0001256;HP:0001336;HP:0003581;HP:0008936;HP:0002066;HP:0001251;HP:0001332;HP:0007338;HP:0002380;HP:0002460;HP:0001270	Abnormality of the cerebral white matter;Pes cavus;Babinski sign;Macrosaccadic oscillations;Dysarthria;Peripheral axonal neuropathy;Nystagmus;Spasticity;Hyperreflexia;Microcephaly;Tremor;Frequent falls;Variable expressivity;Autosomal recessive inheritance;Distal amyotrophy;Intellectual disability, mild;Myoclonus;Adult onset;Muscular hypotonia of the trunk;Gait ataxia;Ataxia;Dystonia;Hypermetric saccades;Fasciculations;Distal muscle weakness;Motor delay	NA	NA	NA	Widely expressed. {ECO:0000269|PubMed:15498460}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	amygdala;alveolus;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;head and neck;hypopharynx;mammary gland;atrium;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;oesophagus;nervous;frontal lobe;colon;placenta;prostate;nasopharynx;breast;optic nerve;hypothalamus;	ciliary ganglion;amygdala;prefrontal cortex;subthalamic nucleus;superior cervical ganglion;atrioventricular node;trigeminal ganglion;parietal lobe;skeletal muscle;globus pallidus;	0.655	E	E	E	E	0.582221207941028	E	Vps13d	mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.7877	0.8977	0.8962	0.7844	0.9189	0.796725	0.7886	0.786187	0.793103	PASS	0.853535	0.803	244	0.75	51	chr1	12341811	NA	A	C	3219.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.99;AS_ReadPosRankSum=.;AS_SOR=0.782;DP=115;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.99;SOR=0.782	GT:AD:DP:GQ:PL	1/1:0,115:115:99:3233,344,0
chr1	12568430	12568430	G	A	DHRS3	intronic	NA	NA	NA	0.2098	GnomAdExome_AF_afr	6	2	HeterozygousVariant	het	65	29	36	0.553846153846154	828.64	PASS	NA	NA	612830	NA	NA	NA	Optic cup area[25631615;25631615];	NA	NA	NA	NA	NA	Widely expressed with highest levels found in heart, placenta, lung, liver, kidney, pancreas, thyroid, testis, stomach, trachea and spinal cord. Lower levels found in skeletal muscle, intestine and lymph node. No expression detected in brain. In the retina, expressed in cone but not rod outer segments. {ECO:0000269|PubMed:11861404, ECO:0000269|PubMed:9705317}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0.002	Medium	Medium	Medium	NA	NA	0.0298	NA	N	N	N	0.945477499888518	E	Dhrs3	vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); growth/size/body region phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.0602	0.2098	0.2048	0.0907	0.2052	0.126797	0.0946	0.0611894	0.08046	PASS	0	0.076	103	0.077465	18	chr1	12568430	NA	G	A	828.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=2.058;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.75;AS_ReadPosRankSum=0.3;AS_SOR=0.475;BaseQRankSum=-1.168;DP=66;ExcessHet=3.0103;FS=2.058;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.75;ReadPosRankSum=0.304;SOR=0.475	GT:AD:DP:GQ:PL	0/1:29,36:65:99:836,0,678
chr1	12568442	12568442	A	C	DHRS3	intronic	NA	NA	NA	0.2633	GnomAdExome_AF_asj	14	6	HeterozygousVariant	het	53	30	23	0.433962264150943	486.64	PASS	NA	NA	612830	NA	NA	NA	Optic cup area[25631615;25631615];	NA	NA	NA	NA	NA	Widely expressed with highest levels found in heart, placenta, lung, liver, kidney, pancreas, thyroid, testis, stomach, trachea and spinal cord. Lower levels found in skeletal muscle, intestine and lymph node. No expression detected in brain. In the retina, expressed in cone but not rod outer segments. {ECO:0000269|PubMed:11861404, ECO:0000269|PubMed:9705317}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0298	NA	N	N	N	0.945477499888518	E	Dhrs3	vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); growth/size/body region phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.1891	0.2398	0.238	0.1697	0.2539	0.110224	0.1827	0.18763	0.155993	PASS	0	0.17	134	0.176056	38	chr1	12568442	NA	A	C	486.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=1.092;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.19;AS_ReadPosRankSum=-1;AS_SOR=0.459;BaseQRankSum=-1.294;DP=56;ExcessHet=3.0103;FS=1.092;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.18;ReadPosRankSum=-0.916;SOR=0.459	GT:AD:DP:GQ:PL	0/1:30,23:53:99:494,0,800
chr1	12579281	12579281	G	C	DHRS3	intronic	NA	NA	NA	0.2019	GnomAdExome_AF_afr	6	1	HeterozygousVariant	het	50	24	26	0.52	568.64	PASS	NA	NA	612830	NA	NA	NA	Optic cup area[25631615;25631615];	NA	NA	NA	NA	NA	Widely expressed with highest levels found in heart, placenta, lung, liver, kidney, pancreas, thyroid, testis, stomach, trachea and spinal cord. Lower levels found in skeletal muscle, intestine and lymph node. No expression detected in brain. In the retina, expressed in cone but not rod outer segments. {ECO:0000269|PubMed:11861404, ECO:0000269|PubMed:9705317}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0298	NA	N	N	N	0.945477499888518	E	Dhrs3	vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); growth/size/body region phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.0583	0.2019	0.1961	0.0869	0.1962	0.126398	0.0915	0.059443	0.071429	VQSRTrancheSNP99.00to99.90	0	0.07	94	0.056338	14	chr1	12579281	NA	G	C	568.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=2.381;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.38;AS_ReadPosRankSum=-0.6;AS_SOR=0.419;BaseQRankSum=-0.565;DP=50;ExcessHet=3.0103;FS=2.381;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.37;ReadPosRankSum=-0.573;SOR=0.419	GT:AD:DP:GQ:PL	0/1:24,26:50:99:576,0,552
chr1	12716341	12716341	T	A	AADACL3	exonic	synonymous SNV	NA	AADACL3:NM_001103170:exon1:c.T165A:p.T55T	0.5152	GnomAdGenome_AF_afr			HomozygousVariant	hom	82	0	82	1	2268.06	PASS	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.92	NA	N	N	N	0.070422688089105	N	Aadacl3	NA	NA	NA	NA	NA	0	0	0	0.2818	0.5152	0	0	0.0041785	0		0					chr1	12716341	NA	T	A	2268.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.66;AS_ReadPosRankSum=.;AS_SOR=1.151;DP=83;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.66;SOR=1.151	GT:AD:DP:GQ:PL	1/1:0,82:82:99:2282,245,0
chr1	12725527	12725527	T	G	AADACL3	exonic	nonsynonymous SNV	NA	AADACL3:NM_001103170:exon4:c.T755G:p.F252C	0.4764	GnomAdGenome_AF_afr			HeterozygousVariant	het	127	68	59	0.464566929133858	1452.64	PASS	12.61	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.92	NA	N	N	N	0.070422688089105	N	Aadacl3	NA	NA	NA	NA	NA	0	0	0	0.3301	0.4764	0	0	0.0000259	0		0					chr1	12725527	NA	T	G	1452.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=8.014;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.44;AS_ReadPosRankSum=-0.5;AS_SOR=0.508;BaseQRankSum=1.35;DP=128;ExcessHet=3.0103;FS=8.014;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.44;ReadPosRankSum=-0.404;SOR=0.508	GT:AD:DP:GQ:PL	0/1:68,59:127:99:1460,0,1654
chr1	12760937	12760937	C	T	C1orf158	exonic	nonsynonymous SNV	NA	C1orf158:NM_001330361:exon3:c.C457T:p.L153F,C1orf158:NM_152290:exon4:c.C571T:p.L191F	0.2346	GnomAdGenome_AF_fin			HeterozygousVariant	het	98	40	58	0.591836734693878	1388.64	PASS	7.774	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	T	.;.;	NA	NA	.;.	NA	NA	Medium	Medium	Medium	lung;testis;unclassifiable (Anatomical System);medulla oblongata;	NA	0.839	NA	N	N	N	NA	NA	1700012P22Rik	NA	NA	NA	NA	NA	0	0	0	0.1807	0.2346	0	0	0.0061707	0		0					chr1	12760937	NA	C	T	1388.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=5.198;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.17;AS_ReadPosRankSum=-0.2;AS_SOR=1.21;BaseQRankSum=-0.35;DP=103;ExcessHet=3.0103;FS=5.198;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.17;ReadPosRankSum=-0.119;SOR=1.21	GT:AD:DP:GQ:PL	0/1:40,58:98:99:1396,0,882
chr1	12775725	12775725	C	T	PRAMEF12	exonic	nonsynonymous SNV	NA	PRAMEF12:NM_001080830:exon2:c.C470T:p.T157M	0.3922	GnomAdGenome_AF_afr			HeterozygousVariant	het	102	55	47	0.46078431372549	1047.64	PASS	0.053	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	T	.;	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.803	NA	N	N	N	0.0823890746513071	N	Pramef12	NA	NA	NA	NA	NA	0	0	0	0.2615	0.3922	0	0	0.0052069	0		0					chr1	12775725	NA	C	T	1047.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=3.649;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.27;AS_ReadPosRankSum=0;AS_SOR=0.997;BaseQRankSum=-0.238;DP=106;ExcessHet=3.0103;FS=3.649;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.27;ReadPosRankSum=0.04;SOR=0.997	GT:AD:DP:GQ:PL	0/1:55,47:102:99:1055,0,1305
chr1	12777320	12777320	C	T	PRAMEF12	exonic	synonymous SNV	NA	PRAMEF12:NM_001080830:exon3:c.C1173T:p.A391A	0.152344	GME_CA	5	3	HeterozygousVariant	het	273	129	144	0.527472527472527	3561.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.803	NA	N	N	N	0.0823890746513071	N	Pramef12	NA	NA	NA	NA	NA	0.0826	0.1219	0.1173	0.0695	0.1073	0.0493211	0.0717	0.0110283	0.066102	VQSRTrancheSNP99.00to99.90	0.152344	0.082	67	0.119718	28	chr1	12777320	NA	C	T	3561.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.8;AS_FS=1.448;AS_MQ=55.32;AS_MQRankSum=-7.7;AS_QD=13.05;AS_ReadPosRankSum=0;AS_SOR=0.65;BaseQRankSum=2.85;DP=286;ExcessHet=3.0103;FS=1.448;MLEAC=1;MLEAF=0.5;MQ=57.69;MQRankSum=-7.608;QD=13.05;ReadPosRankSum=0.006;SOR=0.65	GT:AD:DP:GQ:PL	0/1:129,144:273:99:3569,0,2796
chr1	12794381	12794381	G	C	PRAMEF1	exonic	nonsynonymous SNV	NA	PRAMEF1:NM_023013:exon3:c.G754C:p.E252Q	0.2111	GnomAdGenome_AF_eas			HeterozygousVariant	het	145	86	59	0.406896551724138	1402.64	PASS	0.044	NA	NA	Uncertain significance	NA	NA	Molybdenum levels[26025379];	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	T	.;	NA	NA	NA	NA	NA	Medium	Medium	Medium	testis;	NA	0.994	NA	N	NA	N	0.100781743081942	N	NA	NA	NA	NA	NA	NA	0	0	0	0.1282	0.2111	0	0	0.0000129	0		0					chr1	12794381	NA	G	C	1402.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=3.016;AS_MQ=59.89;AS_MQRankSum=0.6;AS_QD=9.68;AS_ReadPosRankSum=0.4;AS_SOR=0.976;BaseQRankSum=1.39;DP=147;ExcessHet=3.0103;FS=3.016;MLEAC=1;MLEAF=0.5;MQ=59.65;MQRankSum=0.667;QD=9.67;ReadPosRankSum=0.497;SOR=0.976	GT:AD:DP:GQ:PL	0/1:86,59:145:99:1410,0,2054
chr1	12825431	12825431	T	G	PRAMEF11	exonic	synonymous SNV	NA	PRAMEF11:NM_001146344:exon4:c.A948C:p.L316L	0.3422	GnomAdGenome_AF_afr			HeterozygousVariant	het	16	7	9	0.5625	200.64	MQ40	NA	NA	NA	Likely benign	NA	NA	Molybdenum levels[26025379];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	N	NA	0.0239285502929103	N	NA	NA	NA	NA	NA	NA	0	0	0	0.3177	0.3422	0	0	0.0000065	0		0					chr1	12825431	NA	T	G	200.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.9;AS_FS=0;AS_MQ=24.66;AS_MQRankSum=-0.6;AS_QD=12.56;AS_ReadPosRankSum=0.5;AS_SOR=0.941;BaseQRankSum=3.92;DP=16;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=25.03;MQRankSum=-0.561;QD=12.54;ReadPosRankSum=0.566;SOR=0.941	GT:AD:DP:GQ:PL	0/1:7,9:16:99:208,0,150
chr1	12827195	12827195	C	G	PRAMEF11	intronic	NA	NA	NA	0.2563	GnomAdGenome_AF_afr			HeterozygousVariant	het	63	0	31	0.492063492063492	1744.1	MQ40;SOR3	NA	NA	NA	NA	NA	NA	Molybdenum levels[26025379];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	N	NA	0.0239285502929103	N	NA	NA	NA	NA	NA	NA	0	0	0	0.1794	0.2563	0.233626	0	0.0722299	0		0					chr1	12827195	NA	C	G	1744.1	MQ40;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=33.82;AS_MQRankSum=.;AS_QD=20.94;AS_ReadPosRankSum=.;AS_SOR=1.839;DP=63;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=35.32;QD=27.68;SOR=3.021	GT:AD:DP:GQ:PL	1/0:0,31:63:99:1761,1020,927
chr1	12827195	12827195	C	T	PRAMEF11	intronic	NA	NA	NA	0.6417	GnomAdGenome_AF_afr			HeterozygousVariant	het	63	0	32	0.507936507936508	1744.1	MQ40;SOR3	NA	NA	NA	NA	NA	NA	Molybdenum levels[26025379];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	N	NA	0.0239285502929103	N	NA	NA	NA	NA	NA	NA	0	0	0	0.6108	0.6417	0	0	0.0000768	0		0					chr1	12827195	NA	C	T	1744.1	MQ40;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=36.72;AS_MQRankSum=.;AS_QD=29.06;AS_ReadPosRankSum=.;AS_SOR=4.68;DP=63;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=35.32;QD=27.68;SOR=3.021	GT:AD:DP:GQ:PL	0/1:0,32:63:99:1761,741,646
chr1	12827720	12827720	T	G	PRAMEF11	exonic	nonsynonymous SNV	NA	PRAMEF11:NM_001146344:exon3:c.A404C:p.K135T	0.9982	GnomAdGenome_AF_afr			HomozygousVariant	hom	223	4	219	0.982062780269058	6592.06	PASS	2.598	NA	NA	NA	NA	NA	Molybdenum levels[26025379];	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	N	NA	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	N	NA	0.0239285502929103	N	NA	NA	NA	NA	NA	NA	0	0	0	0.9927	0.9982	0	0	0.0000384	0		0					chr1	12827720	NA	T	G	6592.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.5;AS_FS=0;AS_MQ=50.11;AS_MQRankSum=3.3;AS_QD=29.56;AS_ReadPosRankSum=-0.9;AS_SOR=0.88;BaseQRankSum=1.56;DP=227;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=49.94;MQRankSum=3.33;QD=29.56;ReadPosRankSum=-0.821;SOR=0.88	GT:AD:DP:GQ:PL	1/1:4,219:223:99:6606,570,0
chr1	12827898	12827898	C	G	PRAMEF11	intronic	NA	NA	NA	0.137931	abraom_freq	0	2	HeterozygousVariant	het	32	18	14	0.4375	442.64	PASS	NA	NA	NA	NA	NA	NA	Molybdenum levels[26025379];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	N	NA	0.0239285502929103	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0176	0.0494	0.0405351	0	0.0018693	0.137931	VQSRTrancheSNP99.90to100.00	0	0.017	6	0.028409	1	chr1	12827898	NA	C	G	442.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=0;AS_MQ=49.15;AS_MQRankSum=-4.2;AS_QD=13.84;AS_ReadPosRankSum=-0.6;AS_SOR=0.927;BaseQRankSum=-0.161;DP=33;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=55.65;MQRankSum=-4.149;QD=13.83;ReadPosRankSum=-0.513;SOR=0.927	GT:AD:DP:GQ:PL	0/1:18,14:32:99:450,0,586
chr1	12828529	12828529	C	A	PRAMEF11	exonic	synonymous SNV	NA	PRAMEF11:NM_001146344:exon2:c.G261T:p.L87L	0.4554	GnomAdGenome_AF_afr			WT/SomaticVariant	het	84	63	21	0.25	483.64	MQ40	NA	NA	NA	Likely benign	NA	NA	Molybdenum levels[26025379];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	N	NA	0.0239285502929103	N	NA	NA	NA	NA	NA	NA	0	0	0	0.3821	0.4554	0	0	0.0000384	0		0					chr1	12828529	NA	C	A	483.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.3;AS_FS=7.92;AS_MQ=36.73;AS_MQRankSum=-3.2;AS_QD=5.76;AS_ReadPosRankSum=-1.5;AS_SOR=1.815;BaseQRankSum=2.38;DP=86;ExcessHet=3.0103;FS=7.92;MLEAC=1;MLEAF=0.5;MQ=38.31;MQRankSum=-3.194;QD=5.76;ReadPosRankSum=-1.421;SOR=1.815	GT:AD:DP:GQ:PL	0/1:63,21:84:99:491,0,1590
chr1	12838794	12838794	C	T	PRAMEF11;HNRNPCL1	intergenic	NA	dist=7384;dist=8583	NA	0.1405	GnomAdGenome_AF_fin	1	1	HeterozygousVariant	het	146	54	92	0.63013698630137	2262.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1038	0.1405	0.0888578	0	0.0085186	0		0	0.061	23	0.15625	3	chr1	12838794	NA	C	T	2262.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-4.3;AS_FS=0;AS_MQ=51.32;AS_MQRankSum=1;AS_QD=15.5;AS_ReadPosRankSum=1.6;AS_SOR=0.678;BaseQRankSum=-4.248;DP=148;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=50.79;MQRankSum=1.04;QD=15.5;ReadPosRankSum=1.63;SOR=0.678	GT:AD:DP:GQ:PL	0/1:54,92:146:99:2270,0,1852
chr1	12838801	12838801	G	A	PRAMEF11;HNRNPCL1	intergenic	NA	dist=7391;dist=8576	NA	0.6027	GnomAdGenome_AF_afr			HeterozygousVariant	het	138	92	46	0.333333333333333	996.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.5329	0.6027	0	0	0.0000384	0		0					chr1	12838801	NA	G	A	996.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.438;AS_MQ=48.6;AS_MQRankSum=-1.8;AS_QD=7.22;AS_ReadPosRankSum=-1.3;AS_SOR=0.873;BaseQRankSum=0.458;DP=141;ExcessHet=3.0103;FS=1.438;MLEAC=1;MLEAF=0.5;MQ=49.91;MQRankSum=-1.787;QD=7.22;ReadPosRankSum=-1.252;SOR=0.873	GT:AD:DP:GQ:PL	0/1:92,46:138:99:1004,0,3635
chr1	12838814	12838814	C	G	PRAMEF11;HNRNPCL1	intergenic	NA	dist=7404;dist=8563	NA	0.2139	GnomAdGenome_AF_eas	7	2	HeterozygousVariant	het	145	98	47	0.324137931034483	1175.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1232	0.2139	0.141973	0	0.0533656	0		0	0.112	32	0.28125	5	chr1	12838814	NA	C	G	1175.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.4;AS_FS=0;AS_MQ=46.65;AS_MQRankSum=-2.4;AS_QD=8.11;AS_ReadPosRankSum=-0.8;AS_SOR=0.735;BaseQRankSum=3.43;DP=147;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=48.7;MQRankSum=-2.328;QD=8.11;ReadPosRankSum=-0.78;SOR=0.735	GT:AD:DP:GQ:PL	0/1:98,47:145:99:1183,0,3866
chr1	12838820	12838820	T	G	PRAMEF11;HNRNPCL1	intergenic	NA	dist=7410;dist=8557	NA	0.2653	GnomAdGenome_AF_ami			HeterozygousVariant	het	143	93	50	0.34965034965035	1739.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1821	0.2653	0	0	0.0000384	0		0					chr1	12838820	NA	T	G	1739.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.6;AS_FS=0;AS_MQ=45.99;AS_MQRankSum=-2.5;AS_QD=12.17;AS_ReadPosRankSum=-1.4;AS_SOR=0.751;BaseQRankSum=3.67;DP=145;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=48.25;MQRankSum=-2.499;QD=12.17;ReadPosRankSum=-1.33;SOR=0.751	GT:AD:DP:GQ:PL	0/1:93,50:143:99:1747,0,2296
chr1	12838849	12838849	C	T	PRAMEF11;HNRNPCL1	intergenic	NA	dist=7439;dist=8528	NA	0.1907	GnomAdGenome_AF_amr	5	0	HeterozygousVariant	het	133	92	41	0.308270676691729	788.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1178	0.1907	0.108826	0	0.0631627	0		0	0.143	49	0.28125	9	chr1	12838849	NA	C	T	788.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.8;AS_FS=1.498;AS_MQ=39.01;AS_MQRankSum=-3.5;AS_QD=5.93;AS_ReadPosRankSum=0;AS_SOR=0.54;BaseQRankSum=1.85;DP=135;ExcessHet=3.0103;FS=1.498;MLEAC=1;MLEAF=0.5;MQ=43.62;MQRankSum=-3.438;QD=5.93;ReadPosRankSum=0.088;SOR=0.54	GT:AD:DP:GQ:PL	0/1:92,41:133:99:796,0,2162
chr1	12838922	12838922	C	G	PRAMEF11;HNRNPCL1	intergenic	NA	dist=7512;dist=8455	NA	0.8024	GnomAdGenome_AF_afr	63	7	HomozygousVariant	hom	74	2	72	0.972972972972973	3104.06	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.6681	0.8024	0.683307	0	0.349508	0		0	0.566	72	0.65625	7	chr1	12838922	NA	C	G	3104.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.6;AS_FS=4.626;AS_MQ=36.88;AS_MQRankSum=-1.9;AS_QD=34.55;AS_ReadPosRankSum=2.2;AS_SOR=2.964;BaseQRankSum=1.65;DP=76;ExcessHet=3.0103;FS=4.626;MLEAC=2;MLEAF=1;MQ=37.01;MQRankSum=-1.884;QD=28.41;ReadPosRankSum=2.22;SOR=2.964	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:2,72:74:99:1|1:12838922_C_G:3118,173,0:12838922
chr1	12838925	12838925	T	A	PRAMEF11;HNRNPCL1	intergenic	NA	dist=7515;dist=8452	NA	0.8005	GnomAdGenome_AF_afr	63	7	HomozygousVariant	hom	74	2	72	0.972972972972973	3109.06	MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.6648	0.8005	0.678315	0	0.342862	0		0	0.565	73	0.65625	7	chr1	12838925	NA	T	A	3109.06	MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=4.915;AS_MQ=36.88;AS_MQRankSum=-1.9;AS_QD=28.96;AS_ReadPosRankSum=.;AS_SOR=3.136;DP=75;ExcessHet=3.0103;FS=4.915;MLEAC=2;MLEAF=1;MQ=37.19;MQRankSum=-1.884;QD=33.52;SOR=3.136	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:2,72:74:99:1|1:12838922_C_G:3123,173,0:12838922
chr1	12838957	12838957	T	C	PRAMEF11;HNRNPCL1	intergenic	NA	dist=7547;dist=8420	NA	0.4752	GnomAdGenome_AF_sas	42	1	HeterozygousVariant	het	59	27	32	0.542372881355932	883.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.336	0.4752	0.366414	0	0.231558	0		0	0.457	77	0.392857	9	chr1	12838957	NA	T	C	883.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.1;AS_FS=1.207;AS_MQ=35.62;AS_MQRankSum=-2.7;AS_QD=14.98;AS_ReadPosRankSum=-0.9;AS_SOR=0.919;BaseQRankSum=2.17;DP=64;ExcessHet=3.0103;FS=1.207;MLEAC=1;MLEAF=0.5;MQ=37.12;MQRankSum=-2.671;QD=14.98;ReadPosRankSum=-0.898;SOR=0.919	GT:AD:DP:GQ:PL	0/1:27,32:59:99:891,0,590
chr1	12882298	12882298	T	C	PRAMEF4	exonic	nonsynonymous SNV	NA	PRAMEF4:NM_001009611:exon3:c.A431G:p.K144R	0.9162	GnomAdGenome_AF_afr			HomozygousVariant	hom	142	2	140	0.985915492957746	4155.06	MQ40	0.256	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	0.993	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.7373	0.9162	0	0	0.0000384	0		0					chr1	12882298	NA	T	C	4155.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.3;AS_FS=0;AS_MQ=31.78;AS_MQRankSum=-2.5;AS_QD=29.26;AS_ReadPosRankSum=1.3;AS_SOR=0.693;BaseQRankSum=1.34;DP=150;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=32.41;MQRankSum=-2.48;QD=29.26;ReadPosRankSum=1.36;SOR=0.693	GT:AD:DP:GQ:PL	1/1:2,140:142:99:4169,376,0
chr1	12893161	12893161	G	C	PRAMEF10	exonic	nonsynonymous SNV	NA	PRAMEF10:NM_001039361:exon4:c.C1180G:p.L394V	0.1425	GnomAdGenome_AF_ami	0		HeterozygousVariant	het	70	48	22	0.314285714285714	591.64	MQ40	11.93	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	D	D	D	N	N	M	T	N	T	T	T	NA	T	T	T	T	NA	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.12211359038666	N	NA	NA	NA	NA	NA	NA	0.0214	0.0793	0.0772	0.0534	0.1425	0.0351438	0	0.0012742	0.031746	VQSRTrancheSNP99.00to99.90	0	0.003953	2			chr1	12893161	NA	G	C	591.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=9.112;AS_MQ=35.45;AS_MQRankSum=-2.5;AS_QD=8.46;AS_ReadPosRankSum=0.5;AS_SOR=0.126;BaseQRankSum=0.361;DP=71;ExcessHet=3.0103;FS=9.112;MLEAC=1;MLEAF=0.5;MQ=37.45;MQRankSum=-2.404;QD=8.45;ReadPosRankSum=0.589;SOR=0.126	GT:AD:DP:GQ:PL	0/1:48,22:70:99:599,0,1554
chr1	12893335	12893335	T	G	PRAMEF10	exonic	nonsynonymous SNV	NA	PRAMEF10:NM_001039361:exon4:c.A1006C:p.N336H	0.5359	GnomAdGenome_AF_ami			HomozygousVariant	het	252	64	188	0.746031746031746	5003.64	PASS	0.842	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.12211359038666	N	NA	NA	NA	NA	NA	NA	0	0	0	0.4853	0.5359	0	0	0.0000065	0		0					chr1	12893335	NA	T	G	5003.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=6.019;AS_MQ=54.19;AS_MQRankSum=0.8;AS_QD=19.86;AS_ReadPosRankSum=0.4;AS_SOR=0.837;BaseQRankSum=0.811;DP=257;ExcessHet=3.0103;FS=6.019;MLEAC=1;MLEAF=0.5;MQ=53.87;MQRankSum=0.89;QD=19.86;ReadPosRankSum=0.468;SOR=0.837	GT:AD:DP:GQ:PL	0/1:64,188:252:99:5011,0,1122
chr1	12893425	12893425	T	C	PRAMEF10	exonic	nonsynonymous SNV	NA	PRAMEF10:NM_001039361:exon4:c.A916G:p.T306A	0.4104	GnomAdGenome_AF_afr	2	1	HomozygousVariant	het	95	23	72	0.757894736842105	2450.64	SOR3	0.013	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	N	L	T	N	T	T	T	NA	T	T	T	T	NA	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.12211359038666	N	NA	NA	NA	NA	NA	NA	0.2727	0.3701	0.3748	0.3346	0.4104	0	0	0.0010284	0		0.230769	0.014	4	0.043478	2	chr1	12893425	NA	T	C	2450.64	SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=6.5;AS_FS=44.327;AS_MQ=38.99;AS_MQRankSum=-5.2;AS_QD=25.8;AS_ReadPosRankSum=0.5;AS_SOR=4.705;BaseQRankSum=6.58;DP=102;ExcessHet=3.0103;FS=44.327;MLEAC=1;MLEAF=0.5;MQ=41.87;MQRankSum=-5.138;QD=25.8;ReadPosRankSum=0.574;SOR=4.705	GT:AD:DP:GQ:PL	0/1:23,72:95:99:2458,0,293
chr1	12893460	12893460	G	A	PRAMEF10	exonic	nonsynonymous SNV	NA	PRAMEF10:NM_001039361:exon4:c.C881T:p.P294L	0.0521	GnomAdGenome_AF_afr			WT/SomaticVariant	het	56	44	12	0.214285714285714	168.64	MQ40	13.86	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	D	B	B	D	N	M	T	D	T	T	T	T	T	T	T	T	NA	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.12211359038666	N	NA	NA	NA	NA	NA	NA	0.0019	0.0091	0.0083	0.03	0.0521	0	0	0.0002305	0		0					chr1	12893460	NA	G	A	168.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-4.3;AS_FS=36.833;AS_MQ=43.72;AS_MQRankSum=5;AS_QD=3.02;AS_ReadPosRankSum=-3.5;AS_SOR=0.001;BaseQRankSum=-4.233;DP=60;ExcessHet=3.0103;FS=36.833;MLEAC=1;MLEAF=0.5;MQ=39.96;MQRankSum=5.01;QD=3.01;ReadPosRankSum=-3.416;SOR=0.001	GT:AD:DP:GQ:PL	0/1:44,12:56:99:176,0,1444
chr1	12895136	12895136	T	G	PRAMEF10	exonic	synonymous SNV	NA	PRAMEF10:NM_001039361:exon3:c.A316C:p.R106R	0.706	GnomAdGenome_AF_ami			HomozygousVariant	hom	87	0	87	1	2633.06	MQ40	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.12211359038666	N	NA	NA	NA	NA	NA	NA	0	0	0	0.5767	0.706	0	0	0	0		0					chr1	12895136	NA	T	G	2633.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=36.63;AS_MQRankSum=.;AS_QD=30.26;AS_ReadPosRankSum=.;AS_SOR=2.441;DP=90;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=36.46;QD=30.27;SOR=2.441	GT:AD:DP:GQ:PL	1/1:0,87:87:99:2647,261,0
chr1	12895167	12895167	A	G	PRAMEF10	intronic	NA	NA	NA	0.1152	GnomAdGenome_AF_ami			WT/SomaticVariant	het	30	26	4	0.133333333333333	36.64	MQ40;QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.12211359038666	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0678	0.1152	0	0	0	0		0					chr1	12895167	NA	A	G	36.64	MQ40;QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=0;AS_MQ=32.51;AS_MQRankSum=1.4;AS_QD=1.23;AS_ReadPosRankSum=0;AS_SOR=0.034;BaseQRankSum=0.678;DP=32;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=30.52;MQRankSum=1.44;QD=1.22;ReadPosRankSum=0.031;SOR=0.034	GT:AD:DP:GQ:PL	0/1:26,4:30:44:44,0,765
chr1	12920302	12920302	C	G	PRAMEF7	exonic	nonsynonymous SNV	NA	PRAMEF7:NM_001012277:exon4:c.C1314G:p.N438K	0.5843	GnomAdGenome_AF_eas			HomozygousVariant	hom	296	2	294	0.993243243243243	11075.1	MQ40	1.393	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;.;	NA	NA	.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	NA	0.0774679464911517	N	Pramef8	NA	NA	NA	NA	NA	0	0	0	0.5013	0.5843	0	0	0	0		0					chr1	12920302	NA	C	G	11075.1	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=38.07;AS_MQRankSum=-1.9;AS_QD=29;AS_ReadPosRankSum=2;AS_SOR=1.091;BaseQRankSum=0.83;DP=301;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=38.04;MQRankSum=-1.894;QD=30.65;ReadPosRankSum=2.07;SOR=1.091	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:2,294:296:99:1|1:12920302_C_G:11089,839,0:12920302
chr1	12920307	12920307	T	C	PRAMEF7	exonic	nonsynonymous SNV	NA	PRAMEF7:NM_001012277:exon4:c.T1319C:p.L440P	0.4537	GnomAdGenome_AF_ami			HeterozygousVariant	het	288	106	182	0.631944444444444	3978.64	MQ40	14.02	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;.;	NA	NA	.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	NA	0.0774679464911517	N	Pramef8	NA	NA	NA	NA	NA	0	0	0	0.3944	0.4537	0	0	0.0000384	0		0					chr1	12920307	NA	T	C	3978.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0.449;AS_MQ=38.12;AS_MQRankSum=-2.5;AS_QD=13.82;AS_ReadPosRankSum=-1;AS_SOR=0.731;BaseQRankSum=-0.329;DP=289;ExcessHet=3.0103;FS=0.449;MLEAC=1;MLEAF=0.5;MQ=38.19;MQRankSum=-2.462;QD=13.81;ReadPosRankSum=-0.963;SOR=0.731	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:106,182:288:99:0|1:12920302_C_G:3986,0,2023:12920302
chr1	12938780	12938780	C	A	PRAMEF6	exonic	synonymous SNV	NA	PRAMEF6:NM_001010889:exon4:c.G1326T:p.V442V	0.3608	GnomAdGenome_AF_fin			WT/SomaticVariant	het	373	281	92	0.246648793565684	1346.64	MQ40	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	NA	NA	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.0006	0.0016	0.0016	0.237	0.3608	0.00159744	0	0.0005379	0		0.041667					chr1	12938780	NA	C	A	1346.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=1.457;AS_MQ=39.11;AS_MQRankSum=-0.8;AS_QD=3.61;AS_ReadPosRankSum=0.2;AS_SOR=0.795;BaseQRankSum=-1.546;DP=379;ExcessHet=3.0103;FS=1.457;MLEAC=1;MLEAF=0.5;MQ=38.44;MQRankSum=-0.775;QD=3.61;ReadPosRankSum=0.224;SOR=0.795	GT:AD:DP:GQ:PL	0/1:281,92:373:99:1354,0,6535
chr1	12938859	12938859	G	A	PRAMEF6	exonic	nonsynonymous SNV	NA	PRAMEF6:NM_001010889:exon4:c.C1247T:p.P416L	0.3715	GnomAdGenome_AF_ami			WT/SomaticVariant	het	371	291	80	0.215633423180593	1063.64	MQ40	22.5	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	D	D	D	D	N	M	T	D	T	T	D	T	T	T	T	D	NA	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	NA	NA	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.0001	0.0002	0.0002	0.2381	0.3715	0	0	0.0000384	0.2	LowQual	0					chr1	12938859	NA	G	A	1063.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.4;AS_FS=0.973;AS_MQ=38.01;AS_MQRankSum=-1;AS_QD=2.87;AS_ReadPosRankSum=-0.5;AS_SOR=0.611;BaseQRankSum=-2.302;DP=376;ExcessHet=3.0103;FS=0.973;MLEAC=1;MLEAF=0.5;MQ=37.52;MQRankSum=-0.962;QD=2.87;ReadPosRankSum=-0.47;SOR=0.611	GT:AD:DP:GQ:PL	0/1:291,80:371:99:1071,0,6992
chr1	12939075	12939075	A	G	PRAMEF6	exonic	nonsynonymous SNV	NA	PRAMEF6:NM_001010889:exon4:c.T1031C:p.L344P	0.3844	GnomAdGenome_AF_ami			WT/SomaticVariant	het	25	20	5	0.2	74.64	MQ40	22.7	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	D	D	D	D	N	H	T	D	T	T	D	T	T	T	T	T	NA	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	NA	NA	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.0049	0.0285	0.026	0.2452	0.3844	0	0	0.0000384	0		0					chr1	12939075	NA	A	G	74.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.6;AS_FS=0;AS_MQ=26.61;AS_MQRankSum=0.7;AS_QD=3;AS_ReadPosRankSum=-0.4;AS_SOR=0.641;BaseQRankSum=2.62;DP=27;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=26.02;MQRankSum=0.784;QD=2.99;ReadPosRankSum=-0.34;SOR=0.641	GT:AD:DP:GQ:PL	0/1:20,5:25:82:82,0,538
chr1	12941356	12941356	C	T	PRAMEF6	exonic	nonsynonymous SNV	NA	PRAMEF6:NM_001010889:exon3:c.G497A:p.C166Y	0.7846	GnomAdExome_AF_afr	148	18	HomozygousVariant	hom	15	2	13	0.866666666666667	316.04	MQ40;SOR3	0.045	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	NA	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	NA	NA	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.5974	0.7846	0.7901	0.0142	0.0224	0	0	0.0383817	0.655797	VQSRTrancheSNP99.90to100.00	0.643251	0.643	371	0.596591	69	chr1	12941356	NA	C	T	316.04	MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=2.3;AS_FS=8.751;AS_MQ=22.08;AS_MQRankSum=-3.1;AS_QD=21.07;AS_ReadPosRankSum=0;AS_SOR=5.283;BaseQRankSum=2.38;DP=16;ExcessHet=3.0103;FS=8.751;MLEAC=2;MLEAF=1;MQ=23.83;MQRankSum=-3.041;QD=21.07;ReadPosRankSum=0.086;SOR=5.283	GT:AD:DP:GQ:PL	1/1:2,13:15:25:330,25,0
chr1	12941422	12941422	T	C	PRAMEF6	exonic	nonsynonymous SNV	NA	PRAMEF6:NM_001010889:exon3:c.A431G:p.Q144R	0.216254	1000g2015aug_all	37	4	HomozygousVariant	hom	38	1	37	0.973684210526316	942.06	MQ40	4.143	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	N	L	T	N	T	T	T	NA	T	T	T	T	NA	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	unclassifiable (Anatomical System);	NA	NA	NA	N	NA	NA	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.0061	0.0387	0.0376	0.0297	0.0636	0.216254	0	0.0095924	0.04023	VQSRTrancheSNP99.90to100.00	0	0.283	223	0.207865	29	chr1	12941422	NA	T	C	942.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=2.4;AS_FS=3.757;AS_MQ=26.16;AS_MQRankSum=-1;AS_QD=24.79;AS_ReadPosRankSum=0.3;AS_SOR=0.84;BaseQRankSum=2.43;DP=40;ExcessHet=3.0103;FS=3.757;MLEAC=2;MLEAF=1;MQ=27.04;MQRankSum=-0.932;QD=24.79;ReadPosRankSum=0.366;SOR=0.84	GT:AD:DP:GQ:PL	1/1:1,37:38:99:956,104,0
chr1	13030255	13030255	T	C	PRAMEF6;PRAMEF27	intergenic	NA	dist=82675;dist=19553	NA	0.1327	GnomAdGenome_AF_ami			HomozygousVariant	hom	52	0	52	1	1998.06	MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0755	0.1327	0	0	0	0		0					chr1	13030255	NA	T	C	1998.06	MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=38.78;AS_MQRankSum=.;AS_QD=29.76;AS_ReadPosRankSum=.;AS_SOR=7.941;DP=54;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=38.83;QD=32.91;SOR=7.941	GT:AD:DP:GQ:PL	1/1:0,52:52:99:2012,156,0
chr1	13030353	13030353	G	A	PRAMEF6;PRAMEF27	intergenic	NA	dist=82773;dist=19455	NA	0.2086	GnomAdGenome_AF_afr			HomozygousVariant	hom	9	0	9	1	260.05	DP10;MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1708	0.2086	0	0	0	0		0					chr1	13030353	NA	G	A	260.05	DP10;MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=32.83;AS_MQRankSum=.;AS_QD=28.89;AS_ReadPosRankSum=.;AS_SOR=4.615;DP=9;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=32.83;QD=28.89;SOR=4.615	GT:AD:DP:GQ:PL	1/1:0,9:9:27:274,27,0
chr1	13030384	13030384	T	G	PRAMEF6;PRAMEF27	intergenic	NA	dist=82804;dist=19424	NA	0.1025	GnomAdGenome_AF_afr			HomozygousVariant	hom	5	0	5	1	135.96	DP10;MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0746	0.1025	0	0	0	0		0					chr1	13030384	NA	T	G	135.96	DP10;MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=28.07;AS_MQRankSum=.;AS_QD=27.2;AS_ReadPosRankSum=.;AS_SOR=3.611;DP=5;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=28.07;QD=27.19;SOR=3.611	GT:AD:DP:GQ:PL	1/1:0,5:5:15:150,15,0
chr1	13030987	13030987	T	C	PRAMEF6;PRAMEF27	intergenic	NA	dist=83407;dist=18821	NA	0.0845	GnomAdGenome_AF_asj			HomozygousVariant	het	16	4	12	0.75	274.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0636	0.0845	0	0	0	0		0					chr1	13030987	NA	T	C	274.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.5;AS_FS=0;AS_MQ=24.42;AS_MQRankSum=-2.2;AS_QD=17.19;AS_ReadPosRankSum=-1.1;AS_SOR=2.049;BaseQRankSum=2.56;DP=16;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=24.7;MQRankSum=-2.177;QD=17.16;ReadPosRankSum=-1.094;SOR=2.049	GT:AD:DP:GQ:PL	0/1:4,12:16:73:282,0,73
chr1	13031829	13031829	G	A	PRAMEF6;PRAMEF27	intergenic	NA	dist=84249;dist=17979	NA	0.1529	GnomAdGenome_AF_sas			HomozygousVariant	hom	70	0	70	1	2307.06	MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0648	0.1529	0	0	0	0		0					chr1	13031829	NA	G	A	2307.06	MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=32.06;AS_MQRankSum=.;AS_QD=32.96;AS_ReadPosRankSum=.;AS_SOR=8.526;DP=72;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=31.93;QD=32.96;SOR=8.526	GT:AD:DP:GQ:PL	1/1:0,70:70:99:2321,210,0
chr1	13031877	13031877	T	G	PRAMEF6;PRAMEF27	intergenic	NA	dist=84297;dist=17931	NA	0.1909	GnomAdGenome_AF_afr			HomozygousVariant	hom	128	1	127	0.9921875	3838.06	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0897	0.1909	0	0	0	0		0					chr1	13031877	NA	T	G	3838.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.7;AS_FS=0;AS_MQ=34.46;AS_MQRankSum=-0.8;AS_QD=29.98;AS_ReadPosRankSum=1.1;AS_SOR=1.193;BaseQRankSum=1.76;DP=131;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=34.74;MQRankSum=-0.721;QD=29.98;ReadPosRankSum=1.15;SOR=1.193	GT:AD:DP:GQ:PL	1/1:1,127:128:99:3852,360,0
chr1	13053512	13053512	A	G	PRAMEF27	exonic	nonsynonymous SNV	NA	PRAMEF27:NM_001300891:exon1:c.T148C:p.C50R	0.0175	GnomAdGenome_AF_amr			HeterozygousVariant	het	5	2	3	0.6	66.64	DP10;MQ40	1.59	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.006	0.0175	0	0	0	0		0					chr1	13053512	NA	A	G	66.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=3.979;AS_MQ=25;AS_MQRankSum=-1.7;AS_QD=13.4;AS_ReadPosRankSum=0;AS_SOR=2.833;BaseQRankSum=1.65;DP=5;ExcessHet=3.0103;FS=3.979;MLEAC=1;MLEAF=0.5;MQ=32.87;MQRankSum=-1.645;QD=13.33;ReadPosRankSum=0;SOR=2.833	GT:AD:DP:GQ:PL	0/1:2,3:5:34:74,0,34
chr1	13053588	13053588	G	A	PRAMEF27	exonic	synonymous SNV	NA	PRAMEF27:NM_001300891:exon1:c.C72T:p.A24A	0.2922	GnomAdGenome_AF_afr			HomozygousVariant	hom	35	2	33	0.942857142857143	904.06	MQ40	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1619	0.2922	0	0	0	0		0					chr1	13053588	NA	G	A	904.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.3;AS_FS=3.432;AS_MQ=33.63;AS_MQRankSum=-1.7;AS_QD=25.83;AS_ReadPosRankSum=0.6;AS_SOR=2.235;BaseQRankSum=1.38;DP=36;ExcessHet=3.0103;FS=3.432;MLEAC=2;MLEAF=1;MQ=34.4;MQRankSum=-1.645;QD=25.83;ReadPosRankSum=0.676;SOR=2.235	GT:AD:DP:GQ:PL	1/1:2,33:35:56:918,56,0
chr1	13104656	13104656	C	G	PRAMEF36P;HNRNPCL2	intergenic	NA	dist=4939;dist=10832	NA	0.3639	GnomAdGenome_AF_eas	25		HomozygousVariant	hom	83	0	83	1	2754.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1967	0.3639	0.263978	0	0.119563	0		0	0.343	72			chr1	13104656	NA	C	G	2754.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=47.94;AS_MQRankSum=.;AS_QD=33.18;AS_ReadPosRankSum=.;AS_SOR=0.766;DP=90;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=47.93;QD=33.18;SOR=0.766	GT:AD:DP:GQ:PL	1/1:0,83:83:99:2768,248,0
chr1	13115950	13115950	T	C	HNRNPCL2;HNRNPCL3	exonic	nonsynonymous SNV	NA	HNRNPCL3:NM_001146181:exon1:c.A451G:p.N151D,HNRNPCL2:NM_001136561:exon2:c.A451G:p.N151D	0.2243	GnomAdGenome_AF_sas	0	0	HomozygousVariant	hom	99	0	99	1	3307.06	PASS	7.598	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	B	B	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	T	NA	NA	.;	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0541	0.1288	0.1278	0.1349	0.2243	0.15635	0.0817	0.0935693	0.078818	PASS	0.180769	0.213	253	0.193662	55	chr1	13115950	NA	T	C	3307.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=46.59;AS_MQRankSum=.;AS_QD=33.4;AS_ReadPosRankSum=.;AS_SOR=0.888;DP=105;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=46.69;QD=33.4;SOR=0.888	GT:AD:DP:GQ:PL	1/1:0,99:99:99:3321,296,0
chr1	13116324	13116324	A	G	HNRNPCL2;HNRNPCL3	exonic	nonsynonymous SNV	NA	HNRNPCL3:NM_001146181:exon1:c.T77C:p.L26P,HNRNPCL2:NM_001136561:exon2:c.T77C:p.L26P	0.0783	GnomAdExome_AF_sas	5	1	HeterozygousVariant	het	190	82	108	0.568421052631579	2722.64	PASS	4.897	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	B	B	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	T	NA	NA	.;	N	NA	RNA recognition motif domain|RNA recognition motif domain|RNA recognition motif domain	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0272	0.0783	0.0805	0.0228	0.0681	0.0429313	0.0219	0.0258082	0.039423	VQSRTrancheSNP99.00to99.90	0.03629	0.08	73	0.056738	14	chr1	13116324	NA	A	G	2722.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=3.49;AS_MQ=52.51;AS_MQRankSum=-0.5;AS_QD=14.33;AS_ReadPosRankSum=-2.3;AS_SOR=0.474;BaseQRankSum=-0.426;DP=196;ExcessHet=3.0103;FS=3.49;MLEAC=1;MLEAF=0.5;MQ=52.56;MQRankSum=-0.401;QD=14.33;ReadPosRankSum=-2.274;SOR=0.474	GT:AD:DP:GQ:PL	0/1:82,108:190:99:2730,0,2054
chr1	13149619	13149619	G	A	PRAMEF25;PRAMEF26	exonic	nonsynonymous SNV	NA	PRAMEF26:NM_001306072:exon3:c.C1055T:p.A352V,PRAMEF25:NM_001310134:exon3:c.C1055T:p.A352V	0.1031	GnomAdGenome_AF_eas	0		WT/SomaticVariant	het	99	80	19	0.191919191919192	174.64	MQ40;QD2	15.9	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	T	NA	NA	.;	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0011	0.0132	0.0132	0.043	0.1031	0	0	0	0		0	0.063	1			chr1	13149619	NA	G	A	174.64	MQ40;QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-4.1;AS_FS=0;AS_MQ=21.38;AS_MQRankSum=-1;AS_QD=1.77;AS_ReadPosRankSum=-0.4;AS_SOR=0.059;BaseQRankSum=-4.073;DP=100;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=21.75;MQRankSum=-0.99;QD=1.76;ReadPosRankSum=-0.396;SOR=0.059	GT:AD:DP:GQ:PL	0/1:80,19:99:99:182,0,1785
chr1	13175322	13175322	G	T	PRAMEF9	exonic	synonymous SNV	NA	PRAMEF9:NM_001010890:exon1:c.G42T:p.L14L	0.8206	GnomAdGenome_AF_ami			WT/SomaticVariant	het	129	97	32	0.248062015503876	645.64	PASS	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.6546	0.8206	0	0	0	0		0					chr1	13175322	NA	G	T	645.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=4.9;AS_FS=9.896;AS_MQ=32.55;AS_MQRankSum=-8;AS_QD=5.01;AS_ReadPosRankSum=-0.5;AS_SOR=1.178;BaseQRankSum=4.93;DP=133;ExcessHet=3.0103;FS=9.896;MLEAC=1;MLEAF=0.5;MQ=41.96;MQRankSum=-7.971;QD=5;ReadPosRankSum=-0.472;SOR=1.178	GT:AD:DP:GQ:PL	0/1:97,32:129:99:653,0,2419
chr1	13175352	13175352	C	T	PRAMEF9	exonic	synonymous SNV	NA	PRAMEF9:NM_001010890:exon1:c.C72T:p.A24A	0.7444	GnomAdGenome_AF_ami			WT/SomaticVariant	het	135	101	34	0.251851851851852	643.64	PASS	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.5197	0.7444	0	0	0	0		0					chr1	13175352	NA	C	T	643.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=6.3;AS_FS=1.585;AS_MQ=29.66;AS_MQRankSum=-8.1;AS_QD=4.77;AS_ReadPosRankSum=-2.3;AS_SOR=0.867;BaseQRankSum=6.31;DP=139;ExcessHet=3.0103;FS=1.585;MLEAC=1;MLEAF=0.5;MQ=41.16;MQRankSum=-8.075;QD=4.77;ReadPosRankSum=-2.242;SOR=0.867	GT:AD:DP:GQ:PL	0/1:101,34:135:99:651,0,2410
chr1	13175471	13175471	G	A	PRAMEF9	exonic	nonsynonymous SNV	NA	PRAMEF9:NM_001010890:exon1:c.G191A:p.R64H	0.1506	GnomAdGenome_AF_ami			WT/SomaticVariant	het	189	154	35	0.185185185185185	913.64	MQ40	0.081	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0788	0.1506	0	0	0	0		0					chr1	13175471	NA	G	A	913.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=0.689;AS_MQ=35.19;AS_MQRankSum=-2.5;AS_QD=4.84;AS_ReadPosRankSum=-1.3;AS_SOR=0.725;BaseQRankSum=-0.894;DP=193;ExcessHet=3.0103;FS=0.689;MLEAC=1;MLEAF=0.5;MQ=37.21;MQRankSum=-2.499;QD=4.83;ReadPosRankSum=-1.209;SOR=0.725	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:154,35:189:99:0|1:13175471_G_A:921,0,6264:13175471
chr1	13175474	13175474	G	A	PRAMEF9	exonic	nonsynonymous SNV	NA	PRAMEF9:NM_001010890:exon1:c.G194A:p.R65H	0.0398	GnomAdGenome_AF_sas			WT/SomaticVariant	het	190	155	35	0.184210526315789	910.64	MQ40	3.516	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0136	0.0398	0	0	0	0		0					chr1	13175474	NA	G	A	910.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=35.19;AS_MQRankSum=-2.6;AS_QD=4.79;AS_ReadPosRankSum=-1;AS_SOR=0.737;BaseQRankSum=-1.801;DP=198;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=37.35;MQRankSum=-2.546;QD=4.79;ReadPosRankSum=-0.977;SOR=0.737	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:155,35:190:99:0|1:13175471_G_A:918,0,6285:13175471
chr1	13175561	13175561	G	A	PRAMEF9	exonic	nonsynonymous SNV	NA	PRAMEF9:NM_001010890:exon1:c.G281A:p.G94E	0.1496	GnomAdGenome_AF_ami			WT/SomaticVariant	het	231	186	45	0.194805194805195	436.64	MQ40;QD2	0.59	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0892	0.1496	0	0	0	0		0					chr1	13175561	NA	G	A	436.64	MQ40;QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.7;AS_FS=0;AS_MQ=39.06;AS_MQRankSum=-2.7;AS_QD=1.89;AS_ReadPosRankSum=0.7;AS_SOR=0.671;BaseQRankSum=-1.62;DP=231;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=39.81;MQRankSum=-2.663;QD=1.89;ReadPosRankSum=0.729;SOR=0.671	GT:AD:DP:GQ:PL	0/1:186,45:231:99:444,0,6040
chr1	13175583	13175583	C	G	PRAMEF9	intronic	NA	NA	NA	0.7861	GnomAdGenome_AF_fin			HeterozygousVariant	het	184	86	98	0.532608695652174	2064.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.612	0.7861	0	0	0	0		0					chr1	13175583	NA	C	G	2064.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=0;AS_MQ=40;AS_MQRankSum=0.2;AS_QD=11.22;AS_ReadPosRankSum=0.2;AS_SOR=0.684;BaseQRankSum=0.32;DP=184;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=40.27;MQRankSum=0.223;QD=11.22;ReadPosRankSum=0.296;SOR=0.684	GT:AD:DP:GQ:PL	0/1:86,98:184:99:2072,0,2462
chr1	13176208	13176208	T	G	PRAMEF9	intronic	NA	NA	NA	0.1563	GnomAdGenome_AF_ami			WT/SomaticVariant	het	34	29	5	0.147058823529412	33.64	MQ40;QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0929	0.1563	0	0	0	0		0					chr1	13176208	NA	T	G	33.64	MQ40;QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=0;AS_MQ=26.61;AS_MQRankSum=-0.4;AS_QD=1;AS_ReadPosRankSum=0;AS_SOR=0.536;BaseQRankSum=1.67;DP=35;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=27.11;MQRankSum=-0.33;QD=0.99;ReadPosRankSum=0.024;SOR=0.536	GT:AD:DP:GQ:PL	0/1:29,5:34:41:41,0,686
chr1	13176222	13176222	C	T	PRAMEF9	intronic	NA	NA	NA	0.9195	GnomAdGenome_AF_ami			HomozygousVariant	hom	33	0	33	1	899.06	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.6826	0.9195	0	0	0	0		0					chr1	13176222	NA	C	T	899.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=27.18;AS_MQRankSum=.;AS_QD=27.24;AS_ReadPosRankSum=.;AS_SOR=0.88;DP=33;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=27.18;QD=27.24;SOR=0.88	GT:AD:DP:GQ:PL	1/1:0,33:33:99:913,99,0
chr1	13176324	13176324	C	G	PRAMEF9	exonic	nonsynonymous SNV	NA	PRAMEF9:NM_001010890:exon2:c.C377G:p.S126C	0.6404	GnomAdGenome_AF_ami			HomozygousVariant	het	24	6	18	0.75	479.64	MQ40;SOR3	0.057	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	P	NA	NA	NA	NA	NA	T	NA	NA	NA	T	T	NA	.;	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.521	0.6404	0	0	0	0		0					chr1	13176324	NA	C	G	479.64	MQ40;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=6.021;AS_MQ=26.4;AS_MQRankSum=0.2;AS_QD=20;AS_ReadPosRankSum=-0.5;AS_SOR=3.716;BaseQRankSum=-1.381;DP=25;ExcessHet=3.0103;FS=6.021;MLEAC=1;MLEAF=0.5;MQ=26.42;MQRankSum=0.29;QD=19.98;ReadPosRankSum=-0.434;SOR=3.716	GT:AD:DP:GQ:PL	0/1:6,18:24:99:487,0,114
chr1	13176384	13176384	A	G	PRAMEF9	exonic	nonsynonymous SNV	NA	PRAMEF9:NM_001010890:exon2:c.A437G:p.Q146R	0.8874	GnomAdGenome_AF_ami			HomozygousVariant	hom	14	0	14	1	415.06	MQ40	0.286	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.6312	0.8874	0	0	0	0		0					chr1	13176384	NA	A	G	415.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=25.93;AS_MQRankSum=.;AS_QD=29.64;AS_ReadPosRankSum=.;AS_SOR=2.985;DP=15;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=26;QD=29.65;SOR=2.985	GT:AD:DP:GQ:PL	1/1:0,14:14:42:429,42,0
chr1	13178567	13178567	C	A	PRAMEF9	intronic	NA	NA	NA	0.2246	GnomAdGenome_AF_afr			HomozygousVariant	hom	2	0	2	1	50.32	DP10;MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0834	0.2246	0	0	0	0		0					chr1	13178567	NA	C	A	50.32	DP10;MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=26.02;AS_MQRankSum=.;AS_QD=25;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=2;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=26.02;QD=25.16;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,2:2:6:62,6,0
chr1	13178750	13178750	C	T	PRAMEF9	exonic	nonsynonymous SNV	NA	PRAMEF9:NM_001010890:exon3:c.C1055T:p.A352V	0.6397	GnomAdGenome_AF_fin			HeterozygousVariant	het	33	16	17	0.515151515151515	425.64	MQ40	12.49	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.4465	0.6397	0	0	0	0		0					chr1	13178750	NA	C	T	425.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-4.4;AS_FS=0;AS_MQ=27.39;AS_MQRankSum=-0.8;AS_QD=12.91;AS_ReadPosRankSum=-0.9;AS_SOR=0.223;BaseQRankSum=-4.331;DP=33;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=28.43;MQRankSum=-0.733;QD=12.9;ReadPosRankSum=-0.847;SOR=0.223	GT:AD:DP:GQ:PL	0/1:16,17:33:99:433,0,421
chr1	13178764	13178764	T	C	PRAMEF9	exonic	synonymous SNV	NA	PRAMEF9:NM_001010890:exon3:c.T1069C:p.L357L	0.7607	GnomAdGenome_AF_ami			HomozygousVariant	het	43	9	34	0.790697674418605	930.64	MQ40	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.5316	0.7607	0	0	0	0		0					chr1	13178764	NA	T	C	930.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.6;AS_FS=0;AS_MQ=29.61;AS_MQRankSum=0.5;AS_QD=21.65;AS_ReadPosRankSum=1.2;AS_SOR=0.793;BaseQRankSum=2.6;DP=45;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=28.95;MQRankSum=0.593;QD=21.64;ReadPosRankSum=1.24;SOR=0.793	GT:AD:DP:GQ:PL	0/1:9,34:43:99:938,0,153
chr1	13178805	13178805	C	T	PRAMEF9	exonic	synonymous SNV	NA	PRAMEF9:NM_001010890:exon3:c.C1110T:p.N370N	0.7729	GnomAdGenome_AF_ami			HomozygousVariant	het	83	15	68	0.819277108433735	1918.64	MQ40	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.5337	0.7729	0	0	0	0		0					chr1	13178805	NA	C	T	1918.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-5.1;AS_FS=0;AS_MQ=29.68;AS_MQRankSum=0.4;AS_QD=23.12;AS_ReadPosRankSum=0.2;AS_SOR=1.708;BaseQRankSum=-5.003;DP=84;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=29.54;MQRankSum=0.46;QD=23.12;ReadPosRankSum=0.243;SOR=1.708	GT:AD:DP:GQ:PL	0/1:15,68:83:99:1926,0,234
chr1	13178835	13178835	T	G	PRAMEF9	exonic	nonsynonymous SNV	NA	PRAMEF9:NM_001010890:exon3:c.T1140G:p.F380L	0.6462	GnomAdGenome_AF_fin			HeterozygousVariant	het	104	46	58	0.557692307692308	1598.64	MQ40	3.207	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.4589	0.6462	0	0	0	0		0					chr1	13178835	NA	T	G	1598.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=6.9;AS_FS=0;AS_MQ=30.15;AS_MQRankSum=0.2;AS_QD=15.38;AS_ReadPosRankSum=1;AS_SOR=0.323;BaseQRankSum=6.98;DP=104;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=30.06;MQRankSum=0.258;QD=15.37;ReadPosRankSum=1.01;SOR=0.323	GT:AD:DP:GQ:PL	0/1:46,58:104:99:1606,0,1157
chr1	13178951	13178951	G	A	PRAMEF9	exonic	nonsynonymous SNV	NA	PRAMEF9:NM_001010890:exon3:c.G1256A:p.R419Q	0.8312	GnomAdGenome_AF_ami			HomozygousVariant	het	345	93	252	0.730434782608696	6342.64	PASS	0.199	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.587	0.8312	0	0	0	0		0					chr1	13178951	NA	G	A	6342.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.5;AS_FS=2.647;AS_MQ=42.87;AS_MQRankSum=0.1;AS_QD=18.39;AS_ReadPosRankSum=-1;AS_SOR=0.538;BaseQRankSum=1.55;DP=353;ExcessHet=3.0103;FS=2.647;MLEAC=1;MLEAF=0.5;MQ=43.04;MQRankSum=0.183;QD=18.38;ReadPosRankSum=-0.986;SOR=0.538	GT:AD:DP:GQ:PL	0/1:93,252:345:99:6350,0,1648
chr1	13178963	13178963	G	A	PRAMEF9	exonic	nonsynonymous SNV	NA	PRAMEF9:NM_001010890:exon3:c.G1268A:p.G423D	0.2811	GnomAdGenome_AF_afr			WT/SomaticVariant	het	352	259	93	0.264204545454545	1713.64	PASS	0.012	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.1066	0.2811	0	0	0	0		0					chr1	13178963	NA	G	A	1713.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3;AS_FS=3.283;AS_MQ=44.08;AS_MQRankSum=-0.7;AS_QD=4.87;AS_ReadPosRankSum=1;AS_SOR=0.892;BaseQRankSum=-2.946;DP=357;ExcessHet=3.0103;FS=3.283;MLEAC=1;MLEAF=0.5;MQ=44.19;MQRankSum=-0.687;QD=4.87;ReadPosRankSum=1.04;SOR=0.892	GT:AD:DP:GQ:PL	0/1:259,93:352:99:1721,0,6727
chr1	13196971	13196971	T	C	PRAMEF13	exonic	nonsynonymous SNV	NA	PRAMEF13:NM_001291380:exon4:c.A1277G:p.N426S	0.3667	GnomAdGenome_AF_ami			HomozygousVariant	hom	108	0	108	1	2997.06	PASS	0.128	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;.;	NA	NA	.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0371	0.3667	0	0	0	0		0					chr1	13196971	NA	T	C	2997.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=44.84;AS_MQRankSum=.;AS_QD=27.75;AS_ReadPosRankSum=.;AS_SOR=0.73;DP=109;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=45.01;QD=27.75;SOR=0.73	GT:AD:DP:GQ:PL	1/1:0,108:108:99:3011,323,0
chr1	13197228	13197228	G	T	PRAMEF13	exonic	synonymous SNV	NA	PRAMEF13:NM_001291380:exon4:c.C1020A:p.L340L	0.3665	GnomAdGenome_AF_afr			HeterozygousVariant	het	4	2	2	0.5	41.64	DP10;MQ40	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0	0	0	0.231	0.3665	0	0	0	0		0					chr1	13197228	NA	G	T	41.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=0;AS_MQ=26.02;AS_MQRankSum=-0.7;AS_QD=10.5;AS_ReadPosRankSum=0;AS_SOR=0.105;BaseQRankSum=1.38;DP=5;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=26.61;MQRankSum=-0.674;QD=10.41;ReadPosRankSum=0;SOR=0.105	GT:AD:DP:GQ:PL	0/1:2,2:4:49:49,0,51
chr1	13198460	13198460	G	T	PRAMEF13	exonic	nonsynonymous SNV	NA	PRAMEF13:NM_001291380:exon3:c.C734A:p.S245Y	0.4952	GnomAdGenome_AF_ami			HomozygousVariant	het	129	33	96	0.744186046511628	2572.64	MQ40	1.367	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0	0	0	0.1936	0.4952	0	0	0	0		0					chr1	13198460	NA	G	T	2572.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=3.069;AS_MQ=40.31;AS_MQRankSum=5.4;AS_QD=19.95;AS_ReadPosRankSum=-0.5;AS_SOR=1.098;BaseQRankSum=-0.915;DP=138;ExcessHet=3.0103;FS=3.069;MLEAC=1;MLEAF=0.5;MQ=39.24;MQRankSum=5.4;QD=19.94;ReadPosRankSum=-0.429;SOR=1.098	GT:AD:DP:GQ:PL	0/1:33,96:129:99:2580,0,611
chr1	13198491	13198491	C	G	PRAMEF13	exonic	nonsynonymous SNV	NA	PRAMEF13:NM_001291380:exon3:c.G703C:p.G235R	0.4573	GnomAdGenome_AF_afr			WT/SomaticVariant	het	179	143	36	0.201117318435754	1062.64	PASS	0.757	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0	0	0	0.2658	0.4573	0	0	0	0		0					chr1	13198491	NA	C	G	1062.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=31.84;AS_MQRankSum=-7.1;AS_QD=5.94;AS_ReadPosRankSum=1.7;AS_SOR=0.737;BaseQRankSum=0.16;DP=180;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=45.22;MQRankSum=-7.022;QD=5.94;ReadPosRankSum=1.77;SOR=0.737	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:143,36:179:99:0|1:13198491_C_G:1070,0,5779:13198491
chr1	13198496	13198496	G	T	PRAMEF13	exonic	nonsynonymous SNV	NA	PRAMEF13:NM_001291380:exon3:c.C698A:p.T233N	0.4593	GnomAdGenome_AF_afr			WT/SomaticVariant	het	179	143	36	0.201117318435754	1062.64	PASS	0.171	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0	0	0	0.268	0.4593	0	0	0	0		0					chr1	13198496	NA	G	T	1062.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=0.719;AS_MQ=31.84;AS_MQRankSum=-7.1;AS_QD=5.94;AS_ReadPosRankSum=1.6;AS_SOR=0.768;BaseQRankSum=0.544;DP=181;ExcessHet=3.0103;FS=0.719;MLEAC=1;MLEAF=0.5;MQ=45.61;MQRankSum=-7.045;QD=5.94;ReadPosRankSum=1.63;SOR=0.768	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:143,36:179:99:0|1:13198491_C_G:1070,0,5763:13198491
chr1	13198698	13198698	A	G	PRAMEF13	exonic	nonsynonymous SNV	NA	PRAMEF13:NM_001291380:exon3:c.T496C:p.Y166H	0.207	GnomAdGenome_AF_ami			HeterozygousVariant	het	124	46	78	0.629032258064516	2112.64	MQ40	5.319	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	B	B	N	N	L	NA	NA	T	T	T	T	T	T	NA	NA	NA	.;	N	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0929	0.207	0	0	0	0		0					chr1	13198698	NA	A	G	2112.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.8;AS_FS=25.072;AS_MQ=39.55;AS_MQRankSum=1.7;AS_QD=17.04;AS_ReadPosRankSum=-0.7;AS_SOR=2.287;BaseQRankSum=1.82;DP=124;ExcessHet=3.0103;FS=25.072;MLEAC=1;MLEAF=0.5;MQ=38.84;MQRankSum=1.79;QD=17.04;ReadPosRankSum=-0.636;SOR=2.287	GT:AD:DP:GQ:PL	0/1:46,78:124:99:2120,0,1026
chr1	13199525	13199525	G	T	PRAMEF13	exonic	nonsynonymous SNV	NA	PRAMEF13:NM_001291380:exon2:c.C65A:p.A22D	0.276	GnomAdGenome_AF_ami			HeterozygousVariant	het	80	50	30	0.375	539.64	MQ40	0.959	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	P	P	N	N	L	NA	NA	T	T	T	T	T	T	NA	NA	NA	.;	N	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0	0	0	0.093	0.276	0	0	0	0		0					chr1	13199525	NA	G	T	539.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=4.632;AS_MQ=26.95;AS_MQRankSum=-1;AS_QD=6.75;AS_ReadPosRankSum=1.2;AS_SOR=1.282;BaseQRankSum=0.129;DP=80;ExcessHet=3.0103;FS=4.632;MLEAC=1;MLEAF=0.5;MQ=27.76;MQRankSum=-0.986;QD=6.75;ReadPosRankSum=1.3;SOR=1.282	GT:AD:DP:GQ:PL	0/1:50,30:80:99:547,0,1047
chr1	13199641	13199641	A	G	PRAMEF13	intronic	NA	NA	NA	0.2317	GnomAdGenome_AF_ami			HeterozygousVariant	het	12	5	7	0.583333333333333	156.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0267	0.2317	0	0	0	0		0					chr1	13199641	NA	A	G	156.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0;AS_MQ=25.88;AS_MQRankSum=0.6;AS_QD=13.08;AS_ReadPosRankSum=-0.2;AS_SOR=0.293;BaseQRankSum=-1.009;DP=12;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=25.68;MQRankSum=0.682;QD=13.05;ReadPosRankSum=-0.156;SOR=0.293	GT:AD:DP:GQ:PL	0/1:5,7:12:99:164,0,115
chr1	13223363	13223363	G	A	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon3:c.C1409T:p.S470F,PRAMEF22:NM_001100631:exon3:c.C1409T:p.S470F	0.0189	GnomAdGenome_AF_fin			HomozygousVariant	het	9	1	8	0.888888888888889	222.66	DP10;MQ40	1.09	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0059	0.0189	0	0	0	0		0					chr1	13223363	NA	G	A	222.66	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=0;AS_MQ=29.12;AS_MQRankSum=-1.6;AS_QD=24.78;AS_ReadPosRankSum=0.4;AS_SOR=0.859;BaseQRankSum=-1.593;DP=9;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=33.39;MQRankSum=-1.593;QD=24.74;ReadPosRankSum=0.431;SOR=0.859	GT:AD:DP:GQ:PL	0/1:1,8:9:14:230,0,14
chr1	13223492	13223492	A	G	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon3:c.T1280C:p.L427S,PRAMEF22:NM_001100631:exon3:c.T1280C:p.L427S	0.2522	GnomAdGenome_AF_fin			HomozygousVariant	hom	22	1	21	0.954545454545455	845.02	MQ40	0.006	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1455	0.2522	0	0	0	0		0					chr1	13223492	NA	A	G	845.02	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.4;AS_FS=0;AS_MQ=32.9;AS_MQRankSum=-0.8;AS_QD=30.02;AS_ReadPosRankSum=0.7;AS_SOR=0.26;BaseQRankSum=-1.335;DP=22;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=33.25;MQRankSum=-0.708;QD=27.51;ReadPosRankSum=0.789;SOR=0.26	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:1,21:22:21:1|1:13223492_A_G:859,21,0:13223492
chr1	13223511	13223511	T	C	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon3:c.A1261G:p.N421D,PRAMEF22:NM_001100631:exon3:c.A1261G:p.N421D	0.2565	GnomAdGenome_AF_fin			HomozygousVariant	hom	20	1	19	0.95	795.96	MQ40	0.041	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1517	0.2565	0	0	0	0		0					chr1	13223511	NA	T	C	795.96	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0;AS_MQ=31.04;AS_MQRankSum=-1.1;AS_QD=25.42;AS_ReadPosRankSum=-1.4;AS_SOR=0.264;BaseQRankSum=-0.491;DP=20;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=31.55;MQRankSum=-1.019;QD=25.11;ReadPosRankSum=-1.39;SOR=0.264	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:1,19:20:15:1|1:13223492_A_G:810,15,0:13223492
chr1	13223512	13223512	G	A	PRAMEF18;PRAMEF22	exonic	synonymous SNV	NA	PRAMEF18:NM_001099850:exon3:c.C1260T:p.D420D,PRAMEF22:NM_001100631:exon3:c.C1260T:p.D420D	0.2608	GnomAdGenome_AF_fin			HomozygousVariant	hom	20	1	19	0.95	795.96	MQ40	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1507	0.2608	0	0	0	0		0					chr1	13223512	NA	G	A	795.96	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.7;AS_FS=0;AS_MQ=31.04;AS_MQRankSum=-1.1;AS_QD=27.95;AS_ReadPosRankSum=-1.4;AS_SOR=0.264;BaseQRankSum=-1.688;DP=20;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=31.55;MQRankSum=-1.019;QD=25.27;ReadPosRankSum=-1.372;SOR=0.264	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:1,19:20:15:1|1:13223492_A_G:810,15,0:13223492
chr1	13223594	13223594	G	C	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon3:c.C1178G:p.A393G,PRAMEF22:NM_001100631:exon3:c.C1178G:p.A393G	0.0598	GnomAdGenome_AF_fin			HomozygousVariant	het	5	1	4	0.8	95.64	DP10;MQ40	0.531	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0176	0.0598	0	0	0	0		0					chr1	13223594	NA	G	C	95.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=0;AS_MQ=27;AS_MQRankSum=-1.3;AS_QD=19.2;AS_ReadPosRankSum=1.2;AS_SOR=1.981;BaseQRankSum=-0.253;DP=5;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=30.05;MQRankSum=-1.282;QD=19.13;ReadPosRankSum=1.28;SOR=1.981	GT:AD:DP:GQ:PL	0/1:1,4:5:26:103,0,26
chr1	13223649	13223649	G	A	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon3:c.C1123T:p.R375C,PRAMEF22:NM_001100631:exon3:c.C1123T:p.R375C	0.0648	GnomAdGenome_AF_afr			HomozygousVariant	hom	3	0	3	1	81.84	DP10;MQ40	18.66	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.029	0.0648	0	0	0	0		0					chr1	13223649	NA	G	A	81.84	DP10;MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=27;AS_MQRankSum=.;AS_QD=27.33;AS_ReadPosRankSum=.;AS_SOR=2.833;DP=3;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=27;QD=27.28;SOR=2.833	GT:AD:DP:GQ:PL	1/1:0,3:3:9:95,9,0
chr1	13224919	13224919	T	A	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon2:c.A802T:p.N268Y,PRAMEF22:NM_001100631:exon2:c.A802T:p.N268Y	1	GME_Israel			HeterozygousVariant	het	201	113	88	0.437810945273632	1880.64	PASS	1.472	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0011	0.0019	0.0011	0.3977	0.4469	0.133187	0	0.008952	0.468085	VQSRTrancheSNP99.90to100.00	1					chr1	13224919	NA	T	A	1880.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.2;AS_FS=4.059;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.36;AS_ReadPosRankSum=1.1;AS_SOR=0.972;BaseQRankSum=-2.188;DP=203;ExcessHet=3.0103;FS=4.059;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.36;ReadPosRankSum=1.1;SOR=0.972	GT:AD:DP:GQ:PL	0/1:113,88:201:99:1888,0,2790
chr1	13225001	13225001	A	G	PRAMEF18;PRAMEF22	exonic	synonymous SNV	NA	PRAMEF18:NM_001099850:exon2:c.T720C:p.S240S,PRAMEF22:NM_001100631:exon2:c.T720C:p.S240S	0.9344	GnomAdGenome_AF_ami			HomozygousVariant	hom	207	2	205	0.990338164251208	5946.06	PASS	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.8511	0.9344	0	0	0	0		0					chr1	13225001	NA	A	G	5946.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=28.72;AS_ReadPosRankSum=0.9;AS_SOR=1.118;BaseQRankSum=1.13;DP=211;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=28.72;ReadPosRankSum=0.908;SOR=1.118	GT:AD:DP:GQ:PL	1/1:2,205:207:99:5960,570,0
chr1	13225047	13225047	C	A	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon2:c.G674T:p.S225I,PRAMEF22:NM_001100631:exon2:c.G674T:p.S225I	0.2483	GnomAdGenome_AF_afr			HeterozygousVariant	het	196	121	75	0.38265306122449	1845.64	PASS	11.73	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1401	0.2483	0	0	0	0		0					chr1	13225047	NA	C	A	1845.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.9;AS_FS=1.13;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.42;AS_ReadPosRankSum=0.3;AS_SOR=0.609;BaseQRankSum=-1.833;DP=204;ExcessHet=3.0103;FS=1.13;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.42;ReadPosRankSum=0.374;SOR=0.609	GT:AD:DP:GQ:PL	0/1:121,75:196:99:1853,0,3312
chr1	13225068	13225068	A	G	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon2:c.T653C:p.L218P,PRAMEF22:NM_001100631:exon2:c.T653C:p.L218P	0.5023	GnomAdGenome_AF_ami			HeterozygousVariant	het	192	117	75	0.390625	1748.64	PASS	6.526	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4859	0.5023	0	0	0	0		0					chr1	13225068	NA	A	G	1748.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=1.149;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.11;AS_ReadPosRankSum=0;AS_SOR=0.729;BaseQRankSum=0.225;DP=194;ExcessHet=3.0103;FS=1.149;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.11;ReadPosRankSum=0.052;SOR=0.729	GT:AD:DP:GQ:PL	0/1:117,75:192:99:1756,0,3084
chr1	13225208	13225208	C	G	PRAMEF18;PRAMEF22	exonic	synonymous SNV	NA	PRAMEF18:NM_001099850:exon2:c.G513C:p.V171V,PRAMEF22:NM_001100631:exon2:c.G513C:p.V171V	1	GnomAdExome_AF_afr			HeterozygousVariant	het	266	136	130	0.488721804511278	3030.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.5	1	1	0.485	0.5022	0	0	0.028182	0.842105	VQSRTrancheSNP99.00to99.90	1					chr1	13225208	NA	C	G	3030.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=2.05;AS_MQ=58.45;AS_MQRankSum=0.7;AS_QD=11.39;AS_ReadPosRankSum=1.3;AS_SOR=0.618;BaseQRankSum=-0.513;DP=276;ExcessHet=3.0103;FS=2.05;MLEAC=1;MLEAF=0.5;MQ=58.02;MQRankSum=0.776;QD=11.39;ReadPosRankSum=1.34;SOR=0.618	GT:AD:DP:GQ:PL	0/1:136,130:266:99:3038,0,3322
chr1	13225359	13225359	A	G	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon2:c.T362C:p.L121P,PRAMEF22:NM_001100631:exon2:c.T362C:p.L121P	0.9343	GnomAdGenome_AF_ami			HomozygousVariant	hom	76	0	76	1	2460.06	SOR3	0.961	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.851	0.9343	0	0	0	0		0					chr1	13225359	NA	A	G	2460.06	SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=39.96;AS_MQRankSum=.;AS_QD=32.37;AS_ReadPosRankSum=.;AS_SOR=3.855;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=40.9;QD=32.37;SOR=3.855	GT:AD:DP:GQ:PL	1/1:0,76:76:99:2474,227,0
chr1	13225408	13225408	T	A	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon2:c.A313T:p.M105L,PRAMEF22:NM_001100631:exon2:c.A313T:p.M105L	0.5012	GnomAdGenome_AF_ami			HeterozygousVariant	het	43	30	13	0.302325581395349	397.64	MQ40	0.233	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4834	0.5012	0	0	0	0		0					chr1	13225408	NA	T	A	397.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.2;AS_FS=0;AS_MQ=38.29;AS_MQRankSum=1.4;AS_QD=9.26;AS_ReadPosRankSum=-1;AS_SOR=0.186;BaseQRankSum=-3.118;DP=43;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=36.38;MQRankSum=1.45;QD=9.25;ReadPosRankSum=-0.979;SOR=0.186	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:30,13:43:99:0|1:13225408_T_A:405,0,1117:13225408
chr1	13225429	13225429	A	G	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon2:c.T292C:p.W98R,PRAMEF22:NM_001100631:exon2:c.T292C:p.W98R	0.4756	GnomAdGenome_AF_afr			WT/SomaticVariant	het	32	24	8	0.25	249.64	MQ40	14.59	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.3503	0.4756	0	0	0	0		0					chr1	13225429	NA	A	G	249.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3;AS_FS=0;AS_MQ=38.62;AS_MQRankSum=1.5;AS_QD=7.81;AS_ReadPosRankSum=0.6;AS_SOR=0.122;BaseQRankSum=3.08;DP=32;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=35.94;MQRankSum=1.52;QD=7.8;ReadPosRankSum=0.637;SOR=0.122	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:24,8:32:99:0|1:13225408_T_A:257,0,943:13225408
chr1	13226025	13226025	G	A	PRAMEF18;PRAMEF22	exonic	synonymous SNV	NA	PRAMEF18:NM_001099850:exon1:c.C82T:p.L28L,PRAMEF22:NM_001100631:exon1:c.C82T:p.L28L	0.5011	GnomAdGenome_AF_ami			HeterozygousVariant	het	237	146	91	0.383966244725738	3335.64	PASS	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.485	0.5011	0	0	0	0		0					chr1	13226025	NA	G	A	3335.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=1.613;AS_MQ=56.19;AS_MQRankSum=-0.8;AS_QD=14.08;AS_ReadPosRankSum=1.3;AS_SOR=0.813;BaseQRankSum=-1.011;DP=240;ExcessHet=3.0103;FS=1.613;MLEAC=1;MLEAF=0.5;MQ=55.92;MQRankSum=-0.703;QD=14.07;ReadPosRankSum=1.35;SOR=0.813	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:146,91:237:99:0|1:13226025_G_A:3343,0,5794:13226025
chr1	13226028	13226028	C	T	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon1:c.G79A:p.V27I,PRAMEF22:NM_001100631:exon1:c.G79A:p.V27I	0.5011	GnomAdGenome_AF_ami			HeterozygousVariant	het	238	147	91	0.382352941176471	3332.64	PASS	0.195	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.485	0.5011	0	0	0	0		0					chr1	13226028	NA	C	T	3332.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=1.028;AS_MQ=56.19;AS_MQRankSum=-0.8;AS_QD=14;AS_ReadPosRankSum=0.9;AS_SOR=0.798;BaseQRankSum=-0.377;DP=242;ExcessHet=3.0103;FS=1.028;MLEAC=1;MLEAF=0.5;MQ=55.86;MQRankSum=-0.745;QD=14;ReadPosRankSum=0.943;SOR=0.798	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:147,91:238:99:0|1:13226025_G_A:3340,0,5817:13226025
chr1	13226052	13226052	T	C	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon1:c.A55G:p.R19G,PRAMEF22:NM_001100631:exon1:c.A55G:p.R19G	0.5	GnomAdGenome_AF_ami			HeterozygousVariant	het	227	148	79	0.348017621145374	1761.64	PASS	15.26	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4847	0.5	0	0	0	0		0					chr1	13226052	NA	T	C	1761.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.6;AS_FS=1.716;AS_MQ=54.55;AS_MQRankSum=-3.1;AS_QD=7.76;AS_ReadPosRankSum=-0.7;AS_SOR=0.836;BaseQRankSum=2.63;DP=234;ExcessHet=3.0103;FS=1.716;MLEAC=1;MLEAF=0.5;MQ=55.61;MQRankSum=-3.024;QD=7.76;ReadPosRankSum=-0.656;SOR=0.836	GT:AD:DP:GQ:PL	0/1:148,79:227:99:1769,0,3546
chr1	13226098	13226098	G	T	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon1:c.C9A:p.F3L,PRAMEF22:NM_001100631:exon1:c.C9A:p.F3L	0.5011	GnomAdGenome_AF_ami			HeterozygousVariant	het	188	124	64	0.340425531914894	2296.64	PASS	0.099	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4849	0.5011	0	0	0	0		0					chr1	13226098	NA	G	T	2296.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=5.822;AS_MQ=49.79;AS_MQRankSum=-6.7;AS_QD=12.22;AS_ReadPosRankSum=-1.4;AS_SOR=1.145;BaseQRankSum=0.355;DP=189;ExcessHet=3.0103;FS=5.822;MLEAC=1;MLEAF=0.5;MQ=54.13;MQRankSum=-6.658;QD=12.22;ReadPosRankSum=-1.378;SOR=1.145	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:124,64:188:99:0|1:13226098_G_T:2304,0,4981:13226098
chr1	13226100	13226100	A	G	PRAMEF18;PRAMEF22	exonic	nonsynonymous SNV	NA	PRAMEF18:NM_001099850:exon1:c.T7C:p.F3L,PRAMEF22:NM_001100631:exon1:c.T7C:p.F3L	0.5012	GnomAdGenome_AF_ami			HeterozygousVariant	het	188	124	64	0.340425531914894	2296.64	PASS	0.121	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4848	0.5012	0	0	0	0		0					chr1	13226100	NA	A	G	2296.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.9;AS_FS=5.822;AS_MQ=49.79;AS_MQRankSum=-6.7;AS_QD=12.22;AS_ReadPosRankSum=-1.3;AS_SOR=1.145;BaseQRankSum=1.96;DP=188;ExcessHet=3.0103;FS=5.822;MLEAC=1;MLEAF=0.5;MQ=54.1;MQRankSum=-6.658;QD=12.22;ReadPosRankSum=-1.232;SOR=1.145	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:124,64:188:99:0|1:13226098_G_T:2304,0,4981:13226098
chr1	13226110	13226110	G	C	PRAMEF18;PRAMEF22	UTR5	NA	NM_001099850:c.-4C>G;NM_001100631:c.-4C>G	NA	0.5012	GnomAdGenome_AF_ami			HeterozygousVariant	het	171	116	55	0.321637426900585	1952.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4847	0.5012	0	0	0	0		0					chr1	13226110	NA	G	C	1952.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=2.102;AS_MQ=48.37;AS_MQRankSum=-6.8;AS_QD=11.42;AS_ReadPosRankSum=0.3;AS_SOR=0.874;BaseQRankSum=0.285;DP=171;ExcessHet=3.0103;FS=2.102;MLEAC=1;MLEAF=0.5;MQ=53.76;MQRankSum=-6.722;QD=11.42;ReadPosRankSum=0.386;SOR=0.874	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:116,55:171:99:0|1:13226098_G_T:1960,0,4700:13226098
chr1	13226138	13226138	-	AA	PRAMEF18	UTR5	NA	NM_001099850:c.-33_-32insTT	NA	0.5012	GnomAdGenome_AF_ami			HeterozygousVariant	het	110	69	41	0.372727272727273	1477.6	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	N	0.0147671268152564	N	NA	NA	NA	NA	NA	NA	0	0	0	0.4842	0.5012	0	0	0	0		0					chr1	13226138	NA	G	GAA	1477.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.9;AS_FS=0.805;AS_MQ=45.64;AS_MQRankSum=-10.1;AS_QD=13.44;AS_ReadPosRankSum=-0.2;AS_SOR=0.564;BaseQRankSum=-1.838;DP=120;ExcessHet=3.0103;FS=0.805;MLEAC=1;MLEAF=0.5;MQ=55.5;MQRankSum=-10.08;QD=13.43;ReadPosRankSum=-0.111;SOR=0.564	GT:AD:DP:GQ:PL	0/1:69,41:110:99:1485,0,2759
chr1	13260365	13260365	A	G	PRAMEF5	exonic	nonsynonymous SNV	NA	PRAMEF5:NM_001013407:exon3:c.A431G:p.Q144R	0.641	GnomAdExome_AF_eas	118	20	WT/SomaticVariant	het	249	217	32	0.1285140562249	378.64	FS60;QD2;SOR3	1.472	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	N	P	L	NA	NA	T	T	T	T	T	T	T	T	NA	.;	N	N	NA	NA	NA	Low	Low	Low	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.4611	0.641	0.653	0.3778	0.4182	0	0	0.0196711	0.092105	VQSRTrancheSNP99.90to100.00	0.166667	0.416	164	0.448529	21	chr1	13260365	NA	A	G	378.64	FS60;QD2;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=7.2;AS_FS=76.818;AS_MQ=36.15;AS_MQRankSum=-5.1;AS_QD=1.52;AS_ReadPosRankSum=1.5;AS_SOR=6.683;BaseQRankSum=7.2;DP=253;ExcessHet=3.0103;FS=76.818;MLEAC=1;MLEAF=0.5;MQ=41.69;MQRankSum=-5.068;QD=1.52;ReadPosRankSum=1.59;SOR=6.683	GT:AD:DP:GQ:PL	0/1:217,32:249:99:386,0,5398
chr1	13260421	13260421	T	C	PRAMEF5	exonic	nonsynonymous SNV	NA	PRAMEF5:NM_001013407:exon3:c.T487C:p.Y163H	0.4139	GnomAdExome_AF_eas	20	2	WT/SomaticVariant	het	150	106	44	0.293333333333333	874.64	MQ40	16.56	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	N	P	L	NA	NA	T	T	T	T	D	T	T	T	NA	.;	N	N	NA	NA	NA	Low	Low	Low	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.3581	0.4139	0.4109	0.1098	0.2284	0	0	0.0022284	0		0.25	0.096	36	0.08	4	chr1	13260421	NA	T	C	874.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.2;AS_FS=2.42;AS_MQ=34.6;AS_MQRankSum=-3.2;AS_QD=5.83;AS_ReadPosRankSum=-0.7;AS_SOR=0.932;BaseQRankSum=3.24;DP=152;ExcessHet=3.0103;FS=2.42;MLEAC=1;MLEAF=0.5;MQ=38.19;MQRankSum=-3.182;QD=5.83;ReadPosRankSum=-0.611;SOR=0.932	GT:AD:DP:GQ:PL	0/1:106,44:150:99:882,0,2633
chr1	13260431	13260431	G	A	PRAMEF5	exonic	nonsynonymous SNV	NA	PRAMEF5:NM_001013407:exon3:c.G497A:p.C166Y	0.75	GME_AP	83	12	WT/SomaticVariant	het	130	116	14	0.107692307692308	35.64	MQ40;QD2;SOR3	0.061	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	N	P	N	NA	NA	T	T	T	T	T	T	T	T	NA	.;	N	N	NA	NA	NA	Low	Low	Low	NA	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0.4288	0.5158	0.5197	0.3384	0.3862	0	0	0.0034194	0		0.75	0.332	85	0.380435	11	chr1	13260431	NA	G	A	35.64	MQ40;QD2;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=19.888;AS_MQ=31.01;AS_MQRankSum=-1.8;AS_QD=0.28;AS_ReadPosRankSum=-1.6;AS_SOR=3.947;BaseQRankSum=0.428;DP=132;ExcessHet=3.0103;FS=19.888;MLEAC=1;MLEAF=0.5;MQ=37.58;MQRankSum=-1.797;QD=0.27;ReadPosRankSum=-1.591;SOR=3.947	GT:AD:DP:GQ:PL	0/1:116,14:130:43:43,0,3503
chr1	13281806	13281806	C	T	PRAMEF8	exonic	synonymous SNV	NA	PRAMEF8:NM_001012276:exon4:c.G990A:p.T330T	0.3224	GnomAdGenome_AF_eas			WT/SomaticVariant	het	448	340	108	0.241071428571429	1688.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.0657663628172644	N	Pramef8	NA	NA	NA	NA	NA	0	0	0	0.1575	0.3224	0	0	0	0		0					chr1	13281806	NA	C	T	1688.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=2.094;AS_MQ=46.04;AS_MQRankSum=-1.4;AS_QD=3.77;AS_ReadPosRankSum=-0.3;AS_SOR=0.878;BaseQRankSum=-0.258;DP=456;ExcessHet=3.0103;FS=2.094;MLEAC=1;MLEAF=0.5;MQ=46.28;MQRankSum=-1.393;QD=3.77;ReadPosRankSum=-0.292;SOR=0.878	GT:AD:DP:GQ:PL	0/1:340,108:448:99:1696,0,8373
chr1	13281951	13281951	G	T	PRAMEF8	intronic	NA	NA	NA	0.2498	GnomAdGenome_AF_sas			WT/SomaticVariant	het	165	121	44	0.266666666666667	830.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	N	0.0657663628172644	N	Pramef8	NA	NA	NA	NA	NA	0	0	0	0.1161	0.2498	0	0	0	0		0					chr1	13281951	NA	G	T	830.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.6;AS_FS=0.761;AS_MQ=36.96;AS_MQRankSum=-3.4;AS_QD=5.04;AS_ReadPosRankSum=0.3;AS_SOR=0.812;BaseQRankSum=-2.574;DP=173;ExcessHet=3.0103;FS=0.761;MLEAC=1;MLEAF=0.5;MQ=40.63;MQRankSum=-3.343;QD=5.03;ReadPosRankSum=0.3;SOR=0.812	GT:AD:DP:GQ:PL	0/1:121,44:165:99:838,0,3504
chr1	13306141	13306141	C	A	PRAMEF33	exonic	nonsynonymous SNV	NA	PRAMEF33:NM_001291381:exon2:c.C187A:p.R63S	0.4835	GnomAdGenome_AF_afr			HeterozygousVariant	het	49	29	20	0.408163265306122	446.64	MQ40	0.091	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.447	0.4835	0	0	0.0000384	0		0					chr1	13306141	NA	C	A	446.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=8.439;AS_MQ=26.73;AS_MQRankSum=-0.3;AS_QD=9.12;AS_ReadPosRankSum=0.4;AS_SOR=1.662;BaseQRankSum=-0.35;DP=50;ExcessHet=3.0103;FS=8.439;MLEAC=1;MLEAF=0.5;MQ=26.79;MQRankSum=-0.237;QD=9.12;ReadPosRankSum=0.499;SOR=1.662	GT:AD:DP:GQ:PL	0/1:29,20:49:99:454,0,766
chr1	13306172	13306172	C	T	PRAMEF33	exonic	nonsynonymous SNV	NA	PRAMEF33:NM_001291381:exon2:c.C218T:p.P73L	0.4708	GnomAdGenome_AF_afr			HeterozygousVariant	het	52	35	17	0.326923076923077	380.64	MQ40	8.551	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4475	0.4708	0	0	0.0000384	0		0					chr1	13306172	NA	C	T	380.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1;AS_FS=2.645;AS_MQ=28.02;AS_MQRankSum=0;AS_QD=7.33;AS_ReadPosRankSum=0.1;AS_SOR=0.362;BaseQRankSum=1.06;DP=54;ExcessHet=3.0103;FS=2.645;MLEAC=1;MLEAF=0.5;MQ=28.25;MQRankSum=0;QD=7.32;ReadPosRankSum=0.166;SOR=0.362	GT:AD:DP:GQ:PL	0/1:35,17:52:99:388,0,888
chr1	13306635	13306635	T	C	PRAMEF33	intronic	NA	NA	NA	0.5054	GnomAdGenome_AF_ami			HomozygousVariant	hom	10	0	10	1	307.06	MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4755	0.5054	0	0	0.0000384	0		0					chr1	13306635	NA	T	C	307.06	MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=28.71;AS_MQRankSum=.;AS_QD=30.7;AS_ReadPosRankSum=.;AS_SOR=4.804;DP=12;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=29.47;QD=30.71;SOR=4.804	GT:AD:DP:GQ:PL	1/1:0,10:10:30:321,30,0
chr1	13306667	13306667	A	G	PRAMEF33	exonic	nonsynonymous SNV	NA	PRAMEF33:NM_001291381:exon3:c.A317G:p.Q106R	0.9136	GnomAdGenome_AF_ami			HomozygousVariant	hom	24	0	24	1	676.06	MQ40	1.262	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.7529	0.9136	0	0	0.0000384	0		0					chr1	13306667	NA	A	G	676.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=36.21;AS_MQRankSum=.;AS_QD=28.17;AS_ReadPosRankSum=.;AS_SOR=2.925;DP=24;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=36.21;QD=28.17;SOR=2.925	GT:AD:DP:GQ:PL	1/1:0,24:24:72:690,72,0
chr1	13307108	13307108	G	A	PRAMEF33	exonic	stopgain	NA	PRAMEF33:NM_001291381:exon3:c.G758A:p.W253X	0.5376	GnomAdGenome_AF_fin			HeterozygousVariant	het	5	2	3	0.6	71.64	DP10;MQ40	23.4	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4564	0.5376	0	0	0.0000384	0		0					chr1	13307108	NA	G	A	71.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.7;AS_FS=10;AS_MQ=27;AS_MQRankSum=0;AS_QD=14.4;AS_ReadPosRankSum=1;AS_SOR=2.78;BaseQRankSum=-1.645;DP=5;ExcessHet=3.0103;FS=10;MLEAC=1;MLEAF=0.5;MQ=27;MQRankSum=0;QD=14.33;ReadPosRankSum=1.04;SOR=2.78	GT:AD:DP:GQ:PL	0/1:2,3:5:48:79,0,48
chr1	13308468	13308468	A	C	PRAMEF33	exonic	nonsynonymous SNV	NA	PRAMEF33:NM_001291381:exon4:c.A1006C:p.N336H	0.2584	GnomAdGenome_AF_sas			HeterozygousVariant	het	9	3	6	0.666666666666667	230.64	MQ40	9.326	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.09	0.2584	0	0	0.0012294	0		0					chr1	13308468	NA	A	C	230.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.2;AS_FS=6.455;AS_MQ=32.57;AS_MQRankSum=-1.6;AS_QD=25.67;AS_ReadPosRankSum=2.2;AS_SOR=2.245;BaseQRankSum=2.26;DP=12;ExcessHet=3.0103;FS=6.455;MLEAC=1;MLEAF=0.5;MQ=39.76;MQRankSum=-1.51;QD=25.63;ReadPosRankSum=2.26;SOR=2.245	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:3,6:9:95:0|1:13308468_A_C:238,0,95:13308468
chr1	13308474	13308474	C	G	PRAMEF33	exonic	nonsynonymous SNV	NA	PRAMEF33:NM_001291381:exon4:c.C1012G:p.Q338E	0.206	GnomAdGenome_AF_sas			HeterozygousVariant	het	9	3	6	0.666666666666667	230.64	DP10;MQ40	0.303	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.11	0.206	0	0	0	0		0					chr1	13308474	NA	C	G	230.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.9;AS_FS=6.455;AS_MQ=32.57;AS_MQRankSum=-1.6;AS_QD=25.67;AS_ReadPosRankSum=-0.8;AS_SOR=2.245;BaseQRankSum=1.98;DP=9;ExcessHet=3.0103;FS=6.455;MLEAC=1;MLEAF=0.5;MQ=39.85;MQRankSum=-1.51;QD=25.63;ReadPosRankSum=-0.792;SOR=2.245	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:3,6:9:95:0|1:13308468_A_C:238,0,95:13308468
chr1	13318452	13318452	A	G	PRAMEF15	exonic	synonymous SNV	NA	PRAMEF15:NM_001098376:exon2:c.A45G:p.A15A	0.1193	GnomAdGenome_AF_eas			HeterozygousVariant	het	271	183	86	0.317343173431734	1517.64	PASS	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	unclassifiable (Anatomical System);	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0291	0.1193	0	0	0.0000384	0		0					chr1	13318452	NA	A	G	1517.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.2;AS_FS=15.14;AS_MQ=33.85;AS_MQRankSum=-11;AS_QD=5.64;AS_ReadPosRankSum=-2.1;AS_SOR=1.476;BaseQRankSum=2.15;DP=281;ExcessHet=3.0103;FS=14.866;MLEAC=1;MLEAF=0.5;MQ=43.66;MQRankSum=-10.87;QD=5.64;ReadPosRankSum=-1.928;SOR=1.44	GT:AD:DP:GQ:PL	0/1:183,86:271:99:1525,0,4164
chr1	13319836	13319836	A	G	PRAMEF15	exonic	nonsynonymous SNV	NA	PRAMEF15:NM_001098376:exon3:c.A758G:p.E253G	0.0083	GnomAdGenome_AF_sas			WT/SomaticVariant	het	239	187	52	0.217573221757322	529.64	MQ40	3.103	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	D	NA	NA	N	N	NA	T	D	T	T	T	T	T	NA	T	D	T	.;	N	N	NA	NA	NA	NA	NA	NA	unclassifiable (Anatomical System);	NA	NA	NA	N	NA	N	0.11437135981131	N	NA	NA	NA	NA	NA	NA	0	0	0	0.0017	0.0083	0	0	0.0000384	0		0					chr1	13319836	NA	A	G	529.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.3;AS_FS=7.905;AS_MQ=27.13;AS_MQRankSum=-2.7;AS_QD=2.22;AS_ReadPosRankSum=2.8;AS_SOR=0.946;BaseQRankSum=-3.265;DP=243;ExcessHet=3.0103;FS=7.905;MLEAC=1;MLEAF=0.5;MQ=31.27;MQRankSum=-2.63;QD=2.22;ReadPosRankSum=2.89;SOR=0.946	GT:AD:DP:GQ:PL	0/1:187,52:239:99:537,0,4466
chr1	13342520	13342520	C	T	PRAMEF14	UTR3	NA	NM_001024661:c.*8G>A	NA	0.1557	GnomAdExome_AF_sas	39	8	HomozygousVariant	hom	77	1	76	0.987012987012987	2336.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0.0445	0.1557	0.1597	0.0269	0.1353	0.0509185	0	0.0069469	0.020202	VQSRTrancheSNP99.00to99.90	0	0.685	7	0.8	0	chr1	13342520	NA	C	T	2336.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=58.81;AS_MQRankSum=-0.6;AS_QD=30.34;AS_ReadPosRankSum=-0.2;AS_SOR=0.888;BaseQRankSum=-1.78;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.53;MQRankSum=-0.555;QD=30.34;ReadPosRankSum=-0.113;SOR=0.888	GT:AD:DP:GQ:PL	1/1:1,76:77:99:2350,190,0
chr1	13342520	13342520	C	T	PRAMEF14	UTR3	NA	NM_001024661:c.*8G>A	NA	0.827586	abraom_freq	39	8	HomozygousVariant	hom	77	1	76	0.987012987012987	2336.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0.0445	0.1557	0.1597	0.0269	0.1353	0.0509185	0	0.0069469	0.827586	VQSRTrancheSNP99.90to100.00	0	0.685	7	0.8	0	chr1	13342520	NA	C	T	2336.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=58.81;AS_MQRankSum=-0.6;AS_QD=30.34;AS_ReadPosRankSum=-0.2;AS_SOR=0.888;BaseQRankSum=-1.78;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.53;MQRankSum=-0.555;QD=30.34;ReadPosRankSum=-0.113;SOR=0.888	GT:AD:DP:GQ:PL	1/1:1,76:77:99:2350,190,0
chr1	13342520	13342520	C	T	PRAMEF14	UTR3	NA	NM_001024661:c.*8G>A	NA	0.1557	GnomAdExome_AF_sas	39	5	HomozygousVariant	hom	77	1	76	0.987012987012987	2336.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0.0445	0.1557	0.1597	0.0269	0.1353	0.0509185	0	0.0069469	0.020202	VQSRTrancheSNP99.00to99.90	0	0.685	7	0.121622	8	chr1	13342520	NA	C	T	2336.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=58.81;AS_MQRankSum=-0.6;AS_QD=30.34;AS_ReadPosRankSum=-0.2;AS_SOR=0.888;BaseQRankSum=-1.78;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.53;MQRankSum=-0.555;QD=30.34;ReadPosRankSum=-0.113;SOR=0.888	GT:AD:DP:GQ:PL	1/1:1,76:77:99:2350,190,0
chr1	13342520	13342520	C	T	PRAMEF14	UTR3	NA	NM_001024661:c.*8G>A	NA	0.827586	abraom_freq	39	5	HomozygousVariant	hom	77	1	76	0.987012987012987	2336.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0.0445	0.1557	0.1597	0.0269	0.1353	0.0509185	0	0.0069469	0.827586	VQSRTrancheSNP99.90to100.00	0	0.685	7	0.121622	8	chr1	13342520	NA	C	T	2336.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=58.81;AS_MQRankSum=-0.6;AS_QD=30.34;AS_ReadPosRankSum=-0.2;AS_SOR=0.888;BaseQRankSum=-1.78;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.53;MQRankSum=-0.555;QD=30.34;ReadPosRankSum=-0.113;SOR=0.888	GT:AD:DP:GQ:PL	1/1:1,76:77:99:2350,190,0
chr1	13342520	13342520	C	T	PRAMEF14	UTR3	NA	NM_001024661:c.*8G>A	NA	0.1557	GnomAdExome_AF_sas	23	8	HomozygousVariant	hom	77	1	76	0.987012987012987	2336.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0.0445	0.1557	0.1597	0.0269	0.1353	0.0509185	0	0.0069469	0.020202	VQSRTrancheSNP99.00to99.90	0	0.129	62	0.8	0	chr1	13342520	NA	C	T	2336.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=58.81;AS_MQRankSum=-0.6;AS_QD=30.34;AS_ReadPosRankSum=-0.2;AS_SOR=0.888;BaseQRankSum=-1.78;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.53;MQRankSum=-0.555;QD=30.34;ReadPosRankSum=-0.113;SOR=0.888	GT:AD:DP:GQ:PL	1/1:1,76:77:99:2350,190,0
chr1	13342520	13342520	C	T	PRAMEF14	UTR3	NA	NM_001024661:c.*8G>A	NA	0.827586	abraom_freq	23	8	HomozygousVariant	hom	77	1	76	0.987012987012987	2336.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0.0445	0.1557	0.1597	0.0269	0.1353	0.0509185	0	0.0069469	0.827586	VQSRTrancheSNP99.90to100.00	0	0.129	62	0.8	0	chr1	13342520	NA	C	T	2336.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=58.81;AS_MQRankSum=-0.6;AS_QD=30.34;AS_ReadPosRankSum=-0.2;AS_SOR=0.888;BaseQRankSum=-1.78;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.53;MQRankSum=-0.555;QD=30.34;ReadPosRankSum=-0.113;SOR=0.888	GT:AD:DP:GQ:PL	1/1:1,76:77:99:2350,190,0
chr1	13342520	13342520	C	T	PRAMEF14	UTR3	NA	NM_001024661:c.*8G>A	NA	0.1557	GnomAdExome_AF_sas	23	5	HomozygousVariant	hom	77	1	76	0.987012987012987	2336.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0.0445	0.1557	0.1597	0.0269	0.1353	0.0509185	0	0.0069469	0.020202	VQSRTrancheSNP99.00to99.90	0	0.129	62	0.121622	8	chr1	13342520	NA	C	T	2336.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=58.81;AS_MQRankSum=-0.6;AS_QD=30.34;AS_ReadPosRankSum=-0.2;AS_SOR=0.888;BaseQRankSum=-1.78;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.53;MQRankSum=-0.555;QD=30.34;ReadPosRankSum=-0.113;SOR=0.888	GT:AD:DP:GQ:PL	1/1:1,76:77:99:2350,190,0
chr1	13342520	13342520	C	T	PRAMEF14	UTR3	NA	NM_001024661:c.*8G>A	NA	0.827586	abraom_freq	23	5	HomozygousVariant	hom	77	1	76	0.987012987012987	2336.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	NA	N	0.0766411730720256	N	NA	NA	NA	NA	NA	NA	0.0445	0.1557	0.1597	0.0269	0.1353	0.0509185	0	0.0069469	0.827586	VQSRTrancheSNP99.90to100.00	0	0.129	62	0.121622	8	chr1	13342520	NA	C	T	2336.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=58.81;AS_MQRankSum=-0.6;AS_QD=30.34;AS_ReadPosRankSum=-0.2;AS_SOR=0.888;BaseQRankSum=-1.78;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.53;MQRankSum=-0.555;QD=30.34;ReadPosRankSum=-0.113;SOR=0.888	GT:AD:DP:GQ:PL	1/1:1,76:77:99:2350,190,0
chr1	13369246	13369246	T	C	PRAMEF19	exonic	nonsynonymous SNV	NA	PRAMEF19:NM_001099790:exon3:c.A1261G:p.N421D	0.1333	GnomAdGenome_AF_afr			HeterozygousVariant	het	228	149	79	0.346491228070175	2840.64	PASS	0.03	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	T	T	T	T	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0.0000267	0.00007641	0.00008131	0.093	0.1333	0	0	0	0		0					chr1	13369246	NA	T	C	2840.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=9.099;AS_MQ=45.23;AS_MQRankSum=-9.5;AS_QD=12.46;AS_ReadPosRankSum=3.9;AS_SOR=1.262;BaseQRankSum=-0.116;DP=230;ExcessHet=3.0103;FS=9.099;MLEAC=1;MLEAF=0.5;MQ=53.08;MQRankSum=-9.459;QD=12.46;ReadPosRankSum=3.97;SOR=1.262	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:149,79:228:99:0|1:13369246_T_C:2848,0,5952:13369246
chr1	13369247	13369247	G	A	PRAMEF19	exonic	synonymous SNV	NA	PRAMEF19:NM_001099790:exon3:c.C1260T:p.D420D	0.1345	GnomAdGenome_AF_afr			HeterozygousVariant	het	228	149	79	0.346491228070175	2840.64	PASS	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0.0003	0.0005	0.0005	0.0942	0.1345	0	0	0	0		0					chr1	13369247	NA	G	A	2840.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.3;AS_FS=9.099;AS_MQ=45.23;AS_MQRankSum=-9.5;AS_QD=12.46;AS_ReadPosRankSum=4.1;AS_SOR=1.262;BaseQRankSum=-3.275;DP=231;ExcessHet=3.0103;FS=9.099;MLEAC=1;MLEAF=0.5;MQ=53.11;MQRankSum=-9.459;QD=12.46;ReadPosRankSum=4.18;SOR=1.262	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:149,79:228:99:0|1:13369246_T_C:2848,0,5952:13369246
chr1	13369358	13369358	G	A	PRAMEF19	exonic	synonymous SNV	NA	PRAMEF19:NM_001099790:exon3:c.C1149T:p.C383C	1	abraom_freq	0	86	HeterozygousVariant	het	222	155	67	0.301801801801802	1294.64	MQRankSum-12.5	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0.9894	0.9998	0.9999	0.0611	0.0792	0	0	0.0377286	1	VQSRTrancheSNP99.00to99.90	0.008772	0.0009597	1	0.994253	1	chr1	13369358	NA	G	A	1294.64	MQRankSum-12.5	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=11.008;AS_MQ=33.96;AS_MQRankSum=-13.7;AS_QD=5.83;AS_ReadPosRankSum=-0.2;AS_SOR=1.181;BaseQRankSum=0.023;DP=231;ExcessHet=3.0103;FS=11.008;MLEAC=1;MLEAF=0.5;MQ=52.61;MQRankSum=-13.67;QD=5.83;ReadPosRankSum=-0.165;SOR=1.181	GT:AD:DP:GQ:PL	0/1:155,67:222:99:1302,0,4144
chr1	13369358	13369358	G	A	PRAMEF19	exonic	synonymous SNV	NA	PRAMEF19:NM_001099790:exon3:c.C1149T:p.C383C	1	abraom_freq	0	86	HeterozygousVariant	het	222	155	67	0.301801801801802	1294.64	MQRankSum-12.5	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0.9894	0.9998	0.9999	0.0611	0.0792	0	0	0.0377286	1	VQSRTrancheSNP99.00to99.90	1	0.0009597	1	0.994253	1	chr1	13369358	NA	G	A	1294.64	MQRankSum-12.5	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=11.008;AS_MQ=33.96;AS_MQRankSum=-13.7;AS_QD=5.83;AS_ReadPosRankSum=-0.2;AS_SOR=1.181;BaseQRankSum=0.023;DP=231;ExcessHet=3.0103;FS=11.008;MLEAC=1;MLEAF=0.5;MQ=52.61;MQRankSum=-13.67;QD=5.83;ReadPosRankSum=-0.165;SOR=1.181	GT:AD:DP:GQ:PL	0/1:155,67:222:99:1302,0,4144
chr1	13369358	13369358	G	A	PRAMEF19	exonic	synonymous SNV	NA	PRAMEF19:NM_001099790:exon3:c.C1149T:p.C383C	1	abraom_freq	512	86	HeterozygousVariant	het	222	155	67	0.301801801801802	1294.64	MQRankSum-12.5	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0.9894	0.9998	0.9999	0.0611	0.0792	0	0	0.0377286	1	VQSRTrancheSNP99.00to99.90	0.008772	0.994	6	0.994253	1	chr1	13369358	NA	G	A	1294.64	MQRankSum-12.5	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=11.008;AS_MQ=33.96;AS_MQRankSum=-13.7;AS_QD=5.83;AS_ReadPosRankSum=-0.2;AS_SOR=1.181;BaseQRankSum=0.023;DP=231;ExcessHet=3.0103;FS=11.008;MLEAC=1;MLEAF=0.5;MQ=52.61;MQRankSum=-13.67;QD=5.83;ReadPosRankSum=-0.165;SOR=1.181	GT:AD:DP:GQ:PL	0/1:155,67:222:99:1302,0,4144
chr1	13369358	13369358	G	A	PRAMEF19	exonic	synonymous SNV	NA	PRAMEF19:NM_001099790:exon3:c.C1149T:p.C383C	1	abraom_freq	512	86	HeterozygousVariant	het	222	155	67	0.301801801801802	1294.64	MQRankSum-12.5	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0.9894	0.9998	0.9999	0.0611	0.0792	0	0	0.0377286	1	VQSRTrancheSNP99.00to99.90	1	0.994	6	0.994253	1	chr1	13369358	NA	G	A	1294.64	MQRankSum-12.5	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=11.008;AS_MQ=33.96;AS_MQRankSum=-13.7;AS_QD=5.83;AS_ReadPosRankSum=-0.2;AS_SOR=1.181;BaseQRankSum=0.023;DP=231;ExcessHet=3.0103;FS=11.008;MLEAC=1;MLEAF=0.5;MQ=52.61;MQRankSum=-13.67;QD=5.83;ReadPosRankSum=-0.165;SOR=1.181	GT:AD:DP:GQ:PL	0/1:155,67:222:99:1302,0,4144
chr1	13369384	13369384	G	A	PRAMEF19	exonic	nonsynonymous SNV	NA	PRAMEF19:NM_001099790:exon3:c.C1123T:p.R375C	0.1041	GnomAdGenome_AF_afr			WT/SomaticVariant	het	229	172	57	0.248908296943231	984.64	MQRankSum-12.5	17.85	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	T	T	T	T	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0.000003986	0.00006192	0.0001	0.079	0.1041	0	0	0.0000384	0		0					chr1	13369384	NA	G	A	984.64	MQRankSum-12.5	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.2;AS_FS=14.852;AS_MQ=33.13;AS_MQRankSum=-12.7;AS_QD=4.3;AS_ReadPosRankSum=2.8;AS_SOR=1.422;BaseQRankSum=2.26;DP=242;ExcessHet=3.0103;FS=14.852;MLEAC=1;MLEAF=0.5;MQ=52.82;MQRankSum=-12.65;QD=4.3;ReadPosRankSum=2.8;SOR=1.422	GT:AD:DP:GQ:PL	0/1:172,57:229:99:992,0,4326
chr1	13369423	13369423	C	G	PRAMEF19	exonic	nonsynonymous SNV	NA	PRAMEF19:NM_001099790:exon3:c.G1084C:p.G362R	0.1439	GnomAdGenome_AF_ami			WT/SomaticVariant	het	244	186	58	0.237704918032787	863.64	PASS	0.004	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	T	T	T	T	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0	0	0	0.1014	0.1439	0	0	0.0000768	0		0					chr1	13369423	NA	C	G	863.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=17.808;AS_MQ=33.27;AS_MQRankSum=-12.4;AS_QD=3.54;AS_ReadPosRankSum=0.5;AS_SOR=1.449;BaseQRankSum=-0.703;DP=255;ExcessHet=3.0103;FS=17.808;MLEAC=1;MLEAF=0.5;MQ=52.78;MQRankSum=-12.3;QD=3.54;ReadPosRankSum=0.547;SOR=1.449	GT:AD:DP:GQ:PL	0/1:186,58:244:99:871,0,4936
chr1	13371202	13371202	T	A	PRAMEF19	exonic	nonsynonymous SNV	NA	PRAMEF19:NM_001099790:exon2:c.A313T:p.M105L	0.43	GnomAdGenome_AF_ami			WT/SomaticVariant	het	68	49	19	0.279411764705882	541.64	PASS	0.314	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	T	T	T	T	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0	0	0	0.3503	0.43	0	0	0	0		0					chr1	13371202	NA	T	A	541.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-4.7;AS_FS=27.959;AS_MQ=46.06;AS_MQRankSum=4.9;AS_QD=7.97;AS_ReadPosRankSum=0.9;AS_SOR=0.021;BaseQRankSum=-4.613;DP=70;ExcessHet=3.0103;FS=27.959;MLEAC=1;MLEAF=0.5;MQ=44.7;MQRankSum=4.99;QD=7.97;ReadPosRankSum=0.909;SOR=0.021	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:49,19:68:99:0|1:13371202_T_A:549,0,1836:13371202
chr1	13371223	13371223	A	G	PRAMEF19	exonic	nonsynonymous SNV	NA	PRAMEF19:NM_001099790:exon2:c.T292C:p.W98R	0.2674	GnomAdGenome_AF_afr			WT/SomaticVariant	het	53	38	15	0.283018867924528	487.64	PASS	20.7	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	N	NA	NA	NA	T	T	T	T	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0	0	0	0.1137	0.2674	0	0	0	0		0					chr1	13371223	NA	A	G	487.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=22.849;AS_MQ=42.59;AS_MQRankSum=3;AS_QD=9.21;AS_ReadPosRankSum=0.3;AS_SOR=0.009;BaseQRankSum=-1.531;DP=53;ExcessHet=3.0103;FS=22.849;MLEAC=1;MLEAF=0.5;MQ=43.4;MQRankSum=3.08;QD=9.2;ReadPosRankSum=0.323;SOR=0.009	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:38,15:53:99:0|1:13371202_T_A:495,0,1496:13371202
chr1	13371759	13371759	A	G	PRAMEF19	exonic	nonsynonymous SNV	NA	PRAMEF19:NM_001099790:exon1:c.T142C:p.C48R	0.9545	GnomAdGenome_AF_ami			HomozygousVariant	hom	24	0	24	1	799.06	MQ40	4.84	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	T	.;	NA	NA	NA	NA	NA	Medium	Low	Low	NA	NA	NA	NA	NA	NA	NA	0.0132931844613083	N	NA	NA	NA	NA	NA	NA	0	0	0	0.8655	0.9545	0	0	0	0		0					chr1	13371759	NA	A	G	799.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=37.18;AS_MQRankSum=.;AS_QD=33.29;AS_ReadPosRankSum=.;AS_SOR=1.802;DP=26;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=38.12;QD=33.29;SOR=1.802	GT:AD:DP:GQ:PL	1/1:0,24:24:72:813,72,0
chr1	13418237	13418237	C	G	PRAMEF20	exonic	nonsynonymous SNV	NA	PRAMEF20:NM_001099852:exon3:c.C403G:p.L135V	0.8724	GnomAdGenome_AF_afr			HomozygousVariant	hom	119	0	119	1	3766.06	PASS	0.017	NA	NA	Uncertain significance	NA	NA	Copper levels[26025379];	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	T	NA	NA	T	.;.;	NA	NA	.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	NA	0.110718267434167	N	Pramef20	NA	NA	NA	NA	NA	0	0	0	0.696	0.8724	0	0	0.0000065	0		0					chr1	13418237	NA	C	G	3766.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=31.65;AS_ReadPosRankSum=.;AS_SOR=0.973;DP=125;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=31.65;SOR=0.973	GT:AD:DP:GQ:PL	1/1:0,119:119:99:3780,357,0
chr1	13421192	13421192	C	T	PRAMEF20	exonic	synonymous SNV	NA	PRAMEF20:NM_001099852:exon4:c.C1362T:p.T454T	0.3566	GnomAdGenome_AF_eas			HeterozygousVariant	het	101	52	49	0.485148514851485	1041.64	PASS	NA	NA	NA	Likely benign	NA	NA	Copper levels[26025379];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	NA	NA	0.110718267434167	N	Pramef20	NA	NA	NA	NA	NA	0	0	0	0.1284	0.3566	0	0	0.0001537	0		0					chr1	13421192	NA	C	T	1041.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=1.647;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.32;AS_ReadPosRankSum=1.7;AS_SOR=0.941;BaseQRankSum=-0.327;DP=103;ExcessHet=3.0103;FS=1.647;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.31;ReadPosRankSum=1.72;SOR=0.941	GT:AD:DP:GQ:PL	0/1:52,49:101:99:1049,0,1128
chr1	13475857	13475857	T	C	LRRC38	exonic	nonsynonymous SNV	NA	LRRC38:NM_001010847:exon2:c.A874G:p.K292E	0.6378	GnomAdGenome_AF_eas	73	25	HomozygousVariant	hom	51	0	51	1	1520.06	PASS	12.7	NA	615212	Benign	NA	NA	Copper levels[26025379];	NA	NA	NA	NA	NA	Mainly expressed in adrenal gland, thymus and skeletal muscle. {ECO:0000269|PubMed:22547800}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.160382217503467	N	Lrrc38	NA	NA	NA	NA	NA	0.4058	0.626	0.628	0.4319	0.6378	0.462061	0	0.126389	0.422824	PASS	0.52	0.362	233	0.361702	52	chr1	13475857	NA	T	C	1520.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.8;AS_ReadPosRankSum=.;AS_SOR=1.201;DP=53;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.81;SOR=1.201	GT:AD:DP:GQ:PL	1/1:0,51:51:99:1534,153,0
chr1	13583922	13583922	C	T	PDPN	exonic	synonymous SNV	NA	PDPN:NM_006474:exon1:c.C117T:p.P39P,PDPN:NM_198389:exon1:c.C117T:p.P39P	0.6998	GnomAdExome_AF_eas	254	73	HeterozygousVariant	het	124	66	58	0.467741935483871	1254.64	PASS	NA	NA	608863	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors and expressed in 25% of early oral squamous cell carcinomas. {ECO:0000269|PubMed:10393083, ECO:0000269|PubMed:14522983, ECO:0000269|PubMed:15515019}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	cochlea;tongue;skin;cerebellum cortex;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);larynx;kidney;uterus;whole body;pancreas;head and neck;skeletal muscle;visual apparatus;fovea centralis;spleen;liver;peripheral nerve;cartilage;endometrium;bone;parathyroid;brain;heart;lung;cerebral cortex;ovary;thyroid;macula lutea;lymph node;colon;placenta;prostate;nasopharynx;	pons;appendix;dorsal root ganglion;trigeminal ganglion;cingulate cortex;superior cervical ganglion;	0.847	E	N	N	N	0.479790542818645	N	Pdpn	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; digestive/alimentary phenotype; 	NA	NA	NA	NA	0.4421	0.6998	0.6924	0.4264	0.6886	0.563099	0.4057	0.415376	0.388342	PASS	0.596491	0.644	248	0.676056	46	chr1	13583922	NA	C	T	1254.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.12;AS_ReadPosRankSum=-0.4;AS_SOR=0.643;BaseQRankSum=-1.752;DP=130;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.12;ReadPosRankSum=-0.383;SOR=0.643	GT:AD:DP:GQ:PL	0/1:66,58:124:99:1262,0,1604
chr1	13584043	13584043	G	A	PDPN	exonic	nonsynonymous SNV	NA	PDPN:NM_006474:exon1:c.G238A:p.V80M,PDPN:NM_198389:exon1:c.G238A:p.V80M	0	GnomAdExome_AF			HeterozygousVariant	het	119	50	69	0.579831932773109	1880.64	PASS	23	NA	608863	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors and expressed in 25% of early oral squamous cell carcinomas. {ECO:0000269|PubMed:10393083, ECO:0000269|PubMed:14522983, ECO:0000269|PubMed:15515019}.;	D	T	D	P	N	N	L	T	N	T	T	D	T	T	T	T	D	T	.;.;.;.;.;	N	N	.;.;.;.;.	NA	NA	Medium	Medium	Medium	cochlea;tongue;skin;cerebellum cortex;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);larynx;kidney;uterus;whole body;pancreas;head and neck;skeletal muscle;visual apparatus;fovea centralis;spleen;liver;peripheral nerve;cartilage;endometrium;bone;parathyroid;brain;heart;lung;cerebral cortex;ovary;thyroid;macula lutea;lymph node;colon;placenta;prostate;nasopharynx;	pons;appendix;dorsal root ganglion;trigeminal ganglion;cingulate cortex;superior cervical ganglion;	0.847	E	N	N	N	0.479790542818645	N	Pdpn	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; digestive/alimentary phenotype; 	NA	NA	NA	NA	0	0	0	0	0	0	0	0	0		0					chr1	13584043	NA	G	A	1880.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.5;AS_FS=4.502;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.81;AS_ReadPosRankSum=0.1;AS_SOR=0.67;BaseQRankSum=-1.46;DP=125;ExcessHet=3.0103;FS=4.502;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.8;ReadPosRankSum=0.135;SOR=0.67	GT:AD:DP:GQ:PL	0/1:50,69:119:99:1888,0,1286
chr1	13584186	13584186	G	C	PDPN	intronic	NA	NA	NA	0.1276	GnomAdExome_AF_amr	5	3	HeterozygousVariant	het	103	54	49	0.475728155339806	1118.64	PASS	16.42	NA	608863	NA	NA	NA	NA	NA	NA	NA	NA	NA	Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors and expressed in 25% of early oral squamous cell carcinomas. {ECO:0000269|PubMed:10393083, ECO:0000269|PubMed:14522983, ECO:0000269|PubMed:15515019}.;	T	T	NA	NA	NA	D	NA	T	N	T	T	T	NA	NA	NA	T	T	T	.;	N	N	NA	0.0095	0.014	Medium	Medium	Medium	cochlea;tongue;skin;cerebellum cortex;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);larynx;kidney;uterus;whole body;pancreas;head and neck;skeletal muscle;visual apparatus;fovea centralis;spleen;liver;peripheral nerve;cartilage;endometrium;bone;parathyroid;brain;heart;lung;cerebral cortex;ovary;thyroid;macula lutea;lymph node;colon;placenta;prostate;nasopharynx;	pons;appendix;dorsal root ganglion;trigeminal ganglion;cingulate cortex;superior cervical ganglion;	0.847	E	N	N	N	0.479790542818645	N	Pdpn	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; digestive/alimentary phenotype; 	NA	NA	NA	NA	0.0509	0.1276	0.1299	0.0271	0.1	0.038738	0	0.0347602	0.03202	PASS	0	0.08	69	0.126761	30	chr1	13584186	NA	G	C	1118.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.5;AS_FS=2.556;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.86;AS_ReadPosRankSum=-0.2;AS_SOR=0.483;BaseQRankSum=-1.474;DP=103;ExcessHet=3.0103;FS=2.556;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.86;ReadPosRankSum=-0.175;SOR=0.483	GT:AD:DP:GQ:PL	0/1:54,49:103:99:1126,0,1393
chr1	13614369	13614369	C	G	PDPN	exonic	nonsynonymous SNV	NA	PDPN:NM_001006624:exon5:c.C314G:p.A105G,PDPN:NM_001006625:exon5:c.C314G:p.A105G,PDPN:NM_006474:exon5:c.C668G:p.A223G,PDPN:NM_198389:exon5:c.C668G:p.A223G	1	GnomAdGenome_AF_eas	573	142	HomozygousVariant	hom	59	0	59	1	1618.06	PASS	7.993	NA	608863	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors and expressed in 25% of early oral squamous cell carcinomas. {ECO:0000269|PubMed:10393083, ECO:0000269|PubMed:14522983, ECO:0000269|PubMed:15515019}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;.;.;.;.;.;.;	N	N	.;.;.;.;.;.;.;.;.;.	NA	NA	Medium	Medium	Medium	cochlea;tongue;skin;cerebellum cortex;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);larynx;kidney;uterus;whole body;pancreas;head and neck;skeletal muscle;visual apparatus;fovea centralis;spleen;liver;peripheral nerve;cartilage;endometrium;bone;parathyroid;brain;heart;lung;cerebral cortex;ovary;thyroid;macula lutea;lymph node;colon;placenta;prostate;nasopharynx;	pons;appendix;dorsal root ganglion;trigeminal ganglion;cingulate cortex;superior cervical ganglion;	0.847	E	N	N	N	0.479790542818645	N	Pdpn	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; digestive/alimentary phenotype; 	NA	NA	NA	NA	0.9564	0.9999	1	0.9606	1	0.98143	0.9669	0.938196	0.973727	PASS	1	0.991	11	1	0	chr1	13614369	NA	C	G	1618.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.42;AS_ReadPosRankSum=.;AS_SOR=0.871;DP=59;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.42;SOR=0.871	GT:AD:DP:GQ:PL	1/1:0,59:59:99:1632,176,0
chr1	13816508	13816508	A	G	PRDM2	exonic	nonsynonymous SNV	NA	PRDM2:NM_001135610:exon7:c.A593G:p.Q198R	0.95	GME_Israel	438	72	HomozygousVariant	hom	125	0	125	1	3342.06	PASS	0.296	NA	601196	Benign	NA	NA	'Parkinson''s disease[26227905];Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)[26252872];Copper levels[26025379];Left ventricular function change in anthracycline treatment[28542097];'	NA	NA	NA	NA	NA	Highly expressed in retinoblastoma cell lines and in brain tumors. Also expressed in a number of other cell lines and in brain, heart, skeletal muscle, liver and spleen. Isoform 1 is expressed in testis at much higher level than isoform 3. {ECO:0000269|PubMed:8654390, ECO:0000269|PubMed:9006946}.;	D	T	NA	NA	NA	P	NA	T	N	T	T	T	NA	NA	NA	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	thymus;amygdala;skin;stomach;lacrimal gland;testis;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;whole body;pancreas;bile duct;head and neck;hypopharynx;urinary;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;cerebral cortex;ovary;thyroid;macula lutea;lymph node;bladder;frontal lobe;colon;placenta;prostate;nasopharynx;breast;optic nerve;	ciliary ganglion;temporal lobe;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;cingulate cortex;cerebellum;pons;occipital lobe;subthalamic nucleus;whole brain;dorsal root ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.554	N	N	N	N	0.72998120164245	E	Prdm2	mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); neoplasm; 	NA	NA	NA	NA	0.8223	0.9301	0.9308	0.8656	0.9334	0.821286	0.8744	0.820901	0.857964	PASS	0.95	0.719	324	0.71831	60	chr1	13816508	NA	A	G	3342.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.74;AS_ReadPosRankSum=.;AS_SOR=0.775;DP=127;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.74;SOR=0.775	GT:AD:DP:GQ:PL	1/1:0,125:125:99:3356,373,0
chr1	13823127	13823127	T	C	PRDM2	intronic	NA	NA	NA	0.7814	GnomAdGenome_AF_amr	265	56	HomozygousVariant	hom	34	0	34	1	946.06	PASS	NA	NA	601196	NA	NA	NA	'Parkinson''s disease[26227905];Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)[26252872];Copper levels[26025379];Left ventricular function change in anthracycline treatment[28542097];'	NA	NA	NA	NA	NA	Highly expressed in retinoblastoma cell lines and in brain tumors. Also expressed in a number of other cell lines and in brain, heart, skeletal muscle, liver and spleen. Isoform 1 is expressed in testis at much higher level than isoform 3. {ECO:0000269|PubMed:8654390, ECO:0000269|PubMed:9006946}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;amygdala;skin;stomach;lacrimal gland;testis;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;whole body;pancreas;bile duct;head and neck;hypopharynx;urinary;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;cerebral cortex;ovary;thyroid;macula lutea;lymph node;bladder;frontal lobe;colon;placenta;prostate;nasopharynx;breast;optic nerve;	ciliary ganglion;temporal lobe;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;cingulate cortex;cerebellum;pons;occipital lobe;subthalamic nucleus;whole brain;dorsal root ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.554	N	N	N	N	0.72998120164245	E	Prdm2	mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); neoplasm; 	NA	NA	NA	NA	0.7372	0.7632	0.7657	0.749	0.7814	0.714657	0.7514	0.710702	0.7578	PASS	0	0.655	261	0.637324	69	chr1	13823127	NA	T	C	946.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.82;AS_ReadPosRankSum=.;AS_SOR=1.085;DP=34;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.83;SOR=1.085	GT:AD:DP:GQ:PL	1/1:0,34:34:99:960,102,0
chr1	13893691	13893691	A	G	PRDM2;KAZN-AS1	intergenic	NA	dist=68612;dist=455264	NA	0.5832	GnomAdExome_AF_amr	38	7	HeterozygousVariant	het	79	41	38	0.481012658227848	778.64	PASS	13.46	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	T	NA	NA	NA	NA	NA	T	.;.;	N	NA	.;.	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.3602	0.5832	0.5892	0.3584	0.5068	0.315695	0	0.101092	0		0	0.251	218	0.225352	50	chr1	13893691	NA	A	G	778.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.86;AS_ReadPosRankSum=-0.2;AS_SOR=0.648;BaseQRankSum=-0.124;DP=80;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.86;ReadPosRankSum=-0.113;SOR=0.648	GT:AD:DP:GQ:PL	0/1:41,38:79:99:786,0,896
chr1	15056111	15056111	G	A	KAZN	exonic	synonymous SNV	NA	KAZN:NM_001017999:exon5:c.G465A:p.T155T,KAZN:NM_001018000:exon5:c.G729A:p.T243T,KAZN:NM_001018001:exon5:c.G465A:p.T155T,KAZN:NM_001370229:exon5:c.G720A:p.T240T,KAZN:NM_001370230:exon5:c.G552A:p.T184T,KAZN:NM_015209:exon5:c.G747A:p.T249T,KAZN:NM_201628:exon5:c.G747A:p.T249T,KAZN:NM_001370231:exon6:c.G744A:p.T248T	0.103448	GME_SD	6	2	HeterozygousVariant	het	78	35	43	0.551282051282051	1031.64	PASS	NA	NA	NA	Benign	NA	NA	Conotruncal heart defects (inherited effects)[28468790];Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)[26252872];Copper levels[26025379];Mercury levels[26025379];Non-response to antidepressants and depression[27622933];	NA	NA	NA	NA	NA	Isoform 2, isoform 3 and isoform 4 are expressed in several cell lines including keratinocytes and bladder and epidermoid carcinoma (at protein level). Isoform 2, isoform 3 and isoform 4 are expressed in hair follicle and interfollicular epidermis (at protein level). {ECO:0000269|PubMed:15337775}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;cartilage;skin;stomach;bone;testis;parathyroid;brain;lens;blood;unclassifiable (Anatomical System);bone marrow;lung;choroid;ovary;uterus;whole body;retina;macula lutea;oesophagus;placenta;aorta;prostate;optic nerve;	ciliary ganglion;amygdala;prefrontal cortex;superior cervical ganglion;cingulate cortex;trigeminal ganglion;cerebellum peduncles;cerebellum;occipital lobe;subthalamic nucleus;whole brain;dorsal root ganglion;atrioventricular node;uterus corpus;placenta;parietal lobe;skeletal muscle;	NA	NA	N	N	N	0.11437135981131	N	Kazn	homeostasis/metabolism phenotype; growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0473	0.0703	0.0698	0.0511	0.0768	0.0449281	0.0567	0.0468105	0.046798	PASS	0.103448	0.075	76	0.073944	17	chr1	15056111	NA	G	A	1031.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.23;AS_ReadPosRankSum=1.1;AS_SOR=0.776;BaseQRankSum=3.05;DP=82;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.23;ReadPosRankSum=1.15;SOR=0.776	GT:AD:DP:GQ:PL	0/1:35,43:78:99:1039,0,657
chr1	15056171	15056171	T	C	KAZN	exonic	synonymous SNV	NA	KAZN:NM_001017999:exon5:c.T525C:p.N175N,KAZN:NM_001018000:exon5:c.T789C:p.N263N,KAZN:NM_001018001:exon5:c.T525C:p.N175N,KAZN:NM_001370229:exon5:c.T780C:p.N260N,KAZN:NM_001370230:exon5:c.T612C:p.N204N,KAZN:NM_015209:exon5:c.T807C:p.N269N,KAZN:NM_201628:exon5:c.T807C:p.N269N,KAZN:NM_001370231:exon6:c.T804C:p.N268N	0.0763	GnomAdGenome_AF_eas	5	4	HeterozygousVariant	het	122	73	49	0.401639344262295	939.64	PASS	NA	NA	NA	Likely benign	NA	NA	Conotruncal heart defects (inherited effects)[28468790];Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)[26252872];Copper levels[26025379];Mercury levels[26025379];Non-response to antidepressants and depression[27622933];	NA	NA	NA	NA	NA	Isoform 2, isoform 3 and isoform 4 are expressed in several cell lines including keratinocytes and bladder and epidermoid carcinoma (at protein level). Isoform 2, isoform 3 and isoform 4 are expressed in hair follicle and interfollicular epidermis (at protein level). {ECO:0000269|PubMed:15337775}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;cartilage;skin;stomach;bone;testis;parathyroid;brain;lens;blood;unclassifiable (Anatomical System);bone marrow;lung;choroid;ovary;uterus;whole body;retina;macula lutea;oesophagus;placenta;aorta;prostate;optic nerve;	ciliary ganglion;amygdala;prefrontal cortex;superior cervical ganglion;cingulate cortex;trigeminal ganglion;cerebellum peduncles;cerebellum;occipital lobe;subthalamic nucleus;whole brain;dorsal root ganglion;atrioventricular node;uterus corpus;placenta;parietal lobe;skeletal muscle;	NA	NA	N	N	N	0.11437135981131	N	Kazn	homeostasis/metabolism phenotype; growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0178	0.0684	0.069	0.0159	0.0763	0.0379393	0.0115	0.0172896	0.013136	PASS	0.056818	0.065	67	0.102113	21	chr1	15056171	NA	T	C	939.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.9;AS_FS=0.684;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.7;AS_ReadPosRankSum=0.2;AS_SOR=0.603;BaseQRankSum=-1.847;DP=124;ExcessHet=3.0103;FS=0.684;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.7;ReadPosRankSum=0.209;SOR=0.603	GT:AD:DP:GQ:PL	0/1:73,49:122:99:947,0,1755
chr1	15063649	15063649	A	G	KAZN	intronic	NA	NA	NA	0.7167	GnomAdGenome_AF_eas	30	25	HomozygousVariant	hom	109	1	108	0.990825688073394	4342.06	PASS	NA	NA	NA	NA	NA	NA	Conotruncal heart defects (inherited effects)[28468790];Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)[26252872];Copper levels[26025379];Mercury levels[26025379];Non-response to antidepressants and depression[27622933];	NA	NA	NA	NA	NA	Isoform 2, isoform 3 and isoform 4 are expressed in several cell lines including keratinocytes and bladder and epidermoid carcinoma (at protein level). Isoform 2, isoform 3 and isoform 4 are expressed in hair follicle and interfollicular epidermis (at protein level). {ECO:0000269|PubMed:15337775}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	fovea centralis;cartilage;skin;stomach;bone;testis;parathyroid;brain;lens;blood;unclassifiable (Anatomical System);bone marrow;lung;choroid;ovary;uterus;whole body;retina;macula lutea;oesophagus;placenta;aorta;prostate;optic nerve;	ciliary ganglion;amygdala;prefrontal cortex;superior cervical ganglion;cingulate cortex;trigeminal ganglion;cerebellum peduncles;cerebellum;occipital lobe;subthalamic nucleus;whole brain;dorsal root ganglion;atrioventricular node;uterus corpus;placenta;parietal lobe;skeletal muscle;	NA	NA	N	N	N	0.11437135981131	N	Kazn	homeostasis/metabolism phenotype; growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); 	NA	NA	NA	NA	0.31	0.7133	0.7113	0.3592	0.7167	0.460264	0.3548	0.30182	0.368637	PASS	0	0.336	140	0.401408	64	chr1	15063649	NA	A	G	4342.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.7;AS_FS=3.747;AS_MQ=60;AS_MQRankSum=0;AS_QD=32.59;AS_ReadPosRankSum=-0.5;AS_SOR=0.782;BaseQRankSum=0.701;DP=109;ExcessHet=3.0103;FS=3.747;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=33.09;ReadPosRankSum=-0.49;SOR=0.782	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:1,108:109:99:1|1:15063649_A_G:4356,294,0:15063649
chr1	15114594	15114594	C	T	KAZN	exonic	nonsynonymous SNV	NA	KAZN:NM_201628:exon15:c.C2287T:p.R763C	0.16	GnomAdExome_AF_eas	5	2	HeterozygousVariant	het	72	39	33	0.458333333333333	762.64	PASS	21.9	NA	NA	Benign	NA	NA	Conotruncal heart defects (inherited effects)[28468790];Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)[26252872];Copper levels[26025379];Mercury levels[26025379];Non-response to antidepressants and depression[27622933];	NA	NA	NA	NA	NA	Isoform 2, isoform 3 and isoform 4 are expressed in several cell lines including keratinocytes and bladder and epidermoid carcinoma (at protein level). Isoform 2, isoform 3 and isoform 4 are expressed in hair follicle and interfollicular epidermis (at protein level). {ECO:0000269|PubMed:15337775}.;	T	D	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	fovea centralis;cartilage;skin;stomach;bone;testis;parathyroid;brain;lens;blood;unclassifiable (Anatomical System);bone marrow;lung;choroid;ovary;uterus;whole body;retina;macula lutea;oesophagus;placenta;aorta;prostate;optic nerve;	ciliary ganglion;amygdala;prefrontal cortex;superior cervical ganglion;cingulate cortex;trigeminal ganglion;cerebellum peduncles;cerebellum;occipital lobe;subthalamic nucleus;whole brain;dorsal root ganglion;atrioventricular node;uterus corpus;placenta;parietal lobe;skeletal muscle;	NA	NA	N	N	N	0.11437135981131	N	Kazn	homeostasis/metabolism phenotype; growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0221	0.16	0.158	0.0079	0.1516	0.0513179	0.0025	0.0196699	0.004105	PASS	0.056818	0.072	74	0.080986	19	chr1	15114594	NA	C	T	762.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.4;AS_FS=3.132;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.6;AS_ReadPosRankSum=0.1;AS_SOR=0.988;BaseQRankSum=1.49;DP=73;ExcessHet=3.0103;FS=3.132;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.59;ReadPosRankSum=0.153;SOR=0.988	GT:AD:DP:GQ:PL	0/1:39,33:72:99:770,0,836
chr1	15164466	15164466	A	G	C1orf195;TMEM51	intronic	NA	NA	NA	0.3073	GnomAdExome_AF_eas	27	10	HeterozygousVariant	het	64	29	35	0.546875	779.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0.002	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.2145	0.3073	0.2985	0.2158	0.3041	0.262979	0	0.0517716	0		0	0.258	98	0.217391	40	chr1	15164466	NA	A	G	779.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.19;AS_ReadPosRankSum=0.5;AS_SOR=0.752;BaseQRankSum=-0.517;DP=66;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.18;ReadPosRankSum=0.56;SOR=0.752	GT:AD:DP:GQ:PL	0/1:29,35:64:99:787,0,651
chr1	15168614	15168614	A	G	C1orf195	exonic	nonsynonymous SNV	NA	C1orf195:NM_001278501:exon3:c.T262C:p.Y88H	0.3404	GnomAdExome_AF_afr	44	9	HeterozygousVariant	het	56	19	37	0.660714285714286	938.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	N	N	NA	NA	NA	NA	NA	NA	NA	NA	0.2116	0.3404	0.3395	0.2339	0.3353	0.285343	0	0.0618297	0		0	0.257	213	0.214789	43	chr1	15168614	NA	A	G	938.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.4;AS_FS=1.055;AS_MQ=60;AS_MQRankSum=0;AS_QD=16.77;AS_ReadPosRankSum=-1.2;AS_SOR=0.869;BaseQRankSum=1.41;DP=58;ExcessHet=3.0103;FS=1.055;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=16.76;ReadPosRankSum=-1.109;SOR=0.869	GT:AD:DP:GQ:PL	0/1:19,37:56:99:946,0,360
chr1	15171231	15171231	T	C	C1orf195	exonic	synonymous SNV	NA	C1orf195:NM_001278501:exon2:c.A48G:p.R16R,C1orf195:NM_001278502:exon2:c.A48G:p.R16R	0.9891	GnomAdGenome_AF_eas	568	136	HomozygousVariant	hom	108	0	108	1	2988.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	N	N	NA	NA	NA	NA	NA	NA	NA	NA	0.9579	0.987	0.9876	0.9382	0.9891	0.95627	0	0.0001153	0		0	0.993	8	0.978873	6	chr1	15171231	NA	T	C	2988.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.67;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=110;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.67;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,108:108:99:3002,324,0
chr1	15219581	15219581	G	A	TMEM51	exonic	synonymous SNV	NA	TMEM51:NM_001136217:exon3:c.G600A:p.P200P,TMEM51:NM_018022:exon3:c.G600A:p.P200P,TMEM51:NM_001136216:exon4:c.G600A:p.P200P,TMEM51:NM_001136218:exon4:c.G600A:p.P200P	0.4287	GnomAdGenome_AF_ami	88	21	HomozygousVariant	hom	87	0	87	1	2599.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;alveolus;skin;stomach;testis;lens;unclassifiable (Anatomical System);amniotic fluid;choroid;kidney;uterus;retina;pancreas;head and neck;mammary gland;islets of Langerhans;visual apparatus;fovea centralis;iris;spleen;liver;peripheral nerve;endometrium;bone;parathyroid;brain;blood;trabecular meshwork;lung;salivary gland;ovary;macula lutea;bladder;colon;placenta;prostate;optic nerve;	ciliary ganglion;trigeminal ganglion;atrioventricular node;	0.138	NA	N	N	N	0.550077692199613	E	Tmem51	NA	NA	NA	NA	NA	0.2812	0.3665	0.3619	0.2551	0.4287	0.204273	0.2749	0.283522	0.265189	PASS	0.353448	0.375	264	0.380282	66	chr1	15219581	NA	G	A	2599.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.87;AS_ReadPosRankSum=.;AS_SOR=1.03;DP=89;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.87;SOR=1.03	GT:AD:DP:GQ:PL	1/1:0,87:87:99:2613,261,0
chr1	15289643	15289643	G	A	FHAD1	exonic	nonsynonymous SNV	NA	FHAD1:NM_052929:exon4:c.G545A:p.R182H	0.416667	GME_Israel	46	6	HomozygousVariant	hom	38	0	38	1	1085.06	PASS	0.022	NA	NA	Benign	NA	NA	Coronary artery aneurysm in Kawasaki disease[27171184];Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Pelvic organ prolapse[26545240];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	High	High	High	lung;cervix;ovary;retina;cartilage;colon;skin;endometrium;testis;brain;unclassifiable (Anatomical System);	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;	NA	NA	NA	N	N	0.0583656520709602	N	Fhad1	NA	NA	NA	NA	NA	0.2721	0.3364	0.3354	0.2825	0.359	0.208067	0	0.0933041	0.289819	PASS	0.416667	0.277	233	0.25	59	chr1	15289643	NA	G	A	1085.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.55;AS_ReadPosRankSum=.;AS_SOR=1.863;DP=38;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.55;SOR=1.863	GT:AD:DP:GQ:PL	1/1:0,38:38:99:1099,113,0
chr1	15324566	15324566	A	G	FHAD1	intronic	NA	NA	NA	0.3955	GnomAdExome_AF_afr	25	19	HomozygousVariant	hom	50	0	50	1	1409.06	PASS	NA	NA	NA	NA	NA	NA	Coronary artery aneurysm in Kawasaki disease[27171184];Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Pelvic organ prolapse[26545240];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0003	0	High	High	High	lung;cervix;ovary;retina;cartilage;colon;skin;endometrium;testis;brain;unclassifiable (Anatomical System);	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;	NA	NA	NA	N	N	0.0583656520709602	N	Fhad1	NA	NA	NA	NA	NA	0.3183	0.3955	0.3999	0.3356	0.388	0.311102	0.3445	0.105639	0.347291	PASS	0	0.332	88	0.390845	73	chr1	15324566	NA	A	G	1409.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.18;AS_ReadPosRankSum=.;AS_SOR=0.952;DP=50;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.18;SOR=0.952	GT:AD:DP:GQ:PL	1/1:0,50:50:99:1423,150,0
chr1	15327067	15327067	C	T	FHAD1	exonic	synonymous SNV	NA	FHAD1:NM_052929:exon12:c.C1482T:p.H494H	0.3397	GnomAdExome_AF_amr	62	10	HomozygousVariant	hom	40	0	40	1	1159.06	PASS	NA	NA	NA	Benign	NA	NA	Coronary artery aneurysm in Kawasaki disease[27171184];Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Pelvic organ prolapse[26545240];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	lung;cervix;ovary;retina;cartilage;colon;skin;endometrium;testis;brain;unclassifiable (Anatomical System);	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;	NA	NA	NA	N	N	0.0583656520709602	N	Fhad1	NA	NA	NA	NA	NA	0.2845	0.3397	0.3461	0.2528	0.3264	0.221046	0.2547	0.092308	0.284072	PASS	0.318182	0.315	245	0.323944	72	chr1	15327067	NA	C	T	1159.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.98;AS_ReadPosRankSum=.;AS_SOR=0.902;DP=40;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.98;SOR=0.902	GT:AD:DP:GQ:PL	1/1:0,40:40:99:1173,119,0
chr1	15341780	15341780	G	A	FHAD1	exonic	nonsynonymous SNV	NA	FHAD1:NM_052929:exon15:c.G1951A:p.G651R	0.495	GnomAdGenome_AF_afr	82	16	HomozygousVariant	hom	47	0	47	1	1325.06	PASS	9.071	NA	NA	Benign	NA	NA	Coronary artery aneurysm in Kawasaki disease[27171184];Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Pelvic organ prolapse[26545240];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	High	High	High	lung;cervix;ovary;retina;cartilage;colon;skin;endometrium;testis;brain;unclassifiable (Anatomical System);	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;	NA	NA	NA	N	N	0.0583656520709602	N	Fhad1	NA	NA	NA	NA	NA	0.372	0.4829	0.4815	0.4163	0.495	0.345847	0.4319	0.129229	0.434319	PASS	0.469565	0.355	253	0.355634	69	chr1	15341780	NA	G	A	1325.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.19;AS_ReadPosRankSum=.;AS_SOR=1.022;DP=47;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.19;SOR=1.022	GT:AD:DP:GQ:PL	1/1:0,47:47:99:1339,141,0
chr1	15397347	15397347	G	A	FHAD1	exonic	synonymous SNV	NA	FHAD1:NM_052929:exon31:c.G4173A:p.L1391L	0.4952	GnomAdGenome_AF_eas	52	18	HeterozygousVariant	het	78	38	40	0.512820512820513	812.64	PASS	NA	NA	NA	Benign	NA	NA	Coronary artery aneurysm in Kawasaki disease[27171184];Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Pelvic organ prolapse[26545240];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	lung;cervix;ovary;retina;cartilage;colon;skin;endometrium;testis;brain;unclassifiable (Anatomical System);	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;	NA	NA	NA	N	N	0.0583656520709602	N	Fhad1	NA	NA	NA	NA	NA	0.3928	0.479	0.4785	0.3539	0.4952	0.310703	0.3647	0.129849	0.3711	PASS	0.471264	0.295	240	0.330986	58	chr1	15397347	NA	G	A	812.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0.858;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.42;AS_ReadPosRankSum=-0.1;AS_SOR=0.902;BaseQRankSum=-0.547;DP=80;ExcessHet=3.0103;FS=0.858;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.42;ReadPosRankSum=-0.045;SOR=0.902	GT:AD:DP:GQ:PL	0/1:38,40:78:99:820,0,805
chr1	15467418	15467418	G	A	CELA2A	exonic	synonymous SNV	NA	CELA2A:NM_033440:exon7:c.G672A:p.A224A	0.2769	GnomAdGenome_AF_afr	37	6	HeterozygousVariant	het	119	75	44	0.369747899159664	884.64	PASS	NA	NA	609443	Benign	NA	NA	Systolic blood pressure[28135244;28739976;28739976];Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779];Blood protein levels[30072576];	NA	NA	NA	NA	NA	Pancreas. Not detected in keratinocytes. {ECO:0000269|PubMed:10620133}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	liver;pancreas;muscle;unclassifiable (Anatomical System);islets of Langerhans;	NA	0.325	NA	N	N	N	0.147766254894979	N	Cela2a	NA	NA	NA	NA	NA	0.1784	0.2718	0.2686	0.2102	0.2769	0.179912	0.2176	0.17906	0.20197	PASS	0.263158	0.242	209	0.246479	58	chr1	15467418	NA	G	A	884.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=4.639;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.44;AS_ReadPosRankSum=-1.8;AS_SOR=0.901;BaseQRankSum=1.21;DP=121;ExcessHet=3.0103;FS=4.639;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.43;ReadPosRankSum=-1.704;SOR=0.901	GT:AD:DP:GQ:PL	0/1:75,44:119:99:892,0,1714
chr1	15482272	15482272	G	A	CELA2B	exonic	nonsynonymous SNV	NA	CELA2B:NM_015849:exon4:c.G235A:p.G79R	0.5671	GnomAdGenome_AF_eas	24	4	HeterozygousVariant	het	38	14	24	0.631578947368421	538.64	PASS	0.001	NA	609444	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779];	NA	NA	NA	NA	NA	Pancreas.;	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain;Serine proteases, trypsin domain	NA	NA	Medium	Medium	Medium	NA	NA	0.306	NA	N	S	N	0.0145944360636592	N	NA	NA	NA	NA	NA	NA	0.2814	0.5623	0.5529	0.2652	0.5671	0.326478	0.2508	0.273774	0.237274	PASS	0.179348	0.187	172	0.144366	33	chr1	15482272	NA	G	A	538.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.18;AS_ReadPosRankSum=-0.9;AS_SOR=0.601;BaseQRankSum=-0.985;DP=39;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.17;ReadPosRankSum=-0.879;SOR=0.601	GT:AD:DP:GQ:PL	0/1:14,24:38:99:546,0,295
chr1	15482377	15482377	G	A	CELA2B	exonic	nonsynonymous SNV	NA	CELA2B:NM_015849:exon4:c.G340A:p.D114N	0.551	GnomAdGenome_AF_eas	18	4	HeterozygousVariant	het	50	24	26	0.52	656.64	PASS	0.639	NA	609444	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779];	NA	NA	NA	NA	NA	Pancreas.;	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain	NA	NA	Medium	Medium	Medium	NA	NA	0.306	NA	N	S	N	0.0145944360636592	N	NA	NA	NA	NA	NA	NA	0.2736	0.5474	0.5395	0.2602	0.551	0.315096	0.2508	0.267247	0.23399	PASS	0.181818	0.174	138	0.140845	32	chr1	15482377	NA	G	A	656.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=6.048;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.14;AS_ReadPosRankSum=-1.5;AS_SOR=1.697;BaseQRankSum=0.558;DP=50;ExcessHet=3.0103;FS=6.048;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.13;ReadPosRankSum=-1.429;SOR=1.697	GT:AD:DP:GQ:PL	0/1:24,26:50:99:664,0,568
chr1	15485937	15485937	A	G	CELA2B	exonic	nonsynonymous SNV	NA	CELA2B:NM_015849:exon6:c.A530G:p.Q177R	1	GnomAdExome_AF_fin	583	142	HomozygousVariant	hom	139	0	139	1	3813.06	PASS	7	NA	609444	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779;28754779];	NA	NA	NA	NA	NA	Pancreas.;	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain	NA	NA	Medium	Medium	Medium	NA	NA	0.306	NA	N	S	N	0.0145944360636592	N	NA	NA	NA	NA	NA	NA	0.9983	0.9999	0.9999	0.9943	1	0.993211	0.9928	0.936346	0.994253	PASS	1	1	0	1	0	chr1	15485937	NA	A	G	3813.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.43;AS_ReadPosRankSum=.;AS_SOR=0.767;DP=139;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.43;SOR=0.767	GT:AD:DP:GQ:PL	1/1:0,139:139:99:3827,416,0
chr1	15493812	15493812	-	C	CASP9	intronic	NA	NA	NA	0.4255	GnomAdGenome_AF_afr	45	7	HeterozygousVariant	het	68	41	27	0.397058823529412	667.6	PASS	NA	NA	602234	NA	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Glomerular filtration rate in non diabetics (creatinine)[26831199];Glomerular filtration rate (creatinine)[26831199;28452372];	NA	NA	NA	NA	NA	Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes. {ECO:0000269|PubMed:16857965}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;testis;unclassifiable (Anatomical System);kidney;uterus;retina;pancreas;muscle;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;parathyroid;brain;blood;heart;lung;salivary gland;ovary;lymph node;bladder;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;testis;skeletal muscle;adrenal cortex;thalamus;	0.882	E	N	S	N	0.970938792810873	E	Casp9	growth/size/body region phenotype; taste/olfaction phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; embryo phenotype; respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; 	casp9	retinal ganglion cell	occurrence	abnormal	0.2122	0.4137	0.4144	0.2841	0.4255	0.235823	0	0.0001153	0.240558	PASS	0	0.237	259	0.25	57	chr1	15493812	NA	A	AC	667.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.82;AS_ReadPosRankSum=0.1;AS_SOR=0.625;BaseQRankSum=0.188;DP=74;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.82;ReadPosRankSum=0.151;SOR=0.625	GT:AD:DP:GQ:PL	0/1:41,27:68:99:675,0,1130
chr1	15506048	15506048	T	C	CASP9	exonic	nonsynonymous SNV	NA	CASP9:NM_001229:exon5:c.A662G:p.Q221R,CASP9:NM_032996:exon5:c.A413G:p.Q138R	0.7035	GnomAdGenome_AF_afr	169	26	HomozygousVariant	hom	96	1	95	0.989583333333333	2458.06	PASS	0.001	NA	602234	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Glomerular filtration rate in non diabetics (creatinine)[26831199];Glomerular filtration rate (creatinine)[26831199;28452372];	NA	NA	NA	NA	NA	Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes. {ECO:0000269|PubMed:16857965}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	Peptidase C14,  p20 domain|Peptidase C14A, caspase catalytic domain|Peptidase C14A, caspase catalytic domain;Peptidase C14,  p20 domain|Peptidase C14A, caspase catalytic domain|Peptidase C14A, caspase catalytic domain;.;Peptidase C14,  p20 domain|Peptidase C14A, caspase catalytic domain|Peptidase C14A, caspase catalytic domain	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;testis;unclassifiable (Anatomical System);kidney;uterus;retina;pancreas;muscle;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;parathyroid;brain;blood;heart;lung;salivary gland;ovary;lymph node;bladder;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;testis;skeletal muscle;adrenal cortex;thalamus;	0.882	E	N	S	N	0.970938792810873	E	Casp9	growth/size/body region phenotype; taste/olfaction phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; embryo phenotype; respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; 	casp9	retinal ganglion cell	occurrence	abnormal	0.5319	0.7011	0.7029	0.5911	0.7035	0.584864	0.5877	0.0001537	0.528736	PASS	0.590643	0.445	404	0.426056	69	chr1	15506048	NA	T	C	2458.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=25.6;AS_ReadPosRankSum=-0.2;AS_SOR=0.309;BaseQRankSum=0.415;DP=99;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=25.6;ReadPosRankSum=-0.181;SOR=0.309	GT:AD:DP:GQ:PL	1/1:1,95:96:99:2472,263,0
chr1	15518120	15518120	A	G	CASP9	exonic	synonymous SNV	NA	CASP9:NM_001229:exon2:c.T408C:p.F136F,CASP9:NM_001278054:exon2:c.T408C:p.F136F,CASP9:NM_032996:exon2:c.T159C:p.F53F	0.7031	GnomAdGenome_AF_afr	152	26	HomozygousVariant	hom	78	0	78	1	2222.06	PASS	NA	NA	602234	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Glomerular filtration rate in non diabetics (creatinine)[26831199];Glomerular filtration rate (creatinine)[26831199;28452372];	NA	NA	NA	NA	NA	Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes. {ECO:0000269|PubMed:16857965}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;testis;unclassifiable (Anatomical System);kidney;uterus;retina;pancreas;muscle;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;parathyroid;brain;blood;heart;lung;salivary gland;ovary;lymph node;bladder;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;testis;skeletal muscle;adrenal cortex;thalamus;	0.882	E	N	S	N	0.970938792810873	E	Casp9	growth/size/body region phenotype; taste/olfaction phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; embryo phenotype; respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; 	casp9	retinal ganglion cell	occurrence	abnormal	0.5317	0.7005	0.7024	0.591	0.7031	0.584864	0.5875	0.530802	0.529557	PASS	0.584795	0.443	354	0.422535	68	chr1	15518120	NA	A	G	2222.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.49;AS_ReadPosRankSum=.;AS_SOR=1.58;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.49;SOR=1.58	GT:AD:DP:GQ:PL	1/1:0,78:78:99:2236,234,0
chr1	15524058	15524058	-	GGGGGCG	CASP9	intronic	NA	NA	NA	0.7016	GnomAdGenome_AF_afr	143	23	HomozygousVariant	hom	33	0	33	1	1445.03	PASS	NA	NA	602234	NA	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Glomerular filtration rate in non diabetics (creatinine)[26831199];Glomerular filtration rate (creatinine)[26831199;28452372];	NA	NA	NA	NA	NA	Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes. {ECO:0000269|PubMed:16857965}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;testis;unclassifiable (Anatomical System);kidney;uterus;retina;pancreas;muscle;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;parathyroid;brain;blood;heart;lung;salivary gland;ovary;lymph node;bladder;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;testis;skeletal muscle;adrenal cortex;thalamus;	0.882	E	N	S	N	0.970938792810873	E	Casp9	growth/size/body region phenotype; taste/olfaction phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; embryo phenotype; respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; 	casp9	retinal ganglion cell	occurrence	abnormal	0.4388	0.5293	0.4928	0.5892	0.7016	0.555711	0.4068	0.0001153	0.482471	VQSRTrancheINDEL99.00to99.90	0	0.403	297	0.32971	45	chr1	15524058	NA	C	CGGGGGCG	1445.03	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=25.58;AS_ReadPosRankSum=.;AS_SOR=1.352;DP=35;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.33;SOR=1.352	GT:AD:DP:GQ:PL	1/1:0,33:33:99:1459,99,0
chr1	15524108	15524108	G	A	CASP9	exonic	synonymous SNV	NA	CASP9:NM_001229:exon1:c.C93T:p.S31S,CASP9:NM_001278054:exon1:c.C93T:p.S31S	0.4243	GnomAdGenome_AF_afr	52	8	HeterozygousVariant	het	60	33	27	0.45	586.64	PASS	NA	NA	602234	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Glomerular filtration rate in non diabetics (creatinine)[26831199];Glomerular filtration rate (creatinine)[26831199;28452372];	NA	NA	NA	NA	NA	Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes. {ECO:0000269|PubMed:16857965}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;testis;unclassifiable (Anatomical System);kidney;uterus;retina;pancreas;muscle;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;parathyroid;brain;blood;heart;lung;salivary gland;ovary;lymph node;bladder;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;testis;skeletal muscle;adrenal cortex;thalamus;	0.882	E	N	S	N	0.970938792810873	E	Casp9	growth/size/body region phenotype; taste/olfaction phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; embryo phenotype; respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; 	casp9	retinal ganglion cell	occurrence	abnormal	0.2037	0.4035	0.3938	0.2832	0.4243	0.235623	0.2514	0.0001537	0.225671	VQSRTrancheSNP99.00to99.90	0.275758	0.233	285	0.235714	50	chr1	15524108	NA	G	A	586.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0.996;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.78;AS_ReadPosRankSum=-0.1;AS_SOR=0.498;BaseQRankSum=-1.082;DP=60;ExcessHet=3.0103;FS=0.996;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.78;ReadPosRankSum=-0.082;SOR=0.498	GT:AD:DP:GQ:PL	0/1:33,27:60:99:594,0,825
chr1	15524118	15524118	G	A	CASP9	exonic	nonsynonymous SNV	NA	CASP9:NM_001229:exon1:c.C83T:p.A28V,CASP9:NM_001278054:exon1:c.C83T:p.A28V	0.7026	GnomAdGenome_AF_afr	167	27	HomozygousVariant	hom	64	0	64	1	2184.06	PASS	16.93	NA	602234	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779;28754779;28754779;28754779;28754779];Glomerular filtration rate in non diabetics (creatinine)[26831199];Glomerular filtration rate (creatinine)[26831199;28452372];	NA	NA	NA	NA	NA	Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes. {ECO:0000269|PubMed:16857965}.;	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	CARD domain|CARD domain|CARD domain;CARD domain|CARD domain|CARD domain;.;CARD domain|CARD domain|CARD domain	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;testis;unclassifiable (Anatomical System);kidney;uterus;retina;pancreas;muscle;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;parathyroid;brain;blood;heart;lung;salivary gland;ovary;lymph node;bladder;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;testis;skeletal muscle;adrenal cortex;thalamus;	0.882	E	N	S	N	0.970938792810873	E	Casp9	growth/size/body region phenotype; taste/olfaction phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; embryo phenotype; respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; 	casp9	retinal ganglion cell	occurrence	abnormal	0.5035	0.6849	0.6828	0.5904	0.7026	0.584665	0	0.25836	0.496644	VQSRTrancheSNP99.00to99.90	0.560606	0.432	386	0.408451	62	chr1	15524118	NA	G	A	2184.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=34.13;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=64;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=34.13;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,64:64:99:2198,192,0
chr1	15534308	15534308	C	T	DNAJC16	intronic	NA	NA	NA	0.4154	GnomAdGenome_AF_afr	37	7	HeterozygousVariant	het	47	27	20	0.425531914893617	498.64	PASS	NA	NA	NA	NA	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779];Cough in response to angiotensin-converting enzyme inhibitor drugs[28084903];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0002	0.014	Medium	Medium	Medium	NA	NA	0.751	NA	N	N	N	0.306426535438403	N	Dnajc16	limbs/digits/tail phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); embryo phenotype; 	NA	NA	NA	NA	0.2164	0.4028	0.4047	0.2807	0.4154	0.229832	0.2888	0.221019	0.238916	PASS	0	0.25	214	0.25	57	chr1	15534308	NA	C	T	498.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.1;AS_FS=4.501;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.62;AS_ReadPosRankSum=0.1;AS_SOR=1.514;BaseQRankSum=3.15;DP=47;ExcessHet=3.0103;FS=4.501;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.61;ReadPosRankSum=0.162;SOR=1.514	GT:AD:DP:GQ:PL	0/1:27,20:47:99:506,0,581
chr1	15546891	15546891	A	G	DNAJC16	intronic	NA	NA	NA	0.5902	GnomAdGenome_AF_eas	13	6	HeterozygousVariant	het	33	22	11	0.333333333333333	183.64	PASS	NA	NA	NA	NA	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779];Cough in response to angiotensin-converting enzyme inhibitor drugs[28084903];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.751	NA	N	N	N	0.306426535438403	N	Dnajc16	limbs/digits/tail phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); embryo phenotype; 	NA	NA	NA	NA	0.3215	0.5872	0.5847	0.3037	0.5902	0.346246	0.2929	0.288819	0.287356	PASS	0	0.216	63	0.167883	34	chr1	15546891	NA	A	G	183.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=1.465;AS_MQ=60;AS_MQRankSum=0;AS_QD=5.58;AS_ReadPosRankSum=1.4;AS_SOR=0.399;BaseQRankSum=-1.755;DP=33;ExcessHet=3.0103;FS=1.465;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=5.56;ReadPosRankSum=1.47;SOR=0.399	GT:AD:DP:GQ:PL	0/1:22,11:33:99:191,0,574
chr1	15565920	15565920	A	C	DNAJC16	exonic	synonymous SNV	NA	DNAJC16:NM_001287811:exon11:c.A664C:p.R222R,DNAJC16:NM_015291:exon12:c.A1600C:p.R534R	0.5827	GnomAdGenome_AF_afr	40	7	HeterozygousVariant	het	57	32	25	0.43859649122807	601.64	PASS	NA	NA	NA	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779];Cough in response to angiotensin-converting enzyme inhibitor drugs[28084903];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0007	0.004	Medium	Medium	Medium	NA	NA	0.751	NA	N	N	N	0.306426535438403	N	Dnajc16	limbs/digits/tail phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); embryo phenotype; 	NA	NA	NA	NA	0.2465	0.5755	0.5804	0.3481	0.5827	0.288139	0.3588	0.232022	0.292282	PASS	0.339181	0.253	217	0.260563	60	chr1	15565920	NA	A	C	601.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.1;AS_FS=2.411;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.56;AS_ReadPosRankSum=-0.3;AS_SOR=1.151;BaseQRankSum=1.1;DP=60;ExcessHet=3.0103;FS=2.411;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.56;ReadPosRankSum=-0.241;SOR=1.151	GT:AD:DP:GQ:PL	0/1:32,25:57:99:609,0,784
chr1	15577823	15577823	C	T	AGMAT	exonic	synonymous SNV	NA	AGMAT:NM_024758:exon5:c.G762A:p.S254S	0.4292	GnomAdGenome_AF_afr	37	7	HeterozygousVariant	het	104	49	55	0.528846153846154	1214.64	PASS	NA	NA	617887	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779];	NA	NA	NA	NA	NA	Highly expressed in liver and kidney. Also found in skeletal muscle, fetal liver, brain, testis, skin and the gastrointestinal tract. Within brain, expression is higher in the cerebral cortex with lower levels in the medulla and spinal cord. {ECO:0000269|PubMed:11804860, ECO:0000269|PubMed:11914032}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.309	NA	N	N	N	0.946101854127817	E	Agmat	NA	NA	NA	NA	NA	0.2186	0.4176	0.4202	0.2851	0.4292	0.23742	0.2932	0.223283	0.240558	PASS	0.28655	0.244	211	0.25	57	chr1	15577823	NA	C	T	1214.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=1.601;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.68;AS_ReadPosRankSum=1.6;AS_SOR=0.52;BaseQRankSum=0.5;DP=104;ExcessHet=3.0103;FS=1.601;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.68;ReadPosRankSum=1.6;SOR=0.52	GT:AD:DP:GQ:PL	0/1:49,55:104:99:1222,0,1076
chr1	15583249	15583249	C	T	AGMAT	exonic	nonsynonymous SNV	NA	AGMAT:NM_024758:exon2:c.G419A:p.R140Q	0.5229	GnomAdGenome_AF_afr	40	8	HeterozygousVariant	het	100	55	45	0.45	955.64	PASS	14.49	NA	617887	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779];	NA	NA	NA	NA	NA	Highly expressed in liver and kidney. Also found in skeletal muscle, fetal liver, brain, testis, skin and the gastrointestinal tract. Within brain, expression is higher in the cerebral cortex with lower levels in the medulla and spinal cord. {ECO:0000269|PubMed:11804860, ECO:0000269|PubMed:11914032}.;	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	D	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.309	NA	N	N	N	0.946101854127817	E	Agmat	NA	NA	NA	NA	NA	0.2425	0.517	0.5218	0.3298	0.5229	0.272364	0.3415	0.237461	0.280788	PASS	0.350877	0.253	216	0.264085	59	chr1	15583249	NA	C	T	955.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.56;AS_ReadPosRankSum=-2.3;AS_SOR=0.633;BaseQRankSum=-1.438;DP=108;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.56;ReadPosRankSum=-2.232;SOR=0.633	GT:AD:DP:GQ:PL	0/1:55,45:100:99:963,0,1331
chr1	15583355	15583355	C	G	AGMAT	exonic	nonsynonymous SNV	NA	AGMAT:NM_024758:exon2:c.G313C:p.G105R	0.8597	GnomAdExome_AF_afr	130	27	HomozygousVariant	hom	110	0	110	1	3104.06	PASS	13.28	NA	617887	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779];	NA	NA	NA	NA	NA	Highly expressed in liver and kidney. Also found in skeletal muscle, fetal liver, brain, testis, skin and the gastrointestinal tract. Within brain, expression is higher in the cerebral cortex with lower levels in the medulla and spinal cord. {ECO:0000269|PubMed:11804860, ECO:0000269|PubMed:11914032}.;	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.309	NA	N	N	N	0.946101854127817	E	Agmat	NA	NA	NA	NA	NA	0.5584	0.8597	0.862	0.6538	0.8556	0.633187	0.6539	0.561487	0.579639	PASS	0.654971	0.465	285	0.433099	69	chr1	15583355	NA	C	G	3104.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.22;AS_ReadPosRankSum=.;AS_SOR=1.069;DP=118;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.22;SOR=1.069	GT:AD:DP:GQ:PL	1/1:0,110:110:99:3118,330,0
chr1	15584854	15584854	G	A	AGMAT	exonic	synonymous SNV	NA	AGMAT:NM_024758:exon1:c.C114T:p.D38D	0.5903	GnomAdExome_AF_eas	34	7	HeterozygousVariant	het	54	32	22	0.407407407407407	435.64	PASS	NA	NA	617887	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779;28754779];	NA	NA	NA	NA	NA	Highly expressed in liver and kidney. Also found in skeletal muscle, fetal liver, brain, testis, skin and the gastrointestinal tract. Within brain, expression is higher in the cerebral cortex with lower levels in the medulla and spinal cord. {ECO:0000269|PubMed:11804860, ECO:0000269|PubMed:11914032}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.309	NA	N	N	N	0.946101854127817	E	Agmat	NA	NA	NA	NA	NA	0.3044	0.5903	0.5864	0.2992	0.5669	0.33766	0.2322	0.201731	0.282753	PASS	0.4	0.214	181	0.17029	33	chr1	15584854	NA	G	A	435.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=5.681;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.07;AS_ReadPosRankSum=0.8;AS_SOR=0.577;BaseQRankSum=-0.606;DP=57;ExcessHet=3.0103;FS=5.681;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.07;ReadPosRankSum=0.889;SOR=0.577	GT:AD:DP:GQ:PL	0/1:32,22:54:99:443,0,744
chr1	15633482	15633482	C	T	DDI2	exonic	synonymous SNV	NA	DDI2:NM_032341:exon4:c.C549T:p.A183A	0.4285	GnomAdGenome_AF_afr	55	10	HeterozygousVariant	het	25	12	13	0.52	281.64	PASS	NA	NA	NA	Benign	NA	NA	Alcoholic chronic pancreatitis[28754779;28754779];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;larynx;uterus;thyroid;liver;lymph node;colon;head and neck;stomach;germinal center;unclassifiable (Anatomical System);	NA	0.224	NA	E	E	K	0.418364277205413	N	Ddi2	NA	NA	NA	NA	NA	0.2569	0.4277	0.4351	0.3198	0.4285	0.250998	0.3275	0.238768	0.288177	PASS	0.4	0.25	270	0.260563	54	chr1	15633482	NA	C	T	281.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.28;AS_ReadPosRankSum=-1.6;AS_SOR=0.551;BaseQRankSum=-1.687;DP=26;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.27;ReadPosRankSum=-1.503;SOR=0.551	GT:AD:DP:GQ:PL	0/1:12,13:25:99:289,0,312
chr1	15660052	15660052	T	C	RSC1A1	exonic	nonsynonymous SNV	NA	RSC1A1:NM_006511:exon1:c.T184C:p.F62L	0.428	GnomAdGenome_AF_afr	57	10	HeterozygousVariant	het	40	22	18	0.45	524.64	PASS	17.16	NA	601966	Benign	X-linked retinoschisis	Disease-causing germline mutation(s) in	Alcoholic chronic pancreatitis[28754779;28754779];	HP:0030502;HP:0000504;HP:0000496;HP:0000512;HP:0000501;HP:0000518;HP:0000541;HP:0001105;HP:0007984;HP:0007722;HP:0000540;HP:0000529;HP:0030502;HP:0030824;HP:0007401;HP:0007902;HP:0001423;HP:0007667;HP:0001419	Retinoschisis;Abnormality of vision;Abnormality of eye movement;Abnormal electroretinogram;Glaucoma;Cataract;Retinal detachment;Retinal atrophy;Electronegative electroretinogram;Retinal pigment epithelial atrophy;Hypermetropia;Progressive visual loss;Retinoschisis;Mizuo phenomenon;Macular atrophy;Vitreous hemorrhage;X-linked dominant inheritance;Peripheral cystoid retinal degeneration;X-linked recessive inheritance	NA	NA	NA	Expressed in small intestine, kidney and brain. {ECO:0000269|PubMed:8836035}.;	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;	D	N	NA	NA	NA	Medium	Medium	Medium	cochlea;spleen;liver;stomach;brain;unclassifiable (Anatomical System);larynx;kidney;thyroid;lymph node;frontal lobe;sympathetic chain;colon;head and neck;placenta;nasopharynx;skeletal muscle;breast;	NA	0.915	N	N	N	N	0.34196078824737	N	Rsc1a1	growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); digestive/alimentary phenotype; 	NA	NA	NA	NA	0.2568	0.4277	0.4351	0.3196	0.428	0.250799	0.3272	0.247403	0.288177	PASS	0.4	0.247	286	0.260563	54	chr1	15660052	NA	T	C	524.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.1;AS_FS=4.442;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.13;AS_ReadPosRankSum=-0.7;AS_SOR=1.087;BaseQRankSum=2.16;DP=40;ExcessHet=3.0103;FS=4.442;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.12;ReadPosRankSum=-0.667;SOR=1.087	GT:AD:DP:GQ:PL	0/1:22,18:40:99:532,0,631
chr1	15660373	15660373	G	A	RSC1A1	exonic	nonsynonymous SNV	NA	RSC1A1:NM_006511:exon1:c.G505A:p.E169K	0.046	GnomAdExome_AF_asj	0	0	HeterozygousVariant	het	55	31	24	0.436363636363636	607.64	PASS	6.965	NA	601966	Likely benign	X-linked retinoschisis	Disease-causing germline mutation(s) in	Alcoholic chronic pancreatitis[28754779;28754779];	HP:0030502;HP:0000504;HP:0000496;HP:0000512;HP:0000501;HP:0000518;HP:0000541;HP:0001105;HP:0007984;HP:0007722;HP:0000540;HP:0000529;HP:0030502;HP:0030824;HP:0007401;HP:0007902;HP:0001423;HP:0007667;HP:0001419	Retinoschisis;Abnormality of vision;Abnormality of eye movement;Abnormal electroretinogram;Glaucoma;Cataract;Retinal detachment;Retinal atrophy;Electronegative electroretinogram;Retinal pigment epithelial atrophy;Hypermetropia;Progressive visual loss;Retinoschisis;Mizuo phenomenon;Macular atrophy;Vitreous hemorrhage;X-linked dominant inheritance;Peripheral cystoid retinal degeneration;X-linked recessive inheritance	NA	NA	NA	Expressed in small intestine, kidney and brain. {ECO:0000269|PubMed:8836035}.;	T	T	B	B	N	N	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	cochlea;spleen;liver;stomach;brain;unclassifiable (Anatomical System);larynx;kidney;thyroid;lymph node;frontal lobe;sympathetic chain;colon;head and neck;placenta;nasopharynx;skeletal muscle;breast;	NA	0.915	N	N	N	N	0.34196078824737	N	Rsc1a1	growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); digestive/alimentary phenotype; 	NA	NA	NA	NA	0.0163	0.0296	0.0286	0.0198	0.0439	0.0147764	0.0187	0.0162935	0.018062	PASS	0.027439	0.014	23	0.010563	3	chr1	15660373	NA	G	A	607.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=2.307;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.05;AS_ReadPosRankSum=0;AS_SOR=1.01;BaseQRankSum=0.123;DP=58;ExcessHet=3.0103;FS=2.307;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.05;ReadPosRankSum=0.085;SOR=1.01	GT:AD:DP:GQ:PL	0/1:31,24:55:99:615,0,811
chr1	15716271	15716271	T	C	PLEKHM2	exonic	nonsynonymous SNV	NA	PLEKHM2:NM_015164:exon2:c.T95C:p.I32T	0.6816	GnomAdExome_AF_afr	39	9	HeterozygousVariant	het	70	39	31	0.442857142857143	644.64	PASS	19.33	NA	609613	Benign	Left ventricular noncompaction	Major susceptibility factor in	Alcoholic chronic pancreatitis[28754779;28754779;28754779];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	D	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.449	NA	N	N	N	0.374929485434601	N	Plekhm2	growth/size/body region phenotype; homeostasis/metabolism phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); immune system phenotype; 	NA	NA	NA	NA	0.2516	0.6816	0.6851	0.3778	0.6757	0.323083	0.3821	0.255508	0.324302	PASS	0.45	0.232	273	0.253521	54	chr1	15716271	NA	T	C	644.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.21;AS_ReadPosRankSum=-0.3;AS_SOR=0.73;BaseQRankSum=0.136;DP=73;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.21;ReadPosRankSum=-0.284;SOR=0.73	GT:AD:DP:GQ:PL	0/1:39,31:70:99:652,0,858
chr1	15929512	15929512	T	C	SPEN	exonic	nonsynonymous SNV	NA	SPEN:NM_015001:exon11:c.T3272C:p.L1091P	0.9246	GnomAdExome_AF_afr	305	64	HomozygousVariant	hom	50	0	50	1	1748.06	PASS	7.765	NA	613484	Benign	NA	NA	Heel bone mineral density[28869591;28869591;28869591];	NA	NA	NA	NA	NA	Expressed at high level in brain, testis, spleen and thymus. Expressed at intermediate level in kidney, liver, mammary gland and skin.;	T	T	B	B	NA	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.206	E	E	N	K	0.858825914755972	E	Spen	liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.6155	0.9246	0.9246	0.6859	0.9134	0.648962	0.6878	0.0001153	0.639573	PASS	0.659091	0.606	369	0.644366	55	chr1	15929512	NA	T	C	1748.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=34.96;AS_ReadPosRankSum=.;AS_SOR=0.952;DP=50;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=34.96;SOR=0.952	GT:AD:DP:GQ:PL	1/1:0,50:50:99:1762,150,0
chr1	15933318	15933318	A	G	SPEN	exonic	nonsynonymous SNV	NA	SPEN:NM_015001:exon11:c.A7078G:p.N2360D	0.9246	GnomAdExome_AF_afr	305	64	HomozygousVariant	hom	125	2	123	0.984	3565.06	PASS	6.106	NA	613484	Benign	NA	NA	Heel bone mineral density[28869591;28869591;28869591];	NA	NA	NA	NA	NA	Expressed at high level in brain, testis, spleen and thymus. Expressed at intermediate level in kidney, liver, mammary gland and skin.;	T	T	B	B	NA	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.206	E	E	N	K	0.858825914755972	E	Spen	liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.6156	0.9246	0.9247	0.6858	0.9134	0.648962	0.6896	0.604662	0.646141	PASS	0.659091	0.607	369	0.640845	54	chr1	15933318	NA	A	G	3565.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=28.52;AS_ReadPosRankSum=-0.4;AS_SOR=1.133;BaseQRankSum=1.87;DP=130;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=28.52;ReadPosRankSum=-0.344;SOR=1.133	GT:AD:DP:GQ:PL	1/1:2,123:125:99:3579,339,0
chr1	15935319	15935319	C	A	SPEN	exonic	synonymous SNV	NA	SPEN:NM_015001:exon11:c.C9079A:p.R3027R	0.0482	GnomAdGenome_AF_asj	1	0	HeterozygousVariant	het	170	84	86	0.505882352941176	1934.64	PASS	NA	NA	613484	Likely benign	NA	NA	Heel bone mineral density[28869591;28869591;28869591];	NA	NA	NA	NA	NA	Expressed at high level in brain, testis, spleen and thymus. Expressed at intermediate level in kidney, liver, mammary gland and skin.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.206	E	E	N	K	0.858825914755972	E	Spen	liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.0191	0.0256	0.0254	0.0153	0.0482	0.0105831	0.0157	0.0190554	0.021346	PASS	0.034483	0.029	45	0.024648	7	chr1	15935319	NA	C	A	1934.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=6.599;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.38;AS_ReadPosRankSum=-0.1;AS_SOR=1.004;BaseQRankSum=-1.139;DP=180;ExcessHet=3.0103;FS=6.599;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.38;ReadPosRankSum=-0.025;SOR=1.004	GT:AD:DP:GQ:PL	0/1:84,86:170:99:1942,0,2022
chr1	15944765	15944765	G	A	ZBTB17	exonic	synonymous SNV	NA	ZBTB17:NM_001242884:exon7:c.C756T:p.F252F,ZBTB17:NM_001324137:exon7:c.C774T:p.F258F,ZBTB17:NM_001324138:exon7:c.C813T:p.F271F,ZBTB17:NM_001287603:exon8:c.C1002T:p.F334F,ZBTB17:NM_001287604:exon8:c.C774T:p.F258F,ZBTB17:NM_003443:exon8:c.C1002T:p.F334F	0.4263	GnomAdExome_AF_sas	92	27	HomozygousVariant	hom	124	2	122	0.983870967741935	3414.06	PASS	NA	NA	604084	Benign	NA	NA	Idiopathic dilated cardiomyopathy[21459883];Glomerular filtration rate[29403010];	NA	NA	NA	NA	NA	Expressed in germinal center B-cells. {ECO:0000269|PubMed:16142238}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.433	E	N	E	E	0.95203009852707	E	Zbtb17	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype; cellular phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); pigmentation phenotype; embryo phenotype; immune system phenotype; 	NA	NA	NA	NA	0.2853	0.4263	0.4267	0.236	0.4154	0.208267	0.2368	0.277137	0.259442	PASS	0.390152	0.396	283	0.426056	67	chr1	15944765	NA	G	A	3414.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=27.53;AS_ReadPosRankSum=-0.5;AS_SOR=0.76;BaseQRankSum=0.742;DP=131;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=27.53;ReadPosRankSum=-0.466;SOR=0.76	GT:AD:DP:GQ:PL	1/1:2,122:124:99:3428,321,0
chr1	15945755	15945755	A	G	ZBTB17	exonic	synonymous SNV	NA	ZBTB17:NM_001242884:exon5:c.T375C:p.A125A,ZBTB17:NM_001324137:exon5:c.T393C:p.A131A,ZBTB17:NM_001324138:exon5:c.T432C:p.A144A,ZBTB17:NM_001287603:exon6:c.T621C:p.A207A,ZBTB17:NM_001287604:exon6:c.T393C:p.A131A,ZBTB17:NM_003443:exon6:c.T621C:p.A207A	0.6997	GnomAdExome_AF_amr	180	56	HomozygousVariant	hom	153	1	152	0.993464052287582	4071.06	PASS	NA	NA	604084	NA	NA	NA	Idiopathic dilated cardiomyopathy[21459883];Glomerular filtration rate[29403010];	NA	NA	NA	NA	NA	Expressed in germinal center B-cells. {ECO:0000269|PubMed:16142238}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.433	E	N	E	E	0.95203009852707	E	Zbtb17	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype; cellular phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); pigmentation phenotype; embryo phenotype; immune system phenotype; 	NA	NA	NA	NA	0.5298	0.6997	0.6983	0.5035	0.6103	0.483027	0.4772	0.492109	0.502463	PASS	0.587121	0.55	282	0.602113	59	chr1	15945755	NA	A	G	4071.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=26.61;AS_ReadPosRankSum=-1.6;AS_SOR=0.256;BaseQRankSum=-1.378;DP=161;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=26.61;ReadPosRankSum=-1.585;SOR=0.256	GT:AD:DP:GQ:PL	1/1:1,152:153:99:4085,424,0
chr1	16035421	16035421	G	A	CLCNKA;CLCNKB	intergenic	NA	dist=1371;dist=8315	NA	0.7877	GnomAdGenome_AF_eas	115	15	HeterozygousVariant	het	88	59	29	0.329545454545454	594.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.5398	0.7877	0	0	0.0542108	0		0	0.663	168	0.5625	42	chr1	16035421	NA	G	A	594.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.9;AS_FS=9.534;AS_MQ=45.67;AS_MQRankSum=-0.2;AS_QD=6.76;AS_ReadPosRankSum=-0.7;AS_SOR=0.849;BaseQRankSum=-1.877;DP=89;ExcessHet=3.0103;FS=9.534;MLEAC=1;MLEAF=0.5;MQ=45.98;MQRankSum=-0.129;QD=6.76;ReadPosRankSum=-0.639;SOR=0.849	GT:AD:DP:GQ:PL	0/1:59,29:88:99:602,0,1523
chr1	16044572	16044572	G	T	CLCNKB	exonic	nonsynonymous SNV	NA	CLCNKB:NM_000085:exon2:c.G80T:p.R27L	0.7589	GnomAdGenome_AF_ami	413	65	HomozygousVariant	hom	62	0	62	1	1776.06	PASS	18.63	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	Benign	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	D	D	P	B	N	P	M	D	D	T	T	T	NA	NA	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.6267	0.7293	0.7302	0.5401	0.7589	0.555511	0.5263	0.0001153	0.616585	PASS	0.75	0.692	330	0.640845	52	chr1	16044572	NA	G	T	1776.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.65;AS_ReadPosRankSum=.;AS_SOR=0.758;DP=64;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.65;SOR=0.758	GT:AD:DP:GQ:PL	1/1:0,62:62:99:1790,186,0
chr1	16046629	16046629	A	G	CLCNKB	exonic	synonymous SNV	NA	CLCNKB:NM_000085:exon4:c.A324G:p.S108S	0.9891	GnomAdExome_AF_eas	662	112	HomozygousVariant	hom	132	0	132	1	3536.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	Benign	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.8121	0.9891	0.9895	0.6916	0.9869	0.740415	0.6722	0.793224	0.758621	VQSRTrancheSNP99.00to99.90	0.9	0.886	155	0.866197	22	chr1	16046629	NA	A	G	3536.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.86;AS_MQRankSum=.;AS_QD=26.79;AS_ReadPosRankSum=.;AS_SOR=0.889;DP=139;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.81;QD=26.79;SOR=0.889	GT:AD:DP:GQ:PL	1/1:0,132:132:99:3550,394,0
chr1	16048038	16048038	G	C	CLCNKB	exonic	synonymous SNV	NA	CLCNKB:NM_000085:exon5:c.G492C:p.G164G	0.9997	GnomAdExome_AF_eas	725	124	HomozygousVariant	hom	118	0	118	1	3342.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	Benign	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.9317	0.9997	0.9997	0.887	0.9997	0.89397	0.8784	0.920615	0.895731	PASS	0.920455	0.929	102	0.919014	13	chr1	16048038	NA	G	C	3342.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.32;AS_ReadPosRankSum=.;AS_SOR=0.955;DP=121;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.32;SOR=0.955	GT:AD:DP:GQ:PL	1/1:0,118:118:99:3356,353,0
chr1	16048499	16048499	C	T	CLCNKB	intronic	NA	NA	NA	0.989	GnomAdExome_AF_eas	655	112	HomozygousVariant	hom	114	0	114	1	3439.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	NA	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.8104	0.989	0.9894	0.6896	0.9872	0.738618	0	0.737306	0.760611	VQSRTrancheSNP99.00to99.90	0	0.885	151	0.862676	21	chr1	16048499	NA	C	T	3439.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=51.61;AS_MQRankSum=.;AS_QD=30.17;AS_ReadPosRankSum=.;AS_SOR=0.802;DP=122;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=51.96;QD=30.17;SOR=0.802	GT:AD:DP:GQ:PL	1/1:0,114:114:99:3453,340,0
chr1	16048568	16048568	C	G	CLCNKB	exonic	nonsynonymous SNV	NA	CLCNKB:NM_000085:exon7:c.C641G:p.A214G	0.9997	GnomAdExome_AF_eas	722	124	HomozygousVariant	hom	117	0	117	1	5183.06	PASS	5.967	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	Benign	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	Bartter_syndrome_type_3|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	T	T	B	B	N	P	N	D	N	T	T	T	NA	NA	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.9069	0.9997	0.9997	0.8186	0.9987	0.827276	0	0.0872304	0.526961	VQSRTrancheSNP99.00to99.90	0.913386	0.928	105	0.919014	13	chr1	16048568	NA	C	G	5183.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=56.79;AS_MQRankSum=.;AS_QD=30.22;AS_ReadPosRankSum=.;AS_SOR=1.309;DP=120;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=56.35;QD=34.61;SOR=1.309	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,117:117:99:1|1:16048568_C_G:5197,352,0:16048568
chr1	16048569	16048569	A	C	CLCNKB	exonic	synonymous SNV	NA	CLCNKB:NM_000085:exon7:c.A642C:p.A214A	0.9997	GnomAdExome_AF_eas	722	124	HomozygousVariant	hom	117	0	117	1	5183.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	Benign	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	not_specified	criteria_provided,_single_submitter	Benign	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.9069	0.9997	0.9997	0.8186	0.9987	0.827276	0	0.793179	0.5025	VQSRTrancheSNP99.00to99.90	0.944444	0.928	105	0.919014	13	chr1	16048569	NA	A	C	5183.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=56.79;AS_MQRankSum=.;AS_QD=28.65;AS_ReadPosRankSum=.;AS_SOR=1.309;DP=120;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=56.35;QD=31.58;SOR=1.309	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,117:117:99:1|1:16048568_C_G:5197,352,0:16048568
chr1	16049824	16049824	T	C	CLCNKB	exonic	synonymous SNV	NA	CLCNKB:NM_001165945:exon3:c.T369C:p.C123C,CLCNKB:NM_000085:exon10:c.T876C:p.C292C	0.9998	GnomAdExome_AF_eas	724	123	HomozygousVariant	hom	114	0	114	1	3345.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	Benign	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.9168	0.9998	0.9997	0.8277	0.9994	0.830072	0.8151	0.893843	0.852217	VQSRTrancheSNP99.90to100.00	0.916667	0.929	103	0.915493	14	chr1	16049824	NA	T	C	3345.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.34;AS_ReadPosRankSum=.;AS_SOR=1.009;DP=117;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.34;SOR=1.009	GT:AD:DP:GQ:PL	1/1:0,114:114:99:3359,341,0
chr1	16050613	16050613	G	C	CLCNKB	intronic	NA	NA	NA	0.4232	GnomAdGenome_AF_ami	84	11	HomozygousVariant	hom	127	0	127	1	3456.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	NA	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	not_specified	criteria_provided,_single_submitter	Benign	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.2388	0.3554	0.3558	0.1895	0.4232	0.16254	0.1809	0.227313	0.236453	PASS	0	0.292	314	0.242958	47	chr1	16050613	NA	G	C	3456.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.21;AS_ReadPosRankSum=.;AS_SOR=0.879;DP=128;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.21;SOR=0.879	GT:AD:DP:GQ:PL	1/1:0,127:127:99:3470,379,0
chr1	16053701	16053701	T	C	CLCNKB	exonic	nonsynonymous SNV	NA	CLCNKB:NM_001165945:exon9:c.T1178C:p.M393T,CLCNKB:NM_000085:exon16:c.T1685C:p.M562T	0.9967	GnomAdGenome_AF_ami	617	118	HomozygousVariant	hom	210	0	210	1	5719.06	PASS	0.027	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	Benign	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	T	T	B	B	N	P	N	D	N	T	T	T	NA	NA	T	T	T	T	.;.;.;	N	N	CBS domain|CBS domain|CBS domain;.;CBS domain|CBS domain|CBS domain	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.9347	0.9843	0.9835	0.8854	0.9967	0.838259	0.8882	0.912304	0.901478	PASS	0.982759	0.907	116	0.911972	23	chr1	16053701	NA	T	C	5719.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.85;AS_MQRankSum=.;AS_QD=27.23;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=215;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.85;QD=27.23;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,210:210:99:5733,628,0
chr1	16056382	16056382	A	G	CLCNKB	intronic	NA	NA	NA	0.884	GnomAdExome_AF_amr	430	98	HomozygousVariant	hom	63	0	63	1	2671.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	NA	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	NA	NA	NA	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.7963	0.884	0.8826	0.7651	0.8722	0.784145	0.762	0.772914	0.809524	VQSRTrancheSNP99.00to99.90	0	0.836	153	0.820423	37	chr1	16056382	NA	A	G	2671.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.7;AS_MQRankSum=.;AS_QD=25.27;AS_ReadPosRankSum=.;AS_SOR=1.27;DP=64;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.71;QD=35.69;SOR=1.27	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,63:63:99:1|1:16056382_A_G:2685,189,0:16056382
chr1	16056385	16056385	T	A	CLCNKB	intronic	NA	NA	NA	0.4471	GnomAdExome_AF_amr	89	23	HomozygousVariant	hom	63	0	63	1	2671.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	NA	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	NA	NA	NA	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.2984	0.4471	0.4491	0.3017	0.4395	0.295128	0.3085	0.28715	0.344007	VQSRTrancheSNP99.00to99.90	0	0.358	256	0.361702	56	chr1	16056385	NA	T	A	2671.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.7;AS_MQRankSum=.;AS_QD=31.8;AS_ReadPosRankSum=.;AS_SOR=1.27;DP=65;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.71;QD=28.24;SOR=1.27	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,63:63:99:1|1:16056382_A_G:2685,189,0:16056382
chr1	16056834	16056834	-	C	CLCNKB	intronic	NA	NA	NA	0.7923	GnomAdGenome_AF_eas	346	77	HomozygousVariant	hom	48	0	45	0.9375	2032.03	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	NA	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	NA	NA	NA	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0	0	0	0.6498	0.7923	0.632788	0	0.2641	0.628302	VQSRTrancheINDEL99.00to99.90	0	0.738	155	0.740458	40	chr1	16056834	NA	T	TC	2032.03	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=48.08;AS_MQRankSum=.;AS_QD=27.91;AS_ReadPosRankSum=.;AS_SOR=2.687;DP=51;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=49.52;QD=28.2;SOR=2.608	GT:AD:DP:GQ:PL	1/1:0,45:48:99:2046,150,0
chr1	16056841	16056841	G	C	CLCNKB	intronic	NA	NA	NA	0.8343	GnomAdExome_AF_amr	387	78	HomozygousVariant	hom	60	0	60	1	2408.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	NA	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	NA	NA	NA	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.7085	0.8343	0.8382	0.7162	0.8209	0.714657	0	0.211234	0.190184	VQSRTrancheSNP99.00to99.90	0	0.774	141	0.763359	44	chr1	16056841	NA	G	C	2408.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=47.42;AS_MQRankSum=.;AS_QD=27.28;AS_ReadPosRankSum=.;AS_SOR=1.812;DP=65;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=47.33;QD=24.86;SOR=1.812	GT:AD:DP:GQ:PL	1/1:0,60:60:99:2422,180,0
chr1	16056853	16056853	C	T	CLCNKB	intronic	NA	NA	NA	0.4342	GnomAdExome_AF_amr	118	23	HomozygousVariant	hom	85	0	85	1	2254.06	PASS	NA	[MIM:613090]Bartter syndrome 4B, neonatal, with sensorineural deafness [recessive?];	602023	NA	Gitelman syndrome;Infantile Bartter syndrome with sensorineural deafness;Classic Bartter syndrome	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Red blood cell count[27863252];	HP:0000127;HP:0002902;HP:0000083;HP:0002914;HP:0000407;HP:0003577;HP:0001265;HP:0012213;HP:0003113;HP:0001270;HP:0001563;HP:0001561;HP:0003081;HP:0001290;HP:0012605;HP:0001249;HP:0004909;HP:0000859;HP:0001252;HP:0002900;HP:0001622;HP:0000969;HP:0001508;HP:0000103;HP:0001425;HP:0000360;HP:0001279;HP:0000093;HP:0001959;HP:0001970;HP:0003201;HP:0001891;HP:0000934;HP:0002019;HP:0005978;HP:0030880;HP:0012250;HP:0002514;HP:0100324;HP:0001962;HP:0000872;HP:0002917;HP:0040168;HP:0002619;HP:0001698;HP:0002315;HP:0000855;HP:0001324;HP:0002098;HP:0000097;HP:0000622;HP:0001997;HP:0100785;HP:0002897;HP:0003470;HP:0001994;HP:0009800;HP:0002027;HP:0030083;HP:0006789;HP:0012364;HP:0012248;HP:0001508;HP:0001947;HP:0003401;HP:0100651;HP:0000020;HP:0002632;HP:0005135;HP:0002829;HP:0000017;HP:0025072;HP:0002017;HP:0002901;HP:0000975;HP:0200114;HP:0001657;HP:0011736;HP:0002894;HP:0000805;HP:0002014;HP:0002900;HP:0000823;HP:0003326;HP:0002321;HP:0000128;HP:0100647;HP:0002918;HP:0001953;HP:0001663;HP:0002189;HP:0003394;HP:0000848;HP:0000610;HP:0000841;HP:0002900;HP:0000007;HP:0001960;HP:0001944;HP:0003324;HP:0000128;HP:0005579;HP:0002615;HP:0003081;HP:0000103;HP:0000591;HP:0008046;HP:0000127;HP:0003127;HP:0002914;HP:0000859	Renal salt wasting;Hyponatremia;Renal insufficiency;Hyperchloriduria;Sensorineural hearing impairment;Congenital onset;Hyporeflexia;Decreased glomerular filtration rate;Hypochloremia;Motor delay;Fetal polyuria;Polyhydramnios;Increased urinary potassium;Generalized hypotonia;Hypernatriuria;Intellectual disability;Hypokalemic hypochloremic metabolic alkalosis;Hyperaldosteronism;Muscular hypotonia;Hypokalemia;Premature birth;Edema;Failure to thrive;Polyuria;Heterogeneous;Tinnitus;Syncope;Proteinuria;Polydipsia;Tubulointerstitial nephritis;Rhabdomyolysis;Iron deficiency anemia;Chondrocalcinosis;Constipation;Type II diabetes mellitus;Raynaud phenomenon;ST segment depression;Cerebral calcification;Scleroderma;Palpitations;Hashimoto thyroiditis;Hypomagnesemia;Focal seizures, afebril;Varicose veins;Pericardial effusion;Headache;Insulin resistance;Muscle weakness;Respiratory distress;Focal segmental glomerulosclerosis;Blurred vision;Gout;Insomnia;Parathyroid adenoma;Paralysis;Renal Fanconi syndrome;Maternal diabetes;Abdominal pain;Salt craving;Mitochondrial encephalopathy;Decreased urinary potassium;Prolonged PR interval;Failure to thrive;Renal tubular acidosis;Paresthesia;Type I diabetes mellitus;Urinary incontinence;Low-to-normal blood pressure;Abnormal T-wave;Arthralgia;Nocturia;Prominent U wave;Nausea and vomiting;Hypocalcemia;Hyperhidrosis;Metabolic alkalosis;Prolonged QT interval;Primary hyperaldosteronism;Neoplasm of the pancreas;Enuresis;Diarrhea;Hypokalemia;Delayed puberty;Myalgia;Vertigo;Renal potassium wasting;Graves disease;Hypermagnesemia;Diabetic ketoacidosis;Ventricular fibrillation;Excessive daytime sleepiness;Muscle spasm;Increased circulating renin level;Abnormal choroid morphology;Hyperactive renin-angiotensin system;Hypokalemia;Autosomal recessive inheritance;Hypokalemic metabolic alkalosis;Dehydration;Generalized muscle weakness;Renal potassium wasting;Impaired reabsorption of chloride;Hypotension;Increased urinary potassium;Polyuria;Abnormal sclera morphology;Abnormal retinal vascular morphology;Renal salt wasting;Hypocalciuria;Hyperchloriduria;Hyperaldosteronism	NA	NA	NA	Expressed predominantly in the kidney. {ECO:0000269|PubMed:11734858}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	kidney;ovary;thyroid;placenta;prostate;parathyroid;brain;unclassifiable (Anatomical System);heart;	kidney;thyroid;atrioventricular node;superior cervical ganglion;globus pallidus;	0.12	NA	N	S	N	0.179821650795768	N	Clcnkb	growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); renal/urinary system phenotype; 	NA	NA	NA	NA	0.2789	0.4342	0.4363	0.2504	0.4185	0.251398	0	0.23021	0.338235	VQSRTrancheSNP99.00to99.90	0	0.357	350	0.351064	53	chr1	16056853	NA	C	T	2254.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=46.34;AS_MQRankSum=.;AS_QD=26.52;AS_ReadPosRankSum=.;AS_SOR=1.872;DP=87;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=46.35;QD=26.52;SOR=1.872	GT:AD:DP:GQ:PL	1/1:0,85:85:99:2268,248,0
chr1	16058680	16058680	G	A	FAM131C	exonic	synonymous SNV	NA	FAM131C:NM_182623:exon7:c.C600T:p.S200S	0.7244	GnomAdGenome_AF_eas	124	30	HeterozygousVariant	het	159	51	108	0.679245283018868	2433.64	PASS	NA	NA	NA	Benign	NA	NA	Cognitive performance[19734545];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.632	NA	N	N	N	0.876490382749226	E	Fam131c	NA	NA	NA	NA	NA	0.5658	0.6868	0.6838	0.6099	0.7244	0	0	0.171008	0.577303	VQSRTrancheSNP99.00to99.90	0.7	0.58	428	0.549645	95	chr1	16058680	NA	G	A	2433.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.5;AS_FS=7.782;AS_MQ=45.61;AS_MQRankSum=-2.3;AS_QD=15.31;AS_ReadPosRankSum=-0.3;AS_SOR=1.293;BaseQRankSum=2.58;DP=163;ExcessHet=3.0103;FS=7.782;MLEAC=1;MLEAF=0.5;MQ=45.84;MQRankSum=-2.26;QD=15.31;ReadPosRankSum=-0.223;SOR=1.293	GT:AD:DP:GQ:PL	0/1:51,108:159:99:2441,0,809
chr1	16058755	16058755	A	G	FAM131C	intronic	NA	NA	NA	0.7355	GnomAdGenome_AF_eas	127	58	HomozygousVariant	hom	17	0	17	1	523.06	MQ40;SOR3	NA	NA	NA	NA	NA	NA	Cognitive performance[19734545];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.632	NA	N	N	N	0.876490382749226	E	Fam131c	NA	NA	NA	NA	NA	0.5128	0.6811	0.6706	0.6133	0.7355	0.598043	0	0.0027663	0.623333	VQSRTrancheSNP99.00to99.90	0	0.711	80	0.641221	52	chr1	16058755	NA	A	G	523.06	MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=33.23;AS_MQRankSum=.;AS_QD=30.76;AS_ReadPosRankSum=.;AS_SOR=4.294;DP=20;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=35.77;QD=30.77;SOR=4.294	GT:AD:DP:GQ:PL	1/1:0,17:17:51:537,51,0
chr1	16059485	16059485	G	A	FAM131C	intronic	NA	NA	NA	0.8502	GnomAdExome_AF_amr	202	80	HomozygousVariant	hom	75	1	74	0.986666666666667	1893.06	PASS	NA	NA	NA	NA	NA	NA	Cognitive performance[19734545];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.632	NA	N	N	N	0.876490382749226	E	Fam131c	NA	NA	NA	NA	NA	0.7492	0.8502	0.8485	0.6857	0.8154	0.715056	0.6771	0.0169817	0.731527	PASS	0	0.812	80	0.744681	50	chr1	16059485	NA	G	A	1893.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.7;AS_FS=3.31;AS_MQ=56.69;AS_MQRankSum=-0.6;AS_QD=25.24;AS_ReadPosRankSum=0.4;AS_SOR=0.484;BaseQRankSum=1.75;DP=76;ExcessHet=3.0103;FS=3.31;MLEAC=2;MLEAF=1;MQ=56.78;MQRankSum=-0.504;QD=25.24;ReadPosRankSum=0.462;SOR=0.484	GT:AD:DP:GQ:PL	1/1:1,74:75:99:1907,210,0
chr1	16059513	16059513	T	C	FAM131C	exonic	synonymous SNV	NA	FAM131C:NM_182623:exon6:c.A543G:p.Q181Q	0.8686	GnomAdExome_AF_amr	324	89	HomozygousVariant	hom	77	0	77	1	2143.06	PASS	NA	NA	NA	NA	NA	NA	Cognitive performance[19734545];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.632	NA	N	N	N	0.876490382749226	E	Fam131c	NA	NA	NA	NA	NA	0.7649	0.8686	0.8659	0.6975	0.8198	0.721645	0	0.648239	0.736453	VQSRTrancheSNP99.90to100.00	0.85	0.799	140	0.78169	44	chr1	16059513	NA	T	C	2143.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=55.67;AS_MQRankSum=.;AS_QD=27.83;AS_ReadPosRankSum=.;AS_SOR=0.772;DP=80;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=55.62;QD=27.83;SOR=0.772	GT:AD:DP:GQ:PL	1/1:0,77:77:99:2157,229,0
chr1	16059921	16059921	G	A	FAM131C	exonic	synonymous SNV	NA	FAM131C:NM_182623:exon5:c.C399T:p.D133D	0.8603	GnomAdExome_AF_amr	387	88	HomozygousVariant	hom	153	0	153	1	4273.06	PASS	NA	NA	NA	NA	NA	NA	Cognitive performance[19734545];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.632	NA	N	N	N	0.876490382749226	E	Fam131c	NA	NA	NA	NA	NA	0.7541	0.8603	0.8584	0.704	0.828	0.710463	0.6852	0.673859	0.726151	VQSRTrancheSNP99.00to99.90	0.833333	0.802	164	0.780142	44	chr1	16059921	NA	G	A	4273.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=56.91;AS_MQRankSum=.;AS_QD=27.93;AS_ReadPosRankSum=.;AS_SOR=0.875;DP=158;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=56.69;QD=27.93;SOR=0.875	GT:AD:DP:GQ:PL	1/1:0,153:153:99:4287,457,0
chr1	16059952	16059952	G	C	FAM131C	exonic	nonsynonymous SNV	NA	FAM131C:NM_182623:exon5:c.C368G:p.P123R	0.9921	GnomAdGenome_AF_ami	490	117	HomozygousVariant	hom	135	0	135	1	3716.06	PASS	0.448	NA	NA	Benign	NA	NA	Cognitive performance[19734545];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	High	High	High	NA	NA	0.632	NA	N	N	N	0.876490382749226	E	Fam131c	NA	NA	NA	NA	NA	0.9548	0.9825	0.9825	0.9614	0.9921	0.915935	0	0.0002305	0.959638	VQSRTrancheSNP99.00to99.90	0.982759	0.91	85	0.908451	24	chr1	16059952	NA	G	C	3716.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=55.04;AS_MQRankSum=.;AS_QD=27.53;AS_ReadPosRankSum=.;AS_SOR=0.738;DP=137;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=54.93;QD=27.53;SOR=0.738	GT:AD:DP:GQ:PL	1/1:0,135:135:99:3730,405,0
chr1	16062085	16062085	C	T	FAM131C	intronic	NA	NA	NA	0.4151	GnomAdExome_AF_amr	61	18	HomozygousVariant	hom	50	1	49	0.98	1846.06	PASS	NA	NA	NA	NA	NA	NA	Cognitive performance[19734545];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.632	NA	N	N	N	0.876490382749226	E	Fam131c	NA	NA	NA	NA	NA	0.2471	0.4151	0.4184	0.263	0.4133	0.222045	0	0.197268	0.337	VQSRTrancheSNP99.00to99.90	0	0.313	201	0.287234	45	chr1	16062085	NA	C	T	1846.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.6;AS_FS=0;AS_MQ=46.6;AS_MQRankSum=-1.4;AS_QD=25.56;AS_ReadPosRankSum=0.5;AS_SOR=0.286;BaseQRankSum=0.688;DP=58;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=48.53;MQRankSum=-1.344;QD=29.57;ReadPosRankSum=0.589;SOR=0.286	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:1,49:50:99:1|1:16062039_C_T:1860,125,0:16062039
chr1	16062151	16062151	T	C	FAM131C	exonic	synonymous SNV	NA	FAM131C:NM_182623:exon4:c.A216G:p.R72R	0.95	GME_Israel	422	97	HomozygousVariant	hom	98	0	98	1	2745.06	PASS	NA	NA	NA	Benign	NA	NA	Cognitive performance[19734545];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.632	NA	N	N	N	0.876490382749226	E	Fam131c	NA	NA	NA	NA	NA	0.8549	0.9048	0.9035	0.8206	0.8782	0.816693	0.8218	0.745896	0.834975	VQSRTrancheSNP99.00to99.90	0.95	0.848	150	0.823944	40	chr1	16062151	NA	T	C	2745.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=54.34;AS_MQRankSum=.;AS_QD=28.01;AS_ReadPosRankSum=.;AS_SOR=0.734;DP=98;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=54.34;QD=28.01;SOR=0.734	GT:AD:DP:GQ:PL	1/1:0,98:98:99:2759,294,0
chr1	16062531	16062531	T	C	FAM131C	exonic	nonsynonymous SNV	NA	FAM131C:NM_182623:exon3:c.A142G:p.K48E	0.4188	GnomAdExome_AF_amr	55	22	HomozygousVariant	hom	54	0	54	1	1536.06	PASS	25.9	NA	NA	Benign	NA	NA	Cognitive performance[19734545];	NA	NA	NA	NA	NA	NA	D	D	P	P	D	P	M	T	N	T	T	T	NA	T	T	T	T	T	.;	D	N	NA	NA	NA	High	High	High	NA	NA	0.632	NA	N	N	N	0.876490382749226	E	Fam131c	NA	NA	NA	NA	NA	0.2885	0.4188	0.4192	0.3051	0.4067	0.298323	0.3124	0.221647	0.339374	PASS	0.397727	0.303	136	0.287879	32	chr1	16062531	NA	T	C	1536.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=55.05;AS_MQRankSum=.;AS_QD=28.44;AS_ReadPosRankSum=.;AS_SOR=0.846;DP=57;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=55.32;QD=28.45;SOR=0.846	GT:AD:DP:GQ:PL	1/1:0,54:54:99:1550,161,0
chr1	16125272	16125272	G	A	EPHA2	exonic	synonymous SNV	NA	EPHA2:NM_001329090:exon16:c.C2712T:p.I904I,EPHA2:NM_004431:exon17:c.C2874T:p.I958I	0.4744	GnomAdGenome_AF_ami	117	22	HomozygousVariant	hom	89	2	87	0.97752808988764	2424.06	PASS	NA	[MIM:116600]Cataract 6, multiple types;	176946	NA	Early-onset posterior subcapsular cataract;Early-onset nuclear cataract;Total early-onset cataract;Early-onset posterior polar cataract	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Liver enzyme levels (gamma-glutamyl transferase)[22001757];Blood protein levels[30072576];Gamma glutamyl transferase levels[29403010];	HP:0001139;HP:0000006;HP:0000545;HP:0000519;HP:0001115	Choroideremia;Autosomal dominant inheritance;Myopia;Developmental cataract;Posterior polar cataract	Cataract_6,_multiple_types|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g. skin, intestine, lung, and ovary. {ECO:0000269|PubMed:17332925}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;head and neck;hypopharynx;urinary;mammary gland;islets of Langerhans;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;brain;duodenum;lung;ovary;macula lutea;lymph node;colon;placenta;prostate;nasopharynx;breast;optic nerve;	superior cervical ganglion;	0.473	N	N	N	N	0.756597060386493	E	Epha2	homeostasis/metabolism phenotype; neoplasm; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; vision/eye phenotype; skeleton phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; 	NA	NA	NA	NA	0.2781	0.3596	0.3617	0.2389	0.4744	0.236621	0.2279	0.0001153	0.294745	PASS	0.45	0.356	360	0.355634	57	chr1	16125272	NA	G	A	2424.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=27.24;AS_ReadPosRankSum=-1.1;AS_SOR=0.812;BaseQRankSum=0.856;DP=98;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=27.24;ReadPosRankSum=-1.025;SOR=0.812	GT:AD:DP:GQ:PL	1/1:2,87:89:99:2438,216,0
chr1	16138178	16138178	G	A	EPHA2	exonic	synonymous SNV	NA	EPHA2:NM_001329090:exon4:c.C825T:p.P275P,EPHA2:NM_004431:exon5:c.C987T:p.P329P	0.6	GME_Israel	186	31	HeterozygousVariant	het	96	54	42	0.4375	1025.64	PASS	NA	[MIM:116600]Cataract 6, multiple types;	176946	Benign	Early-onset posterior subcapsular cataract;Early-onset nuclear cataract;Total early-onset cataract;Early-onset posterior polar cataract	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Liver enzyme levels (gamma-glutamyl transferase)[22001757];Blood protein levels[30072576];Gamma glutamyl transferase levels[29403010];	HP:0001139;HP:0000006;HP:0000545;HP:0000519;HP:0001115	Choroideremia;Autosomal dominant inheritance;Myopia;Developmental cataract;Posterior polar cataract	Cataract_6,_multiple_types|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g. skin, intestine, lung, and ovary. {ECO:0000269|PubMed:17332925}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;head and neck;hypopharynx;urinary;mammary gland;islets of Langerhans;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;brain;duodenum;lung;ovary;macula lutea;lymph node;colon;placenta;prostate;nasopharynx;breast;optic nerve;	superior cervical ganglion;	0.473	N	N	N	N	0.756597060386493	E	Epha2	homeostasis/metabolism phenotype; neoplasm; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; vision/eye phenotype; skeleton phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; 	NA	NA	NA	NA	0.377	0.459	0.4619	0.3796	0.4689	0.349441	0.3888	0.370519	0.401478	PASS	0.6	0.461	398	0.454225	67	chr1	16138178	NA	G	A	1025.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=1.669;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.69;AS_ReadPosRankSum=-1.3;AS_SOR=0.883;BaseQRankSum=0.165;DP=98;ExcessHet=3.0103;FS=1.669;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.68;ReadPosRankSum=-1.264;SOR=0.883	GT:AD:DP:GQ:PL	0/1:54,42:96:99:1033,0,1377
chr1	16148628	16148628	C	T	EPHA2	exonic	synonymous SNV	NA	EPHA2:NM_001329090:exon2:c.G411A:p.L137L,EPHA2:NM_004431:exon3:c.G573A:p.L191L	0.5	GME_Israel	97	17	HomozygousVariant	hom	135	1	134	0.992592592592593	5799.06	PASS	NA	[MIM:116600]Cataract 6, multiple types;	176946	Benign	Early-onset posterior subcapsular cataract;Early-onset nuclear cataract;Total early-onset cataract;Early-onset posterior polar cataract	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Liver enzyme levels (gamma-glutamyl transferase)[22001757];Blood protein levels[30072576];Gamma glutamyl transferase levels[29403010];	HP:0001139;HP:0000006;HP:0000545;HP:0000519;HP:0001115	Choroideremia;Autosomal dominant inheritance;Myopia;Developmental cataract;Posterior polar cataract	Cataract_6,_multiple_types|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g. skin, intestine, lung, and ovary. {ECO:0000269|PubMed:17332925}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;head and neck;hypopharynx;urinary;mammary gland;islets of Langerhans;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;brain;duodenum;lung;ovary;macula lutea;lymph node;colon;placenta;prostate;nasopharynx;breast;optic nerve;	superior cervical ganglion;	0.473	N	N	N	N	0.756597060386493	E	Epha2	homeostasis/metabolism phenotype; neoplasm; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; vision/eye phenotype; skeleton phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; 	NA	NA	NA	NA	0.2983	0.3364	0.338	0.2776	0.4029	0.226438	0.2849	0.289214	0.319376	PASS	0.5	0.327	352	0.338028	62	chr1	16148628	NA	C	T	5799.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=28.52;AS_ReadPosRankSum=-1.7;AS_SOR=0.275;BaseQRankSum=-1.871;DP=136;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=27.43;ReadPosRankSum=-1.668;SOR=0.275	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:1,134:135:99:1|1:16148628_C_T:5813,361,0:16148628
chr1	16148631	16148631	C	T	EPHA2	exonic	synonymous SNV	NA	EPHA2:NM_001329090:exon2:c.G408A:p.A136A,EPHA2:NM_004431:exon3:c.G570A:p.A190A	0.5	GME_Israel	97	17	HomozygousVariant	hom	135	1	134	0.992592592592593	5799.06	PASS	NA	[MIM:116600]Cataract 6, multiple types;	176946	Benign	Early-onset posterior subcapsular cataract;Early-onset nuclear cataract;Total early-onset cataract;Early-onset posterior polar cataract	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	Liver enzyme levels (gamma-glutamyl transferase)[22001757];Blood protein levels[30072576];Gamma glutamyl transferase levels[29403010];	HP:0001139;HP:0000006;HP:0000545;HP:0000519;HP:0001115	Choroideremia;Autosomal dominant inheritance;Myopia;Developmental cataract;Posterior polar cataract	Cataract_6,_multiple_types|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in brain and glioma tissue and glioma cell lines (at protein level). Expressed most highly in tissues that contain a high proportion of epithelial cells, e.g. skin, intestine, lung, and ovary. {ECO:0000269|PubMed:17332925}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;head and neck;hypopharynx;urinary;mammary gland;islets of Langerhans;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;brain;duodenum;lung;ovary;macula lutea;lymph node;colon;placenta;prostate;nasopharynx;breast;optic nerve;	superior cervical ganglion;	0.473	N	N	N	N	0.756597060386493	E	Epha2	homeostasis/metabolism phenotype; neoplasm; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; vision/eye phenotype; skeleton phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; 	NA	NA	NA	NA	0.2982	0.3365	0.338	0.2777	0.4029	0.226637	0.2849	0.290164	0.319376	PASS	0.5	0.327	352	0.338028	62	chr1	16148631	NA	C	T	5799.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=32;AS_ReadPosRankSum=-1.7;AS_SOR=0.275;BaseQRankSum=-0.78;DP=142;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=27.64;ReadPosRankSum=-1.694;SOR=0.275	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:1,134:135:99:1|1:16148628_C_T:5813,361,0:16148628
chr1	16206308	16206308	G	A	ARHGEF19	exonic	synonymous SNV	NA	ARHGEF19:NM_153213:exon7:c.C1170T:p.S390S	0.508772	GME_AP	111	39	HeterozygousVariant	het	54	31	23	0.425925925925926	500.64	PASS	NA	NA	612496	Benign	NA	NA	Initial pursuit acceleration[29064472];Gamma glutamyl transferase levels[29403010];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;lacrimal gland;testis;unclassifiable (Anatomical System);kidney;uterus;retina;bile duct;adrenal gland;mammary gland;cervix;iris;liver;peripheral nerve;endometrium;bone;brain;heart;lung;ovary;thyroid;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;skin;atrioventricular node;	0.846	NA	N	S	N	0.340029894877833	N	Arhgef19	NA	arhgef19	periderm	increased size	abnormal	0.2774	0.4431	0.4465	0.2425	0.4018	0.26877	0.2287	0.223018	0.294745	PASS	0.508772	0.408	254	0.471831	56	chr1	16206308	NA	G	A	500.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=1.057;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.28;AS_ReadPosRankSum=2;AS_SOR=0.521;BaseQRankSum=0.299;DP=55;ExcessHet=3.0103;FS=1.057;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.27;ReadPosRankSum=2.01;SOR=0.521	GT:AD:DP:GQ:PL	0/1:31,23:54:99:508,0,716
chr1	16207507	16207507	C	G	ARHGEF19	intronic	NA	NA	NA	0.4528	GnomAdExome_AF_amr	37	39	HeterozygousVariant	het	83	45	38	0.457831325301205	780.64	PASS	NA	NA	612496	NA	NA	NA	Initial pursuit acceleration[29064472];Gamma glutamyl transferase levels[29403010];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;lacrimal gland;testis;unclassifiable (Anatomical System);kidney;uterus;retina;bile duct;adrenal gland;mammary gland;cervix;iris;liver;peripheral nerve;endometrium;bone;brain;heart;lung;ovary;thyroid;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;skin;atrioventricular node;	0.846	NA	N	S	N	0.340029894877833	N	Arhgef19	NA	arhgef19	periderm	increased size	abnormal	0.2823	0.4528	0.4542	0.2404	0.4029	0.266973	0.2321	0.270941	0.295567	PASS	0	0.394	90	0.471831	56	chr1	16207507	NA	C	G	780.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=4.251;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.41;AS_ReadPosRankSum=0.1;AS_SOR=1.179;BaseQRankSum=0.67;DP=86;ExcessHet=3.0103;FS=4.251;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.41;ReadPosRankSum=0.155;SOR=1.179	GT:AD:DP:GQ:PL	0/1:45,38:83:99:788,0,1013
chr1	16207760	16207760	C	G	ARHGEF19	exonic	nonsynonymous SNV	NA	ARHGEF19:NM_153213:exon4:c.G712C:p.E238Q	0.497076	GME_AP	110	39	HeterozygousVariant	het	76	43	33	0.43421052631579	709.64	PASS	18.07	NA	612496	Benign	NA	NA	Initial pursuit acceleration[29064472];Gamma glutamyl transferase levels[29403010];	NA	NA	NA	NA	NA	NA	D	T	B	B	N	P	M	T	N	T	T	T	NA	T	T	T	T	T	.;	D	N	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;lacrimal gland;testis;unclassifiable (Anatomical System);kidney;uterus;retina;bile duct;adrenal gland;mammary gland;cervix;iris;liver;peripheral nerve;endometrium;bone;brain;heart;lung;ovary;thyroid;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;skin;atrioventricular node;	0.846	NA	N	S	N	0.340029894877833	N	Arhgef19	NA	arhgef19	periderm	increased size	abnormal	0.2833	0.4539	0.455	0.2405	0.4029	0.266973	0.2321	0.272222	0.296388	PASS	0.497076	0.404	254	0.46831	55	chr1	16207760	NA	C	G	709.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1;AS_FS=0.874;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.34;AS_ReadPosRankSum=-2.3;AS_SOR=0.561;BaseQRankSum=1.01;DP=76;ExcessHet=3.0103;FS=0.874;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.34;ReadPosRankSum=-2.286;SOR=0.561	GT:AD:DP:GQ:PL	0/1:43,33:76:99:717,0,950
chr1	16208151	16208151	C	G	ARHGEF19	exonic	nonsynonymous SNV	NA	ARHGEF19:NM_153213:exon3:c.G487C:p.G163R	0.479412	GME_AP	109	37	HeterozygousVariant	het	80	39	41	0.5125	959.64	PASS	17.25	NA	612496	Benign	NA	NA	Initial pursuit acceleration[29064472];Gamma glutamyl transferase levels[29403010];	NA	NA	NA	NA	NA	NA	T	D	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;lacrimal gland;testis;unclassifiable (Anatomical System);kidney;uterus;retina;bile duct;adrenal gland;mammary gland;cervix;iris;liver;peripheral nerve;endometrium;bone;brain;heart;lung;ovary;thyroid;colon;placenta;aorta;prostate;	ciliary ganglion;dorsal root ganglion;skin;atrioventricular node;	0.846	NA	N	S	N	0.340029894877833	N	Arhgef19	NA	arhgef19	periderm	increased size	abnormal	0.2771	0.4504	0.4513	0.2196	0.402	0.24401	0.2065	0.265081	0.278325	PASS	0.479412	0.404	256	0.464789	58	chr1	16208151	NA	C	G	959.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0.88;AS_MQ=60;AS_MQRankSum=0;AS_QD=12;AS_ReadPosRankSum=-1.7;AS_SOR=0.887;BaseQRankSum=-0.482;DP=82;ExcessHet=3.0103;FS=0.88;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12;ReadPosRankSum=-1.613;SOR=0.887	GT:AD:DP:GQ:PL	0/1:39,41:80:99:967,0,949
chr1	16251413	16251413	G	C	FBXO42	exonic	nonsynonymous SNV	NA	FBXO42:NM_018994:exon10:c.C1411G:p.P471A	0.4338	GnomAdExome_AF_afr	18	7	HeterozygousVariant	het	91	52	39	0.428571428571429	933.64	PASS	1.478	NA	609109	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.389	NA	N	N	N	0.658443435942939	E	Fbxo42	NA	NA	NA	NA	NA	0.2972	0.4338	0.4379	0.3608	0.4235	0.270767	0.3804	0.307131	0.325123	PASS	0.336957	0.152	142	0.147887	28	chr1	16251413	NA	G	C	933.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=2.805;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.26;AS_ReadPosRankSum=-0.9;AS_SOR=1.096;BaseQRankSum=-1.083;DP=97;ExcessHet=3.0103;FS=2.805;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.26;ReadPosRankSum=-0.802;SOR=1.096	GT:AD:DP:GQ:PL	0/1:52,39:91:99:941,0,1496
chr1	16367230	16367230	-	G	SZRD1	upstream	NA	dist=12	NA	0.2983	GnomAdGenome_AF_fin	10	2	HeterozygousVariant	het	106	64	42	0.39622641509434	1005.6	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	H	NA	NA	Szrd1	NA	NA	NA	NA	NA	0.1884	0.2429	0.2455	0.1963	0.2983	0.13778	0.1801	0.0014748	0.175456	PASS	0	0.095	90	0.089286	21	chr1	16367230	NA	T	TG	1005.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.8;AS_FS=2.611;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.49;AS_ReadPosRankSum=2.6;AS_SOR=1.012;BaseQRankSum=1.8;DP=108;ExcessHet=3.0103;FS=2.611;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.49;ReadPosRankSum=2.66;SOR=1.012	GT:AD:DP:GQ:PL	0/1:64,42:106:99:1013,0,1667
chr1	16398835	16398835	G	A	SPATA21	intronic	NA	NA	NA	0.1537	GnomAdGenome_AF_ami	4	0	HeterozygousVariant	het	64	38	26	0.40625	521.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	liver;	NA	0.882	NA	N	N	N	0.0664767659086445	N	Spata21	NA	NA	NA	NA	NA	0.0888	0.1506	0.1521	0.0785	0.1537	0.0603035	0.0794	0.0896237	0.047071	PASS	0	0.036	52	0.017606	5	chr1	16398835	NA	G	A	521.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.16;AS_ReadPosRankSum=1.4;AS_SOR=0.582;BaseQRankSum=-0.509;DP=65;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.15;ReadPosRankSum=1.48;SOR=0.582	GT:AD:DP:GQ:PL	0/1:38,26:64:99:529,0,877
chr1	16405015	16405015	C	G	SPATA21	exonic	nonsynonymous SNV	NA	SPATA21:NM_001353349:exon6:c.G694C:p.V232L,SPATA21:NM_198546:exon8:c.G763C:p.V255L	0.494152	GME_AP	174	40	HeterozygousVariant	het	121	58	63	0.520661157024793	1472.64	PASS	5.493	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	EF-hand domain|EF-hand domain;.	NA	NA	Medium	Medium	Medium	liver;	NA	0.882	NA	N	N	N	0.0664767659086445	N	Spata21	NA	NA	NA	NA	NA	0.2733	0.4378	0.4403	0.2362	0.4166	0.280152	0.2275	0.268742	0.273399	PASS	0.494152	0.45	403	0.507092	63	chr1	16405015	NA	C	G	1472.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.17;AS_ReadPosRankSum=-0.3;AS_SOR=0.714;BaseQRankSum=0.118;DP=126;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.17;ReadPosRankSum=-0.273;SOR=0.714	GT:AD:DP:GQ:PL	0/1:58,63:121:99:1480,0,1355
chr1	16476395	16476395	G	A	CROCCP3	ncRNA_intronic	NA	NA	NA	0.6477	GnomAdGenome_AF_sas	84	30	HomozygousVariant	hom	23	0	23	1	636.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	kidney;spleen;liver;retina;cartilage;frontal lobe;unclassifiable (Anatomical System);hypothalamus;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4443	0.6477	0.407947	0	0.0001537	0.44087	PASS	0	0.618	89	0.619403	23	chr1	16476395	NA	G	A	636.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.2;AS_MQRankSum=.;AS_QD=27.65;AS_ReadPosRankSum=.;AS_SOR=0.963;DP=24;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.23;QD=27.65;SOR=0.963	GT:AD:DP:GQ:PL	1/1:0,23:23:69:650,69,0
chr1	16539538	16539538	C	T	LINC01783;MIR3675	intergenic	NA	dist=3886;dist=9376	NA	0.8906	GnomAdGenome_AF_eas			HeterozygousVariant	het	86	36	50	0.581395348837209	1223.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.4924	0.8123	0.8061	0.4989	0.8906	0.585264	0	0.0712927	0		0					chr1	16539538	NA	C	T	1223.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0.901;AS_MQ=48.24;AS_MQRankSum=-0.7;AS_QD=14.23;AS_ReadPosRankSum=0.3;AS_SOR=0.533;BaseQRankSum=-0.675;DP=87;ExcessHet=3.0103;FS=0.901;MLEAC=1;MLEAF=0.5;MQ=48.97;MQRankSum=-0.672;QD=14.23;ReadPosRankSum=0.385;SOR=0.533	GT:AD:DP:GQ:PL	0/1:36,50:86:99:1231,0,827
chr1	16575173	16575173	T	C	NBPF1	exonic	unknown	NA	UNKNOWN	0.5436	GnomAdExome_AF_eas	2	0	WT/SomaticVariant	het	46	37	9	0.195652173913043	91.64	QD2	0.073	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	T	NA	T	NA	T	.;.;	N	N	.;Neuroblastoma breakpoint family (NBPF) domain|Neuroblastoma breakpoint family (NBPF) domain|Neuroblastoma breakpoint family (NBPF) domain	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.353	0.5436	0.5425	0.3415	0.5353	0	0.2968	0.299026	0.26087	VQSRTrancheSNP99.00to99.90	0.396396	0.306	463	0.288889	52	chr1	16575173	NA	T	C	91.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=1.44;AS_MQ=46.87;AS_MQRankSum=-0.8;AS_QD=2;AS_ReadPosRankSum=-0.7;AS_SOR=0.777;BaseQRankSum=-0.42;DP=46;ExcessHet=3.0103;FS=1.44;MLEAC=1;MLEAF=0.5;MQ=46.63;MQRankSum=-0.769;QD=1.99;ReadPosRankSum=-0.623;SOR=0.777	GT:AD:DP:GQ:PL	0/1:37,9:46:99:99,0,854
chr1	16575219	16575219	G	A	NBPF1	exonic	unknown	NA	UNKNOWN	0.6539	GnomAdExome_AF_eas	255	43	HomozygousVariant	hom	36	0	36	1	1027.06	PASS	NA	NA	610501	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.5843	0.6539	0.6529	0.4928	0.5339	0	0	0.112033	0.538071	VQSRTrancheSNP99.00to99.90	0.585586	0.662	502	0.738889	47	chr1	16575219	NA	G	A	1027.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=43.24;AS_MQRankSum=.;AS_QD=28.53;AS_ReadPosRankSum=.;AS_SOR=1.371;DP=37;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=43.37;QD=28.53;SOR=1.371	GT:AD:DP:GQ:PL	1/1:0,36:36:99:1041,108,0
chr1	16576389	16576389	T	C	NBPF1	exonic	unknown	NA	UNKNOWN	0.4855	GnomAdGenome_AF_eas	3	0	WT/SomaticVariant	het	552	406	146	0.264492753623188	2532.64	PASS	0.031	NA	610501	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	T	NA	T	NA	T	.;.;	N	N	.;.	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.2543	0.4757	0.477	0.3492	0.4855	0	0	0.0083756	0.238095	VQSRTrancheSNP99.00to99.90	0.294737	0.37	485	0.377778	68	chr1	16576389	NA	T	C	2532.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.9;AS_FS=1.286;AS_MQ=34.07;AS_MQRankSum=-6.9;AS_QD=4.59;AS_ReadPosRankSum=0;AS_SOR=0.801;BaseQRankSum=2.99;DP=583;ExcessHet=3.0103;FS=1.286;MLEAC=1;MLEAF=0.5;MQ=40.56;MQRankSum=-6.896;QD=4.59;ReadPosRankSum=0.052;SOR=0.801	GT:AD:DP:GQ:PL	0/1:406,146:552:99:2540,0,12443
chr1	16576399	16576399	A	G	NBPF1	exonic	unknown	NA	UNKNOWN	0.8063	GnomAdExome_AF_eas	156	20	HeterozygousVariant	het	450	169	281	0.624444444444444	8623.64	MQ40;MQRankSum-12.5	0.88	NA	610501	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	T	NA	T	NA	T	.;.;	N	N	.;.	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.523	0.8063	0.7943	0.6452	0.8057	0.68151	0	0.232096	0.473451	VQSRTrancheSNP99.90to100.00	0	0.612	484	0.601124	67	chr1	16576399	NA	A	G	8623.64	MQ40;MQRankSum-12.5	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=7.8;AS_FS=6.597;AS_MQ=30.86;AS_MQRankSum=-15.5;AS_QD=19.16;AS_ReadPosRankSum=1.8;AS_SOR=1.189;BaseQRankSum=7.87;DP=470;ExcessHet=3.0103;FS=6.597;MLEAC=1;MLEAF=0.5;MQ=39.79;MQRankSum=-15.44;QD=19.16;ReadPosRankSum=1.9;SOR=1.189	GT:AD:DP:GQ:PL	0/1:169,281:450:99:8631,0,3518
chr1	16576448	16576448	T	C	NBPF1	exonic	unknown	NA	UNKNOWN	0.392	GnomAdGenome_AF_eas	2	0	WT/SomaticVariant	het	320	283	37	0.115625	332.64	MQ40;QD2	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.153	0.3787	0.3693	0.229	0.392	0	0	0.111933	0.163428	VQSRTrancheSNP99.00to99.90	0.284884	0.354	463	0.370787	66	chr1	16576448	NA	T	C	332.64	MQ40;QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=6.1;AS_FS=9.703;AS_MQ=35.09;AS_MQRankSum=-0.7;AS_QD=1.04;AS_ReadPosRankSum=1;AS_SOR=1.581;BaseQRankSum=6.16;DP=328;ExcessHet=3.0103;FS=9.703;MLEAC=1;MLEAF=0.5;MQ=37.58;MQRankSum=-0.695;QD=1.04;ReadPosRankSum=1.09;SOR=1.581	GT:AD:DP:GQ:PL	0/1:283,37:320:99:340,0,7725
chr1	16577417	16577417	T	A	NBPF1	exonic	unknown	NA	UNKNOWN	0.8694	GnomAdExome_AF_afr	250	46	HomozygousVariant	hom	38	0	38	1	1206.06	MQ40;SOR3	6.25	NA	610501	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	T	NA	T	NA	T	.;.;	N	N	.;.	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.7019	0.8694	0.8751	0.7267	0.8597	0	0	0.0113776	0.718391	VQSRTrancheSNP99.90to100.00	0.75	0.691	331	0.744318	39	chr1	16577417	NA	T	A	1206.06	MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=32;AS_MQRankSum=.;AS_QD=31.74;AS_ReadPosRankSum=.;AS_SOR=7.328;DP=45;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=31.98;QD=31.74;SOR=7.328	GT:AD:DP:GQ:PL	1/1:0,38:38:99:1220,113,0
chr1	16579347	16579347	A	G	NBPF1	exonic	unknown	NA	UNKNOWN	0.5372	GnomAdGenome_AF_eas	16	2	WT/SomaticVariant	het	22	16	6	0.272727272727273	126.64	MQ40	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.2535	0.4471	0.4499	0.4056	0.5372	0	0	0.056785	0.270833	VQSRTrancheSNP99.00to99.90	0.442308	0.352	482	0.412791	67	chr1	16579347	NA	A	G	126.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.4;AS_FS=0;AS_MQ=29.57;AS_MQRankSum=-2.2;AS_QD=5.77;AS_ReadPosRankSum=-0.4;AS_SOR=0.551;BaseQRankSum=2.45;DP=23;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=36.47;MQRankSum=-2.106;QD=5.76;ReadPosRankSum=-0.332;SOR=0.551	GT:AD:DP:GQ:PL	0/1:16,6:22:99:134,0,487
chr1	16581376	16581376	C	T	NBPF1	intronic	NA	NA	NA	0.5	abraom_freq	1	1	WT/SomaticVariant	het	34	27	7	0.205882352941176	133.64	PASS	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.4925	0.498	0.4983	0.3092	0.3386	0	0	0.0201322	0.5	VQSRTrancheSNP99.00to99.90	0	0.496	233	0.494444	87	chr1	16581376	NA	C	T	133.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.1;AS_FS=8.22;AS_MQ=29.21;AS_MQRankSum=-3.4;AS_QD=3.94;AS_ReadPosRankSum=-1.1;AS_SOR=2.93;BaseQRankSum=1.12;DP=34;ExcessHet=3.0103;FS=8.22;MLEAC=1;MLEAF=0.5;MQ=45.21;MQRankSum=-3.369;QD=3.93;ReadPosRankSum=-1.025;SOR=2.93	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:27,7:34:99:1|0:16581368_G_C:141,0,730:16581368
chr1	16581532	16581532	C	A	NBPF1	intronic	NA	NA	NA	0.2466	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	70	58	12	0.171428571428571	121.64	QD2	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.0009	0.0024	0.002	0.1583	0.2466	0	0	0.0000384	0.06357	VQSRTrancheSNP99.00to99.90	0	0.12	109	0.044444	8	chr1	16581532	NA	C	A	121.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=12.708;AS_MQ=36.63;AS_MQRankSum=-4;AS_QD=1.74;AS_ReadPosRankSum=1.5;AS_SOR=1.261;BaseQRankSum=-0.874;DP=74;ExcessHet=3.0103;FS=12.708;MLEAC=1;MLEAF=0.5;MQ=45.76;MQRankSum=-3.992;QD=1.74;ReadPosRankSum=1.53;SOR=1.261	GT:AD:DP:GQ:PL	0/1:58,12:70:99:129,0,1491
chr1	16582557	16582557	C	T	NBPF1	exonic	unknown	NA	UNKNOWN	0.9609	GnomAdExome_AF_afr	454	65	HomozygousVariant	hom	17	0	17	1	571.06	MQ40;SOR3	NA	NA	610501	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.9122	0.9609	0.9629	0.7589	0.8052	0.82528	0	0.214423	0.945361	VQSRTrancheSNP99.90to100.00	0.960526	0.86	175	0.861111	25	chr1	16582557	NA	C	T	571.06	MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=34.63;AS_MQRankSum=.;AS_QD=33.59;AS_ReadPosRankSum=.;AS_SOR=3.383;DP=17;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=34.63;QD=33.59;SOR=3.383	GT:AD:DP:GQ:PL	1/1:0,17:17:51:585,51,0
chr1	16582605	16582605	G	C	NBPF1	exonic	unknown	NA	UNKNOWN	0.4766	GnomAdExome_AF_eas	2	0	HeterozygousVariant	het	17	8	9	0.529411764705882	285.64	MQ40	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.4644	0.4766	0.4754	0.4527	0.4759	0	0	0.0083372	0.318277	VQSRTrancheSNP99.00to99.90	0.448087	0.46	564	0.477011	83	chr1	16582605	NA	G	C	285.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2;AS_FS=0;AS_MQ=35.43;AS_MQRankSum=-0.5;AS_QD=16.82;AS_ReadPosRankSum=-0.8;AS_SOR=0.804;BaseQRankSum=-1.935;DP=17;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=36.1;MQRankSum=-0.478;QD=16.8;ReadPosRankSum=-0.706;SOR=0.804	GT:AD:DP:GQ:PL	0/1:8,9:17:99:293,0,265
chr1	16582634	16582634	T	C	NBPF1	exonic	unknown	NA	UNKNOWN	0.60041	abraom_freq	8	1	HeterozygousVariant	het	13	6	7	0.538461538461538	218.64	MQ40	2.476	NA	610501	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	T	NA	T	NA	D	.;.;	N	N	.;.	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.5042	0.5166	0.52	0.4857	0.4908	0	0	0.061818	0.60041	VQSRTrancheSNP99.90to100.00	0.5375	0.481	570	0.5	85	chr1	16582634	NA	T	C	218.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.4;AS_FS=0;AS_MQ=35.07;AS_MQRankSum=-0.1;AS_QD=16.85;AS_ReadPosRankSum=2;AS_SOR=0.836;BaseQRankSum=3.44;DP=13;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=35.37;MQRankSum=-0.088;QD=16.82;ReadPosRankSum=2.03;SOR=0.836	GT:AD:DP:GQ:PL	0/1:6,7:13:99:226,0,165
chr1	16583569	16583569	A	G	NBPF1	intronic	NA	NA	NA	0.6208	GnomAdGenome_AF_eas	13	4	HeterozygousVariant	het	166	73	93	0.560240963855422	2205.64	PASS	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.1251	0.3046	0.3129	0.525	0.6208	0.489617	0	0.0202326	0.055462	VQSRTrancheSNP99.90to100.00	0	0.517	219	0.505556	83	chr1	16583569	NA	A	G	2205.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.9;AS_FS=11.805;AS_MQ=46.29;AS_MQRankSum=-8;AS_QD=13.29;AS_ReadPosRankSum=-0.4;AS_SOR=1.501;BaseQRankSum=2.99;DP=181;ExcessHet=3.0103;FS=11.805;MLEAC=1;MLEAF=0.5;MQ=50.68;MQRankSum=-7.94;QD=13.29;ReadPosRankSum=-0.33;SOR=1.501	GT:AD:DP:GQ:PL	0/1:73,93:166:99:2213,0,1451
chr1	16585519	16585519	A	C	NBPF1	exonic	unknown	NA	UNKNOWN	0.4943	GnomAdGenome_AF_eas	6	0	HeterozygousVariant	het	15	9	6	0.4	217.64	MQ40	5.265	NA	610501	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	T	NA	T	NA	T	.;.;	N	N	.;.	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.4804	0.4937	0.4945	0.4815	0.4943	0.403954	0	0.116989	0.291429	VQSRTrancheSNP99.00to99.90	0.473214	0.458	638	0.44186	76	chr1	16585519	NA	A	C	217.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.7;AS_FS=3.136;AS_MQ=34.12;AS_MQRankSum=0;AS_QD=14.53;AS_ReadPosRankSum=-0.3;AS_SOR=2.066;BaseQRankSum=2.73;DP=15;ExcessHet=3.0103;FS=3.136;MLEAC=1;MLEAF=0.5;MQ=34.76;MQRankSum=0.082;QD=14.51;ReadPosRankSum=-0.227;SOR=2.066	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:9,6:15:99:0|1:16585519_A_C:225,0,360:16585519
chr1	16585520	16585520	G	A	NBPF1	exonic	unknown	NA	UNKNOWN	0.3973	GnomAdGenome_AF_eas	1	0	HeterozygousVariant	het	15	9	6	0.4	217.64	MQ40	NA	NA	610501	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.2425	0.3762	0.3813	0.1879	0.3973	0.132388	0	0.028162	0		0.286885	0.35	494	0.360465	62	chr1	16585520	NA	G	A	217.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=3.136;AS_MQ=34.12;AS_MQRankSum=0;AS_QD=14.53;AS_ReadPosRankSum=-0.2;AS_SOR=2.066;BaseQRankSum=-1.798;DP=15;ExcessHet=3.0103;FS=3.136;MLEAC=1;MLEAF=0.5;MQ=34.76;MQRankSum=0.082;QD=14.51;ReadPosRankSum=-0.114;SOR=2.066	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:9,6:15:99:0|1:16585519_A_C:225,0,360:16585519
chr1	16585643	16585643	A	G	NBPF1	exonic	unknown	NA	UNKNOWN	0.121739	GME_AP	0	0	WT/SomaticVariant	het	61	52	9	0.147540983606557	37.64	MQ40;QD2	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.0012	0.0019	0.0023	0.0006	0.0016	0	0	0.0000384	0.016129	VQSRTrancheSNP99.00to99.90	0.121739	0.06	90	0.097701	17	chr1	16585643	NA	A	G	37.64	MQ40;QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.1;AS_FS=6.894;AS_MQ=25.79;AS_MQRankSum=-3.2;AS_QD=0.62;AS_ReadPosRankSum=-1.2;AS_SOR=0.111;BaseQRankSum=-2.022;DP=62;ExcessHet=3.0103;FS=6.894;MLEAC=1;MLEAF=0.5;MQ=34.87;MQRankSum=-3.169;QD=0.62;ReadPosRankSum=-1.13;SOR=0.111	GT:AD:DP:GQ:PL	0/1:52,9:61:45:45,0,1547
chr1	16587665	16587665	G	A	NBPF1	intronic	NA	NA	NA	0.4886	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	27	17	10	0.37037037037037	340.64	PASS	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4581	0.4886	0	0	0.0016521	0.252941	VQSRTrancheSNP99.00to99.90	0	0.498	209	0.488764	87	chr1	16587665	NA	G	A	340.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.768;AS_MQ=32.18;AS_MQRankSum=-5;AS_QD=12.63;AS_ReadPosRankSum=0.9;AS_SOR=1.402;BaseQRankSum=0.409;DP=28;ExcessHet=3.0103;FS=1.768;MLEAC=1;MLEAF=0.5;MQ=50.77;MQRankSum=-4.907;QD=12.62;ReadPosRankSum=0.95;SOR=1.402	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:17,10:27:99:0|1:16587665_G_A:348,0,662:16587665
chr1	16587673	16587673	C	G	NBPF1	intronic	NA	NA	NA	0.4959	GnomAdGenome_AF_sas	1	0	HeterozygousVariant	het	33	21	12	0.363636363636364	372.64	PASS	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4866	0.4959	0	0	0.0023821	0.282303	VQSRTrancheSNP99.90to100.00	0	0.502	209	0.483146	86	chr1	16587673	NA	C	G	372.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.8;AS_FS=0;AS_MQ=35.68;AS_MQRankSum=-5.2;AS_QD=11.3;AS_ReadPosRankSum=0.5;AS_SOR=0.653;BaseQRankSum=1.9;DP=35;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=50.48;MQRankSum=-5.136;QD=11.29;ReadPosRankSum=0.507;SOR=0.653	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:21,12:33:99:0|1:16587665_G_A:380,0,780:16587665
chr1	16587701	16587701	T	C	NBPF1	intronic	NA	NA	NA	0.1693	GnomAdExome_AF_eas	0	0	HeterozygousVariant	het	62	43	19	0.306451612903226	324.64	PASS	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.057	0.1693	0.214	0.0122	0.0866	0	0.0168	0.115943	0.093023	VQSRTrancheSNP99.00to99.90	0	0.228	208	0.188889	34	chr1	16587701	NA	T	C	324.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=5.808;AS_MQ=35.46;AS_MQRankSum=-3.1;AS_QD=5.24;AS_ReadPosRankSum=-2.5;AS_SOR=0.415;BaseQRankSum=0.418;DP=64;ExcessHet=3.0103;FS=5.808;MLEAC=1;MLEAF=0.5;MQ=44.79;MQRankSum=-3.027;QD=5.24;ReadPosRankSum=-2.469;SOR=0.415	GT:AD:DP:GQ:PL	0/1:43,19:62:99:332,0,1035
chr1	16587757	16587757	C	T	NBPF1	exonic	unknown	NA	UNKNOWN	0.3941	GnomAdGenome_AF_sas	1	0	WT/SomaticVariant	het	95	77	18	0.189473684210526	185.64	QD2	NA	NA	610501	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.3215	0.3786	0.3814	0.3141	0.3941	0	0	0.0283157	0.228365	VQSRTrancheSNP99.00to99.90	0.327586	0.419	638	0.438889	79	chr1	16587757	NA	C	T	185.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=2.194;AS_MQ=36.49;AS_MQRankSum=-3.8;AS_QD=1.96;AS_ReadPosRankSum=2.1;AS_SOR=0.82;BaseQRankSum=0.947;DP=95;ExcessHet=3.0103;FS=2.194;MLEAC=1;MLEAF=0.5;MQ=45.57;MQRankSum=-3.761;QD=1.95;ReadPosRankSum=2.13;SOR=0.82	GT:AD:DP:GQ:PL	0/1:77,18:95:99:193,0,1681
chr1	16587811	16587811	A	G	NBPF1	intronic	NA	NA	NA	0.4163	GnomAdExome_AF_sas	1	0	WT/SomaticVariant	het	71	58	13	0.183098591549296	135.64	QD2	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.3561	0.4163	0.4152	0.3202	0.3877	0	0	0.033464	0.267532	VQSRTrancheSNP99.00to99.90	0	0.423	384	0.455556	82	chr1	16587811	NA	A	G	135.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=0;AS_MQ=35.72;AS_MQRankSum=-3.4;AS_QD=1.92;AS_ReadPosRankSum=-1.2;AS_SOR=0.765;BaseQRankSum=0.263;DP=74;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=44.68;MQRankSum=-3.332;QD=1.91;ReadPosRankSum=-1.19;SOR=0.765	GT:AD:DP:GQ:PL	0/1:58,13:71:99:143,0,1357
chr1	16587844	16587844	G	C	NBPF1	intronic	NA	NA	NA	0.034974	abraom_freq	0	0	WT/SomaticVariant	het	46	37	9	0.195652173913043	135.64	PASS	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.001	0.0043	0.0041	0.0084	0.0152	0	0	0.0003458	0.034974	VQSRTrancheSNP99.00to99.90	0	0.036	17	0.033333	6	chr1	16587844	NA	G	C	135.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=3.872;AS_MQ=36.47;AS_MQRankSum=-3.1;AS_QD=2.96;AS_ReadPosRankSum=-0.8;AS_SOR=1.802;BaseQRankSum=1.28;DP=49;ExcessHet=3.0103;FS=3.872;MLEAC=1;MLEAF=0.5;MQ=47.11;MQRankSum=-3.033;QD=2.95;ReadPosRankSum=-0.79;SOR=1.802	GT:AD:DP:GQ:PL	0/1:37,9:46:99:143,0,953
chr1	16589018	16589018	C	G	NBPF1	exonic	unknown	NA	UNKNOWN	0.5561	GnomAdExome_AF_fin	0	0	HeterozygousVariant	het	20	11	9	0.45	223.64	MQ40	16.77	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	D	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	T	NA	T	NA	T	.;.;	N	N	.;.	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.4725	0.5427	0.5366	0.2526	0.4019	0	0	0.160606	0.480226	VQSRTrancheSNP99.00to99.90	0.485849	0.214	257	0.293103	51	chr1	16589018	NA	C	G	223.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=15.849;AS_MQ=29.02;AS_MQRankSum=2.5;AS_QD=11.2;AS_ReadPosRankSum=1.6;AS_SOR=0.01;BaseQRankSum=1.64;DP=20;ExcessHet=3.0103;FS=15.849;MLEAC=1;MLEAF=0.5;MQ=25.81;MQRankSum=2.54;QD=11.18;ReadPosRankSum=1.6;SOR=0.01	GT:AD:DP:GQ:PL	0/1:11,9:20:99:231,0,226
chr1	16589863	16589863	G	C	NBPF1	intronic	NA	NA	NA	0.5737	GnomAdExome_AF_afr	31	23	HeterozygousVariant	het	63	25	38	0.603174603174603	1027.64	PASS	NA	NA	610501	NA	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.2664	0.5737	0.579	0.4838	0.5039	0.373602	0	0.191848	0.238731	VQSRTrancheSNP99.90to100.00	0	0.536	192	0.588889	60	chr1	16589863	NA	G	C	1027.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=4.6;AS_FS=15.098;AS_MQ=38.83;AS_MQRankSum=-4.7;AS_QD=16.32;AS_ReadPosRankSum=-0.9;AS_SOR=2.289;BaseQRankSum=4.67;DP=67;ExcessHet=3.0103;FS=15.098;MLEAC=1;MLEAF=0.5;MQ=45.08;MQRankSum=-4.603;QD=16.31;ReadPosRankSum=-0.815;SOR=2.289	GT:AD:DP:GQ:PL	0/1:25,38:63:99:1035,0,445
chr1	16591862	16591862	G	T	NBPF1	exonic	unknown	NA	UNKNOWN	0.0083	GnomAdGenome_AF_sas	0		WT/SomaticVariant	het	35	26	9	0.257142857142857	171.64	MQ40	NA	NA	610501	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. The only tissue which shows a weak expression is kidney. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	skin;stomach;testis;pituitary gland;unclassifiable (Anatomical System);amniotic fluid;larynx;kidney;uterus;whole body;retina;pancreas;bile duct;head and neck;hypopharynx;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;gall bladder;brain;blood;heart;bone marrow;lung;cerebral cortex;thyroid;lymph node;bladder;frontal lobe;colon;placenta;aorta;prostate;breast;	NA	NA	NA	NA	NA	NA	0.999999841714435	E	NA	NA	NA	NA	NA	NA	0.00002403	0.0002	0.0002	0.0002	0.0083	0	0	0.0010026	0		0	0.009162	14			chr1	16591862	NA	G	T	171.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=4.5;AS_FS=0;AS_MQ=26.79;AS_MQRankSum=-0.1;AS_QD=4.91;AS_ReadPosRankSum=0.5;AS_SOR=0.465;BaseQRankSum=4.54;DP=38;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=29.7;MQRankSum=-0.027;QD=4.9;ReadPosRankSum=0.548;SOR=0.465	GT:AD:DP:GQ:PL	0/1:26,9:35:99:179,0,690
chr1	16622227	16622227	C	T	CROCCP2	ncRNA_intronic	NA	NA	NA	0.5003	GnomAdGenome_AF_eas			HeterozygousVariant	het	45	28	17	0.377777777777778	504.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	lung;adrenal medulla;uterus;liver;frontal lobe;germinal center;nasopharynx;brain;blood;unclassifiable (Anatomical System);heart;bone marrow;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4869	0.5003	0	0	0.128707	0		0					chr1	16622227	NA	C	T	504.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.22;AS_ReadPosRankSum=-1;AS_SOR=0.976;BaseQRankSum=-3.347;DP=47;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.21;ReadPosRankSum=-0.926;SOR=0.976	GT:AD:DP:GQ:PL	0/1:28,17:45:99:512,0,960
chr1	16623975	16623975	C	T	CROCCP2	ncRNA_intronic	NA	NA	NA	0.362	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	169	143	26	0.153846153846154	206.64	QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	lung;adrenal medulla;uterus;liver;frontal lobe;germinal center;nasopharynx;brain;blood;unclassifiable (Anatomical System);heart;bone marrow;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0609	0.362	0	0	0.0049417	0		0	0.163	88	0.149254	20	chr1	16623975	NA	C	T	206.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0.802;AS_MQ=56.57;AS_MQRankSum=-1.1;AS_QD=1.22;AS_ReadPosRankSum=0.5;AS_SOR=0.838;BaseQRankSum=-0.674;DP=171;ExcessHet=3.0103;FS=0.802;MLEAC=1;MLEAF=0.5;MQ=57.8;MQRankSum=-1.005;QD=1.22;ReadPosRankSum=0.569;SOR=0.838	GT:AD:DP:GQ:PL	0/1:143,26:169:99:214,0,3549
chr1	16627177	16627177	C	T	CROCCP2	ncRNA_exonic	NA	NA	NA	0.323	GnomAdGenome_AF_sas	0	0	WT/SomaticVariant	het	285	223	62	0.217543859649123	923.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	lung;adrenal medulla;uterus;liver;frontal lobe;germinal center;nasopharynx;brain;blood;unclassifiable (Anatomical System);heart;bone marrow;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1602	0.323	0	0	0.0101616	0.293103	VQSRTrancheSNP99.00to99.90	0	0.378	137	0.4375	14	chr1	16627177	NA	C	T	923.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=0;AS_MQ=57.04;AS_MQRankSum=-1;AS_QD=3.24;AS_ReadPosRankSum=0.4;AS_SOR=0.703;BaseQRankSum=0.709;DP=296;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=57.16;MQRankSum=-0.949;QD=3.24;ReadPosRankSum=0.475;SOR=0.703	GT:AD:DP:GQ:PL	0/1:223,62:285:99:931,0,5430
chr1	16628633	16628633	A	G	CROCCP2	ncRNA_exonic	NA	NA	NA	0.3196	GnomAdGenome_AF_afr	0	0	WT/SomaticVariant	het	54	42	12	0.222222222222222	171.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	lung;adrenal medulla;uterus;liver;frontal lobe;germinal center;nasopharynx;brain;blood;unclassifiable (Anatomical System);heart;bone marrow;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.2632	0.3196	0	0	0.0057114	0.270936	PASS	0	0.313	130	0.40625	13	chr1	16628633	NA	A	G	171.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=1.298;AS_MQ=56.83;AS_MQRankSum=-2.6;AS_QD=3.19;AS_ReadPosRankSum=-0.6;AS_SOR=1.055;BaseQRankSum=-0.092;DP=57;ExcessHet=3.0103;FS=1.298;MLEAC=1;MLEAF=0.5;MQ=59.09;MQRankSum=-2.52;QD=3.18;ReadPosRankSum=-0.541;SOR=1.055	GT:AD:DP:GQ:PL	0/1:42,12:54:99:179,0,1067
chr1	16628722	16628722	C	T	CROCCP2	ncRNA_intronic	NA	NA	NA	0.1917	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	18	11	7	0.388888888888889	180.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	lung;adrenal medulla;uterus;liver;frontal lobe;germinal center;nasopharynx;brain;blood;unclassifiable (Anatomical System);heart;bone marrow;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0985	0.1917	0	0	0.0342324	0.116027	PASS	0	0.227	94	0.25	8	chr1	16628722	NA	C	T	180.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=1.2;AS_QD=10.06;AS_ReadPosRankSum=2.2;AS_SOR=0.743;BaseQRankSum=-1.285;DP=19;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=58.65;MQRankSum=1.24;QD=10.04;ReadPosRankSum=2.22;SOR=0.743	GT:AD:DP:GQ:PL	0/1:11,7:18:99:188,0,361
chr1	16642886	16642886	C	T	CROCCP2;MST1P2	intergenic	NA	dist=11980;dist=2688	NA	0.7405	GnomAdGenome_AF_eas	15	3	HomozygousVariant	het	196	56	140	0.714285714285714	3357.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.558	0.7405	0	0	0.026979	0		0	0.542	164	0.522059	65	chr1	16642886	NA	C	T	3357.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=1.239;AS_MQ=54.87;AS_MQRankSum=-5.2;AS_QD=17.13;AS_ReadPosRankSum=-1.2;AS_SOR=0.844;BaseQRankSum=-1.301;DP=201;ExcessHet=3.0103;FS=1.239;MLEAC=1;MLEAF=0.5;MQ=56.33;MQRankSum=-5.162;QD=17.13;ReadPosRankSum=-1.191;SOR=0.844	GT:AD:DP:GQ:PL	0/1:56,140:196:99:3365,0,1057
chr1	16645572	16645572	C	T	MST1P2	upstream	NA	dist=2	NA	0.4915	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	148	122	26	0.175675675675676	717.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.2508	0.4915	0.281949	0	0.0704626	0.253289	VQSRTrancheSNP99.00to99.90	0	0.362	197	0.375	51	chr1	16645572	NA	C	T	717.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=2.87;AS_MQ=50.87;AS_MQRankSum=-2.3;AS_QD=4.85;AS_ReadPosRankSum=-0.9;AS_SOR=1.088;BaseQRankSum=0.607;DP=151;ExcessHet=3.0103;FS=2.87;MLEAC=1;MLEAF=0.5;MQ=50.5;MQRankSum=-2.209;QD=4.85;ReadPosRankSum=-0.84;SOR=1.088	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:122,26:148:99:0|1:16645572_C_T:725,0,4965:16645572
chr1	16645573	16645573	A	G	MST1P2	upstream	NA	dist=1	NA	0.5	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	148	122	26	0.175675675675676	717.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4324	0.5	0.453275	0	0.0001537	0.396382	VQSRTrancheSNP99.00to99.90	0	0.439	239	0.441176	60	chr1	16645573	NA	A	G	717.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.6;AS_FS=2.87;AS_MQ=50.87;AS_MQRankSum=-2.3;AS_QD=4.85;AS_ReadPosRankSum=-0.9;AS_SOR=1.088;BaseQRankSum=2.63;DP=150;ExcessHet=3.0103;FS=2.87;MLEAC=1;MLEAF=0.5;MQ=50.43;MQRankSum=-2.209;QD=4.85;ReadPosRankSum=-0.871;SOR=1.088	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:122,26:148:99:0|1:16645572_C_T:725,0,4965:16645572
chr1	16645639	16645639	C	T	MST1P2	ncRNA_exonic	NA	NA	NA	0.4757	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	190	165	25	0.131578947368421	125.64	QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4453	0.4757	0	0	0.04718	0.302542	VQSRTrancheSNP99.00to99.90	0	0.397	216	0.411765	56	chr1	16645639	NA	C	T	125.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=0;AS_MQ=39.81;AS_MQRankSum=-7;AS_QD=0.66;AS_ReadPosRankSum=0.9;AS_SOR=0.757;BaseQRankSum=0.667;DP=193;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=53.12;MQRankSum=-6.989;QD=0.66;ReadPosRankSum=0.956;SOR=0.757	GT:AD:DP:GQ:PL	0/1:165,25:190:99:133,0,4010
chr1	16646425	16646425	C	T	MST1P2	ncRNA_exonic	NA	NA	NA	0.402	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	296	203	93	0.314189189189189	1719.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.3181	0.402	0	0	0.0088938	0.236842	VQSRTrancheSNP99.00to99.90	0	0.401	145	0.46875	15	chr1	16646425	NA	C	T	1719.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=2.086;AS_MQ=59.05;AS_MQRankSum=-2.4;AS_QD=5.81;AS_ReadPosRankSum=-0.3;AS_SOR=0.575;BaseQRankSum=0.645;DP=303;ExcessHet=3.0103;FS=2.086;MLEAC=1;MLEAF=0.5;MQ=59.44;MQRankSum=-2.366;QD=5.81;ReadPosRankSum=-0.221;SOR=0.575	GT:AD:DP:GQ:PL	0/1:203,93:296:99:1727,0,4630
chr1	16646445	16646445	G	A	MST1P2	ncRNA_exonic	NA	NA	NA	0.6771	GnomAdGenome_AF_eas	10	3	WT/SomaticVariant	het	339	290	49	0.144542772861357	362.64	QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4244	0.6771	0	0	0.0703473	0.401381	VQSRTrancheSNP99.00to99.90	0	0.431	136	0.426471	52	chr1	16646445	NA	G	A	362.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=1.204;AS_MQ=59.69;AS_MQRankSum=1;AS_QD=1.07;AS_ReadPosRankSum=-1.5;AS_SOR=0.657;BaseQRankSum=0.678;DP=350;ExcessHet=3.0103;FS=1.204;MLEAC=1;MLEAF=0.5;MQ=59.15;MQRankSum=1.03;QD=1.07;ReadPosRankSum=-1.403;SOR=0.657	GT:AD:DP:GQ:PL	0/1:290,49:339:99:370,0,6879
chr1	16647111	16647111	G	T	MST1P2	ncRNA_exonic	NA	NA	NA	0.2367	GnomAdGenome_AF_afr	0	0	WT/SomaticVariant	het	147	123	24	0.163265306122449	209.64	MQ40;QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.118	0.2367	0	0	0.0073383	0.19287	VQSRTrancheSNP99.00to99.90	0	0.311	169	0.345588	47	chr1	16647111	NA	G	T	209.64	MQ40;QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=1.866;AS_MQ=38.27;AS_MQRankSum=-0.5;AS_QD=1.43;AS_ReadPosRankSum=-0.8;AS_SOR=0.489;BaseQRankSum=-1.258;DP=152;ExcessHet=3.0103;FS=1.866;MLEAC=1;MLEAF=0.5;MQ=37.23;MQRankSum=-0.482;QD=1.43;ReadPosRankSum=-0.766;SOR=0.489	GT:AD:DP:GQ:PL	0/1:123,24:147:99:217,0,3102
chr1	16648016	16648016	G	A	MST1P2	ncRNA_exonic	NA	NA	NA	0.495	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	274	212	62	0.226277372262774	1063.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.3831	0.495	0	0	0.0242431	0.293103	VQSRTrancheSNP99.00to99.90	0	0.415	226	0.419118	57	chr1	16648016	NA	G	A	1063.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=0.535;AS_MQ=50.36;AS_MQRankSum=-2.7;AS_QD=3.88;AS_ReadPosRankSum=-0.8;AS_SOR=0.626;BaseQRankSum=0.762;DP=284;ExcessHet=3.0103;FS=0.535;MLEAC=1;MLEAF=0.5;MQ=52.1;MQRankSum=-2.621;QD=3.88;ReadPosRankSum=-0.713;SOR=0.626	GT:AD:DP:GQ:PL	0/1:212,62:274:99:1071,0,5538
chr1	16648142	16648142	T	C	MST1P2	ncRNA_exonic	NA	NA	NA	0.4973	GnomAdGenome_AF_eas	0	0	HeterozygousVariant	het	298	195	103	0.345637583892617	1877.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4719	0.4973	0	0	0.0089585	0.355652	VQSRTrancheSNP99.00to99.90	0	0.467	254	0.470588	64	chr1	16648142	NA	T	C	1877.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=2.674;AS_MQ=42.33;AS_MQRankSum=-5.3;AS_QD=6.3;AS_ReadPosRankSum=0;AS_SOR=0.882;BaseQRankSum=-1.231;DP=300;ExcessHet=3.0103;FS=2.674;MLEAC=1;MLEAF=0.5;MQ=43.14;MQRankSum=-5.301;QD=6.3;ReadPosRankSum=0.004;SOR=0.882	GT:AD:DP:GQ:PL	0/1:195,103:298:99:1885,0,4505
chr1	16648167	16648167	C	A	MST1P2	ncRNA_exonic	NA	NA	NA	0.4798	GnomAdGenome_AF_eas	0	0	HeterozygousVariant	het	221	145	76	0.343891402714932	1370.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4223	0.4798	0	0	0.0125634	0.283514	VQSRTrancheSNP99.00to99.90	0	0.406	221	0.411765	56	chr1	16648167	NA	C	A	1370.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2;AS_FS=4.982;AS_MQ=39.72;AS_MQRankSum=-5.4;AS_QD=6.2;AS_ReadPosRankSum=0.5;AS_SOR=1.027;BaseQRankSum=-1.977;DP=225;ExcessHet=3.0103;FS=4.982;MLEAC=1;MLEAF=0.5;MQ=41.59;MQRankSum=-5.397;QD=6.2;ReadPosRankSum=0.539;SOR=1.027	GT:AD:DP:GQ:PL	0/1:145,76:221:99:1378,0,3671
chr1	16648250	16648250	G	A	MST1P2	ncRNA_exonic	NA	NA	NA	0.4796	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	87	66	21	0.241379310344828	618.64	MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4055	0.4796	0	0	0.0041009	0.113265	VQSRTrancheSNP99.00to99.90	0	0.202	110	0.246269	33	chr1	16648250	NA	G	A	618.64	MQ40;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.3;AS_FS=44.649;AS_MQ=25.3;AS_MQRankSum=-6.8;AS_QD=7.11;AS_ReadPosRankSum=0.1;AS_SOR=5.949;BaseQRankSum=-2.207;DP=89;ExcessHet=3.0103;FS=44.649;MLEAC=1;MLEAF=0.5;MQ=31.86;MQRankSum=-6.759;QD=7.11;ReadPosRankSum=0.153;SOR=5.949	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:66,21:87:99:0|1:16648250_G_A:626,0,2673:16648250
chr1	16648263	16648263	G	A	MST1P2	ncRNA_exonic	NA	NA	NA	0.6769	GnomAdGenome_AF_eas	13	3	WT/SomaticVariant	het	83	65	18	0.216867469879518	539.64	MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.5095	0.6769	0	0	0.0322345	0.267368	VQSRTrancheSNP99.90to100.00	0	0.408	195	0.41791	50	chr1	16648263	NA	G	A	539.64	MQ40;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=41.768;AS_MQ=25.23;AS_MQRankSum=-6.5;AS_QD=6.51;AS_ReadPosRankSum=0.4;AS_SOR=5.713;BaseQRankSum=0.394;DP=84;ExcessHet=3.0103;FS=41.768;MLEAC=1;MLEAF=0.5;MQ=33.37;MQRankSum=-6.461;QD=6.5;ReadPosRankSum=0.481;SOR=5.713	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:65,18:83:99:0|1:16648250_G_A:547,0,2675:16648250
chr1	16648285	16648285	C	T	MST1P2	ncRNA_exonic	NA	NA	NA	0.4663	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	76	64	12	0.157894736842105	303.64	MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.3766	0.4663	0	0	0.0001921	0.048864	VQSRTrancheSNP99.00to99.90	0	0.155	84	0.134328	18	chr1	16648285	NA	C	T	303.64	MQ40;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=31.112;AS_MQ=25.17;AS_MQRankSum=-5.5;AS_QD=4;AS_ReadPosRankSum=-0.3;AS_SOR=5.135;BaseQRankSum=0.916;DP=77;ExcessHet=3.0103;FS=31.112;MLEAC=1;MLEAF=0.5;MQ=38.87;MQRankSum=-5.442;QD=4;ReadPosRankSum=-0.239;SOR=5.135	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:64,12:76:99:0|1:16648250_G_A:311,0,2631:16648250
chr1	16648291	16648291	G	C	MST1P2	ncRNA_exonic	NA	NA	NA	0.5217	GnomAdGenome_AF_afr	4	0	WT/SomaticVariant	het	75	64	11	0.146666666666667	261.64	SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4811	0.5217	0.211262	0	0.0173801	0.244898	VQSRTrancheSNP99.00to99.90	0	0.345	179	0.291045	39	chr1	16648291	NA	G	C	261.64	SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=31.528;AS_MQ=25.19;AS_MQRankSum=-5.3;AS_QD=3.49;AS_ReadPosRankSum=-0.8;AS_SOR=4.975;BaseQRankSum=-0.545;DP=78;ExcessHet=3.0103;FS=31.528;MLEAC=1;MLEAF=0.5;MQ=40.3;MQRankSum=-5.224;QD=3.49;ReadPosRankSum=-0.775;SOR=4.975	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:64,11:75:99:0|1:16648250_G_A:269,0,2619:16648250
chr1	16648374	16648374	G	C	MST1P2	ncRNA_exonic	NA	NA	NA	0.4627	GnomAdGenome_AF_ami	1	2	HeterozygousVariant	het	145	47	98	0.675862068965517	2401.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.3821	0.4627	0	0	0.0095794	0.374179	VQSRTrancheSNP99.00to99.90	0	0.416	171	0.440299	55	chr1	16648374	NA	G	C	2401.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.6;AS_FS=0;AS_MQ=56.83;AS_MQRankSum=-0.8;AS_QD=16.57;AS_ReadPosRankSum=0.5;AS_SOR=0.646;BaseQRankSum=-2.502;DP=148;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=57.2;MQRankSum=-0.742;QD=16.56;ReadPosRankSum=0.566;SOR=0.646	GT:AD:DP:GQ:PL	0/1:47,98:145:99:2409,0,1095
chr1	16649000	16649000	T	C	MST1P2	ncRNA_exonic	NA	NA	NA	0.5773	GnomAdGenome_AF_amr	35	3	HomozygousVariant	hom	59	0	59	1	1855.06	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.5259	0.5773	0.560903	0	0.0402	0.17233	VQSRTrancheSNP99.00to99.90	0	0.547	128	0.6	12	chr1	16649000	NA	T	C	1855.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=30.11;AS_MQRankSum=.;AS_QD=31.44;AS_ReadPosRankSum=.;AS_SOR=0.95;DP=61;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=30.44;QD=31.44;SOR=0.95	GT:AD:DP:GQ:PL	1/1:0,59:59:99:1869,177,0
chr1	16649230	16649230	C	-	MST1P2	ncRNA_exonic	NA	NA	NA	0.4828	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	260	226	34	0.130769230769231	423.6	QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.2327	0.4828	0.245807	0	0.0510604	0.292	PASS	0	0.32	133	0.345588	47	chr1	16649229	NA	GC	G	423.6	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.1;AS_FS=2.386;AS_MQ=42.19;AS_MQRankSum=-2;AS_QD=1.63;AS_ReadPosRankSum=-1.7;AS_SOR=0.932;BaseQRankSum=-2.091;DP=274;ExcessHet=3.0103;FS=2.386;MLEAC=1;MLEAF=0.5;MQ=42.58;MQRankSum=-1.933;QD=1.63;ReadPosRankSum=-1.653;SOR=0.932	GT:AD:DP:GQ:PL	0/1:226,34:260:99:431,0,7251
chr1	16649336	16649336	C	T	MST1P2	ncRNA_intronic	NA	NA	NA	0.4932	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	93	67	26	0.279569892473118	465.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4536	0.4932	0	0	0.0312356	0.034743	VQSRTrancheSNP99.00to99.90	0	0.408	222	0.389706	53	chr1	16649336	NA	C	T	465.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=17.605;AS_MQ=26.21;AS_MQRankSum=-4.9;AS_QD=5.01;AS_ReadPosRankSum=-0.3;AS_SOR=2.509;BaseQRankSum=-0.611;DP=97;ExcessHet=3.0103;FS=17.605;MLEAC=1;MLEAF=0.5;MQ=32.04;MQRankSum=-4.895;QD=5.01;ReadPosRankSum=-0.291;SOR=2.509	GT:AD:DP:GQ:PL	0/1:67,26:93:99:473,0,1930
chr1	16649499	16649499	T	C	MST1P2	ncRNA_exonic	NA	NA	NA	0.6546	GnomAdGenome_AF_eas	15	3	WT/SomaticVariant	het	225	199	26	0.115555555555556	136.64	QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.5103	0.6546	0	0	0.0158471	0.298867	VQSRTrancheSNP99.90to100.00	0	0.428	203	0.492647	61	chr1	16649499	NA	T	C	136.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=5.3;AS_FS=21.583;AS_MQ=32.94;AS_MQRankSum=-7.2;AS_QD=0.61;AS_ReadPosRankSum=-0.7;AS_SOR=2.293;BaseQRankSum=5.38;DP=227;ExcessHet=3.0103;FS=21.583;MLEAC=1;MLEAF=0.5;MQ=49.54;MQRankSum=-7.153;QD=0.61;ReadPosRankSum=-0.67;SOR=2.293	GT:AD:DP:GQ:PL	0/1:199,26:225:99:144,0,5007
chr1	16649537	16649537	A	C	MST1P2	ncRNA_intronic	NA	NA	NA	0.3993	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	199	134	65	0.326633165829146	1354.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.3368	0.3993	0	0	0.0474489	0.255344	VQSRTrancheSNP99.00to99.90	0	0.397	216	0.433824	59	chr1	16649537	NA	A	C	1354.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0;AS_MQ=57.66;AS_MQRankSum=3.7;AS_QD=6.81;AS_ReadPosRankSum=0.7;AS_SOR=0.724;BaseQRankSum=0.043;DP=212;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=54.13;MQRankSum=3.71;QD=6.81;ReadPosRankSum=0.709;SOR=0.724	GT:AD:DP:GQ:PL	0/1:134,65:199:99:1362,0,3357
chr1	16649698	16649698	C	T	MST1P2	ncRNA_exonic	NA	NA	NA	0.641	GnomAdGenome_AF_eas	11	3	WT/SomaticVariant	het	226	181	43	0.190265486725664	525.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4859	0.641	0	0	0.0428385	0.360927	VQSRTrancheSNP99.90to100.00	0	0.365	130	0.455882	56	chr1	16649698	NA	C	T	525.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=24.334;AS_MQ=36.66;AS_MQRankSum=-11;AS_QD=2.35;AS_ReadPosRankSum=-1.5;AS_SOR=1.924;BaseQRankSum=-0.261;DP=227;ExcessHet=3.0103;FS=23.54;MLEAC=1;MLEAF=0.5;MQ=53.89;MQRankSum=-10.93;QD=2.35;ReadPosRankSum=-1.457;SOR=1.847	GT:AD:DP:GQ:PL	0/1:181,43:226:99:533,0,4491
chr1	16650125	16650125	A	G	MST1P2	ncRNA_exonic	NA	NA	NA	0.3828	GnomAdGenome_AF_afr	0	0	WT/SomaticVariant	het	178	139	39	0.219101123595506	857.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.2454	0.3828	0	0	0.0168665	0.225636	VQSRTrancheSNP99.00to99.90	0	0.294	160	0.272059	37	chr1	16650125	NA	A	G	857.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=7.2;AS_FS=24.698;AS_MQ=44.21;AS_MQRankSum=3.6;AS_QD=4.82;AS_ReadPosRankSum=-3.3;AS_SOR=2.336;BaseQRankSum=7.24;DP=180;ExcessHet=3.0103;FS=24.698;MLEAC=1;MLEAF=0.5;MQ=40.55;MQRankSum=3.6;QD=4.82;ReadPosRankSum=-3.214;SOR=2.336	GT:AD:DP:GQ:PL	0/1:139,39:178:99:865,0,3390
chr1	16650146	16650146	C	T	MST1P2	ncRNA_exonic	NA	NA	NA	0.4809	GnomAdGenome_AF_eas	0	0	HeterozygousVariant	het	185	124	61	0.32972972972973	2170.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4419	0.4809	0	0	0.0149839	0.254149	VQSRTrancheSNP99.00to99.90	0	0.426	232	0.455882	62	chr1	16650146	NA	C	T	2170.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.8;AS_FS=1.962;AS_MQ=41.84;AS_MQRankSum=1;AS_QD=11.74;AS_ReadPosRankSum=0.3;AS_SOR=0.544;BaseQRankSum=-3.766;DP=186;ExcessHet=3.0103;FS=1.962;MLEAC=1;MLEAF=0.5;MQ=40.11;MQRankSum=1.08;QD=11.73;ReadPosRankSum=0.396;SOR=0.544	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:124,61:185:99:0|1:16650146_C_T:2178,0,4881:16650146
chr1	16650154	16650154	C	T	MST1P2	ncRNA_exonic	NA	NA	NA	0.4885	GnomAdGenome_AF_eas	0	0	HeterozygousVariant	het	187	126	61	0.32620320855615	2164.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4474	0.4885	0	0	0.0122945	0.2423	VQSRTrancheSNP99.00to99.90	0	0.41	222	0.441176	60	chr1	16650154	NA	C	T	2164.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.1;AS_FS=1.973;AS_MQ=41.84;AS_MQRankSum=1.1;AS_QD=11.58;AS_ReadPosRankSum=2.1;AS_SOR=0.522;BaseQRankSum=-3.013;DP=189;ExcessHet=3.0103;FS=1.973;MLEAC=1;MLEAF=0.5;MQ=39.91;MQRankSum=1.16;QD=11.58;ReadPosRankSum=2.13;SOR=0.522	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:126,61:187:99:0|1:16650146_C_T:2172,0,4931:16650146
chr1	16650184	16650184	G	A	MST1P2	ncRNA_exonic	NA	NA	NA	0.4802	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	127	70	57	0.448818897637795	1392.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4611	0.4802	0	0	0.0523283	0.425121	VQSRTrancheSNP99.90to100.00	0	0.47	255	0.470588	64	chr1	16650184	NA	G	A	1392.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.1;AS_FS=0.682;AS_MQ=33.34;AS_MQRankSum=-5.7;AS_QD=10.97;AS_ReadPosRankSum=-1.1;AS_SOR=0.827;BaseQRankSum=2.2;DP=134;ExcessHet=3.0103;FS=0.682;MLEAC=1;MLEAF=0.5;MQ=38.15;MQRankSum=-5.618;QD=10.97;ReadPosRankSum=-1.076;SOR=0.827	GT:AD:DP:GQ:PL	0/1:70,57:127:99:1400,0,2292
chr1	16650186	16650186	G	T	MST1P2	ncRNA_exonic	NA	NA	NA	0.4589	GnomAdGenome_AF_afr	0	0	HeterozygousVariant	het	126	80	46	0.365079365079365	876.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99630119257639	E	NA	NA	NA	NA	NA	NA	0	0	0	0.4336	0.4589	0	0	0.0078201	0.230864	VQSRTrancheSNP99.00to99.90	0	0.343	186	0.382353	52	chr1	16650186	NA	G	T	876.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=0.697;AS_MQ=41.26;AS_MQRankSum=3;AS_QD=6.96;AS_ReadPosRankSum=1.8;AS_SOR=0.621;BaseQRankSum=-1.557;DP=128;ExcessHet=3.0103;FS=0.697;MLEAC=1;MLEAF=0.5;MQ=38.2;MQRankSum=3.03;QD=6.96;ReadPosRankSum=1.89;SOR=0.621	GT:AD:DP:GQ:PL	0/1:80,46:126:99:884,0,2768
chr1	16681123	16681123	-	TTGCATGCTGGG	MIR3675	upstream	NA	dist=132	NA	0.0043	GnomAdGenome_AF_sas			HeterozygousVariant	het	17	11	6	0.352941176470588	210.6	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.00009176	0.0043	0	0	0	0		0					chr1	16681123	NA	T	TTTGCATGCTGGG	210.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=7.911;AS_MQ=33.49;AS_MQRankSum=1.4;AS_QD=12.41;AS_ReadPosRankSum=-0.8;AS_SOR=1.09;BaseQRankSum=-0.213;DP=21;ExcessHet=3.0103;FS=7.911;MLEAC=1;MLEAF=0.5;MQ=29.68;MQRankSum=1.48;QD=12.39;ReadPosRankSum=-0.704;SOR=1.09	GT:AD:DP:GQ:PL	0/1:11,6:17:99:218,0,444
chr1	16687422	16687422	T	-	MIR3675;ESPNP	intergenic	NA	dist=6094;dist=3796	NA	0.479	GnomAdGenome_AF_sas			HomozygousVariant	hom	98	0	98	1	3655.03	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4512	0.479	0	0	0.0001153	0		0					chr1	16687421	NA	GT	G	3655.03	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=56.89;AS_MQRankSum=.;AS_QD=28.31;AS_ReadPosRankSum=.;AS_SOR=0.82;DP=98;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=56.89;QD=29.97;SOR=0.82	GT:AD:DP:GQ:PL	1/1:0,98:98:99:3669,295,0
chr1	16692382	16692382	T	C	ESPNP	ncRNA_intronic	NA	NA	NA	0.491014	1000g2015aug_all			HomozygousVariant	hom	8	0	8	1	206.04	DP10;MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	choroid;fovea centralis;ovary;retina;macula lutea;stomach;testis;mammary gland;lens;optic nerve;unclassifiable (Anatomical System);	NA	NA	NA	NA	NA	NA	0.404376440750944	N	NA	NA	NA	NA	NA	NA	0	0	0	0.1845	0.2353	0.491014	0	0.287921	0		0					chr1	16692382	NA	T	C	206.04	DP10;MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=38.59;AS_MQRankSum=.;AS_QD=25.75;AS_ReadPosRankSum=.;AS_SOR=1.863;DP=8;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=38.59;QD=25.75;SOR=1.863	GT:AD:DP:GQ:PL	1/1:0,8:8:24:220,24,0
chr1	16707546	16707546	T	C	ESPNP	ncRNA_exonic	NA	NA	NA	0.8091	GnomAdExome_AF_fin	295	76	HomozygousVariant	hom	20	0	20	1	584.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	choroid;fovea centralis;ovary;retina;macula lutea;stomach;testis;mammary gland;lens;optic nerve;unclassifiable (Anatomical System);	NA	NA	NA	NA	NA	NA	0.404376440750944	N	NA	NA	NA	NA	NA	NA	0.76	0.7842	0.7885	0.7095	0.7824	0.73742	0	0.483221	0.718287	VQSRTrancheSNP99.00to99.90	0	0.751	283	0.769784	62	chr1	16707546	NA	T	C	584.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=43.27;AS_MQRankSum=.;AS_QD=29.2;AS_ReadPosRankSum=.;AS_SOR=1.721;DP=20;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=43.27;QD=29.2;SOR=1.721	GT:AD:DP:GQ:PL	1/1:0,20:20:60:598,60,0
chr1	16757312	16757312	T	C	MST1L	exonic	nonsynonymous SNV	NA	MST1L:NM_001271733:exon15:c.A1990G:p.T664A	0.8885	GnomAdGenome_AF_eas	206	47	WT/SomaticVariant	het	46	35	11	0.239130434782609	178.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.6344	0.8561	0.8609	0.6835	0.8885	0.689696	0	0.0002305	0.583333	VQSRTrancheSNP99.90to100.00	0	0.625	349	0.614286	78	chr1	16757312	NA	T	C	178.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.3;AS_FS=0;AS_MQ=32.85;AS_MQRankSum=-5.4;AS_QD=3.89;AS_ReadPosRankSum=-0.8;AS_SOR=0.685;BaseQRankSum=3.39;DP=46;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=45.85;MQRankSum=-5.312;QD=3.88;ReadPosRankSum=-0.709;SOR=0.685	GT:AD:DP:GQ:PL	0/1:35,11:46:99:186,0,730
chr1	16758320	16758320	G	A	MST1L	intronic	NA	NA	NA	0.6696	GnomAdExome_AF_asj	22	24	HeterozygousVariant	het	26	10	16	0.615384615384615	457.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.6323	0.6544	0.6522	0.2745	0.3144	0.591653	0	0.195712	0.605882	VQSRTrancheSNP99.00to99.90	0	0.555	157	0.627778	65	chr1	16758320	NA	G	A	457.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.9;AS_FS=25.927;AS_MQ=31.64;AS_MQRankSum=3.1;AS_QD=17.62;AS_ReadPosRankSum=1.6;AS_SOR=0.907;BaseQRankSum=-1.822;DP=27;ExcessHet=3.0103;FS=25.927;MLEAC=1;MLEAF=0.5;MQ=29.87;MQRankSum=3.14;QD=17.6;ReadPosRankSum=1.69;SOR=0.907	GT:AD:DP:GQ:PL	0/1:10,16:26:99:465,0,225
chr1	16758453	16758453	A	C	MST1L	intronic	NA	NA	NA	0.4841	GnomAdGenome_AF_eas	0	0	WT/SomaticVariant	het	246	193	53	0.215447154471545	634.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.2744	0.4788	0.4766	0.3541	0.4841	0	0	0.0140618	0.228814	VQSRTrancheSNP99.00to99.90	0	0.322	158	0.330986	94	chr1	16758453	NA	A	C	634.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=4.48;AS_MQ=44.03;AS_MQRankSum=3.2;AS_QD=2.58;AS_ReadPosRankSum=-0.3;AS_SOR=0.959;BaseQRankSum=0.209;DP=249;ExcessHet=3.0103;FS=4.48;MLEAC=1;MLEAF=0.5;MQ=40.47;MQRankSum=3.29;QD=2.58;ReadPosRankSum=-0.272;SOR=0.959	GT:AD:DP:GQ:PL	0/1:193,53:246:99:642,0,4179
chr1	16758533	16758533	G	A	MST1L	exonic	nonsynonymous SNV	NA	MST1L:NM_001271733:exon11:c.C1447T:p.R483C	0.0634	GnomAdGenome_AF_ami	0		WT/SomaticVariant	het	115	91	24	0.208695652173913	345.64	SOR3	NA	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.00008813	0.0001	0.0001	0.0291	0.0634	0	0	0.0000768	0.018085	LowQual	0	0.0008117	1			chr1	16758533	NA	G	A	345.64	SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=4.6;AS_FS=44.42;AS_MQ=25.28;AS_MQRankSum=-7.2;AS_QD=3.01;AS_ReadPosRankSum=0.3;AS_SOR=5.702;BaseQRankSum=4.61;DP=127;ExcessHet=3.0103;FS=44.42;MLEAC=1;MLEAF=0.5;MQ=40.23;MQRankSum=-7.153;QD=3.01;ReadPosRankSum=0.351;SOR=5.702	GT:AD:DP:GQ:PL	0/1:91,24:115:99:353,0,2203
chr1	16758932	16758932	T	C	MST1L	exonic	nonsynonymous SNV	NA	MST1L:NM_001271733:exon10:c.A1264G:p.I422V	0.5171	GnomAdExome_AF_amr	13	1	WT/SomaticVariant	het	86	74	12	0.13953488372093	148.64	MQ40;QD2	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.5015	0.5171	0.5187	0.3256	0.369	0	0	0.0120891	0.486301	VQSRTrancheSNP99.00to99.90	0	0.502	592	0.489362	136	chr1	16758932	NA	T	C	148.64	MQ40;QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=4.2;AS_FS=19.908;AS_MQ=34.8;AS_MQRankSum=-2.2;AS_QD=1.73;AS_ReadPosRankSum=-0.1;AS_SOR=2.633;BaseQRankSum=4.29;DP=91;ExcessHet=3.0103;FS=19.908;MLEAC=1;MLEAF=0.5;MQ=38.99;MQRankSum=-2.2;QD=1.73;ReadPosRankSum=-0.087;SOR=2.633	GT:AD:DP:GQ:PL	0/1:74,12:86:99:156,0,1747
chr1	16759007	16759007	T	C	MST1L	exonic	nonsynonymous SNV	NA	MST1L:NM_001271733:exon10:c.A1189G:p.M397V	0.5014	GnomAdGenome_AF_sas	1	1	HeterozygousVariant	het	76	24	52	0.68421052631579	1380.64	MQ40	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.4946	0.4994	0.4993	0.4901	0.5014	0	0	0.0802981	0.356299	VQSRTrancheSNP99.00to99.90	0	0.501	551	0.503521	141	chr1	16759007	NA	T	C	1380.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.9;AS_FS=7.227;AS_MQ=31.02;AS_MQRankSum=0.2;AS_QD=18.17;AS_ReadPosRankSum=0.6;AS_SOR=0.201;BaseQRankSum=3.93;DP=79;ExcessHet=3.0103;FS=7.227;MLEAC=1;MLEAF=0.5;MQ=33.09;MQRankSum=0.266;QD=18.17;ReadPosRankSum=0.625;SOR=0.201	GT:AD:DP:GQ:PL	0/1:24,52:76:99:1388,0,418
chr1	16759069	16759069	A	G	MST1L	exonic	nonsynonymous SNV	NA	MST1L:NM_001271733:exon9:c.T1157C:p.L386P	0.4584	GnomAdGenome_AF_afr	0	0	WT/SomaticVariant	het	134	117	17	0.126865671641791	280.64	MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.225	0.3625	0.3726	0.3704	0.4584	0	0	0.0064618	0.420949	VQSRTrancheSNP99.00to99.90	0	0.488	601	0.471831	134	chr1	16759069	NA	A	G	280.64	MQ40;SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.5;AS_FS=33.85;AS_MQ=28.24;AS_MQRankSum=-4.6;AS_QD=2.1;AS_ReadPosRankSum=1.2;AS_SOR=4.293;BaseQRankSum=3.56;DP=136;ExcessHet=3.0103;FS=33.85;MLEAC=1;MLEAF=0.5;MQ=39.67;MQRankSum=-4.599;QD=2.09;ReadPosRankSum=1.21;SOR=4.293	GT:AD:DP:GQ:PL	0/1:117,17:134:99:288,0,2694
chr1	16759176	16759176	C	G	MST1L	intronic	NA	NA	NA	0.4977	GnomAdExome_AF_eas	0	0	WT/SomaticVariant	het	106	76	30	0.283018867924528	942.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.4791	0.4977	0.4971	0.4527	0.4834	0	0	0.0240894	0.474472	VQSRTrancheSNP99.00to99.90	0	0.48	289	0.478873	136	chr1	16759176	NA	C	G	942.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.8;AS_FS=2.887;AS_MQ=32.21;AS_MQRankSum=-5.6;AS_QD=8.9;AS_ReadPosRankSum=2.3;AS_SOR=1.112;BaseQRankSum=1.84;DP=110;ExcessHet=3.0103;FS=2.887;MLEAC=1;MLEAF=0.5;MQ=40.84;MQRankSum=-5.537;QD=8.89;ReadPosRankSum=2.39;SOR=1.112	GT:AD:DP:GQ:PL	0/1:76,30:106:99:950,0,1985
chr1	16759182	16759182	G	A	MST1L	intronic	NA	NA	NA	0.4538	GnomAdExome_AF_afr	0	0	WT/SomaticVariant	het	103	76	27	0.262135922330097	404.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.4058	0.4538	0.4571	0.3401	0.4009	0	0	0.0057891	0.352473	VQSRTrancheSNP99.00to99.90	0	0.449	270	0.43662	124	chr1	16759182	NA	G	A	404.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=7.573;AS_MQ=32.85;AS_MQRankSum=-4.8;AS_QD=3.93;AS_ReadPosRankSum=2.4;AS_SOR=1.532;BaseQRankSum=-0.127;DP=108;ExcessHet=3.0103;FS=7.573;MLEAC=1;MLEAF=0.5;MQ=41.27;MQRankSum=-4.755;QD=3.93;ReadPosRankSum=2.5;SOR=1.532	GT:AD:DP:GQ:PL	0/1:76,27:103:99:412,0,3004
chr1	16759217	16759217	C	T	MST1L	intronic	NA	NA	NA	0.4696	GnomAdExome_AF_afr	0	1	HeterozygousVariant	het	97	61	36	0.371134020618557	663.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.4272	0.4696	0.471	0.3735	0.4294	0	0	0.0052393	0.333333	VQSRTrancheSNP99.00to99.90	0	0.439	264	0.433099	121	chr1	16759217	NA	C	T	663.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.4;AS_FS=19.593;AS_MQ=37;AS_MQRankSum=-3.6;AS_QD=6.85;AS_ReadPosRankSum=-0.4;AS_SOR=1.897;BaseQRankSum=-2.396;DP=100;ExcessHet=3.0103;FS=19.593;MLEAC=1;MLEAF=0.5;MQ=40.61;MQRankSum=-3.536;QD=6.84;ReadPosRankSum=-0.4;SOR=1.897	GT:AD:DP:GQ:PL	0/1:61,36:97:99:671,0,1666
chr1	16759300	16759300	G	T	MST1L	exonic	synonymous SNV	NA	MST1L:NM_001271733:exon8:c.C1026A:p.I342I	0.2744	GnomAdGenome_AF_afr	0	0	WT/SomaticVariant	het	125	106	19	0.152	130.64	QD2	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0959	0.2431	0.257	0.1701	0.2744	0	0	0.0137544	0.174292	VQSRTrancheSNP99.00to99.90	0	0.185	228	0.18662	53	chr1	16759300	NA	G	T	130.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=6.746;AS_MQ=40.82;AS_MQRankSum=-2.3;AS_QD=1.05;AS_ReadPosRankSum=-0.8;AS_SOR=1.609;BaseQRankSum=-0.555;DP=126;ExcessHet=3.0103;FS=6.746;MLEAC=1;MLEAF=0.5;MQ=46.6;MQRankSum=-2.291;QD=1.05;ReadPosRankSum=-0.702;SOR=1.609	GT:AD:DP:GQ:PL	0/1:106,19:125:99:138,0,2730
chr1	16759339	16759339	G	T	MST1L	exonic	synonymous SNV	NA	MST1L:NM_001271733:exon8:c.C987A:p.T329T	0.8531	GnomAdExome_AF_afr	338	89	HomozygousVariant	hom	115	0	115	1	3207.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.7915	0.8531	0.8582	0.8068	0.8524	0	0	0.239588	0.817372	VQSRTrancheSNP99.00to99.90	0	0.773	276	0.81338	53	chr1	16759339	NA	G	T	3207.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=48.66;AS_MQRankSum=.;AS_QD=27.89;AS_ReadPosRankSum=.;AS_SOR=0.859;DP=120;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=48.92;QD=27.89;SOR=0.859	GT:AD:DP:GQ:PL	1/1:0,115:115:99:3221,345,0
chr1	16759500	16759500	-	C	MST1L	exonic	frameshift insertion	NA	MST1L:NM_001271733:exon7:c.901dupG:p.A301Gfs*81	0.2853	GnomAdGenome_AF_amr	6	0	HeterozygousVariant	het	20	10	10	0.5	234.6	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0309	0.0486	0.0501	0.2411	0.2853	0.053115	0	0.0008837	0.128086	PASS	0	0.243	287	0.232394	66	chr1	16759500	NA	G	GC	234.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=3.245;AS_MQ=44.3;AS_MQRankSum=-1;AS_QD=11.75;AS_ReadPosRankSum=-0.4;AS_SOR=0.072;BaseQRankSum=-0.397;DP=25;ExcessHet=3.0103;FS=3.245;MLEAC=1;MLEAF=0.5;MQ=48.11;MQRankSum=-0.96;QD=11.73;ReadPosRankSum=-0.303;SOR=0.072	GT:AD:DP:GQ:PL	0/1:10,10:20:99:242,0,245
chr1	16759557	16759557	T	C	MST1L	exonic	nonsynonymous SNV	NA	MST1L:NM_001271733:exon7:c.A845G:p.H282R	1	GnomAdGenome_AF_ami	601	133	HomozygousVariant	hom	6	0	6	1	180.97	DP10;MQ40;SOR3	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.9926	0.9999	1	0.9786	1	0.994808	0	0.759311	0.98374	VQSRTrancheSNP99.00to99.90	0	0.999	1	1	0	chr1	16759557	NA	T	C	180.97	DP10;MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=35.55;AS_MQRankSum=.;AS_QD=30.17;AS_ReadPosRankSum=.;AS_SOR=3.912;DP=6;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=35.55;QD=30.16;SOR=3.912	GT:AD:DP:GQ:PL	1/1:0,6:6:18:195,18,0
chr1	16760870	16760870	C	G	MST1L	exonic	synonymous SNV	NA	MST1L:NM_001271733:exon3:c.G219C:p.A73A	0.630324	abraom_freq	86	24	HeterozygousVariant	het	97	59	38	0.391752577319588	1020.64	SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.5501	0.5841	0.5859	0.5207	0.5927	0	0	0.0142754	0.630324	VQSRTrancheSNP99.00to99.90	0	0.57	530	0.584507	118	chr1	16760870	NA	C	G	1020.64	SOR3	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=6.1;AS_FS=32.267;AS_MQ=35.49;AS_MQRankSum=-8.2;AS_QD=10.53;AS_ReadPosRankSum=1.5;AS_SOR=3.463;BaseQRankSum=6.13;DP=100;ExcessHet=3.0103;FS=32.267;MLEAC=1;MLEAF=0.5;MQ=46.17;MQRankSum=-8.141;QD=10.52;ReadPosRankSum=1.57;SOR=3.463	GT:AD:DP:GQ:PL	0/1:59,38:97:99:1028,0,1438
chr1	16760937	16760937	G	T	MST1L	intronic	NA	NA	NA	0.2576	GnomAdGenome_AF_afr	0	0	WT/SomaticVariant	het	255	197	58	0.227450980392157	934.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0645	0.1007	0.0972	0.213	0.2576	0	0	0.0784789	0.125212	VQSRTrancheSNP99.00to99.90	0	0.259	156	0.221831	63	chr1	16760937	NA	G	T	934.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=1.177;AS_MQ=49.02;AS_MQRankSum=-3;AS_QD=3.67;AS_ReadPosRankSum=2.8;AS_SOR=0.568;BaseQRankSum=0.854;DP=260;ExcessHet=3.0103;FS=1.177;MLEAC=1;MLEAF=0.5;MQ=50.64;MQRankSum=-2.97;QD=3.67;ReadPosRankSum=2.82;SOR=0.568	GT:AD:DP:GQ:PL	0/1:197,58:255:99:942,0,4722
chr1	16760970	16760970	G	A	MST1L	exonic	nonsynonymous SNV	NA	MST1L:NM_001271733:exon2:c.C200T:p.P67L	0.4902	GnomAdExome_AF_eas	0	0	HeterozygousVariant	het	341	214	127	0.372434017595308	2344.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.4572	0.4902	0.4919	0.4556	0.4828	0	0	0.007833	0.361538	VQSRTrancheSNP99.00to99.90	0	0.481	531	0.478873	136	chr1	16760970	NA	G	A	2344.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=1.329;AS_MQ=49.66;AS_MQRankSum=-3;AS_QD=6.88;AS_ReadPosRankSum=3.1;AS_SOR=0.788;BaseQRankSum=0.389;DP=351;ExcessHet=3.0103;FS=1.329;MLEAC=1;MLEAF=0.5;MQ=51.7;MQRankSum=-2.958;QD=6.88;ReadPosRankSum=3.19;SOR=0.788	GT:AD:DP:GQ:PL	0/1:214,127:341:99:2352,0,4735
chr1	16761036	16761036	G	A	MST1L	exonic	nonsynonymous SNV	NA	MST1L:NM_001271733:exon2:c.C134T:p.A45V	0.0175	GnomAdGenome_AF_amr	0	0	WT/SomaticVariant	het	354	298	56	0.15819209039548	401.64	QD2	NA	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0033	0.0093	0.0093	0.0072	0.0175	0	0	0.0000384	0.007353	VQSRTrancheSNP99.00to99.90	0	0.002435	3	0.003521	1	chr1	16761036	NA	G	A	401.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=1.788;AS_MQ=55.43;AS_MQRankSum=1.5;AS_QD=1.14;AS_ReadPosRankSum=2.1;AS_SOR=0.557;BaseQRankSum=-0.986;DP=356;ExcessHet=3.0103;FS=1.788;MLEAC=1;MLEAF=0.5;MQ=53.71;MQRankSum=1.5;QD=1.13;ReadPosRankSum=2.18;SOR=0.557	GT:AD:DP:GQ:PL	0/1:298,56:354:99:409,0,7135
chr1	16761047	16761051	GTGCT	-	MST1L	exonic	frameshift deletion	NA	MST1L:NM_001271733:exon2:c.119_123del:p.Q40Pfs*18	0.4774	GnomAdGenome_AF_afr	0	0	WT/SomaticVariant	het	324	236	88	0.271604938271605	2953.6	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.3526	0.4537	0.474	0.4355	0.4774	0	0	0.0008409	0.291434	VQSRTrancheINDEL99.00to99.90	0	0.48	591	0.471831	134	chr1	16761046	NA	GGTGCT	G	2953.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.9;AS_FS=1.51;AS_MQ=45.8;AS_MQRankSum=-10.4;AS_QD=9.12;AS_ReadPosRankSum=-2;AS_SOR=0.811;BaseQRankSum=1.92;DP=349;ExcessHet=3.0103;FS=1.51;MLEAC=1;MLEAF=0.5;MQ=53.63;MQRankSum=-10.33;QD=9.12;ReadPosRankSum=-1.928;SOR=0.811	GT:AD:DP:GQ:PL	0/1:236,88:324:99:2961,0,9530
chr1	16761087	16761087	G	A	MST1L	exonic	nonsynonymous SNV	NA	MST1L:NM_001271733:exon2:c.C83T:p.S28L	0.4982	GnomAdExome_AF_afr	0	0	WT/SomaticVariant	het	195	151	44	0.225641025641026	769.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.4729	0.4982	0.5021	0.3439	0.4287	0	0	0.0073673	0.373757	VQSRTrancheSNP99.00to99.90	0	0.488	601	0.471831	134	chr1	16761087	NA	G	A	769.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.9;AS_FS=1.374;AS_MQ=35.11;AS_MQRankSum=-11.7;AS_QD=3.95;AS_ReadPosRankSum=-1.2;AS_SOR=0.872;BaseQRankSum=2.99;DP=210;ExcessHet=3.0103;FS=1.374;MLEAC=1;MLEAF=0.5;MQ=54.16;MQRankSum=-11.64;QD=3.95;ReadPosRankSum=-1.151;SOR=0.872	GT:AD:DP:GQ:PL	0/1:151,44:195:99:777,0,3721
chr1	16761145	16761145	A	C	MST1L	intronic	NA	NA	NA	0.0292558	Kaviar_AF	0	0	WT/SomaticVariant	het	81	71	10	0.123456790123457	58.64	QD2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0073	0.0083	0.0078	0.0103	0.0246	0	0	0.0292558	0.02017	VQSRTrancheSNP99.00to99.90	0	0.117	49	0.144366	41	chr1	16761145	NA	A	C	58.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.7;AS_FS=1.456;AS_MQ=35.03;AS_MQRankSum=-3.8;AS_QD=0.73;AS_ReadPosRankSum=1.4;AS_SOR=1.066;BaseQRankSum=1.74;DP=87;ExcessHet=3.0103;FS=1.456;MLEAC=1;MLEAF=0.5;MQ=49.03;MQRankSum=-3.764;QD=0.72;ReadPosRankSum=1.43;SOR=1.066	GT:AD:DP:GQ:PL	0/1:71,10:81:66:66,0,1976
chr1	16922005	16922005	A	G	CROCC	UTR5	NA	NM_014675:c.-14A>G	NA	0.5503	GnomAdGenome_AF_ami	97	19	HeterozygousVariant	het	77	30	47	0.61038961038961	1009.64	PASS	NA	NA	615776	NA	NA	NA	Allergic rhinitis[22036096];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.881	N	N	N	N	0.224815496700198	N	Crocc	immune system phenotype; respiratory system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.5203	0.5415	0.542	0.4841	0.5503	0	0.432	0.193865	0.512521	PASS	0	0.508	395	0.461268	93	chr1	16922005	NA	A	G	1009.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=3.185;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.12;AS_ReadPosRankSum=-1.4;AS_SOR=0.378;BaseQRankSum=-0.46;DP=78;ExcessHet=3.0103;FS=3.185;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.11;ReadPosRankSum=-1.328;SOR=0.378	GT:AD:DP:GQ:PL	0/1:30,47:77:99:1017,0,597
chr1	16930355	16930355	C	T	CROCC	intronic	NA	NA	NA	0.0466	GnomAdExome_AF_sas	1	1	HeterozygousVariant	het	31	19	12	0.387096774193548	232.64	PASS	NA	NA	615776	NA	NA	NA	Allergic rhinitis[22036096];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0.002	Medium	Medium	Medium	NA	NA	0.881	N	N	N	N	0.224815496700198	N	Crocc	immune system phenotype; respiratory system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0206	0.0466	0.0471	0.0147	0.0345	0.0153754	0.0125	0.0191459	0.016722	PASS	0	0.033	36	0.038732	9	chr1	16930355	NA	C	T	232.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.52;AS_ReadPosRankSum=0.4;AS_SOR=0.801;BaseQRankSum=-1.914;DP=31;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.5;ReadPosRankSum=0.426;SOR=0.801	GT:AD:DP:GQ:PL	0/1:19,12:31:99:240,0,514
chr1	16944256	16944256	G	A	CROCC	exonic	synonymous SNV	NA	CROCC:NM_014675:exon14:c.G1965A:p.A655A	0.4495	GnomAdGenome_AF_eas	17	2	HomozygousVariant	hom	35	0	35	1	995.06	PASS	NA	NA	615776	Benign	NA	NA	Allergic rhinitis[22036096];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.881	N	N	N	N	0.224815496700198	N	Crocc	immune system phenotype; respiratory system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.2448	0.446	0.4486	0.1883	0.4495	0.23762	0	0.0062241	0.209866	PASS	0.294643	0.202	203	0.166667	43	chr1	16944256	NA	G	A	995.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.43;AS_ReadPosRankSum=.;AS_SOR=0.869;DP=37;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.43;SOR=0.869	GT:AD:DP:GQ:PL	1/1:0,35:35:99:1009,105,0
chr1	16948842	16948842	C	T	CROCC	exonic	nonsynonymous SNV	NA	CROCC:NM_014675:exon19:c.C2752T:p.R918W	0.181034	GME_SD	0	0	WT/SomaticVariant	het	54	46	8	0.148148148148148	52.64	QD2	26.6	NA	615776	Benign	NA	NA	Allergic rhinitis[22036096];	NA	NA	NA	NA	NA	NA	D	D	NA	NA	NA	D	NA	T	D	T	T	T	NA	T	NA	T	T	NA	.;	D	D	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.881	N	N	N	N	0.224815496700198	N	Crocc	immune system phenotype; respiratory system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.035	0.0541	0.0517	0.0007	0.0025	0	0	0.117851	0.048841	VQSRTrancheSNP99.00to99.90	0.181034	0.041	48	0.060714	17	chr1	16948842	NA	C	T	52.64	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=1.524;AS_MQ=42.6;AS_MQRankSum=-5.4;AS_QD=0.98;AS_ReadPosRankSum=-0.4;AS_SOR=1.13;BaseQRankSum=0.046;DP=54;ExcessHet=3.0103;FS=1.524;MLEAC=1;MLEAF=0.5;MQ=56.4;MQRankSum=-5.356;QD=0.97;ReadPosRankSum=-0.353;SOR=1.13	GT:AD:DP:GQ:PL	0/1:46,8:54:60:60,0,1105
chr1	16961117	16961117	C	G	CROCC	exonic	nonsynonymous SNV	NA	CROCC:NM_014675:exon27:c.C4392G:p.D1464E	0.0509	GnomAdGenome_AF_sas	7	1	HeterozygousVariant	het	25	12	13	0.52	270.64	PASS	0.001	NA	615776	Benign	NA	NA	Allergic rhinitis[22036096];	NA	NA	NA	NA	NA	NA	T	T	NA	NA	NA	N	NA	T	N	T	T	T	NA	T	NA	T	T	NA	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.881	N	N	N	N	0.224815496700198	N	Crocc	immune system phenotype; respiratory system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0098	0.0408	0.0379	0.0012	0.0509	0.0145767	0	0.0020892	0		0.013158	0.064	61	0.044444	10	chr1	16961117	NA	C	G	270.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=1.58;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.84;AS_ReadPosRankSum=-1.2;AS_SOR=0.625;BaseQRankSum=0.755;DP=27;ExcessHet=3.0103;FS=1.58;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.83;ReadPosRankSum=-1.201;SOR=0.625	GT:AD:DP:GQ:PL	0/1:12,13:25:99:278,0,226
chr1	16969184	16969184	T	C	CROCC	exonic	synonymous SNV	NA	CROCC:NM_014675:exon32:c.T5145C:p.A1715A	0.9831	GnomAdExome_AF_afr	457	107	HomozygousVariant	hom	119	0	119	1	3442.06	PASS	NA	NA	615776	Benign	NA	NA	Allergic rhinitis[22036096];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.881	N	N	N	N	0.224815496700198	N	Crocc	immune system phenotype; respiratory system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.9154	0.9831	0.9815	0.9257	0.9803	0.944688	0.9264	0.874187	0.918719	PASS	0.964912	0.878	119	0.862676	31	chr1	16969184	NA	T	C	3442.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.92;AS_ReadPosRankSum=.;AS_SOR=0.932;DP=120;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.92;SOR=0.932	GT:AD:DP:GQ:PL	1/1:0,119:119:99:3456,356,0
chr1	16974953	16974953	C	T	MFAP2	exonic	synonymous SNV	NA	MFAP2:NM_001135247:exon9:c.G516A:p.A172A,MFAP2:NM_001135248:exon9:c.G516A:p.A172A,MFAP2:NM_002403:exon9:c.G519A:p.A173A,MFAP2:NM_017459:exon9:c.G519A:p.A173A	0.5932	GnomAdExome_AF_eas	34	8	HomozygousVariant	hom	26	0	26	1	913.06	MQ40;SOR3	NA	NA	156790	NA	NA	NA	Waist circumference adjusted for BMI in smokers[28443625];Lung function (FEV1/FVC)[28166213];Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)[28448500;28448500;28448500;28448500;28448500];Pulmonary function[21946350];Waist circumference adjusted for BMI in non-smokers[28443625;28443625];Pulmonary function (smoking interaction)[23284291];Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)[28443625;28443625;28443625];Waist circumference adjusted for BMI (adjusted for smoking behaviour)[28443625;28443625;28443625];Height[23563607;20881960;25429064;25282103];Waist circumference adjusted for body mass index[28448500;28448500;28448500;28448500;28448500;25673412;25673412;25673412];Blood protein levels[29875488;30072576;30072576];Waist circumference adjusted for BMI in active individuals[28448500;28448500;28448500;28448500;28448500];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.256	N	N	N	N	0.080277923791753	N	Mfap2	growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); homeostasis/metabolism phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; immune system phenotype; skeleton phenotype; 	mfap2	hyaloid vessel	hypoplastic	abnormal	0.3151	0.5932	0.5984	0.2735	0.5927	0.341054	0	0.093317	0.302345	VQSRTrancheSNP99.00to99.90	0.468944	0.232	144	0.177778	32	chr1	16974953	NA	C	T	913.06	MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=39.09;AS_MQRankSum=.;AS_QD=29.55;AS_ReadPosRankSum=.;AS_SOR=4.255;DP=26;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=39.09;QD=30.03;SOR=4.255	GT:AD:DP:GQ:PL	1/1:0,26:26:78:927,78,0
chr1	16986959	16986959	G	A	ATP13A2	intronic	NA	NA	NA	0.5508	GnomAdGenome_AF_eas	59	7	HomozygousVariant	hom	78	0	78	1	2203.06	PASS	NA	[MIM:606693]Kufor-Rakeb syndrome [recessive?];[MIM:617225]Spastic paraplegia 78, autosomal recessive [recessive?];	610513	NA	ATP13A2-related juvenile neuronal ceroid lipofuscinosis;Kufor-Rakeb syndrome;Autosomal recessive spastic paraplegia type 78	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)[28448500];Hip circumference adjusted for BMI[25673412;25673412;25673412];Height[20189936;25429064];Waist circumference adjusted for BMI in active individuals[28448500];Intraocular pressure[29617998];	HP:0000514;HP:0000458;HP:0000726;HP:0001336;HP:0001288;HP:0000725;HP:0003678;HP:0000473;HP:0002385;HP:0000738;HP:0000007;HP:0001260;HP:0002936;HP:0002063;HP:0001347;HP:0000298;HP:0002172;HP:0002304;HP:0001250;HP:0002425;HP:0001337;HP:0002548;HP:0001258;HP:0001300;HP:0003487;HP:0001257;HP:0004409;HP:0000718;HP:0000605;HP:0002375;HP:0001251;HP:0002425;HP:0000643;HP:0000511;HP:0000658;HP:0002067;HP:0002355;HP:0002063;HP:0007350;HP:0025403;HP:0001300;HP:0002367;HP:0002015;HP:0001760;HP:0008969;HP:0001260;HP:0000736;HP:0001254;HP:0000639;HP:0100660;HP:0002607;HP:0007083;HP:0001289;HP:0001336;HP:0001167;HP:0002120;HP:0012378;HP:0000726;HP:0001276;HP:0003487;HP:0010553;HP:0000514;HP:0000741;HP:0000183;HP:0001945;HP:0031008;HP:0000020;HP:0000338;HP:0003324;HP:0001260;HP:0001272;HP:0002510;HP:0000639;HP:0000605;HP:0002120;HP:0001300;HP:0002936;HP:0001347;HP:0003487;HP:0001251;HP:0001288;HP:0000726;HP:0000007;HP:0000718;HP:0000738;HP:0001258;HP:0001761;HP:0001324;HP:0002172;HP:0100543;HP:0002548;HP:0000716;HP:0002067;HP:0001288;HP:0001332;HP:0003487;HP:0012378;HP:0002174;HP:0002506;HP:0002339;HP:0002063;HP:0025331;HP:0001260;HP:0001336;HP:0002120;HP:0001260;HP:0001347;HP:0007240;HP:0007020;HP:0002079;HP:0008075;HP:0002518;HP:0001272;HP:0000486;HP:0001332;HP:0003482;HP:0007153;HP:0003390;HP:0002355;HP:0000666;HP:0000726;HP:0000738;HP:0003487;HP:0000317;HP:0000011;HP:0000605;HP:0002478;HP:0002073	Slow saccadic eye movements;Anosmia;Dementia;Myoclonus;Gait disturbance;Psychotic episodes;Rapidly progressive;Torticollis;Paraparesis;Hallucinations;Autosomal recessive inheritance;Dysarthria;Distal sensory impairment;Rigidity;Hyperreflexia;Mask-like facies;Postural instability;Akinesia;Seizure;Anarthria;Tremor;Parkinsonism with favorable response to dopaminergic medication;Spastic paraplegia;Parkinsonism;Babinski sign;Spasticity;Hyposmia;Aggressive behavior;Supranuclear gaze palsy;Hypokinesia;Ataxia;Anarthria;Blepharospasm;Vertical supranuclear gaze palsy;Eyelid apraxia;Bradykinesia;Difficulty walking;Rigidity;Hyperreflexia in upper limbs;Stooped posture;Parkinsonism;Visual hallucinations;Dysphagia;Abnormality of the foot;Leg muscle stiffness;Dysarthria;Short attention span;Lethargy;Nystagmus;Dyskinesia;Bowel incontinence;Hyperactive patellar reflex;Confusion;Myoclonus;Abnormality of finger;Cerebral cortical atrophy;Fatigue;Dementia;Hypertonia;Babinski sign;Oculogyric crisis;Slow saccadic eye movements;Apathy;Difficulty in tongue movements;Fever;Lingual dystonia;Urinary incontinence;Hypomimic face;Generalized muscle weakness;Dysarthria;Cerebellar atrophy;Spastic tetraplegia;Nystagmus;Supranuclear gaze palsy;Cerebral cortical atrophy;Parkinsonism;Distal sensory impairment;Hyperreflexia;Babinski sign;Ataxia;Gait disturbance;Dementia;Autosomal recessive inheritance;Aggressive behavior;Hallucinations;Spastic paraplegia;Pes cavus;Muscle weakness;Postural instability;Cognitive impairment;Parkinsonism with favorable response to dopaminergic medication;Depressivity;Bradykinesia;Gait disturbance;Dystonia;Babinski sign;Fatigue;Postural tremor;Diffuse cerebral atrophy;Abnormal caudate nucleus morphology;Rigidity;Upgaze palsy;Dysarthria;Myoclonus;Cerebral cortical atrophy;Dysarthria;Hyperreflexia;Progressive gait ataxia;Progressive spastic paraplegia;Hypoplasia of the corpus callosum;Progressive pes cavus;Abnormality of the periventricular white matter;Cerebellar atrophy;Strabismus;Dystonia;EMG: axonal abnormality;Progressive extrapyramidal movement disorder;Sensory axonal neuropathy;Difficulty walking;Horizontal nystagmus;Dementia;Hallucinations;Babinski sign;Facial myokymia;Neurogenic bladder;Supranuclear gaze palsy;Progressive spastic quadriplegia;Progressive cerebellar ataxia	Kufor-Rakeb_syndrome|History_of_neurodevelopmental_disorder|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in brain; protein levels are markedly increased in brain from subjects with Parkinson disease and subjects with dementia with Lewy bodies. Detected in pyramidal neurons located throughout the cingulate cortex (at protein level). In the substantia nigra, it is found in neuromelanin- positive dopaminergic neurons (at protein level). {ECO:0000269|PubMed:22186024}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0011	0.1	Medium	Medium	Medium	skin;testis;lens;unclassifiable (Anatomical System);cerebellum;kidney;adrenal medulla;uterus;retina;pancreas;islets of Langerhans;cervix;iris;hippocampus;spleen;liver;cartilage;endometrium;bone;germinal center;brain;blood;heart;bone marrow;lung;ovary;lymph node;frontal lobe;colon;placenta;breast;optic nerve;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;cerebellum;pons;fetal brain;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;globus pallidus;medulla oblongata;hypothalamus;thalamus;	0.0289	NA	N	N	N	0.226815082334292	N	Atp13a2	cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; pigmentation phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; 	atp13a2	whole organism	increased curvature	abnormal	0.2819	0.5506	0.5464	0.2368	0.5508	0.30651	0.2153	0.268405	0.281609	PASS	0	0.258	308	0.200704	43	chr1	16986959	NA	G	A	2203.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.24;AS_ReadPosRankSum=.;AS_SOR=1.409;DP=85;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.24;SOR=1.409	GT:AD:DP:GQ:PL	1/1:0,78:78:99:2217,231,0
chr1	16988207	16988207	C	T	ATP13A2	exonic	synonymous SNV	NA	ATP13A2:NM_001141974:exon24:c.G2658A:p.S886S,ATP13A2:NM_001141973:exon25:c.G2775A:p.S925S,ATP13A2:NM_022089:exon25:c.G2790A:p.S930S	0.552	GnomAdGenome_AF_eas	57	7	HomozygousVariant	hom	71	2	69	0.971830985915493	2114.06	PASS	NA	[MIM:606693]Kufor-Rakeb syndrome [recessive?];[MIM:617225]Spastic paraplegia 78, autosomal recessive [recessive?];	610513	Benign	ATP13A2-related juvenile neuronal ceroid lipofuscinosis;Kufor-Rakeb syndrome;Autosomal recessive spastic paraplegia type 78	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)[28448500];Hip circumference adjusted for BMI[25673412;25673412;25673412];Height[20189936;25429064];Waist circumference adjusted for BMI in active individuals[28448500];Intraocular pressure[29617998];	HP:0000514;HP:0000458;HP:0000726;HP:0001336;HP:0001288;HP:0000725;HP:0003678;HP:0000473;HP:0002385;HP:0000738;HP:0000007;HP:0001260;HP:0002936;HP:0002063;HP:0001347;HP:0000298;HP:0002172;HP:0002304;HP:0001250;HP:0002425;HP:0001337;HP:0002548;HP:0001258;HP:0001300;HP:0003487;HP:0001257;HP:0004409;HP:0000718;HP:0000605;HP:0002375;HP:0001251;HP:0002425;HP:0000643;HP:0000511;HP:0000658;HP:0002067;HP:0002355;HP:0002063;HP:0007350;HP:0025403;HP:0001300;HP:0002367;HP:0002015;HP:0001760;HP:0008969;HP:0001260;HP:0000736;HP:0001254;HP:0000639;HP:0100660;HP:0002607;HP:0007083;HP:0001289;HP:0001336;HP:0001167;HP:0002120;HP:0012378;HP:0000726;HP:0001276;HP:0003487;HP:0010553;HP:0000514;HP:0000741;HP:0000183;HP:0001945;HP:0031008;HP:0000020;HP:0000338;HP:0003324;HP:0001260;HP:0001272;HP:0002510;HP:0000639;HP:0000605;HP:0002120;HP:0001300;HP:0002936;HP:0001347;HP:0003487;HP:0001251;HP:0001288;HP:0000726;HP:0000007;HP:0000718;HP:0000738;HP:0001258;HP:0001761;HP:0001324;HP:0002172;HP:0100543;HP:0002548;HP:0000716;HP:0002067;HP:0001288;HP:0001332;HP:0003487;HP:0012378;HP:0002174;HP:0002506;HP:0002339;HP:0002063;HP:0025331;HP:0001260;HP:0001336;HP:0002120;HP:0001260;HP:0001347;HP:0007240;HP:0007020;HP:0002079;HP:0008075;HP:0002518;HP:0001272;HP:0000486;HP:0001332;HP:0003482;HP:0007153;HP:0003390;HP:0002355;HP:0000666;HP:0000726;HP:0000738;HP:0003487;HP:0000317;HP:0000011;HP:0000605;HP:0002478;HP:0002073	Slow saccadic eye movements;Anosmia;Dementia;Myoclonus;Gait disturbance;Psychotic episodes;Rapidly progressive;Torticollis;Paraparesis;Hallucinations;Autosomal recessive inheritance;Dysarthria;Distal sensory impairment;Rigidity;Hyperreflexia;Mask-like facies;Postural instability;Akinesia;Seizure;Anarthria;Tremor;Parkinsonism with favorable response to dopaminergic medication;Spastic paraplegia;Parkinsonism;Babinski sign;Spasticity;Hyposmia;Aggressive behavior;Supranuclear gaze palsy;Hypokinesia;Ataxia;Anarthria;Blepharospasm;Vertical supranuclear gaze palsy;Eyelid apraxia;Bradykinesia;Difficulty walking;Rigidity;Hyperreflexia in upper limbs;Stooped posture;Parkinsonism;Visual hallucinations;Dysphagia;Abnormality of the foot;Leg muscle stiffness;Dysarthria;Short attention span;Lethargy;Nystagmus;Dyskinesia;Bowel incontinence;Hyperactive patellar reflex;Confusion;Myoclonus;Abnormality of finger;Cerebral cortical atrophy;Fatigue;Dementia;Hypertonia;Babinski sign;Oculogyric crisis;Slow saccadic eye movements;Apathy;Difficulty in tongue movements;Fever;Lingual dystonia;Urinary incontinence;Hypomimic face;Generalized muscle weakness;Dysarthria;Cerebellar atrophy;Spastic tetraplegia;Nystagmus;Supranuclear gaze palsy;Cerebral cortical atrophy;Parkinsonism;Distal sensory impairment;Hyperreflexia;Babinski sign;Ataxia;Gait disturbance;Dementia;Autosomal recessive inheritance;Aggressive behavior;Hallucinations;Spastic paraplegia;Pes cavus;Muscle weakness;Postural instability;Cognitive impairment;Parkinsonism with favorable response to dopaminergic medication;Depressivity;Bradykinesia;Gait disturbance;Dystonia;Babinski sign;Fatigue;Postural tremor;Diffuse cerebral atrophy;Abnormal caudate nucleus morphology;Rigidity;Upgaze palsy;Dysarthria;Myoclonus;Cerebral cortical atrophy;Dysarthria;Hyperreflexia;Progressive gait ataxia;Progressive spastic paraplegia;Hypoplasia of the corpus callosum;Progressive pes cavus;Abnormality of the periventricular white matter;Cerebellar atrophy;Strabismus;Dystonia;EMG: axonal abnormality;Progressive extrapyramidal movement disorder;Sensory axonal neuropathy;Difficulty walking;Horizontal nystagmus;Dementia;Hallucinations;Babinski sign;Facial myokymia;Neurogenic bladder;Supranuclear gaze palsy;Progressive spastic quadriplegia;Progressive cerebellar ataxia	Kufor-Rakeb_syndrome|History_of_neurodevelopmental_disorder|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed in brain; protein levels are markedly increased in brain from subjects with Parkinson disease and subjects with dementia with Lewy bodies. Detected in pyramidal neurons located throughout the cingulate cortex (at protein level). In the substantia nigra, it is found in neuromelanin- positive dopaminergic neurons (at protein level). {ECO:0000269|PubMed:22186024}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;testis;lens;unclassifiable (Anatomical System);cerebellum;kidney;adrenal medulla;uterus;retina;pancreas;islets of Langerhans;cervix;iris;hippocampus;spleen;liver;cartilage;endometrium;bone;germinal center;brain;blood;heart;bone marrow;lung;ovary;lymph node;frontal lobe;colon;placenta;breast;optic nerve;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;cerebellum;pons;fetal brain;occipital lobe;subthalamic nucleus;whole brain;spinal cord;parietal lobe;globus pallidus;medulla oblongata;hypothalamus;thalamus;	0.0289	NA	N	N	N	0.226815082334292	N	Atp13a2	cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; pigmentation phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; 	atp13a2	whole organism	increased curvature	abnormal	0.2494	0.5507	0.5468	0.2052	0.552	0.290935	0.1781	0.236278	0.238916	PASS	0.27193	0.25	304	0.193662	41	chr1	16988207	NA	C	T	2114.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=29.77;AS_ReadPosRankSum=-0.6;AS_SOR=1.054;BaseQRankSum=1.39;DP=71;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=29.78;ReadPosRankSum=-0.539;SOR=1.054	GT:AD:DP:GQ:PL	1/1:2,69:71:99:2128,164,0
chr1	17054002	17054002	G	T	SDHB	exonic	synonymous SNV	NA	SDHB:NM_003000:exon1:c.C18A:p.A6A	0.9991	GnomAdExome_AF_eas	815	141	HomozygousVariant	hom	58	0	58	1	1507.06	PASS	NA	[MIM:171300]Pheochromocytoma;[MIM:115310]Paragangliomas 4;[MIM:606864]Paraganglioma and gastric stromal sarcoma [dominant?];	185470	NA	Cowden syndrome;Sporadic pheochromocytoma;Isolated succinate-CoQ reductase deficiency;Hereditary pheochromocytoma-paraganglioma;Gastrointestinal stromal tumor;Carney-Stratakis syndrome	Disease-causing germline mutation(s) in;Major susceptibility factor in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Candidate gene tested in;Disease-causing germline mutation(s) (loss of function) in	Height[20189936];	HP:0005214;HP:0100723;HP:0002668;HP:0001824;HP:0000360;HP:0002239;HP:0000365;HP:0006824;HP:0002027;HP:0002015;HP:0001025;HP:0000953;HP:0001067;HP:0003745;HP:0001176;HP:0002015;HP:0002019;HP:0005214;HP:0100723;HP:0000006;HP:0000988;HP:0005214;HP:0100273;HP:0100751;HP:0100723;HP:0100833;HP:0100743;HP:0001903;HP:0002017;HP:0100242;HP:0012378;HP:0006753;HP:0002239;HP:0001392;HP:0007400;HP:0002015;HP:0002019;HP:0011166;HP:0001251;HP:0001270;HP:0012817;HP:0007350;HP:0006957;HP:0003701;HP:0002359;HP:0000737;HP:0000076;HP:0002474;HP:0001285;HP:0007272;HP:0001824;HP:0007083;HP:0001511;HP:0005150;HP:0006380;HP:0000580;HP:0003756;HP:0000639;HP:0002376;HP:0000618;HP:0002333;HP:0002313;HP:0003487;HP:0008872;HP:0000544;HP:0000726;HP:0040196;HP:0006895;HP:0001290;HP:0003510;HP:0003324;HP:0002421;HP:0003388;HP:0006801;HP:0001712;HP:0005162;HP:0011343;HP:0002123;HP:0001639;HP:0003693;HP:0003006;HP:0000006;HP:0006824;HP:0002331;HP:0000975;HP:0001962;HP:0002640;HP:0002864;HP:0003829;HP:0008629;HP:0001649;HP:0100723;HP:0000740;HP:0006737;HP:0030074;HP:0006748;HP:0011976;HP:0005584;HP:0003001;HP:0003581;HP:0012114;HP:0001156;HP:0001263;HP:0001053;HP:0100780;HP:0012062;HP:0000365;HP:0001317;HP:0002861;HP:0001048;HP:0004322;HP:0005595;HP:0002808;HP:0009720;HP:0001250;HP:0100579;HP:0007565;HP:0000771;HP:0012032;HP:0100543;HP:0000995;HP:0005374;HP:0005584;HP:0200034;HP:0200063;HP:0000767;HP:0000221;HP:0000982;HP:0000218;HP:0001249;HP:0002516;HP:0000545;HP:0000256;HP:0012740;HP:0000518;HP:0000036;HP:0000717;HP:0012733;HP:0000158;HP:0003002;HP:0006731;HP:0001508;HP:0000853;HP:0001482;HP:0002858;HP:0008675;HP:0002650;HP:0001251;HP:0004390;HP:0002668;HP:0007378;HP:0002574;HP:0000405;HP:0100749;HP:0000740;HP:0001095;HP:0000980;HP:0001337;HP:0001069;HP:0006737;HP:0001618;HP:0000096;HP:0003574;HP:0001342;HP:0000093;HP:0010532;HP:0001605;HP:0002018;HP:0008629;HP:0012378;HP:0031284;HP:0003072;HP:0002331;HP:0011979;HP:0025269;HP:0000790;HP:0001962;HP:0003345;HP:0002864;HP:0003639;HP:0006748;HP:0011703;HP:0001293;HP:0001635;HP:0001824;HP:0002664;HP:0003345;HP:0001649;HP:0003574;HP:0001635;HP:0001028;HP:0000093;HP:0002666;HP:0003072;HP:0000006;HP:0001095;HP:0001920;HP:0000957;HP:0000519;HP:0001342;HP:0000875;HP:0000975;HP:0003345;HP:0031284;HP:0002864;HP:0006748;HP:0002018;HP:0002331;HP:0001824;HP:0000790;HP:0000096;HP:0011979;HP:0001342;HP:0001095;HP:0000980;HP:0011703;HP:0001635;HP:0000740;HP:0008629;HP:0001618;HP:0001069;HP:0003072;HP:0005584;HP:0003528;HP:0000405;HP:0003574;HP:0100749;HP:0001962;HP:0025269;HP:0010532;HP:0001337;HP:0006737;HP:0002574;HP:0001293;HP:0012222;HP:0003639;HP:0000526;HP:0009711;HP:0012378;HP:0000093;HP:0001605	Intestinal obstruction;Gastrointestinal stroma tumor;Paraganglioma;Weight loss;Tinnitus;Gastrointestinal hemorrhage;Hearing impairment;Cranial nerve paralysis;Abdominal pain;Dysphagia;Urticaria;Hyperpigmentation of the skin;Neurofibromas;Sporadic;Large hands;Dysphagia;Constipation;Intestinal obstruction;Gastrointestinal stroma tumor;Autosomal dominant inheritance;Skin rash;Intestinal obstruction;Neoplasm of the colon;Esophageal neoplasm;Gastrointestinal stroma tumor;Neoplasm of the small intestine;Neoplasm of the rectum;Anemia;Nausea and vomiting;Sarcoma;Fatigue;Neoplasm of the stomach;Gastrointestinal hemorrhage;Abnormality of the liver;Irregular hyperpigmentation;Dysphagia;Constipation;Focal myoclonic seizure;Ataxia;Motor delay;Noncompaction cardiomyopathy;Hyperreflexia in upper limbs;Loss of ability to walk;Proximal muscle weakness;Frequent falls;Irritability;Vesicoureteral reflux;Expressive language delay;Spastic tetraparesis;Progressive psychomotor deterioration;Weight loss;Hyperactive patellar reflex;Intrauterine growth retardation;Abnormal atrioventricular conduction;Knee flexion contracture;Pigmentary retinopathy;Skeletal myopathy;Nystagmus;Developmental regression;Blindness;Motor deterioration;Spastic paraparesis;Babinski sign;Feeding difficulties in infancy;External ophthalmoplegia;Dementia;Mild microcephaly;Lower limb hypertonia;Generalized hypotonia;Severe short stature;Generalized muscle weakness;Poor head control;Easy fatigability;Hyperactive deep tendon reflexes;Left ventricular hypertrophy;Left ventricular dysfunction;Moderate global developmental delay;Generalized myoclonic seizure;Hypertrophic cardiomyopathy;Distal amyotrophy;Neuroblastoma;Autosomal dominant inheritance;Cranial nerve paralysis;Recurrent paroxysmal headache;Hyperhidrosis;Palpitations;Hypertension associated with pheochromocytoma;Paraganglioma of head and neck;Incomplete penetrance;Pulsatile tinnitus;Tachycardia;Gastrointestinal stroma tumor;Episodic paroxysmal anxiety;Extraadrenal pheochromocytoma;Chemodectoma;Adrenal pheochromocytoma;Elevated urinary catecholamines;Renal cell carcinoma;Glomus jugular tumor;Adult onset;Endometrial carcinoma;Brachydactyly;Global developmental delay;Hypopigmented skin patches;Conjunctival hamartoma;Bone cyst;Hearing impairment;Abnormal cerebellum morphology;Melanoma;Cavernous hemangioma;Short stature;Generalized hyperkeratosis;Kyphosis;Adenoma sebaceum;Seizure;Mucosal telangiectasiae;Multiple cafe-au-lait spots;Gynecomastia;Lipoma;Cognitive impairment;Melanocytic nevus;Cellular immunodeficiency;Renal cell carcinoma;Papule;Colorectal polyposis;Pectus excavatum;Furrowed tongue;Palmoplantar keratoderma;High palate;Intellectual disability;Increased intracranial pressure;Myopia;Macrocephaly;Papilloma;Cataract;Abnormality of the penis;Autism;Macule;Macroglossia;Breast carcinoma;Follicular thyroid carcinoma;Failure to thrive;Goiter;Subcutaneous nodule;Meningioma;Enlarged polycystic ovaries;Scoliosis;Ataxia;Hamartomatous polyposis;Paraganglioma;Neoplasm of the gastrointestinal tract;Episodic abdominal pain;Conductive hearing impairment;Chest pain;Episodic paroxysmal anxiety;Hypertensive retinopathy;Pallor;Tremor;Episodic hyperhidrosis;Extraadrenal pheochromocytoma;Dysphonia;Glomerulosclerosis;Positive regitine blocking test;Cerebral hemorrhage;Proteinuria;Paroxysmal vertigo;Vocal cord paralysis;Nausea;Pulsatile tinnitus;Fatigue;Flushing;Hypercalcemia;Recurrent paroxysmal headache;Elevated urinary dopamine;Panic attack;Hematuria;Palpitations;Elevated urinary norepinephrine;Paraganglioma of head and neck;Elevated urinary epinephrine;Adrenal pheochromocytoma;Sinus tachycardia;Cranial nerve compression;Congestive heart failure;Weight loss;Neoplasm;Elevated urinary norepinephrine;Tachycardia;Positive regitine blocking test;Congestive heart failure;Hemangioma;Proteinuria;Pheochromocytoma;Hypercalcemia;Autosomal dominant inheritance;Hypertensive retinopathy;Renal artery stenosis;Cafe-au-lait spot;Developmental cataract;Cerebral hemorrhage;Episodic hypertension;Hyperhidrosis;Elevated urinary norepinephrine;Flushing;Paraganglioma of head and neck;Adrenal pheochromocytoma;Nausea;Recurrent paroxysmal headache;Weight loss;Hematuria;Glomerulosclerosis;Elevated urinary dopamine;Cerebral hemorrhage;Hypertensive retinopathy;Pallor;Sinus tachycardia;Congestive heart failure;Episodic paroxysmal anxiety;Pulsatile tinnitus;Dysphonia;Episodic hyperhidrosis;Hypercalcemia;Renal cell carcinoma;Elevated calcitonin;Conductive hearing impairment;Positive regitine blocking test;Chest pain;Palpitations;Panic attack;Paroxysmal vertigo;Tremor;Extraadrenal pheochromocytoma;Episodic abdominal pain;Cranial nerve compression;Arachnoid hemangiomatosis;Elevated urinary epinephrine;Aniridia;Retinal capillary hemangioma;Fatigue;Proteinuria;Vocal cord paralysis	Carney-Stratakis_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|not_specified|none_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.14	NA	E	S	E	0.986750554860504	E	Sdhb	homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); renal/urinary system phenotype; neoplasm; 	NA	NA	NA	NA	0.9737	0.9991	0.9992	0.9545	0.9968	0.957069	0.9515	0.90059	0.958949	PASS	0	0.988	20	0.996479	1	chr1	17054002	NA	G	T	1507.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=25.98;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=60;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=25.98;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,58:58:99:1521,173,0
chr1	17082522	17082522	G	A	PADI2	intronic	NA	NA	NA	0.6126	GnomAdGenome_AF_eas	138	35	HomozygousVariant	hom	65	0	65	1	1754.06	PASS	NA	NA	607935	NA	NA	NA	Prudent dietary pattern[28644415];	NA	NA	NA	NA	NA	Detected in keratinocytes in epidermis (at protein level). {ECO:0000269|PubMed:12392711}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.8	NA	N	N	N	0.259563703496052	N	Padi2	immune system phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	padi2	ocular blood vessel	morphology	abnormal	0.353	0.5864	0.58	0.3218	0.6126	0.395367	0.3042	0.340442	0.318555	PASS	0	0.446	314	0.485915	68	chr1	17082522	NA	G	A	1754.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.98;AS_ReadPosRankSum=.;AS_SOR=0.854;DP=66;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.99;SOR=0.854	GT:AD:DP:GQ:PL	1/1:0,65:65:99:1768,194,0
chr1	17086626	17086626	A	C	PADI2	exonic	synonymous SNV	NA	PADI2:NM_007365:exon7:c.T729G:p.G243G	0.5919	GnomAdGenome_AF_eas	144	37	HeterozygousVariant	het	107	45	62	0.579439252336449	1478.64	PASS	NA	NA	607935	Benign	NA	NA	Prudent dietary pattern[28644415];	NA	NA	Rheumatoid_arthritis|Interstitial_pulmonary_abnormality	no_assertion_criteria_provided	association	Detected in keratinocytes in epidermis (at protein level). {ECO:0000269|PubMed:12392711}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.8	NA	N	N	N	0.259563703496052	N	Padi2	immune system phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	padi2	ocular blood vessel	morphology	abnormal	0.2987	0.5666	0.561	0.2702	0.5919	0.363618	0.2513	0.288631	0.2578	PASS	0.4	0.433	371	0.478873	62	chr1	17086626	NA	A	C	1478.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=0.721;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.82;AS_ReadPosRankSum=-0.6;AS_SOR=0.779;BaseQRankSum=0.841;DP=110;ExcessHet=3.0103;FS=0.721;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.82;ReadPosRankSum=-0.502;SOR=0.779	GT:AD:DP:GQ:PL	0/1:45,62:107:99:1486,0,947
chr1	17092529	17092529	G	A	PADI2	exonic	synonymous SNV	NA	PADI2:NM_007365:exon6:c.C534T:p.L178L	0.5082	GnomAdGenome_AF_eas	71	9	HeterozygousVariant	het	66	36	30	0.454545454545455	591.64	PASS	NA	NA	607935	Benign	NA	NA	Prudent dietary pattern[28644415];	NA	NA	NA	NA	NA	Detected in keratinocytes in epidermis (at protein level). {ECO:0000269|PubMed:12392711}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.8	NA	N	N	N	0.259563703496052	N	Padi2	immune system phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	padi2	ocular blood vessel	morphology	abnormal	0.2514	0.4955	0.4877	0.194	0.5082	0.28135	0.1679	0.23882	0.198686	PASS	0.234848	0.303	319	0.262411	56	chr1	17092529	NA	G	A	591.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.97;AS_ReadPosRankSum=1.2;AS_SOR=0.628;BaseQRankSum=-1.063;DP=69;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.96;ReadPosRankSum=1.28;SOR=0.628	GT:AD:DP:GQ:PL	0/1:36,30:66:99:599,0,816
chr1	17230544	17230544	T	C	PADI1	intronic	NA	NA	NA	0.5651	GnomAdExome_AF_afr	62	36	HeterozygousVariant	het	40	27	13	0.325	239.64	PASS	NA	NA	607934	NA	NA	NA	IgA nephropathy[25305756];	NA	NA	NA	NA	NA	Detected in epidermal keratinocytes (at protein level). Epidermis, prostate, testis, placenta, spleen and thymus. {ECO:0000269|PubMed:12416996}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.875	NA	N	N	N	0.48789462664294	N	Padi1	NA	NA	NA	NA	NA	0.4156	0.5651	0.5693	0.4618	0.5583	0.480232	0.4681	0.410978	0.415435	PASS	0	0.519	94	0.489209	64	chr1	17230544	NA	T	C	239.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=6;AS_ReadPosRankSum=-1.3;AS_SOR=0.622;BaseQRankSum=-0.161;DP=42;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=5.99;ReadPosRankSum=-1.272;SOR=0.622	GT:AD:DP:GQ:PL	0/1:27,13:40:99:247,0,663
chr1	17230638	17230638	A	C	PADI1	exonic	synonymous SNV	NA	PADI1:NM_013358:exon10:c.A1120C:p.R374R	0.5	GME_Israel	154	37	HeterozygousVariant	het	60	39	21	0.35	398.64	PASS	NA	NA	607934	Benign	NA	NA	IgA nephropathy[25305756];	NA	NA	NA	NA	NA	Detected in epidermal keratinocytes (at protein level). Epidermis, prostate, testis, placenta, spleen and thymus. {ECO:0000269|PubMed:12416996}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.875	NA	N	N	N	0.48789462664294	N	Padi1	NA	NA	NA	NA	NA	0.4027	0.4675	0.4637	0.409	0.4829	0.407947	0.4125	0.407407	0.389984	PASS	0.5	0.485	263	0.503521	69	chr1	17230638	NA	A	C	398.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.65;AS_ReadPosRankSum=2.7;AS_SOR=0.614;BaseQRankSum=-0.791;DP=62;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.64;ReadPosRankSum=2.72;SOR=0.614	GT:AD:DP:GQ:PL	0/1:39,21:60:99:406,0,985
chr1	17230683	17230683	C	T	PADI1	intronic	NA	NA	NA	0.4208	GnomAdGenome_AF_sas	123	29	HeterozygousVariant	het	36	21	15	0.416666666666667	294.64	PASS	NA	NA	607934	NA	NA	NA	IgA nephropathy[25305756];	NA	NA	NA	NA	NA	Detected in epidermal keratinocytes (at protein level). Epidermis, prostate, testis, placenta, spleen and thymus. {ECO:0000269|PubMed:12416996}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0002	0.004	Medium	Medium	Medium	NA	NA	0.875	NA	N	N	N	0.48789462664294	N	Padi1	NA	NA	NA	NA	NA	0.3169	0.4068	0.4041	0.335	0.4208	0.358427	0.3299	0.314977	0.321018	PASS	0	0.426	247	0.43662	66	chr1	17230683	NA	C	T	294.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.19;AS_ReadPosRankSum=-0.6;AS_SOR=0.612;BaseQRankSum=-0.529;DP=37;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.18;ReadPosRankSum=-0.546;SOR=0.612	GT:AD:DP:GQ:PL	0/1:21,15:36:99:302,0,477
chr1	17237472	17237472	T	C	PADI1	intronic	NA	NA	NA	0.5635	GnomAdGenome_AF_ami	98	51	HeterozygousVariant	het	51	26	25	0.490196078431373	631.64	PASS	NA	NA	607934	NA	NA	NA	IgA nephropathy[25305756];	NA	NA	NA	NA	NA	Detected in epidermal keratinocytes (at protein level). Epidermis, prostate, testis, placenta, spleen and thymus. {ECO:0000269|PubMed:12416996}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.875	NA	N	N	N	0.48789462664294	N	Padi1	NA	NA	NA	NA	NA	0.4289	0.5384	0.5319	0.4516	0.5635	0.484026	0.4549	0.431489	0.456486	PASS	0	0.558	139	0.571429	58	chr1	17237472	NA	T	C	631.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.7;AS_FS=3.978;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.39;AS_ReadPosRankSum=1.3;AS_SOR=1.358;BaseQRankSum=1.74;DP=53;ExcessHet=3.0103;FS=3.978;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.39;ReadPosRankSum=1.33;SOR=1.358	GT:AD:DP:GQ:PL	0/1:26,25:51:99:639,0,602
chr1	17243971	17243971	T	C	PADI1	intronic	NA	NA	NA	0.5853	GnomAdExome_AF_afr	101	50	HeterozygousVariant	het	39	20	19	0.487179487179487	448.64	PASS	NA	NA	607934	NA	NA	NA	IgA nephropathy[25305756];	NA	NA	NA	NA	NA	Detected in epidermal keratinocytes (at protein level). Epidermis, prostate, testis, placenta, spleen and thymus. {ECO:0000269|PubMed:12416996}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.875	NA	N	N	N	0.48789462664294	N	Padi1	NA	NA	NA	NA	NA	0.4472	0.5853	0.5823	0.4861	0.5833	0.512181	0.4926	0.439917	0.475954	PASS	0	0.562	134	0.556738	57	chr1	17243971	NA	T	C	448.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=3.005;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.51;AS_ReadPosRankSum=-1.5;AS_SOR=0.316;BaseQRankSum=-0.078;DP=43;ExcessHet=3.0103;FS=3.005;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.5;ReadPosRankSum=-1.449;SOR=0.316	GT:AD:DP:GQ:PL	0/1:20,19:39:99:456,0,509
chr1	17282953	17282953	G	T	PADI3	exonic	synonymous SNV	NA	PADI3:NM_016233:exon16:c.G1869T:p.P623P	0.6435	GnomAdGenome_AF_eas	216	40	HeterozygousVariant	het	115	72	43	0.373913043478261	844.64	PASS	NA	NA	606755	Benign	Uncombable hair syndrome	Disease-causing germline mutation(s) (loss of function) in	IgA nephropathy[25305756];Pulmonary function (smoking interaction)[23284291];	HP:0000006;HP:0000007;HP:0011359;HP:0002235;HP:0030056;HP:0002208;HP:0002232;HP:0002224;HP:0002552;HP:0011364	Autosomal dominant inheritance;Autosomal recessive inheritance;Dry hair;Pili canaliculi;Uncombable hair;Coarse hair;Patchy alopecia;Woolly hair;Trichodysplasia;White hair	NA	NA	NA	Hair follicles, and epidermis at very low levels.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.908	NA	N	N	N	0.11926934917424	N	Padi3	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	NA	NA	NA	NA	0.4435	0.6364	0.6402	0.382	0.6435	0.404952	0.371	0.0001153	0.394089	PASS	0.5	0.522	413	0.514085	66	chr1	17282953	NA	G	T	844.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=1.541;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.35;AS_ReadPosRankSum=1.2;AS_SOR=0.535;BaseQRankSum=0.153;DP=117;ExcessHet=3.0103;FS=1.541;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.34;ReadPosRankSum=1.26;SOR=0.535	GT:AD:DP:GQ:PL	0/1:72,43:115:99:852,0,1646
chr1	17331039	17331039	G	A	PADI4	exonic	nonsynonymous SNV	NA	PADI4:NM_012387:exon2:c.G163A:p.G55S	0.65	GME_Israel	232	34	HeterozygousVariant	het	107	50	57	0.532710280373832	1183.64	PASS	0.001	[MIM:180300]Rheumatoid arthritis;	605347	Benign	NA	NA	Rheumatoid arthritis (ACPA-positive)[23143596;24532676;23143596];Basal cell carcinoma[18849993];IgA nephropathy[25305756];Rheumatoid arthritis[21452313;24390342;24390342;24390342;21505073;23143596;23143596];	HP:0002086;HP:0002633;HP:0001370;HP:0001871;HP:0002715;HP:0000707	Abnormality of the respiratory system;Vasculitis;Rheumatoid arthritis;Abnormality of blood and blood-forming tissues;Abnormality of the immune system;Abnormality of the nervous system	Rheumatoid_arthritis|Interstitial_pulmonary_abnormality	no_assertion_criteria_provided	association	Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes. {ECO:0000269|PubMed:11435484}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	NA	.;.;	N	N	Protein-arginine deiminase (PAD) N-terminal;Protein-arginine deiminase (PAD) N-terminal	NA	NA	Medium	Medium	Medium	bone marrow;	skeletal muscle;bone marrow;	0.911	N	N	N	N	0.731812543257109	E	Padi4	immune system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.5589	0.5858	0.5856	0.5501	0.6488	0.524561	0.5454	0.556526	0.554187	PASS	0.65	0.541	413	0.5	74	chr1	17331039	NA	G	A	1183.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0.723;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.07;AS_ReadPosRankSum=-0.8;AS_SOR=0.58;BaseQRankSum=-0.651;DP=107;ExcessHet=3.0103;FS=0.723;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.06;ReadPosRankSum=-0.778;SOR=0.58	GT:AD:DP:GQ:PL	0/1:50,57:107:99:1191,0,1033
chr1	17331121	17331121	T	C	PADI4	exonic	nonsynonymous SNV	NA	PADI4:NM_012387:exon2:c.T245C:p.V82A	0.6437	GnomAdGenome_AF_ami	234	36	HeterozygousVariant	het	84	48	36	0.428571428571429	748.64	PASS	5.742	[MIM:180300]Rheumatoid arthritis;	605347	Benign	NA	NA	Rheumatoid arthritis (ACPA-positive)[23143596;24532676;23143596];Basal cell carcinoma[18849993];IgA nephropathy[25305756];Rheumatoid arthritis[21452313;24390342;24390342;24390342;21505073;23143596;23143596];	HP:0002086;HP:0002633;HP:0001370;HP:0001871;HP:0002715;HP:0000707	Abnormality of the respiratory system;Vasculitis;Rheumatoid arthritis;Abnormality of blood and blood-forming tissues;Abnormality of the immune system;Abnormality of the nervous system	Rheumatoid_arthritis|Interstitial_pulmonary_abnormality	no_assertion_criteria_provided	association	Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes. {ECO:0000269|PubMed:11435484}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	NA	.;.;	N	N	Protein-arginine deiminase (PAD) N-terminal;Protein-arginine deiminase (PAD) N-terminal	NA	NA	Medium	Medium	Medium	bone marrow;	skeletal muscle;bone marrow;	0.911	N	N	N	N	0.731812543257109	E	Padi4	immune system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.5617	0.586	0.5862	0.5581	0.6437	0.533347	0.5535	0.559055	0.557471	PASS	0.6	0.544	413	0.503521	71	chr1	17331121	NA	T	C	748.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.92;AS_ReadPosRankSum=0.1;AS_SOR=0.745;BaseQRankSum=-1.312;DP=90;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.91;ReadPosRankSum=0.131;SOR=0.745	GT:AD:DP:GQ:PL	0/1:48,36:84:99:756,0,1176
chr1	17334004	17334004	G	C	PADI4	exonic	nonsynonymous SNV	NA	PADI4:NM_012387:exon3:c.G335C:p.G112A	0.6362	GnomAdGenome_AF_ami	230	35	HeterozygousVariant	het	79	37	42	0.531645569620253	878.64	PASS	17.9	[MIM:180300]Rheumatoid arthritis;	605347	Benign	NA	NA	Rheumatoid arthritis (ACPA-positive)[23143596;24532676;23143596];Basal cell carcinoma[18849993];IgA nephropathy[25305756];Rheumatoid arthritis[21452313;24390342;24390342;24390342;21505073;23143596;23143596];	HP:0002086;HP:0002633;HP:0001370;HP:0001871;HP:0002715;HP:0000707	Abnormality of the respiratory system;Vasculitis;Rheumatoid arthritis;Abnormality of blood and blood-forming tissues;Abnormality of the immune system;Abnormality of the nervous system	Rheumatoid_arthritis|Interstitial_pulmonary_abnormality	no_assertion_criteria_provided	association	Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes. {ECO:0000269|PubMed:11435484}.;	T	D	P	B	D	P	L	T	D	T	T	T	NA	T	T	T	T	NA	.;.;	D	N	.;.	NA	NA	Medium	Medium	Medium	bone marrow;	skeletal muscle;bone marrow;	0.911	N	N	N	N	0.731812543257109	E	Padi4	immune system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.5453	0.5781	0.5842	0.5351	0.6362	0.521965	0.5291	0.540989	0.541872	PASS	0.6	0.543	417	0.496479	71	chr1	17334004	NA	G	C	878.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.13;AS_ReadPosRankSum=0.4;AS_SOR=0.722;BaseQRankSum=-0.171;DP=80;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.12;ReadPosRankSum=0.491;SOR=0.722	GT:AD:DP:GQ:PL	0/1:37,42:79:99:886,0,771
chr1	17336144	17336144	T	C	PADI4	intronic	NA	NA	NA	0.6444	GnomAdGenome_AF_ami	228	36	HeterozygousVariant	het	70	29	41	0.585714285714286	905.64	PASS	NA	[MIM:180300]Rheumatoid arthritis;	605347	NA	NA	NA	Rheumatoid arthritis (ACPA-positive)[23143596;24532676;23143596];Basal cell carcinoma[18849993];IgA nephropathy[25305756];Rheumatoid arthritis[21452313;24390342;24390342;24390342;21505073;23143596;23143596];	HP:0002086;HP:0002633;HP:0001370;HP:0001871;HP:0002715;HP:0000707	Abnormality of the respiratory system;Vasculitis;Rheumatoid arthritis;Abnormality of blood and blood-forming tissues;Abnormality of the immune system;Abnormality of the nervous system	Rheumatoid_arthritis	no_assertion_criteria_provided	association	Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes. {ECO:0000269|PubMed:11435484}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	bone marrow;	skeletal muscle;bone marrow;	0.911	N	N	N	N	0.731812543257109	E	Padi4	immune system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.559	0.5863	0.5862	0.5444	0.6444	0.515176	0.5398	0.554178	0.550903	PASS	0	0.543	412	0.507042	72	chr1	17336144	NA	T	C	905.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0.919;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.94;AS_ReadPosRankSum=-0.3;AS_SOR=0.876;BaseQRankSum=0.173;DP=71;ExcessHet=3.0103;FS=0.919;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.94;ReadPosRankSum=-0.203;SOR=0.876	GT:AD:DP:GQ:PL	0/1:29,41:70:99:913,0,576
chr1	17336167	17336167	T	C	PADI4	exonic	synonymous SNV	NA	PADI4:NM_012387:exon4:c.T349C:p.L117L	0.7027	GnomAdGenome_AF_ami	271	41	HeterozygousVariant	het	89	40	49	0.550561797752809	1060.64	PASS	NA	[MIM:180300]Rheumatoid arthritis;	605347	Benign	NA	NA	Rheumatoid arthritis (ACPA-positive)[23143596;24532676;23143596];Basal cell carcinoma[18849993];IgA nephropathy[25305756];Rheumatoid arthritis[21452313;24390342;24390342;24390342;21505073;23143596;23143596];	HP:0002086;HP:0002633;HP:0001370;HP:0001871;HP:0002715;HP:0000707	Abnormality of the respiratory system;Vasculitis;Rheumatoid arthritis;Abnormality of blood and blood-forming tissues;Abnormality of the immune system;Abnormality of the nervous system	Rheumatoid_arthritis|Interstitial_pulmonary_abnormality	no_assertion_criteria_provided	association	Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes. {ECO:0000269|PubMed:11435484}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	bone marrow;	skeletal muscle;bone marrow;	0.911	N	N	N	N	0.731812543257109	E	Padi4	immune system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.6321	0.6763	0.6793	0.6366	0.7027	0.591853	0.6362	0.633038	0.612479	PASS	0.65	0.588	409	0.552817	75	chr1	17336167	NA	T	C	1060.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0.802;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.92;AS_ReadPosRankSum=-0.1;AS_SOR=0.553;BaseQRankSum=-1.1;DP=90;ExcessHet=3.0103;FS=0.802;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.92;ReadPosRankSum=-0.012;SOR=0.553	GT:AD:DP:GQ:PL	0/1:40,49:89:99:1068,0,876
chr1	17348042	17348042	C	A	PADI4	exonic	synonymous SNV	NA	PADI4:NM_012387:exon10:c.C1149A:p.R383R	0.6009	GnomAdGenome_AF_eas	169	27	HeterozygousVariant	het	113	55	58	0.513274336283186	1280.64	PASS	NA	[MIM:180300]Rheumatoid arthritis;	605347	Benign	NA	NA	Rheumatoid arthritis (ACPA-positive)[23143596;24532676;23143596];Basal cell carcinoma[18849993];IgA nephropathy[25305756];Rheumatoid arthritis[21452313;24390342;24390342;24390342;21505073;23143596;23143596];	HP:0002086;HP:0002633;HP:0001370;HP:0001871;HP:0002715;HP:0000707	Abnormality of the respiratory system;Vasculitis;Rheumatoid arthritis;Abnormality of blood and blood-forming tissues;Abnormality of the immune system;Abnormality of the nervous system	NA	NA	NA	Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes. {ECO:0000269|PubMed:11435484}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	bone marrow;	skeletal muscle;bone marrow;	0.911	N	N	N	N	0.731812543257109	E	Padi4	immune system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.3891	0.5831	0.5893	0.3687	0.6009	0.421326	0.3584	0.381198	0.418719	PASS	0.4	0.458	402	0.447183	73	chr1	17348042	NA	C	A	1280.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=1.536;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.34;AS_ReadPosRankSum=0.8;AS_SOR=0.516;BaseQRankSum=0.379;DP=115;ExcessHet=3.0103;FS=1.536;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.33;ReadPosRankSum=0.851;SOR=0.516	GT:AD:DP:GQ:PL	0/1:55,58:113:99:1288,0,1170
chr1	17363588	17363588	C	T	PADI4	exonic	nonsynonymous SNV	NA	PADI4:NM_012387:exon16:c.C1825T:p.R609C	0.0578	GnomAdGenome_AF_ami	0	0	HeterozygousVariant	het	106	47	59	0.556603773584906	1408.64	PASS	22.7	[MIM:180300]Rheumatoid arthritis;	605347	Uncertain significance	NA	NA	Rheumatoid arthritis (ACPA-positive)[23143596;24532676;23143596];Basal cell carcinoma[18849993];IgA nephropathy[25305756];Rheumatoid arthritis[21452313;24390342;24390342;24390342;21505073;23143596;23143596];	HP:0002086;HP:0002633;HP:0001370;HP:0001871;HP:0002715;HP:0000707	Abnormality of the respiratory system;Vasculitis;Rheumatoid arthritis;Abnormality of blood and blood-forming tissues;Abnormality of the immune system;Abnormality of the nervous system	NA	NA	NA	Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes. {ECO:0000269|PubMed:11435484}.;	D	D	D	P	N	D	M	T	D	T	T	T	T	T	T	T	T	NA	.;	N	N	Protein-arginine deiminase, C-terminal	NA	NA	Medium	Medium	Medium	bone marrow;	skeletal muscle;bone marrow;	0.911	N	N	N	N	0.731812543257109	E	Padi4	immune system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.0015	0.0018	0.0015	0.0021	0.0578	0.00219649	0.0013	0.001423	0.001642	PASS	0.003788	0.002463	4	0.007042	2	chr1	17363588	NA	C	T	1408.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.29;AS_ReadPosRankSum=-0.7;AS_SOR=0.722;BaseQRankSum=-1.083;DP=107;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.29;ReadPosRankSum=-0.611;SOR=0.722	GT:AD:DP:GQ:PL	0/1:47,59:106:99:1416,0,1111
chr1	17372230	17372230	C	T	PADI6	UTR5	NA	NM_207421:c.-16C>T	NA	0.3494	GnomAdGenome_AF_afr	18	14	HeterozygousVariant	het	73	35	38	0.520547945205479	754.64	PASS	NA	[MIM:617234]Preimplantation embryonic lethality 2 [recessive?];	610363	NA	NA	NA	Mean platelet volume[27863252];Basal cell carcinoma[18849993;24403052;25855136];	HP:0000789;HP:0000007;HP:0032479	Infertility;Autosomal recessive inheritance;Preimplantation lethality	NA	NA	NA	Highly expressed in oocytes and weakly expressed in other somatic tissues. {ECO:0000269|PubMed:15625577, ECO:0000269|PubMed:27545678}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Padi6	embryo phenotype; reproductive system phenotype; 	NA	NA	NA	NA	0.2172	0.3429	0.3447	0.2499	0.3494	0.261382	0.2555	0.216446	0.261905	PASS	0	0.213	137	0.264085	47	chr1	17372230	NA	C	T	754.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.3;AS_FS=1.973;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.34;AS_ReadPosRankSum=0.9;AS_SOR=0.44;BaseQRankSum=-2.28;DP=75;ExcessHet=3.0103;FS=1.973;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.34;ReadPosRankSum=0.983;SOR=0.44	GT:AD:DP:GQ:PL	0/1:35,38:73:99:762,0,811
chr1	17372396	17372396	C	T	PADI6	intronic	NA	NA	NA	0.2996	GnomAdExome_AF_asj	20	12	HeterozygousVariant	het	54	21	33	0.611111111111111	702.64	PASS	NA	[MIM:617234]Preimplantation embryonic lethality 2 [recessive?];	610363	NA	NA	NA	Mean platelet volume[27863252];Basal cell carcinoma[18849993;24403052;25855136];	HP:0000789;HP:0000007;HP:0032479	Infertility;Autosomal recessive inheritance;Preimplantation lethality	NA	NA	NA	Highly expressed in oocytes and weakly expressed in other somatic tissues. {ECO:0000269|PubMed:15625577, ECO:0000269|PubMed:27545678}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Padi6	embryo phenotype; reproductive system phenotype; 	NA	NA	NA	NA	0.1788	0.262	0.2616	0.1801	0.2977	0.197484	0.182	0.175289	0.211823	PASS	0	0.203	157	0.242958	45	chr1	17372396	NA	C	T	702.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.3;AS_FS=3.869;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.02;AS_ReadPosRankSum=-0.8;AS_SOR=0.337;BaseQRankSum=-2.261;DP=57;ExcessHet=3.0103;FS=3.869;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.01;ReadPosRankSum=-0.701;SOR=0.337	GT:AD:DP:GQ:PL	0/1:21,33:54:99:710,0,489
chr1	17381106	17381106	T	C	PADI6	exonic	synonymous SNV	NA	PADI6:NM_207421:exon5:c.T495C:p.P165P	0.2956	GnomAdGenome_AF_eas	33	8	HeterozygousVariant	het	118	63	55	0.466101694915254	1101.64	PASS	NA	[MIM:617234]Preimplantation embryonic lethality 2 [recessive?];	610363	Benign	NA	NA	Mean platelet volume[27863252];Basal cell carcinoma[18849993;24403052;25855136];	HP:0000789;HP:0000007;HP:0032479	Infertility;Autosomal recessive inheritance;Preimplantation lethality	NA	NA	NA	Highly expressed in oocytes and weakly expressed in other somatic tissues. {ECO:0000269|PubMed:15625577, ECO:0000269|PubMed:27545678}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Padi6	embryo phenotype; reproductive system phenotype; 	NA	NA	NA	NA	0.1608	0.2748	0.2726	0.1398	0.2956	0.162141	0.1407	0.155127	0.173235	PASS	0.25731	0.205	246	0.235915	51	chr1	17381106	NA	T	C	1101.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.474;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.34;AS_ReadPosRankSum=3.9;AS_SOR=0.726;BaseQRankSum=0.464;DP=120;ExcessHet=3.0103;FS=1.474;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.34;ReadPosRankSum=3.96;SOR=0.726	GT:AD:DP:GQ:PL	0/1:63,55:118:99:1109,0,1310
chr1	17388586	17388586	C	T	PADI6	intronic	NA	NA	NA	0.3685	GnomAdExome_AF_afr	42	16	HeterozygousVariant	het	38	22	16	0.421052631578947	405.64	PASS	NA	[MIM:617234]Preimplantation embryonic lethality 2 [recessive?];	610363	NA	NA	NA	Mean platelet volume[27863252];Basal cell carcinoma[18849993;24403052;25855136];	HP:0000789;HP:0000007;HP:0032479	Infertility;Autosomal recessive inheritance;Preimplantation lethality	NA	NA	NA	Highly expressed in oocytes and weakly expressed in other somatic tissues. {ECO:0000269|PubMed:15625577, ECO:0000269|PubMed:27545678}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Padi6	embryo phenotype; reproductive system phenotype; 	NA	NA	NA	NA	0.2868	0.3685	0.3685	0.2985	0.3665	0.321086	0.304	0.271361	0.329228	PASS	0	0.295	145	0.323944	60	chr1	17388586	NA	C	T	405.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.68;AS_ReadPosRankSum=-1.8;AS_SOR=0.693;BaseQRankSum=0.062;DP=39;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.67;ReadPosRankSum=-1.702;SOR=0.693	GT:AD:DP:GQ:PL	0/1:22,16:38:99:413,0,585
chr1	17410082	17410082	A	G	RCC2	intronic	NA	NA	NA	0.7051	GnomAdExome_AF_afr	88	39	HomozygousVariant	hom	64	1	63	0.984375	1776.06	PASS	NA	NA	609587	NA	NA	NA	Basal cell carcinoma[18849993;24403052;27539887;25855136];Non-melanoma skin cancer[29739929];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.225	NA	N	S	N	0.64404350350141	E	Rcc2	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; vision/eye phenotype; hematopoietic system phenotype; pigmentation phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	rcc2	pharyngeal arch 1	morphology	abnormal	0.6369	0.7051	0.7035	0.6535	0.6997	0.63778	0.6592	0.627075	0.649425	PASS	0	0.682	68	0.736486	31	chr1	17410082	NA	A	G	1776.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=27.75;AS_ReadPosRankSum=0.9;AS_SOR=0.402;BaseQRankSum=-1.221;DP=69;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=27.75;ReadPosRankSum=0.948;SOR=0.402	GT:AD:DP:GQ:PL	1/1:1,63:64:99:1790,153,0
chr1	17412075	17412075	C	-	RCC2	intronic	NA	NA	NA	0.3839	GnomAdGenome_AF_eas	61	17	HeterozygousVariant	het	42	17	25	0.595238095238095	757.6	PASS	NA	NA	609587	NA	NA	NA	Basal cell carcinoma[18849993;24403052;27539887;25855136];Non-melanoma skin cancer[29739929];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.225	NA	N	S	N	0.64404350350141	E	Rcc2	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; vision/eye phenotype; hematopoietic system phenotype; pigmentation phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	rcc2	pharyngeal arch 1	morphology	abnormal	0.2679	0.3727	0.3691	0.2285	0.3839	0.244808	0.2396	0.0001921	0.264368	PASS	0	0.315	242	0.334507	61	chr1	17412074	NA	AC	A	757.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=2.727;AS_MQ=60;AS_MQRankSum=0;AS_QD=18.05;AS_ReadPosRankSum=0;AS_SOR=1.206;BaseQRankSum=0.771;DP=44;ExcessHet=3.0103;FS=2.727;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=18.04;ReadPosRankSum=0.051;SOR=1.206	GT:AD:DP:GQ:PL	0/1:17,25:42:99:765,0,479
chr1	17413090	17413090	G	A	RCC2	exonic	synonymous SNV	NA	RCC2:NM_001136204:exon9:c.C1296T:p.I432I,RCC2:NM_018715:exon10:c.C1296T:p.I432I	0.4149	GnomAdGenome_AF_fin	55	23	HeterozygousVariant	het	108	72	36	0.333333333333333	706.64	PASS	NA	NA	609587	Benign	NA	NA	Basal cell carcinoma[18849993;24403052;27539887;25855136];Non-melanoma skin cancer[29739929];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.225	NA	N	S	N	0.64404350350141	E	Rcc2	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; vision/eye phenotype; hematopoietic system phenotype; pigmentation phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	rcc2	pharyngeal arch 1	morphology	abnormal	0.3521	0.4027	0.4002	0.3693	0.4149	0.330871	0.3638	0.35171	0.33908	PASS	0.378049	0.35	215	0.373239	60	chr1	17413090	NA	G	A	706.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.55;AS_ReadPosRankSum=0.4;AS_SOR=0.746;BaseQRankSum=0.172;DP=108;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.54;ReadPosRankSum=0.469;SOR=0.746	GT:AD:DP:GQ:PL	0/1:72,36:108:99:714,0,1779
chr1	17587562	17587562	G	A	ARHGEF10L	exonic	nonsynonymous SNV	NA	ARHGEF10L:NM_001011722:exon2:c.G140A:p.S47N,ARHGEF10L:NM_001319837:exon2:c.G140A:p.S47N,ARHGEF10L:NM_018125:exon3:c.G140A:p.S47N	0.0956	GnomAdGenome_AF_ami	3	1	HeterozygousVariant	het	101	51	50	0.495049504950495	1066.64	PASS	12.8	NA	612494	Uncertain significance	NA	NA	Initial pursuit acceleration in psychotic disorders[29064472];Basal cell carcinoma[18849993];Insomnia[27992416];Response to hepatitis C treatment[22095909];Obesity-related traits[23251661];	NA	NA	NA	NA	NA	Detected in heart, liver, skeletal muscle, kidney and pancreas. {ECO:0000269|PubMed:16112081}.;	T	T	B	B	N	N	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	alveolus;smooth muscle;skin;stomach;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;skeletal muscle;islets of Langerhans;fovea centralis;iris;liver;endometrium;bone;brain;trabecular meshwork;lung;macula lutea;colon;placenta;prostate;breast;optic nerve;	cerebellum;	0.569	NA	N	N	N	0.222571241195872	N	Arhgef10l	NA	NA	NA	NA	NA	0.0463	0.0577	0.0573	0.0422	0.0956	0.0295527	0.0458	0.0468105	0.041051	PASS	0.060345	0.049	69	0.077465	20	chr1	17587562	NA	G	A	1066.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.56;AS_ReadPosRankSum=-0.5;AS_SOR=0.656;BaseQRankSum=-1.585;DP=102;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.56;ReadPosRankSum=-0.411;SOR=0.656	GT:AD:DP:GQ:PL	0/1:51,50:101:99:1074,0,1212
chr1	17607852	17607852	C	A	ARHGEF10L	exonic	synonymous SNV	NA	ARHGEF10L:NM_001011722:exon6:c.C484A:p.R162R,ARHGEF10L:NM_001319837:exon6:c.C484A:p.R162R,ARHGEF10L:NM_018125:exon7:c.C484A:p.R162R	0.09	GnomAdGenome_AF_ami	1	2	HomozygousVariant	hom	118	0	118	1	3286.06	PASS	NA	NA	612494	Likely benign	NA	NA	Initial pursuit acceleration in psychotic disorders[29064472];Basal cell carcinoma[18849993];Insomnia[27992416];Response to hepatitis C treatment[22095909];Obesity-related traits[23251661];	NA	NA	NA	NA	NA	Detected in heart, liver, skeletal muscle, kidney and pancreas. {ECO:0000269|PubMed:16112081}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	alveolus;smooth muscle;skin;stomach;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;skeletal muscle;islets of Langerhans;fovea centralis;iris;liver;endometrium;bone;brain;trabecular meshwork;lung;macula lutea;colon;placenta;prostate;breast;optic nerve;	cerebellum;	0.569	NA	N	N	N	0.222571241195872	N	Arhgef10l	NA	NA	NA	NA	NA	0.0152	0.0194	0.0202	0.0132	0.09	0.00898562	0.0149	0.0136544	0.01318	PASS	0.055556	0.024	34	0.035211	6	chr1	17607852	NA	C	A	3286.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.85;AS_ReadPosRankSum=.;AS_SOR=0.836;DP=122;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.85;SOR=0.836	GT:AD:DP:GQ:PL	1/1:0,118:118:99:3300,353,0
chr1	17696870	17696870	C	T	ARHGEF10L	exonic	synonymous SNV	NA	ARHGEF10L:NM_001319838:exon18:c.C2439T:p.N813N,ARHGEF10L:NM_001328124:exon21:c.C2664T:p.N888N,ARHGEF10L:NM_001319837:exon26:c.C3198T:p.N1066N,ARHGEF10L:NM_001011722:exon27:c.C3213T:p.N1071N,ARHGEF10L:NM_018125:exon29:c.C3330T:p.N1110N	0.8923	GnomAdExome_AF_sas	603	116	HomozygousVariant	hom	62	0	62	1	1708.06	PASS	NA	NA	612494	Benign	NA	NA	Initial pursuit acceleration in psychotic disorders[29064472];Basal cell carcinoma[18849993];Insomnia[27992416];Response to hepatitis C treatment[22095909];Obesity-related traits[23251661];	NA	NA	NA	NA	NA	Detected in heart, liver, skeletal muscle, kidney and pancreas. {ECO:0000269|PubMed:16112081}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	alveolus;smooth muscle;skin;stomach;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;skeletal muscle;islets of Langerhans;fovea centralis;iris;liver;endometrium;bone;brain;trabecular meshwork;lung;macula lutea;colon;placenta;prostate;breast;optic nerve;	cerebellum;	0.569	NA	N	N	N	0.222571241195872	N	Arhgef10l	NA	NA	NA	NA	NA	0.8221	0.8923	0.8934	0.7709	0.8871	0.784744	0.7648	0.806432	0.817734	PASS	0.87931	0.889	124	0.906475	20	chr1	17696870	NA	C	T	1708.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.55;AS_ReadPosRankSum=.;AS_SOR=1.057;DP=66;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.55;SOR=1.057	GT:AD:DP:GQ:PL	1/1:0,62:62:99:1722,184,0
chr1	17697014	17697014	T	C	ARHGEF10L	exonic	synonymous SNV	NA	ARHGEF10L:NM_001319838:exon18:c.T2583C:p.D861D,ARHGEF10L:NM_001328124:exon21:c.T2808C:p.D936D,ARHGEF10L:NM_001319837:exon26:c.T3342C:p.D1114D,ARHGEF10L:NM_001011722:exon27:c.T3357C:p.D1119D,ARHGEF10L:NM_018125:exon29:c.T3474C:p.D1158D	0.9055	GnomAdGenome_AF_eas	613	120	HomozygousVariant	hom	98	0	98	1	2941.06	PASS	NA	NA	612494	Benign	NA	NA	Initial pursuit acceleration in psychotic disorders[29064472];Basal cell carcinoma[18849993];Insomnia[27992416];Response to hepatitis C treatment[22095909];Obesity-related traits[23251661];	NA	NA	NA	NA	NA	Detected in heart, liver, skeletal muscle, kidney and pancreas. {ECO:0000269|PubMed:16112081}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	alveolus;smooth muscle;skin;stomach;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;skeletal muscle;islets of Langerhans;fovea centralis;iris;liver;endometrium;bone;brain;trabecular meshwork;lung;macula lutea;colon;placenta;prostate;breast;optic nerve;	cerebellum;	0.569	NA	N	N	N	0.222571241195872	N	Arhgef10l	NA	NA	NA	NA	NA	0.839	0.8968	0.8956	0.8099	0.9055	0.834665	0.8062	0.794828	0.849754	PASS	0.905325	0.894	128	0.915493	20	chr1	17697014	NA	T	C	2941.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.01;AS_ReadPosRankSum=.;AS_SOR=0.866;DP=101;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.01;SOR=0.866	GT:AD:DP:GQ:PL	1/1:0,98:98:99:2955,294,0
chr1	17697195	17697195	A	G	ARHGEF10L	exonic	nonsynonymous SNV	NA	ARHGEF10L:NM_001319838:exon18:c.A2764G:p.I922V,ARHGEF10L:NM_001328124:exon21:c.A2989G:p.I997V,ARHGEF10L:NM_001319837:exon26:c.A3523G:p.I1175V,ARHGEF10L:NM_001011722:exon27:c.A3538G:p.I1180V,ARHGEF10L:NM_018125:exon29:c.A3655G:p.I1219V	0.9048	GnomAdGenome_AF_eas	619	119	HomozygousVariant	hom	95	0	95	1	2731.06	PASS	12.57	NA	612494	Benign	NA	NA	Initial pursuit acceleration in psychotic disorders[29064472];Basal cell carcinoma[18849993];Insomnia[27992416];Response to hepatitis C treatment[22095909];Obesity-related traits[23251661];	NA	NA	NA	NA	NA	Detected in heart, liver, skeletal muscle, kidney and pancreas. {ECO:0000269|PubMed:16112081}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	alveolus;smooth muscle;skin;stomach;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;skeletal muscle;islets of Langerhans;fovea centralis;iris;liver;endometrium;bone;brain;trabecular meshwork;lung;macula lutea;colon;placenta;prostate;breast;optic nerve;	cerebellum;	0.569	NA	N	N	N	0.222571241195872	N	Arhgef10l	NA	NA	NA	NA	NA	0.839	0.8964	0.8975	0.798	0.9048	0.822684	0.7951	0.0001537	0.838259	PASS	0.903509	0.898	128	0.914894	20	chr1	17697195	NA	A	G	2731.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.75;AS_ReadPosRankSum=.;AS_SOR=0.848;DP=98;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.75;SOR=0.848	GT:AD:DP:GQ:PL	1/1:0,95:95:99:2745,284,0
chr1	18481042	18481042	G	T	KLHDC7A	exonic	nonsynonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.G61T:p.V21L	0.1922	GnomAdGenome_AF_asj	8	1	HeterozygousVariant	het	53	22	31	0.584905660377358	658.64	PASS	15.3	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;	D	N	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.1124	0.1548	0.1514	0.1173	0.1922	0.0944489	0.1139	0.10853	0.130542	PASS	0.13587	0.074	71	0.066901	17	chr1	18481042	NA	G	T	658.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.43;AS_ReadPosRankSum=-0.8;AS_SOR=0.841;BaseQRankSum=-1.176;DP=56;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.43;ReadPosRankSum=-0.777;SOR=0.841	GT:AD:DP:GQ:PL	0/1:22,31:53:99:666,0,490
chr1	18481126	18481126	G	C	KLHDC7A	exonic	nonsynonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.G145C:p.G49R	0.1918	GnomAdGenome_AF_asj	7	1	HeterozygousVariant	het	80	44	36	0.45	895.64	PASS	23.2	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	D	D	D	D	NA	P	L	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.1123	0.1548	0.151	0.1173	0.1918	0.0944489	0.114	0.106519	0.130542	PASS	0.13587	0.072	70	0.06338	16	chr1	18481126	NA	G	C	895.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=3.7;AS_FS=2.97;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.2;AS_ReadPosRankSum=1.8;AS_SOR=1.061;BaseQRankSum=3.77;DP=82;ExcessHet=3.0103;FS=2.97;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.2;ReadPosRankSum=1.82;SOR=1.061	GT:AD:DP:GQ:PL	0/1:44,36:80:99:903,0,932
chr1	18481261	18481261	G	A	KLHDC7A	exonic	nonsynonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.G280A:p.G94S	0.1916	GnomAdGenome_AF_asj	7	1	HeterozygousVariant	het	120	60	60	0.5	1451.64	PASS	16.91	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.112	0.1545	0.1513	0.1173	0.1916	0.0944489	0.1141	0.106829	0.130542	PASS	0.137228	0.071	68	0.066901	17	chr1	18481261	NA	G	A	1451.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0.686;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.1;AS_ReadPosRankSum=0.6;AS_SOR=0.57;BaseQRankSum=-0.651;DP=122;ExcessHet=3.0103;FS=0.686;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.1;ReadPosRankSum=0.649;SOR=0.57	GT:AD:DP:GQ:PL	0/1:60,60:120:99:1459,0,1478
chr1	18481287	18481287	C	T	KLHDC7A	exonic	synonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.C306T:p.G102G	0.1915	GnomAdGenome_AF_asj	7	1	HeterozygousVariant	het	129	62	67	0.51937984496124	1595.64	PASS	NA	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.1111	0.1548	0.1512	0.112	0.1915	0.0888578	0.1092	0.10311	0.12069	PASS	0.134511	0.071	68	0.066901	17	chr1	18481287	NA	C	T	1595.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=5.388;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.37;AS_ReadPosRankSum=0.9;AS_SOR=0.424;BaseQRankSum=-0.519;DP=136;ExcessHet=3.0103;FS=5.388;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.37;ReadPosRankSum=0.927;SOR=0.424	GT:AD:DP:GQ:PL	0/1:62,67:129:99:1603,0,1467
chr1	18481403	18481403	C	G	KLHDC7A	exonic	nonsynonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.C422G:p.P141R	0.8957	GnomAdExome_AF_eas	160	38	HeterozygousVariant	het	112	49	63	0.5625	1498.64	PASS	1.062	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.6593	0.8957	0.8995	0.6322	0.8859	0.646965	0.6213	0.637333	0.639573	PASS	0.666667	0.502	267	0.492958	64	chr1	18481403	NA	C	G	1498.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=7.334;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.38;AS_ReadPosRankSum=0.1;AS_SOR=1.248;BaseQRankSum=-0.585;DP=112;ExcessHet=3.0103;FS=7.334;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.38;ReadPosRankSum=0.15;SOR=1.248	GT:AD:DP:GQ:PL	0/1:49,63:112:99:1506,0,1145
chr1	18481562	18481562	G	C	KLHDC7A	exonic	nonsynonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.G581C:p.R194P	0.1921	GnomAdGenome_AF_asj	7	1	HeterozygousVariant	het	132	62	70	0.53030303030303	1735.64	PASS	7.435	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.1124	0.1555	0.1518	0.1173	0.1921	0.0944489	0.1152	0.108666	0.130542	PASS	0.13587	0.072	71	0.066901	17	chr1	18481562	NA	G	C	1735.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=2.221;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.15;AS_ReadPosRankSum=1.4;AS_SOR=0.927;BaseQRankSum=-0.274;DP=142;ExcessHet=3.0103;FS=2.221;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.15;ReadPosRankSum=1.44;SOR=0.927	GT:AD:DP:GQ:PL	0/1:62,70:132:99:1743,0,1507
chr1	18481575	18481575	A	G	KLHDC7A	exonic	synonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.A594G:p.G198G	0.1918	GnomAdGenome_AF_asj	7	1	HeterozygousVariant	het	143	64	79	0.552447552447552	1869.64	PASS	NA	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.1124	0.1554	0.1517	0.1174	0.1918	0.0944489	0.1164	0.108686	0.130542	PASS	0.13587	0.073	71	0.066901	17	chr1	18481575	NA	A	G	1869.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=3.01;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.08;AS_ReadPosRankSum=0.2;AS_SOR=1.003;BaseQRankSum=-1.195;DP=148;ExcessHet=3.0103;FS=3.01;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.07;ReadPosRankSum=0.234;SOR=1.003	GT:AD:DP:GQ:PL	0/1:64,79:143:99:1877,0,1564
chr1	18481798	18481798	C	A	KLHDC7A	exonic	nonsynonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.C817A:p.H273N	0.8953	GnomAdExome_AF_eas	159	38	HeterozygousVariant	het	130	67	63	0.484615384615385	1513.64	PASS	14.28	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.6652	0.8953	0.8986	0.6593	0.8858	0.672923	0.641	0.647191	0.665025	PASS	0.684211	0.501	268	0.489437	63	chr1	18481798	NA	C	A	1513.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.2;AS_FS=1.404;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.65;AS_ReadPosRankSum=0.7;AS_SOR=0.846;BaseQRankSum=-3.111;DP=132;ExcessHet=3.0103;FS=1.404;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.64;ReadPosRankSum=0.701;SOR=0.846	GT:AD:DP:GQ:PL	0/1:67,63:130:99:1521,0,1849
chr1	18481971	18481971	T	A	KLHDC7A	exonic	synonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.T990A:p.A330A	0.8951	GnomAdExome_AF_eas	160	37	HeterozygousVariant	het	83	49	34	0.409638554216867	793.64	PASS	NA	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.6657	0.8951	0.899	0.6595	0.8856	0.672724	0.6403	0.0001153	0.665025	PASS	0.684211	0.501	268	0.489437	65	chr1	18481971	NA	T	A	793.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.57;AS_ReadPosRankSum=1;AS_SOR=0.655;BaseQRankSum=0.918;DP=90;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.56;ReadPosRankSum=1.03;SOR=0.655	GT:AD:DP:GQ:PL	0/1:49,34:83:99:801,0,1226
chr1	18482032	18482032	A	C	KLHDC7A	exonic	nonsynonymous SNV	NA	KLHDC7A:NM_152375:exon1:c.A1051C:p.T351P	0.8953	GnomAdExome_AF_eas	159	37	HeterozygousVariant	het	89	43	46	0.51685393258427	1098.64	PASS	0.841	NA	NA	Benign	NA	NA	Pelvic organ prolapse (moderate/severe)[26545240];Diabetic retinopathy[21441570];Urate levels in lean individuals[25811787];Breast cancer[29059683];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	NA	NA	0.813	NA	N	N	N	0.100713392074127	N	Klhdc7a	NA	NA	NA	NA	NA	0.6652	0.8953	0.8993	0.6595	0.8858	0.672724	0.641	0.0215153	0.665846	PASS	0.687135	0.5	268	0.485915	64	chr1	18482032	NA	A	C	1098.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=2.786;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.35;AS_ReadPosRankSum=-1.3;AS_SOR=0.6;BaseQRankSum=1.33;DP=92;ExcessHet=3.0103;FS=2.786;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.34;ReadPosRankSum=-1.248;SOR=0.6	GT:AD:DP:GQ:PL	0/1:43,46:89:99:1106,0,951
chr1	18691911	18691911	G	A	PAX7	exonic	synonymous SNV	NA	PAX7:NM_001135254:exon5:c.G744A:p.E248E,PAX7:NM_002584:exon5:c.G744A:p.E248E,PAX7:NM_013945:exon5:c.G738A:p.E246E	0.2375	GnomAdGenome_AF_eas	14	2	HeterozygousVariant	het	82	37	45	0.548780487804878	1070.64	PASS	NA	[MIM:268220]Rhabdomyosarcoma 2;	167410	Benign	Alveolar rhabdomyosarcoma	Part of a fusion gene in	Body mass index[23669352];Urate levels in lean individuals[25811787];Cleft lip with or without cleft palate[28054174;28054174];Knee osteoarthritis[28916551];Percentage gas trapping[26030696];Response to amphetamines[22952603];Orofacial clefts[22863734;28054174;28054174];Nonsyndromic cleft lip with cleft palate[28232668];	HP:0001428;HP:0006779;HP:0000007	Somatic mutation;Alveolar rhabdomyosarcoma;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.00758	E	N	N	N	0.937954045572612	E	Pax7	growth/size/body region phenotype; endocrine/exocrine gland phenotype; muscle phenotype; craniofacial phenotype; cellular phenotype; skeleton phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; neoplasm; digestive/alimentary phenotype; vision/eye phenotype; immune system phenotype; 	pax7a	xanthophore	morphology	abnormal	0.0868	0.2324	0.2283	0.0521	0.2375	0.101038	0.0405	0.0794104	0.068144	PASS	0.125	0.114	163	0.109155	27	chr1	18691911	NA	G	A	1070.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.06;AS_ReadPosRankSum=-1;AS_SOR=0.718;BaseQRankSum=-1.852;DP=86;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.06;ReadPosRankSum=-0.984;SOR=0.718	GT:AD:DP:GQ:PL	0/1:37,45:82:99:1078,0,937
chr1	18691938	18691938	A	C	PAX7	exonic	synonymous SNV	NA	PAX7:NM_001135254:exon5:c.A771C:p.T257T,PAX7:NM_002584:exon5:c.A771C:p.T257T,PAX7:NM_013945:exon5:c.A765C:p.T255T	0.2418	GnomAdGenome_AF_eas	27	6	HeterozygousVariant	het	65	31	34	0.523076923076923	733.64	PASS	NA	[MIM:268220]Rhabdomyosarcoma 2;	167410	Benign	Alveolar rhabdomyosarcoma	Part of a fusion gene in	Body mass index[23669352];Urate levels in lean individuals[25811787];Cleft lip with or without cleft palate[28054174;28054174];Knee osteoarthritis[28916551];Percentage gas trapping[26030696];Response to amphetamines[22952603];Orofacial clefts[22863734;28054174;28054174];Nonsyndromic cleft lip with cleft palate[28232668];	HP:0001428;HP:0006779;HP:0000007	Somatic mutation;Alveolar rhabdomyosarcoma;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.00758	E	N	N	N	0.937954045572612	E	Pax7	growth/size/body region phenotype; endocrine/exocrine gland phenotype; muscle phenotype; craniofacial phenotype; cellular phenotype; skeleton phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; neoplasm; digestive/alimentary phenotype; vision/eye phenotype; immune system phenotype; 	pax7a	xanthophore	morphology	abnormal	0.0937	0.2354	0.2312	0.0648	0.2418	0.1248	0.0548	0.0867518	0.082923	PASS	0.121212	0.151	198	0.158451	33	chr1	18691938	NA	A	C	733.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.2;AS_FS=2.216;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.29;AS_ReadPosRankSum=-1.1;AS_SOR=0.383;BaseQRankSum=-2.142;DP=67;ExcessHet=3.0103;FS=2.216;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.29;ReadPosRankSum=-1.052;SOR=0.383	GT:AD:DP:GQ:PL	0/1:31,34:65:99:741,0,774
chr1	18700745	18700745	A	G	PAX7	exonic	synonymous SNV	NA	PAX7:NM_001135254:exon6:c.A879G:p.P293P,PAX7:NM_002584:exon6:c.A879G:p.P293P,PAX7:NM_013945:exon6:c.A873G:p.P291P	0.6023	GnomAdGenome_AF_eas	131	30	HeterozygousVariant	het	164	95	69	0.420731707317073	1373.64	PASS	NA	[MIM:268220]Rhabdomyosarcoma 2;	167410	Benign	Alveolar rhabdomyosarcoma	Part of a fusion gene in	Body mass index[23669352];Urate levels in lean individuals[25811787];Cleft lip with or without cleft palate[28054174;28054174];Knee osteoarthritis[28916551];Percentage gas trapping[26030696];Response to amphetamines[22952603];Orofacial clefts[22863734;28054174;28054174];Nonsyndromic cleft lip with cleft palate[28232668];	HP:0001428;HP:0006779;HP:0000007	Somatic mutation;Alveolar rhabdomyosarcoma;Autosomal recessive inheritance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.00758	E	N	N	N	0.937954045572612	E	Pax7	growth/size/body region phenotype; endocrine/exocrine gland phenotype; muscle phenotype; craniofacial phenotype; cellular phenotype; skeleton phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; neoplasm; digestive/alimentary phenotype; vision/eye phenotype; immune system phenotype; 	pax7a	xanthophore	morphology	abnormal	0.3619	0.5905	0.5919	0.3864	0.6023	0.488618	0.3721	0.354135	0.387521	PASS	0.415205	0.384	380	0.461268	71	chr1	18700745	NA	A	G	1373.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=1.235;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.38;AS_ReadPosRankSum=-0.7;AS_SOR=0.81;BaseQRankSum=0.212;DP=165;ExcessHet=3.0103;FS=1.235;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.38;ReadPosRankSum=-0.69;SOR=0.81	GT:AD:DP:GQ:PL	0/1:95,69:164:99:1381,0,2062
chr1	18849352	18849352	T	C	TAS1R2	exonic	nonsynonymous SNV	NA	TAS1R2:NM_152232:exon4:c.A1456G:p.I486V	0.2671	GnomAdGenome_AF_fin	5	2	HeterozygousVariant	het	67	35	32	0.477611940298507	851.64	PASS	0.695	NA	606226	Benign	NA	NA	'Parkinson''s disease[20070850];Knee osteoarthritis[28916551];Anorexia nervosa[23568457];'	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0823	N	N	N	N	0.705616796201017	E	Tas1r2	taste/olfaction phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.1791	0.2101	0.2121	0.1896	0.2671	0.125998	0.1863	0.174855	0.168309	PASS	0.25	0.088	121	0.102113	25	chr1	18849352	NA	T	C	851.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.8;AS_FS=0.985;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.72;AS_ReadPosRankSum=-2;AS_SOR=0.963;BaseQRankSum=1.89;DP=68;ExcessHet=3.0103;FS=0.985;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.71;ReadPosRankSum=-1.953;SOR=0.963	GT:AD:DP:GQ:PL	0/1:35,32:67:99:859,0,811
chr1	18859635	18859635	G	C	TAS1R2	exonic	nonsynonymous SNV	NA	TAS1R2:NM_152232:exon1:c.C26G:p.S9C	0.8711	GnomAdGenome_AF_ami	524	84	HomozygousVariant	hom	109	0	109	1	3206.06	PASS	0.582	NA	606226	NA	NA	NA	'Parkinson''s disease[20070850];Knee osteoarthritis[28916551];Anorexia nervosa[23568457];'	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	N	D	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0823	N	N	N	N	0.705616796201017	E	Tas1r2	taste/olfaction phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.7819	0.8304	0.831	0.7872	0.8711	0.797923	0.7926	0.774861	0.80624	PASS	0.833333	0.784	261	0.764085	49	chr1	18859635	NA	G	C	3206.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.41;AS_ReadPosRankSum=.;AS_SOR=0.827;DP=110;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.41;SOR=0.827	GT:AD:DP:GQ:PL	1/1:0,109:109:99:3220,327,0
chr1	18872993	18872993	A	G	ALDH4A1	intronic	NA	NA	NA	0.3664	GnomAdGenome_AF_ami	4	1	HeterozygousVariant	het	24	10	14	0.583333333333333	381.64	PASS	NA	NA	606811	NA	Hyperprolinemia type 2	Disease-causing germline mutation(s) in	'Anorexia nervosa[23568457];Alzheimer''s disease (survival time)[25649651];'	HP:0008358;HP:0003137;HP:0003108;HP:0003080;HP:0000007;HP:0001249;HP:0001250	Hyperprolinemia;Prolinuria;Hyperglycinuria;Hydroxyprolinuria;Autosomal recessive inheritance;Intellectual disability;Seizure	NA	NA	NA	Highest expression is found in liver followed by skeletal muscle, kidney, heart, brain, placenta, lung and pancreas.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;retina;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;bone;parathyroid;brain;heart;duodenum;lung;ovary;thyroid;macula lutea;bladder;colon;placenta;prostate;optic nerve;	ciliary ganglion;kidney;amygdala;liver;prefrontal cortex;dorsal root ganglion;whole brain;superior cervical ganglion;trigeminal ganglion;fetal liver;prostate;globus pallidus;	0.915	NA	N	N	N	0.938659699961253	E	Aldh4a1	NA	NA	NA	NA	NA	0.1962	0.252	0.2537	0.19	0.3664	0.114816	0.1984	0.19437	0.213465	PASS	0	0.096	108	0.098592	26	chr1	18872993	NA	A	G	381.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.92;AS_ReadPosRankSum=0.4;AS_SOR=0.693;BaseQRankSum=0.675;DP=26;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.9;ReadPosRankSum=0.411;SOR=0.693	GT:AD:DP:GQ:PL	0/1:10,14:24:99:389,0,258
chr1	18875462	18875462	A	G	ALDH4A1	exonic	synonymous SNV	NA	ALDH4A1:NM_001319218:exon12:c.T1227C:p.D409D,ALDH4A1:NM_001161504:exon13:c.T1200C:p.D400D,ALDH4A1:NM_003748:exon13:c.T1380C:p.D460D,ALDH4A1:NM_170726:exon13:c.T1380C:p.D460D	0.8178	GnomAdExome_AF_amr	497	93	HomozygousVariant	hom	88	0	88	1	2408.06	PASS	NA	NA	606811	Benign	Hyperprolinemia type 2	Disease-causing germline mutation(s) in	'Anorexia nervosa[23568457];Alzheimer''s disease (survival time)[25649651];'	HP:0008358;HP:0003137;HP:0003108;HP:0003080;HP:0000007;HP:0001249;HP:0001250	Hyperprolinemia;Prolinuria;Hyperglycinuria;Hydroxyprolinuria;Autosomal recessive inheritance;Intellectual disability;Seizure	Deficiency_of_pyrroline-5-carboxylate_reductase	criteria_provided,_single_submitter	Benign	Highest expression is found in liver followed by skeletal muscle, kidney, heart, brain, placenta, lung and pancreas.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;retina;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;bone;parathyroid;brain;heart;duodenum;lung;ovary;thyroid;macula lutea;bladder;colon;placenta;prostate;optic nerve;	ciliary ganglion;kidney;amygdala;liver;prefrontal cortex;dorsal root ganglion;whole brain;superior cervical ganglion;trigeminal ganglion;fetal liver;prostate;globus pallidus;	0.915	NA	N	N	N	0.938659699961253	E	Aldh4a1	NA	NA	NA	NA	NA	0.7321	0.8178	0.8197	0.7125	0.7933	0.73722	0.7022	0.722798	0.738095	PASS	0.731707	0.767	287	0.802817	42	chr1	18875462	NA	A	G	2408.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.36;AS_ReadPosRankSum=.;AS_SOR=0.739;DP=94;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.36;SOR=0.739	GT:AD:DP:GQ:PL	1/1:0,88:88:99:2422,263,0
chr1	18876402	18876402	G	A	ALDH4A1	exonic	synonymous SNV	NA	ALDH4A1:NM_001161504:exon12:c.C1071T:p.A357A,ALDH4A1:NM_003748:exon12:c.C1251T:p.A417A,ALDH4A1:NM_170726:exon12:c.C1251T:p.A417A	0.6932	GnomAdExome_AF_amr	166	31	HomozygousVariant	hom	87	0	87	1	2304.06	PASS	NA	NA	606811	Benign	Hyperprolinemia type 2	Disease-causing germline mutation(s) in	'Anorexia nervosa[23568457];Alzheimer''s disease (survival time)[25649651];'	HP:0008358;HP:0003137;HP:0003108;HP:0003080;HP:0000007;HP:0001249;HP:0001250	Hyperprolinemia;Prolinuria;Hyperglycinuria;Hydroxyprolinuria;Autosomal recessive inheritance;Intellectual disability;Seizure	Deficiency_of_pyrroline-5-carboxylate_reductase	criteria_provided,_single_submitter	Benign	Highest expression is found in liver followed by skeletal muscle, kidney, heart, brain, placenta, lung and pancreas.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;retina;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;bone;parathyroid;brain;heart;duodenum;lung;ovary;thyroid;macula lutea;bladder;colon;placenta;prostate;optic nerve;	ciliary ganglion;kidney;amygdala;liver;prefrontal cortex;dorsal root ganglion;whole brain;superior cervical ganglion;trigeminal ganglion;fetal liver;prostate;globus pallidus;	0.915	NA	N	N	N	0.938659699961253	E	Aldh4a1	NA	NA	NA	NA	NA	0.5117	0.6932	0.698	0.4735	0.611	0.515974	0.4547	0.490201	0.491776	PASS	0.6	0.444	409	0.492958	78	chr1	18876402	NA	G	A	2304.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.48;AS_ReadPosRankSum=.;AS_SOR=0.863;DP=88;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.48;SOR=0.863	GT:AD:DP:GQ:PL	1/1:0,87:87:99:2318,260,0
chr1	18876423	18876423	T	C	ALDH4A1	exonic	synonymous SNV	NA	ALDH4A1:NM_001161504:exon12:c.A1050G:p.S350S,ALDH4A1:NM_003748:exon12:c.A1230G:p.S410S,ALDH4A1:NM_170726:exon12:c.A1230G:p.S410S	0.7945	GnomAdExome_AF_amr	475	88	HomozygousVariant	hom	74	0	74	1	3028.06	PASS	NA	NA	606811	Benign	Hyperprolinemia type 2	Disease-causing germline mutation(s) in	'Anorexia nervosa[23568457];Alzheimer''s disease (survival time)[25649651];'	HP:0008358;HP:0003137;HP:0003108;HP:0003080;HP:0000007;HP:0001249;HP:0001250	Hyperprolinemia;Prolinuria;Hyperglycinuria;Hydroxyprolinuria;Autosomal recessive inheritance;Intellectual disability;Seizure	Deficiency_of_pyrroline-5-carboxylate_reductase	criteria_provided,_single_submitter	Benign	Highest expression is found in liver followed by skeletal muscle, kidney, heart, brain, placenta, lung and pancreas.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;retina;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;bone;parathyroid;brain;heart;duodenum;lung;ovary;thyroid;macula lutea;bladder;colon;placenta;prostate;optic nerve;	ciliary ganglion;kidney;amygdala;liver;prefrontal cortex;dorsal root ganglion;whole brain;superior cervical ganglion;trigeminal ganglion;fetal liver;prostate;globus pallidus;	0.915	NA	N	N	N	0.938659699961253	E	Aldh4a1	NA	NA	NA	NA	NA	0.6986	0.7945	0.7971	0.6371	0.7899	0.660942	0.623	0.0242431	0.665557	PASS	0.709877	0.748	299	0.774648	44	chr1	18876423	NA	T	C	3028.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=31.92;AS_ReadPosRankSum=.;AS_SOR=1.061;DP=76;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.69;SOR=1.061	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,74:74:99:1|1:18876423_T_C:3042,223,0:18876423
chr1	18876432	18876432	T	C	ALDH4A1	exonic	synonymous SNV	NA	ALDH4A1:NM_001161504:exon12:c.A1041G:p.A347A,ALDH4A1:NM_003748:exon12:c.A1221G:p.A407A,ALDH4A1:NM_170726:exon12:c.A1221G:p.A407A	0.7939	GnomAdExome_AF_amr	474	88	HomozygousVariant	hom	61	0	61	1	2666.06	PASS	NA	NA	606811	Benign	Hyperprolinemia type 2	Disease-causing germline mutation(s) in	'Anorexia nervosa[23568457];Alzheimer''s disease (survival time)[25649651];'	HP:0008358;HP:0003137;HP:0003108;HP:0003080;HP:0000007;HP:0001249;HP:0001250	Hyperprolinemia;Prolinuria;Hyperglycinuria;Hydroxyprolinuria;Autosomal recessive inheritance;Intellectual disability;Seizure	Deficiency_of_pyrroline-5-carboxylate_reductase	criteria_provided,_single_submitter	Benign	Highest expression is found in liver followed by skeletal muscle, kidney, heart, brain, placenta, lung and pancreas.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;retina;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;bone;parathyroid;brain;heart;duodenum;lung;ovary;thyroid;macula lutea;bladder;colon;placenta;prostate;optic nerve;	ciliary ganglion;kidney;amygdala;liver;prefrontal cortex;dorsal root ganglion;whole brain;superior cervical ganglion;trigeminal ganglion;fetal liver;prostate;globus pallidus;	0.915	NA	N	N	N	0.938659699961253	E	Aldh4a1	NA	NA	NA	NA	NA	0.6978	0.7939	0.7964	0.6365	0.7904	0.660144	0.6213	0.02359	0.661046	PASS	0.709375	0.748	301	0.774648	44	chr1	18876432	NA	T	C	2666.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.12;AS_ReadPosRankSum=.;AS_SOR=1.197;DP=62;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.16;SOR=1.197	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,61:61:99:1|1:18876423_T_C:2680,184,0:18876423
chr1	18877503	18877503	C	G	ALDH4A1	exonic	synonymous SNV	NA	ALDH4A1:NM_001161504:exon10:c.G870C:p.A290A,ALDH4A1:NM_001319218:exon10:c.G1050C:p.A350A,ALDH4A1:NM_003748:exon10:c.G1050C:p.A350A,ALDH4A1:NM_170726:exon10:c.G1050C:p.A350A	0.8083	GnomAdGenome_AF_fin	257	40	HomozygousVariant	hom	114	0	114	1	3326.06	PASS	NA	NA	606811	Benign	Hyperprolinemia type 2	Disease-causing germline mutation(s) in	'Anorexia nervosa[23568457];Alzheimer''s disease (survival time)[25649651];'	HP:0008358;HP:0003137;HP:0003108;HP:0003080;HP:0000007;HP:0001249;HP:0001250	Hyperprolinemia;Prolinuria;Hyperglycinuria;Hydroxyprolinuria;Autosomal recessive inheritance;Intellectual disability;Seizure	Deficiency_of_pyrroline-5-carboxylate_reductase	criteria_provided,_single_submitter	Benign	Highest expression is found in liver followed by skeletal muscle, kidney, heart, brain, placenta, lung and pancreas.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;retina;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;bone;parathyroid;brain;heart;duodenum;lung;ovary;thyroid;macula lutea;bladder;colon;placenta;prostate;optic nerve;	ciliary ganglion;kidney;amygdala;liver;prefrontal cortex;dorsal root ganglion;whole brain;superior cervical ganglion;trigeminal ganglion;fetal liver;prostate;globus pallidus;	0.915	NA	N	N	N	0.938659699961253	E	Aldh4a1	NA	NA	NA	NA	NA	0.6895	0.7459	0.7508	0.7151	0.8083	0.641573	0.7115	0.0249731	0.713465	PASS	0.69898	0.544	394	0.528169	70	chr1	18877503	NA	C	G	3326.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.18;AS_ReadPosRankSum=.;AS_SOR=0.841;DP=117;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.18;SOR=0.841	GT:AD:DP:GQ:PL	1/1:0,114:114:99:3340,342,0
chr1	18889340	18889340	T	C	ALDH4A1	intronic	NA	NA	NA	0.9999	GnomAdExome_AF_eas	809	139	HomozygousVariant	hom	61	0	61	1	1712.06	PASS	NA	NA	606811	NA	Hyperprolinemia type 2	Disease-causing germline mutation(s) in	'Anorexia nervosa[23568457];Alzheimer''s disease (survival time)[25649651];'	HP:0008358;HP:0003137;HP:0003108;HP:0003080;HP:0000007;HP:0001249;HP:0001250	Hyperprolinemia;Prolinuria;Hyperglycinuria;Hydroxyprolinuria;Autosomal recessive inheritance;Intellectual disability;Seizure	NA	NA	NA	Highest expression is found in liver followed by skeletal muscle, kidney, heart, brain, placenta, lung and pancreas.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;skin;stomach;testis;lens;unclassifiable (Anatomical System);cerebellum;choroid;kidney;uterus;retina;skeletal muscle;visual apparatus;cervix;fovea centralis;spleen;liver;endometrium;bone;parathyroid;brain;heart;duodenum;lung;ovary;thyroid;macula lutea;bladder;colon;placenta;prostate;optic nerve;	ciliary ganglion;kidney;amygdala;liver;prefrontal cortex;dorsal root ganglion;whole brain;superior cervical ganglion;trigeminal ganglion;fetal liver;prostate;globus pallidus;	0.915	NA	N	N	N	0.938659699961253	E	Aldh4a1	NA	NA	NA	NA	NA	0.9677	0.9999	1	0.9687	0.9997	0.984425	0.9723	0.50262	0.959167	PASS	0	0.99	16	0.989437	3	chr1	18889340	NA	T	C	1712.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.07;AS_ReadPosRankSum=.;AS_SOR=1.107;DP=63;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.07;SOR=1.107	GT:AD:DP:GQ:PL	1/1:0,61:61:99:1726,183,0
chr1	18908644	18908644	C	T	IFFO2	exonic	nonsynonymous SNV	NA	IFFO2:NM_001136265:exon9:c.G1471A:p.V491M	0.0497	GnomAdGenome_AF_sas	1	1	HomozygousVariant	hom	57	0	57	1	1640.06	PASS	21	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	T	B	B	N	N	N	D	N	T	T	T	NA	T	T	T	T	T	.;.;	D	N	.;.	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;adrenal medulla;uterus;whole body;retina;head and neck;mammary gland;fovea centralis;spleen;liver;endometrium;bone;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;oesophagus;frontal lobe;colon;placenta;prostate;optic nerve;	ciliary ganglion;trigeminal ganglion;skin;atrioventricular node;cerebellum peduncles;globus pallidus;cerebellum;	NA	NA	N	N	N	0.354034803354116	N	Iffo2	NA	NA	NA	NA	NA	0.0127	0.0418	0.043	0.0048	0.0497	0.0191693	0.0031	0.0039003	0.003284	PASS	0.029412	0.043	48	0.03169	7	chr1	18908644	NA	C	T	1640.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.77;AS_ReadPosRankSum=.;AS_SOR=0.8;DP=57;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.77;SOR=0.8	GT:AD:DP:GQ:PL	1/1:0,57:57:99:1654,170,0
chr1	18910350	18910350	G	A	IFFO2	exonic	synonymous SNV	NA	IFFO2:NM_001136265:exon8:c.C1440T:p.S480S	0.03	GnomAdGenome_AF_sas	1	1	HeterozygousVariant	het	64	27	37	0.578125	796.64	PASS	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;adrenal medulla;uterus;whole body;retina;head and neck;mammary gland;fovea centralis;spleen;liver;endometrium;bone;parathyroid;brain;blood;heart;bone marrow;lung;ovary;thyroid;macula lutea;oesophagus;frontal lobe;colon;placenta;prostate;optic nerve;	ciliary ganglion;trigeminal ganglion;skin;atrioventricular node;cerebellum peduncles;globus pallidus;cerebellum;	NA	NA	N	N	N	0.354034803354116	N	Iffo2	NA	NA	NA	NA	NA	0.0063	0.0254	0.0254	0.0032	0.03	0.0091853	0.0031	0.0055562	0.003284	PASS	0	0.024	22	0.021127	4	chr1	18910350	NA	G	A	796.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=2.151;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.45;AS_ReadPosRankSum=0.7;AS_SOR=0.411;BaseQRankSum=-0.983;DP=66;ExcessHet=3.0103;FS=2.151;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.45;ReadPosRankSum=0.728;SOR=0.411	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:27,37:64:99:0|1:18910335_C_T:804,0,554:18910335
chr1	19081800	19081800	-	C	UBR4	intronic	NA	NA	NA	0.4933	GnomAdExome_AF_amr	93	20	HeterozygousVariant	het	86	49	37	0.430232558139535	939.6	PASS	NA	NA	609890	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.3935	0.4933	0.4969	0.379	0.4237	0.369409	0	0.0002305	0.378489	VQSRTrancheINDEL99.00to99.90	0	0.333	348	0.323944	52	chr1	19081800	NA	G	GC	939.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=0.872;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.93;AS_ReadPosRankSum=1.8;AS_SOR=0.818;BaseQRankSum=0.345;DP=99;ExcessHet=3.0103;FS=0.872;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.93;ReadPosRankSum=1.81;SOR=0.818	GT:AD:DP:GQ:PL	0/1:49,37:86:99:947,0,1342
chr1	19084635	19084635	A	G	UBR4	exonic	synonymous SNV	NA	UBR4:NM_020765:exon102:c.T14877C:p.H4959H	0.813	GnomAdExome_AF_eas	242	57	HeterozygousVariant	het	85	43	42	0.494117647058824	971.64	PASS	NA	NA	609890	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.6468	0.813	0.8124	0.6741	0.8073	0.71885	0.6715	0.639791	0.671593	PASS	0.626263	0.541	394	0.598592	56	chr1	19084635	NA	A	G	971.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.44;AS_ReadPosRankSum=0.4;AS_SOR=0.653;BaseQRankSum=-0.055;DP=90;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.43;ReadPosRankSum=0.449;SOR=0.653	GT:AD:DP:GQ:PL	0/1:43,42:85:99:979,0,1021
chr1	19086767	19086767	T	A	UBR4	exonic	nonsynonymous SNV	NA	UBR4:NM_020765:exon100:c.A14599T:p.M4867L	0.7627	GnomAdExome_AF_eas	177	37	HeterozygousVariant	het	110	56	54	0.490909090909091	1101.64	PASS	22.5	NA	609890	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	D	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.5902	0.7627	0.7638	0.5699	0.7601	0.601438	0.5599	0.579184	0.571429	PASS	0.508621	0.465	397	0.478873	62	chr1	19086767	NA	T	A	1101.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=0.716;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.02;AS_ReadPosRankSum=0.1;AS_SOR=0.568;BaseQRankSum=-0.923;DP=115;ExcessHet=3.0103;FS=0.716;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.01;ReadPosRankSum=0.105;SOR=0.568	GT:AD:DP:GQ:PL	0/1:56,54:110:99:1109,0,1231
chr1	19088810	19088810	C	T	UBR4	exonic	synonymous SNV	NA	UBR4:NM_020765:exon98:c.G14379A:p.K4793K	0.7614	GnomAdExome_AF_eas	166	35	HeterozygousVariant	het	107	46	61	0.570093457943925	1321.64	PASS	NA	NA	609890	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.5884	0.7614	0.7625	0.5621	0.7585	0.591853	0.5526	0.57573	0.562397	PASS	0.508621	0.462	355	0.46831	63	chr1	19088810	NA	C	T	1321.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.5;AS_FS=1.572;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.36;AS_ReadPosRankSum=0.9;AS_SOR=0.531;BaseQRankSum=-3.467;DP=111;ExcessHet=3.0103;FS=1.572;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.35;ReadPosRankSum=0.96;SOR=0.531	GT:AD:DP:GQ:PL	0/1:46,61:107:99:1329,0,1154
chr1	19093323	19093323	T	C	UBR4	exonic	nonsynonymous SNV	NA	UBR4:NM_020765:exon96:c.A14101G:p.S4701G	0.0062	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	68	35	33	0.485294117647059	798.64	PASS	22.1	NA	609890	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	D	D	L	T	N	T	T	T	T	T	T	T	T	D	.;.;	D	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0004	0.0032	0.0034	0.0001	0.0062	0.000599042	0	0.0003558	0.000821	PASS	0	0.007398	12	0.003521	1	chr1	19093323	NA	T	C	798.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.9;AS_FS=0.933;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.75;AS_ReadPosRankSum=-0.4;AS_SOR=0.846;BaseQRankSum=1.91;DP=69;ExcessHet=3.0103;FS=0.933;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.74;ReadPosRankSum=-0.325;SOR=0.846	GT:AD:DP:GQ:PL	0/1:35,33:68:99:806,0,782
chr1	19095566	19095566	G	A	UBR4	exonic	synonymous SNV	NA	UBR4:NM_020765:exon93:c.C13605T:p.V4535V	0.0713	GnomAdExome_AF_eas	1	0	HeterozygousVariant	het	70	36	34	0.485714285714286	760.64	PASS	NA	NA	609890	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0151	0.0713	0.0698	0.01	0.0685	0.0261581	0.0058	0.0131434	0.007389	PASS	0.011364	0.041	64	0.035211	10	chr1	19095566	NA	G	A	760.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=0.91;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.87;AS_ReadPosRankSum=1.1;AS_SOR=0.504;BaseQRankSum=0.764;DP=73;ExcessHet=3.0103;FS=0.91;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.87;ReadPosRankSum=1.12;SOR=0.504	GT:AD:DP:GQ:PL	0/1:36,34:70:99:768,0,781
chr1	19099705	19099705	G	A	UBR4	intronic	NA	NA	NA	0.8126	GnomAdExome_AF_eas	127	54	HeterozygousVariant	het	45	18	27	0.6	687.64	PASS	NA	NA	609890	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.6451	0.8126	0.812	0.6694	0.8068	0.714257	0.6664	0.630095	0.667488	PASS	0	0.537	207	0.580986	57	chr1	19099705	NA	G	A	687.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.3;AS_FS=1.311;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.29;AS_ReadPosRankSum=0.8;AS_SOR=1.098;BaseQRankSum=-2.296;DP=52;ExcessHet=3.0103;FS=1.311;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.28;ReadPosRankSum=0.893;SOR=1.098	GT:AD:DP:GQ:PL	0/1:18,27:45:99:695,0,482
chr1	19106955	19106955	A	G	UBR4	exonic	synonymous SNV	NA	UBR4:NM_020765:exon82:c.T12117C:p.V4039V	0.8131	GnomAdExome_AF_eas	215	53	WT/SomaticVariant	het	39	28	11	0.282051282051282	190.64	PASS	NA	NA	609890	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.647	0.8131	0.8124	0.6744	0.8099	0.719249	0.6718	0.63699	0.671593	PASS	0.612245	0.543	348	0.58156	58	chr1	19106955	NA	A	G	190.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=4.9;AS_ReadPosRankSum=-1.4;AS_SOR=0.714;BaseQRankSum=1.75;DP=40;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=4.89;ReadPosRankSum=-1.359;SOR=0.714	GT:AD:DP:GQ:PL	0/1:28,11:39:99:198,0,605
chr1	19121349	19121349	C	G	UBR4	exonic	synonymous SNV	NA	UBR4:NM_020765:exon68:c.G9981C:p.L3327L	0.7623	GnomAdExome_AF_eas	177	34	HeterozygousVariant	het	76	34	42	0.552631578947368	1007.64	PASS	NA	NA	609890	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.5902	0.7623	0.7635	0.5707	0.7604	0.600439	0.5601	0.579294	0.570608	PASS	0.508621	0.464	398	0.46831	65	chr1	19121349	NA	C	G	1007.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.26;AS_ReadPosRankSum=1.8;AS_SOR=0.788;BaseQRankSum=0.157;DP=80;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.26;ReadPosRankSum=1.85;SOR=0.788	GT:AD:DP:GQ:PL	0/1:34,42:76:99:1015,0,768
chr1	19144894	19144894	A	G	UBR4	exonic	synonymous SNV	NA	UBR4:NM_020765:exon54:c.T7959C:p.I2653I	0.2622	GnomAdExome_AF_afr	1	0	WT/SomaticVariant	het	25	19	6	0.24	88.64	PASS	NA	NA	609890	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0369	0.2622	0.2636	0.0846	0.2584	0.10623	0.0892	0.0376515	0.069787	PASS	0.075758	0.047	75	0.045775	13	chr1	19144894	NA	A	G	88.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=2.006;AS_MQ=60;AS_MQRankSum=0;AS_QD=3.56;AS_ReadPosRankSum=0.5;AS_SOR=0.223;BaseQRankSum=-0.379;DP=25;ExcessHet=3.0103;FS=2.006;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=3.55;ReadPosRankSum=0.574;SOR=0.223	GT:AD:DP:GQ:PL	0/1:19,6:25:96:96,0,500
chr1	19161162	19161162	T	C	UBR4	intronic	NA	NA	NA	0.8043	GnomAdExome_AF_eas	117	42	HeterozygousVariant	het	35	22	13	0.371428571428571	277.64	PASS	NA	NA	609890	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.4911	0.8043	0.8042	0.4772	0.7998	0.5623	0.4636	0.477853	0.471264	PASS	0	0.475	260	0.521127	64	chr1	19161162	NA	T	C	277.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=1.491;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.94;AS_ReadPosRankSum=-1.3;AS_SOR=1.061;BaseQRankSum=0.883;DP=41;ExcessHet=3.0103;FS=1.491;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.93;ReadPosRankSum=-1.264;SOR=1.061	GT:AD:DP:GQ:PL	0/1:22,13:35:99:285,0,506
chr1	19165363	19165363	T	C	UBR4	intronic	NA	NA	NA	0.8132	GnomAdExome_AF_eas	153	54	HeterozygousVariant	het	53	32	21	0.39622641509434	386.64	PASS	NA	NA	609890	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.6476	0.8132	0.8127	0.6747	0.808	0.718051	0.6718	0.0001153	0.672414	PASS	0	0.541	257	0.588028	59	chr1	19165363	NA	T	C	386.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2;AS_FS=2.416;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.3;AS_ReadPosRankSum=0.9;AS_SOR=0.407;BaseQRankSum=-1.936;DP=56;ExcessHet=3.0103;FS=2.416;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.3;ReadPosRankSum=0.956;SOR=0.407	GT:AD:DP:GQ:PL	0/1:32,21:53:99:394,0,804
chr1	19183900	19183900	A	G	UBR4	intronic	NA	NA	NA	0.8145	GnomAdExome_AF_eas	238	54	HeterozygousVariant	het	31	14	17	0.548387096774194	476.64	PASS	NA	NA	609890	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.004	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.6464	0.8145	0.8148	0.6742	0.8097	0.716853	0.6717	0.639267	0.670772	PASS	0	0.543	391	0.588028	59	chr1	19183900	NA	A	G	476.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.1;AS_FS=3.192;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.39;AS_ReadPosRankSum=2.3;AS_SOR=0.915;BaseQRankSum=1.13;DP=31;ExcessHet=3.0103;FS=3.192;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.38;ReadPosRankSum=2.3;SOR=0.915	GT:AD:DP:GQ:PL	0/1:14,17:31:99:484,0,363
chr1	19192165	19192165	G	A	UBR4	intronic	NA	NA	NA	0.6715	GnomAdExome_AF_eas	77	22	HeterozygousVariant	het	25	17	8	0.32	241.64	PASS	NA	NA	609890	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.297	E	E	E	E	0.911215212696026	E	Ubr4	growth/size/body region phenotype; cellular phenotype; embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.4368	0.6715	0.6753	0.4327	0.669	0.487819	0.4096	0.0001153	0.42775	PASS	0	0.384	245	0.379433	63	chr1	19192165	NA	G	A	241.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=8.541;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.68;AS_ReadPosRankSum=0.6;AS_SOR=2.904;BaseQRankSum=0.852;DP=27;ExcessHet=3.0103;FS=8.541;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.67;ReadPosRankSum=0.67;SOR=2.904	GT:AD:DP:GQ:PL	0/1:17,8:25:99:249,0,512
chr1	19222849	19222849	G	C	EMC1-AS1	ncRNA_intronic	NA	NA	NA	0.6648	GnomAdExome_AF_eas	50	21	HeterozygousVariant	het	80	38	42	0.525	912.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.3047	0.6648	0.6634	0.2422	0.6573	0.333466	0.2191	0.288496	0.262726	PASS	0	0.316	229	0.355072	56	chr1	19222849	NA	G	C	912.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.41;AS_ReadPosRankSum=-0.5;AS_SOR=0.635;BaseQRankSum=-1.58;DP=85;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.41;ReadPosRankSum=-0.429;SOR=0.635	GT:AD:DP:GQ:PL	0/1:38,42:80:99:920,0,909
chr1	19238844	19238844	C	T	EMC1	exonic	nonsynonymous SNV	NA	EMC1:NM_001271429:exon9:c.G974A:p.S325N,EMC1:NM_001271427:exon10:c.G1037A:p.S346N,EMC1:NM_001271428:exon10:c.G1040A:p.S347N,EMC1:NM_015047:exon10:c.G1040A:p.S347N	0.2993	GnomAdExome_AF_afr	15	1	HeterozygousVariant	het	51	26	25	0.490196078431373	956.64	PASS	5.708	[MIM:616875]Cerebellar atrophy, visual impairment, and psychomotor retardation [recessive?];	616846	Benign	Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome	Disease-causing germline mutation(s) in	Brain structure[20171287];	HP:0000750;HP:0001999;HP:0001045;HP:0002059;HP:0007371;HP:0000377;HP:0001265;HP:0000212;HP:0002187;HP:0100275;HP:0008755;HP:0000483;HP:0000278;HP:0000545;HP:0100704;HP:0001263;HP:0000490;HP:0000347;HP:0002650;HP:0001212;HP:0000322;HP:0000649;HP:0002023;HP:0000648;HP:0031954;HP:0000565;HP:0002353;HP:0000294;HP:0000253;HP:0002509;HP:0002079;HP:0000007;HP:0001212;HP:0000648;HP:0002509;HP:0000278;HP:0001332;HP:0000565;HP:0002650;HP:0000212;HP:0000512;HP:0001265;HP:0008755;HP:0025356;HP:0000490;HP:0002059;HP:0000316;HP:0000540;HP:0000649;HP:0000750;HP:0000322;HP:0000483;HP:0008936;HP:0005484;HP:0000294;HP:0001249;HP:0003676;HP:0001263;HP:0001290;HP:0000347;HP:0000188;HP:0001250;HP:0002023;HP:0001272;HP:0100704;HP:0007371;HP:0000545	Delayed speech and language development;Abnormal facial shape;Vitiligo;Cerebral atrophy;Corpus callosum atrophy;Abnormality of the pinna;Hyporeflexia;Gingival overgrowth;Intellectual disability, profound;Diffuse cerebellar atrophy;Laryngotracheomalacia;Astigmatism;Retrognathia;Myopia;Cerebral visual impairment;Global developmental delay;Deeply set eye;Micrognathia;Scoliosis;Prominent fingertip pads;Short philtrum;Abnormality of visual evoked potentials;Anal atresia;Optic atrophy;Dystonic gait;Esotropia;EEG abnormality;Low anterior hairline;Progressive microcephaly;Limb hypertonia;Hypoplasia of the corpus callosum;Autosomal recessive inheritance;Prominent fingertip pads;Optic atrophy;Limb hypertonia;Retrognathia;Dystonia;Esotropia;Scoliosis;Gingival overgrowth;Abnormal electroretinogram;Hyporeflexia;Laryngotracheomalacia;Psychomotor retardation;Deeply set eye;Cerebral atrophy;Hypertelorism;Hypermetropia;Abnormality of visual evoked potentials;Delayed speech and language development;Short philtrum;Astigmatism;Muscular hypotonia of the trunk;Postnatal microcephaly;Low anterior hairline;Intellectual disability;Progressive;Global developmental delay;Generalized hypotonia;Micrognathia;Short upper lip;Seizure;Anal atresia;Cerebellar atrophy;Cerebral visual impairment;Corpus callosum atrophy;Myopia	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	E	E	K	NA	NA	Emc1	NA	NA	NA	NA	NA	0.1362	0.2993	0.2987	0.1804	0.2976	0.170128	0.1919	0.141337	0.149425	PASS	0.140152	0.134	187	0.144366	39	chr1	19238844	NA	C	T	956.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=5.785;AS_MQ=60;AS_MQRankSum=0;AS_QD=18.76;AS_ReadPosRankSum=-1.4;AS_SOR=1.292;BaseQRankSum=-0.232;DP=51;ExcessHet=3.0103;FS=5.785;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=18.76;ReadPosRankSum=-1.395;SOR=1.292	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:26,25:51:99:0|1:19238844_C_T:964,0,1015:19238844
chr1	19238850	19238850	C	G	EMC1	exonic	nonsynonymous SNV	NA	EMC1:NM_001271429:exon9:c.G968C:p.S323T,EMC1:NM_001271427:exon10:c.G1031C:p.S344T,EMC1:NM_001271428:exon10:c.G1034C:p.S345T,EMC1:NM_015047:exon10:c.G1034C:p.S345T	0.7233	GnomAdExome_AF_eas	159	38	HeterozygousVariant	het	51	26	25	0.490196078431373	956.64	PASS	19.64	[MIM:616875]Cerebellar atrophy, visual impairment, and psychomotor retardation [recessive?];	616846	Benign	Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome	Disease-causing germline mutation(s) in	Brain structure[20171287];	HP:0000750;HP:0001999;HP:0001045;HP:0002059;HP:0007371;HP:0000377;HP:0001265;HP:0000212;HP:0002187;HP:0100275;HP:0008755;HP:0000483;HP:0000278;HP:0000545;HP:0100704;HP:0001263;HP:0000490;HP:0000347;HP:0002650;HP:0001212;HP:0000322;HP:0000649;HP:0002023;HP:0000648;HP:0031954;HP:0000565;HP:0002353;HP:0000294;HP:0000253;HP:0002509;HP:0002079;HP:0000007;HP:0001212;HP:0000648;HP:0002509;HP:0000278;HP:0001332;HP:0000565;HP:0002650;HP:0000212;HP:0000512;HP:0001265;HP:0008755;HP:0025356;HP:0000490;HP:0002059;HP:0000316;HP:0000540;HP:0000649;HP:0000750;HP:0000322;HP:0000483;HP:0008936;HP:0005484;HP:0000294;HP:0001249;HP:0003676;HP:0001263;HP:0001290;HP:0000347;HP:0000188;HP:0001250;HP:0002023;HP:0001272;HP:0100704;HP:0007371;HP:0000545	Delayed speech and language development;Abnormal facial shape;Vitiligo;Cerebral atrophy;Corpus callosum atrophy;Abnormality of the pinna;Hyporeflexia;Gingival overgrowth;Intellectual disability, profound;Diffuse cerebellar atrophy;Laryngotracheomalacia;Astigmatism;Retrognathia;Myopia;Cerebral visual impairment;Global developmental delay;Deeply set eye;Micrognathia;Scoliosis;Prominent fingertip pads;Short philtrum;Abnormality of visual evoked potentials;Anal atresia;Optic atrophy;Dystonic gait;Esotropia;EEG abnormality;Low anterior hairline;Progressive microcephaly;Limb hypertonia;Hypoplasia of the corpus callosum;Autosomal recessive inheritance;Prominent fingertip pads;Optic atrophy;Limb hypertonia;Retrognathia;Dystonia;Esotropia;Scoliosis;Gingival overgrowth;Abnormal electroretinogram;Hyporeflexia;Laryngotracheomalacia;Psychomotor retardation;Deeply set eye;Cerebral atrophy;Hypertelorism;Hypermetropia;Abnormality of visual evoked potentials;Delayed speech and language development;Short philtrum;Astigmatism;Muscular hypotonia of the trunk;Postnatal microcephaly;Low anterior hairline;Intellectual disability;Progressive;Global developmental delay;Generalized hypotonia;Micrognathia;Short upper lip;Seizure;Anal atresia;Cerebellar atrophy;Cerebral visual impairment;Corpus callosum atrophy;Myopia	NA	NA	NA	NA	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	E	E	K	NA	NA	Emc1	NA	NA	NA	NA	NA	0.4396	0.7233	0.7208	0.4756	0.7126	0.572284	0.4696	0.433099	0.477833	PASS	0.414141	0.454	417	0.5	66	chr1	19238850	NA	C	G	956.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=5.785;AS_MQ=60;AS_MQRankSum=0;AS_QD=18.76;AS_ReadPosRankSum=-1.3;AS_SOR=1.292;BaseQRankSum=0.282;DP=51;ExcessHet=3.0103;FS=5.785;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=18.76;ReadPosRankSum=-1.292;SOR=1.292	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:26,25:51:99:0|1:19238844_C_T:964,0,1015:19238844
chr1	19239888	19239888	A	G	EMC1	exonic	nonsynonymous SNV	NA	EMC1:NM_001271429:exon7:c.T818C:p.L273S,EMC1:NM_001271427:exon8:c.T884C:p.L295S,EMC1:NM_001271428:exon8:c.T884C:p.L295S,EMC1:NM_015047:exon8:c.T884C:p.L295S	0.071	GnomAdExome_AF_eas	1	0	HeterozygousVariant	het	119	60	59	0.495798319327731	1332.64	PASS	26.4	[MIM:616875]Cerebellar atrophy, visual impairment, and psychomotor retardation [recessive?];	616846	Uncertain significance	Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome	Disease-causing germline mutation(s) in	Brain structure[20171287];	HP:0000750;HP:0001999;HP:0001045;HP:0002059;HP:0007371;HP:0000377;HP:0001265;HP:0000212;HP:0002187;HP:0100275;HP:0008755;HP:0000483;HP:0000278;HP:0000545;HP:0100704;HP:0001263;HP:0000490;HP:0000347;HP:0002650;HP:0001212;HP:0000322;HP:0000649;HP:0002023;HP:0000648;HP:0031954;HP:0000565;HP:0002353;HP:0000294;HP:0000253;HP:0002509;HP:0002079;HP:0000007;HP:0001212;HP:0000648;HP:0002509;HP:0000278;HP:0001332;HP:0000565;HP:0002650;HP:0000212;HP:0000512;HP:0001265;HP:0008755;HP:0025356;HP:0000490;HP:0002059;HP:0000316;HP:0000540;HP:0000649;HP:0000750;HP:0000322;HP:0000483;HP:0008936;HP:0005484;HP:0000294;HP:0001249;HP:0003676;HP:0001263;HP:0001290;HP:0000347;HP:0000188;HP:0001250;HP:0002023;HP:0001272;HP:0100704;HP:0007371;HP:0000545	Delayed speech and language development;Abnormal facial shape;Vitiligo;Cerebral atrophy;Corpus callosum atrophy;Abnormality of the pinna;Hyporeflexia;Gingival overgrowth;Intellectual disability, profound;Diffuse cerebellar atrophy;Laryngotracheomalacia;Astigmatism;Retrognathia;Myopia;Cerebral visual impairment;Global developmental delay;Deeply set eye;Micrognathia;Scoliosis;Prominent fingertip pads;Short philtrum;Abnormality of visual evoked potentials;Anal atresia;Optic atrophy;Dystonic gait;Esotropia;EEG abnormality;Low anterior hairline;Progressive microcephaly;Limb hypertonia;Hypoplasia of the corpus callosum;Autosomal recessive inheritance;Prominent fingertip pads;Optic atrophy;Limb hypertonia;Retrognathia;Dystonia;Esotropia;Scoliosis;Gingival overgrowth;Abnormal electroretinogram;Hyporeflexia;Laryngotracheomalacia;Psychomotor retardation;Deeply set eye;Cerebral atrophy;Hypertelorism;Hypermetropia;Abnormality of visual evoked potentials;Delayed speech and language development;Short philtrum;Astigmatism;Muscular hypotonia of the trunk;Postnatal microcephaly;Low anterior hairline;Intellectual disability;Progressive;Global developmental delay;Generalized hypotonia;Micrognathia;Short upper lip;Seizure;Anal atresia;Cerebellar atrophy;Cerebral visual impairment;Corpus callosum atrophy;Myopia	NA	NA	NA	NA	T	D	D	P	D	D	M	T	N	T	T	T	NA	T	T	T	T	D	.;.;.;	D	D	.;.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	E	E	K	NA	NA	Emc1	NA	NA	NA	NA	NA	0.0136	0.071	0.07	0.0036	0.0689	0.0203674	0.0002	0.0112547	0.002463	PASS	0.011364	0.039	61	0.035211	10	chr1	19239888	NA	A	G	1332.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=0.679;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.2;AS_ReadPosRankSum=-0.1;AS_SOR=0.666;BaseQRankSum=1.37;DP=120;ExcessHet=3.0103;FS=0.679;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.2;ReadPosRankSum=-0.019;SOR=0.666	GT:AD:DP:GQ:PL	0/1:60,59:119:99:1340,0,1280
chr1	19242478	19242478	A	G	EMC1	intronic	NA	NA	NA	0.7231	GnomAdExome_AF_eas	104	39	HeterozygousVariant	het	83	45	38	0.457831325301205	882.64	PASS	NA	[MIM:616875]Cerebellar atrophy, visual impairment, and psychomotor retardation [recessive?];	616846	NA	Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome	Disease-causing germline mutation(s) in	Brain structure[20171287];	HP:0000750;HP:0001999;HP:0001045;HP:0002059;HP:0007371;HP:0000377;HP:0001265;HP:0000212;HP:0002187;HP:0100275;HP:0008755;HP:0000483;HP:0000278;HP:0000545;HP:0100704;HP:0001263;HP:0000490;HP:0000347;HP:0002650;HP:0001212;HP:0000322;HP:0000649;HP:0002023;HP:0000648;HP:0031954;HP:0000565;HP:0002353;HP:0000294;HP:0000253;HP:0002509;HP:0002079;HP:0000007;HP:0001212;HP:0000648;HP:0002509;HP:0000278;HP:0001332;HP:0000565;HP:0002650;HP:0000212;HP:0000512;HP:0001265;HP:0008755;HP:0025356;HP:0000490;HP:0002059;HP:0000316;HP:0000540;HP:0000649;HP:0000750;HP:0000322;HP:0000483;HP:0008936;HP:0005484;HP:0000294;HP:0001249;HP:0003676;HP:0001263;HP:0001290;HP:0000347;HP:0000188;HP:0001250;HP:0002023;HP:0001272;HP:0100704;HP:0007371;HP:0000545	Delayed speech and language development;Abnormal facial shape;Vitiligo;Cerebral atrophy;Corpus callosum atrophy;Abnormality of the pinna;Hyporeflexia;Gingival overgrowth;Intellectual disability, profound;Diffuse cerebellar atrophy;Laryngotracheomalacia;Astigmatism;Retrognathia;Myopia;Cerebral visual impairment;Global developmental delay;Deeply set eye;Micrognathia;Scoliosis;Prominent fingertip pads;Short philtrum;Abnormality of visual evoked potentials;Anal atresia;Optic atrophy;Dystonic gait;Esotropia;EEG abnormality;Low anterior hairline;Progressive microcephaly;Limb hypertonia;Hypoplasia of the corpus callosum;Autosomal recessive inheritance;Prominent fingertip pads;Optic atrophy;Limb hypertonia;Retrognathia;Dystonia;Esotropia;Scoliosis;Gingival overgrowth;Abnormal electroretinogram;Hyporeflexia;Laryngotracheomalacia;Psychomotor retardation;Deeply set eye;Cerebral atrophy;Hypertelorism;Hypermetropia;Abnormality of visual evoked potentials;Delayed speech and language development;Short philtrum;Astigmatism;Muscular hypotonia of the trunk;Postnatal microcephaly;Low anterior hairline;Intellectual disability;Progressive;Global developmental delay;Generalized hypotonia;Micrognathia;Short upper lip;Seizure;Anal atresia;Cerebellar atrophy;Cerebral visual impairment;Corpus callosum atrophy;Myopia	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0101	0.188	Medium	Medium	Medium	NA	NA	NA	NA	E	E	K	NA	NA	Emc1	NA	NA	NA	NA	NA	0.4457	0.7231	0.7218	0.4871	0.7127	0.581869	0.4822	0.442627	0.486864	PASS	0	0.456	267	0.507042	66	chr1	19242478	NA	A	G	882.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=4.165;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.64;AS_ReadPosRankSum=-0.7;AS_SOR=1.148;BaseQRankSum=1.61;DP=84;ExcessHet=3.0103;FS=4.165;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.63;ReadPosRankSum=-0.608;SOR=1.148	GT:AD:DP:GQ:PL	0/1:45,38:83:99:890,0,1012
chr1	19243932	19243932	C	G	EMC1	intronic	NA	NA	NA	0.2022	GnomAdGenome_AF_afr	4	0	HeterozygousVariant	het	53	31	22	0.415094339622642	443.64	PASS	NA	[MIM:616875]Cerebellar atrophy, visual impairment, and psychomotor retardation [recessive?];	616846	NA	Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome	Disease-causing germline mutation(s) in	Brain structure[20171287];	HP:0000750;HP:0001999;HP:0001045;HP:0002059;HP:0007371;HP:0000377;HP:0001265;HP:0000212;HP:0002187;HP:0100275;HP:0008755;HP:0000483;HP:0000278;HP:0000545;HP:0100704;HP:0001263;HP:0000490;HP:0000347;HP:0002650;HP:0001212;HP:0000322;HP:0000649;HP:0002023;HP:0000648;HP:0031954;HP:0000565;HP:0002353;HP:0000294;HP:0000253;HP:0002509;HP:0002079;HP:0000007;HP:0001212;HP:0000648;HP:0002509;HP:0000278;HP:0001332;HP:0000565;HP:0002650;HP:0000212;HP:0000512;HP:0001265;HP:0008755;HP:0025356;HP:0000490;HP:0002059;HP:0000316;HP:0000540;HP:0000649;HP:0000750;HP:0000322;HP:0000483;HP:0008936;HP:0005484;HP:0000294;HP:0001249;HP:0003676;HP:0001263;HP:0001290;HP:0000347;HP:0000188;HP:0001250;HP:0002023;HP:0001272;HP:0100704;HP:0007371;HP:0000545	Delayed speech and language development;Abnormal facial shape;Vitiligo;Cerebral atrophy;Corpus callosum atrophy;Abnormality of the pinna;Hyporeflexia;Gingival overgrowth;Intellectual disability, profound;Diffuse cerebellar atrophy;Laryngotracheomalacia;Astigmatism;Retrognathia;Myopia;Cerebral visual impairment;Global developmental delay;Deeply set eye;Micrognathia;Scoliosis;Prominent fingertip pads;Short philtrum;Abnormality of visual evoked potentials;Anal atresia;Optic atrophy;Dystonic gait;Esotropia;EEG abnormality;Low anterior hairline;Progressive microcephaly;Limb hypertonia;Hypoplasia of the corpus callosum;Autosomal recessive inheritance;Prominent fingertip pads;Optic atrophy;Limb hypertonia;Retrognathia;Dystonia;Esotropia;Scoliosis;Gingival overgrowth;Abnormal electroretinogram;Hyporeflexia;Laryngotracheomalacia;Psychomotor retardation;Deeply set eye;Cerebral atrophy;Hypertelorism;Hypermetropia;Abnormality of visual evoked potentials;Delayed speech and language development;Short philtrum;Astigmatism;Muscular hypotonia of the trunk;Postnatal microcephaly;Low anterior hairline;Intellectual disability;Progressive;Global developmental delay;Generalized hypotonia;Micrognathia;Short upper lip;Seizure;Anal atresia;Cerebellar atrophy;Cerebral visual impairment;Corpus callosum atrophy;Myopia	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	E	E	K	NA	NA	Emc1	NA	NA	NA	NA	NA	0.1049	0.2002	0.1992	0.134	0.2022	0.119609	0.1437	0.106163	0.10509	PASS	0	0.09	69	0.056338	16	chr1	19243932	NA	C	G	443.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.38;AS_ReadPosRankSum=1.4;AS_SOR=0.725;BaseQRankSum=0.116;DP=58;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.37;ReadPosRankSum=1.47;SOR=0.725	GT:AD:DP:GQ:PL	0/1:31,22:53:99:451,0,677
chr1	19257142	19257142	C	T	MRTO4	exonic	synonymous SNV	NA	MRTO4:NM_016183:exon4:c.C270T:p.H90H	0.3258	GnomAdGenome_AF_fin	19	3	HeterozygousVariant	het	43	22	21	0.488372093023256	486.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0598	NA	N	E	E	0.925146329900424	E	Mrto4	NA	NA	NA	NA	NA	0.1654	0.1907	0.187	0.1664	0.3258	0.135982	0.1652	0.164687	0.176519	PASS	0.25	0.162	206	0.158451	39	chr1	19257142	NA	C	T	486.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.33;AS_ReadPosRankSum=0.4;AS_SOR=0.818;BaseQRankSum=-0.566;DP=44;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.32;ReadPosRankSum=0.426;SOR=0.818	GT:AD:DP:GQ:PL	0/1:22,21:43:99:494,0,542
chr1	19257510	19257510	G	A	MRTO4	exonic	synonymous SNV	NA	MRTO4:NM_016183:exon5:c.G330A:p.E110E	0.4704	GnomAdExome_AF_afr	23	5	HeterozygousVariant	het	127	56	71	0.559055118110236	1601.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0598	NA	N	E	E	0.925146329900424	E	Mrto4	NA	NA	NA	NA	NA	0.2194	0.4704	0.4658	0.2943	0.462	0.251398	0.3225	0.228263	0.261905	PASS	0.262626	0.165	204	0.176056	40	chr1	19257510	NA	G	A	1601.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0.658;AS_MQ=60;AS_MQRankSum=1.6;AS_QD=12.61;AS_ReadPosRankSum=0.7;AS_SOR=0.625;BaseQRankSum=-1.058;DP=128;ExcessHet=3.0103;FS=0.658;MLEAC=1;MLEAF=0.5;MQ=59.95;MQRankSum=1.61;QD=12.61;ReadPosRankSum=0.78;SOR=0.625	GT:AD:DP:GQ:PL	0/1:56,71:127:99:1609,0,1223
chr1	19257541	19257541	G	A	MRTO4	intronic	NA	NA	NA	0.3261	GnomAdGenome_AF_fin	11	3	HeterozygousVariant	het	77	45	32	0.415584415584416	697.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0598	NA	N	E	E	0.925146329900424	E	Mrto4	NA	NA	NA	NA	NA	0.1654	0.1908	0.1871	0.1665	0.3261	0.135982	0.1651	0.164364	0.176519	PASS	0	0.153	123	0.158451	39	chr1	19257541	NA	G	A	697.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.06;AS_ReadPosRankSum=-0.1;AS_SOR=0.716;BaseQRankSum=0.838;DP=79;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.06;ReadPosRankSum=-0.098;SOR=0.716	GT:AD:DP:GQ:PL	0/1:45,32:77:99:705,0,1026
chr1	19258713	19258713	G	A	MRTO4	exonic	synonymous SNV	NA	MRTO4:NM_016183:exon8:c.G603A:p.K201K	0.1557	GnomAdGenome_AF_sas	12	2	HeterozygousVariant	het	87	42	45	0.517241379310345	1093.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0598	NA	N	E	E	0.925146329900424	E	Mrto4	NA	NA	NA	NA	NA	0.1269	0.1486	0.1492	0.1239	0.1557	0.109225	0.1302	0.129759	0.101806	PASS	0.143939	0.148	173	0.161972	42	chr1	19258713	NA	G	A	1093.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=4.046;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.57;AS_ReadPosRankSum=-0.3;AS_SOR=0.977;BaseQRankSum=0.767;DP=87;ExcessHet=3.0103;FS=4.046;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.57;ReadPosRankSum=-0.276;SOR=0.977	GT:AD:DP:GQ:PL	0/1:42,45:87:99:1101,0,949
chr1	19268643	19268643	C	T	AKR7L	exonic	unknown	NA	UNKNOWN	0.7876	GnomAdGenome_AF_sas	330	87	HomozygousVariant	hom	133	0	133	1	3610.06	PASS	0.029	NA	608478	Benign	NA	NA	Brain structure[20171287];	NA	NA	NA	NA	NA	Mainly expressed in uterus. {ECO:0000269|PubMed:12879023}.;	NA	NA	NA	NA	N	P	NA	NA	NA	T	T	T	NA	NA	NA	T	T	T	.;	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	0.6922	0.7807	0.7816	0.6151	0.7876	0.665136	0.5883	0.668885	0.655993	PASS	0	0.797	166	0.78169	48	chr1	19268643	NA	C	T	3610.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.87;AS_MQRankSum=.;AS_QD=27.14;AS_ReadPosRankSum=.;AS_SOR=0.708;DP=141;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.88;QD=27.14;SOR=0.708	GT:AD:DP:GQ:PL	1/1:0,133:133:99:3624,398,0
chr1	19269630	19269630	C	T	AKR7L	exonic	unknown	NA	UNKNOWN	0.7884	GnomAdGenome_AF_sas	330	87	HomozygousVariant	hom	76	0	76	1	1996.06	PASS	26.2	NA	608478	Benign	NA	NA	Brain structure[20171287];	NA	NA	NA	NA	NA	Mainly expressed in uterus. {ECO:0000269|PubMed:12879023}.;	NA	NA	NA	NA	D	P	NA	NA	NA	T	T	T	NA	NA	NA	T	T	D	.;	D	D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	0.6919	0.78	0.7811	0.615	0.7884	0.664936	0.594	0.665334	0.64527	PASS	0	0.798	164	0.778169	47	chr1	19269630	NA	C	T	1996.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=58.68;AS_MQRankSum=.;AS_QD=26.26;AS_ReadPosRankSum=.;AS_SOR=0.746;DP=77;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.7;QD=26.26;SOR=0.746	GT:AD:DP:GQ:PL	1/1:0,76:76:99:2010,226,0
chr1	19269662	19269662	G	T	AKR7L	exonic	unknown	NA	UNKNOWN	0.7886	GnomAdGenome_AF_sas	332	87	HomozygousVariant	hom	67	0	67	1	1782.06	PASS	NA	NA	608478	Benign	NA	NA	Brain structure[20171287];	NA	NA	NA	NA	NA	Mainly expressed in uterus. {ECO:0000269|PubMed:12879023}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	NA	NA	NA	NA	NA	NA	0.6918	0.7816	0.7826	0.6155	0.7886	0.665935	0.5946	0.0001153	0.657454	PASS	0	0.8	162	0.78169	48	chr1	19269662	NA	G	T	1782.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.17;AS_MQRankSum=.;AS_QD=26.6;AS_ReadPosRankSum=.;AS_SOR=0.784;DP=69;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.2;QD=26.6;SOR=0.784	GT:AD:DP:GQ:PL	1/1:0,67:67:99:1796,200,0
chr1	19282760	19282760	T	C	AKR7A3	exonic	nonsynonymous SNV	NA	AKR7A3:NM_012067:exon7:c.A967G:p.T323A	0.9	GME_Israel	635	114	HomozygousVariant	hom	116	0	116	1	3395.06	PASS	10.58	NA	608477	Benign	NA	NA	'Late-onset Alzheimer''s disease[27770636];'	NA	NA	NA	NA	NA	Expressed in colon, kidney, liver, pancreas, adenocarcinoma and endometrium. {ECO:0000269|PubMed:12879023, ECO:0000269|PubMed:18416522}.;	T	T	B	B	N	P	NA	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	High	High	Medium	liver;stomach;unclassifiable (Anatomical System);islets of Langerhans;	kidney;liver;pancreas;superior cervical ganglion;skeletal muscle;heart;	0.935	NA	N	NA	N	0.728648592024266	E	Akr7a5	NA	NA	NA	NA	NA	0.8266	0.8698	0.8702	0.8061	0.8734	0.83147	0.7973	0.0004528	0.838259	PASS	0.9	0.868	180	0.894366	26	chr1	19282760	NA	T	C	3395.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=55.54;AS_MQRankSum=.;AS_QD=29.27;AS_ReadPosRankSum=.;AS_SOR=1.29;DP=120;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=55.12;QD=29.27;SOR=1.29	GT:AD:DP:GQ:PL	1/1:0,116:116:99:3409,348,0
chr1	19284733	19284733	G	A	AKR7A3	exonic	synonymous SNV	NA	AKR7A3:NM_012067:exon5:c.C657T:p.P219P	0.35	GME_Israel	53	5	HomozygousVariant	hom	100	0	100	1	2808.06	PASS	NA	NA	608477	Benign	NA	NA	'Late-onset Alzheimer''s disease[27770636];'	NA	NA	NA	NA	NA	Expressed in colon, kidney, liver, pancreas, adenocarcinoma and endometrium. {ECO:0000269|PubMed:12879023, ECO:0000269|PubMed:18416522}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	Medium	liver;stomach;unclassifiable (Anatomical System);islets of Langerhans;	kidney;liver;pancreas;superior cervical ganglion;skeletal muscle;heart;	0.935	NA	N	NA	N	0.728648592024266	E	Akr7a5	NA	NA	NA	NA	NA	0.1633	0.2723	0.2687	0.1566	0.2638	0.146765	0.1659	0.162559	0.174877	PASS	0.35	0.256	275	0.232394	56	chr1	19284733	NA	G	A	2808.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.66;AS_MQRankSum=.;AS_QD=28.08;AS_ReadPosRankSum=.;AS_SOR=0.733;DP=106;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.68;QD=28.08;SOR=0.733	GT:AD:DP:GQ:PL	1/1:0,100:100:99:2822,299,0
chr1	19284747	19284747	T	C	AKR7A3	exonic	nonsynonymous SNV	NA	AKR7A3:NM_012067:exon5:c.A643G:p.N215D	0.9	GME_Israel	571	114	HomozygousVariant	hom	104	0	104	1	3049.06	PASS	7.396	NA	608477	NA	NA	NA	'Late-onset Alzheimer''s disease[27770636];'	NA	NA	NA	NA	NA	Expressed in colon, kidney, liver, pancreas, adenocarcinoma and endometrium. {ECO:0000269|PubMed:12879023, ECO:0000269|PubMed:18416522}.;	T	T	B	B	N	P	NA	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NADP-dependent oxidoreductase domain|NADP-dependent oxidoreductase domain	NA	NA	High	High	Medium	liver;stomach;unclassifiable (Anatomical System);islets of Langerhans;	kidney;liver;pancreas;superior cervical ganglion;skeletal muscle;heart;	0.935	NA	N	NA	N	0.728648592024266	E	Akr7a5	NA	NA	NA	NA	NA	0.8258	0.8719	0.8724	0.7848	0.8767	0.807708	0.7737	0.815293	0.829228	PASS	0.9	0.872	156	0.894366	26	chr1	19284747	NA	T	C	3049.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=59.58;AS_MQRankSum=.;AS_QD=29.32;AS_ReadPosRankSum=.;AS_SOR=0.772;DP=106;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=59.58;QD=29.32;SOR=0.772	GT:AD:DP:GQ:PL	1/1:0,104:104:99:3063,312,0
chr1	19285983	19285983	C	T	AKR7A3	exonic	nonsynonymous SNV	NA	AKR7A3:NM_012067:exon3:c.G412A:p.V138M	0.6812	GnomAdExome_AF_eas	120	20	HeterozygousVariant	het	83	37	46	0.55421686746988	946.64	PASS	21.1	NA	608477	NA	NA	NA	'Late-onset Alzheimer''s disease[27770636];'	NA	NA	NA	NA	NA	Expressed in colon, kidney, liver, pancreas, adenocarcinoma and endometrium. {ECO:0000269|PubMed:12879023, ECO:0000269|PubMed:18416522}.;	T	T	B	B	N	P	NA	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NADP-dependent oxidoreductase domain|NADP-dependent oxidoreductase domain	NA	NA	High	High	Medium	liver;stomach;unclassifiable (Anatomical System);islets of Langerhans;	kidney;liver;pancreas;superior cervical ganglion;skeletal muscle;heart;	0.935	NA	N	NA	N	0.728648592024266	E	Akr7a5	NA	NA	NA	NA	NA	0.4324	0.6812	0.676	0.395	0.6689	0.463259	0.3634	0.414762	0.417763	PASS	0.371212	0.392	415	0.40493	75	chr1	19285983	NA	C	T	946.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=1.801;AS_MQ=59.64;AS_MQRankSum=-0.4;AS_QD=11.41;AS_ReadPosRankSum=-0.9;AS_SOR=0.65;BaseQRankSum=-1.551;DP=88;ExcessHet=3.0103;FS=1.801;MLEAC=1;MLEAF=0.5;MQ=59.33;MQRankSum=-0.354;QD=11.41;ReadPosRankSum=-0.871;SOR=0.65	GT:AD:DP:GQ:PL	0/1:37,46:83:99:954,0,762
chr1	19311815	19311815	A	G	AKR7A2	intronic	NA	NA	NA	0.8316	GnomAdExome_AF_afr	343	55	HomozygousVariant	hom	28	0	28	1	765.06	PASS	NA	NA	603418	NA	NA	NA	Blood protein levels[30072576];	NA	NA	NA	NA	NA	'Detected in brain, liver, small intestine and testis, and at lower levels in heart, prostate, skeletal muscle and spleen. Detected in kidney proximal and distal tubules, endothelial cells lining the Bowman''s capsules and some cysts. Detected at low levels in lung and pancreas (at protein level). Widely expressed. {ECO:0000269|PubMed:10510318, ECO:0000269|PubMed:9576847}.;'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;epididymis;ganglion;skin;stomach;testis;adrenal cortex;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;pancreas;mammary gland;islets of Langerhans;visual apparatus;tonsil;cervix;vein;hippocampus;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;ovary;lymph node;frontal lobe;colon;placenta;aorta;prostate;nasopharynx;optic nerve;hypothalamus;	kidney;liver;superior cervical ganglion;trigeminal ganglion;skeletal muscle;heart;	0.72	NA	N	N	N	0.926485086633281	E	Akr7a5	NA	NA	NA	NA	NA	0.7178	0.8316	0.8315	0.7516	0.8306	0.710064	0.765	0.686065	0.705292	PASS	0	0.698	295	0.617021	64	chr1	19311815	NA	A	G	765.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.32;AS_ReadPosRankSum=.;AS_SOR=2.147;DP=30;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.32;SOR=2.147	GT:AD:DP:GQ:PL	1/1:0,28:28:84:779,84,0
chr1	19324608	19324608	A	G	SLC66A1	intronic	NA	NA	NA	0.3314	GnomAdGenome_AF_sas	43	16	HeterozygousVariant	het	32	19	13	0.40625	249.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.2449	0.3183	0.317	0.2551	0.3314	0.222045	0.2696	0.24825	0.230706	VQSRTrancheSNP99.00to99.90	0	0.325	220	0.312057	56	chr1	19324608	NA	A	G	249.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=1.427;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.81;AS_ReadPosRankSum=-0.2;AS_SOR=0.402;BaseQRankSum=-0.68;DP=32;ExcessHet=3.0103;FS=1.427;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.8;ReadPosRankSum=-0.154;SOR=0.402	GT:AD:DP:GQ:PL	0/1:19,13:32:99:257,0,446
chr1	19325569	19325569	G	A	SLC66A1	exonic	synonymous SNV	NA	SLC66A1:NM_001040125:exon4:c.G369A:p.T123T,SLC66A1:NM_001040126:exon4:c.G174A:p.T58T,SLC66A1:NM_001287531:exon4:c.G36A:p.T12T,SLC66A1:NM_017765:exon5:c.G369A:p.T123T	0.347561	GME_TP	77	16	HeterozygousVariant	het	43	23	20	0.465116279069767	423.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.2414	0.3182	0.3169	0.2402	0.3305	0.20607	0.2527	0.246336	0.213465	PASS	0.347561	0.333	350	0.31338	57	chr1	19325569	NA	G	A	423.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.86;AS_ReadPosRankSum=0.3;AS_SOR=0.616;BaseQRankSum=-1.077;DP=44;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.85;ReadPosRankSum=0.329;SOR=0.616	GT:AD:DP:GQ:PL	0/1:23,20:43:99:431,0,570
chr1	19374521	19374521	G	A	CAPZB	intronic	NA	NA	NA	0.6142	GnomAdGenome_AF_sas			HeterozygousVariant	het	52	23	29	0.557692307692308	655.64	PASS	NA	NA	601572	NA	NA	NA	'Thyroid hormone levels[23408906;23408906;23408906];Thyroid function[22494929];Serum thyroid-stimulating hormone levels[24852370];Plateletcrit[27863252];Hypothyroidism[27182965];Lead levels in blood[25820613];Crohn''s disease and psoriasis[22482804];Thyroid volume[21565293;21565293;21565293;21565293];'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	pharynx;cornea;stomach;testis;choroid;larynx;kidney;uterus;whole body;pancreas;skeletal muscle;islets of Langerhans;visual apparatus;spleen;liver;peripheral nerve;germinal center;heart;lung;salivary gland;thyroid;placenta;nasopharynx;thymus;intestine;epididymis;tongue;alveolus;skin;myocardium;adrenal cortex;lens;unclassifiable (Anatomical System);lymphoreticular;amniotic fluid;retina;head and neck;mammary gland;cervix;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;ovary;frontal lobe;bladder;colon;aorta;prostate;breast;hypothalamus;	amygdala;thyroid;testis - seminiferous tubule;testis - interstitial;superior cervical ganglion;prostate;testis;cerebellum;	0.287	NA	E	S	E	0.788879629080027	E	Capzb	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; 	capzb	epidermal cell	decreased size	abnormal	0	0	0	0.5472	0.6142	0.522764	0	0.561088	0		0					chr1	19374521	NA	G	A	655.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=2.399;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.62;AS_ReadPosRankSum=0;AS_SOR=1.143;BaseQRankSum=-0.369;DP=53;ExcessHet=3.0103;FS=2.399;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.61;ReadPosRankSum=0.092;SOR=1.143	GT:AD:DP:GQ:PL	0/1:23,29:52:99:663,0,518
chr1	19623568	19623568	T	C	MICOS10	exonic	synonymous SNV	NA	MICOS10:NM_001204082:exon2:c.T159C:p.H53H,MICOS10:NM_001032363:exon3:c.T207C:p.H69H,MICOS10:NM_001204083:exon3:c.T207C:p.H69H	0.6562	GnomAdExome_AF_afr	48	12	HeterozygousVariant	het	54	33	21	0.388888888888889	440.64	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.2344	0.6562	0.655	0.3412	0.6428	0.345647	0.354	0.24208	0.312808	PASS	0.30303	0.295	248	0.288732	58	chr1	19623568	NA	T	C	440.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=1.088;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.17;AS_ReadPosRankSum=-1;AS_SOR=0.999;BaseQRankSum=-0.651;DP=54;ExcessHet=3.0103;FS=1.088;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.16;ReadPosRankSum=-0.941;SOR=0.999	GT:AD:DP:GQ:PL	0/1:33,21:54:99:448,0,826
chr1	19666020	19666020	C	T	HTR6	exonic	synonymous SNV	NA	HTR6:NM_000871:exon1:c.C267T:p.Y89Y	0.2633	GnomAdGenome_AF_ami	35	4	HeterozygousVariant	het	119	59	60	0.504201680672269	1450.64	PASS	NA	NA	601109	Benign	NA	NA	Morning vs. evening chronotype[27494321;26955885];Chronotype[27494321;26955885];	NA	NA	NA	NA	NA	Expressed in several human brain regions, most prominently in the caudate nucleus.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	ovary;mammary gland;brain;unclassifiable (Anatomical System);	NA	0.571	N	N	N	N	0.334161791141397	N	Htr6	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.1464	0.2227	0.2246	0.1572	0.2633	0.172524	0.1522	0.0289259	0.151067	PASS	0.20788	0.189	245	0.151408	35	chr1	19666020	NA	C	T	1450.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=3.323;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.19;AS_ReadPosRankSum=1.3;AS_SOR=0.831;BaseQRankSum=0.99;DP=122;ExcessHet=3.0103;FS=3.323;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.19;ReadPosRankSum=1.32;SOR=0.831	GT:AD:DP:GQ:PL	0/1:59,60:119:99:1458,0,1363
chr1	19679371	19679371	C	T	HTR6	UTR3	NA	NM_000871:c.*3C>T	NA	0.0153	GnomAdGenome_AF_eas	0		HeterozygousVariant	het	53	24	29	0.547169811320755	679.64	PASS	NA	NA	601109	NA	NA	NA	Morning vs. evening chronotype[27494321;26955885];Chronotype[27494321;26955885];	NA	NA	NA	NA	NA	Expressed in several human brain regions, most prominently in the caudate nucleus.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	ovary;mammary gland;brain;unclassifiable (Anatomical System);	NA	0.571	N	N	N	N	0.334161791141397	N	Htr6	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.0017	0.0151	0.0163	0.0006	0.0153	0.00479233	0.000092	0.0013907	0		0	0.002203	2			chr1	19679371	NA	C	T	679.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=8.39;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.83;AS_ReadPosRankSum=0.6;AS_SOR=0.159;BaseQRankSum=-0.815;DP=53;ExcessHet=3.0103;FS=8.39;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.82;ReadPosRankSum=0.617;SOR=0.159	GT:AD:DP:GQ:PL	0/1:24,29:53:99:687,0,593
chr1	19683244	19683244	G	A	TMCO4	exonic	synonymous SNV	NA	TMCO4:NM_001349112:exon15:c.C1701T:p.S567S,TMCO4:NM_001349113:exon16:c.C1701T:p.S567S,TMCO4:NM_181719:exon16:c.C1701T:p.S567S,TMCO4:NM_001349114:exon17:c.C1701T:p.S567S	0.2667	GnomAdGenome_AF_ami	30	5	HeterozygousVariant	het	128	68	60	0.46875	1374.64	PASS	NA	NA	NA	Benign	NA	NA	'Late-onset Alzheimer''s disease[27770636];'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;stomach;lacrimal gland;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;mammary gland;islets of Langerhans;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;blood;lung;ovary;thyroid;macula lutea;colon;placenta;prostate;optic nerve;	ciliary ganglion;thyroid;dorsal root ganglion;trigeminal ganglion;atrioventricular node;skin;superior cervical ganglion;placenta;skeletal muscle;globus pallidus;	0.934	NA	N	N	N	0.272820001977311	N	Tmco4	NA	NA	NA	NA	NA	0.1355	0.2235	0.2258	0.1178	0.2667	0.1252	0.106	0.133679	0.12069	PASS	0.189655	0.188	160	0.140845	30	chr1	19683244	NA	G	A	1374.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.74;AS_ReadPosRankSum=1.7;AS_SOR=0.645;BaseQRankSum=2.37;DP=133;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.74;ReadPosRankSum=1.75;SOR=0.645	GT:AD:DP:GQ:PL	0/1:68,60:128:99:1382,0,1437
chr1	19694500	19694500	A	G	TMCO4	exonic	synonymous SNV	NA	TMCO4:NM_001349112:exon14:c.T1434C:p.R478R,TMCO4:NM_001349113:exon15:c.T1434C:p.R478R,TMCO4:NM_181719:exon15:c.T1434C:p.R478R,TMCO4:NM_001349114:exon16:c.T1434C:p.R478R	0.8499	GnomAdExome_AF_fin	354	80	HomozygousVariant	hom	63	0	63	1	2166.06	PASS	NA	NA	NA	NA	NA	NA	'Late-onset Alzheimer''s disease[27770636];'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;stomach;lacrimal gland;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;mammary gland;islets of Langerhans;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;blood;lung;ovary;thyroid;macula lutea;colon;placenta;prostate;optic nerve;	ciliary ganglion;thyroid;dorsal root ganglion;trigeminal ganglion;atrioventricular node;skin;superior cervical ganglion;placenta;skeletal muscle;globus pallidus;	0.934	NA	N	N	N	0.272820001977311	N	Tmco4	NA	NA	NA	NA	NA	0.7574	0.8209	0.8223	0.7291	0.8428	0.660144	0.7275	0.0218227	0.69376	PASS	0.810606	0.782	205	0.760563	56	chr1	19694500	NA	A	G	2166.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=34.38;AS_ReadPosRankSum=.;AS_SOR=0.724;DP=66;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=34.38;SOR=0.724	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,63:63:99:1|1:19694500_A_G:2180,189,0:19694500
chr1	19694501	19694501	C	T	TMCO4	exonic	nonsynonymous SNV	NA	TMCO4:NM_001349112:exon14:c.G1433A:p.R478H,TMCO4:NM_001349113:exon15:c.G1433A:p.R478H,TMCO4:NM_181719:exon15:c.G1433A:p.R478H,TMCO4:NM_001349114:exon16:c.G1433A:p.R478H	0.7118	GnomAdExome_AF_fin	212	49	HeterozygousVariant	het	62	37	25	0.403225806451613	489.64	PASS	6.033	NA	NA	Benign	NA	NA	'Late-onset Alzheimer''s disease[27770636];'	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	tongue;spinal ganglion;skin;stomach;lacrimal gland;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;mammary gland;islets of Langerhans;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;blood;lung;ovary;thyroid;macula lutea;colon;placenta;prostate;optic nerve;	ciliary ganglion;thyroid;dorsal root ganglion;trigeminal ganglion;atrioventricular node;skin;superior cervical ganglion;placenta;skeletal muscle;globus pallidus;	0.934	NA	N	N	N	0.272820001977311	N	Tmco4	NA	NA	NA	NA	NA	0.574	0.6541	0.6573	0.513	0.697	0.430112	0.5127	0.542024	0.490969	PASS	0.662879	0.585	262	0.573944	65	chr1	19694501	NA	C	T	489.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.9;AS_ReadPosRankSum=-0.4;AS_SOR=0.724;BaseQRankSum=-0.303;DP=66;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.9;ReadPosRankSum=-0.309;SOR=0.724	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:37,25:62:99:0|1:19694500_A_G:497,0,857:19694500
chr1	19978469	19978469	C	G	PLA2G2A	exonic	synonymous SNV	NA	PLA2G2A:NM_001161728:exon3:c.G96C:p.T32T,PLA2G2A:NM_001161729:exon3:c.G96C:p.T32T,PLA2G2A:NM_000300:exon4:c.G96C:p.T32T,PLA2G2A:NM_001161727:exon4:c.G96C:p.T32T	0.2247	GnomAdExome_AF_eas	18	2	HeterozygousVariant	het	70	37	33	0.471428571428571	820.64	PASS	NA	NA	172411	Benign	NA	NA	Immunoglobulin light chain (AL) amyloidosis[28025584];Blood protein levels[29875488;30072576];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.829	NA	N	N	N	0.97125005788996	E	Pla2g2a	neoplasm; 	NA	NA	NA	NA	0.1095	0.2247	0.2261	0.074	0.2212	0.0970447	0.0673	0.102858	0.061576	PASS	0.157895	0.135	190	0.119718	30	chr1	19978469	NA	C	G	820.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=3.26;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.73;AS_ReadPosRankSum=-0.4;AS_SOR=1.133;BaseQRankSum=0.033;DP=74;ExcessHet=3.0103;FS=3.26;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.72;ReadPosRankSum=-0.365;SOR=1.133	GT:AD:DP:GQ:PL	0/1:37,33:70:99:828,0,942
chr1	20084808	20084808	T	-	PLA2G5	intronic	NA	NA	NA	0.1537	GnomAdExome_AF_eas	14	1	HeterozygousVariant	het	108	60	48	0.444444444444444	1109.6	PASS	NA	[MIM:228980]Fleck retina, familial benign [recessive?];	601192	NA	Familial benign flecked retina	Disease-causing germline mutation(s) in	Blood protein levels[28240269];	NA	NA	NA	NA	NA	Heart, placenta and less abundantly, in lung. Detected in the outer and inner plexiform layers of the retina (at protein level). {ECO:0000269|PubMed:22137173}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.588	N	N	N	N	0.171156976162434	N	Pla2g5	cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; immune system phenotype; muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; 	NA	NA	NA	NA	0.0676	0.1537	0.1474	0.0379	0.1368	0.0740815	0.0264	0.0113724	0.051809	PASS	0	0.122	174	0.112676	30	chr1	20084807	NA	GT	G	1109.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.551;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.28;AS_ReadPosRankSum=1.5;AS_SOR=0.885;BaseQRankSum=0.476;DP=121;ExcessHet=3.0103;FS=1.551;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.27;ReadPosRankSum=1.53;SOR=0.885	GT:AD:DP:GQ:PL	0/1:60,48:108:99:1117,0,1413
chr1	20115561	20115561	T	C	PLA2G2D	exonic	nonsynonymous SNV	NA	PLA2G2D:NM_012400:exon3:c.A238G:p.S80G	0.9181	GnomAdExome_AF_afr	501	80	HomozygousVariant	hom	111	0	111	1	3041.06	PASS	0.113	NA	605630	NA	NA	NA	Obesity-related traits[23251661];	NA	NA	NA	NA	NA	Broadly expressed.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Phospholipase A2 domain|Phospholipase A2 domain|Phospholipase A2 domain	NA	NA	Medium	Medium	Medium	NA	NA	0.682	NA	N	N	N	0.2690440965701	N	Pla2g2d	immune system phenotype; hematopoietic system phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.6583	0.9181	0.9225	0.7009	0.9129	0.769369	0.6909	0.648905	0.687192	PASS	0.823232	0.767	276	0.746479	52	chr1	20115561	NA	T	C	3041.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.4;AS_ReadPosRankSum=.;AS_SOR=0.907;DP=114;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.4;SOR=0.907	GT:AD:DP:GQ:PL	1/1:0,111:111:99:3055,332,0
chr1	20164025	20164025	T	C	PLA2G2C	exonic	nonsynonymous SNV	NA	PLA2G2C:NM_001316722:exon4:c.A410G:p.Q137R,PLA2G2C:NM_001367969:exon4:c.A416G:p.Q139R	0.7286	GnomAdExome_AF_eas	294	72	HeterozygousVariant	het	31	15	16	0.516129032258065	347.64	PASS	8.122	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	Phospholipase A2 domain;Phospholipase A2 domain	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	N	N	0.0205961659258351	N	Pla2g2c	NA	NA	NA	NA	NA	0.5904	0.7286	0.732	0.621	0.7255	0.659944	0.6364	0.5915	0.591954	PASS	0.674242	0.698	229	0.697183	54	chr1	20164025	NA	T	C	347.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.5;AS_FS=5.391;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.23;AS_ReadPosRankSum=2.1;AS_SOR=1.085;BaseQRankSum=1.52;DP=32;ExcessHet=3.0103;FS=5.391;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.21;ReadPosRankSum=2.14;SOR=1.085	GT:AD:DP:GQ:PL	0/1:15,16:31:99:355,0,298
chr1	20172803	20172803	C	T	PLA2G2C	exonic	nonsynonymous SNV	NA	PLA2G2C:NM_001316722:exon3:c.G268A:p.A90T,PLA2G2C:NM_001367969:exon3:c.G274A:p.A92T	0.0000952	GnomAdGenome_AF_afr			HeterozygousVariant	het	50	28	22	0.44	505.64	PASS	4.487	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	N	N	T	N	T	T	T	T	T	T	T	T	T	.;.;	N	N	Phospholipase A2 domain|Phospholipase A2 domain;Phospholipase A2 domain|Phospholipase A2 domain	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	NA	N	N	0.0205961659258351	N	Pla2g2c	NA	NA	NA	NA	NA	0.000008033	0.00006464	0.00006386	0.0000349	0.0000952	0	0	0.0000065	0		0					chr1	20172803	NA	C	T	505.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.12;AS_ReadPosRankSum=-0.5;AS_SOR=0.693;BaseQRankSum=0.875;DP=50;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.11;ReadPosRankSum=-0.489;SOR=0.693	GT:AD:DP:GQ:PL	0/1:28,22:50:99:513,0,655
chr1	20330331	20330331	A	G	VWA5B1	exonic	nonsynonymous SNV	NA	VWA5B1:NM_001039500:exon10:c.A1406G:p.N469S	0.3967	GnomAdGenome_AF_eas	29	6	HeterozygousVariant	het	81	39	42	0.518518518518518	973.64	PASS	0.948	NA	NA	Benign	NA	NA	Psychosis proneness (perceptual aberration scale)[28525603];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	von Willebrand factor, type A|von Willebrand factor, type A|von Willebrand factor, type A;.	NA	NA	High	High	High	lung;testis;	NA	NA	NA	NA	N	N	0.265079143840323	N	Vwa5b1	NA	NA	NA	NA	NA	0.205	0.3932	0.3838	0.1472	0.3967	0.179912	0.1351	0.0651027	0.137931	PASS	0.3125	0.218	159	0.21831	50	chr1	20330331	NA	A	G	973.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.4;AS_FS=0.839;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.02;AS_ReadPosRankSum=0.8;AS_SOR=0.823;BaseQRankSum=1.4;DP=82;ExcessHet=3.0103;FS=0.839;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.02;ReadPosRankSum=0.89;SOR=0.823	GT:AD:DP:GQ:PL	0/1:39,42:81:99:981,0,857
chr1	20330859	20330859	T	C	VWA5B1	intronic	NA	NA	NA	0.9105	GnomAdExome_AF_eas	128	41	HeterozygousVariant	het	23	13	10	0.434782608695652	221.64	PASS	NA	NA	NA	NA	NA	NA	Psychosis proneness (perceptual aberration scale)[28525603];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0	High	High	High	lung;testis;	NA	NA	NA	NA	N	N	0.265079143840323	N	Vwa5b1	NA	NA	NA	NA	NA	0.517	0.9105	0.9171	0.5162	0.9079	0.605032	0.4851	0.16505	0.495895	PASS	0	0.461	277	0.492958	58	chr1	20330859	NA	T	C	221.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.65;AS_ReadPosRankSum=-2.2;AS_SOR=0.627;BaseQRankSum=1.25;DP=24;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.64;ReadPosRankSum=-2.18;SOR=0.627	GT:AD:DP:GQ:PL	0/1:13,10:23:99:229,0,281
chr1	20336445	20336445	A	G	VWA5B1	exonic	nonsynonymous SNV	NA	VWA5B1:NM_001039500:exon13:c.A1901G:p.K634R	0.3974	GnomAdGenome_AF_eas	35	7	HeterozygousVariant	het	90	41	49	0.544444444444444	1142.64	PASS	3.144	NA	NA	Benign	NA	NA	Psychosis proneness (perceptual aberration scale)[28525603];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	High	High	High	lung;testis;	NA	NA	NA	NA	N	N	0.265079143840323	N	Vwa5b1	NA	NA	NA	NA	NA	0.2227	0.3922	0.3831	0.1924	0.3974	0.224042	0.184	0.0671725	0.173235	PASS	0.25	0.207	170	0.219858	48	chr1	20336445	NA	A	G	1142.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=1.704;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.7;AS_ReadPosRankSum=-0.9;AS_SOR=0.518;BaseQRankSum=-0.338;DP=92;ExcessHet=3.0103;FS=1.704;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.7;ReadPosRankSum=-0.888;SOR=0.518	GT:AD:DP:GQ:PL	0/1:41,49:90:99:1150,0,962
chr1	20345468	20345468	G	A	VWA5B1	exonic	nonsynonymous SNV	NA	VWA5B1:NM_001039500:exon17:c.G2639A:p.R880H	0.5178	GnomAdGenome_AF_ami	42	9	HeterozygousVariant	het	46	29	17	0.369565217391304	323.64	PASS	29.2	NA	NA	Benign	NA	NA	Psychosis proneness (perceptual aberration scale)[28525603];	NA	NA	NA	NA	NA	NA	D	D	D	D	D	P	M	T	D	T	T	T	NA	T	T	T	T	T	.;.;	D	D	.;.	NA	NA	High	High	High	lung;testis;	NA	NA	NA	NA	N	N	0.265079143840323	N	Vwa5b1	NA	NA	NA	NA	NA	0.3311	0.3953	0.4007	0.3107	0.5178	0.301717	0.3062	0.10311	0.302135	PASS	0.333333	0.259	219	0.267606	58	chr1	20345468	NA	G	A	323.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=2.581;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.04;AS_ReadPosRankSum=-0.1;AS_SOR=1.019;BaseQRankSum=-0.201;DP=46;ExcessHet=3.0103;FS=2.581;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.04;ReadPosRankSum=-0.023;SOR=1.019	GT:AD:DP:GQ:PL	0/1:29,17:46:99:331,0,669
chr1	20345608	20345608	C	T	VWA5B1	intronic	NA	NA	NA	0.5179	GnomAdGenome_AF_ami	10	8	HeterozygousVariant	het	21	12	9	0.428571428571429	182.64	PASS	NA	NA	NA	NA	NA	NA	Psychosis proneness (perceptual aberration scale)[28525603];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	lung;testis;	NA	NA	NA	NA	N	N	0.265079143840323	N	Vwa5b1	NA	NA	NA	NA	NA	0.3314	0.3926	0.3977	0.3106	0.5179	0.301118	0	0.099837	0.303777	PASS	0	0.243	81	0.244681	53	chr1	20345608	NA	C	T	182.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.71;AS_ReadPosRankSum=0.6;AS_SOR=0.593;BaseQRankSum=0.118;DP=26;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.7;ReadPosRankSum=0.605;SOR=0.593	GT:AD:DP:GQ:PL	0/1:12,9:21:99:190,0,257
chr1	20354225	20354225	G	A	VWA5B1	exonic	nonsynonymous SNV	NA	VWA5B1:NM_001039500:exon22:c.G3610A:p.E1204K	0.3775	GnomAdGenome_AF_ami	27	5	HeterozygousVariant	het	25	14	11	0.44	249.64	PASS	21.5	NA	NA	Benign	NA	NA	Psychosis proneness (perceptual aberration scale)[28525603];	NA	NA	NA	NA	NA	NA	T	T	P	B	N	P	M	T	N	T	T	T	NA	T	T	T	T	T	.;.;	D	N	.;.	NA	NA	High	High	High	lung;testis;	NA	NA	NA	NA	N	N	0.265079143840323	N	Vwa5b1	NA	NA	NA	NA	NA	0.2274	0.3125	0.3035	0.2261	0.3775	0.229433	0	0.0741194	0.215589	PASS	0.285714	0.216	199	0.204225	48	chr1	20354225	NA	G	A	249.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1;AS_FS=1.697;AS_MQ=60;AS_MQRankSum=0;AS_QD=10;AS_ReadPosRankSum=0.4;AS_SOR=1.402;BaseQRankSum=1.02;DP=25;ExcessHet=3.0103;FS=1.697;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.99;ReadPosRankSum=0.411;SOR=1.402	GT:AD:DP:GQ:PL	0/1:14,11:25:99:257,0,325
chr1	20354267	20354267	A	G	VWA5B1	UTR3	NA	NM_001039500:c.*4A>G	NA	0.9114	GnomAdExome_AF_eas	62	39	HeterozygousVariant	het	13	6	7	0.538461538461538	142.64	PASS	NA	NA	NA	NA	NA	NA	Psychosis proneness (perceptual aberration scale)[28525603];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	lung;testis;	NA	NA	NA	NA	N	N	0.265079143840323	N	Vwa5b1	NA	NA	NA	NA	NA	0.5196	0.9114	0.9177	0.5033	0.9072	0.587859	0	0.159461	0.475914	PASS	0	0.426	131	0.477941	52	chr1	20354267	NA	A	G	142.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11;AS_ReadPosRankSum=0.9;AS_SOR=0.446;BaseQRankSum=0.615;DP=13;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.97;ReadPosRankSum=0.976;SOR=0.446	GT:AD:DP:GQ:PL	0/1:6,7:13:99:150,0,109
chr1	20637835	20637835	A	G	PINK1	intronic	NA	NA	NA	0.9295	GnomAdExome_AF_fin	563	113	HomozygousVariant	hom	68	0	68	1	1919.06	PASS	NA	[MIM:605909]Parkinson disease 6 [recessive?];	608309	NA	Young-onset Parkinson disease	Disease-causing germline mutation(s) in	Itch intensity from mosquito bite adjusted by bite size[28199695];Paclitaxel disposition in epithelial ovarian cancer[29367611];	HP:0012332;HP:0040307;HP:0000738;HP:0001337;HP:0100785;HP:0000736;HP:0002172;HP:0002063;HP:0100660;HP:0002019;HP:0100710;HP:0000727;HP:0002578;HP:0000735;HP:0002018;HP:0000739;HP:0004409;HP:0030014;HP:0001332;HP:0000551;HP:0001347;HP:0002014;HP:0002141;HP:0000741;HP:0002067;HP:0012452;HP:0000651;HP:0001257;HP:0003394;HP:0000713;HP:0025269;HP:0000716;HP:0002322;HP:0000007;HP:0000739;HP:0001332;HP:0003677;HP:0000716;HP:0003593;HP:0001347;HP:0002063;HP:0002067;HP:0000012;HP:0002172;HP:0001300;HP:0000726	Abnormal autonomic nervous system physiology;Male sexual dysfunction;Hallucinations;Tremor;Insomnia;Short attention span;Postural instability;Rigidity;Dyskinesia;Constipation;Impulsivity;Frontal lobe dementia;Gastroparesis;Impaired social interactions;Nausea;Anxiety;Hyposmia;Female sexual dysfunction;Dystonia;Color vision defect;Hyperreflexia;Diarrhea;Gait imbalance;Apathy;Bradykinesia;Restless legs;Diplopia;Spasticity;Muscle spasm;Agitation;Panic attack;Depressivity;Resting tremor;Autosomal recessive inheritance;Anxiety;Dystonia;Slow progression;Depressivity;Infantile onset;Hyperreflexia;Rigidity;Bradykinesia;Urinary urgency;Postural instability;Parkinsonism;Dementia	Parkinson_disease_6,_autosomal_recessive_early-onset|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Highly expressed in heart, skeletal muscle and testis, and at lower levels in brain, placenta, liver, kidney, pancreas, prostate, ovary and small intestine. Present in the embryonic testis from an early stage of development. {ECO:0000269|PubMed:11494141}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0	Medium	Medium	Medium	NA	NA	0.788	N	N	N	N	0.987543230398009	E	Pink1	taste/olfaction phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; immune system phenotype; 	pink1	dopaminergic neuron	decreased amount	abnormal	0.8617	0.8827	0.8831	0.8393	0.9267	0.821885	0.8434	0.849219	0.861248	PASS	0	0.866	150	0.883803	25	chr1	20637835	NA	A	G	1919.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.22;AS_ReadPosRankSum=.;AS_SOR=1.863;DP=69;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.22;SOR=1.863	GT:AD:DP:GQ:PL	1/1:0,68:68:99:1933,204,0
chr1	20644540	20644540	G	A	PINK1	exonic	nonsynonymous SNV	NA	PINK1:NM_032409:exon4:c.G827A:p.R276Q	0.0063	GnomAdExome_AF_sas	0	0	HeterozygousVariant	het	162	94	68	0.419753086419753	1329.64	PASS	25	[MIM:605909]Parkinson disease 6 [recessive?];	608309	Uncertain significance	Young-onset Parkinson disease	Disease-causing germline mutation(s) in	Itch intensity from mosquito bite adjusted by bite size[28199695];Paclitaxel disposition in epithelial ovarian cancer[29367611];	HP:0012332;HP:0040307;HP:0000738;HP:0001337;HP:0100785;HP:0000736;HP:0002172;HP:0002063;HP:0100660;HP:0002019;HP:0100710;HP:0000727;HP:0002578;HP:0000735;HP:0002018;HP:0000739;HP:0004409;HP:0030014;HP:0001332;HP:0000551;HP:0001347;HP:0002014;HP:0002141;HP:0000741;HP:0002067;HP:0012452;HP:0000651;HP:0001257;HP:0003394;HP:0000713;HP:0025269;HP:0000716;HP:0002322;HP:0000007;HP:0000739;HP:0001332;HP:0003677;HP:0000716;HP:0003593;HP:0001347;HP:0002063;HP:0002067;HP:0000012;HP:0002172;HP:0001300;HP:0000726	Abnormal autonomic nervous system physiology;Male sexual dysfunction;Hallucinations;Tremor;Insomnia;Short attention span;Postural instability;Rigidity;Dyskinesia;Constipation;Impulsivity;Frontal lobe dementia;Gastroparesis;Impaired social interactions;Nausea;Anxiety;Hyposmia;Female sexual dysfunction;Dystonia;Color vision defect;Hyperreflexia;Diarrhea;Gait imbalance;Apathy;Bradykinesia;Restless legs;Diplopia;Spasticity;Muscle spasm;Agitation;Panic attack;Depressivity;Resting tremor;Autosomal recessive inheritance;Anxiety;Dystonia;Slow progression;Depressivity;Infantile onset;Hyperreflexia;Rigidity;Bradykinesia;Urinary urgency;Postural instability;Parkinsonism;Dementia	Parkinson_disease_6,_autosomal_recessive_early-onset	criteria_provided,_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Highly expressed in heart, skeletal muscle and testis, and at lower levels in brain, placenta, liver, kidney, pancreas, prostate, ovary and small intestine. Present in the embryonic testis from an early stage of development. {ECO:0000269|PubMed:11494141}.;	T	T	P	B	D	D	N	T	N	T	T	T	T	T	T	T	T	T	.;	D	D	Protein kinase domain|Protein kinase domain|Protein kinase domain	NA	NA	Medium	Medium	Medium	NA	NA	0.788	N	N	N	N	0.987543230398009	E	Pink1	taste/olfaction phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; immune system phenotype; 	pink1	dopaminergic neuron	decreased amount	abnormal	0.0008	0.0063	0.0061	0.0001	0.0052	0.00179712	0	0.0007891	0		0.003788	0.005389	9	0.010563	3	chr1	20644540	NA	G	A	1329.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=3.663;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.21;AS_ReadPosRankSum=0.3;AS_SOR=0.473;BaseQRankSum=-0.05;DP=164;ExcessHet=3.0103;FS=3.663;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.21;ReadPosRankSum=0.367;SOR=0.473	GT:AD:DP:GQ:PL	0/1:94,68:162:99:1337,0,1979
chr1	20645618	20645618	G	A	PINK1	exonic	nonsynonymous SNV	NA	PINK1:NM_032409:exon5:c.G1018A:p.A340T	0.2651	GnomAdExome_AF_eas	64	13	HomozygousVariant	hom	131	0	131	1	3554.06	PASS	11.75	[MIM:605909]Parkinson disease 6 [recessive?];	608309	Benign	Young-onset Parkinson disease	Disease-causing germline mutation(s) in	Itch intensity from mosquito bite adjusted by bite size[28199695];Paclitaxel disposition in epithelial ovarian cancer[29367611];	HP:0012332;HP:0040307;HP:0000738;HP:0001337;HP:0100785;HP:0000736;HP:0002172;HP:0002063;HP:0100660;HP:0002019;HP:0100710;HP:0000727;HP:0002578;HP:0000735;HP:0002018;HP:0000739;HP:0004409;HP:0030014;HP:0001332;HP:0000551;HP:0001347;HP:0002014;HP:0002141;HP:0000741;HP:0002067;HP:0012452;HP:0000651;HP:0001257;HP:0003394;HP:0000713;HP:0025269;HP:0000716;HP:0002322;HP:0000007;HP:0000739;HP:0001332;HP:0003677;HP:0000716;HP:0003593;HP:0001347;HP:0002063;HP:0002067;HP:0000012;HP:0002172;HP:0001300;HP:0000726	Abnormal autonomic nervous system physiology;Male sexual dysfunction;Hallucinations;Tremor;Insomnia;Short attention span;Postural instability;Rigidity;Dyskinesia;Constipation;Impulsivity;Frontal lobe dementia;Gastroparesis;Impaired social interactions;Nausea;Anxiety;Hyposmia;Female sexual dysfunction;Dystonia;Color vision defect;Hyperreflexia;Diarrhea;Gait imbalance;Apathy;Bradykinesia;Restless legs;Diplopia;Spasticity;Muscle spasm;Agitation;Panic attack;Depressivity;Resting tremor;Autosomal recessive inheritance;Anxiety;Dystonia;Slow progression;Depressivity;Infantile onset;Hyperreflexia;Rigidity;Bradykinesia;Urinary urgency;Postural instability;Parkinsonism;Dementia	Parkinson_disease_6,_autosomal_recessive_early-onset	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Highly expressed in heart, skeletal muscle and testis, and at lower levels in brain, placenta, liver, kidney, pancreas, prostate, ovary and small intestine. Present in the embryonic testis from an early stage of development. {ECO:0000269|PubMed:11494141}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Protein kinase domain|Protein kinase domain|Protein kinase domain	NA	NA	Medium	Medium	Medium	NA	NA	0.788	N	N	N	N	0.987543230398009	E	Pink1	taste/olfaction phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; immune system phenotype; 	pink1	dopaminergic neuron	decreased amount	abnormal	0.0921	0.2651	0.2698	0.0505	0.2638	0.122804	0.0374	0.0860726	0.052545	PASS	0.166667	0.253	295	0.285211	55	chr1	20645618	NA	G	A	3554.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.13;AS_ReadPosRankSum=.;AS_SOR=1.061;DP=133;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.13;SOR=1.061	GT:AD:DP:GQ:PL	1/1:0,131:131:99:3568,392,0
chr1	20650507	20650507	A	C	PINK1	exonic	nonsynonymous SNV	NA	PINK1:NM_032409:exon8:c.A1562C:p.N521T	0.397727	GME_CA	141	26	HomozygousVariant	hom	97	0	97	1	2897.06	PASS	17.27	[MIM:605909]Parkinson disease 6 [recessive?];	608309	Benign	Young-onset Parkinson disease	Disease-causing germline mutation(s) in	Itch intensity from mosquito bite adjusted by bite size[28199695];Paclitaxel disposition in epithelial ovarian cancer[29367611];	HP:0012332;HP:0040307;HP:0000738;HP:0001337;HP:0100785;HP:0000736;HP:0002172;HP:0002063;HP:0100660;HP:0002019;HP:0100710;HP:0000727;HP:0002578;HP:0000735;HP:0002018;HP:0000739;HP:0004409;HP:0030014;HP:0001332;HP:0000551;HP:0001347;HP:0002014;HP:0002141;HP:0000741;HP:0002067;HP:0012452;HP:0000651;HP:0001257;HP:0003394;HP:0000713;HP:0025269;HP:0000716;HP:0002322;HP:0000007;HP:0000739;HP:0001332;HP:0003677;HP:0000716;HP:0003593;HP:0001347;HP:0002063;HP:0002067;HP:0000012;HP:0002172;HP:0001300;HP:0000726	Abnormal autonomic nervous system physiology;Male sexual dysfunction;Hallucinations;Tremor;Insomnia;Short attention span;Postural instability;Rigidity;Dyskinesia;Constipation;Impulsivity;Frontal lobe dementia;Gastroparesis;Impaired social interactions;Nausea;Anxiety;Hyposmia;Female sexual dysfunction;Dystonia;Color vision defect;Hyperreflexia;Diarrhea;Gait imbalance;Apathy;Bradykinesia;Restless legs;Diplopia;Spasticity;Muscle spasm;Agitation;Panic attack;Depressivity;Resting tremor;Autosomal recessive inheritance;Anxiety;Dystonia;Slow progression;Depressivity;Infantile onset;Hyperreflexia;Rigidity;Bradykinesia;Urinary urgency;Postural instability;Parkinsonism;Dementia	Parkinson_disease_6,_autosomal_recessive_early-onset|Congenital_disorder_of_glycosylation|not_specified|Parkinson_Disease,_Recessive	criteria_provided,_multiple_submitters,_no_conflicts	Benign/Likely_benign	Highly expressed in heart, skeletal muscle and testis, and at lower levels in brain, placenta, liver, kidney, pancreas, prostate, ovary and small intestine. Present in the embryonic testis from an early stage of development. {ECO:0000269|PubMed:11494141}.;	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.788	N	N	N	N	0.987543230398009	E	Pink1	taste/olfaction phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; immune system phenotype; 	pink1	dopaminergic neuron	decreased amount	abnormal	0.2923	0.3735	0.3729	0.2757	0.3848	0.300519	0.27	0.290514	0.27422	PASS	0.397727	0.387	364	0.401408	62	chr1	20650507	NA	A	C	2897.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.87;AS_ReadPosRankSum=.;AS_SOR=0.756;DP=100;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.87;SOR=0.756	GT:AD:DP:GQ:PL	1/1:0,97:97:99:2911,291,0
chr1	20650728	20650728	A	T	PINK1-AS	ncRNA_exonic	NA	NA	NA	0.9192	GnomAdExome_AF_fin	543	114	HomozygousVariant	hom	13	0	13	1	450.06	PASS	NA	NA	NA	NA	NA	NA	Intelligence (MTAG)[29326435];	NA	NA	Parkinson_disease_6,_autosomal_recessive_early-onset|Congenital_disorder_of_glycosylation|Parkinson_Disease,_Recessive	criteria_provided,_single_submitter	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.8618	0.8867	0.8867	0.8483	0.9162	0.834465	0.8534	0.84986	0.871921	PASS	0	0.871	142	0.887324	24	chr1	20650728	NA	A	T	450.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=34.62;AS_ReadPosRankSum=.;AS_SOR=2.833;DP=16;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=34.62;SOR=2.833	GT:AD:DP:GQ:PL	1/1:0,13:13:39:464,39,0
chr1	20661380	20661380	G	C	DDOST	exonic	nonsynonymous SNV	NA	DDOST:NM_005216:exon1:c.C22G:p.R8G	1	GnomAdExome_AF_sas	835	142	HomozygousVariant	hom	53	0	53	1	1615.06	PASS	15.86	[MIM:614507]Congenital disorder of glycosylation 1R;	602202	Benign	DDOST-CDG	Disease-causing germline mutation(s) in	NA	HP:0000832;HP:0007301;HP:0002019;HP:0012758;HP:0001250;HP:0001337;HP:0002910;HP:0001508;HP:0003429;HP:0003642;HP:0004322;HP:0001290;HP:0002167;HP:0005616;HP:0012593;HP:0000958;HP:0001397;HP:0000938;HP:0003256;HP:0002020;HP:0009125;HP:0410018;HP:0000565;HP:0000007;HP:0001263;HP:0001508;HP:0002019;HP:0410018;HP:0000486;HP:0002020;HP:0001410;HP:0001290;HP:0003642;HP:0003593	Primary hypothyroidism;Oromotor apraxia;Constipation;Neurodevelopmental delay;Seizure;Tremor;Elevated hepatic transaminase;Failure to thrive;CNS hypomyelination;Type I transferrin isoform profile;Short stature;Generalized hypotonia;Neurological speech impairment;Accelerated skeletal maturation;Nephrotic range proteinuria;Dry skin;Hepatic steatosis;Osteopenia;Abnormality of the coagulation cascade;Gastroesophageal reflux;Lipodystrophy;Recurrent ear infections;Esotropia;Autosomal recessive inheritance;Global developmental delay;Failure to thrive;Constipation;Recurrent ear infections;Strabismus;Gastroesophageal reflux;Decreased liver function;Generalized hypotonia;Type I transferrin isoform profile;Infantile onset	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.387	NA	E	E	E	0.833652258579226	E	Ddost	immune system phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.994	1	0.9999	0.976	1	0.973043	0.9746	0.946585	0.981117	PASS	1	1	0	1	0	chr1	20661380	NA	G	C	1615.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.47;AS_ReadPosRankSum=.;AS_SOR=1.402;DP=54;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.47;SOR=1.402	GT:AD:DP:GQ:PL	1/1:0,53:53:99:1629,159,0
chr1	20698408	20698408	C	T	KIF17	exonic	nonsynonymous SNV	NA	KIF17:NM_001122819:exon6:c.G1204A:p.V402M,KIF17:NM_001287212:exon6:c.G904A:p.V302M,KIF17:NM_020816:exon6:c.G1204A:p.V402M	0.724138	GME_SD	257	46	HeterozygousVariant	het	71	48	23	0.323943661971831	385.64	PASS	8.3	NA	605037	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	lung;spleen;pancreas;frontal lobe;placenta;bone;testis;brain;blood;unclassifiable (Anatomical System);	pons;temporal lobe;subthalamic nucleus;testis - interstitial;whole brain;cingulate cortex;atrioventricular node;	0.854	NA	N	N	N	0.7659523685588	E	Kif17	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	kif17	retinal rod cell	cellular quality	abnormal	0.6281	0.6642	0.663	0.595	0.7011	0.596845	0.5914	0.614209	0.623974	PASS	0.724138	0.55	404	0.584507	74	chr1	20698408	NA	C	T	385.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=2.054;AS_MQ=60;AS_MQRankSum=0;AS_QD=5.44;AS_ReadPosRankSum=0.3;AS_SOR=0.963;BaseQRankSum=0.361;DP=72;ExcessHet=3.0103;FS=2.054;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=5.43;ReadPosRankSum=0.332;SOR=0.963	GT:AD:DP:GQ:PL	0/1:48,23:71:99:393,0,1031
chr1	20704549	20704549	T	C	KIF17	exonic	nonsynonymous SNV	NA	KIF17:NM_001122819:exon5:c.A1021G:p.I341V,KIF17:NM_001287212:exon5:c.A721G:p.I241V,KIF17:NM_020816:exon5:c.A1021G:p.I341V	0.4	GME_Israel	78	10	HeterozygousVariant	het	106	39	67	0.632075471698113	1556.64	PASS	16.86	NA	605037	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	U	P	M	T	N	T	T	T	NA	T	T	T	T	D	.;.;.;	D	N	Kinesin motor domain;.;Kinesin motor domain	NA	NA	Medium	Medium	Medium	lung;spleen;pancreas;frontal lobe;placenta;bone;testis;brain;blood;unclassifiable (Anatomical System);	pons;temporal lobe;subthalamic nucleus;testis - interstitial;whole brain;cingulate cortex;atrioventricular node;	0.854	NA	N	N	N	0.7659523685588	E	Kif17	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	kif17	retinal rod cell	cellular quality	abnormal	0.1177	0.3203	0.3174	0.094	0.3233	0.163738	0.0883	0.116137	0.104269	PASS	0.4	0.284	318	0.299296	65	chr1	20704549	NA	T	C	1556.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.5;AS_FS=6.309;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.69;AS_ReadPosRankSum=2.3;AS_SOR=0.385;BaseQRankSum=-1.445;DP=109;ExcessHet=3.0103;FS=6.309;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.69;ReadPosRankSum=2.3;SOR=0.385	GT:AD:DP:GQ:PL	0/1:39,67:106:99:1564,0,855
chr1	20713586	20713586	C	A	KIF17	intronic	NA	NA	NA	0.908	GnomAdExome_AF_eas	347	91	HomozygousVariant	hom	37	0	37	1	1387.06	PASS	NA	NA	605037	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;pancreas;frontal lobe;placenta;bone;testis;brain;blood;unclassifiable (Anatomical System);	pons;temporal lobe;subthalamic nucleus;testis - interstitial;whole brain;cingulate cortex;atrioventricular node;	0.854	NA	N	N	N	0.7659523685588	E	Kif17	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	kif17	retinal rod cell	cellular quality	abnormal	0.7199	0.908	0.9091	0.7151	0.8938	0.751797	0.716	0.0001153	0.720033	PASS	0	0.748	213	0.795775	44	chr1	20713586	NA	C	A	1387.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=36.46;AS_ReadPosRankSum=.;AS_SOR=0.746;DP=41;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.6;SOR=0.746	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,37:37:99:1|1:20713586_C_A:1401,111,0:20713586
chr1	20713595	20713595	C	T	KIF17	intronic	NA	NA	NA	0.3143	GnomAdExome_AF_eas	34	4	HeterozygousVariant	het	33	10	23	0.696969696969697	563.64	PASS	NA	NA	605037	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;pancreas;frontal lobe;placenta;bone;testis;brain;blood;unclassifiable (Anatomical System);	pons;temporal lobe;subthalamic nucleus;testis - interstitial;whole brain;cingulate cortex;atrioventricular node;	0.854	NA	N	N	N	0.7659523685588	E	Kif17	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	kif17	retinal rod cell	cellular quality	abnormal	0.1077	0.3143	0.3142	0.0914	0.3017	0.152356	0.0889	0.099533	0.097701	PASS	0	0.222	201	0.200704	49	chr1	20713595	NA	C	T	563.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=17.09;AS_ReadPosRankSum=-0.4;AS_SOR=0.776;BaseQRankSum=1.25;DP=35;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=17.08;ReadPosRankSum=-0.314;SOR=0.776	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:10,23:33:99:0|1:20713586_C_A:571,0,168:20713586
chr1	20715601	20715601	G	A	KIF17	exonic	synonymous SNV	NA	KIF17:NM_001122819:exon2:c.C270T:p.Y90Y,KIF17:NM_020816:exon2:c.C270T:p.Y90Y	0.7534	GnomAdExome_AF_eas	101	19	HeterozygousVariant	het	82	45	37	0.451219512195122	793.64	PASS	NA	NA	605037	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;pancreas;frontal lobe;placenta;bone;testis;brain;blood;unclassifiable (Anatomical System);	pons;temporal lobe;subthalamic nucleus;testis - interstitial;whole brain;cingulate cortex;atrioventricular node;	0.854	NA	N	N	N	0.7659523685588	E	Kif17	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	kif17	retinal rod cell	cellular quality	abnormal	0.2032	0.7534	0.7478	0.1319	0.7438	0.280351	0.1134	0.194474	0.127258	PASS	0	0.335	357	0.369718	67	chr1	20715601	NA	G	A	793.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.68;AS_ReadPosRankSum=0.9;AS_SOR=0.72;BaseQRankSum=0.512;DP=87;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.68;ReadPosRankSum=0.939;SOR=0.72	GT:AD:DP:GQ:PL	0/1:45,37:82:99:801,0,1003
chr1	20717668	20717668	A	G	KIF17	exonic	synonymous SNV	NA	KIF17:NM_001122819:exon1:c.T39C:p.R13R,KIF17:NM_020816:exon1:c.T39C:p.R13R	0.9023	GnomAdExome_AF_eas	484	95	HomozygousVariant	hom	71	1	70	0.985915492957746	2146.06	PASS	NA	NA	605037	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;pancreas;frontal lobe;placenta;bone;testis;brain;blood;unclassifiable (Anatomical System);	pons;temporal lobe;subthalamic nucleus;testis - interstitial;whole brain;cingulate cortex;atrioventricular node;	0.854	NA	N	N	N	0.7659523685588	E	Kif17	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	kif17	retinal rod cell	cellular quality	abnormal	0.7067	0.9023	0.9035	0.6765	0.8889	0.712061	0.6696	0.0001921	0.701149	PASS	0.734848	0.753	286	0.817857	39	chr1	20717668	NA	A	G	2146.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-0.3;AS_FS=3.889;AS_MQ=60;AS_MQRankSum=0;AS_QD=30.23;AS_ReadPosRankSum=1.5;AS_SOR=0.896;BaseQRankSum=-0.241;DP=72;ExcessHet=3.0103;FS=3.889;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=30.23;ReadPosRankSum=1.54;SOR=0.896	GT:AD:DP:GQ:PL	1/1:1,70:71:99:2160,184,0
chr1	20717726	20717726	A	C	KIF17	UTR5	NA	NM_001287212:c.-2156T>G;NM_020816:c.-20T>G;NM_001122819:c.-20T>G	NA	0.999	GnomAdExome_AF_eas	650	131	HomozygousVariant	hom	36	0	36	1	1092.06	PASS	NA	NA	605037	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;pancreas;frontal lobe;placenta;bone;testis;brain;blood;unclassifiable (Anatomical System);	pons;temporal lobe;subthalamic nucleus;testis - interstitial;whole brain;cingulate cortex;atrioventricular node;	0.854	NA	N	N	N	0.7659523685588	E	Kif17	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	kif17	retinal rod cell	cellular quality	abnormal	0.854	0.999	0.9989	0.8738	0.9984	0.92472	0.882	0.0001153	0.858678	PASS	0	0.934	77	0.960993	9	chr1	20717726	NA	A	C	1092.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.33;AS_ReadPosRankSum=.;AS_SOR=1.061;DP=36;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.34;SOR=1.061	GT:AD:DP:GQ:PL	1/1:0,36:36:99:1106,108,0
chr1	20724465	20724465	C	T	SH2D5	exonic	synonymous SNV	NA	SH2D5:NM_001103160:exon5:c.G309A:p.Q103Q,SH2D5:NM_001103161:exon6:c.G561A:p.Q187Q	0.9925	GnomAdExome_AF_eas	455	117	HomozygousVariant	hom	155	0	155	1	4149.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.269	NA	N	N	N	0.178662703066337	N	Sh2d5	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.7993	0.9925	0.9929	0.826	0.9911	0.879593	0.8203	0.78933	0.816913	PASS	0.8125	0.87	110	0.897887	21	chr1	20724465	NA	C	T	4149.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.77;AS_ReadPosRankSum=.;AS_SOR=0.706;DP=158;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.77;SOR=0.706	GT:AD:DP:GQ:PL	1/1:0,155:155:99:4163,461,0
chr1	20840911	20840911	A	G	EIF4G3	exonic	synonymous SNV	NA	EIF4G3:NM_003760:exon25:c.T3838C:p.L1280L,EIF4G3:NM_001198801:exon28:c.T3946C:p.L1316L,EIF4G3:NM_001198802:exon28:c.T3856C:p.L1286L	1	GnomAdExome_AF_eas	754	142	HomozygousVariant	hom	76	0	76	1	2118.06	PASS	NA	NA	603929	Benign	NA	NA	Cognitive decline rate in late mild cognitive impairment[26252872;26252872];Superior frontal gyrus grey matter volume[25335168;25335168];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;cochlea;pharynx;stomach;testis;pineal gland;kidney;uterus;whole body;adrenal gland;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;sympathetic chain;placenta;intestine;alveolus;skin;myocardium;pituitary gland;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;trabecular meshwork;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;aorta;prostate;breast;	ciliary ganglion;testis - seminiferous tubule;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;testis;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.282	N	N	N	NA	0.794093492497297	E	Eif4g3	cellular phenotype; reproductive system phenotype; endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.9859	1	1	0.9416	1	0.9377	0.9369	0.967478	0.946634	PASS	1	1	0	1	0	chr1	20840911	NA	A	G	2118.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.87;AS_ReadPosRankSum=.;AS_SOR=1.121;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.87;SOR=1.121	GT:AD:DP:GQ:PL	1/1:0,76:76:99:2132,227,0
chr1	20853688	20853688	C	T	EIF4G3	intronic	NA	NA	NA	0.851	GnomAdExome_AF_eas	191	46	HeterozygousVariant	het	29	16	13	0.448275862068966	249.64	PASS	NA	NA	603929	NA	NA	NA	Cognitive decline rate in late mild cognitive impairment[26252872;26252872];Superior frontal gyrus grey matter volume[25335168;25335168];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0004	0.042	Medium	Medium	Medium	developmental;cochlea;pharynx;stomach;testis;pineal gland;kidney;uterus;whole body;adrenal gland;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;sympathetic chain;placenta;intestine;alveolus;skin;myocardium;pituitary gland;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;trabecular meshwork;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;aorta;prostate;breast;	ciliary ganglion;testis - seminiferous tubule;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;testis;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.282	N	N	N	NA	0.794093492497297	E	Eif4g3	cellular phenotype; reproductive system phenotype; endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.577	0.851	0.8427	0.5141	0.8507	0.572684	0.5038	0.0187106	0.494253	PASS	0	0.636	215	0.573944	71	chr1	20853688	NA	C	T	249.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=1.569;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.62;AS_ReadPosRankSum=-2.1;AS_SOR=1.061;BaseQRankSum=-0.866;DP=30;ExcessHet=3.0103;FS=1.569;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.61;ReadPosRankSum=-2.02;SOR=1.061	GT:AD:DP:GQ:PL	0/1:16,13:29:99:257,0,362
chr1	20862210	20862210	A	T	EIF4G3	intronic	NA	NA	NA	0.8487	GnomAdGenome_AF_eas	125	37	HeterozygousVariant	het	29	13	16	0.551724137931034	346.64	PASS	NA	NA	603929	NA	NA	NA	Cognitive decline rate in late mild cognitive impairment[26252872;26252872];Superior frontal gyrus grey matter volume[25335168;25335168];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;cochlea;pharynx;stomach;testis;pineal gland;kidney;uterus;whole body;adrenal gland;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;sympathetic chain;placenta;intestine;alveolus;skin;myocardium;pituitary gland;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;trabecular meshwork;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;aorta;prostate;breast;	ciliary ganglion;testis - seminiferous tubule;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;testis;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.282	N	N	N	NA	0.794093492497297	E	Eif4g3	cellular phenotype; reproductive system phenotype; endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.5054	0.7541	0.7538	0.5121	0.8487	0.575679	0.4934	0.0002523	0		0	0.645	137	0.538732	79	chr1	20862210	NA	A	T	346.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=1.455;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.97;AS_ReadPosRankSum=0.8;AS_SOR=0.845;BaseQRankSum=0.321;DP=31;ExcessHet=3.0103;FS=1.455;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.95;ReadPosRankSum=0.882;SOR=0.845	GT:AD:DP:GQ:PL	0/1:13,16:29:99:354,0,245
chr1	21176232	21176234	GCC	-	EIF4G3	UTR5	NA	NM_001198801:c.-173490_-173492delGGC;NM_001198802:c.-173490_-173492delGGC	NA	0.430958	abraom_freq	56	20	HeterozygousVariant	het	66	1	25	0.378787878787879	2247.02	PASS	NA	NA	603929	NA	NA	NA	Cognitive decline rate in late mild cognitive impairment[26252872;26252872];Superior frontal gyrus grey matter volume[25335168;25335168];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;cochlea;pharynx;stomach;testis;pineal gland;kidney;uterus;whole body;adrenal gland;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;sympathetic chain;placenta;intestine;alveolus;skin;myocardium;pituitary gland;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;trabecular meshwork;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;aorta;prostate;breast;	ciliary ganglion;testis - seminiferous tubule;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;testis;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.282	N	N	N	NA	0.794093492497297	E	Eif4g3	cellular phenotype; reproductive system phenotype; endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.2493	0.2743	0.4	0.3412	0.3839	0	0	0.0005763	0.430958	PASS	0	0.269	152	0.315789	44	chr1	21176231	NA	TGCC	T	2247.02	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=3.736;AS_MQ=60;AS_MQRankSum=0;AS_QD=23.58;AS_ReadPosRankSum=-0.2;AS_SOR=0.861;BaseQRankSum=0.337;DP=81;ExcessHet=3.0103;FS=3.282;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=34.05;ReadPosRankSum=-0.244;SOR=0.469	GT:AD:DP:GQ:PL	1/0:1,25:66:99:2264,1698,1803
chr1	21176231	21176231	-	GCC	EIF4G3	UTR5	NA	NM_001198801:c.-173490_-173489insGGC;NM_001198802:c.-173490_-173489insGGC	NA	0.2672	GnomAdGenome_AF_eas	33	4	HeterozygousVariant	het	66	1	40	0.606060606060606	2247.02	PASS	NA	NA	603929	NA	NA	NA	Cognitive decline rate in late mild cognitive impairment[26252872;26252872];Superior frontal gyrus grey matter volume[25335168;25335168];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;cochlea;pharynx;stomach;testis;pineal gland;kidney;uterus;whole body;adrenal gland;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;sympathetic chain;placenta;intestine;alveolus;skin;myocardium;pituitary gland;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;trabecular meshwork;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;aorta;prostate;breast;	ciliary ganglion;testis - seminiferous tubule;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;testis;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.282	N	N	N	NA	0.794093492497297	E	Eif4g3	cellular phenotype; reproductive system phenotype; endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.0152	0.0286	0.0303	0.069	0.2672	0	0	0.0004226	0.118483	PASS	0	0.197	127	0.165414	36	chr1	21176231	NA	T	TGCC	2247.02	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=30.1;AS_ReadPosRankSum=-0.3;AS_SOR=0.223;BaseQRankSum=0.337;DP=81;ExcessHet=3.0103;FS=3.282;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=34.05;ReadPosRankSum=-0.244;SOR=0.469	GT:AD:DP:GQ:PL	0/1:1,40:66:99:2264,623,986
chr1	21176267	21176267	T	C	EIF4G3	UTR5	NA	NM_001198801:c.-173525A>G;NM_001198802:c.-173525A>G	NA	0.049	GnomAdGenome_AF_asj	1	0	HeterozygousVariant	het	79	29	50	0.632911392405063	1574.64	PASS	NA	NA	603929	NA	NA	NA	Cognitive decline rate in late mild cognitive impairment[26252872;26252872];Superior frontal gyrus grey matter volume[25335168;25335168];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	developmental;cochlea;pharynx;stomach;testis;pineal gland;kidney;uterus;whole body;adrenal gland;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;sympathetic chain;placenta;intestine;alveolus;skin;myocardium;pituitary gland;adrenal cortex;lens;unclassifiable (Anatomical System);retina;head and neck;cervix;hippocampus;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;trabecular meshwork;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;aorta;prostate;breast;	ciliary ganglion;testis - seminiferous tubule;prefrontal cortex;superior cervical ganglion;trigeminal ganglion;testis;pons;subthalamic nucleus;testis - interstitial;dorsal root ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.282	N	N	N	NA	0.794093492497297	E	Eif4g3	cellular phenotype; reproductive system phenotype; endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.0026	0.0049	0.0033	0.017	0.049	0	0	0.0004592	0.013629	VQSRTrancheSNP99.00to99.90	0	0.013	11	0.007634	2	chr1	21176267	NA	T	C	1574.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.2;AS_FS=4.686;AS_MQ=53.67;AS_MQRankSum=0;AS_QD=19.94;AS_ReadPosRankSum=-0.2;AS_SOR=0.336;BaseQRankSum=-1.189;DP=83;ExcessHet=3.0103;FS=4.686;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=19.93;ReadPosRankSum=-0.17;SOR=0.336	GT:AD:DP:GQ:PL	0/1:29,50:79:99:1582,0,999
chr1	21255932	21255932	C	T	ECE1	intronic	NA	NA	NA	0.1782	GnomAdGenome_AF_sas	27	9	HeterozygousVariant	het	54	27	27	0.5	672.64	PASS	NA	NA	600423	NA	Hirschsprung disease	Major susceptibility factor in	Height[25282103];Obesity-related traits[23251661];	HP:0200008;HP:0000407;HP:0001531;HP:0002014;HP:0001249;HP:0004322;HP:0002019;HP:0100031;HP:0001824;HP:0002251;HP:0002027;HP:0005214;HP:0001181;HP:0100806;HP:0002017;HP:0001795;HP:0000414;HP:0001631;HP:0012332;HP:0000822;HP:0001182;HP:0000006;HP:0001643;HP:0009626;HP:0000713;HP:0001649;HP:0002251;HP:0000054;HP:0000426;HP:0003196;HP:0000358;HP:0000378;HP:0001629;HP:0002133;HP:0004972;HP:0001426;HP:0004421;HP:0005117	Intestinal polyposis;Sensorineural hearing impairment;Failure to thrive in infancy;Diarrhea;Intellectual disability;Short stature;Constipation;Neoplasm of the thyroid gland;Weight loss;Aganglionic megacolon;Abdominal pain;Intestinal obstruction;Adducted thumb;Sepsis;Nausea and vomiting;Hyperconvex nail;Bulbous nose;Atrial septal defect;Abnormal autonomic nervous system physiology;Hypertension;Tapered finger;Autosomal dominant inheritance;Patent ductus arteriosus;Contractures of the interphalangeal joint of the thumb;Agitation;Tachycardia;Aganglionic megacolon;Micropenis;Prominent nasal bridge;Short nose;Posteriorly rotated ears;Cupped ear;Ventricular septal defect;Status epilepticus;Elevated mean arterial pressure;Multifactorial inheritance;Elevated systolic blood pressure;Elevated diastolic blood pressure	not_specified	criteria_provided,_single_submitter	Benign	All isoforms are expressed in umbilical vein endothelial cells, polynuclear neutrophils, fibroblasts, atrium cardiomyocytes and ventricles. Isoforms A, B and C are also expressed in placenta, lung, heart, adrenal gland and phaeochromocytoma; isoforms A and C in liver, testis and small intestine; isoform B, C and D in endothelial cells and umbilical vein smooth muscle cells; isoforms C and D in saphenous vein cells, and isoform C in kidney. {ECO:0000269|PubMed:10491078, ECO:0000269|PubMed:9396733}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;skin;myocardium;stomach;lens;unclassifiable (Anatomical System);amniotic fluid;choroid;larynx;kidney;uterus;retina;pancreas;head and neck;hypopharynx;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;vein;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;macula lutea;bladder;colon;placenta;prostate;nasopharynx;breast;optic nerve;amnion;	ciliary ganglion;pons;adrenal gland;adrenal cortex;skeletal muscle;	0.0216	E	N	N	N	0.531371481367368	E	Ece1	muscle phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; endocrine/exocrine gland phenotype; pigmentation phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; digestive/alimentary phenotype; vision/eye phenotype; immune system phenotype; skeleton phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	ece1	ceratobranchial cartilage	decreased amount	abnormal	0.1272	0.1684	0.1638	0.0997	0.1782	0.114617	0.0928	0.12538	0.084565	PASS	0	0.174	202	0.193662	37	chr1	21255932	NA	C	T	672.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.1;AS_FS=5.949;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.46;AS_ReadPosRankSum=-0.3;AS_SOR=1.714;BaseQRankSum=1.2;DP=56;ExcessHet=3.0103;FS=5.949;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.46;ReadPosRankSum=-0.26;SOR=1.714	GT:AD:DP:GQ:PL	0/1:27,27:54:99:680,0,604
chr1	21345450	21345450	T	G	ECE1	UTR5	NA	NM_001113348:c.-72A>C	NA	0.7633	GnomAdGenome_AF_afr	123	53	HomozygousVariant	hom	20	0	20	1	612.06	PASS	NA	NA	600423	NA	Hirschsprung disease	Major susceptibility factor in	Height[25282103];Obesity-related traits[23251661];	HP:0200008;HP:0000407;HP:0001531;HP:0002014;HP:0001249;HP:0004322;HP:0002019;HP:0100031;HP:0001824;HP:0002251;HP:0002027;HP:0005214;HP:0001181;HP:0100806;HP:0002017;HP:0001795;HP:0000414;HP:0001631;HP:0012332;HP:0000822;HP:0001182;HP:0000006;HP:0001643;HP:0009626;HP:0000713;HP:0001649;HP:0002251;HP:0000054;HP:0000426;HP:0003196;HP:0000358;HP:0000378;HP:0001629;HP:0002133;HP:0004972;HP:0001426;HP:0004421;HP:0005117	Intestinal polyposis;Sensorineural hearing impairment;Failure to thrive in infancy;Diarrhea;Intellectual disability;Short stature;Constipation;Neoplasm of the thyroid gland;Weight loss;Aganglionic megacolon;Abdominal pain;Intestinal obstruction;Adducted thumb;Sepsis;Nausea and vomiting;Hyperconvex nail;Bulbous nose;Atrial septal defect;Abnormal autonomic nervous system physiology;Hypertension;Tapered finger;Autosomal dominant inheritance;Patent ductus arteriosus;Contractures of the interphalangeal joint of the thumb;Agitation;Tachycardia;Aganglionic megacolon;Micropenis;Prominent nasal bridge;Short nose;Posteriorly rotated ears;Cupped ear;Ventricular septal defect;Status epilepticus;Elevated mean arterial pressure;Multifactorial inheritance;Elevated systolic blood pressure;Elevated diastolic blood pressure	NA	NA	NA	All isoforms are expressed in umbilical vein endothelial cells, polynuclear neutrophils, fibroblasts, atrium cardiomyocytes and ventricles. Isoforms A, B and C are also expressed in placenta, lung, heart, adrenal gland and phaeochromocytoma; isoforms A and C in liver, testis and small intestine; isoform B, C and D in endothelial cells and umbilical vein smooth muscle cells; isoforms C and D in saphenous vein cells, and isoform C in kidney. {ECO:0000269|PubMed:10491078, ECO:0000269|PubMed:9396733}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;skin;myocardium;stomach;lens;unclassifiable (Anatomical System);amniotic fluid;choroid;larynx;kidney;uterus;retina;pancreas;head and neck;hypopharynx;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;vein;spleen;liver;peripheral nerve;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;duodenum;lung;cerebral cortex;ovary;thyroid;macula lutea;bladder;colon;placenta;prostate;nasopharynx;breast;optic nerve;amnion;	ciliary ganglion;pons;adrenal gland;adrenal cortex;skeletal muscle;	0.0216	E	N	N	N	0.531371481367368	E	Ece1	muscle phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; endocrine/exocrine gland phenotype; pigmentation phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; digestive/alimentary phenotype; vision/eye phenotype; immune system phenotype; skeleton phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); 	ece1	ceratobranchial cartilage	decreased amount	abnormal	0	0	0	0.6054	0.7633	0.611022	0	0.0002689	0.598754	PASS	0	0.623	128	0.627907	56	chr1	21345450	NA	T	G	612.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.6;AS_ReadPosRankSum=.;AS_SOR=1.721;DP=23;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.6;SOR=1.721	GT:AD:DP:GQ:PL	1/1:0,20:20:60:626,60,0
chr1	21424721	21424721	G	A	ECE1;NBPF3	intergenic	NA	dist=79217;dist=15416	NA	0.5584	GnomAdGenome_AF_ami	0	0	HeterozygousVariant	het	45	25	20	0.444444444444444	399.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.4655	0.5584	0	0	0.10189	0		0	0.448	243	0.441176	60	chr1	21424721	NA	G	A	399.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=1.137;AS_MQ=46.08;AS_MQRankSum=-0.9;AS_QD=8.89;AS_ReadPosRankSum=-1.8;AS_SOR=0.519;BaseQRankSum=-0.684;DP=46;ExcessHet=3.0103;FS=1.137;MLEAC=1;MLEAF=0.5;MQ=46.05;MQRankSum=-0.865;QD=8.88;ReadPosRankSum=-1.737;SOR=0.519	GT:AD:DP:GQ:PL	0/1:25,20:45:99:407,0,594
chr1	21426188	21426188	C	T	ECE1;NBPF3	intergenic	NA	dist=80684;dist=13949	NA	0.2477	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	4	2	2	0.5	58.64	DP10;MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0927	0.2477	0	0	0.0078265	0		0	0.26	94	0.25	34	chr1	21426188	NA	C	T	58.64	DP10;MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0;AS_MQ=46.01;AS_MQRankSum=1.3;AS_QD=14.75;AS_ReadPosRankSum=-0.5;AS_SOR=0.693;BaseQRankSum=0;DP=5;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=39.02;MQRankSum=1.38;QD=14.66;ReadPosRankSum=-0.431;SOR=0.693	GT:AD:DP:GQ:PL	0/1:2,2:4:45:66,0,45
chr1	21426259	21426259	G	A	ECE1;NBPF3	intergenic	NA	dist=80755;dist=13878	NA	0.247	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	12	8	4	0.333333333333333	136.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0906	0.247	0	0	0.0310435	0		0	0.261	141	0.25	34	chr1	21426259	NA	G	A	136.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=0;AS_MQ=46.51;AS_MQRankSum=1.3;AS_QD=11.42;AS_ReadPosRankSum=0.5;AS_SOR=0.693;BaseQRankSum=-0.799;DP=12;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=37.06;MQRankSum=1.31;QD=11.39;ReadPosRankSum=0.568;SOR=0.693	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:8,4:12:99:0|1:21426259_G_A:144,0,324:21426259
chr1	21426269	21426269	T	A	ECE1;NBPF3	intergenic	NA	dist=80765;dist=13868	NA	0.2475	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	13	9	4	0.307692307692308	133.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.093	0.2475	0	0	0.0253957	0		0	0.261	141	0.25	34	chr1	21426269	NA	T	A	133.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0;AS_MQ=46.51;AS_MQRankSum=1.5;AS_QD=10.31;AS_ReadPosRankSum=0;AS_SOR=0.527;BaseQRankSum=-0.396;DP=13;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=36.39;MQRankSum=1.54;QD=10.28;ReadPosRankSum=0.068;SOR=0.527	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:9,4:13:99:0|1:21426259_G_A:141,0,346:21426259
chr1	21426273	21426273	A	G	ECE1;NBPF3	intergenic	NA	dist=80769;dist=13864	NA	0.4749	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	13	7	6	0.461538461538462	101.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.3948	0.4749	0	0	0.0068369	0		0	0.487	263	0.477941	65	chr1	21426273	NA	A	G	101.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=0;AS_MQ=32.59;AS_MQRankSum=-1.1;AS_QD=7.85;AS_ReadPosRankSum=1;AS_SOR=0.495;BaseQRankSum=-0.615;DP=13;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=36.39;MQRankSum=-1.034;QD=7.82;ReadPosRankSum=1.05;SOR=0.495	GT:AD:DP:GQ:PL	0/1:7,6:13:99:109,0,222
chr1	21426289	21426289	T	G	ECE1;NBPF3	intergenic	NA	dist=80785;dist=13848	NA	0.4497	GnomAdGenome_AF_sas	0	0	HeterozygousVariant	het	12	7	5	0.416666666666667	81.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.3306	0.4497	0	0	0.0022315	0		0	0.48	259	0.485294	66	chr1	21426289	NA	T	G	81.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0;AS_MQ=34.44;AS_MQRankSum=-0.8;AS_QD=6.83;AS_ReadPosRankSum=1.3;AS_SOR=0.76;BaseQRankSum=-0.305;DP=12;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=37.49;MQRankSum=-0.754;QD=6.8;ReadPosRankSum=1.35;SOR=0.76	GT:AD:DP:GQ:PL	0/1:7,5:12:89:89,0,166
chr1	21426337	21426337	C	T	ECE1;NBPF3	intergenic	NA	dist=80833;dist=13800	NA	0.2621	GnomAdGenome_AF_eas	0	0	HeterozygousVariant	het	9	6	3	0.333333333333333	40.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1406	0.2621	0	0	0.0000582	0		0	0.404	218	0.375	51	chr1	21426337	NA	C	T	40.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=0;AS_MQ=21;AS_MQRankSum=-2.6;AS_QD=4.56;AS_ReadPosRankSum=-0.5;AS_SOR=0.593;BaseQRankSum=-0.531;DP=11;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=36.73;MQRankSum=-2.515;QD=4.52;ReadPosRankSum=-0.48;SOR=0.593	GT:AD:DP:GQ:PL	0/1:6,3:9:48:48,0,162
chr1	21428562	21428562	C	A	ECE1;NBPF3	intergenic	NA	dist=83058;dist=11575	NA	0.895	GnomAdGenome_AF_ami	128	33	HeterozygousVariant	het	42	24	18	0.428571428571429	425.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.7396	0.895	0.683107	0	0.0001153	0		0	0.69	118	0.69697	26	chr1	21428562	NA	C	A	425.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.5;AS_FS=0;AS_MQ=38.34;AS_MQRankSum=0.4;AS_QD=10.14;AS_ReadPosRankSum=-0.5;AS_SOR=0.553;BaseQRankSum=2.55;DP=44;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=37.14;MQRankSum=0.42;QD=10.13;ReadPosRankSum=-0.458;SOR=0.553	GT:AD:DP:GQ:PL	0/1:24,18:42:99:433,0,555
chr1	21428649	21428649	C	T	ECE1;NBPF3	intergenic	NA	dist=83145;dist=11488	NA	0.2868	GnomAdGenome_AF_sas	22	6	HeterozygousVariant	het	24	10	14	0.583333333333333	392.64	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.0963	0.2868	0.142971	0	0.0814507	0		0	0.297	116	0.265625	22	chr1	21428649	NA	C	T	392.64	MQ40	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=6.752;AS_MQ=33.2;AS_MQRankSum=-1.3;AS_QD=16.38;AS_ReadPosRankSum=0.1;AS_SOR=1.677;BaseQRankSum=-0.804;DP=25;ExcessHet=3.0103;FS=6.752;MLEAC=1;MLEAF=0.5;MQ=34.38;MQRankSum=-1.254;QD=16.36;ReadPosRankSum=0.117;SOR=1.677	GT:AD:DP:GQ:PL	0/1:10,14:24:99:400,0,290
chr1	21428852	21428852	T	C	ECE1;NBPF3	intergenic	NA	dist=83348;dist=11285	NA	0.2352	GnomAdGenome_AF_fin	7	3	HeterozygousVariant	het	69	41	28	0.405797101449275	707.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.1699	0.2352	0.142173	0	0.0241394	0		0	0.202	59	0.25	28	chr1	21428852	NA	T	C	707.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.3;AS_FS=3.329;AS_MQ=56.85;AS_MQRankSum=0.2;AS_QD=10.26;AS_ReadPosRankSum=1.7;AS_SOR=0.903;BaseQRankSum=2.39;DP=74;ExcessHet=3.0103;FS=3.329;MLEAC=1;MLEAF=0.5;MQ=57.51;MQRankSum=0.268;QD=10.26;ReadPosRankSum=1.76;SOR=0.903	GT:AD:DP:GQ:PL	0/1:41,28:69:99:715,0,974
chr1	21429046	21429046	C	A	ECE1;NBPF3	intergenic	NA	dist=83542;dist=11091	NA	0.8943	GnomAdGenome_AF_ami	126	30	WT/SomaticVariant	het	27	21	6	0.222222222222222	128.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.7387	0.8943	0.687899	0	0.0001153	0		0	0.673	110	0.620968	17	chr1	21429046	NA	C	A	128.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.9;AS_FS=0;AS_MQ=38.14;AS_MQRankSum=-1.4;AS_QD=4.78;AS_ReadPosRankSum=-0.9;AS_SOR=0.972;BaseQRankSum=2.93;DP=29;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=44.85;MQRankSum=-1.359;QD=4.76;ReadPosRankSum=-0.876;SOR=0.972	GT:AD:DP:GQ:PL	0/1:21,6:27:99:136,0,504
chr1	21429263	21429263	G	C	ECE1;NBPF3	intergenic	NA	dist=83759;dist=10874	NA	0.8951	GnomAdGenome_AF_ami	128	34	HeterozygousVariant	het	107	57	50	0.467289719626168	1214.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.7404	0.8951	0.688498	0	0.0006147	0		0	0.691	120	0.698529	27	chr1	21429263	NA	G	C	1214.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=6.074;AS_MQ=56.15;AS_MQRankSum=-0.7;AS_QD=11.36;AS_ReadPosRankSum=1.1;AS_SOR=1.242;BaseQRankSum=-0.14;DP=109;ExcessHet=3.0103;FS=6.074;MLEAC=1;MLEAF=0.5;MQ=55.47;MQRankSum=-0.648;QD=11.35;ReadPosRankSum=1.13;SOR=1.242	GT:AD:DP:GQ:PL	0/1:57,50:107:99:1222,0,1389
chr1	21429374	21429374	A	G	ECE1;NBPF3	intergenic	NA	dist=83870;dist=10763	NA	0.8956	GnomAdGenome_AF_ami	128	34	HeterozygousVariant	het	108	56	52	0.481481481481481	1199.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.7402	0.8956	0.688498	0	0.0727998	0		0	0.689	119	0.698529	27	chr1	21429374	NA	A	G	1199.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1;AS_FS=0;AS_MQ=47.51;AS_MQRankSum=-7.7;AS_QD=11.11;AS_ReadPosRankSum=0.9;AS_SOR=0.627;BaseQRankSum=1.06;DP=112;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=53.8;MQRankSum=-7.661;QD=11.11;ReadPosRankSum=0.972;SOR=0.627	GT:AD:DP:GQ:PL	0/1:56,52:108:99:1207,0,1232
chr1	21429413	21429413	G	A	ECE1;NBPF3	intergenic	NA	dist=83909;dist=10724	NA	0.8964	GnomAdGenome_AF_ami	128	34	HeterozygousVariant	het	106	48	58	0.547169811320755	1379.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.7404	0.8964	0.688498	0	0.0528712	0		0	0.691	120	0.698529	27	chr1	21429413	NA	G	A	1379.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.1;AS_FS=0;AS_MQ=50.02;AS_MQRankSum=-6.3;AS_QD=13.02;AS_ReadPosRankSum=0;AS_SOR=0.653;BaseQRankSum=0.198;DP=112;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=54.43;MQRankSum=-6.262;QD=13.02;ReadPosRankSum=0.067;SOR=0.653	GT:AD:DP:GQ:PL	0/1:48,58:106:99:1387,0,1054
chr1	21429515	21429515	G	T	ECE1;NBPF3	intergenic	NA	dist=84011;dist=10622	NA	0.8956	GnomAdGenome_AF_ami	128	36	HeterozygousVariant	het	75	41	34	0.453333333333333	825.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.7399	0.8956	0.688698	0	0.0644041	0		0	0.691	120	0.698529	23	chr1	21429515	NA	G	T	825.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=0.945;AS_MQ=56.38;AS_MQRankSum=-0.8;AS_QD=11.01;AS_ReadPosRankSum=-0.5;AS_SOR=0.909;BaseQRankSum=0.748;DP=76;ExcessHet=3.0103;FS=0.945;MLEAC=1;MLEAF=0.5;MQ=56.77;MQRankSum=-0.747;QD=11.01;ReadPosRankSum=-0.469;SOR=0.909	GT:AD:DP:GQ:PL	0/1:41,34:75:99:833,0,972
chr1	21429576	21429576	G	A	ECE1;NBPF3	intergenic	NA	dist=84072;dist=10561	NA	0.8949	GnomAdGenome_AF_ami	85	34	HeterozygousVariant	het	39	25	14	0.358974358974359	349.64	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.7398	0.8949	0.688698	0	0.335831	0		0	0.682	77	0.679104	23	chr1	21429576	NA	G	A	349.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.4;AS_FS=5.743;AS_MQ=55.65;AS_MQRankSum=-0.5;AS_QD=8.97;AS_ReadPosRankSum=0.2;AS_SOR=2.015;BaseQRankSum=2.46;DP=40;ExcessHet=3.0103;FS=5.743;MLEAC=1;MLEAF=0.5;MQ=55.68;MQRankSum=-0.481;QD=8.97;ReadPosRankSum=0.293;SOR=2.015	GT:AD:DP:GQ:PL	0/1:25,14:39:99:357,0,575
chr1	21468895	21468895	A	G	NBPF3	exonic	nonsynonymous SNV	NA	NBPF3:NM_001256416:exon3:c.A341G:p.Y114C,NBPF3:NM_032264:exon3:c.A341G:p.Y114C,NBPF3:NM_001330381:exon7:c.A173G:p.Y58C	0.654971	GME_AP	157	33	HomozygousVariant	hom	30	0	30	1	991.06	SOR3	18.54	NA	612992	Benign	NA	NA	Vitamin B levels in ischemic stroke[25147783];Phosphorus levels[20558539;29403010];Liver enzyme levels (alkaline phosphatase)[22001757];Liver enzyme levels[18940312];Folate pathway vitamin levels[19744961];	NA	NA	NA	NA	NA	Expressed in testis and fetal heart, as well as in non small cell lung carcinoma and neuroblastoma cell line. {ECO:0000269|PubMed:16079250}.;	D	D	D	D	NA	P	M	T	D	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	0.0004	0.024	Medium	Medium	Medium	liver;ganglion;skin;stomach;bone;testis;pituitary gland;brain;unclassifiable (Anatomical System);heart;lung;larynx;uterus;thyroid;whole body;pancreas;colon;bile duct;head and neck;breast;hypothalamus;	NA	0.995	NA	N	N	NA	0.255884594851652	N	NA	NA	NA	NA	NA	NA	0.5264	0.5689	0.5676	0.4522	0.5783	0.423922	0.4403	0.513286	0.507389	PASS	0.654971	0.507	295	0.485915	72	chr1	21468895	NA	A	G	991.06	SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=33.03;AS_ReadPosRankSum=.;AS_SOR=3.407;DP=31;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=33.04;SOR=3.407	GT:AD:DP:GQ:PL	1/1:0,30:30:89:1005,89,0
chr1	21481666	21481666	G	A	NBPF3	exonic	synonymous SNV	NA	NBPF3:NM_001256417:exon12:c.G1293A:p.S431S,NBPF3:NM_001256416:exon13:c.G1467A:p.S489S,NBPF3:NM_032264:exon13:c.G1503A:p.S501S,NBPF3:NM_001330381:exon17:c.G1335A:p.S445S	0.6139	GnomAdGenome_AF_sas	136	36	HomozygousVariant	hom	2	0	2	1	37.32	DP10	NA	NA	612992	Benign	NA	NA	Vitamin B levels in ischemic stroke[25147783];Phosphorus levels[20558539;29403010];Liver enzyme levels (alkaline phosphatase)[22001757];Liver enzyme levels[18940312];Folate pathway vitamin levels[19744961];	NA	NA	NA	NA	NA	Expressed in testis and fetal heart, as well as in non small cell lung carcinoma and neuroblastoma cell line. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	liver;ganglion;skin;stomach;bone;testis;pituitary gland;brain;unclassifiable (Anatomical System);heart;lung;larynx;uterus;thyroid;whole body;pancreas;colon;bile duct;head and neck;breast;hypothalamus;	NA	0.995	NA	N	N	NA	0.255884594851652	N	NA	NA	NA	NA	NA	NA	0.4923	0.5903	0.5897	0.4579	0.6139	0.467053	0	0.182227	0.453416	VQSRTrancheSNP99.00to99.90	0.563559	0.607	444	0.618705	100	chr1	21481666	NA	G	A	37.32	DP10	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=50;AS_MQRankSum=.;AS_QD=18.5;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=2;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=50;QD=18.66;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,2:2:6:49,6,0
chr1	21483257	21483257	T	C	NBPF3	exonic	synonymous SNV	NA	NBPF3:NM_001256417:exon14:c.T1563C:p.Y521Y,NBPF3:NM_001256416:exon15:c.T1737C:p.Y579Y,NBPF3:NM_032264:exon15:c.T1773C:p.Y591Y,NBPF3:NM_001330381:exon19:c.T1605C:p.Y535Y	0.948	GnomAdExome_AF_sas	489	116	HomozygousVariant	hom	6	0	6	1	232.97	DP10;MQ40;SOR3	NA	NA	612992	Benign	NA	NA	Vitamin B levels in ischemic stroke[25147783];Phosphorus levels[20558539;29403010];Liver enzyme levels (alkaline phosphatase)[22001757];Liver enzyme levels[18940312];Folate pathway vitamin levels[19744961];	NA	NA	NA	NA	NA	Expressed in testis and fetal heart, as well as in non small cell lung carcinoma and neuroblastoma cell line. {ECO:0000269|PubMed:16079250}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	liver;ganglion;skin;stomach;bone;testis;pituitary gland;brain;unclassifiable (Anatomical System);heart;lung;larynx;uterus;thyroid;whole body;pancreas;colon;bile duct;head and neck;breast;hypothalamus;	NA	0.995	NA	N	N	NA	0.255884594851652	N	NA	NA	NA	NA	NA	NA	0.8103	0.948	0.9461	0.1628	0.3051	0	0	0.0001153	0.680769	VQSRTrancheSNP99.90to100.00	0.831858	0.896	78	0.894161	13	chr1	21483257	NA	T	C	232.97	DP10;MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=39.17;AS_MQRankSum=.;AS_QD=34.12;AS_ReadPosRankSum=.;AS_SOR=3.912;DP=6;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=39.17;QD=33.98;SOR=3.912	GT:AD:DP:GQ:PL	1/1:0,6:6:18:247,18,0
chr1	21563142	21563142	T	C	ALPL	exonic	synonymous SNV	NA	ALPL:NM_001177520:exon3:c.T99C:p.S33S,ALPL:NM_001127501:exon4:c.T165C:p.S55S,ALPL:NM_000478:exon5:c.T330C:p.S110S,ALPL:NM_001369803:exon5:c.T330C:p.S110S,ALPL:NM_001369804:exon5:c.T330C:p.S110S,ALPL:NM_001369805:exon5:c.T330C:p.S110S	1	GME_Israel	758	127	HomozygousVariant	hom	100	0	100	1	2709.06	PASS	NA	[MIM:146300]Hypophosphatasia;[MIM:241510]Hypophosphatasia childhood type;[MIM:241500]Hypophosphatasia infantile type;	171760	Benign	Odontohypophosphatasia;Perinatal lethal hypophosphatasia;Prenatal benign hypophosphatasia;Infantile hypophosphatasia;Childhood-onset hypophosphatasia;Adult hypophosphatasia	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) (loss of function) in	Blood metabolite ratios[24816252;24816252];Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)[23648065];Vitamin B levels in ischemic stroke[25147783];Phosphorus levels[20558539;29403010];Response to TNF-alpha inhibitors in rheumatoid arthritis[22569225];Serum alkaline phosphatase levels[29403010];Liver enzyme levels (alkaline phosphatase)[22001757];Liver enzyme levels[18940312];Hematological and biochemical traits[20139978];Folate pathway vitamin levels[19744961;19303062];Metabolic traits[21886157];Kidney stones[26272126];	HP:0006323;HP:0000007;HP:0002007;HP:0003198;HP:0003491;HP:0003239;HP:0011864;HP:0003282;HP:0000268;HP:0001363;HP:0000520;HP:0001250;HP:0000897;HP:0004322;HP:0000670;HP:0002979;HP:0001024;HP:0002515;HP:0000670;HP:0002748;HP:0002757;HP:0006323;HP:0000007;HP:0003040;HP:0002756;HP:0000934;HP:0003282;HP:0000006;HP:0002749;HP:0006357;HP:0001760;HP:0001508;HP:0000897;HP:0002659;HP:0004492;HP:0001903;HP:0003072;HP:0002013;HP:0001250;HP:0000121;HP:0000926;HP:0003239;HP:0002150;HP:0000007;HP:0001290;HP:0001363;HP:0003021;HP:0000592;HP:0008428;HP:0000737;HP:0001561;HP:0002979;HP:0004606;HP:0000164;HP:0008873;HP:0001024;HP:0001608;HP:0003491;HP:0002170;HP:0005474;HP:0001522;HP:0000773;HP:0001252;HP:0002039;HP:0002104;HP:0002983;HP:0006385;HP:0001945;HP:0011864;HP:0003826;HP:0002019;HP:0002205	Premature loss of primary teeth;Autosomal recessive inheritance;Frontal bossing;Myopathy;Elevated urine pyrophosphate;Phosphoethanolaminuria;Elevated plasma pyrophosphate;Low alkaline phosphatase;Dolichocephaly;Craniosynostosis;Proptosis;Seizure;Rachitic rosary;Short stature;Carious teeth;Bowing of the legs;Skin dimple over apex of long bone angulation;Waddling gait;Carious teeth;Rickets;Recurrent fractures;Premature loss of primary teeth;Autosomal recessive inheritance;Arthropathy;Pathologic fracture;Chondrocalcinosis;Low alkaline phosphatase;Autosomal dominant inheritance;Osteomalacia;Premature loss of permanent teeth;Abnormality of the foot;Failure to thrive;Rachitic rosary;Increased susceptibility to fractures;Widely patent fontanelles and sutures;Anemia;Hypercalcemia;Vomiting;Seizure;Nephrocalcinosis;Platyspondyly;Phosphoethanolaminuria;Hypercalciuria;Autosomal recessive inheritance;Generalized hypotonia;Craniosynostosis;Metaphyseal cupping;Blue sclerae;Vertebral clefting;Irritability;Polyhydramnios;Bowing of the legs;Unossified vertebral bodies;Abnormality of the dentition;Disproportionate short-limb short stature;Skin dimple over apex of long bone angulation;Abnormality of the voice;Elevated urine pyrophosphate;Intracranial hemorrhage;Decreased calvarial ossification;Death in infancy;Short ribs;Muscular hypotonia;Anorexia;Apnea;Micromelia;Short lower limbs;Fever;Elevated plasma pyrophosphate;Stillbirth;Constipation;Recurrent respiratory infections	not_specified	criteria_provided,_single_submitter	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0447	E	N	N	N	0.944084126099184	E	Alpl	muscle phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; reproductive system phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; digestive/alimentary phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.9472	0.9864	0.9851	0.9238	0.9879	0.929513	0.9217	0.925906	0.917898	PASS	1	0.95	71	0.933099	11	chr1	21563142	NA	T	C	2709.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.09;AS_ReadPosRankSum=.;AS_SOR=0.909;DP=102;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.09;SOR=0.909	GT:AD:DP:GQ:PL	1/1:0,100:100:99:2723,299,0
chr1	21603938	21603939	AG	-	RAP1GAP	intronic	NA	NA	NA	0.0222	GnomAdExome_AF_asj		0	WT/SomaticVariant	het	29	25	4	0.137931034482759	46.6	QD2	NA	NA	600278	NA	NA	NA	High light scatter reticulocyte percentage of red cells[27863252];High light scatter reticulocyte count[27863252];Liver enzyme levels[18940312];Neurocognitive impairment in HIV-1 infection (continuous)[28447399];Immature fraction of reticulocytes[27863252];	NA	NA	NA	NA	NA	Significant expression seen in the brain, kidney and pancreas. Abundant in the cerebral cortex and expressed at much lower levels in the spinal cord. Not detected in the lymphoid tissues. {ECO:0000269|PubMed:9346962}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	hippocampus;skin;stomach;testis;brain;unclassifiable (Anatomical System);cerebellum;lung;kidney;ovary;thyroid;frontal lobe;sympathetic chain;placenta;prostate;hypothalamus;islets of Langerhans;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;superior cervical ganglion;trigeminal ganglion;adrenal cortex;fetal thyroid;pons;kidney;thyroid;occipital lobe;subthalamic nucleus;whole brain;uterus corpus;adrenal gland;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.0176	NA	N	N	N	0.863026334527466	E	Rap1gap	NA	NA	NA	NA	NA	0.0139	0.0197	0.022	0.00002819	0.0002	0	0	0.0007684	0.018062	PASS	0			0.014286	4	chr1	21603937	NA	CAG	C	46.6	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=2.062;AS_MQ=60;AS_MQRankSum=0;AS_QD=1.62;AS_ReadPosRankSum=-0.6;AS_SOR=0.297;BaseQRankSum=0.237;DP=32;ExcessHet=3.0103;FS=2.062;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=1.61;ReadPosRankSum=-0.506;SOR=0.297	GT:AD:DP:GQ:PL	0/1:25,4:29:54:54,0,872
chr1	21608940	21608940	G	T	RAP1GAP	intronic	NA	NA	NA	0.6497	GnomAdExome_AF_eas	167	39	HomozygousVariant	hom	67	0	67	1	1823.06	PASS	NA	NA	600278	NA	NA	NA	High light scatter reticulocyte percentage of red cells[27863252];High light scatter reticulocyte count[27863252];Liver enzyme levels[18940312];Neurocognitive impairment in HIV-1 infection (continuous)[28447399];Immature fraction of reticulocytes[27863252];	NA	NA	NA	NA	NA	Significant expression seen in the brain, kidney and pancreas. Abundant in the cerebral cortex and expressed at much lower levels in the spinal cord. Not detected in the lymphoid tissues. {ECO:0000269|PubMed:9346962}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0076	0	Medium	Medium	Medium	hippocampus;skin;stomach;testis;brain;unclassifiable (Anatomical System);cerebellum;lung;kidney;ovary;thyroid;frontal lobe;sympathetic chain;placenta;prostate;hypothalamus;islets of Langerhans;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;superior cervical ganglion;trigeminal ganglion;adrenal cortex;fetal thyroid;pons;kidney;thyroid;occipital lobe;subthalamic nucleus;whole brain;uterus corpus;adrenal gland;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.0176	NA	N	N	N	0.863026334527466	E	Rap1gap	NA	NA	NA	NA	NA	0.4959	0.6497	0.6534	0.4234	0.6462	0.454673	0.4153	0.48295	0.424466	PASS	0	0.534	283	0.528169	72	chr1	21608940	NA	G	T	1823.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.21;AS_ReadPosRankSum=.;AS_SOR=0.917;DP=69;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.21;SOR=0.917	GT:AD:DP:GQ:PL	1/1:0,67:67:99:1837,201,0
chr1	21613248	21613248	G	C	RAP1GAP	intronic	NA	NA	NA	0.6662	GnomAdExome_AF_amr	49	28	HeterozygousVariant	het	82	53	29	0.353658536585366	578.64	PASS	NA	NA	600278	NA	NA	NA	High light scatter reticulocyte percentage of red cells[27863252];High light scatter reticulocyte count[27863252];Liver enzyme levels[18940312];Neurocognitive impairment in HIV-1 infection (continuous)[28447399];Immature fraction of reticulocytes[27863252];	NA	NA	NA	NA	NA	Significant expression seen in the brain, kidney and pancreas. Abundant in the cerebral cortex and expressed at much lower levels in the spinal cord. Not detected in the lymphoid tissues. {ECO:0000269|PubMed:9346962}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	hippocampus;skin;stomach;testis;brain;unclassifiable (Anatomical System);cerebellum;lung;kidney;ovary;thyroid;frontal lobe;sympathetic chain;placenta;prostate;hypothalamus;islets of Langerhans;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;superior cervical ganglion;trigeminal ganglion;adrenal cortex;fetal thyroid;pons;kidney;thyroid;occipital lobe;subthalamic nucleus;whole brain;uterus corpus;adrenal gland;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.0176	NA	N	N	N	0.863026334527466	E	Rap1gap	NA	NA	NA	NA	NA	0.4761	0.6662	0.662	0.4429	0.5775	0.48103	0.4278	0.459612	0.495074	PASS	0	0.474	99	0.43617	67	chr1	21613248	NA	G	C	578.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.3;AS_FS=4.59;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.06;AS_ReadPosRankSum=1.3;AS_SOR=0.316;BaseQRankSum=-1.266;DP=82;ExcessHet=3.0103;FS=4.59;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.06;ReadPosRankSum=1.36;SOR=0.316	GT:AD:DP:GQ:PL	0/1:53,29:82:99:586,0,1384
chr1	21614062	21614062	C	T	RAP1GAP	exonic	nonsynonymous SNV	NA	RAP1GAP:NM_001145658:exon8:c.G511A:p.A171T,RAP1GAP:NM_002885:exon8:c.G319A:p.A107T,RAP1GAP:NM_001145657:exon9:c.G319A:p.A107T,RAP1GAP:NM_001330383:exon9:c.G319A:p.A107T,RAP1GAP:NM_001350524:exon10:c.G319A:p.A107T,RAP1GAP:NM_001350525:exon10:c.G319A:p.A107T,RAP1GAP:NM_001350527:exon10:c.G319A:p.A107T,RAP1GAP:NM_001350528:exon10:c.G319A:p.A107T,RAP1GAP:NM_001350526:exon11:c.G319A:p.A107T	0.462	GnomAdGenome_AF_nfe	130	28	HeterozygousVariant	het	71	29	42	0.591549295774648	821.64	PASS	2.519	NA	600278	Benign	NA	NA	High light scatter reticulocyte percentage of red cells[27863252];High light scatter reticulocyte count[27863252];Liver enzyme levels[18940312];Neurocognitive impairment in HIV-1 infection (continuous)[28447399];Immature fraction of reticulocytes[27863252];	NA	NA	NA	NA	NA	Significant expression seen in the brain, kidney and pancreas. Abundant in the cerebral cortex and expressed at much lower levels in the spinal cord. Not detected in the lymphoid tissues. {ECO:0000269|PubMed:9346962}.;	T	T	B	B	N	P	L	D	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;.;.;	N	N	.;.;.;.;.;.	NA	NA	Medium	Medium	Medium	hippocampus;skin;stomach;testis;brain;unclassifiable (Anatomical System);cerebellum;lung;kidney;ovary;thyroid;frontal lobe;sympathetic chain;placenta;prostate;hypothalamus;islets of Langerhans;	caudate nucleus;temporal lobe;amygdala;prefrontal cortex;cingulate cortex;superior cervical ganglion;trigeminal ganglion;adrenal cortex;fetal thyroid;pons;kidney;thyroid;occipital lobe;subthalamic nucleus;whole brain;uterus corpus;adrenal gland;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.0176	NA	N	N	N	0.863026334527466	E	Rap1gap	NA	NA	NA	NA	NA	0.4081	0.4522	0.4515	0.4144	0.462	0.392971	0.4254	0.409755	0.373563	PASS	0.458333	0.45	269	0.46831	77	chr1	21614062	NA	C	T	821.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.58;AS_ReadPosRankSum=0.4;AS_SOR=0.631;BaseQRankSum=-2.385;DP=71;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.57;ReadPosRankSum=0.433;SOR=0.631	GT:AD:DP:GQ:PL	0/1:29,42:71:99:829,0,637
chr1	21687278	21687278	G	A	USP48	intronic	NA	NA	NA	0.7354	GnomAdExome_AF_amr	60	27	HeterozygousVariant	het	31	19	12	0.387096774193548	286.64	PASS	NA	NA	617445	NA	NA	NA	High light scatter reticulocyte percentage of red cells[27863252];High light scatter reticulocyte count[27863252];Immature fraction of reticulocytes[27863252];	NA	NA	NA	NA	NA	Widely expressed. {ECO:0000269|PubMed:14715245, ECO:0000269|PubMed:15354349, ECO:0000269|PubMed:16214042}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;skin;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);larynx;kidney;uterus;whole body;retina;pancreas;muscle;head and neck;skeletal muscle;islets of Langerhans;visual apparatus;spleen;liver;cartilage;endometrium;bone;germinal center;brain;blood;heart;lung;ovary;thyroid;frontal lobe;colon;placenta;prostate;breast;	ciliary ganglion;caudate nucleus;fetal brain;subthalamic nucleus;prefrontal cortex;dorsal root ganglion;superior cervical ganglion;cingulate cortex;trigeminal ganglion;parietal lobe;globus pallidus;medulla oblongata;	0.533	NA	N	S	N	0.868319930408785	E	Usp48	NA	usp48	pharyngeal arch cartilage	malformed	abnormal	0.4994	0.7354	0.7408	0.4353	0.6622	0.478435	0.4085	0.462581	0.445813	PASS	0	0.463	157	0.478873	82	chr1	21687278	NA	G	A	286.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=1.702;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.26;AS_ReadPosRankSum=-0.5;AS_SOR=0.275;BaseQRankSum=-0.919;DP=32;ExcessHet=3.0103;FS=1.702;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.25;ReadPosRankSum=-0.426;SOR=0.275	GT:AD:DP:GQ:PL	0/1:19,12:31:99:294,0,553
chr1	21724156	21724156	C	A	USP48	intronic	NA	NA	NA	0.8642	GnomAdExome_AF_amr	358	74	HeterozygousVariant	het	59	36	23	0.389830508474576	483.64	PASS	8.102	NA	617445	NA	NA	NA	High light scatter reticulocyte percentage of red cells[27863252];High light scatter reticulocyte count[27863252];Immature fraction of reticulocytes[27863252];	NA	NA	NA	NA	NA	Widely expressed. {ECO:0000269|PubMed:14715245, ECO:0000269|PubMed:15354349, ECO:0000269|PubMed:16214042}.;	D	T	NA	NA	NA	P	NA	NA	N	T	T	T	NA	NA	NA	T	T	T	.;	N	N	Peptidase C19, ubiquitin-specific peptidase, DUSP domain	NA	NA	Medium	Medium	Medium	tongue;skin;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);larynx;kidney;uterus;whole body;retina;pancreas;muscle;head and neck;skeletal muscle;islets of Langerhans;visual apparatus;spleen;liver;cartilage;endometrium;bone;germinal center;brain;blood;heart;lung;ovary;thyroid;frontal lobe;colon;placenta;prostate;breast;	ciliary ganglion;caudate nucleus;fetal brain;subthalamic nucleus;prefrontal cortex;dorsal root ganglion;superior cervical ganglion;cingulate cortex;trigeminal ganglion;parietal lobe;globus pallidus;medulla oblongata;	0.533	NA	N	S	N	0.868319930408785	E	Usp48	NA	usp48	pharyngeal arch cartilage	malformed	abnormal	0.7688	0.8642	0.8683	0.7316	0.8073	0.688099	0	0.706272	0.720033	PASS	0	0.732	247	0.711268	54	chr1	21724156	NA	C	A	483.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.2;AS_FS=5.77;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.2;AS_ReadPosRankSum=-0.8;AS_SOR=0.238;BaseQRankSum=-2.114;DP=60;ExcessHet=3.0103;FS=5.77;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.2;ReadPosRankSum=-0.739;SOR=0.238	GT:AD:DP:GQ:PL	0/1:36,23:59:99:491,0,1012
chr1	21736656	21736656	G	A	USP48	intronic	NA	NA	NA	0.8199	GnomAdExome_AF_amr	128	55	HeterozygousVariant	het	16	8	8	0.5	195.64	PASS	NA	NA	617445	NA	NA	NA	High light scatter reticulocyte percentage of red cells[27863252];High light scatter reticulocyte count[27863252];Immature fraction of reticulocytes[27863252];	NA	NA	NA	NA	NA	Widely expressed. {ECO:0000269|PubMed:14715245, ECO:0000269|PubMed:15354349, ECO:0000269|PubMed:16214042}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	tongue;skin;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);larynx;kidney;uterus;whole body;retina;pancreas;muscle;head and neck;skeletal muscle;islets of Langerhans;visual apparatus;spleen;liver;cartilage;endometrium;bone;germinal center;brain;blood;heart;lung;ovary;thyroid;frontal lobe;colon;placenta;prostate;breast;	ciliary ganglion;caudate nucleus;fetal brain;subthalamic nucleus;prefrontal cortex;dorsal root ganglion;superior cervical ganglion;cingulate cortex;trigeminal ganglion;parietal lobe;globus pallidus;medulla oblongata;	0.533	NA	N	S	N	0.868319930408785	E	Usp48	NA	usp48	pharyngeal arch cartilage	malformed	abnormal	0.6509	0.8199	0.8131	0.5909	0.7167	0.586062	0.5804	0.613472	0.59688	PASS	0	0.661	134	0.606299	44	chr1	21736656	NA	G	A	195.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.25;AS_ReadPosRankSum=-0.1;AS_SOR=0.346;BaseQRankSum=-0.908;DP=18;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.23;ReadPosRankSum=-0.052;SOR=0.346	GT:AD:DP:GQ:PL	0/1:8,8:16:99:203,0,214
chr1	21814537	21814537	C	T	LDLRAD2	exonic	synonymous SNV	NA	LDLRAD2:NM_001013693:exon2:c.C225T:p.D75D	0.2747	GnomAdExome_AF_eas	35	5	HeterozygousVariant	het	187	77	110	0.588235294117647	2711.64	PASS	NA	NA	NA	Benign	NA	NA	Coronary artery disease[29212778];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	pharynx;cornea;stomach;lacrimal gland;testis;choroid;larynx;kidney;uterus;whole body;pancreas;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;heart;lung;salivary gland;thyroid;sympathetic chain;placenta;nasopharynx;optic nerve;thymus;intestine;spinal ganglion;smooth muscle;skin;myocardium;lens;unclassifiable (Anatomical System);muscle;head and neck;mammary gland;substantia nigra;cartilage;endometrium;bone;parathyroid;brain;blood;ovary;bladder;colon;aorta;prostate;	NA	0.462	NA	N	N	N	0.0199295808949353	N	Ldlrad2	NA	NA	NA	NA	NA	0.0985	0.2747	0.2767	0.0879	0.2701	0.148762	0.0806	0.0960531	0.08867	PASS	0.2	0.171	191	0.197183	46	chr1	21814537	NA	C	T	2711.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.1;AS_FS=3.397;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.5;AS_ReadPosRankSum=-2;AS_SOR=0.828;BaseQRankSum=-2.051;DP=191;ExcessHet=3.0103;FS=3.397;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.5;ReadPosRankSum=-1.951;SOR=0.828	GT:AD:DP:GQ:PL	0/1:77,110:187:99:2719,0,1815
chr1	21814713	21814713	A	C	LDLRAD2	exonic	nonsynonymous SNV	NA	LDLRAD2:NM_001013693:exon2:c.A401C:p.N134T	0.8575	GnomAdGenome_AF_ami	286	44	HeterozygousVariant	het	117	71	46	0.393162393162393	1056.64	PASS	13.36	NA	NA	Benign	NA	NA	Coronary artery disease[29212778];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	pharynx;cornea;stomach;lacrimal gland;testis;choroid;larynx;kidney;uterus;whole body;pancreas;skeletal muscle;islets of Langerhans;visual apparatus;iris;spleen;liver;peripheral nerve;heart;lung;salivary gland;thyroid;sympathetic chain;placenta;nasopharynx;optic nerve;thymus;intestine;spinal ganglion;smooth muscle;skin;myocardium;lens;unclassifiable (Anatomical System);muscle;head and neck;mammary gland;substantia nigra;cartilage;endometrium;bone;parathyroid;brain;blood;ovary;bladder;colon;aorta;prostate;	NA	0.462	NA	N	N	N	0.0199295808949353	N	Ldlrad2	NA	NA	NA	NA	NA	0.6853	0.8316	0.8335	0.6352	0.8575	0.612819	0.635	0.508337	0.672757	PASS	0.734375	0.601	336	0.517857	57	chr1	21814713	NA	A	C	1056.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=0.72;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.03;AS_ReadPosRankSum=-2.2;AS_SOR=0.791;BaseQRankSum=0.926;DP=121;ExcessHet=3.0103;FS=0.72;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.03;ReadPosRankSum=-2.146;SOR=0.791	GT:AD:DP:GQ:PL	0/1:71,46:117:99:1064,0,1735
chr1	21823442	21823442	T	C	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon97:c.A13053G:p.S4351S,HSPG2:NM_005529:exon97:c.A13050G:p.S4350S	0.896552	GME_SD	578	105	HomozygousVariant	hom	93	0	93	1	2537.06	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|none_provided|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.8075	0.8256	0.8262	0.7898	0.8952	0.780351	0.7923	0.760333	0.792282	PASS	0.896552	0.833	235	0.859155	34	chr1	21823442	NA	T	C	2537.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.28;AS_ReadPosRankSum=.;AS_SOR=0.758;DP=95;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.28;SOR=0.758	GT:AD:DP:GQ:PL	1/1:0,93:93:99:2551,277,0
chr1	21823627	21823627	C	T	HSPG2	exonic	nonsynonymous SNV	NA	HSPG2:NM_001291860:exon96:c.G12995A:p.S4332N,HSPG2:NM_005529:exon96:c.G12992A:p.S4331N	0.2962	GnomAdGenome_AF_sas	79	18	HeterozygousVariant	het	81	41	40	0.493827160493827	901.64	PASS	9.47	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome	criteria_provided,_single_submitter	Benign	Found in the basement membranes.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Laminin G domain|Laminin G domain|Laminin G domain	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.1814	0.285	0.2822	0.1504	0.2962	0.176118	0.1459	0.178452	0.116585	PASS	0.208333	0.313	364	0.323944	56	chr1	21823627	NA	C	T	901.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=4.241;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.14;AS_ReadPosRankSum=-0.2;AS_SOR=0.93;BaseQRankSum=-0.331;DP=83;ExcessHet=3.0103;FS=4.241;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.13;ReadPosRankSum=-0.109;SOR=0.93	GT:AD:DP:GQ:PL	0/1:41,40:81:99:909,0,955
chr1	21823667	21823667	G	T	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon96:c.C12955A:p.R4319R,HSPG2:NM_005529:exon96:c.C12952A:p.R4318R	0.2959	GnomAdGenome_AF_sas	78	18	HeterozygousVariant	het	92	45	47	0.510869565217391	1044.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|none_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.1781	0.285	0.2822	0.1369	0.2959	0	0.1296	0.169267	0.110837	PASS	0.215909	0.312	365	0.330986	58	chr1	21823667	NA	G	T	1044.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=5.312;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.36;AS_ReadPosRankSum=-1.3;AS_SOR=1.227;BaseQRankSum=1.39;DP=94;ExcessHet=3.0103;FS=5.312;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.35;ReadPosRankSum=-1.25;SOR=1.227	GT:AD:DP:GQ:PL	0/1:45,47:92:99:1052,0,900
chr1	21828352	21828352	A	G	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon89:c.T12315C:p.D4105D,HSPG2:NM_005529:exon89:c.T12312C:p.D4104D	0.4734	GnomAdGenome_AF_sas	199	38	HeterozygousVariant	het	106	47	59	0.556603773584906	1350.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome	criteria_provided,_single_submitter	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.2911	0.473	0.4692	0.2497	0.4734	0.257188	0.2523	0.292616	0.233169	PASS	0.4	0.486	414	0.507042	68	chr1	21828352	NA	A	G	1350.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.75;AS_ReadPosRankSum=1.1;AS_SOR=0.669;BaseQRankSum=1.04;DP=107;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.74;ReadPosRankSum=1.15;SOR=0.669	GT:AD:DP:GQ:PL	0/1:47,59:106:99:1358,0,924
chr1	21831196	21831196	G	A	HSPG2	intronic	NA	NA	NA	0.892	GnomAdGenome_AF_asj	539	102	HomozygousVariant	hom	57	0	57	1	1679.06	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	NA	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	NA	NA	NA	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.791	0.8091	0.8093	0.7684	0.892	0.759185	0.7698	0.773024	0.768473	PASS	0	0.808	256	0.848592	37	chr1	21831196	NA	G	A	1679.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.46;AS_ReadPosRankSum=.;AS_SOR=0.96;DP=58;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.46;SOR=0.96	GT:AD:DP:GQ:PL	1/1:0,57:57:99:1693,171,0
chr1	21832515	21832515	C	A	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon81:c.G11190T:p.V3730V,HSPG2:NM_005529:exon81:c.G11187T:p.V3729V	0.2697	GnomAdGenome_AF_sas	69	17	HeterozygousVariant	het	140	78	62	0.442857142857143	1237.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome	criteria_provided,_single_submitter	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.1703	0.26	0.2569	0.1369	0.2697	0.157748	0.1325	0.168685	0.112479	PASS	0.200758	0.284	336	0.292254	49	chr1	21832515	NA	C	A	1237.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=6.29;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.84;AS_ReadPosRankSum=-0.1;AS_SOR=0.486;BaseQRankSum=-1.337;DP=145;ExcessHet=3.0103;FS=6.29;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.84;ReadPosRankSum=-0.013;SOR=0.486	GT:AD:DP:GQ:PL	0/1:78,62:140:99:1245,0,1880
chr1	21834782	21834782	G	A	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon77:c.C10620T:p.V3540V,HSPG2:NM_005529:exon77:c.C10617T:p.V3539V	0.2784	GnomAdGenome_AF_sas	72	17	HeterozygousVariant	het	113	57	56	0.495575221238938	1288.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome	criteria_provided,_single_submitter	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.1721	0.2689	0.2651	0.1374	0.2784	0.159545	0.1332	0.169073	0.111658	PASS	0.200758	0.295	348	0.292254	49	chr1	21834782	NA	G	A	1288.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=2.419;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.41;AS_ReadPosRankSum=0.9;AS_SOR=0.966;BaseQRankSum=-0.239;DP=118;ExcessHet=3.0103;FS=2.419;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.4;ReadPosRankSum=0.925;SOR=0.966	GT:AD:DP:GQ:PL	0/1:57,56:113:99:1296,0,1342
chr1	21839408	21839408	A	G	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon73:c.T9855C:p.A3285A,HSPG2:NM_005529:exon73:c.T9852C:p.A3284A	0.5383	GnomAdExome_AF_afr	133	26	HeterozygousVariant	het	97	44	53	0.54639175257732	1187.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|none_provided|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.2762	0.5383	0.5247	0.3403	0.5341	0.346046	0.3499	0.282732	0.297209	PASS	0.37069	0.41	419	0.429577	70	chr1	21839408	NA	A	G	1187.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=3.759;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.25;AS_ReadPosRankSum=-1.5;AS_SOR=1.077;BaseQRankSum=-0.531;DP=98;ExcessHet=3.0103;FS=3.759;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.24;ReadPosRankSum=-1.406;SOR=1.077	GT:AD:DP:GQ:PL	0/1:44,53:97:99:1195,0,1020
chr1	21839494	21839494	G	A	HSPG2	exonic	nonsynonymous SNV	NA	HSPG2:NM_001291860:exon73:c.C9769T:p.H3257Y,HSPG2:NM_005529:exon73:c.C9766T:p.H3256Y	0.2783	GnomAdGenome_AF_sas	72	17	HeterozygousVariant	het	111	40	71	0.63963963963964	1623.64	PASS	22.5	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	T	D	B	B	N	P	N	T	D	T	T	T	NA	T	T	T	T	T	.;	D	D	Immunoglobulin I-set|Immunoglobulin-like domain|Immunoglobulin V-set domain|Immunoglobulin subtype 2|Immunoglobulin subtype	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.1696	0.269	0.2654	0.1308	0.2783	0.152157	0.1246	0.167456	0.110016	PASS	0.200758	0.295	349	0.302817	52	chr1	21839494	NA	G	A	1623.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=2.562;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.63;AS_ReadPosRankSum=0.8;AS_SOR=0.621;BaseQRankSum=-1.77;DP=112;ExcessHet=3.0103;FS=2.562;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.63;ReadPosRankSum=0.823;SOR=0.621	GT:AD:DP:GQ:PL	0/1:40,71:111:99:1631,0,887
chr1	21850338	21850338	C	T	HSPG2	intronic	NA	NA	NA	0.2763	GnomAdGenome_AF_sas	60	16	HeterozygousVariant	het	31	14	17	0.548387096774194	417.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	NA	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	NA	NA	NA	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.1802	0.2666	0.2615	0.1721	0.2763	0.194888	0.1617	0.169247	0.135468	PASS	0	0.289	304	0.288732	50	chr1	21850338	NA	C	T	417.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.48;AS_ReadPosRankSum=0.3;AS_SOR=0.804;BaseQRankSum=-0.196;DP=31;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.47;ReadPosRankSum=0.357;SOR=0.804	GT:AD:DP:GQ:PL	0/1:14,17:31:99:425,0,335
chr1	21857246	21857246	A	G	HSPG2	intronic	NA	NA	NA	0.5883	GnomAdExome_AF_asj	134	24	HeterozygousVariant	het	57	37	20	0.350877192982456	434.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	NA	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	NA	NA	NA	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.504	0.546	0.543	0.5	0.587	0.446885	0.5085	0.498266	0.519704	PASS	0	0.377	354	0.387324	62	chr1	21857246	NA	A	G	434.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=3.764;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.63;AS_ReadPosRankSum=-1;AS_SOR=0.712;BaseQRankSum=-0.941;DP=57;ExcessHet=3.0103;FS=3.764;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.63;ReadPosRankSum=-0.912;SOR=0.712	GT:AD:DP:GQ:PL	0/1:37,20:57:99:442,0,1055
chr1	21864961	21864961	G	A	HSPG2	exonic	nonsynonymous SNV	NA	HSPG2:NM_001291860:exon36:c.C4511T:p.A1504V,HSPG2:NM_005529:exon36:c.C4508T:p.A1503V	0.8922	GnomAdExome_AF_eas	268	43	HeterozygousVariant	het	147	75	72	0.489795918367347	1494.64	PASS	22.8	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_specified|none_provided|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	T	D	D	D	N	P	M	T	D	T	T	T	NA	T	T	T	T	T	.;	N	N	Laminin IV|Laminin IV|Laminin IV	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.7321	0.8922	0.8927	0.7015	0.8918	0.691494	0.6991	0.675069	0.729885	PASS	0.804124	0.562	403	0.53169	65	chr1	21864961	NA	G	A	1494.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.17;AS_ReadPosRankSum=-0.9;AS_SOR=0.668;BaseQRankSum=-3.1;DP=152;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.17;ReadPosRankSum=-0.824;SOR=0.668	GT:AD:DP:GQ:PL	0/1:75,72:147:99:1502,0,1839
chr1	21872752	21872752	C	T	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon32:c.G3900A:p.V1300V,HSPG2:NM_005529:exon32:c.G3897A:p.V1299V	0.7476	GnomAdGenome_AF_asj	207	36	HeterozygousVariant	het	75	30	45	0.6	977.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.5558	0.6384	0.6364	0.5049	0.7476	0.42492	0.5247	0.523376	0.5	PASS	0.689655	0.493	409	0.510563	73	chr1	21872752	NA	C	T	977.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.04;AS_ReadPosRankSum=-0.3;AS_SOR=0.617;BaseQRankSum=-1.997;DP=78;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.04;ReadPosRankSum=-0.227;SOR=0.617	GT:AD:DP:GQ:PL	0/1:30,45:75:99:985,0,666
chr1	21873328	21873328	G	A	HSPG2	intronic	NA	NA	NA	0.9771	GnomAdExome_AF_eas	280	72	HeterozygousVariant	het	51	26	25	0.490196078431373	604.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	NA	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	NA	NA	NA	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.8308	0.9771	0.9761	0.7451	0.9751	0.742013	0.7333	0.807092	0.747126	PASS	0	0.734	196	0.71831	60	chr1	21873328	NA	G	A	604.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.86;AS_ReadPosRankSum=1.8;AS_SOR=0.634;BaseQRankSum=-0.343;DP=52;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.86;ReadPosRankSum=1.83;SOR=0.634	GT:AD:DP:GQ:PL	0/1:26,25:51:99:612,0,646
chr1	21873980	21873980	C	T	HSPG2	exonic	nonsynonymous SNV	NA	HSPG2:NM_001291860:exon29:c.G3691A:p.G1231S,HSPG2:NM_005529:exon29:c.G3688A:p.G1230S	0.176	GnomAdGenome_AF_afr	0	0	HeterozygousVariant	het	182	100	82	0.450549450549451	1743.64	PASS	23.5	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	NA	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	D	D	D	D	N	P	L	T	D	T	T	T	NA	T	T	T	T	T	.;	D	N	Laminin EGF domain|Laminin EGF domain|Laminin EGF domain|EGF-like domain	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.033	0.1693	0.1672	0.0739	0.176	0.0621006	0.0779	0.0347279	0.060755	PASS	0.132653	0.014	24	0.014085	4	chr1	21873980	NA	C	T	1743.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=3.406;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.58;AS_ReadPosRankSum=0.9;AS_SOR=0.752;BaseQRankSum=0.289;DP=190;ExcessHet=3.0103;FS=3.406;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.58;ReadPosRankSum=0.939;SOR=0.752	GT:AD:DP:GQ:PL	0/1:100,82:182:99:1751,0,2163
chr1	21874505	21874505	C	T	HSPG2	exonic	nonsynonymous SNV	NA	HSPG2:NM_001291860:exon28:c.G3560A:p.R1187Q,HSPG2:NM_005529:exon28:c.G3557A:p.R1186Q	0.1776	GnomAdGenome_AF_afr	0	0	HeterozygousVariant	het	118	65	52	0.440677966101695	1111.64	PASS	12.78	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Laminin EGF domain|Laminin EGF domain|Laminin EGF domain|Laminin EGF domain|EGF-like domain	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.0343	0.1717	0.1704	0.0746	0.1776	0.0638978	0.0787	0.0372181	0.061576	PASS	0.132653	0.016	26	0.014085	4	chr1	21874505	NA	C	T	1111.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=4.488;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.5;AS_ReadPosRankSum=0.3;AS_SOR=0.695;BaseQRankSum=-0.298;DP=121;ExcessHet=3.0103;FS=3.379;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.5;ReadPosRankSum=0.222;SOR=0.643	GT:AD:DP:GQ:PL	0/1:65,52:118:99:1119,0,1496
chr1	21875616	21875616	C	T	HSPG2	intronic	NA	NA	NA	1	GnomAdExome_AF_eas	734	142	HomozygousVariant	hom	115	0	115	1	3191.06	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	NA	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|none_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.9858	1	1	0.946	1	0.942292	0.9409	0.936288	0.949918	PASS	0	1	0	1	0	chr1	21875616	NA	C	T	3191.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.75;AS_ReadPosRankSum=.;AS_SOR=1.028;DP=116;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.75;SOR=1.028	GT:AD:DP:GQ:PL	1/1:0,115:115:99:3205,344,0
chr1	21880156	21880156	T	C	HSPG2	exonic	nonsynonymous SNV	NA	HSPG2:NM_001291860:exon17:c.A2297G:p.N766S,HSPG2:NM_005529:exon17:c.A2294G:p.N765S	1	GnomAdExome_AF_eas	834	142	HomozygousVariant	hom	87	0	87	1	2551.06	PASS	15.51	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;	D	N	Laminin EGF domain|Laminin EGF domain|Laminin EGF domain	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.9845	1	1	0.9366	1	0.929912	0.9352	0.930195	0.956486	PASS	1	0.999	1	1	0	chr1	21880156	NA	T	C	2551.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.32;AS_ReadPosRankSum=.;AS_SOR=0.917;DP=87;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.32;SOR=0.917	GT:AD:DP:GQ:PL	1/1:0,87:87:99:2565,261,0
chr1	21880449	21880449	G	A	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon16:c.C2112T:p.A704A,HSPG2:NM_005529:exon16:c.C2109T:p.A703A	1	GnomAdExome_AF_eas	835	142	HomozygousVariant	hom	110	1	109	0.990909090909091	3138.06	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.9845	1	1	0.9366	1	0.929912	0.9352	0.938099	0.956486	PASS	1	1	0	1	0	chr1	21880449	NA	G	A	3138.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.9;AS_FS=3.338;AS_MQ=60;AS_MQRankSum=0;AS_QD=28.53;AS_ReadPosRankSum=-1.6;AS_SOR=0.491;BaseQRankSum=1.9;DP=114;ExcessHet=3.0103;FS=3.338;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=28.53;ReadPosRankSum=-1.575;SOR=0.491	GT:AD:DP:GQ:PL	1/1:1,109:110:99:3152,319,0
chr1	21880742	21880742	T	C	HSPG2	exonic	nonsynonymous SNV	NA	HSPG2:NM_001291860:exon15:c.A1915G:p.M639V,HSPG2:NM_005529:exon15:c.A1912G:p.M638V	1	GnomAdExome_AF_sas	835	142	HomozygousVariant	hom	186	0	186	1	5371.06	PASS	7.394	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Laminin IV|Laminin IV|Laminin IV	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.9944	1	1	0.9764	1	0.973642	0.9757	0.933817	0.985222	PASS	1	1	0	1	0	chr1	21880742	NA	T	C	5371.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.88;AS_ReadPosRankSum=.;AS_SOR=0.982;DP=190;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.88;SOR=0.982	GT:AD:DP:GQ:PL	1/1:0,186:186:99:5385,558,0
chr1	21884633	21884633	C	T	HSPG2	exonic	nonsynonymous SNV	NA	HSPG2:NM_001291860:exon13:c.G1552A:p.A518T,HSPG2:NM_005529:exon13:c.G1549A:p.A517T	0.0062	GnomAdGenome_AF_sas	1	0	HeterozygousVariant	het	98	44	54	0.551020408163265	1277.64	PASS	18.88	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Likely benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	not_provided	criteria_provided,_single_submitter	Benign	Found in the basement membranes.;	T	T	B	B	N	N	N	T	N	T	T	T	T	T	T	T	T	T	.;	D	N	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.0009	0.0059	0.0055	0.0003	0.0062	0.000599042	0.0003	0.0007827	0		0.003817	0.006587	9	0.007092	2	chr1	21884633	NA	C	T	1277.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.7;AS_FS=6.637;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.04;AS_ReadPosRankSum=-0.1;AS_SOR=0.284;BaseQRankSum=-1.617;DP=102;ExcessHet=3.0103;FS=6.637;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.04;ReadPosRankSum=-0.036;SOR=0.284	GT:AD:DP:GQ:PL	0/1:44,54:98:99:1285,0,1057
chr1	21887634	21887634	A	G	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon8:c.T744C:p.L248L,HSPG2:NM_005529:exon8:c.T744C:p.L248L	0.6401	GnomAdExome_AF_afr	128	24	HeterozygousVariant	het	136	67	69	0.507352941176471	1537.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|none_provided|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.4187	0.6401	0.638	0.4501	0.6345	0.536342	0.4273	0.408222	0.444992	PASS	0.55	0.397	407	0.401408	66	chr1	21887634	NA	A	G	1537.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=7.875;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.31;AS_ReadPosRankSum=0.3;AS_SOR=0.316;BaseQRankSum=-0.734;DP=138;ExcessHet=3.0103;FS=7.875;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.31;ReadPosRankSum=0.359;SOR=0.316	GT:AD:DP:GQ:PL	0/1:67,69:136:99:1545,0,1587
chr1	21890081	21890081	C	A	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon6:c.G474T:p.G158G,HSPG2:NM_005529:exon6:c.G474T:p.G158G	0.7556	GnomAdGenome_AF_asj	302	51	HeterozygousVariant	het	150	87	63	0.42	1366.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.5774	0.6665	0.6627	0.5295	0.7556	0.444489	0.5503	0.574812	0.535304	PASS	0.724138	0.604	405	0.598592	68	chr1	21890081	NA	C	A	1366.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.4;AS_FS=1.309;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.11;AS_ReadPosRankSum=1.2;AS_SOR=0.549;BaseQRankSum=1.44;DP=151;ExcessHet=3.0103;FS=1.309;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.11;ReadPosRankSum=1.25;SOR=0.549	GT:AD:DP:GQ:PL	0/1:87,63:150:99:1374,0,1934
chr1	21890111	21890111	C	G	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon6:c.G444C:p.L148L,HSPG2:NM_005529:exon6:c.G444C:p.L148L	0.7553	GnomAdGenome_AF_asj	302	51	HeterozygousVariant	het	137	83	54	0.394160583941606	1171.64	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.5775	0.6667	0.663	0.5294	0.7553	0.444489	0.5504	0.574559	0.534483	PASS	0.708589	0.604	405	0.598592	68	chr1	21890111	NA	C	G	1171.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.7;AS_FS=1.377;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.55;AS_ReadPosRankSum=0.1;AS_SOR=0.704;BaseQRankSum=1.72;DP=141;ExcessHet=3.0103;FS=1.377;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.55;ReadPosRankSum=0.134;SOR=0.704	GT:AD:DP:GQ:PL	0/1:83,54:137:99:1179,0,1914
chr1	21890615	21890615	G	A	HSPG2	exonic	synonymous SNV	NA	HSPG2:NM_001291860:exon4:c.C324T:p.F108F,HSPG2:NM_005529:exon4:c.C324T:p.F108F	1	GnomAdExome_AF_eas	835	142	HomozygousVariant	hom	85	0	85	1	2557.06	PASS	NA	[MIM:255800]Schwartz-Jampel syndrome [recessive?];[MIM:224410]Dyssegmental dysplasia Silverman-Handmaker type [recessive?];	142461	Benign	Schwartz-Jampel syndrome;Dyssegmental dysplasia, Silverman-Handmaker type	Disease-causing germline mutation(s) (loss of function) in;Disease-causing germline mutation(s) in	Atrial fibrillation[30061737];	HP:0001537;HP:0000592;HP:0000944;HP:0001631;HP:0002879;HP:0000023;HP:0001387;HP:0008873;HP:0000175;HP:0000347;HP:0000457;HP:0006487;HP:0002644;HP:0002093;HP:0002983;HP:0000774;HP:0000160;HP:0000347;HP:0000431;HP:0002879;HP:0004298;HP:0002089;HP:0003026;HP:0005257;HP:0001548;HP:0003811;HP:0000358;HP:0008873;HP:0000007;HP:0001762;HP:0001195;HP:0000272;HP:0012368;HP:0003026;HP:0006487;HP:0000028;HP:0001362;HP:0002673;HP:0001620;HP:0008734;HP:0000739;HP:0002650;HP:0000298;HP:0000912;HP:0001265;HP:0001083;HP:0002808;HP:0000939;HP:0000768;HP:0000508;HP:0000252;HP:0000600;HP:0000534;HP:0012544;HP:0000482;HP:0001239;HP:0002652;HP:0000470;HP:0011675;HP:0007018;HP:0001618;HP:0011069;HP:0010978;HP:0100813;HP:0000347;HP:0000160;HP:0000944;HP:0002104;HP:0004326;HP:0000175;HP:0003307;HP:0001557;HP:0000426;HP:0000505;HP:0000581;HP:0008056;HP:0005930;HP:0000772;HP:0000232;HP:0007740;HP:0001621;HP:0003202;HP:0011001;HP:0002812;HP:0000218;HP:0100569;HP:0002047;HP:0002486;HP:0002804;HP:0000396;HP:0003273;HP:0100612;HP:0003712;HP:0001522;HP:0000293;HP:0000689;HP:0010508;HP:0000023;HP:0001537;HP:0001387;HP:0001561;HP:0002092;HP:0003179;HP:0000368;HP:0003236;HP:0001601;HP:0000069;HP:0000767;HP:0002645;HP:0001324;HP:0003306;HP:0000486;HP:0002093;HP:0002983;HP:0000545;HP:0000316;HP:0000926;HP:0003457;HP:0001249;HP:0002750;HP:0005830;HP:0000294;HP:0000643;HP:0000205;HP:0000343;HP:0100795;HP:0012368;HP:0004322;HP:0000518;HP:0001762;HP:0008872;HP:0002230;HP:0002857;HP:0003042;HP:0003198;HP:0000787;HP:0001763;HP:0009743;HP:0001385;HP:0001288;HP:0001276;HP:0000737;HP:0003044;HP:0003326;HP:0000211;HP:0000007;HP:0000160;HP:0000470;HP:0008734;HP:0006473;HP:0003417;HP:0002750;HP:0003044;HP:0005830;HP:0000369;HP:0002938;HP:0000545;HP:0003273;HP:0000272;HP:0001374;HP:0000396;HP:0001249;HP:0001621;HP:0000205;HP:0001239;HP:0000768;HP:0001763;HP:0002486;HP:0000926;HP:0002751;HP:0045025;HP:0002230;HP:0006499;HP:0000939;HP:0002673;HP:0004322;HP:0000023;HP:0001762;HP:0000581;HP:0002812;HP:0001265;HP:0003202;HP:0009473;HP:0003016;HP:0000482;HP:0001537;HP:0000293;HP:0001324;HP:0001620;HP:0007740;HP:0000347;HP:0000518;HP:0002047;HP:0012368;HP:0000508;HP:0003712	Umbilical hernia;Blue sclerae;Abnormality of the metaphysis;Atrial septal defect;Anisospondyly;Inguinal hernia;Joint stiffness;Disproportionate short-limb short stature;Cleft palate;Micrognathia;Depressed nasal ridge;Bowing of the long bones;Abnormality of pelvic girdle bone morphology;Respiratory insufficiency;Micromelia;Narrow chest;Narrow mouth;Micrognathia;Wide nasal bridge;Anisospondyly;Abnormality of the abdominal wall;Pulmonary hypoplasia;Short long bone;Thoracic hypoplasia;Overgrowth;Neonatal death;Posteriorly rotated ears;Disproportionate short-limb short stature;Autosomal recessive inheritance;Talipes equinovarus;Single umbilical artery;Malar flattening;Flat face;Short long bone;Bowing of the long bones;Cryptorchidism;Calvarial skull defect;Coxa valga;High pitched voice;Decreased testicular size;Anxiety;Scoliosis;Mask-like facies;Sprengel anomaly;Hyporeflexia;Ectopia lentis;Kyphosis;Osteoporosis;Pectus carinatum;Ptosis;Microcephaly;Abnormality of the pharynx;Abnormal eyebrow morphology;Elevated aldolase level;Microcornea;Wrist flexion contracture;Skeletal dysplasia;Short neck;Arrhythmia;Attention deficit hyperactivity disorder;Dysphonia;Increased number of teeth;Abnormality of immune system physiology;Testicular torsion;Micrognathia;Narrow mouth;Abnormality of the metaphysis;Apnea;Cachexia;Cleft palate;Hyperlordosis;Prenatal movement abnormality;Prominent nasal bridge;Visual impairment;Blepharophimosis;Aplasia/Hypoplasia affecting the eye;Abnormality of epiphysis morphology;Abnormality of the ribs;Everted lower lip vermilion;Long eyelashes in irregular rows;Weak voice;Skeletal muscle atrophy;Increased bone mineral density;Coxa vara;High palate;Abnormally ossified vertebrae;Malignant hyperthermia;Myotonia;Arthrogryposis multiplex congenita;Overfolded helix;Hip contracture;Odontogenic neoplasm;Skeletal muscle hypertrophy;Death in infancy;Full cheeks;Dental malocclusion;Metatarsus valgus;Inguinal hernia;Umbilical hernia;Joint stiffness;Polyhydramnios;Pulmonary arterial hypertension;Protrusio acetabuli;Low-set, posteriorly rotated ears;Elevated serum creatine kinase;Laryngomalacia;Abnormality of the ureter;Pectus excavatum;Wormian bones;Muscle weakness;Spinal rigidity;Strabismus;Respiratory insufficiency;Micromelia;Myopia;Hypertelorism;Platyspondyly;EMG abnormality;Intellectual disability;Delayed skeletal maturation;Flexion contracture of toe;Low anterior hairline;Blepharospasm;Pursed lips;Long philtrum;Abnormally straight spine;Flat face;Short stature;Cataract;Talipes equinovarus;Feeding difficulties in infancy;Generalized hirsutism;Genu valgum;Elbow dislocation;Myopathy;Nephrolithiasis;Pes planus;Distichiasis;Hip dysplasia;Gait disturbance;Hypertonia;Irritability;Shoulder flexion contracture;Myalgia;Trismus;Autosomal recessive inheritance;Narrow mouth;Short neck;Decreased testicular size;Anterior bowing of long bones;Coronal cleft vertebrae;Delayed skeletal maturation;Shoulder flexion contracture;Flexion contracture of toe;Low-set ears;Lumbar hyperlordosis;Myopia;Hip contracture;Malar flattening;Congenital hip dislocation;Overfolded helix;Intellectual disability;Weak voice;Pursed lips;Wrist flexion contracture;Pectus carinatum;Pes planus;Myotonia;Platyspondyly;Kyphoscoliosis;Narrow palpebral fissure;Generalized hirsutism;Abnormality of femoral epiphysis;Osteoporosis;Coxa valga;Short stature;Inguinal hernia;Talipes equinovarus;Blepharophimosis;Coxa vara;Hyporeflexia;Skeletal muscle atrophy;Joint contracture of the hand;Metaphyseal widening;Microcornea;Umbilical hernia;Full cheeks;Muscle weakness;High pitched voice;Long eyelashes in irregular rows;Micrognathia;Cataract;Malignant hyperthermia;Flat face;Ptosis;Skeletal muscle hypertrophy	Lethal_Kniest-like_syndrome|Schwartz-Jampel_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Found in the basement membranes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	NA	NA	0.588	E	N	N	NA	0.85372808695289	E	Hspg2	growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; immune system phenotype; cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; skeleton phenotype; 	hspg2	blood vessel	decreased amount	abnormal	0.9887	1	1	0.954	1	0.948083	0.9538	0.935188	0.966338	PASS	1	1	0	1	0	chr1	21890615	NA	G	A	2557.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.08;AS_ReadPosRankSum=.;AS_SOR=0.716;DP=87;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.08;SOR=0.716	GT:AD:DP:GQ:PL	1/1:0,85:85:99:2571,254,0
chr1	21980847	21980847	C	T	CELA3B	exonic	synonymous SNV	NA	CELA3B:NM_007352:exon3:c.C153T:p.S51S	1	GnomAdGenome_AF_ami	421	128	HomozygousVariant	hom	38	0	38	1	1137.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Pancreas. Not detectable in keratinocytes. {ECO:0000269|PubMed:10620133}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;globus pallidus;bone marrow;	0.276	NA	N	N	N	0.401360136868545	N	Cela3b	NA	NA	NA	NA	NA	0.947	0.9827	0.9834	0.9042	1	0.849241	0	0.786303	0.917077	VQSRTrancheSNP99.90to100.00	1	0.948	30	0.956835	10	chr1	21980847	NA	C	T	1137.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=44.64;AS_MQRankSum=.;AS_QD=29.92;AS_ReadPosRankSum=.;AS_SOR=2.303;DP=41;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=45.94;QD=29.92;SOR=2.303	GT:AD:DP:GQ:PL	1/1:0,38:38:99:1151,114,0
chr1	21980865	21980865	C	G	CELA3B	exonic	synonymous SNV	NA	CELA3B:NM_007352:exon3:c.C171G:p.T57T	1	GnomAdGenome_AF_ami	426	131	HomozygousVariant	hom	57	0	57	1	1504.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Pancreas. Not detectable in keratinocytes. {ECO:0000269|PubMed:10620133}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;globus pallidus;bone marrow;	0.276	NA	N	N	N	0.401360136868545	N	Cela3b	NA	NA	NA	NA	NA	0.9486	0.9837	0.9844	0.9023	1	0.847644	0	0.793909	0.913793	VQSRTrancheSNP99.90to100.00	1	0.955	34	0.957747	10	chr1	21980865	NA	C	G	1504.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=50.38;AS_MQRankSum=.;AS_QD=26.39;AS_ReadPosRankSum=.;AS_SOR=1.569;DP=58;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=50.56;QD=26.39;SOR=1.569	GT:AD:DP:GQ:PL	1/1:0,57:57:99:1518,170,0
chr1	21981045	21981045	C	T	CELA3B	exonic	nonsynonymous SNV	NA	CELA3B:NM_007352:exon4:c.C235T:p.R79W	1	GnomAdGenome_AF_ami	544	132	HomozygousVariant	hom	129	0	129	1	3551.06	PASS	17.13	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Pancreas. Not detectable in keratinocytes. {ECO:0000269|PubMed:10620133}.;	T	T	D	P	N	P	L	D	D	T	T	T	NA	T	T	T	T	T	.;	N	N	Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;globus pallidus;bone marrow;	0.276	NA	N	N	N	0.401360136868545	N	Cela3b	NA	NA	NA	NA	NA	0.9564	0.9933	0.9934	0.9478	1	0.893371	0.9463	0.0001537	0.963054	PASS	1	0.965	41	0.964789	10	chr1	21981045	NA	C	T	3551.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.53;AS_ReadPosRankSum=.;AS_SOR=0.709;DP=130;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.53;SOR=0.709	GT:AD:DP:GQ:PL	1/1:0,129:129:99:3565,385,0
chr1	21983769	21983769	G	C	CELA3B	exonic	synonymous SNV	NA	CELA3B:NM_007352:exon5:c.G438C:p.P146P	1	GnomAdGenome_AF_ami	545	132	HomozygousVariant	hom	144	0	144	1	3930.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Pancreas. Not detectable in keratinocytes. {ECO:0000269|PubMed:10620133}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;globus pallidus;bone marrow;	0.276	NA	N	N	N	0.401360136868545	N	Cela3b	NA	NA	NA	NA	NA	0.9526	0.9922	0.9926	0.9342	1	0.879393	0.9287	0.0001153	0.957307	PASS	1	0.965	41	0.964789	10	chr1	21983769	NA	G	C	3930.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=47.36;AS_MQRankSum=.;AS_QD=27.29;AS_ReadPosRankSum=.;AS_SOR=0.721;DP=155;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=48.09;QD=27.29;SOR=0.721	GT:AD:DP:GQ:PL	1/1:0,144:144:99:3944,432,0
chr1	21984169	21984169	G	T	CELA3B	intronic	NA	NA	NA	0.9722	GnomAdGenome_AF_ami	265	130	HomozygousVariant	hom	50	0	50	1	1563.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Pancreas. Not detectable in keratinocytes. {ECO:0000269|PubMed:10620133}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;globus pallidus;bone marrow;	0.276	NA	N	N	N	0.401360136868545	N	Cela3b	NA	NA	NA	NA	NA	0.9129	0.9491	0.9491	0.8813	0.9722	0.840455	0.8789	0.0001153	0.898194	PASS	0	0.945	33	0.950704	10	chr1	21984169	NA	G	T	1563.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=31.26;AS_ReadPosRankSum=.;AS_SOR=1.958;DP=53;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=31.26;SOR=1.958	GT:AD:DP:GQ:PL	1/1:0,50:50:99:1577,150,0
chr1	21984181	21984181	C	T	CELA3B	intronic	NA	NA	NA	1	GnomAdGenome_AF_ami	273	130	HomozygousVariant	hom	65	0	65	1	1917.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Pancreas. Not detectable in keratinocytes. {ECO:0000269|PubMed:10620133}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.004	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;globus pallidus;bone marrow;	0.276	NA	N	N	N	0.401360136868545	N	Cela3b	NA	NA	NA	NA	NA	0.9367	0.976	0.9758	0.904	1	0.849241	0.9017	0.0001153	0.917077	PASS	0	0.958	25	0.960993	11	chr1	21984181	NA	C	T	1917.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.49;AS_ReadPosRankSum=.;AS_SOR=1.437;DP=73;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.49;SOR=1.437	GT:AD:DP:GQ:PL	1/1:0,65:65:99:1931,194,0
chr1	21984232	21984232	G	C	CELA3B	exonic	synonymous SNV	NA	CELA3B:NM_007352:exon6:c.G543C:p.P181P	0.9722	GnomAdGenome_AF_ami	528	130	HomozygousVariant	hom	115	0	115	1	3250.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Pancreas. Not detectable in keratinocytes. {ECO:0000269|PubMed:10620133}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;globus pallidus;bone marrow;	0.276	NA	N	N	N	0.401360136868545	N	Cela3b	NA	NA	NA	NA	NA	0.9138	0.9495	0.9494	0.8814	0.9722	0	0.8794	0.0001153	0.898194	PASS	0	0.949	56	0.954225	11	chr1	21984232	NA	G	C	3250.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.26;AS_ReadPosRankSum=.;AS_SOR=0.941;DP=116;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.26;SOR=0.941	GT:AD:DP:GQ:PL	1/1:0,115:115:99:3264,345,0
chr1	21986668	21986668	T	C	CELA3B	exonic	synonymous SNV	NA	CELA3B:NM_007352:exon7:c.T780C:p.I260I	1	GnomAdGenome_AF_ami	551	132	HomozygousVariant	hom	73	0	73	1	2042.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Pancreas. Not detectable in keratinocytes. {ECO:0000269|PubMed:10620133}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;globus pallidus;bone marrow;	0.276	NA	N	N	N	0.401360136868545	N	Cela3b	NA	NA	NA	NA	NA	0.9526	0.9924	0.9928	0.931	1	0.880791	0.9284	0.0001153	0.950739	PASS	1	0.969	34	0.961268	9	chr1	21986668	NA	T	C	2042.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=58.61;AS_MQRankSum=.;AS_QD=27.97;AS_ReadPosRankSum=.;AS_SOR=1.257;DP=77;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=58.27;QD=27.97;SOR=1.257	GT:AD:DP:GQ:PL	1/1:0,73:73:99:2056,218,0
chr1	21989245	21989245	C	T	CELA3B	intronic	NA	NA	NA	0.9238	GnomAdGenome_AF_ami	356	83	HomozygousVariant	hom	25	0	25	1	657.06	MQ40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Pancreas. Not detectable in keratinocytes. {ECO:0000269|PubMed:10620133}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;globus pallidus;bone marrow;	0.276	NA	N	N	N	0.401360136868545	N	Cela3b	NA	NA	NA	NA	NA	0.7895	0.8647	0.8702	0.7416	0.9238	0	0	0.170185	0.635246	VQSRTrancheSNP99.00to99.90	0	0.787	160	0.764493	45	chr1	21989245	NA	C	T	657.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=36.81;AS_MQRankSum=.;AS_QD=26.28;AS_ReadPosRankSum=.;AS_SOR=0.941;DP=25;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=36.81;QD=26.28;SOR=0.941	GT:AD:DP:GQ:PL	1/1:0,25:25:75:671,75,0
chr1	22005515	22005515	T	C	CELA3A	exonic	synonymous SNV	NA	CELA3A:NM_005747:exon3:c.T198C:p.D66D	0.498	GnomAdExome_AF_fin	0	0	WT/SomaticVariant	het	218	166	52	0.238532110091743	734.64	MQRankSum-12.5	NA	NA	NA	Benign	NA	NA	Gestational age at birth (maternal effect)[28877031];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;trigeminal ganglion;superior cervical ganglion;atrioventricular node;skeletal muscle;	0.346	NA	N	N	N	0.127826929088466	N	Cela3b	NA	NA	NA	NA	NA	0.4787	0.4941	0.4988	0.2808	0.3501	0	0	0.0035511	0.395731	VQSRTrancheSNP99.90to100.00	0.47541	0.289	288	0.211268	60	chr1	22005515	NA	T	C	734.64	MQRankSum-12.5	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=6.823;AS_MQ=47.64;AS_MQRankSum=-13.1;AS_QD=3.37;AS_ReadPosRankSum=-0.6;AS_SOR=1.121;BaseQRankSum=0;DP=223;ExcessHet=3.0103;FS=6.823;MLEAC=1;MLEAF=0.5;MQ=56.98;MQRankSum=-13.06;QD=3.37;ReadPosRankSum=-0.571;SOR=1.121	GT:AD:DP:GQ:PL	0/1:166,52:218:99:742,0,3821
chr1	22009784	22009784	C	G	CELA3A	exonic	nonsynonymous SNV	NA	CELA3A:NM_005747:exon7:c.C722G:p.A241G	1	GnomAdGenome_AF_ami	542	130	HomozygousVariant	hom	121	0	121	1	3429.06	PASS	3.33	NA	NA	Benign	NA	NA	Gestational age at birth (maternal effect)[28877031];	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	N	T	N	T	T	T	NA	NA	T	T	T	T	.;.;	N	N	Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain|Serine proteases, trypsin domain;Serine proteases, trypsin domain|Serine proteases, trypsin domain	NA	NA	Medium	Medium	Medium	lung;spleen;liver;pancreas;skin;prostate;unclassifiable (Anatomical System);islets of Langerhans;	beta cell islets;pancreas;trigeminal ganglion;superior cervical ganglion;atrioventricular node;skeletal muscle;	0.346	NA	N	N	N	0.127826929088466	N	Cela3b	NA	NA	NA	NA	NA	0.9408	0.9783	0.9793	0.9513	1	0.895767	0.9572	0.0002689	0.950739	PASS	0	0.964	42	0.957747	12	chr1	22009784	NA	C	G	3429.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.34;AS_ReadPosRankSum=.;AS_SOR=0.743;DP=128;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.34;SOR=0.743	GT:AD:DP:GQ:PL	1/1:0,121:121:99:3443,362,0
chr1	22506250	22506250	A	T	ZBTB40	intronic	NA	NA	NA	0.8973	GnomAdExome_AF_afr	360	71	HeterozygousVariant	het	20	14	6	0.3	98.64	PASS	NA	NA	612106	NA	NA	NA	'Bone mineral density (hip)[18445777;19801982];Bone mineral density (total hip)[29883787];Bone mineral density (spine)[18445777;19801982];Dupuytren''s disease[28886342];Heel bone mineral density[28869591;28869591;28869591;28869591;28869591;28869591];Endometriosis[23472165];Bone mineral density[24249740;24249740;21533022;21533022;22504420];Birth weight[27680694];Femoral neck bone mineral density[29499414];Lumbar spine bone mineral density[29499414];'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.524	NA	N	N	H	0.250245214044116	N	Zbtb40	NA	NA	NA	NA	NA	0.6968	0.8973	0.8985	0.7217	0.8903	0.799121	0.7077	0.680088	0.718391	PASS	0	0.686	291	0.676056	50	chr1	22506250	NA	A	T	98.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=4.95;AS_ReadPosRankSum=0.9;AS_SOR=0.454;BaseQRankSum=-0.839;DP=20;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=4.93;ReadPosRankSum=0.91;SOR=0.454	GT:AD:DP:GQ:PL	0/1:14,6:20:99:106,0,372
chr1	22509184	22509184	A	G	ZBTB40	exonic	nonsynonymous SNV	NA	ZBTB40:NM_001330398:exon7:c.A1448G:p.Y483C,ZBTB40:NM_014870:exon9:c.A1784G:p.Y595C,ZBTB40:NM_001083621:exon10:c.A1784G:p.Y595C	0.9128	GnomAdExome_AF_afr	406	68	HeterozygousVariant	het	113	37	76	0.672566371681416	1722.64	PASS	10.71	NA	612106	Benign	NA	NA	'Bone mineral density (hip)[18445777;19801982];Bone mineral density (total hip)[29883787];Bone mineral density (spine)[18445777;19801982];Dupuytren''s disease[28886342];Heel bone mineral density[28869591;28869591;28869591;28869591;28869591;28869591];Endometriosis[23472165];Bone mineral density[24249740;24249740;21533022;21533022;22504420];Birth weight[27680694];Femoral neck bone mineral density[29499414];Lumbar spine bone mineral density[29499414];'	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	.;.;.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.524	NA	N	N	H	0.250245214044116	N	Zbtb40	NA	NA	NA	NA	NA	0.7672	0.9128	0.9104	0.7889	0.9061	0.822484	0.7818	0.754634	0.792282	PASS	0.8	0.687	336	0.661972	52	chr1	22509184	NA	A	G	1722.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=3.738;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.25;AS_ReadPosRankSum=-2;AS_SOR=0.395;BaseQRankSum=-0.059;DP=117;ExcessHet=3.0103;FS=3.738;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.24;ReadPosRankSum=-1.986;SOR=0.395	GT:AD:DP:GQ:PL	0/1:37,76:113:99:1730,0,644
chr1	22520216	22520216	G	A	ZBTB40	exonic	nonsynonymous SNV	NA	ZBTB40:NM_001330398:exon12:c.G2653A:p.V885M,ZBTB40:NM_014870:exon14:c.G2989A:p.V997M,ZBTB40:NM_001083621:exon15:c.G2989A:p.V997M	1	GnomAdExome_AF_eas	744	142	HomozygousVariant	hom	97	0	97	1	2822.06	PASS	16.3	NA	612106	Benign	NA	NA	'Bone mineral density (hip)[18445777;19801982];Bone mineral density (total hip)[29883787];Bone mineral density (spine)[18445777;19801982];Dupuytren''s disease[28886342];Heel bone mineral density[28869591;28869591;28869591;28869591;28869591;28869591];Endometriosis[23472165];Bone mineral density[24249740;24249740;21533022;21533022;22504420];Birth weight[27680694];Femoral neck bone mineral density[29499414];Lumbar spine bone mineral density[29499414];'	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	Zinc finger C2H2-type|Zinc finger C2H2-type|Zinc finger C2H2-type|Zinc finger C2H2-type;Zinc finger C2H2-type|Zinc finger C2H2-type|Zinc finger C2H2-type|Zinc finger C2H2-type;Zinc finger C2H2-type|Zinc finger C2H2-type|Zinc finger C2H2-type|Zinc finger C2H2-type	NA	NA	Medium	Medium	Medium	NA	NA	0.524	NA	N	N	H	0.250245214044116	N	Zbtb40	NA	NA	NA	NA	NA	0.9969	1	1	0.9968	1	0.998403	0.9961	0.98337	0.99179	PASS	1	1	0	1	0	chr1	22520216	NA	G	A	2822.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.09;AS_ReadPosRankSum=.;AS_SOR=0.845;DP=100;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.09;SOR=0.845	GT:AD:DP:GQ:PL	1/1:0,97:97:99:2836,291,0
chr1	22526222	22526222	G	C	ZBTB40	exonic	synonymous SNV	NA	ZBTB40:NM_001330398:exon16:c.G3210C:p.P1070P,ZBTB40:NM_014870:exon18:c.G3546C:p.P1182P,ZBTB40:NM_001083621:exon19:c.G3546C:p.P1182P	0.6158	GnomAdGenome_AF_ami	133	24	HeterozygousVariant	het	78	36	42	0.538461538461538	1045.64	PASS	NA	NA	612106	Benign	NA	NA	'Bone mineral density (hip)[18445777;19801982];Bone mineral density (total hip)[29883787];Bone mineral density (spine)[18445777;19801982];Dupuytren''s disease[28886342];Heel bone mineral density[28869591;28869591;28869591;28869591;28869591;28869591];Endometriosis[23472165];Bone mineral density[24249740;24249740;21533022;21533022;22504420];Birth weight[27680694];Femoral neck bone mineral density[29499414];Lumbar spine bone mineral density[29499414];'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.524	NA	N	N	H	0.250245214044116	N	Zbtb40	NA	NA	NA	NA	NA	0.3388	0.4593	0.4631	0.3014	0.6158	0.318091	0.298	0.337091	0.303777	PASS	0	0.401	404	0.419014	71	chr1	22526222	NA	G	C	1045.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.41;AS_ReadPosRankSum=0.7;AS_SOR=0.758;BaseQRankSum=2.35;DP=79;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.41;ReadPosRankSum=0.717;SOR=0.758	GT:AD:DP:GQ:PL	0/1:36,42:78:99:1053,0,738
chr1	22563618	22563622	GCCCG	-	EPHA8	UTR5	NA	NM_001006943:c.-18_-14del-;NM_020526:c.-18_-14del-	NA	0.537	GnomAdGenome_AF_afr	9		HeterozygousVariant	het	9	6	3	0.333333333333333	100.6	PASS	NA	NA	176945	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;choroid;fovea centralis;retina;macula lutea;pancreas;lens;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	NA	0.421	N	N	N	N	0.778368971674802	E	Epha8	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cellular phenotype; 	NA	NA	NA	NA	0	0	0	0.3294	0.537	0.300519	0	0.0727294	0.158915	PASS	0	0.173	1			chr1	22563617	NA	CGCCCG	C	100.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=2.808;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.22;AS_ReadPosRankSum=-0.5;AS_SOR=0.959;BaseQRankSum=-0.06;DP=10;ExcessHet=3.0103;FS=2.808;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.18;ReadPosRankSum=-0.48;SOR=0.959	GT:AD:DP:GQ:PL	0/1:6,3:9:99:108,0,235
chr1	22576609	22576609	C	T	EPHA8	exonic	synonymous SNV	NA	EPHA8:NM_001006943:exon3:c.C552T:p.A184A,EPHA8:NM_020526:exon3:c.C552T:p.A184A	0.098	GnomAdExome_AF_eas	4	1	HeterozygousVariant	het	109	58	51	0.467889908256881	1260.64	PASS	NA	NA	176945	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;choroid;fovea centralis;retina;macula lutea;pancreas;lens;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	NA	0.421	N	N	N	N	0.778368971674802	E	Epha8	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cellular phenotype; 	NA	NA	NA	NA	0.045	0.098	0.0971	0.0351	0.0938	0.0555112	0.0324	0.0449218	0.034483	PASS	0.05	0.049	71	0.059859	15	chr1	22576609	NA	C	T	1260.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=1.528;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.57;AS_ReadPosRankSum=-0.6;AS_SOR=0.543;BaseQRankSum=-0.711;DP=113;ExcessHet=3.0103;FS=1.528;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.57;ReadPosRankSum=-0.562;SOR=0.543	GT:AD:DP:GQ:PL	0/1:58,51:109:99:1268,0,1530
chr1	22589260	22589260	T	C	EPHA8	exonic	nonsynonymous SNV	NA	EPHA8:NM_001006943:exon5:c.T1369C:p.S457P	0.7	GME_Israel	248	47	HeterozygousVariant	het	118	47	71	0.601694915254237	1835.64	PASS	3.291	NA	176945	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	NA	T	N	T	T	T	NA	NA	NA	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	lung;choroid;fovea centralis;retina;macula lutea;pancreas;lens;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	NA	0.421	N	N	N	N	0.778368971674802	E	Epha8	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cellular phenotype; 	NA	NA	NA	NA	0.3909	0.6669	0.6711	0.4475	0.6562	0.481829	0.4576	0.393585	0.433498	PASS	0.7	0.549	394	0.588028	73	chr1	22589260	NA	T	C	1835.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=1.564;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.56;AS_ReadPosRankSum=0;AS_SOR=0.938;BaseQRankSum=1.31;DP=123;ExcessHet=3.0103;FS=1.564;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.56;ReadPosRankSum=0.069;SOR=0.938	GT:AD:DP:GQ:PL	0/1:47,71:118:99:1843,0,1053
chr1	22589398	22589398	A	T	EPHA8	UTR3	NA	NM_001006943:c.*19A>T	NA	0.0883	GnomAdExome_AF_eas	1	3	HeterozygousVariant	het	27	13	14	0.518518518518518	411.64	PASS	NA	NA	176945	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;choroid;fovea centralis;retina;macula lutea;pancreas;lens;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	NA	0.421	N	N	N	N	0.778368971674802	E	Epha8	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cellular phenotype; 	NA	NA	NA	NA	0.0564	0.0883	0.0874	0.0459	0.0862	0.0565096	0.0408	0.0101874	0.036244	PASS	0	0.049	43	0.064394	11	chr1	22589398	NA	A	T	411.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.8;AS_FS=1.69;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.26;AS_ReadPosRankSum=0.7;AS_SOR=1.179;BaseQRankSum=1.81;DP=29;ExcessHet=3.0103;FS=1.69;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.25;ReadPosRankSum=0.753;SOR=1.179	GT:AD:DP:GQ:PL	0/1:13,14:27:99:419,0,382
chr1	22596067	22596067	G	A	EPHA8	intronic	NA	NA	NA	0.7519	GnomAdExome_AF_afr	84	55	HeterozygousVariant	het	50	21	29	0.58	656.64	PASS	NA	NA	176945	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;choroid;fovea centralis;retina;macula lutea;pancreas;lens;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	NA	0.421	N	N	N	N	0.778368971674802	E	Epha8	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cellular phenotype; 	NA	NA	NA	NA	0.4613	0.7519	0.7534	0.5114	0.737	0.547923	0.519	0.450932	0.530378	PASS	0	0.632	95	0.621429	64	chr1	22596067	NA	G	A	656.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=1.102;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.14;AS_ReadPosRankSum=-0.1;AS_SOR=0.91;BaseQRankSum=0.061;DP=52;ExcessHet=3.0103;FS=1.102;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.13;ReadPosRankSum=-0.079;SOR=0.91	GT:AD:DP:GQ:PL	0/1:21,29:50:99:664,0,441
chr1	22597380	22597380	G	C	EPHA8	exonic	nonsynonymous SNV	NA	EPHA8:NM_020526:exon10:c.G1834C:p.E612Q	0.15	GME_Israel	4	1	HeterozygousVariant	het	158	76	82	0.518987341772152	1951.64	PASS	22.9	NA	176945	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	D	B	B	D	P	L	T	N	T	T	T	NA	T	T	T	T	D	.;	D	D	Ephrin receptor, transmembrane domain	NA	NA	Medium	Medium	Medium	lung;choroid;fovea centralis;retina;macula lutea;pancreas;lens;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	NA	0.421	N	N	N	N	0.778368971674802	E	Epha8	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cellular phenotype; 	NA	NA	NA	NA	0.093	0.1043	0.1044	0.1001	0.1155	0.0916534	0.1051	0.0938927	0.104269	PASS	0.15	0.051	75	0.06338	16	chr1	22597380	NA	G	C	1951.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=1.988;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.35;AS_ReadPosRankSum=0.7;AS_SOR=0.902;BaseQRankSum=0.85;DP=165;ExcessHet=3.0103;FS=1.988;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.35;ReadPosRankSum=0.712;SOR=0.902	GT:AD:DP:GQ:PL	0/1:76,82:158:99:1959,0,1714
chr1	22600821	22600821	A	G	EPHA8	intronic	NA	NA	NA	0.7305	GnomAdExome_AF_afr	143	37	HeterozygousVariant	het	39	16	23	0.58974358974359	602.64	PASS	NA	NA	176945	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;choroid;fovea centralis;retina;macula lutea;pancreas;lens;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	NA	0.421	N	N	N	N	0.778368971674802	E	Epha8	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cellular phenotype; 	NA	NA	NA	NA	0.4574	0.7305	0.7306	0.5053	0.7173	0.531749	0.5102	0.448008	0.51727	PASS	0	0.517	252	0.478417	59	chr1	22600821	NA	A	G	602.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.6;AS_FS=1.264;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.46;AS_ReadPosRankSum=-1.2;AS_SOR=0.595;BaseQRankSum=1.69;DP=40;ExcessHet=3.0103;FS=1.264;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.45;ReadPosRankSum=-1.115;SOR=0.595	GT:AD:DP:GQ:PL	0/1:16,23:39:99:610,0,317
chr1	22638945	22638945	A	G	C1QA	exonic	synonymous SNV	NA	C1QA:NM_001347465:exon3:c.A276G:p.G92G,C1QA:NM_001347466:exon3:c.A276G:p.G92G,C1QA:NM_015991:exon3:c.A276G:p.G92G	0.7372	GnomAdExome_AF_afr	337	69	HeterozygousVariant	het	98	47	51	0.520408163265306	1318.64	PASS	NA	[MIM:613652]Complement component C1q deficiency;	120550	Benign	Immunodeficiency due to a classical component pathway complement deficiency;Autosomal systemic lupus erythematosus	Disease-causing germline mutation(s) in;Major susceptibility factor in	NA	HP:0000793;HP:0005356;HP:0002719;HP:0000007;HP:0002725	Membranoproliferative glomerulonephritis;Decreased serum complement factor I;Recurrent infections;Autosomal recessive inheritance;Systemic lupus erythematosus	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	alveolus;skin;myocardium;pituitary gland;unclassifiable (Anatomical System);choroid;kidney;uterus;pancreas;visual apparatus;spleen;liver;bone;parathyroid;brain;heart;lung;ovary;thyroid;lymph node;oesophagus;colon;placenta;aorta;prostate;	placenta;	0.383	N	N	N	N	0.0298305085971857	N	C1qa	renal/urinary system phenotype; immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cellular phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.4856	0.7372	0.7439	0.5129	0.7295	0.616414	0.488	0.457174	0.493421	PASS	0.520408	0.63	378	0.665493	51	chr1	22638945	NA	A	G	1318.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=4.092;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.46;AS_ReadPosRankSum=0.2;AS_SOR=0.362;BaseQRankSum=1.21;DP=102;ExcessHet=3.0103;FS=4.092;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.46;ReadPosRankSum=0.238;SOR=0.362	GT:AD:DP:GQ:PL	0/1:47,51:98:99:1326,0,1192
chr1	22775195	22775195	T	G	EPHB2	intronic	NA	NA	NA	0.9032	GnomAdGenome_AF_fin	540	107	HomozygousVariant	hom	86	0	86	1	2436.06	PASS	NA	NA	600997	NA	Familial prostate cancer	Major susceptibility factor in	Blood protein levels[28240269;29875488;29875488;29875488;30072576;30072576;30072576];	HP:0100006;HP:0012125;HP:0003540;HP:0001933;HP:0000007;HP:0030138	Neoplasm of the central nervous system;Prostate cancer;Impaired platelet aggregation;Subcutaneous hemorrhage;Autosomal recessive inheritance;Excessive bleeding from superficial cuts	NA	NA	NA	Brain, heart, lung, kidney, placenta, pancreas, liver and skeletal muscle. Preferentially expressed in fetal brain.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.112	N	N	N	N	0.535372852022779	E	Ephb2	renal/urinary system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; digestive/alimentary phenotype; vision/eye phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cellular phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.7905	0.8642	0.8656	0.7909	0.9032	0.691693	0.8069	0.0001921	0		0	0.818	225	0.859155	30	chr1	22775195	NA	T	G	2436.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.33;AS_ReadPosRankSum=.;AS_SOR=0.839;DP=86;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.33;SOR=0.839	GT:AD:DP:GQ:PL	1/1:0,86:86:99:2450,258,0
chr1	22893000	22893000	T	C	EPHB2	exonic	synonymous SNV	NA	EPHB2:NM_001309192:exon7:c.T1545C:p.G515G,EPHB2:NM_001309193:exon7:c.T1545C:p.G515G,EPHB2:NM_004442:exon7:c.T1545C:p.G515G,EPHB2:NM_017449:exon7:c.T1545C:p.G515G	1	GnomAdExome_AF_eas	834	142	HomozygousVariant	hom	76	0	76	1	2205.06	PASS	NA	NA	600997	Benign	Familial prostate cancer	Major susceptibility factor in	Blood protein levels[28240269;29875488;29875488;29875488;30072576;30072576;30072576];	HP:0100006;HP:0012125;HP:0003540;HP:0001933;HP:0000007;HP:0030138	Neoplasm of the central nervous system;Prostate cancer;Impaired platelet aggregation;Subcutaneous hemorrhage;Autosomal recessive inheritance;Excessive bleeding from superficial cuts	NA	NA	NA	Brain, heart, lung, kidney, placenta, pancreas, liver and skeletal muscle. Preferentially expressed in fetal brain.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.112	N	N	N	N	0.535372852022779	E	Ephb2	renal/urinary system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; digestive/alimentary phenotype; vision/eye phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cellular phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; 	NA	NA	NA	NA	0.9965	1	1	0.9961	1	0.998203	0.9942	0.977096	0.997537	PASS	1	0.999	1	1	0	chr1	22893000	NA	T	C	2205.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.01;AS_ReadPosRankSum=.;AS_SOR=1.051;DP=80;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.01;SOR=1.051	GT:AD:DP:GQ:PL	1/1:0,76:76:99:2219,227,0
chr1	23091660	23091660	C	T	LUZP1	exonic	nonsynonymous SNV	NA	LUZP1:NM_001142546:exon3:c.G2602A:p.D868N,LUZP1:NM_033631:exon4:c.G2602A:p.D868N	0.884	GnomAdGenome_AF_fin	248	44	HomozygousVariant	hom	126	0	126	1	3733.06	PASS	15.76	NA	601422	Benign	NA	NA	Global electrical heterogeneity phenotypes[29622589];Height[25282103];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	alveolus;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);pineal gland;amniotic fluid;larynx;uterus;pancreas;head and neck;adrenal gland;mammary gland;skeletal muscle;cartilage;bone;parathyroid;brain;lung;ovary;thyroid;frontal lobe;colon;placenta;breast;	ciliary ganglion;temporal lobe;testis - seminiferous tubule;subthalamic nucleus;superior cervical ganglion;trigeminal ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.429	E	N	N	NA	0.96993174310164	E	Luzp1	homeostasis/metabolism phenotype; craniofacial phenotype; growth/size/body region phenotype; embryo phenotype; vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.7617	0.8367	0.8408	0.8132	0.884	0.746206	0.8257	0.765094	0.78243	PASS	0.8	0.547	385	0.573944	75	chr1	23091660	NA	C	T	3733.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.63;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=134;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.63;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,126:126:99:3747,378,0
chr1	23092768	23092768	G	A	LUZP1	exonic	synonymous SNV	NA	LUZP1:NM_001142546:exon3:c.C1494T:p.S498S,LUZP1:NM_033631:exon4:c.C1494T:p.S498S	0.8836	GnomAdGenome_AF_fin	248	44	HomozygousVariant	hom	125	1	124	0.992	3289.06	PASS	NA	NA	601422	Benign	NA	NA	Global electrical heterogeneity phenotypes[29622589];Height[25282103];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	alveolus;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);pineal gland;amniotic fluid;larynx;uterus;pancreas;head and neck;adrenal gland;mammary gland;skeletal muscle;cartilage;bone;parathyroid;brain;lung;ovary;thyroid;frontal lobe;colon;placenta;breast;	ciliary ganglion;temporal lobe;testis - seminiferous tubule;subthalamic nucleus;superior cervical ganglion;trigeminal ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.429	E	N	N	NA	0.96993174310164	E	Luzp1	homeostasis/metabolism phenotype; craniofacial phenotype; growth/size/body region phenotype; embryo phenotype; vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.7485	0.8359	0.8404	0.7606	0.8836	0.690495	0.7698	0.739201	0.743842	PASS	0.8	0.547	384	0.573944	75	chr1	23092768	NA	G	A	3289.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=26.31;AS_ReadPosRankSum=-0.6;AS_SOR=0.295;BaseQRankSum=1.53;DP=134;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=26.31;ReadPosRankSum=-0.554;SOR=0.295	GT:AD:DP:GQ:PL	1/1:1,124:125:99:3303,360,0
chr1	23092881	23092881	G	T	LUZP1	exonic	nonsynonymous SNV	NA	LUZP1:NM_001142546:exon3:c.C1381A:p.Q461K,LUZP1:NM_033631:exon4:c.C1381A:p.Q461K	0.8838	GnomAdGenome_AF_fin	247	43	HomozygousVariant	hom	100	0	100	1	4370.06	PASS	22.2	NA	601422	Benign	NA	NA	Global electrical heterogeneity phenotypes[29622589];Height[25282103];	NA	NA	NA	NA	NA	NA	T	T	P	B	N	P	M	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	D	N	.;.;.	NA	NA	Medium	Medium	Medium	alveolus;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);pineal gland;amniotic fluid;larynx;uterus;pancreas;head and neck;adrenal gland;mammary gland;skeletal muscle;cartilage;bone;parathyroid;brain;lung;ovary;thyroid;frontal lobe;colon;placenta;breast;	ciliary ganglion;temporal lobe;testis - seminiferous tubule;subthalamic nucleus;superior cervical ganglion;trigeminal ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.429	E	N	N	NA	0.96993174310164	E	Luzp1	homeostasis/metabolism phenotype; craniofacial phenotype; growth/size/body region phenotype; embryo phenotype; vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.7453	0.8358	0.8403	0.7471	0.8838	0.676917	0.7557	0.739279	0.728243	PASS	0.8	0.545	385	0.566901	75	chr1	23092881	NA	G	T	4370.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.75;AS_ReadPosRankSum=.;AS_SOR=0.818;DP=100;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=23.71;SOR=0.818	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,100:100:99:1|1:23092881_G_T:4384,301,0:23092881
chr1	23092890	23092890	C	T	LUZP1	exonic	nonsynonymous SNV	NA	LUZP1:NM_001142546:exon3:c.G1372A:p.G458S,LUZP1:NM_033631:exon4:c.G1372A:p.G458S	0.8834	GnomAdExome_AF_fin	247	43	HomozygousVariant	hom	101	0	101	1	4385.06	PASS	13	NA	601422	Benign	NA	NA	Global electrical heterogeneity phenotypes[29622589];Height[25282103];	NA	NA	NA	NA	NA	NA	T	T	B	B	D	P	M	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	alveolus;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);pineal gland;amniotic fluid;larynx;uterus;pancreas;head and neck;adrenal gland;mammary gland;skeletal muscle;cartilage;bone;parathyroid;brain;lung;ovary;thyroid;frontal lobe;colon;placenta;breast;	ciliary ganglion;temporal lobe;testis - seminiferous tubule;subthalamic nucleus;superior cervical ganglion;trigeminal ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.429	E	N	N	NA	0.96993174310164	E	Luzp1	homeostasis/metabolism phenotype; craniofacial phenotype; growth/size/body region phenotype; embryo phenotype; vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.7485	0.836	0.8403	0.7608	0.8833	0.690296	0.7699	0.750941	0.743842	PASS	0.8	0.545	385	0.566901	75	chr1	23092890	NA	C	T	4385.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.46;AS_ReadPosRankSum=.;AS_SOR=0.839;DP=103;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.39;SOR=0.839	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,101:101:99:1|1:23092881_G_T:4399,304,0:23092881
chr1	23093362	23093362	T	C	LUZP1	exonic	synonymous SNV	NA	LUZP1:NM_001142546:exon3:c.A900G:p.T300T,LUZP1:NM_033631:exon4:c.A900G:p.T300T	0.8842	GnomAdGenome_AF_fin	250	44	HomozygousVariant	hom	50	2	48	0.96	1315.06	PASS	NA	NA	601422	Benign	NA	NA	Global electrical heterogeneity phenotypes[29622589];Height[25282103];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	alveolus;stomach;testis;adrenal cortex;unclassifiable (Anatomical System);pineal gland;amniotic fluid;larynx;uterus;pancreas;head and neck;adrenal gland;mammary gland;skeletal muscle;cartilage;bone;parathyroid;brain;lung;ovary;thyroid;frontal lobe;colon;placenta;breast;	ciliary ganglion;temporal lobe;testis - seminiferous tubule;subthalamic nucleus;superior cervical ganglion;trigeminal ganglion;atrioventricular node;skeletal muscle;globus pallidus;	0.429	E	N	N	NA	0.96993174310164	E	Luzp1	homeostasis/metabolism phenotype; craniofacial phenotype; growth/size/body region phenotype; embryo phenotype; vision/eye phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	NA	NA	NA	NA	0.7625	0.8367	0.841	0.814	0.8842	0.747404	0.8269	0.745107	0.784893	PASS	0.801724	0.548	384	0.573944	75	chr1	23093362	NA	T	C	1315.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=26.3;AS_ReadPosRankSum=-0.4;AS_SOR=0.866;BaseQRankSum=0.883;DP=50;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=26.3;ReadPosRankSum=-0.347;SOR=0.866	GT:AD:DP:GQ:PL	1/1:2,48:50:99:1329,99,0
chr1	23362440	23362440	A	G	ZNF436	exonic	synonymous SNV	NA	ZNF436:NM_001370652:exon3:c.T888C:p.N296N,ZNF436:NM_030634:exon3:c.T942C:p.N314N,ZNF436:NM_001077195:exon4:c.T942C:p.N314N	0.8036	GnomAdGenome_AF_ami	160	43	HeterozygousVariant	het	72	30	42	0.583333333333333	1217.64	PASS	NA	NA	611703	Benign	NA	NA	Glomerular filtration rate[29403010];	NA	NA	NA	NA	NA	Expressed in fetal brain, heart, liver, spleen, bladder, lung, skin, skeletal muscle, stomach and pancreas. {ECO:0000269|PubMed:17089209}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;stomach;testis;unclassifiable (Anatomical System);larynx;kidney;uterus;whole body;retina;pancreas;head and neck;urinary;mammary gland;meninges;pia mater;spleen;liver;cartilage;endometrium;bone;brain;heart;dura mater;lung;cerebral cortex;thyroid;bladder;colon;placenta;prostate;breast;	ciliary ganglion;atrioventricular node;trigeminal ganglion;superior cervical ganglion;	0.457	NA	N	N	N	0.948931996255063	E	Zfp46	NA	NA	NA	NA	NA	0.6593	0.7329	0.7385	0.5854	0.8036	0.509984	0.578	0.648711	0.576355	PASS	0.707317	0.514	285	0.521127	62	chr1	23362440	NA	A	G	1217.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.5;AS_FS=1.985;AS_MQ=60;AS_MQRankSum=0;AS_QD=16.92;AS_ReadPosRankSum=1.6;AS_SOR=0.797;BaseQRankSum=0.503;DP=74;ExcessHet=3.0103;FS=1.985;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=16.91;ReadPosRankSum=1.66;SOR=0.797	GT:AD:DP:GQ:PL	0/1:30,42:72:99:1225,0,775
chr1	23362590	23362590	G	A	ZNF436	exonic	synonymous SNV	NA	ZNF436:NM_001370652:exon3:c.C738T:p.H246H,ZNF436:NM_030634:exon3:c.C792T:p.H264H,ZNF436:NM_001077195:exon4:c.C792T:p.H264H	0.2633	GnomAdGenome_AF_sas	47	9	HeterozygousVariant	het	81	43	38	0.469135802469136	889.64	PASS	NA	NA	611703	NA	NA	NA	Glomerular filtration rate[29403010];	NA	NA	NA	NA	NA	Expressed in fetal brain, heart, liver, spleen, bladder, lung, skin, skeletal muscle, stomach and pancreas. {ECO:0000269|PubMed:17089209}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;stomach;testis;unclassifiable (Anatomical System);larynx;kidney;uterus;whole body;retina;pancreas;head and neck;urinary;mammary gland;meninges;pia mater;spleen;liver;cartilage;endometrium;bone;brain;heart;dura mater;lung;cerebral cortex;thyroid;bladder;colon;placenta;prostate;breast;	ciliary ganglion;atrioventricular node;trigeminal ganglion;superior cervical ganglion;	0.457	NA	N	N	N	0.948931996255063	E	Zfp46	NA	NA	NA	NA	NA	0.1115	0.2451	0.2432	0.0674	0.2633	0.121206	0.0578	0.104423	0.087028	PASS	0.155303	0.269	224	0.267606	58	chr1	23362590	NA	G	A	889.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.4;AS_FS=1.821;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.99;AS_ReadPosRankSum=1.1;AS_SOR=0.879;BaseQRankSum=-2.386;DP=81;ExcessHet=3.0103;FS=1.821;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.98;ReadPosRankSum=1.11;SOR=0.879	GT:AD:DP:GQ:PL	0/1:43,38:81:99:897,0,1172
chr1	23408748	23408748	G	T	TCEA3	intronic	NA	NA	NA	0.9343	GnomAdGenome_AF_ami	240	105	HomozygousVariant	hom	51	0	51	1	1502.06	PASS	NA	NA	604128	NA	NA	NA	QT interval[24952745;29213071];Creatinine levels[29403010];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.636	NA	N	N	N	0.307483654878265	N	Tcea3	NA	NA	NA	NA	NA	0.8757	0.8926	0.8976	0.8447	0.9343	0.842452	0.8459	0.845701	0.853859	PASS	0	0.893	54	0.859155	34	chr1	23408748	NA	G	T	1502.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.45;AS_ReadPosRankSum=.;AS_SOR=1.314;DP=53;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.45;SOR=1.314	GT:AD:DP:GQ:PL	1/1:0,51:51:99:1516,153,0
chr1	23424647	23424647	G	T	TCEA3	UTR5	NA	NM_003196:c.-14C>A	NA	0.7578	GnomAdGenome_AF_ami	150	31	HeterozygousVariant	het	97	45	52	0.536082474226804	1147.64	PASS	NA	NA	604128	NA	NA	NA	QT interval[24952745;29213071];Creatinine levels[29403010];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.636	NA	N	N	N	0.307483654878265	N	Tcea3	NA	NA	NA	NA	NA	0.6254	0.6786	0.681	0.527	0.7578	0.445687	0.5319	0.0001153	0.551724	PASS	0	0.499	274	0.447183	65	chr1	23424647	NA	G	T	1147.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=3.858;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.84;AS_ReadPosRankSum=0.8;AS_SOR=0.369;BaseQRankSum=-0.613;DP=99;ExcessHet=3.0103;FS=3.858;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.83;ReadPosRankSum=0.879;SOR=0.369	GT:AD:DP:GQ:PL	0/1:45,52:97:99:1155,0,954
chr1	23559007	23559007	T	C	ID3	exonic	nonsynonymous SNV	NA	ID3:NM_002167:exon2:c.A313G:p.T105A	0.9756	GnomAdExome_AF_eas	715	126	HomozygousVariant	hom	84	0	84	1	2416.06	PASS	0.121	NA	600277	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed abundantly in lung, kidney and adrenal gland, but not in adult brain.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	NA	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.184	N	N	N	N	0.980118938694226	E	Id3	immune system phenotype; skeleton phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); neoplasm; embryo phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; 	id3	trunk	decreased size	abnormal	0.7973	0.9756	0.9753	0.8191	0.9754	0.890375	0.8219	0.791406	0.853038	PASS	0.956897	0.925	115	0.943662	16	chr1	23559007	NA	T	C	2416.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.76;AS_ReadPosRankSum=.;AS_SOR=0.843;DP=88;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.76;SOR=0.843	GT:AD:DP:GQ:PL	1/1:0,84:84:99:2430,252,0
chr1	23691787	23691787	C	G	RPL11	UTR5	NA	NM_001199802:c.-37C>G	NA	1	GnomAdExome_AF_fin	822	142	HomozygousVariant	hom	85	0	85	1	2474.06	PASS	NA	[MIM:612562]Diamond-Blackfan anemia 7;	604175	NA	Blackfan-Diamond anemia	Disease-causing germline mutation(s) in	NA	HP:0000938;HP:0001561;HP:0010487;HP:0000912;HP:0009778;HP:0001684;HP:0001511;HP:0000939;HP:0001636;HP:0000076;HP:0000365;HP:0001972;HP:0005518;HP:0000175;HP:0025116;HP:0001629;HP:0001875;HP:0100633;HP:0000413;HP:0000006;HP:0001199;HP:0001643;HP:0002650;HP:0100512;HP:0000085;HP:0000453;HP:0000403;HP:0000980;HP:0000078;HP:0000457;HP:0004322;HP:0000179;HP:0000823;HP:0011675;HP:0000175;HP:0001972;HP:0000079;HP:0001155;HP:0002076;HP:0003196;HP:0012378;HP:0002488	Osteopenia;Polyhydramnios;Small hypothenar eminence;Sprengel anomaly;Short thumb;Secundum atrial septal defect;Intrauterine growth retardation;Osteoporosis;Tetralogy of Fallot;Vesicoureteral reflux;Hearing impairment;Macrocytic anemia;Increased mean corpuscular volume;Cleft palate;Fetal distress;Ventricular septal defect;Neutropenia;Esophagitis;Atresia of the external auditory canal;Autosomal dominant inheritance;Triphalangeal thumb;Patent ductus arteriosus;Scoliosis;Low levels of vitamin D;Horseshoe kidney;Choanal atresia;Recurrent otitis media;Pallor;Abnormality of the genital system;Depressed nasal ridge;Short stature;Thick lower lip vermilion;Delayed puberty;Arrhythmia;Cleft palate;Macrocytic anemia;Abnormality of the urinary system;Abnormality of the hand;Migraine;Short nose;Fatigue;Acute leukemia	Diamond-Blackfan_anemia	criteria_provided,_single_submitter	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	E	E	E	0.912016045712689	E	Rpl11	NA	rpl11	erythroid lineage cell	decreased amount	ameliorated	0.9954	0.9997	0.9998	0.9838	1	0.976837	0.9839	0.952523	0.99179	PASS	0	0.998	2	1	0	chr1	23691787	NA	C	G	2474.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.11;AS_ReadPosRankSum=.;AS_SOR=0.979;DP=87;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.11;SOR=0.979	GT:AD:DP:GQ:PL	1/1:0,85:85:99:2488,255,0
chr1	23750961	23750961	C	T	ELOA	exonic	nonsynonymous SNV	NA	ELOA:NM_003198:exon4:c.C434T:p.T145M	0.1581	GnomAdGenome_AF_sas	20	0	HomozygousVariant	hom	88	0	88	1	2608.06	PASS	20.4	NA	600786	Benign	NA	NA	Inflammatory skin disease[25574825];	NA	NA	NA	NA	NA	NA	D	D	D	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	D	D	.;.;.	NA	NA	NA	NA	NA	NA	NA	NA	E	NA	NA	H	NA	NA	Eloa	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; liver/biliary system phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0934	0.1472	0.1491	0.0679	0.1581	0.0806709	0.0685	0.0901282	0.087028	PASS	0.137931	0.139	184	0.130282	37	chr1	23750961	NA	C	T	2608.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.64;AS_ReadPosRankSum=.;AS_SOR=0.887;DP=91;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.64;SOR=0.887	GT:AD:DP:GQ:PL	1/1:0,88:88:99:2622,263,0
chr1	23796496	23796496	C	T	GALE	intronic	NA	NA	NA	0.757	GnomAdGenome_AF_sas	358	65	HomozygousVariant	hom	58	2	56	0.96551724137931	1138.06	SOR3	NA	[MIM:230350]Epimerase-deficiency galactosemia;	606953	NA	Generalized galactose epimerase deficiency;Erythrocyte galactose epimerase deficiency	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0001249;HP:0002013;HP:0000952;HP:0001252;HP:0002240;HP:0001290;HP:0000750;HP:0001744;HP:0002194;HP:0001263;HP:0012023;HP:0000007;HP:0003355;HP:0000407;HP:0012024;HP:0001508	Intellectual disability;Vomiting;Jaundice;Muscular hypotonia;Hepatomegaly;Generalized hypotonia;Delayed speech and language development;Splenomegaly;Delayed gross motor development;Global developmental delay;Galactosuria;Autosomal recessive inheritance;Aminoaciduria;Sensorineural hearing impairment;Hypergalactosemia;Failure to thrive	UDPglucose-4-epimerase_deficiency|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0621	NA	E	N	N	0.466920645152934	N	Gale	NA	NA	NA	NA	NA	0.6427	0.7364	0.7361	0.6676	0.757	0	0.5349	0.0001537	0.534452	PASS	0	0.69	294	0.661871	54	chr1	23796496	NA	C	T	1138.06	SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.5;AS_FS=6.408;AS_MQ=60;AS_MQRankSum=0;AS_QD=19.62;AS_ReadPosRankSum=0.8;AS_SOR=3.99;BaseQRankSum=1.53;DP=68;ExcessHet=3.0103;FS=6.408;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=19.62;ReadPosRankSum=0.896;SOR=3.99	GT:AD:DP:GQ:PL	1/1:2,56:58:99:1152,122,0
chr1	23808231	23808231	T	C	HMGCL	exonic	synonymous SNV	NA	HMGCL:NM_001166059:exon5:c.A441G:p.L147L,HMGCL:NM_000191:exon7:c.A654G:p.L218L	0.9678	GnomAdExome_AF_afr	611	98	HomozygousVariant	hom	73	0	73	1	1854.06	PASS	NA	NA	613898	Benign	3-hydroxy-3-methylglutaric aciduria	Disease-causing germline mutation(s) in	Reticulocyte fraction of red cells[27863252];High light scatter reticulocyte count[27863252];Immature fraction of reticulocytes[27863252];	HP:0001903;HP:0003819;HP:0001257;HP:0001259;HP:0001945;HP:0410066;HP:0001942;HP:0003150;HP:0003344;HP:0001250;HP:0000007;HP:0002353;HP:0001252;HP:0001987;HP:0002500;HP:0002149;HP:0003234;HP:0000741;HP:0000980;HP:0000252;HP:0001943;HP:0032198;HP:0002013;HP:0001336;HP:0002240;HP:0001262;HP:0001263;HP:0025356;HP:0410051;HP:0000741;HP:0011099;HP:0001735;HP:0001298;HP:0001325;HP:0000980;HP:0008151;HP:0001251;HP:0001988;HP:0002151;HP:0002615;HP:0001644;HP:0006561;HP:0001254;HP:0001882;HP:0006582;HP:0010864;HP:0002039;HP:0001256;HP:0002240;HP:0002572;HP:0002045;HP:0002521;HP:0001942;HP:0001894;HP:0002919;HP:0003344;HP:0000969;HP:0000252;HP:0002342;HP:0001265;HP:0001252;HP:0001958;HP:0001824;HP:0001987;HP:0002789;HP:0001974;HP:0001260;HP:0001336;HP:0001695;HP:0002910;HP:0001944;HP:0012378;HP:0001903;HP:0000952;HP:0002352;HP:0002014;HP:0001250;HP:0002104;HP:0002149;HP:0001945	Anemia;Death in childhood;Spasticity;Coma;Fever;Increased level of hippuric acid in urine;Metabolic acidosis;Glutaric aciduria;3-Methylglutaric aciduria;Seizure;Autosomal recessive inheritance;EEG abnormality;Muscular hypotonia;Hyperammonemia;Abnormality of the cerebral white matter;Hyperuricemia;Decreased plasma carnitine;Apathy;Pallor;Microcephaly;Hypoglycemia;Decreased prothrombin time;Vomiting;Myoclonus;Hepatomegaly;Excessive daytime somnolence;Global developmental delay;Psychomotor retardation;Increased level of 3-hydroxy-3-methylglutaric acid in urine;Apathy;Spastic hemiparesis;Acute pancreatitis;Encephalopathy;Hypoglycemic coma;Pallor;Prolonged prothrombin time;Ataxia;Recurrent hypoglycemia;Increased serum lactate;Hypotension;Dilated cardiomyopathy;Lipid accumulation in hepatocytes;Lethargy;Leukopenia;Reye syndrome-like episodes;Intellectual disability, severe;Anorexia;Intellectual disability, mild;Hepatomegaly;Episodic vomiting;Hypothermia;Hypsarrhythmia;Metabolic acidosis;Thrombocytosis;Ketonuria;3-Methylglutaric aciduria;Edema;Microcephaly;Intellectual disability, moderate;Hyporeflexia;Muscular hypotonia;Nonketotic hypoglycemia;Weight loss;Hyperammonemia;Tachypnea;Leukocytosis;Dysarthria;Myoclonus;Cardiac arrest;Elevated hepatic transaminase;Dehydration;Fatigue;Anemia;Jaundice;Leukoencephalopathy;Diarrhea;Seizure;Apnea;Hyperuricemia;Fever	Deficiency_of_hydroxymethylglutaryl-CoA_lyase|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Highest expression in liver. Expressed in pancreas, kidney, intestine, testis, fibroblasts and lymphoblasts. Very low expression in brain and skeletal muscle. The relative expression of isoform 2 (at mRNA level) is highest in heart (30%), skeletal muscle (22%), and brain (14%). {ECO:0000269|PubMed:21952825}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;cerebellum cortex;stomach;testis;pituitary gland;lens;lymphoreticular;unclassifiable (Anatomical System);amniotic fluid;choroid;kidney;uterus;whole body;retina;pancreas;muscle;bile duct;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;cervix;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;heart;bone marrow;lung;salivary gland;ovary;macula lutea;lymph node;colon;placenta;prostate;nasopharynx;breast;optic nerve;hypothalamus;	kidney;liver;skeletal muscle;	0.276	E	N	N	N	0.997288394358286	E	Hmgcl	growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); embryo phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); 	NA	NA	NA	NA	0.902	0.9678	0.9707	0.9257	0.9652	0.88738	0.9263	0.0001537	0.923645	PASS	0.95	0.854	204	0.830986	40	chr1	23808231	NA	T	C	1854.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=25.4;AS_ReadPosRankSum=.;AS_SOR=0.776;DP=77;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=25.4;SOR=0.776	GT:AD:DP:GQ:PL	1/1:0,73:73:99:1868,217,0
chr1	23874493	23874493	C	T	CNR2	UTR3	NA	NM_001841:c.*42G>A	NA	0.7851	GnomAdExome_AF_afr	142	65	HomozygousVariant	hom	31	0	31	1	1282.06	SOR3	NA	NA	605051	NA	NA	NA	Eosinophil percentage of granulocytes[27863252];Eosinophil counts[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	'Preferentially expressed in cells of the immune system with higher expression in B-cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root ganglion sensory neurons (at protein level). Two isoforms are produced by alternative promoter usage and differ only in the 5'' UTR: isoform CB2A is observed predominantly in testis with some expression in brain, while isoform CB2B is predominant in spleen and leukocytes. {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587, ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552, ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827, ECO:0000269|PubMed:7556170}.;'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.727	N	N	N	N	0.14983735818412	N	Cnr2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	cnr2	hepatocyte	decreased amount	abnormal	0.6228	0.7851	0.7884	0.6426	0.778	0.661342	0.6409	0.600872	0.642857	PASS	0	0.673	121	0.652174	50	chr1	23874493	NA	C	T	1282.06	SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.71;AS_ReadPosRankSum=.;AS_SOR=3.981;DP=31;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.35;SOR=3.981	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,31:31:93:1|1:23874479_T_C:1296,93,0:23874479
chr1	23874604	23874604	G	C	CNR2	exonic	synonymous SNV	NA	CNR2:NM_001841:exon2:c.C1014G:p.T338T	0.8	GME_Israel	402	68	HomozygousVariant	hom	113	0	113	1	3250.06	PASS	NA	NA	605051	Benign	NA	NA	Eosinophil percentage of granulocytes[27863252];Eosinophil counts[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	'Preferentially expressed in cells of the immune system with higher expression in B-cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root ganglion sensory neurons (at protein level). Two isoforms are produced by alternative promoter usage and differ only in the 5'' UTR: isoform CB2A is observed predominantly in testis with some expression in brain, while isoform CB2B is predominant in spleen and leukocytes. {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587, ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552, ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827, ECO:0000269|PubMed:7556170}.;'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.727	N	N	N	N	0.14983735818412	N	Cnr2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	cnr2	hepatocyte	decreased amount	abnormal	0.6172	0.7612	0.7637	0.636	0.7543	0.653355	0.6342	0.602295	0.636289	VQSRTrancheSNP99.00to99.90	0.8	0.691	350	0.669014	54	chr1	23874604	NA	G	C	3250.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.76;AS_ReadPosRankSum=.;AS_SOR=0.862;DP=113;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.76;SOR=0.862	GT:AD:DP:GQ:PL	1/1:0,113:113:99:3264,339,0
chr1	23874619	23874619	C	T	CNR2	exonic	synonymous SNV	NA	CNR2:NM_001841:exon2:c.G999A:p.P333P	0.8	GME_Israel	402	68	HomozygousVariant	hom	119	1	118	0.991596638655462	3333.06	PASS	NA	NA	605051	NA	NA	NA	Eosinophil percentage of granulocytes[27863252];Eosinophil counts[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	'Preferentially expressed in cells of the immune system with higher expression in B-cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root ganglion sensory neurons (at protein level). Two isoforms are produced by alternative promoter usage and differ only in the 5'' UTR: isoform CB2A is observed predominantly in testis with some expression in brain, while isoform CB2B is predominant in spleen and leukocytes. {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587, ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552, ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827, ECO:0000269|PubMed:7556170}.;'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.727	N	N	N	N	0.14983735818412	N	Cnr2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	cnr2	hepatocyte	decreased amount	abnormal	0.6173	0.7612	0.7637	0.6361	0.7542	0.653355	0.634	0.602263	0.636289	PASS	0.8	0.692	351	0.669014	54	chr1	23874619	NA	C	T	3333.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=28.01;AS_ReadPosRankSum=1.5;AS_SOR=0.237;BaseQRankSum=-1.985;DP=121;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=28.01;ReadPosRankSum=1.53;SOR=0.237	GT:AD:DP:GQ:PL	1/1:1,118:119:99:3347,314,0
chr1	23874772	23874772	A	G	CNR2	exonic	synonymous SNV	NA	CNR2:NM_001841:exon2:c.T846C:p.A282A	0.8	GME_Israel	400	68	HomozygousVariant	hom	81	3	78	0.962962962962963	2279.06	PASS	NA	NA	605051	Benign	NA	NA	Eosinophil percentage of granulocytes[27863252];Eosinophil counts[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	'Preferentially expressed in cells of the immune system with higher expression in B-cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root ganglion sensory neurons (at protein level). Two isoforms are produced by alternative promoter usage and differ only in the 5'' UTR: isoform CB2A is observed predominantly in testis with some expression in brain, while isoform CB2B is predominant in spleen and leukocytes. {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587, ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552, ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827, ECO:0000269|PubMed:7556170}.;'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.727	N	N	N	N	0.14983735818412	N	Cnr2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	cnr2	hepatocyte	decreased amount	abnormal	0.6173	0.7613	0.7639	0.636	0.7543	0.653355	0.6339	0.606913	0.635468	PASS	0.8	0.69	353	0.669014	54	chr1	23874772	NA	A	G	2279.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=28.14;AS_ReadPosRankSum=1.6;AS_SOR=0.434;BaseQRankSum=0.535;DP=90;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=28.14;ReadPosRankSum=1.63;SOR=0.434	GT:AD:DP:GQ:PL	1/1:3,78:81:99:2293,155,0
chr1	23874867	23874867	A	G	CNR2	exonic	synonymous SNV	NA	CNR2:NM_001841:exon2:c.T751C:p.L251L	0.8	GME_Israel	402	68	HomozygousVariant	hom	91	0	91	1	2809.06	PASS	NA	NA	605051	Benign	NA	NA	Eosinophil percentage of granulocytes[27863252];Eosinophil counts[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	'Preferentially expressed in cells of the immune system with higher expression in B-cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root ganglion sensory neurons (at protein level). Two isoforms are produced by alternative promoter usage and differ only in the 5'' UTR: isoform CB2A is observed predominantly in testis with some expression in brain, while isoform CB2B is predominant in spleen and leukocytes. {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587, ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552, ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827, ECO:0000269|PubMed:7556170}.;'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.727	N	N	N	N	0.14983735818412	N	Cnr2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	cnr2	hepatocyte	decreased amount	abnormal	0.6169	0.7613	0.7639	0.6361	0.7545	0.653355	0.6339	0.607353	0.636289	PASS	0.8	0.692	351	0.669014	54	chr1	23874867	NA	A	G	2809.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.87;AS_ReadPosRankSum=.;AS_SOR=0.76;DP=92;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.87;SOR=0.76	GT:AD:DP:GQ:PL	1/1:0,91:91:99:2823,273,0
chr1	23874958	23874958	C	T	CNR2	exonic	synonymous SNV	NA	CNR2:NM_001841:exon2:c.G660A:p.V220V	0.8	GME_Israel	401	67	HomozygousVariant	hom	84	0	84	1	2457.06	PASS	NA	NA	605051	Benign	NA	NA	Eosinophil percentage of granulocytes[27863252];Eosinophil counts[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	'Preferentially expressed in cells of the immune system with higher expression in B-cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root ganglion sensory neurons (at protein level). Two isoforms are produced by alternative promoter usage and differ only in the 5'' UTR: isoform CB2A is observed predominantly in testis with some expression in brain, while isoform CB2B is predominant in spleen and leukocytes. {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587, ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552, ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827, ECO:0000269|PubMed:7556170}.;'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.727	N	N	N	N	0.14983735818412	N	Cnr2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	cnr2	hepatocyte	decreased amount	abnormal	0.6169	0.7611	0.7634	0.6358	0.754	0.653355	0.6346	0.601616	0.636289	PASS	0.8	0.689	349	0.670213	55	chr1	23874958	NA	C	T	2457.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.25;AS_ReadPosRankSum=.;AS_SOR=0.741;DP=89;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.25;SOR=0.741	GT:AD:DP:GQ:PL	1/1:0,84:84:99:2471,252,0
chr1	23875153	23875153	G	A	CNR2	exonic	synonymous SNV	NA	CNR2:NM_001841:exon2:c.C465T:p.G155G	0.8	GME_Israel	403	67	HomozygousVariant	hom	166	2	164	0.987951807228916	4527.06	PASS	NA	NA	605051	NA	NA	NA	Eosinophil percentage of granulocytes[27863252];Eosinophil counts[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	'Preferentially expressed in cells of the immune system with higher expression in B-cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root ganglion sensory neurons (at protein level). Two isoforms are produced by alternative promoter usage and differ only in the 5'' UTR: isoform CB2A is observed predominantly in testis with some expression in brain, while isoform CB2B is predominant in spleen and leukocytes. {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587, ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552, ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827, ECO:0000269|PubMed:7556170}.;'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.727	N	N	N	N	0.14983735818412	N	Cnr2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	cnr2	hepatocyte	decreased amount	abnormal	0.6174	0.7611	0.7635	0.6357	0.7541	0.653355	0.6339	0.606784	0.635468	PASS	0.8	0.692	350	0.666667	54	chr1	23875153	NA	G	A	4527.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=27.27;AS_ReadPosRankSum=-0.2;AS_SOR=0.794;BaseQRankSum=0.832;DP=171;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=27.27;ReadPosRankSum=-0.126;SOR=0.794	GT:AD:DP:GQ:PL	1/1:2,164:166:99:4541,448,0
chr1	23875429	23875429	T	C	CNR2	exonic	synonymous SNV	NA	CNR2:NM_001841:exon2:c.A189G:p.Q63Q	0.8	GME_Israel	401	67	HomozygousVariant	hom	119	0	119	1	5329.06	PASS	NA	NA	605051	Benign	NA	NA	Eosinophil percentage of granulocytes[27863252];Eosinophil counts[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	'Preferentially expressed in cells of the immune system with higher expression in B-cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root ganglion sensory neurons (at protein level). Two isoforms are produced by alternative promoter usage and differ only in the 5'' UTR: isoform CB2A is observed predominantly in testis with some expression in brain, while isoform CB2B is predominant in spleen and leukocytes. {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587, ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552, ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827, ECO:0000269|PubMed:7556170}.;'	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.727	N	N	N	N	0.14983735818412	N	Cnr2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	cnr2	hepatocyte	decreased amount	abnormal	0.6167	0.7617	0.7644	0.6352	0.7535	0.653954	0.6129	0.575917	0.636289	PASS	0.8	0.691	352	0.665493	55	chr1	23875429	NA	T	C	5329.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.16;AS_ReadPosRankSum=.;AS_SOR=1.059;DP=120;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.09;SOR=1.059	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,119:119:99:1|1:23875429_T_C:5343,358,0:23875429
chr1	23875430	23875430	T	C	CNR2	exonic	nonsynonymous SNV	NA	CNR2:NM_001841:exon2:c.A188G:p.Q63R	0.8	GME_Israel	401	67	HomozygousVariant	hom	119	0	119	1	5329.06	PASS	7.315	NA	605051	Benign	NA	NA	Eosinophil percentage of granulocytes[27863252];Eosinophil counts[27863252];Eosinophil percentage of white cells[27863252];	NA	NA	NA	NA	NA	'Preferentially expressed in cells of the immune system with higher expression in B-cells and NK cells (at protein level). Expressed in skin in suprabasal layers and hair follicles (at protein level). Highly expressed in tonsil and to a lower extent in spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172 could not detect expression in normal brain. Expressed in brain by perivascular microglial cells and dorsal root ganglion sensory neurons (at protein level). Two isoforms are produced by alternative promoter usage and differ only in the 5'' UTR: isoform CB2A is observed predominantly in testis with some expression in brain, while isoform CB2B is predominant in spleen and leukocytes. {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587, ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552, ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827, ECO:0000269|PubMed:7556170}.;'	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	GPCR, rhodopsin-like, 7TM	NA	NA	Medium	Medium	Medium	NA	NA	0.727	N	N	N	N	0.14983735818412	N	Cnr2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	cnr2	hepatocyte	decreased amount	abnormal	0.6166	0.7612	0.7637	0.6349	0.753	0.653355	0.6105	0.576215	0.636289	PASS	0.8	0.691	352	0.665493	55	chr1	23875430	NA	T	C	5329.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.97;AS_ReadPosRankSum=.;AS_SOR=1.059;DP=122;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.44;SOR=1.059	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,119:119:99:1|1:23875429_T_C:5343,358,0:23875429
chr1	23967759	23967759	C	T	SRSF10	UTR3	NA	NM_001300936:c.*167G>A;NM_001191005:c.*3383G>A;NM_001191006:c.*167G>A;NM_054016:c.*3383G>A	NA	1	GnomAdExome_AF_eas	131	31	HomozygousVariant	hom	6	0	6	1	160.97	DP10	NA	NA	605221	NA	NA	NA	Obesity-related traits[23251661];	NA	NA	NA	NA	NA	Widely expressed. {ECO:0000269|PubMed:11684676, ECO:0000269|PubMed:11891055}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	cochlea;intestine;pharynx;alveolus;smooth muscle;skin;stomach;testis;lymphoreticular;unclassifiable (Anatomical System);pineal gland;kidney;larynx;uterus;whole body;retina;pancreas;muscle;head and neck;urinary;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;cervix;liver;cartilage;endometrium;bone;germinal center;parathyroid;artery;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;lymph node;bladder;colon;placenta;prostate;aorta;nasopharynx;breast;	ciliary ganglion;testis - seminiferous tubule;testis - interstitial;dorsal root ganglion;atrioventricular node;trigeminal ganglion;superior cervical ganglion;testis;skeletal muscle;cerebellum;	NA	E	E	NA	E	0.53917561279198	E	Srsf10	growth/size/body region phenotype; homeostasis/metabolism phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); liver/biliary system phenotype; 	NA	NA	NA	NA	0.8888	1	1	0.9892	1	0.983826	0	0.128763	0.954639	VQSRTrancheSNP99.90to100.00	0	0.996	1	1	0	chr1	23967759	NA	C	T	160.97	DP10	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.83;AS_ReadPosRankSum=.;AS_SOR=1.329;DP=6;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.83;SOR=1.329	GT:AD:DP:GQ:PL	1/1:0,6:6:18:175,18,0
chr1	24061332	24061332	T	A	MYOM3	intronic	NA	NA	NA	0.4822	GnomAdExome_AF_afr	119	43	HeterozygousVariant	het	74	42	32	0.432432432432432	734.64	PASS	NA	NA	616832	NA	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.2755	0.4822	0.4881	0.3054	0.4755	0.385583	0.2917	0.0001153	0.287356	PASS	0	0.424	253	0.524648	63	chr1	24061332	NA	T	A	734.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=4.657;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.93;AS_ReadPosRankSum=1.9;AS_SOR=1.336;BaseQRankSum=0.881;DP=76;ExcessHet=3.0103;FS=4.657;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.93;ReadPosRankSum=2;SOR=1.336	GT:AD:DP:GQ:PL	0/1:42,32:74:99:742,0,943
chr1	24074143	24074143	C	G	MYOM3	intronic	NA	NA	NA	1	GnomAdExome_AF_fin	266	123	HomozygousVariant	hom	78	0	78	1	2117.06	PASS	NA	NA	616832	NA	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.9887	0.9991	0.9993	0.9784	1	0.967252	0.9795	0.0004226	0.986043	PASS	0	0.941	29	0.926056	17	chr1	24074143	NA	C	G	2117.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.14;AS_ReadPosRankSum=.;AS_SOR=1.04;DP=79;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.14;SOR=1.04	GT:AD:DP:GQ:PL	1/1:0,78:78:99:2131,233,0
chr1	24089569	24089569	T	C	MYOM3	exonic	nonsynonymous SNV	NA	MYOM3:NM_152372:exon14:c.A1583G:p.D528G	1	GnomAdExome_AF_fin	586	142	HomozygousVariant	hom	58	0	58	1	1616.06	PASS	16.05	NA	616832	Benign	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Fibronectin type III|Fibronectin type III|Fibronectin type III|Fibronectin type III	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.9951	0.9999	0.9999	0.9784	1	0.978834	0.979	0.0001153	0.984401	PASS	1	1	0	1	0	chr1	24089569	NA	T	C	1616.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.86;AS_ReadPosRankSum=.;AS_SOR=0.914;DP=60;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.86;SOR=0.914	GT:AD:DP:GQ:PL	1/1:0,58:58:99:1630,174,0
chr1	24089580	24089580	G	C	MYOM3	exonic	synonymous SNV	NA	MYOM3:NM_152372:exon14:c.C1572G:p.P524P	0.7236	GnomAdExome_AF_eas	89	20	HeterozygousVariant	het	66	35	31	0.46969696969697	677.64	PASS	NA	NA	616832	Benign	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.4834	0.7236	0.7219	0.4858	0.7225	0.500599	0.4726	0.444263	0.480231	PASS	0.463918	0.392	282	0.362676	63	chr1	24089580	NA	G	C	677.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.7;AS_FS=2.021;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.27;AS_ReadPosRankSum=-1.5;AS_SOR=0.976;BaseQRankSum=1.78;DP=68;ExcessHet=3.0103;FS=2.021;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.27;ReadPosRankSum=-1.485;SOR=0.976	GT:AD:DP:GQ:PL	0/1:35,31:66:99:685,0,733
chr1	24090138	24090138	T	C	MYOM3	intronic	NA	NA	NA	0.1697	GnomAdExome_AF_sas	14	5	HeterozygousVariant	het	76	44	32	0.421052631578947	585.64	PASS	NA	NA	616832	NA	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.0733	0.1697	0.1698	0.0508	0.1689	0.0692891	0.0529	0.072554	0.057471	PASS	0	0.153	149	0.158451	35	chr1	24090138	NA	T	C	585.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1;AS_FS=1.949;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.71;AS_ReadPosRankSum=0.1;AS_SOR=1.044;BaseQRankSum=-0.948;DP=78;ExcessHet=3.0103;FS=1.949;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.71;ReadPosRankSum=0.147;SOR=1.044	GT:AD:DP:GQ:PL	0/1:44,32:76:99:593,0,985
chr1	24092278	24092278	T	C	MYOM3	exonic	synonymous SNV	NA	MYOM3:NM_152372:exon11:c.A1128G:p.P376P	0.5597	GnomAdGenome_AF_fin	36	8	HeterozygousVariant	het	79	35	44	0.556962025316456	947.64	PASS	NA	NA	616832	Benign	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.4178	0.4668	0.4702	0.4415	0.5597	0.376198	0.4462	0.365099	0.437603	PASS	0.456522	0.218	181	0.150735	25	chr1	24092278	NA	T	C	947.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=12;AS_ReadPosRankSum=-1.6;AS_SOR=0.798;BaseQRankSum=0.394;DP=81;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12;ReadPosRankSum=-1.521;SOR=0.798	GT:AD:DP:GQ:PL	0/1:35,44:79:99:955,0,683
chr1	24093006	24093006	A	G	MYOM3	exonic	nonsynonymous SNV	NA	MYOM3:NM_152372:exon10:c.T1031C:p.M344T	0.5872	GnomAdGenome_AF_fin	43	8	HeterozygousVariant	het	120	65	55	0.458333333333333	1124.64	PASS	0.271	NA	616832	Benign	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	Immunoglobulin I-set|Immunoglobulin-like domain|Immunoglobulin subtype	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.4154	0.4745	0.4766	0.4557	0.5872	0.378994	0.4637	0.414775	0.448276	PASS	0.467391	0.243	198	0.169014	32	chr1	24093006	NA	A	G	1124.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0.678;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.38;AS_ReadPosRankSum=0.7;AS_SOR=0.783;BaseQRankSum=-0.415;DP=125;ExcessHet=3.0103;FS=0.678;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.37;ReadPosRankSum=0.769;SOR=0.783	GT:AD:DP:GQ:PL	0/1:65,55:120:99:1132,0,1439
chr1	24094844	24094844	G	T	MYOM3	intronic	NA	NA	NA	0.5514	GnomAdGenome_AF_fin	10	5	HeterozygousVariant	het	57	21	36	0.631578947368421	806.64	PASS	NA	NA	616832	NA	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.3432	0.4109	0.4136	0.3041	0.5514	0.229832	0.3075	0.32594	0.302956	PASS	0	0.23	76	0.123239	25	chr1	24094844	NA	G	T	806.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.16;AS_ReadPosRankSum=-1.3;AS_SOR=0.795;BaseQRankSum=-1.729;DP=58;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.15;ReadPosRankSum=-1.209;SOR=0.795	GT:AD:DP:GQ:PL	0/1:21,36:57:99:814,0,469
chr1	24094984	24094984	G	A	MYOM3	exonic	nonsynonymous SNV	NA	MYOM3:NM_152372:exon9:c.C797T:p.T266M	0.5773	GnomAdGenome_AF_fin	41	7	HeterozygousVariant	het	69	48	21	0.304347826086957	434.64	PASS	15.41	NA	616832	Benign	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.3904	0.4561	0.4578	0.3931	0.5773	0.319888	0.3966	0.388255	0.39491	PASS	0.408537	0.234	192	0.147887	28	chr1	24094984	NA	G	A	434.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.7;AS_FS=5.213;AS_MQ=60;AS_MQRankSum=0;AS_QD=6.3;AS_ReadPosRankSum=-0.4;AS_SOR=1.385;BaseQRankSum=1.71;DP=77;ExcessHet=3.0103;FS=5.213;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=6.3;ReadPosRankSum=-0.346;SOR=1.385	GT:AD:DP:GQ:PL	0/1:48,21:69:99:442,0,1128
chr1	24095460	24095460	C	G	MYOM3	exonic	nonsynonymous SNV	NA	MYOM3:NM_152372:exon8:c.G772C:p.D258H	0.5946	GnomAdGenome_AF_fin	43	8	HeterozygousVariant	het	108	49	59	0.546296296296296	1343.64	PASS	24	NA	616832	Benign	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	T	T	D	P	N	P	L	T	N	T	T	T	NA	T	T	T	T	D	.;	D	D	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.422	0.5247	0.5176	0.4774	0.5946	0.410543	0.482	0.423604	0.464696	PASS	0.502717	0.249	205	0.179577	35	chr1	24095460	NA	C	G	1343.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0.722;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.44;AS_ReadPosRankSum=3.1;AS_SOR=0.826;BaseQRankSum=0.045;DP=108;ExcessHet=3.0103;FS=0.722;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.44;ReadPosRankSum=3.17;SOR=0.826	GT:AD:DP:GQ:PL	0/1:49,59:108:99:1351,0,1045
chr1	24106049	24106049	T	A	MYOM3	exonic	nonsynonymous SNV	NA	MYOM3:NM_152372:exon5:c.A431T:p.E144V	0.0368	GnomAdGenome_AF_sas	1	0	HeterozygousVariant	het	83	39	44	0.530120481927711	1702.64	PASS	25.7	NA	616832	Uncertain significance	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	D	T	D	P	D	D	N	T	D	T	T	T	NA	T	T	T	T	T	.;	D	D	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.0055	0.0299	0.0285	0.0014	0.0368	0.00998403	0	0.0052651	0		0.015152	0.034	38	0.010563	3	chr1	24106049	NA	T	A	1702.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=20.52;AS_ReadPosRankSum=0.8;AS_SOR=0.721;BaseQRankSum=-0.074;DP=85;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=20.51;ReadPosRankSum=0.87;SOR=0.721	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:39,44:83:99:0|1:24106049_T_A:1710,0,1471:24106049
chr1	24106050	24106050	C	A	MYOM3	exonic	stopgain	NA	MYOM3:NM_152372:exon5:c.G430T:p.E144X	0.0368	GnomAdGenome_AF_sas	1	0	HeterozygousVariant	het	83	39	44	0.530120481927711	1702.64	PASS	38	NA	616832	NA	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	NA	NA	.;	D	N	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.0055	0.0299	0.0285	0.0014	0.0368	0.00998403	0	0.0052716	0		0.015152	0.034	38	0.010563	3	chr1	24106050	NA	C	A	1702.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=20.52;AS_ReadPosRankSum=1;AS_SOR=0.721;BaseQRankSum=-1.516;DP=84;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=20.51;ReadPosRankSum=1.09;SOR=0.721	GT:AD:DP:GQ:PGT:PID:PL:PS	0|1:39,44:83:99:0|1:24106049_T_A:1710,0,1471:24106049
chr1	24108483	24108483	G	A	MYOM3	exonic	nonsynonymous SNV	NA	MYOM3:NM_152372:exon2:c.C154T:p.R52C	0.004087	GME_NEA	0		HeterozygousVariant	het	50	20	30	0.6	727.64	PASS	24.8	NA	616832	Uncertain significance	NA	NA	Vigorous physical activity[29899525];Bipolar disorder with mood-incongruent psychosis[23092984];	NA	NA	NA	NA	NA	NA	D	D	D	B	N	D	N	T	N	T	T	T	D	T	T	T	T	D	.;	D	D	NA	NA	NA	High	High	High	kidney;uterus;liver;muscle;skin;smooth muscle;skeletal muscle;unclassifiable (Anatomical System);heart;	pons;caudate nucleus;ciliary ganglion;dorsal root ganglion;superior cervical ganglion;trigeminal ganglion;atrioventricular node;parietal lobe;skeletal muscle;globus pallidus;medulla oblongata;	0.963	NA	N	N	N	0.117478393617051	N	Myom3	NA	NA	NA	NA	NA	0.00006089	0.0004	0.0003	0.00001395	0.00003098	0	0	0.0000453	0		0.004087	0.001695	2			chr1	24108483	NA	G	A	727.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.56;AS_ReadPosRankSum=-1.8;AS_SOR=0.583;BaseQRankSum=1.05;DP=51;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.55;ReadPosRankSum=-1.725;SOR=0.583	GT:AD:DP:GQ:PL	0/1:20,30:50:99:735,0,403
chr1	24120978	24120978	G	C	IL22RA1	exonic	nonsynonymous SNV	NA	IL22RA1:NM_021258:exon7:c.C1552G:p.R518G	0.7019	GnomAdExome_AF_eas	191	34	HomozygousVariant	hom	165	0	165	1	4781.06	PASS	20.3	NA	605457	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in colon, liver, lung, pancreas and kidney. No expression in immune cells such as monocytes, T-cells, and NK-cells. Expressed in keratinocytes of normal skin as well as in psoriatic skin lesion. Detected in normal blood brain barrier endothelial cells as well as in multiple sclerosis lesions; Strongly expressed on central nervous system vessels within infiltrated multiple sclerosis lesions. Overexpressed in synovial fluid cells from rheumatoid arthritis and spondyloarthropathy patients. {ECO:0000269|PubMed:12407026, ECO:0000269|PubMed:15308104, ECO:0000269|PubMed:17828272, ECO:0000269|PubMed:17900301, ECO:0000269|PubMed:18061474}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;	D	N	NA	NA	NA	High	High	High	larynx;spleen;liver;pancreas;bladder;colon;skin;stomach;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	ciliary ganglion;pancreas;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;skeletal muscle;	0.631	NA	N	N	N	0.915751013224283	E	Il22ra1	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; immune system phenotype; 	NA	NA	NA	NA	0.4193	0.7019	0.7046	0.3774	0.7001	0.466254	0.3726	0.409859	0.370066	PASS	0.420455	0.548	263	0.528169	82	chr1	24120978	NA	G	C	4781.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.98;AS_ReadPosRankSum=.;AS_SOR=0.861;DP=170;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.98;SOR=0.861	GT:AD:DP:GQ:PL	1/1:0,165:165:99:4795,495,0
chr1	24134307	24134307	T	G	IL22RA1	exonic	synonymous SNV	NA	IL22RA1:NM_021258:exon4:c.A435C:p.P145P	0.716621	GME_NEA	147	27	HeterozygousVariant	het	108	61	47	0.435185185185185	1023.64	PASS	NA	NA	605457	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in colon, liver, lung, pancreas and kidney. No expression in immune cells such as monocytes, T-cells, and NK-cells. Expressed in keratinocytes of normal skin as well as in psoriatic skin lesion. Detected in normal blood brain barrier endothelial cells as well as in multiple sclerosis lesions; Strongly expressed on central nervous system vessels within infiltrated multiple sclerosis lesions. Overexpressed in synovial fluid cells from rheumatoid arthritis and spondyloarthropathy patients. {ECO:0000269|PubMed:12407026, ECO:0000269|PubMed:15308104, ECO:0000269|PubMed:17828272, ECO:0000269|PubMed:17900301, ECO:0000269|PubMed:18061474}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	larynx;spleen;liver;pancreas;bladder;colon;skin;stomach;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	ciliary ganglion;pancreas;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;skeletal muscle;	0.631	NA	N	N	N	0.915751013224283	E	Il22ra1	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; immune system phenotype; 	NA	NA	NA	NA	0.5602	0.698	0.7051	0.6169	0.6942	0.523562	0.6332	0.565019	0.640394	PASS	0.716621	0.47	257	0.464789	78	chr1	24134307	NA	T	G	1023.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.1;AS_FS=1.56;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.48;AS_ReadPosRankSum=2;AS_SOR=0.595;BaseQRankSum=1.1;DP=110;ExcessHet=3.0103;FS=1.56;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.48;ReadPosRankSum=2.02;SOR=0.595	GT:AD:DP:GQ:PL	0/1:61,47:108:99:1031,0,1327
chr1	24138623	24138623	C	T	IL22RA1	exonic	synonymous SNV	NA	IL22RA1:NM_021258:exon2:c.G135A:p.P45P	0.7363	GnomAdExome_AF_eas	176	36	HeterozygousVariant	het	108	56	52	0.481481481481481	1132.64	PASS	NA	NA	605457	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in colon, liver, lung, pancreas and kidney. No expression in immune cells such as monocytes, T-cells, and NK-cells. Expressed in keratinocytes of normal skin as well as in psoriatic skin lesion. Detected in normal blood brain barrier endothelial cells as well as in multiple sclerosis lesions; Strongly expressed on central nervous system vessels within infiltrated multiple sclerosis lesions. Overexpressed in synovial fluid cells from rheumatoid arthritis and spondyloarthropathy patients. {ECO:0000269|PubMed:12407026, ECO:0000269|PubMed:15308104, ECO:0000269|PubMed:17828272, ECO:0000269|PubMed:17900301, ECO:0000269|PubMed:18061474}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	High	High	larynx;spleen;liver;pancreas;bladder;colon;skin;stomach;optic nerve;unclassifiable (Anatomical System);islets of Langerhans;	ciliary ganglion;pancreas;dorsal root ganglion;atrioventricular node;superior cervical ganglion;trigeminal ganglion;skeletal muscle;	0.631	NA	N	N	N	0.915751013224283	E	Il22ra1	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; immune system phenotype; 	NA	NA	NA	NA	0.4302	0.7363	0.7377	0.3633	0.7348	0.470647	0.3443	0.415719	0.345649	PASS	0.359848	0.526	268	0.514085	74	chr1	24138623	NA	C	T	1132.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0.709;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.49;AS_ReadPosRankSum=1;AS_SOR=0.776;BaseQRankSum=-0.309;DP=110;ExcessHet=3.0103;FS=0.709;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.49;ReadPosRankSum=1.1;SOR=0.776	GT:AD:DP:GQ:PL	0/1:56,52:108:99:1140,0,1254
chr1	24187278	24187278	G	A	IFNLR1	UTR5	NA	NM_170743:c.-30C>T;NM_173064:c.-30C>T;NM_173065:c.-30C>T	NA	1	GnomAdExome_AF_afr	233	86	HomozygousVariant	hom	28	1	27	0.964285714285714	726.06	PASS	NA	NA	607404	NA	NA	NA	'Psoriasis vulgaris[26626624];Chronic inflammatory diseases (ankylosing spondylitis, Crohn''s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)[26974007];Blood protein levels[30072576];Inflammatory skin disease[25574825];Molybdenum levels[26025379];'	NA	NA	NA	NA	NA	Widely expressed. {ECO:0000269|PubMed:12469119, ECO:0000269|PubMed:12483210}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	N	N	N	N	NA	NA	Ifnlr1	hematopoietic system phenotype; skeleton phenotype; immune system phenotype; 	NA	NA	NA	NA	0.8846	1	1	0.8741	0.9233	0.838458	0.9403	0.0001153	0.878194	PASS	0	0.89	54	0.849558	20	chr1	24187278	NA	G	A	726.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=1.7;AS_FS=4.472;AS_MQ=60;AS_MQRankSum=0;AS_QD=25.93;AS_ReadPosRankSum=1.6;AS_SOR=1.351;BaseQRankSum=1.77;DP=28;ExcessHet=3.0103;FS=4.472;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=25.93;ReadPosRankSum=1.61;SOR=1.351	GT:AD:DP:GQ:PL	1/1:1,27:28:73:740,73,0
chr1	24331573	24331573	C	G	GRHL3	exonic	nonsynonymous SNV	NA	GRHL3:NM_001195010:exon2:c.C27G:p.D9E,GRHL3:NM_021180:exon2:c.C180G:p.D60E,GRHL3:NM_198173:exon2:c.C165G:p.D55E,GRHL3:NM_198174:exon2:c.C165G:p.D55E	0.2064	GnomAdExome_AF_afr	26	4	HeterozygousVariant	het	100	56	44	0.44	947.64	PASS	16.15	NA	608317	Benign	Van der Woude syndrome;Submucosal cleft palate;Cleft hard palate;Cleft velum;Bifid uvula	Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in	Fasting blood insulin (BMI interaction)[22581228];Cleft palate[28054174;28054174;27018472;27018472;27018472;27018472;27018472];Response to interferon beta in multiple sclerosis[26644207];	HP:0000204;HP:0000196;HP:0000668;HP:0000175;HP:0010286;HP:0011469;HP:0002033;HP:0000405;HP:0011219;HP:0010863;HP:0000185;HP:0000403;HP:0000327;HP:0200136;HP:0009088;HP:0000220;HP:0001611;HP:0011951;HP:0410030;HP:0011819;HP:0000193;HP:0008376;HP:0000204;HP:0000175;HP:0000006;HP:0000674	Cleft upper lip;Lower lip pit;Hypodontia;Cleft palate;Abnormal salivary gland morphology;Nasal regurgitation;Poor suck;Conductive hearing impairment;Short face;Receptive language delay;Cleft soft palate;Recurrent otitis media;Hypoplasia of the maxilla;Oral-pharyngeal dysphagia;Speech articulation difficulties;Velopharyngeal insufficiency;Nasal speech;Aspiration pneumonia;Cleft lip;Submucous cleft soft palate;Bifid uvula;Nasal, dysarthic speech;Cleft upper lip;Cleft palate;Autosomal dominant inheritance;Anodontia	NA	NA	NA	Expressed in brain, colon, pancreas, placenta and kidney. Isoform 1 is expressed in lung and tonsil. Isoform 2 is prostate-specific. {ECO:0000269|PubMed:12549979}.;	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;.;	D	N	.;.;.;.;.	NA	NA	Medium	Medium	Medium	thymus;endometrium;skin;testis;parathyroid;unclassifiable (Anatomical System);heart;lung;larynx;ovary;uterus;colon;head and neck;placenta;breast;	ciliary ganglion;subthalamic nucleus;dorsal root ganglion;trigeminal ganglion;skin;atrioventricular node;superior cervical ganglion;skeletal muscle;	0.45	E	N	N	N	0.575668019492419	E	Grhl3	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; 	grhl3	midbrain hindbrain boundary neural tube	morphology	exacerbated	0.1579	0.2064	0.2125	0.1716	0.2051	0.178514	0.1788	0.159694	0.136289	PASS	0.113636	0.17	224	0.126761	28	chr1	24331573	NA	C	G	947.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.9;AS_FS=4.996;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.48;AS_ReadPosRankSum=1.4;AS_SOR=0.368;BaseQRankSum=-0.881;DP=101;ExcessHet=3.0103;FS=4.996;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.48;ReadPosRankSum=1.41;SOR=0.368	GT:AD:DP:GQ:PL	0/1:56,44:100:99:955,0,1365
chr1	24342177	24342177	C	G	GRHL3	exonic	synonymous SNV	NA	GRHL3:NM_001195010:exon9:c.C972G:p.V324V,GRHL3:NM_021180:exon9:c.C1125G:p.V375V,GRHL3:NM_198173:exon9:c.C1110G:p.V370V,GRHL3:NM_198174:exon9:c.C1110G:p.V370V	0.2556	GnomAdGenome_AF_ami	49	3	HeterozygousVariant	het	88	42	46	0.522727272727273	1047.64	PASS	NA	NA	608317	Benign	Van der Woude syndrome;Submucosal cleft palate;Cleft hard palate;Cleft velum;Bifid uvula	Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in	Fasting blood insulin (BMI interaction)[22581228];Cleft palate[28054174;28054174;27018472;27018472;27018472;27018472;27018472];Response to interferon beta in multiple sclerosis[26644207];	HP:0000204;HP:0000196;HP:0000668;HP:0000175;HP:0010286;HP:0011469;HP:0002033;HP:0000405;HP:0011219;HP:0010863;HP:0000185;HP:0000403;HP:0000327;HP:0200136;HP:0009088;HP:0000220;HP:0001611;HP:0011951;HP:0410030;HP:0011819;HP:0000193;HP:0008376;HP:0000204;HP:0000175;HP:0000006;HP:0000674	Cleft upper lip;Lower lip pit;Hypodontia;Cleft palate;Abnormal salivary gland morphology;Nasal regurgitation;Poor suck;Conductive hearing impairment;Short face;Receptive language delay;Cleft soft palate;Recurrent otitis media;Hypoplasia of the maxilla;Oral-pharyngeal dysphagia;Speech articulation difficulties;Velopharyngeal insufficiency;Nasal speech;Aspiration pneumonia;Cleft lip;Submucous cleft soft palate;Bifid uvula;Nasal, dysarthic speech;Cleft upper lip;Cleft palate;Autosomal dominant inheritance;Anodontia	NA	NA	NA	Expressed in brain, colon, pancreas, placenta and kidney. Isoform 1 is expressed in lung and tonsil. Isoform 2 is prostate-specific. {ECO:0000269|PubMed:12549979}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;endometrium;skin;testis;parathyroid;unclassifiable (Anatomical System);heart;lung;larynx;ovary;uterus;colon;head and neck;placenta;breast;	ciliary ganglion;subthalamic nucleus;dorsal root ganglion;trigeminal ganglion;skin;atrioventricular node;superior cervical ganglion;skeletal muscle;	0.45	E	N	N	N	0.575668019492419	E	Grhl3	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; 	grhl3	midbrain hindbrain boundary neural tube	morphology	exacerbated	0.1971	0.2229	0.2244	0.1786	0.2556	0.157748	0.1819	0.193671	0.174877	PASS	0.25	0.229	272	0.147887	36	chr1	24342177	NA	C	G	1047.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.91;AS_ReadPosRankSum=-0.3;AS_SOR=0.678;BaseQRankSum=-0.724;DP=90;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.9;ReadPosRankSum=-0.288;SOR=0.678	GT:AD:DP:GQ:PL	0/1:42,46:88:99:1055,0,997
chr1	24354425	24354425	C	T	GRHL3	exonic	synonymous SNV	NA	GRHL3:NM_001195010:exon16:c.C1608T:p.V536V,GRHL3:NM_021180:exon16:c.C1761T:p.V587V,GRHL3:NM_198173:exon16:c.C1746T:p.V582V	0.415	GnomAdGenome_AF_eas	63	15	HeterozygousVariant	het	89	51	38	0.426966292134831	818.64	PASS	NA	NA	608317	Benign	Van der Woude syndrome;Submucosal cleft palate;Cleft hard palate;Cleft velum;Bifid uvula	Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in	Fasting blood insulin (BMI interaction)[22581228];Cleft palate[28054174;28054174;27018472;27018472;27018472;27018472;27018472];Response to interferon beta in multiple sclerosis[26644207];	HP:0000204;HP:0000196;HP:0000668;HP:0000175;HP:0010286;HP:0011469;HP:0002033;HP:0000405;HP:0011219;HP:0010863;HP:0000185;HP:0000403;HP:0000327;HP:0200136;HP:0009088;HP:0000220;HP:0001611;HP:0011951;HP:0410030;HP:0011819;HP:0000193;HP:0008376;HP:0000204;HP:0000175;HP:0000006;HP:0000674	Cleft upper lip;Lower lip pit;Hypodontia;Cleft palate;Abnormal salivary gland morphology;Nasal regurgitation;Poor suck;Conductive hearing impairment;Short face;Receptive language delay;Cleft soft palate;Recurrent otitis media;Hypoplasia of the maxilla;Oral-pharyngeal dysphagia;Speech articulation difficulties;Velopharyngeal insufficiency;Nasal speech;Aspiration pneumonia;Cleft lip;Submucous cleft soft palate;Bifid uvula;Nasal, dysarthic speech;Cleft upper lip;Cleft palate;Autosomal dominant inheritance;Anodontia	NA	NA	NA	Expressed in brain, colon, pancreas, placenta and kidney. Isoform 1 is expressed in lung and tonsil. Isoform 2 is prostate-specific. {ECO:0000269|PubMed:12549979}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	thymus;endometrium;skin;testis;parathyroid;unclassifiable (Anatomical System);heart;lung;larynx;ovary;uterus;colon;head and neck;placenta;breast;	ciliary ganglion;subthalamic nucleus;dorsal root ganglion;trigeminal ganglion;skin;atrioventricular node;superior cervical ganglion;skeletal muscle;	0.45	E	N	N	N	0.575668019492419	E	Grhl3	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; 	grhl3	midbrain hindbrain boundary neural tube	morphology	exacerbated	0.2951	0.4092	0.4112	0.237	0.415	0.269968	0.2153	0.282396	0.246305	PASS	0.378049	0.257	289	0.28169	50	chr1	24354425	NA	C	T	818.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=0.803;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.2;AS_ReadPosRankSum=1.3;AS_SOR=0.765;BaseQRankSum=-0.04;DP=90;ExcessHet=3.0103;FS=0.803;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.2;ReadPosRankSum=1.38;SOR=0.765	GT:AD:DP:GQ:PL	0/1:51,38:89:99:826,0,1179
chr1	24364274	24364274	T	A	GRHL3	exonic	nonsynonymous SNV	NA	GRHL3:NM_198174:exon16:c.T1784A:p.M595K	0.426136	GME_TP	105	21	HomozygousVariant	hom	148	1	147	0.993243243243243	4218.06	PASS	8.97	NA	608317	Benign	Van der Woude syndrome;Submucosal cleft palate;Cleft hard palate;Cleft velum;Bifid uvula	Disease-causing germline mutation(s) in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in;Major susceptibility factor in	Fasting blood insulin (BMI interaction)[22581228];Cleft palate[28054174;28054174;27018472;27018472;27018472;27018472;27018472];Response to interferon beta in multiple sclerosis[26644207];	HP:0000204;HP:0000196;HP:0000668;HP:0000175;HP:0010286;HP:0011469;HP:0002033;HP:0000405;HP:0011219;HP:0010863;HP:0000185;HP:0000403;HP:0000327;HP:0200136;HP:0009088;HP:0000220;HP:0001611;HP:0011951;HP:0410030;HP:0011819;HP:0000193;HP:0008376;HP:0000204;HP:0000175;HP:0000006;HP:0000674	Cleft upper lip;Lower lip pit;Hypodontia;Cleft palate;Abnormal salivary gland morphology;Nasal regurgitation;Poor suck;Conductive hearing impairment;Short face;Receptive language delay;Cleft soft palate;Recurrent otitis media;Hypoplasia of the maxilla;Oral-pharyngeal dysphagia;Speech articulation difficulties;Velopharyngeal insufficiency;Nasal speech;Aspiration pneumonia;Cleft lip;Submucous cleft soft palate;Bifid uvula;Nasal, dysarthic speech;Cleft upper lip;Cleft palate;Autosomal dominant inheritance;Anodontia	NA	NA	NA	Expressed in brain, colon, pancreas, placenta and kidney. Isoform 1 is expressed in lung and tonsil. Isoform 2 is prostate-specific. {ECO:0000269|PubMed:12549979}.;	D	D	NA	NA	N	P	M	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	thymus;endometrium;skin;testis;parathyroid;unclassifiable (Anatomical System);heart;lung;larynx;ovary;uterus;colon;head and neck;placenta;breast;	ciliary ganglion;subthalamic nucleus;dorsal root ganglion;trigeminal ganglion;skin;atrioventricular node;superior cervical ganglion;skeletal muscle;	0.45	E	N	N	N	0.575668019492419	E	Grhl3	integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; 	grhl3	midbrain hindbrain boundary neural tube	morphology	exacerbated	0.2918	0.4128	0.4128	0.2573	0.3949	0.298922	0	0.0852447	0.273399	PASS	0.426136	0.355	357	0.373239	64	chr1	24364274	NA	T	A	4218.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=28.5;AS_ReadPosRankSum=1.4;AS_SOR=0.264;BaseQRankSum=2.02;DP=153;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=28.5;ReadPosRankSum=1.44;SOR=0.264	GT:AD:DP:GQ:PL	1/1:1,147:148:99:4232,432,0
chr1	24379839	24379839	C	A	STPG1	intronic	NA	NA	NA	0.132	GnomAdExome_AF_afr	2	2	HeterozygousVariant	het	33	18	15	0.454545454545455	382.64	PASS	NA	NA	615826	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	NA	NA	Stpg1	NA	NA	NA	NA	NA	0.0577	0.132	0.1349	0.0727	0.1295	0.0810703	0.0803	0.0581817	0.059113	PASS	0	0.085	47	0.077465	18	chr1	24379839	NA	C	A	382.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.61;AS_ReadPosRankSum=1.9;AS_SOR=0.914;BaseQRankSum=0.077;DP=33;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.6;ReadPosRankSum=1.94;SOR=0.914	GT:AD:DP:GQ:PL	0/1:18,15:33:99:390,0,463
chr1	24391589	24391589	C	A	STPG1	exonic	nonsynonymous SNV	NA	STPG1:NM_001199012:exon3:c.G161T:p.S54I,STPG1:NM_001199013:exon3:c.G161T:p.S54I	0.3143	GnomAdExome_AF_eas	43	7	WT/SomaticVariant	het	31	25	6	0.193548387096774	79.64	PASS	22.9	NA	615826	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	D	B	B	N	P	M	NA	D	T	T	T	NA	T	T	T	T	T	.;.;	D	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	NA	NA	Stpg1	NA	NA	NA	NA	NA	0.2422	0.3143	0.3096	0.225	0.2952	0.234225	0	0.0692294	0.243021	PASS	0.224638	0.25	206	0.235915	53	chr1	24391589	NA	C	A	79.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=2.58;AS_ReadPosRankSum=1.6;AS_SOR=0.839;BaseQRankSum=-0.463;DP=32;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=2.57;ReadPosRankSum=1.63;SOR=0.839	GT:AD:DP:GQ:PL	0/1:25,6:31:87:87,0,712
chr1	24533127	24533127	G	A	RCAN3	exonic	synonymous SNV	NA	RCAN3:NM_001251980:exon3:c.G384A:p.P128P,RCAN3:NM_001251981:exon3:c.G240A:p.P80P,RCAN3:NM_001251983:exon3:c.G39A:p.P13P,RCAN3:NM_001251984:exon3:c.G39A:p.P13P,RCAN3:NM_001251977:exon4:c.G414A:p.P138P,RCAN3:NM_001251978:exon4:c.G414A:p.P138P,RCAN3:NM_001251979:exon4:c.G414A:p.P138P,RCAN3:NM_013441:exon4:c.G414A:p.P138P	0.6503	GnomAdGenome_AF_eas	86	27	HeterozygousVariant	het	88	46	42	0.477272727272727	969.64	PASS	NA	NA	605860	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Highest expression in heart, skeletal muscle kidney, liver and peripheral blood leukocytes. Lower expression in all other tissues.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.613	NA	N	N	N	0.188173576917583	N	Rcan3	NA	NA	NA	NA	NA	0.3357	0.6382	0.646	0.3089	0.6503	0.383586	0.3016	0.341134	0.283251	PASS	0.382576	0.374	268	0.401408	60	chr1	24533127	NA	G	A	969.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.9;AS_FS=7.059;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.02;AS_ReadPosRankSum=-0.3;AS_SOR=1.426;BaseQRankSum=1.96;DP=91;ExcessHet=3.0103;FS=7.059;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.02;ReadPosRankSum=-0.272;SOR=1.426	GT:AD:DP:GQ:PL	0/1:46,42:88:99:977,0,989
chr1	24533175	24533175	G	A	RCAN3	exonic	synonymous SNV	NA	RCAN3:NM_001251980:exon3:c.G432A:p.P144P,RCAN3:NM_001251981:exon3:c.G288A:p.P96P,RCAN3:NM_001251983:exon3:c.G87A:p.P29P,RCAN3:NM_001251984:exon3:c.G87A:p.P29P,RCAN3:NM_001251977:exon4:c.G462A:p.P154P,RCAN3:NM_001251978:exon4:c.G462A:p.P154P,RCAN3:NM_001251979:exon4:c.G462A:p.P154P,RCAN3:NM_013441:exon4:c.G462A:p.P154P	0.6499	GnomAdGenome_AF_eas	86	26	HeterozygousVariant	het	94	48	46	0.48936170212766	1046.64	PASS	NA	NA	605860	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Highest expression in heart, skeletal muscle kidney, liver and peripheral blood leukocytes. Lower expression in all other tissues.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.613	NA	N	N	N	0.188173576917583	N	Rcan3	NA	NA	NA	NA	NA	0.3449	0.6438	0.6486	0.3092	0.6499	0.383586	0.3018	0.011065	0.283251	PASS	0.382576	0.373	268	0.394366	60	chr1	24533175	NA	G	A	1046.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=5.06;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.14;AS_ReadPosRankSum=-1.1;AS_SOR=0.867;BaseQRankSum=0.463;DP=95;ExcessHet=3.0103;FS=5.06;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.13;ReadPosRankSum=-1.044;SOR=0.867	GT:AD:DP:GQ:PL	0/1:48,46:94:99:1054,0,1070
chr1	24535214	24535214	G	A	RCAN3	exonic	nonsynonymous SNV	NA	RCAN3:NM_001251985:exon2:c.G317A:p.R106Q,RCAN3:NM_001251982:exon3:c.G491A:p.R164Q	0.7127	GnomAdGenome_AF_eas	136	37	HeterozygousVariant	het	152	80	72	0.473684210526316	1587.64	PASS	0.093	NA	605860	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Highest expression in heart, skeletal muscle kidney, liver and peripheral blood leukocytes. Lower expression in all other tissues.;	T	T	NA	NA	NA	P	NA	NA	N	T	T	T	NA	NA	NA	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.613	NA	N	N	N	0.188173576917583	N	Rcan3	NA	NA	NA	NA	NA	0.4722	0.7077	0.7098	0.4626	0.7127	0.509185	0.4622	0.475285	0.437603	PASS	0.465909	0.48	290	0.496479	67	chr1	24535214	NA	G	A	1587.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.45;AS_ReadPosRankSum=-2;AS_SOR=0.693;BaseQRankSum=-1.021;DP=156;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.44;ReadPosRankSum=-1.997;SOR=0.693	GT:AD:DP:GQ:PL	0/1:80,72:152:99:1595,0,1914
chr1	24663271	24663271	G	T	SRRM1	intronic	NA	NA	NA	1	GnomAdExome_AF_eas	295	135	HomozygousVariant	hom	27	0	27	1	803.06	PASS	NA	NA	605975	NA	NA	NA	Systolic blood pressure[29208002];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	pharynx;cornea;stomach;testis;pineal gland;choroid;larynx;kidney;uterus;whole body;bile duct;adrenal gland;islets of Langerhans;visual apparatus;fovea centralis;iris;vein;spleen;liver;germinal center;heart;lung;salivary gland;thyroid;oesophagus;sympathetic chain;placenta;nasopharynx;optic nerve;thymus;intestine;epididymis;skin;pituitary gland;adrenal cortex;lens;unclassifiable (Anatomical System);amniotic fluid;retina;muscle;head and neck;mammary gland;umbilical cord;cervix;hippocampus;cartilage;bone;parathyroid;brain;blood;bone marrow;ovary;macula lutea;lymph node;bladder;frontal lobe;colon;prostate;breast;	ciliary ganglion;pons;kidney;testis - seminiferous tubule;prefrontal cortex;trigeminal ganglion;atrioventricular node;superior cervical ganglion;testis;globus pallidus;cerebellum;	0.413	NA	E	E	E	0.924673540390155	E	Srrm1	NA	NA	NA	NA	NA	0.9847	1	1	0.9834	1	0.990415	0	0.292642	0		0	0.993	4	0.985611	4	chr1	24663271	NA	G	T	803.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.74;AS_ReadPosRankSum=.;AS_SOR=1.302;DP=27;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.74;SOR=1.302	GT:AD:DP:GQ:PL	1/1:0,27:27:81:817,81,0
chr1	24964519	24964519	A	T	RUNX3	exonic	nonsynonymous SNV	NA	RUNX3:NM_001031680:exon1:c.T53A:p.I18N,RUNX3:NM_001320672:exon2:c.T53A:p.I18N	0.7514	GnomAdExome_AF_amr	379	71	HomozygousVariant	hom	91	0	91	1	2474.06	PASS	27.3	NA	600210	Benign	NA	NA	'Psoriasis[23143594];Lead levels[26025379];Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)[24503447];Crohn''s disease[23266558];Itch intensity from mosquito bite[28199695];Albumin-globulin ratio[29403010];Celiac disease[20190752;22057235];Male-pattern baldness[27182965;29146897;29146897;29146897];Psoriasis vulgaris[26626624];Allergic disease (asthma, hay fever or eczema)[29083406];Itch intensity from mosquito bite adjusted by bite size[28199695];Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)[23603761];Mosquito bite size[28199695];Non-albumin protein levels[29403010];Ankylosing spondylitis[21743469;23749187;23749187];'	NA	NA	NA	NA	NA	Expressed in gastric cancer tissues (at protein level). {ECO:0000269|PubMed:20599712}.;	D	T	D	D	N	P	NA	D	N	T	T	T	NA	NA	NA	T	T	T	.;.;	D	D	.;.	NA	NA	Medium	Medium	Medium	cervix;spinal ganglion;skin;stomach;germinal center;testis;blood;unclassifiable (Anatomical System);heart;bone marrow;lung;cerebral cortex;uterus;colon;placenta;prostate;islets of Langerhans;	NA	0.0512	E	N	N	N	0.893743773842274	E	Runx3	digestive/alimentary phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; growth/size/body region phenotype; hematopoietic system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); craniofacial phenotype; muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; 	runx3	neurocranium	aplastic	abnormal	0.5597	0.7514	0.7529	0.4963	0.7193	0.577676	0.4635	0.527361	0.53394	PASS	0.7	0.672	364	0.700704	57	chr1	24964519	NA	A	T	2474.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.19;AS_ReadPosRankSum=.;AS_SOR=0.715;DP=96;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.19;SOR=0.715	GT:AD:DP:GQ:PL	1/1:0,91:91:99:2488,272,0
chr1	25272713	25272713	A	C	RHD;RSRP1	intronic	NA	NA	NA	0.0112	GnomAdGenome_AF_amr	29	5	HomozygousVariant	hom	6	0	6	1	175.97	DP10;MQ40;SOR3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0008	0.0033	0.0026	0.002	0.0112	0	0	0.0001153	0		0	0.109	120	0.095745	17	chr1	25272713	NA	A	C	175.97	DP10;MQ40;SOR3	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=27;AS_MQRankSum=.;AS_QD=29.33;AS_ReadPosRankSum=.;AS_SOR=3.912;DP=6;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=27;QD=29.33;SOR=3.912	GT:AD:DP:GQ:PL	1/1:0,6:6:18:190,18,0
chr1	25420739	25420739	G	C	RHCE	exonic	nonsynonymous SNV	NA	RHCE:NM_001330430:exon1:c.C48G:p.C16W,RHCE:NM_020485:exon1:c.C48G:p.C16W,RHCE:NM_138616:exon1:c.C48G:p.C16W,RHCE:NM_138617:exon1:c.C48G:p.C16W,RHCE:NM_138618:exon1:c.C48G:p.C16W	0.5386	GnomAdGenome_AF_nfe	86	10	HomozygousVariant	hom	13	0	13	1	463.06	MQ40	2.785	NA	111700	NA	Rh deficiency syndrome	Disease-causing germline mutation(s) in	Mean corpuscular hemoglobin concentration[27863252];Reticulocyte fraction of red cells[27863252];Reticulocyte count[27863252];Platelet distribution width[27863252];Blood protein levels[29875488;29875488];Red cell distribution width[27863252];Platelet count[27863252];	NA	NA	NA	NA	NA	Restricted to tissues or cell lines expressing erythroid characters. Isoform 4g and isoform RhPI-Alpha are expressed in immature erythroblasts but not in mature erythroblasts. {ECO:0000269|PubMed:8117271}.;	T	T	B	B	N	P	NA	T	N	T	T	T	NA	T	NA	T	T	T	.;.;.;.;.;	N	N	.;.;.;.;.	NA	NA	Medium	Medium	Medium	skin;stomach;testis;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;urinary;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;cartilage;endometrium;bone;germinal center;parathyroid;brain;blood;trabecular meshwork;lung;ovary;macula lutea;subthalamic nucleus;colon;placenta;aorta;prostate;optic nerve;	superior cervical ganglion;trigeminal ganglion;fetal liver;skeletal muscle;bone marrow;	0.624	NA	N	N	N	0.00564179980959909	N	NA	NA	NA	NA	NA	NA	0.4126	0.491	0.4892	0.5081	0.5386	0.398962	0	0.373812	0.382155	VQSRTrancheSNP99.00to99.90	0.457265	0.256	256	0.257042	53	chr1	25420739	NA	G	C	463.06	MQ40	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=36.5;AS_MQRankSum=.;AS_QD=33.47;AS_ReadPosRankSum=.;AS_SOR=2.833;DP=14;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=35.9;QD=30.21;SOR=2.833	GT:AD:DP:GQ:PL	1/1:0,13:13:39:477,39,0
chr1	25563141	25563141	T	C	LDLRAP1	exonic	nonsynonymous SNV	NA	LDLRAP1:NM_015627:exon6:c.T604C:p.S202P	0.5848	GnomAdGenome_AF_asj	145	17	HomozygousVariant	hom	60	2	58	0.966666666666667	1617.06	PASS	1.096	[MIM:603813]Hypercholesterolemia, autosomal recessive [recessive?];	605747	Benign	Homozygous familial hypercholesterolemia	Disease-causing germline mutation(s) in	Mean platelet volume[27863252;27863252];Total cholesterol levels[28334899];LDL cholesterol levels[28334899];Cholesterol, total[20686565;24097068;25961943];LDL cholesterol[20686565;24097068;25961943];Platelet count[27863252];	HP:0002621;HP:0000007;HP:0003362;HP:0010874;HP:0002155;HP:0003124;HP:0001658;HP:0001653;HP:0001645;HP:0012397;HP:0030882;HP:0001397;HP:0005181;HP:0005162;HP:0003077;HP:0002094;HP:0007201;HP:0010874;HP:0004381;HP:0005177;HP:0012638;HP:0000822;HP:0012373;HP:0004416;HP:0003124;HP:0003141;HP:3000062;HP:0001681;HP:0002829;HP:0006693;HP:0000799;HP:0030148;HP:0001920;HP:0004950;HP:0004963;HP:0001138	Atherosclerosis;Autosomal recessive inheritance;Increased VLDL cholesterol concentration;Tendon xanthomatosis;Hypertriglyceridemia;Hypercholesterolemia;Myocardial infarction;Mitral regurgitation;Sudden cardiac death;Aortic atherosclerotic lesion;Coronary artery aneurysm;Hepatic steatosis;Premature coronary artery atherosclerosis;Left ventricular dysfunction;Hyperlipidemia;Dyspnea;Cerebral artery atherosclerosis;Tendon xanthomatosis;Supravalvular aortic stenosis;Premature arteriosclerosis;Abnormal nervous system physiology;Hypertension;Abnormal eye physiology;Precocious atherosclerosis;Hypercholesterolemia;Increased LDL cholesterol concentration;Abnormal internal carotid artery morphology;Angina pectoris;Arthralgia;Myocardial steatosis;Renal steatosis;Heart murmur;Renal artery stenosis;Peripheral arterial stenosis;Calcification of the aorta;Optic neuropathy	Familial_hypercholesterolemia|Familial_hypercholesterolemia_4|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed at high levels in the kidney, liver, and placenta, with lower levels detectable in brain, heart, muscle, colon, spleen, intestine, lung, and leukocytes.;	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.699	N	N	N	N	0.615525475582644	E	Ldlrap1	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.5054	0.5516	0.5475	0.4771	0.5848	0.434904	0.4693	0.0169817	0.503284	PASS	0.559783	0.421	413	0.366197	70	chr1	25563141	NA	T	C	1617.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.7;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=26.95;AS_ReadPosRankSum=0.1;AS_SOR=1.179;BaseQRankSum=0.717;DP=61;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=26.95;ReadPosRankSum=0.103;SOR=1.179	GT:AD:DP:GQ:PL	1/1:2,58:60:99:1631,131,0
chr1	25563181	25563181	G	A	LDLRAP1	intronic	NA	NA	NA	0.5681	GnomAdGenome_AF_asj	122	19	HomozygousVariant	hom	37	3	34	0.918918918918919	847.03	PASS	NA	[MIM:603813]Hypercholesterolemia, autosomal recessive [recessive?];	605747	NA	Homozygous familial hypercholesterolemia	Disease-causing germline mutation(s) in	Mean platelet volume[27863252;27863252];Total cholesterol levels[28334899];LDL cholesterol levels[28334899];Cholesterol, total[20686565;24097068;25961943];LDL cholesterol[20686565;24097068;25961943];Platelet count[27863252];	HP:0002621;HP:0000007;HP:0003362;HP:0010874;HP:0002155;HP:0003124;HP:0001658;HP:0001653;HP:0001645;HP:0012397;HP:0030882;HP:0001397;HP:0005181;HP:0005162;HP:0003077;HP:0002094;HP:0007201;HP:0010874;HP:0004381;HP:0005177;HP:0012638;HP:0000822;HP:0012373;HP:0004416;HP:0003124;HP:0003141;HP:3000062;HP:0001681;HP:0002829;HP:0006693;HP:0000799;HP:0030148;HP:0001920;HP:0004950;HP:0004963;HP:0001138	Atherosclerosis;Autosomal recessive inheritance;Increased VLDL cholesterol concentration;Tendon xanthomatosis;Hypertriglyceridemia;Hypercholesterolemia;Myocardial infarction;Mitral regurgitation;Sudden cardiac death;Aortic atherosclerotic lesion;Coronary artery aneurysm;Hepatic steatosis;Premature coronary artery atherosclerosis;Left ventricular dysfunction;Hyperlipidemia;Dyspnea;Cerebral artery atherosclerosis;Tendon xanthomatosis;Supravalvular aortic stenosis;Premature arteriosclerosis;Abnormal nervous system physiology;Hypertension;Abnormal eye physiology;Precocious atherosclerosis;Hypercholesterolemia;Increased LDL cholesterol concentration;Abnormal internal carotid artery morphology;Angina pectoris;Arthralgia;Myocardial steatosis;Renal steatosis;Heart murmur;Renal artery stenosis;Peripheral arterial stenosis;Calcification of the aorta;Optic neuropathy	NA	NA	NA	Expressed at high levels in the kidney, liver, and placenta, with lower levels detectable in brain, heart, muscle, colon, spleen, intestine, lung, and leukocytes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.699	N	N	N	N	0.615525475582644	E	Ldlrap1	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.4852	0.5379	0.5335	0.4487	0.5681	0.416534	0.4467	0.455842	0.471264	PASS	0	0.411	360	0.37234	67	chr1	25563181	NA	G	A	847.03	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=22.89;AS_ReadPosRankSum=0.3;AS_SOR=0.872;BaseQRankSum=-0.251;DP=40;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=22.89;ReadPosRankSum=0.307;SOR=0.872	GT:AD:DP:GQ:PL	1/1:3,34:37:23:861,23,0
chr1	25563698	25563698	A	G	LDLRAP1	exonic	synonymous SNV	NA	LDLRAP1:NM_015627:exon7:c.A654G:p.T218T	0.7958	GnomAdExome_AF_afr	159	23	HomozygousVariant	hom	85	0	85	1	2221.06	PASS	NA	[MIM:603813]Hypercholesterolemia, autosomal recessive [recessive?];	605747	Benign	Homozygous familial hypercholesterolemia	Disease-causing germline mutation(s) in	Mean platelet volume[27863252;27863252];Total cholesterol levels[28334899];LDL cholesterol levels[28334899];Cholesterol, total[20686565;24097068;25961943];LDL cholesterol[20686565;24097068;25961943];Platelet count[27863252];	HP:0002621;HP:0000007;HP:0003362;HP:0010874;HP:0002155;HP:0003124;HP:0001658;HP:0001653;HP:0001645;HP:0012397;HP:0030882;HP:0001397;HP:0005181;HP:0005162;HP:0003077;HP:0002094;HP:0007201;HP:0010874;HP:0004381;HP:0005177;HP:0012638;HP:0000822;HP:0012373;HP:0004416;HP:0003124;HP:0003141;HP:3000062;HP:0001681;HP:0002829;HP:0006693;HP:0000799;HP:0030148;HP:0001920;HP:0004950;HP:0004963;HP:0001138	Atherosclerosis;Autosomal recessive inheritance;Increased VLDL cholesterol concentration;Tendon xanthomatosis;Hypertriglyceridemia;Hypercholesterolemia;Myocardial infarction;Mitral regurgitation;Sudden cardiac death;Aortic atherosclerotic lesion;Coronary artery aneurysm;Hepatic steatosis;Premature coronary artery atherosclerosis;Left ventricular dysfunction;Hyperlipidemia;Dyspnea;Cerebral artery atherosclerosis;Tendon xanthomatosis;Supravalvular aortic stenosis;Premature arteriosclerosis;Abnormal nervous system physiology;Hypertension;Abnormal eye physiology;Precocious atherosclerosis;Hypercholesterolemia;Increased LDL cholesterol concentration;Abnormal internal carotid artery morphology;Angina pectoris;Arthralgia;Myocardial steatosis;Renal steatosis;Heart murmur;Renal artery stenosis;Peripheral arterial stenosis;Calcification of the aorta;Optic neuropathy	Familial_hypercholesterolemia|Familial_hypercholesterolemia_4|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed at high levels in the kidney, liver, and placenta, with lower levels detectable in brain, heart, muscle, colon, spleen, intestine, lung, and leukocytes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.699	N	N	N	N	0.615525475582644	E	Ldlrap1	homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.5501	0.7958	0.799	0.6196	0.7876	0.586262	0.6322	0.0004226	0.600985	PASS	0.671196	0.439	408	0.401408	68	chr1	25563698	NA	A	G	2221.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.13;AS_ReadPosRankSum=.;AS_SOR=0.979;DP=87;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.13;SOR=0.979	GT:AD:DP:GQ:PL	1/1:0,85:85:99:2235,254,0
chr1	25783652	25783652	G	A	MAN1C1	intronic	NA	NA	NA	0.7661	GnomAdGenome_AF_ami	157	78	HomozygousVariant	hom	52	0	52	1	1498.06	PASS	NA	NA	616772	NA	NA	NA	Severe influenza A (H1N1) infection[26379185];Blood protein levels[30072576];	NA	NA	NA	NA	NA	Expressed in most tissues with the exception of lung, muscle and pancreas. Highly expressed in placenta.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0006	0.004	Medium	Medium	Medium	cochlea;epididymis;skin;stomach;testis;adrenal cortex;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;pancreas;islets of Langerhans;fovea centralis;spleen;liver;endometrium;germinal center;parathyroid;brain;lung;ovary;macula lutea;placenta;prostate;optic nerve;	ciliary ganglion;kidney;trigeminal ganglion;atrioventricular node;superior cervical ganglion;placenta;parietal lobe;skeletal muscle;cerebellum;	0.342	NA	N	N	N	0.236396028564915	N	Man1c1	NA	NA	NA	NA	NA	0.6376	0.7398	0.7392	0.6092	0.7661	0.642173	0.6055	0.0222069	0.600164	PASS	0	0.731	123	0.746479	56	chr1	25783652	NA	G	A	1498.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.81;AS_ReadPosRankSum=.;AS_SOR=1.48;DP=55;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.81;SOR=1.48	GT:AD:DP:GQ:PL	1/1:0,52:52:99:1512,156,0
chr1	25805163	25805163	G	A	SELENON	exonic	unknown	NA	UNKNOWN	0.961	GnomAdGenome_AF_ami	596	108	HomozygousVariant	hom	105	0	105	1	2747.06	PASS	13.21	[MIM:602771]Rigid spine muscular dystrophy 1;[MIM:255310]Myopathy, congenital, with fiber-type disproportion;	606210	Benign	Congenital fiber-type disproportion myopathy;Classic multiminicore myopathy;Desmin-related myopathy with Mallory body-like inclusions;Rigid spine syndrome	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0000218;HP:0002015;HP:0003324;HP:0000602;HP:0001319;HP:0001644;HP:0003121;HP:0000007;HP:0001374;HP:0002650;HP:0001612;HP:0003755;HP:0002747;HP:0002093;HP:0002938;HP:0000006;HP:0000275;HP:0003577;HP:0011968;HP:0000508;HP:0003828;HP:0001425;HP:0010628;HP:0001508;HP:0003701;HP:0003687;HP:0032341;HP:0001558;HP:0001283;HP:0000276;HP:0003306;HP:0002090;HP:0030878;HP:0003202;HP:0003307;HP:0003273;HP:0002093;HP:0003391;HP:0001263;HP:0003089;HP:0003198;HP:0001290;HP:0000467;HP:0002515;HP:0002650;HP:0001265;HP:0002987;HP:0031546;HP:0002421;HP:0000508;HP:0001315;HP:0001508;HP:0000218;HP:0010804;HP:0006466;HP:0000602;HP:0001388;HP:0003324;HP:0001644;HP:0000767;HP:0001252;HP:0001561;HP:0011807;HP:0001249;HP:0001558;HP:0008981;HP:0012785;HP:0002751;HP:0003307;HP:0004322;HP:0002033;HP:0002089;HP:0001270;HP:0000276;HP:0002747;HP:0002205;HP:0008180;HP:0003691;HP:0003458;HP:0000347;HP:0002515;HP:0002792;HP:0003273;HP:0000028;HP:0001762;HP:0030192;HP:0002987;HP:0006380;HP:0001612;HP:0001374;HP:0005991;HP:0004889;HP:0001763;HP:0100295;HP:0001290;HP:0002421;HP:0000218;HP:0003306;HP:0000303;HP:0002194;HP:0001667;HP:0001385;HP:0009058;HP:0001708;HP:0003741;HP:0000308;HP:0002828;HP:0030319;HP:0002650;HP:0001508;HP:0001620;HP:0003700;HP:0002877;HP:0001635;HP:0002091;HP:0003327;HP:0004322;HP:0001634;HP:0003700;HP:0001270;HP:0002877;HP:0001290;HP:0003324;HP:0001371;HP:0003306;HP:0003593;HP:0003787;HP:0003557;HP:0003680;HP:0002792;HP:0001252;HP:0005991;HP:0001547;HP:0002421;HP:0003560;HP:0000007;HP:0001611;HP:0010628;HP:0000218;HP:0002650;HP:0001620;HP:0003327;HP:0004322;HP:0002091;HP:0001508	High palate;Dysphagia;Generalized muscle weakness;Ophthalmoplegia;Neonatal hypotonia;Dilated cardiomyopathy;Limb joint contracture;Autosomal recessive inheritance;Congenital hip dislocation;Scoliosis;Weak cry;Type 1 fibers relatively smaller than type 2 fibers;Respiratory insufficiency due to muscle weakness;Respiratory insufficiency;Lumbar hyperlordosis;Autosomal dominant inheritance;Narrow face;Congenital onset;Feeding difficulties;Ptosis;Variable expressivity;Heterogeneous;Facial palsy;Failure to thrive;Proximal muscle weakness;Centrally nucleated skeletal muscle fibers;Reduced forced vital capacity;Decreased fetal movement;Bulbar palsy;Long face;Spinal rigidity;Pneumonia;Abnormality on pulmonary function testing;Skeletal muscle atrophy;Hyperlordosis;Hip contracture;Respiratory insufficiency;Gowers sign;Global developmental delay;Hamstring contractures;Myopathy;Generalized hypotonia;Neck muscle weakness;Waddling gait;Scoliosis;Hyporeflexia;Elbow flexion contracture;Cardiac conduction abnormality;Poor head control;Ptosis;Reduced tendon reflexes;Failure to thrive;High palate;Tented upper lip vermilion;Ankle flexion contracture;Ophthalmoplegia;Joint laxity;Generalized muscle weakness;Dilated cardiomyopathy;Pectus excavatum;Muscular hypotonia;Polyhydramnios;Type 1 muscle fiber atrophy;Intellectual disability;Decreased fetal movement;Calf muscle hypertrophy;Flexion contracture of finger;Kyphoscoliosis;Hyperlordosis;Short stature;Poor suck;Pulmonary hypoplasia;Motor delay;Long face;Respiratory insufficiency due to muscle weakness;Recurrent respiratory infections;Mildly elevated creatine kinase;Scapular winging;EMG: myopathic abnormalities;Micrognathia;Waddling gait;Reduced vital capacity;Hip contracture;Cryptorchidism;Talipes equinovarus;Fatigable weakness of bulbar muscles;Elbow flexion contracture;Knee flexion contracture;Weak cry;Congenital hip dislocation;Limited neck flexion;Intermittent episodes of respiratory insufficiency due to muscle weakness;Pes planus;Muscle fiber atrophy;Generalized hypotonia;Poor head control;High palate;Spinal rigidity;Mandibular prognathia;Delayed gross motor development;Right ventricular hypertrophy;Hip dysplasia;Increased muscle lipid content;Right ventricular failure;Congenital muscular dystrophy;Microretrognathia;Multiple joint contractures;Weakness of facial musculature;Scoliosis;Failure to thrive;High pitched voice;Generalized amyotrophy;Nocturnal hypoventilation;Congestive heart failure;Restrictive ventilatory defect;Axial muscle weakness;Short stature;Mitral valve prolapse;Generalized amyotrophy;Motor delay;Nocturnal hypoventilation;Generalized hypotonia;Generalized muscle weakness;Flexion contracture;Spinal rigidity;Infantile onset;Type 1 and type 2 muscle fiber minicore regions;Increased variability in muscle fiber diameter;Nonprogressive;Reduced vital capacity;Muscular hypotonia;Limited neck flexion;Abnormality of the rib cage;Poor head control;Muscular dystrophy;Autosomal recessive inheritance;Nasal speech;Facial palsy;High palate;Scoliosis;High pitched voice;Axial muscle weakness;Short stature;Restrictive ventilatory defect;Failure to thrive	Eichsfeld_type_congenital_muscular_dystrophy|not_specified|SEPN1-Related_Disorders|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Isoform 1 and isoform 2 are expressed in skeletal muscle, brain, lung and placenta. Isoform 2 is also expressed in heart, diaphragm and stomach. {ECO:0000269|PubMed:11528383, ECO:0000269|PubMed:12700173}.;	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	N	NA	NA	Selenon	growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; normal phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; 	selenon	slow muscle cell	decreased amount	abnormal	0.8183	0.9425	0.9432	0.7911	0.961	0.841853	0	0.0001153	0.785714	PASS	0.914141	0.891	135	0.880282	34	chr1	25805163	NA	G	A	2747.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.16;AS_ReadPosRankSum=.;AS_SOR=0.967;DP=107;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.16;SOR=0.967	GT:AD:DP:GQ:PL	1/1:0,105:105:99:2761,313,0
chr1	25811771	25811771	T	C	SELENON	exonic	unknown	NA	UNKNOWN	0.9684	GnomAdGenome_AF_eas	671	109	HomozygousVariant	hom	52	0	52	1	1421.06	PASS	NA	[MIM:602771]Rigid spine muscular dystrophy 1;[MIM:255310]Myopathy, congenital, with fiber-type disproportion;	606210	Benign	Congenital fiber-type disproportion myopathy;Classic multiminicore myopathy;Desmin-related myopathy with Mallory body-like inclusions;Rigid spine syndrome	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0000218;HP:0002015;HP:0003324;HP:0000602;HP:0001319;HP:0001644;HP:0003121;HP:0000007;HP:0001374;HP:0002650;HP:0001612;HP:0003755;HP:0002747;HP:0002093;HP:0002938;HP:0000006;HP:0000275;HP:0003577;HP:0011968;HP:0000508;HP:0003828;HP:0001425;HP:0010628;HP:0001508;HP:0003701;HP:0003687;HP:0032341;HP:0001558;HP:0001283;HP:0000276;HP:0003306;HP:0002090;HP:0030878;HP:0003202;HP:0003307;HP:0003273;HP:0002093;HP:0003391;HP:0001263;HP:0003089;HP:0003198;HP:0001290;HP:0000467;HP:0002515;HP:0002650;HP:0001265;HP:0002987;HP:0031546;HP:0002421;HP:0000508;HP:0001315;HP:0001508;HP:0000218;HP:0010804;HP:0006466;HP:0000602;HP:0001388;HP:0003324;HP:0001644;HP:0000767;HP:0001252;HP:0001561;HP:0011807;HP:0001249;HP:0001558;HP:0008981;HP:0012785;HP:0002751;HP:0003307;HP:0004322;HP:0002033;HP:0002089;HP:0001270;HP:0000276;HP:0002747;HP:0002205;HP:0008180;HP:0003691;HP:0003458;HP:0000347;HP:0002515;HP:0002792;HP:0003273;HP:0000028;HP:0001762;HP:0030192;HP:0002987;HP:0006380;HP:0001612;HP:0001374;HP:0005991;HP:0004889;HP:0001763;HP:0100295;HP:0001290;HP:0002421;HP:0000218;HP:0003306;HP:0000303;HP:0002194;HP:0001667;HP:0001385;HP:0009058;HP:0001708;HP:0003741;HP:0000308;HP:0002828;HP:0030319;HP:0002650;HP:0001508;HP:0001620;HP:0003700;HP:0002877;HP:0001635;HP:0002091;HP:0003327;HP:0004322;HP:0001634;HP:0003700;HP:0001270;HP:0002877;HP:0001290;HP:0003324;HP:0001371;HP:0003306;HP:0003593;HP:0003787;HP:0003557;HP:0003680;HP:0002792;HP:0001252;HP:0005991;HP:0001547;HP:0002421;HP:0003560;HP:0000007;HP:0001611;HP:0010628;HP:0000218;HP:0002650;HP:0001620;HP:0003327;HP:0004322;HP:0002091;HP:0001508	High palate;Dysphagia;Generalized muscle weakness;Ophthalmoplegia;Neonatal hypotonia;Dilated cardiomyopathy;Limb joint contracture;Autosomal recessive inheritance;Congenital hip dislocation;Scoliosis;Weak cry;Type 1 fibers relatively smaller than type 2 fibers;Respiratory insufficiency due to muscle weakness;Respiratory insufficiency;Lumbar hyperlordosis;Autosomal dominant inheritance;Narrow face;Congenital onset;Feeding difficulties;Ptosis;Variable expressivity;Heterogeneous;Facial palsy;Failure to thrive;Proximal muscle weakness;Centrally nucleated skeletal muscle fibers;Reduced forced vital capacity;Decreased fetal movement;Bulbar palsy;Long face;Spinal rigidity;Pneumonia;Abnormality on pulmonary function testing;Skeletal muscle atrophy;Hyperlordosis;Hip contracture;Respiratory insufficiency;Gowers sign;Global developmental delay;Hamstring contractures;Myopathy;Generalized hypotonia;Neck muscle weakness;Waddling gait;Scoliosis;Hyporeflexia;Elbow flexion contracture;Cardiac conduction abnormality;Poor head control;Ptosis;Reduced tendon reflexes;Failure to thrive;High palate;Tented upper lip vermilion;Ankle flexion contracture;Ophthalmoplegia;Joint laxity;Generalized muscle weakness;Dilated cardiomyopathy;Pectus excavatum;Muscular hypotonia;Polyhydramnios;Type 1 muscle fiber atrophy;Intellectual disability;Decreased fetal movement;Calf muscle hypertrophy;Flexion contracture of finger;Kyphoscoliosis;Hyperlordosis;Short stature;Poor suck;Pulmonary hypoplasia;Motor delay;Long face;Respiratory insufficiency due to muscle weakness;Recurrent respiratory infections;Mildly elevated creatine kinase;Scapular winging;EMG: myopathic abnormalities;Micrognathia;Waddling gait;Reduced vital capacity;Hip contracture;Cryptorchidism;Talipes equinovarus;Fatigable weakness of bulbar muscles;Elbow flexion contracture;Knee flexion contracture;Weak cry;Congenital hip dislocation;Limited neck flexion;Intermittent episodes of respiratory insufficiency due to muscle weakness;Pes planus;Muscle fiber atrophy;Generalized hypotonia;Poor head control;High palate;Spinal rigidity;Mandibular prognathia;Delayed gross motor development;Right ventricular hypertrophy;Hip dysplasia;Increased muscle lipid content;Right ventricular failure;Congenital muscular dystrophy;Microretrognathia;Multiple joint contractures;Weakness of facial musculature;Scoliosis;Failure to thrive;High pitched voice;Generalized amyotrophy;Nocturnal hypoventilation;Congestive heart failure;Restrictive ventilatory defect;Axial muscle weakness;Short stature;Mitral valve prolapse;Generalized amyotrophy;Motor delay;Nocturnal hypoventilation;Generalized hypotonia;Generalized muscle weakness;Flexion contracture;Spinal rigidity;Infantile onset;Type 1 and type 2 muscle fiber minicore regions;Increased variability in muscle fiber diameter;Nonprogressive;Reduced vital capacity;Muscular hypotonia;Limited neck flexion;Abnormality of the rib cage;Poor head control;Muscular dystrophy;Autosomal recessive inheritance;Nasal speech;Facial palsy;High palate;Scoliosis;High pitched voice;Axial muscle weakness;Short stature;Restrictive ventilatory defect;Failure to thrive	Eichsfeld_type_congenital_muscular_dystrophy|not_specified|SEPN1-Related_Disorders|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Isoform 1 and isoform 2 are expressed in skeletal muscle, brain, lung and placenta. Isoform 2 is also expressed in heart, diaphragm and stomach. {ECO:0000269|PubMed:11528383, ECO:0000269|PubMed:12700173}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	N	NA	NA	Selenon	growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; normal phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; 	selenon	slow muscle cell	decreased amount	abnormal	0.8099	0.9651	0.9661	0.7425	0.9684	0.791933	0.7372	0.750915	0.750822	PASS	0.840909	0.894	153	0.883803	33	chr1	25811771	NA	T	C	1421.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.33;AS_ReadPosRankSum=.;AS_SOR=0.853;DP=52;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.33;SOR=0.853	GT:AD:DP:GQ:PL	1/1:0,52:52:99:1435,155,0
chr1	25814082	25814082	C	A	SELENON	exonic	unknown	NA	UNKNOWN	0.9673	GnomAdGenome_AF_eas	668	109	HomozygousVariant	hom	109	0	109	1	3050.06	PASS	13.69	[MIM:602771]Rigid spine muscular dystrophy 1;[MIM:255310]Myopathy, congenital, with fiber-type disproportion;	606210	Benign	Congenital fiber-type disproportion myopathy;Classic multiminicore myopathy;Desmin-related myopathy with Mallory body-like inclusions;Rigid spine syndrome	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0000218;HP:0002015;HP:0003324;HP:0000602;HP:0001319;HP:0001644;HP:0003121;HP:0000007;HP:0001374;HP:0002650;HP:0001612;HP:0003755;HP:0002747;HP:0002093;HP:0002938;HP:0000006;HP:0000275;HP:0003577;HP:0011968;HP:0000508;HP:0003828;HP:0001425;HP:0010628;HP:0001508;HP:0003701;HP:0003687;HP:0032341;HP:0001558;HP:0001283;HP:0000276;HP:0003306;HP:0002090;HP:0030878;HP:0003202;HP:0003307;HP:0003273;HP:0002093;HP:0003391;HP:0001263;HP:0003089;HP:0003198;HP:0001290;HP:0000467;HP:0002515;HP:0002650;HP:0001265;HP:0002987;HP:0031546;HP:0002421;HP:0000508;HP:0001315;HP:0001508;HP:0000218;HP:0010804;HP:0006466;HP:0000602;HP:0001388;HP:0003324;HP:0001644;HP:0000767;HP:0001252;HP:0001561;HP:0011807;HP:0001249;HP:0001558;HP:0008981;HP:0012785;HP:0002751;HP:0003307;HP:0004322;HP:0002033;HP:0002089;HP:0001270;HP:0000276;HP:0002747;HP:0002205;HP:0008180;HP:0003691;HP:0003458;HP:0000347;HP:0002515;HP:0002792;HP:0003273;HP:0000028;HP:0001762;HP:0030192;HP:0002987;HP:0006380;HP:0001612;HP:0001374;HP:0005991;HP:0004889;HP:0001763;HP:0100295;HP:0001290;HP:0002421;HP:0000218;HP:0003306;HP:0000303;HP:0002194;HP:0001667;HP:0001385;HP:0009058;HP:0001708;HP:0003741;HP:0000308;HP:0002828;HP:0030319;HP:0002650;HP:0001508;HP:0001620;HP:0003700;HP:0002877;HP:0001635;HP:0002091;HP:0003327;HP:0004322;HP:0001634;HP:0003700;HP:0001270;HP:0002877;HP:0001290;HP:0003324;HP:0001371;HP:0003306;HP:0003593;HP:0003787;HP:0003557;HP:0003680;HP:0002792;HP:0001252;HP:0005991;HP:0001547;HP:0002421;HP:0003560;HP:0000007;HP:0001611;HP:0010628;HP:0000218;HP:0002650;HP:0001620;HP:0003327;HP:0004322;HP:0002091;HP:0001508	High palate;Dysphagia;Generalized muscle weakness;Ophthalmoplegia;Neonatal hypotonia;Dilated cardiomyopathy;Limb joint contracture;Autosomal recessive inheritance;Congenital hip dislocation;Scoliosis;Weak cry;Type 1 fibers relatively smaller than type 2 fibers;Respiratory insufficiency due to muscle weakness;Respiratory insufficiency;Lumbar hyperlordosis;Autosomal dominant inheritance;Narrow face;Congenital onset;Feeding difficulties;Ptosis;Variable expressivity;Heterogeneous;Facial palsy;Failure to thrive;Proximal muscle weakness;Centrally nucleated skeletal muscle fibers;Reduced forced vital capacity;Decreased fetal movement;Bulbar palsy;Long face;Spinal rigidity;Pneumonia;Abnormality on pulmonary function testing;Skeletal muscle atrophy;Hyperlordosis;Hip contracture;Respiratory insufficiency;Gowers sign;Global developmental delay;Hamstring contractures;Myopathy;Generalized hypotonia;Neck muscle weakness;Waddling gait;Scoliosis;Hyporeflexia;Elbow flexion contracture;Cardiac conduction abnormality;Poor head control;Ptosis;Reduced tendon reflexes;Failure to thrive;High palate;Tented upper lip vermilion;Ankle flexion contracture;Ophthalmoplegia;Joint laxity;Generalized muscle weakness;Dilated cardiomyopathy;Pectus excavatum;Muscular hypotonia;Polyhydramnios;Type 1 muscle fiber atrophy;Intellectual disability;Decreased fetal movement;Calf muscle hypertrophy;Flexion contracture of finger;Kyphoscoliosis;Hyperlordosis;Short stature;Poor suck;Pulmonary hypoplasia;Motor delay;Long face;Respiratory insufficiency due to muscle weakness;Recurrent respiratory infections;Mildly elevated creatine kinase;Scapular winging;EMG: myopathic abnormalities;Micrognathia;Waddling gait;Reduced vital capacity;Hip contracture;Cryptorchidism;Talipes equinovarus;Fatigable weakness of bulbar muscles;Elbow flexion contracture;Knee flexion contracture;Weak cry;Congenital hip dislocation;Limited neck flexion;Intermittent episodes of respiratory insufficiency due to muscle weakness;Pes planus;Muscle fiber atrophy;Generalized hypotonia;Poor head control;High palate;Spinal rigidity;Mandibular prognathia;Delayed gross motor development;Right ventricular hypertrophy;Hip dysplasia;Increased muscle lipid content;Right ventricular failure;Congenital muscular dystrophy;Microretrognathia;Multiple joint contractures;Weakness of facial musculature;Scoliosis;Failure to thrive;High pitched voice;Generalized amyotrophy;Nocturnal hypoventilation;Congestive heart failure;Restrictive ventilatory defect;Axial muscle weakness;Short stature;Mitral valve prolapse;Generalized amyotrophy;Motor delay;Nocturnal hypoventilation;Generalized hypotonia;Generalized muscle weakness;Flexion contracture;Spinal rigidity;Infantile onset;Type 1 and type 2 muscle fiber minicore regions;Increased variability in muscle fiber diameter;Nonprogressive;Reduced vital capacity;Muscular hypotonia;Limited neck flexion;Abnormality of the rib cage;Poor head control;Muscular dystrophy;Autosomal recessive inheritance;Nasal speech;Facial palsy;High palate;Scoliosis;High pitched voice;Axial muscle weakness;Short stature;Restrictive ventilatory defect;Failure to thrive	Eichsfeld_type_congenital_muscular_dystrophy|not_specified|SEPN1-Related_Disorders|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Isoform 1 and isoform 2 are expressed in skeletal muscle, brain, lung and placenta. Isoform 2 is also expressed in heart, diaphragm and stomach. {ECO:0000269|PubMed:11528383, ECO:0000269|PubMed:12700173}.;	T	D	B	B	N	P	L	D	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	N	NA	NA	Selenon	growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; normal phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; 	selenon	slow muscle cell	decreased amount	abnormal	0.7864	0.9655	0.9669	0.6455	0.9673	0.697484	0.6319	0.764182	0.679803	PASS	0.840909	0.892	155	0.883803	33	chr1	25814082	NA	C	A	3050.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.98;AS_ReadPosRankSum=.;AS_SOR=0.956;DP=110;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.98;SOR=0.956	GT:AD:DP:GQ:PL	1/1:0,109:109:99:3064,326,0
chr1	25826267	25826267	A	G	MTFR1L	intronic	NA	NA	NA	0.9798	GnomAdGenome_AF_eas	238	109	HomozygousVariant	hom	55	0	55	1	1455.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	NA	NA	Mtfr1l	NA	NA	NA	NA	NA	0.8284	0.9777	0.9785	0.808	0.9798	0.86222	0.8035	0.803612	0.804598	VQSRTrancheSNP99.90to100.00	0	0.898	59	0.882143	29	chr1	25826267	NA	A	G	1455.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.45;AS_ReadPosRankSum=.;AS_SOR=1.262;DP=55;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.46;SOR=1.262	GT:AD:DP:GQ:PL	1/1:0,55:55:99:1469,165,0
chr1	25826774	25826774	C	T	MTFR1L	exonic	synonymous SNV	NA	MTFR1L:NM_001099625:exon5:c.C399T:p.D133D,MTFR1L:NM_001099626:exon5:c.C399T:p.D133D,MTFR1L:NM_001099627:exon5:c.C399T:p.D133D,MTFR1L:NM_019557:exon5:c.C399T:p.D133D	0.0467	GnomAdExome_AF_sas	3	1	HeterozygousVariant	het	75	32	43	0.573333333333333	1027.64	PASS	NA	NA	NA	Likely benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	NA	NA	Mtfr1l	NA	NA	NA	NA	NA	0.006	0.0467	0.0466	0.0011	0.0437	0.00998403	0.0002	0.0058279	0		0.011364	0.05	46	0.045775	11	chr1	25826774	NA	C	T	1027.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.7;AS_FS=10.079;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.71;AS_ReadPosRankSum=0;AS_SOR=1.567;BaseQRankSum=0.713;DP=79;ExcessHet=3.0103;FS=10.079;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.7;ReadPosRankSum=0.016;SOR=1.567	GT:AD:DP:GQ:PL	0/1:32,43:75:99:1035,0,667
chr1	26031165	26031165	C	A	EXTL1	exonic	nonsynonymous SNV	NA	EXTL1:NM_004455:exon5:c.C1135A:p.H379N	0.8223	GnomAdGenome_AF_fin	471	89	HeterozygousVariant	het	99	58	41	0.414141414141414	835.64	PASS	17.65	NA	601738	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	D	B	B	N	P	L	D	N	T	T	T	NA	T	T	T	T	T	.;	D	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.179	NA	E	N	N	0.665963646069647	E	Extl1	NA	NA	NA	NA	NA	0.6849	0.7493	0.748	0.5805	0.8223	0.594249	0.5466	0.0242431	0.60509	PASS	0.651515	0.756	282	0.799296	49	chr1	26031165	NA	C	A	835.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=3.875;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.44;AS_ReadPosRankSum=-0.7;AS_SOR=1.157;BaseQRankSum=-0.046;DP=100;ExcessHet=3.0103;FS=3.875;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.44;ReadPosRankSum=-0.654;SOR=1.157	GT:AD:DP:GQ:PL	0/1:58,41:99:99:843,0,1352
chr1	26042638	26042638	G	T	SLC30A2	exonic	nonsynonymous SNV	NA	SLC30A2:NM_032513:exon4:c.C496A:p.P166T,SLC30A2:NM_001004434:exon5:c.C643A:p.P215T	0.0043	GnomAdGenome_AF_sas	0		HeterozygousVariant	het	140	64	76	0.542857142857143	1738.64	PASS	17.64	[MIM:608118]Zinc deficiency, transient neonatal [dominant?];	609617	NA	NA	NA	NA	HP:0000951;HP:0008277;HP:0000007;HP:0000006;HP:0001596;HP:0002242;HP:0000964	Abnormality of the skin;Abnormal blood zinc concentration;Autosomal recessive inheritance;Autosomal dominant inheritance;Alopecia;Abnormal intestine morphology;Eczema	NA	NA	NA	NA	T	T	B	B	D	D	N	T	N	T	T	T	T	T	T	T	T	D	.;.;	D	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.409	NA	N	N	N	0.237349762397171	N	Slc30a2	hematopoietic system phenotype; immune system phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; cellular phenotype; 	NA	NA	NA	NA	0.0004	0.0037	0.0039	0.00009771	0.0043	0.000998403	0	0.0003687	0		0	0.002994	5			chr1	26042638	NA	G	T	1738.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=2.14;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.42;AS_ReadPosRankSum=-1;AS_SOR=0.91;BaseQRankSum=-0.259;DP=145;ExcessHet=3.0103;FS=2.14;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.42;ReadPosRankSum=-0.941;SOR=0.91	GT:AD:DP:GQ:PL	0/1:64,76:140:99:1746,0,1419
chr1	26161528	26161528	G	A	FAM110D	exonic	synonymous SNV	NA	FAM110D:NM_024869:exon2:c.G237A:p.P79P	0.5903	GnomAdExome_AF_eas	121	23	HomozygousVariant	hom	58	0	58	1	1719.06	PASS	NA	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.11437135981131	N	Grrp1	NA	NA	NA	NA	NA	0.2299	0.5903	0.5882	0.1164	0.5889	0.282149	0.0617	0.103013	0.141068	PASS	0.241803	0.44	274	0.422535	74	chr1	26161528	NA	G	A	1719.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.64;AS_ReadPosRankSum=.;AS_SOR=1.278;DP=64;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.64;SOR=1.278	GT:AD:DP:GQ:PL	1/1:0,58:58:99:1733,174,0
chr1	26164357	26164357	T	C	C1orf232	exonic	nonsynonymous SNV	NA	C1orf232:NM_001364669:exon4:c.A365G:p.Q122R	0.8474	GnomAdGenome_AF_eas			HomozygousVariant	hom	25	0	25	1	660.06	PASS	23.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;	D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Gm30191	NA	NA	NA	NA	NA	0	0	0	0.3716	0.8474	0.488419	0	0.0001153	0		0					chr1	26164357	NA	T	C	660.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.4;AS_ReadPosRankSum=.;AS_SOR=0.77;DP=25;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.4;SOR=0.77	GT:AD:DP:GQ:PL	1/1:0,25:25:75:674,75,0
chr1	26168395	26168395	C	G	C1orf232	intronic	NA	NA	NA	0.6566	GnomAdGenome_AF_eas			HomozygousVariant	hom	62	0	62	1	1719.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Gm30191	NA	NA	NA	NA	NA	0	0	0	0.3797	0.6566	0.497604	0	0.382242	0		0					chr1	26168395	NA	C	G	1719.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.73;AS_ReadPosRankSum=.;AS_SOR=0.899;DP=65;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.73;SOR=0.899	GT:AD:DP:GQ:PL	1/1:0,62:62:99:1733,185,0
chr1	26170160	26170160	T	C	ZNF593	exonic	synonymous SNV	NA	ZNF593:NM_015871:exon1:c.T177C:p.G59G	0.6585	GnomAdGenome_AF_eas	147	37	HomozygousVariant	hom	86	0	86	1	2557.06	PASS	NA	NA	616698	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Ubiquitous. Detected in spleen, prostate, testis, small intestine, colon and to a minor level in thymus and peripheral blood leukocytes.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;stomach;testis;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;muscle;urinary;mammary gland;skeletal muscle;visual apparatus;tonsil;fovea centralis;spleen;liver;germinal center;parathyroid;brain;blood;heart;lung;salivary gland;ovary;macula lutea;lymph node;bladder;colon;placenta;prostate;breast;optic nerve;hypothalamus;	liver;subthalamic nucleus;trigeminal ganglion;superior cervical ganglion;skeletal muscle;	NA	NA	N	N	N	0.776097919550508	E	Zfp593	NA	NA	NA	NA	NA	0.406	0.6478	0.643	0.4087	0.6585	0.534744	0.3691	0.330998	0.407895	PASS	0.510638	0.534	235	0.507092	69	chr1	26170160	NA	T	C	2557.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.73;AS_ReadPosRankSum=.;AS_SOR=1.259;DP=91;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.73;SOR=1.259	GT:AD:DP:GQ:PL	1/1:0,86:86:99:2571,257,0
chr1	26171302	26171302	G	A	ZNF593	downstream	NA	dist=429	NA	0.0053	GnomAdGenome_AF_sas			HeterozygousVariant	het	94	48	46	0.48936170212766	1061.64	PASS	24.8	NA	616698	NA	NA	NA	NA	NA	NA	NA	NA	NA	Ubiquitous. Detected in spleen, prostate, testis, small intestine, colon and to a minor level in thymus and peripheral blood leukocytes.;	NA	D	NA	NA	NA	D	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;.;.;	D	NA	.;.;.	NA	NA	Medium	Medium	Medium	intestine;pharynx;skin;stomach;testis;lens;pineal gland;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;pancreas;muscle;urinary;mammary gland;skeletal muscle;visual apparatus;tonsil;fovea centralis;spleen;liver;germinal center;parathyroid;brain;blood;heart;lung;salivary gland;ovary;macula lutea;lymph node;bladder;colon;placenta;prostate;breast;optic nerve;hypothalamus;	liver;subthalamic nucleus;trigeminal ganglion;superior cervical ganglion;skeletal muscle;	NA	NA	N	N	N	0.776097919550508	E	Zfp593	NA	NA	NA	NA	NA	0	0	0	0.0001	0.0053	0.00159744	0	0.0005379	0		0					chr1	26171302	NA	G	A	1061.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=1.647;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.3;AS_ReadPosRankSum=-1;AS_SOR=0.879;BaseQRankSum=0.67;DP=97;ExcessHet=3.0103;FS=1.647;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.29;ReadPosRankSum=-0.931;SOR=0.879	GT:AD:DP:GQ:PL	0/1:48,46:94:99:1069,0,1084
chr1	26184449	26184449	C	A	CNKSR1	exonic	nonsynonymous SNV	NA	CNKSR1:NM_001297647:exon12:c.C1070A:p.P357Q,CNKSR1:NM_001297648:exon12:c.C275A:p.P92Q,CNKSR1:NM_006314:exon12:c.C1049A:p.P350Q	0.0739	GnomAdGenome_AF_eas	6	1	HeterozygousVariant	het	82	43	39	0.475609756097561	998.64	PASS	12.67	NA	603272	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	D	P	N	N	M	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;.;.	NA	NA	Medium	Medium	Medium	spleen;tongue;endometrium;stomach;testis;parathyroid;brain;unclassifiable (Anatomical System);amniotic fluid;lung;kidney;ovary;pancreas;bladder;frontal lobe;colon;head and neck;placenta;prostate;mammary gland;islets of Langerhans;	parietal lobe;skeletal muscle;	0.984	NA	N	N	N	0.814114995178652	E	Cnksr1	NA	NA	NA	NA	NA	0.0135	0.0664	0.0653	0.0034	0.0739	0.0339457	0	0.013137	0.000821	PASS	0.015152	0.074	111	0.116197	31	chr1	26184449	NA	C	A	998.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.6;AS_FS=2.955;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.18;AS_ReadPosRankSum=-1.3;AS_SOR=0.493;BaseQRankSum=-0.514;DP=86;ExcessHet=3.0103;FS=2.955;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.18;ReadPosRankSum=-1.217;SOR=0.493	GT:AD:DP:GQ:PL	0/1:43,39:82:99:1006,0,1127
chr1	26198060	26198060	A	G	CATSPER4	exonic	nonsynonymous SNV	NA	CATSPER4:NM_198137:exon5:c.A661G:p.I221V	0.0153	GnomAdExome_AF_sas	0	0	HeterozygousVariant	het	74	38	36	0.486486486486487	836.64	PASS	17.4	NA	609121	Uncertain significance	NA	NA	Height[19343178];	NA	NA	NA	NA	NA	Testis-specific. {ECO:0000269|PubMed:12932298, ECO:0000269|PubMed:17347248}.;	T	T	B	B	N	N	L	D	N	D	D	T	NA	T	T	T	T	T	.;.;	D	N	Ion transport domain;Ion transport domain	NA	NA	Medium	Medium	Medium	testis;	NA	0.153	N	N	N	N	0.245395113995841	N	Catsper4	reproductive system phenotype; 	NA	NA	NA	NA	0.0019	0.0153	0.0149	0.0003	0.0112	0.00319489	0	0.0017529	0		0.003049	0.013	22	0.014085	4	chr1	26198060	NA	A	G	836.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=4.438;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.31;AS_ReadPosRankSum=-1.1;AS_SOR=1.209;BaseQRankSum=0.899;DP=76;ExcessHet=3.0103;FS=4.438;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.31;ReadPosRankSum=-1.082;SOR=1.209	GT:AD:DP:GQ:PL	0/1:38,36:74:99:844,0,817
chr1	26199948	26199948	A	G	CATSPER4	exonic	nonsynonymous SNV	NA	CATSPER4:NM_198137:exon7:c.A877G:p.I293V	0.318182	GME_NWA	28	6	HeterozygousVariant	het	143	87	56	0.391608391608392	1088.64	PASS	8.77	NA	609121	Benign	NA	NA	Height[19343178];	NA	NA	NA	NA	NA	Testis-specific. {ECO:0000269|PubMed:12932298, ECO:0000269|PubMed:17347248}.;	T	T	B	B	N	P	L	D	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	Ion transport domain;Ion transport domain	NA	NA	Medium	Medium	Medium	testis;	NA	0.153	N	N	N	N	0.245395113995841	N	Catsper4	reproductive system phenotype; 	NA	NA	NA	NA	0.1548	0.1976	0.2016	0.1741	0.2216	0.132588	0.1908	0.1608	0.155172	PASS	0.318182	0.165	220	0.204225	46	chr1	26199948	NA	A	G	1088.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=1.361;AS_MQ=60;AS_MQRankSum=0;AS_QD=7.62;AS_ReadPosRankSum=-0.5;AS_SOR=0.872;BaseQRankSum=-0.101;DP=146;ExcessHet=3.0103;FS=1.361;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=7.61;ReadPosRankSum=-0.424;SOR=0.872	GT:AD:DP:GQ:PL	0/1:87,56:143:99:1096,0,1982
chr1	26282329	26282352	GGGACTGGGGCCGGGACCGGGACC	-	UBXN11	exonic	nonframeshift deletion	NA	UBXN11:NM_001077262:exon11:c.1150_1173del:p.G384_P391del,UBXN11:NM_145345:exon15:c.1411_1434del:p.G471_P478del,UBXN11:NM_183008:exon16:c.1510_1533del:p.G504_P511del	0.8751	esp6500siv2_all	21	4	HeterozygousVariant	het	42	18	24	0.571428571428571	898.6	PASS	NA	NA	609151	NA	NA	NA	Obesity-related traits[23251661;23251661];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	stomach;testis;unclassifiable (Anatomical System);kidney;larynx;pancreas;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;brain;blood;bone marrow;lung;cerebral cortex;ovary;lymph node;colon;placenta;optic nerve;	NA	0.994	NA	N	N	N	0.635652964787103	E	Ubxn11	NA	NA	NA	NA	NA	0.0281	0.0958	0.0905	0.0591	0.1583	0	0.8751	0.0004995	0.763566	PASS	0	0.105	48	0.070312	10	chr1	26282328	NA	AGGGACTGGGGCCGGGACCGGGACC	A	898.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.2;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=21.4;AS_ReadPosRankSum=0.6;AS_SOR=0.76;BaseQRankSum=1.2;DP=63;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=59.33;MQRankSum=0;QD=21.4;ReadPosRankSum=0.685;SOR=0.76	GT:AD:DP:GQ:PL	0/1:18,24:42:99:906,0,668
chr1	26285568	26285568	G	A	UBXN11	intronic	NA	NA	NA	0.0413	GnomAdExome_AF_sas	3	2	HeterozygousVariant	het	40	21	19	0.475	411.64	PASS	NA	NA	609151	NA	NA	NA	Obesity-related traits[23251661;23251661];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	stomach;testis;unclassifiable (Anatomical System);kidney;larynx;pancreas;head and neck;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;brain;blood;bone marrow;lung;cerebral cortex;ovary;lymph node;colon;placenta;optic nerve;	NA	0.994	NA	N	N	N	0.635652964787103	E	Ubxn11	NA	NA	NA	NA	NA	0.0046	0.0413	0.0401	0.0009	0.041	0.00858626	0	0.004075	0		0	0.07	23	0.053191	11	chr1	26285568	NA	G	A	411.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=1.278;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.3;AS_ReadPosRankSum=0;AS_SOR=0.409;BaseQRankSum=0.266;DP=40;ExcessHet=3.0103;FS=1.278;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.29;ReadPosRankSum=0.027;SOR=0.409	GT:AD:DP:GQ:PL	0/1:21,19:40:99:419,0,465
chr1	26354172	26354172	C	T	CRYBG2	upstream	NA	dist=42	NA	0.5568	GnomAdGenome_AF_eas		3	HomozygousVariant	hom	149	2	147	0.986577181208054	3811.06	PASS	24.8	NA	NA	NA	NA	NA	Monocyte count[27863252];Obesity-related traits[23251661];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;	D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Crybg2	NA	NA	NA	NA	NA	0	0	0	0.118	0.5568	0.254393	0	0.143615	0.152318	PASS	0			0.34375	5	chr1	26354172	NA	C	T	3811.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=25.58;AS_ReadPosRankSum=1.9;AS_SOR=0.734;BaseQRankSum=0.396;DP=158;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=25.58;ReadPosRankSum=1.92;SOR=0.734	GT:AD:DP:GQ:PL	1/1:2,147:149:99:3825,392,0
chr1	26354204	26354204	A	G	CRYBG2	upstream	NA	dist=74	NA	0.8951	GnomAdGenome_AF_eas			HomozygousVariant	hom	145	0	145	1	3999.06	PASS	NA	NA	NA	NA	NA	NA	Monocyte count[27863252];Obesity-related traits[23251661];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Crybg2	NA	NA	NA	NA	NA	0	0	0	0.6593	0.8951	0.742812	0	0.114947	0.70347	PASS	0					chr1	26354204	NA	A	G	3999.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.58;AS_ReadPosRankSum=.;AS_SOR=0.793;DP=149;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.58;SOR=0.793	GT:AD:DP:GQ:PL	1/1:0,145:145:99:4013,434,0
chr1	26354328	26354328	C	T	CRYBG2	upstream	NA	dist=198	NA	0.5579	GnomAdGenome_AF_eas			HomozygousVariant	hom	135	2	133	0.985185185185185	3618.06	PASS	15.25	NA	NA	NA	NA	NA	Monocyte count[27863252];Obesity-related traits[23251661];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Crybg2	NA	NA	NA	NA	NA	0	0	0	0.1291	0.5579	0.269369	0	0.0279104	0.154762	PASS	0					chr1	26354328	NA	C	T	3618.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.6;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=26.8;AS_ReadPosRankSum=1.1;AS_SOR=0.87;BaseQRankSum=0.635;DP=137;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=26.8;ReadPosRankSum=1.17;SOR=0.87	GT:AD:DP:GQ:PL	1/1:2,133:135:99:3632,352,0
chr1	26354815	26354815	G	A	CRYBG2	upstream	NA	dist=685	NA	0.845	GnomAdGenome_AF_eas			HomozygousVariant	hom	45	1	44	0.977777777777778	1402.06	PASS	NA	NA	NA	NA	NA	NA	Monocyte count[27863252];Obesity-related traits[23251661];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Crybg2	NA	NA	NA	NA	NA	0	0	0	0.5193	0.845	0.614617	0	0.581412	0		0					chr1	26354815	NA	G	A	1402.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=31.16;AS_ReadPosRankSum=0;AS_SOR=1.654;BaseQRankSum=-1.736;DP=45;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=31.16;ReadPosRankSum=0;SOR=1.654	GT:AD:DP:GQ:PL	1/1:1,44:45:92:1416,92,0
chr1	26356517	26356517	A	C	CRYBG2;ZNF683	intergenic	NA	dist=2387;dist=5117	NA	0.8452	GnomAdGenome_AF_eas			HomozygousVariant	hom	63	0	63	1	1744.06	PASS	20.6	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	0	0.566	0.8452	0.660942	0	0.567658	0		0					chr1	26356517	NA	A	C	1744.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.68;AS_ReadPosRankSum=.;AS_SOR=0.859;DP=65;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.68;SOR=0.859	GT:AD:DP:GQ:PL	1/1:0,63:63:99:1758,189,0
chr1	26362103	26362113	ACCCATGACCC	-	ZNF683	intronic	NA	NA	NA	0.0982	GnomAdExome_AF_sas	10	1	HeterozygousVariant	het	70	37	33	0.471428571428571	1261.6	PASS	NA	NA	616775	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in terminally differentiated effector CD8(+) T-cells, but not in naive and central memory cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells and natural killer (NKT) T-cells (at protein level) (PubMed:26179882). Expressed strongly in effector-type CD8(+) T-cells and weakly in naive and memory CD8(+) T-cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells (PubMed:26179882). Isoform 2 is strongly expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882). Isoform 1 is expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882). {ECO:0000269|PubMed:26179882}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	lung;cartilage;endometrium;bone;testis;blood;unclassifiable (Anatomical System);	pons;testis - seminiferous tubule;testis - interstitial;subthalamic nucleus;superior cervical ganglion;trigeminal ganglion;atrioventricular node;testis;globus pallidus;	0.992	NA	N	N	N	0.554765377965017	E	Zfp683	immune system phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.046	0.0982	0.097	0.0306	0.0872	0.038139	0.0347	0.0083372	0.036125	PASS	0	0.101	142	0.066901	17	chr1	26362102	NA	TACCCATGACCC	T	1261.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.2;AS_FS=0.913;AS_MQ=60;AS_MQRankSum=0;AS_QD=18.03;AS_ReadPosRankSum=1.8;AS_SOR=0.512;BaseQRankSum=0.227;DP=77;ExcessHet=3.0103;FS=0.913;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=18.02;ReadPosRankSum=1.88;SOR=0.512	GT:AD:DP:GQ:PL	0/1:37,33:70:99:1269,0,1453
chr1	26365191	26365191	C	T	ZNF683	exonic	nonsynonymous SNV	NA	ZNF683:NM_001114759:exon4:c.G355A:p.D119N,ZNF683:NM_001307925:exon4:c.G355A:p.D119N,ZNF683:NM_173574:exon4:c.G355A:p.D119N	0.004	GnomAdExome_AF_sas	0	0	HeterozygousVariant	het	96	45	51	0.53125	1234.64	PASS	6.342	NA	616775	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in terminally differentiated effector CD8(+) T-cells, but not in naive and central memory cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells and natural killer (NKT) T-cells (at protein level) (PubMed:26179882). Expressed strongly in effector-type CD8(+) T-cells and weakly in naive and memory CD8(+) T-cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells (PubMed:26179882). Isoform 2 is strongly expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882). Isoform 1 is expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882). {ECO:0000269|PubMed:26179882}.;	T	T	B	B	N	N	L	T	N	T	T	T	T	T	T	T	T	T	.;.;.;.;.;.;.;.;	N	N	.;.;.;.;.;.;.;.	NA	NA	Medium	Medium	Medium	lung;cartilage;endometrium;bone;testis;blood;unclassifiable (Anatomical System);	pons;testis - seminiferous tubule;testis - interstitial;subthalamic nucleus;superior cervical ganglion;trigeminal ganglion;atrioventricular node;testis;globus pallidus;	0.992	NA	N	N	N	0.554765377965017	E	Zfp683	immune system phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.0005	0.004	0.0043	0.00006982	0.0023	0.000399361	0	0.0004722	0		0	0.001854	3	0.003521	1	chr1	26365191	NA	C	T	1234.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=2.5;AS_FS=6.842;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.86;AS_ReadPosRankSum=0.4;AS_SOR=1.37;BaseQRankSum=2.52;DP=97;ExcessHet=3.0103;FS=6.842;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.86;ReadPosRankSum=0.496;SOR=1.37	GT:AD:DP:GQ:PL	0/1:45,51:96:99:1242,0,926
chr1	26367754	26367754	T	C	ZNF683	exonic	nonsynonymous SNV	NA	ZNF683:NM_001114759:exon3:c.A158G:p.H53R,ZNF683:NM_001307925:exon3:c.A158G:p.H53R,ZNF683:NM_173574:exon3:c.A158G:p.H53R	0.6363	GnomAdGenome_AF_eas	251	45	HomozygousVariant	hom	66	2	64	0.96969696969697	2522.06	PASS	0.117	NA	616775	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in terminally differentiated effector CD8(+) T-cells, but not in naive and central memory cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells and natural killer (NKT) T-cells (at protein level) (PubMed:26179882). Expressed strongly in effector-type CD8(+) T-cells and weakly in naive and memory CD8(+) T-cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells (PubMed:26179882). Isoform 2 is strongly expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882). Isoform 1 is expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882). {ECO:0000269|PubMed:26179882}.;	T	T	B	B	N	P	L	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;.;.;.;	N	N	.;.;.;.;.;.;.	NA	NA	Medium	Medium	Medium	lung;cartilage;endometrium;bone;testis;blood;unclassifiable (Anatomical System);	pons;testis - seminiferous tubule;testis - interstitial;subthalamic nucleus;superior cervical ganglion;trigeminal ganglion;atrioventricular node;testis;globus pallidus;	0.992	NA	N	N	N	0.554765377965017	E	Zfp683	immune system phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.3612	0.6253	0.6154	0.3778	0.6363	0.493011	0.3632	0.345274	0.369458	PASS	0.37069	0.548	380	0.556338	68	chr1	26367754	NA	T	C	2522.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=31.05;AS_ReadPosRankSum=-2;AS_SOR=1.214;BaseQRankSum=0.299;DP=67;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=31.49;ReadPosRankSum=-1.947;SOR=1.214	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:2,64:66:99:1|1:26367754_T_C:2536,119,0:26367754
chr1	26367769	26367769	T	C	ZNF683	exonic	nonsynonymous SNV	NA	ZNF683:NM_001114759:exon3:c.A143G:p.D48G,ZNF683:NM_001307925:exon3:c.A143G:p.D48G,ZNF683:NM_173574:exon3:c.A143G:p.D48G	0.5857	GnomAdGenome_AF_eas	157	28	HomozygousVariant	hom	59	2	57	0.966101694915254	2357.06	PASS	21.8	NA	616775	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in terminally differentiated effector CD8(+) T-cells, but not in naive and central memory cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells and natural killer (NKT) T-cells (at protein level) (PubMed:26179882). Expressed strongly in effector-type CD8(+) T-cells and weakly in naive and memory CD8(+) T-cells (PubMed:26179882). Expressed in terminally differentiated natural killer (NK) cells (PubMed:26179882). Isoform 2 is strongly expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882). Isoform 1 is expressed in effector CD8(+) T and natural killer (NK) cells (PubMed:26179882). {ECO:0000269|PubMed:26179882}.;	D	D	B	B	N	P	L	T	D	T	T	T	NA	T	T	T	T	T	.;.;.;.;.;.;.;	N	N	.;.;.;.;.;.;.	NA	NA	Medium	Medium	Medium	lung;cartilage;endometrium;bone;testis;blood;unclassifiable (Anatomical System);	pons;testis - seminiferous tubule;testis - interstitial;subthalamic nucleus;superior cervical ganglion;trigeminal ganglion;atrioventricular node;testis;globus pallidus;	0.992	NA	N	N	N	0.554765377965017	E	Zfp683	immune system phenotype; hematopoietic system phenotype; 	NA	NA	NA	NA	0.2659	0.5819	0.5731	0.2225	0.5857	0.344649	0.1985	0.247073	0.245066	PASS	0	0.432	382	0.432624	66	chr1	26367769	NA	T	C	2357.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=2.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=35.29;AS_ReadPosRankSum=-1.6;AS_SOR=1.453;BaseQRankSum=2.6;DP=60;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=30.33;ReadPosRankSum=-1.599;SOR=1.453	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:2,57:59:98:1|1:26367754_T_C:2371,98,0:26367754
chr1	26426501	26426501	T	C	LIN28A	UTR3	NA	NM_024674:c.*43T>C	NA	0.9109	GnomAdExome_AF_amr	139	103	HomozygousVariant	hom	32	0	32	1	912.06	PASS	NA	NA	611043	NA	NA	NA	Glucose homeostasis traits[25524916];	NA	NA	NA	NA	NA	Expressed in embryonic stem cells, placenta and testis. Tends to be up-regulated in HER2-overexpressing breast tumors. {ECO:0000269|PubMed:14688391, ECO:0000269|PubMed:15614775, ECO:0000269|PubMed:15722555, ECO:0000269|PubMed:22118463}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	ovary;placenta;brain;unclassifiable (Anatomical System);	superior cervical ganglion;	NA	E	N	S	N	0.282681495523763	N	Lin28a	nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; 	lin28a	post-vent region	decreased length	abnormal	0.8306	0.9109	0.9104	0.8176	0.8738	0.843251	0.8183	0.80116	0.828407	PASS	0	0.817	62	0.85461	35	chr1	26426501	NA	T	C	912.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.5;AS_ReadPosRankSum=.;AS_SOR=2.765;DP=32;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.5;SOR=2.765	GT:AD:DP:GQ:PL	1/1:0,32:32:95:926,95,0
chr1	26460136	26460136	G	A	DHDDS	exonic	nonsynonymous SNV	NA	DHDDS:NM_001243564:exon7:c.G655A:p.V219M,DHDDS:NM_001243565:exon7:c.G640A:p.V214M,DHDDS:NM_001319959:exon8:c.G478A:p.V160M,DHDDS:NM_024887:exon8:c.G757A:p.V253M,DHDDS:NM_205861:exon8:c.G757A:p.V253M	0.7259	GnomAdExome_AF_eas	151	35	HeterozygousVariant	het	44	25	19	0.431818181818182	424.64	PASS	15.41	[MIM:617836]Developmental delay and seizures with or without movement abnormalities [dominant?];	608172	Benign	Retinitis pigmentosa;Undetermined early-onset epileptic encephalopathy	Disease-causing germline mutation(s) in;Disease-causing germline mutation(s) in	NA	HP:0000028;HP:0001257;HP:0000083;HP:0008936;HP:0000407;HP:0002240;HP:0000054;HP:0000510;HP:0001511;HP:0011505;HP:0001508;HP:0002910;HP:0000007;HP:0001250;HP:0011968;HP:0001337;HP:0002123;HP:0001332;HP:0001290;HP:0002067;HP:0002069;HP:0011150;HP:0000750;HP:0001249;HP:0007099;HP:0000006;HP:0200134;HP:0002353;HP:0001263;HP:0003828;HP:0002063;HP:0001251;HP:0004322;HP:0001337;HP:0000546;HP:0001251;HP:0000348;HP:0001257;HP:0001263;HP:0002059;HP:0000252;HP:0001298;HP:0001558;HP:0000750;HP:0001290;HP:0002376;HP:0004322;HP:0000494;HP:0012447;HP:0001249;HP:0001508;HP:0100660;HP:0011968;HP:0000717;HP:0002317;HP:0010844;HP:0001273;HP:0001265;HP:0100710;HP:0000504;HP:0002133;HP:0002355;HP:0002063;HP:0001336;HP:0002521;HP:0000648;HP:0002020;HP:0000508;HP:0001268;HP:0007018;HP:0000639;HP:0002421;HP:0002509;HP:0000668;HP:0000842;HP:0000648;HP:0000639;HP:0008046;HP:0001513;HP:0008736;HP:0000518;HP:0007703;HP:0000563;HP:0007675;HP:0000602;HP:0000035;HP:0000987;HP:0001347;HP:0000407;HP:0000618;HP:0005978;HP:0000405;HP:0000613;HP:0001249;HP:0000463;HP:0000512;HP:0000431;HP:0000135;HP:0000501	Cryptorchidism;Spasticity;Renal insufficiency;Muscular hypotonia of the trunk;Sensorineural hearing impairment;Hepatomegaly;Micropenis;Rod-cone dystrophy;Intrauterine growth retardation;Cystoid macular edema;Failure to thrive;Elevated hepatic transaminase;Autosomal recessive inheritance;Seizure;Feeding difficulties;Tremor;Generalized myoclonic seizure;Dystonia;Generalized hypotonia;Bradykinesia;Bilateral tonic-clonic seizure;Myoclonic absence seizure;Delayed speech and language development;Intellectual disability;Arnold-Chiari type I malformation;Autosomal dominant inheritance;Epileptic encephalopathy;EEG abnormality;Global developmental delay;Variable expressivity;Rigidity;Ataxia;Short stature;Tremor;Retinal degeneration;Ataxia;High forehead;Spasticity;Global developmental delay;Cerebral atrophy;Microcephaly;Encephalopathy;Decreased fetal movement;Delayed speech and language development;Generalized hypotonia;Developmental regression;Short stature;Downslanted palpebral fissures;Abnormal myelination;Intellectual disability;Failure to thrive;Dyskinesia;Feeding difficulties;Autism;Unsteady gait;EEG with multifocal slow activity;Abnormal corpus callosum morphology;Hyporeflexia;Impulsivity;Abnormality of vision;Status epilepticus;Difficulty walking;Rigidity;Myoclonus;Hypsarrhythmia;Optic atrophy;Gastroesophageal reflux;Ptosis;Mental deterioration;Attention deficit hyperactivity disorder;Nystagmus;Poor head control;Limb hypertonia;Hypodontia;Hyperinsulinemia;Optic atrophy;Nystagmus;Abnormal retinal vascular morphology;Obesity;Hypoplasia of penis;Cataract;Abnormality of retinal pigmentation;Keratoconus;Progressive night blindness;Ophthalmoplegia;Abnormal testis morphology;Atypical scarring of skin;Hyperreflexia;Sensorineural hearing impairment;Blindness;Type II diabetes mellitus;Conductive hearing impairment;Photophobia;Intellectual disability;Anteverted nares;Abnormal electroretinogram;Wide nasal bridge;Hypogonadism;Glaucoma	Retinitis_pigmentosa|Retinitis_pigmentosa_59|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	Benign	Expressed at high levels in testis and kidney. Expressed in epididymis (at protein level). Slightly expressed in heart, spleen and thymus. {ECO:0000269|PubMed:20736409}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;.;	D	N	.;.;.;.;.	NA	NA	Medium	Medium	Medium	intestine;pharynx;epididymis;tongue;cornea;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;retina;muscle;head and neck;urinary;mammary gland;skeletal muscle;islets of Langerhans;mesenchyma;visual apparatus;fovea centralis;hippocampus;liver;cartilage;bone;germinal center;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;macula lutea;bladder;frontal lobe;sympathetic chain;colon;placenta;prostate;nasopharynx;breast;optic nerve;	trigeminal ganglion;skeletal muscle;cerebellum peduncles;	0.468	NA	E	E	E	0.962488000204607	E	Dhdds	mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	dhdds	retinal cone cell	absent	abnormal	0.307	0.7259	0.722	0.3038	0.7167	0.455272	0.2875	0.303385	0.292282	PASS	0.322011	0.43	417	0.510563	75	chr1	26460136	NA	G	A	424.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.9;AS_FS=2.649;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.66;AS_ReadPosRankSum=-1.2;AS_SOR=0.883;BaseQRankSum=0.918;DP=45;ExcessHet=3.0103;FS=2.649;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.65;ReadPosRankSum=-1.15;SOR=0.883	GT:AD:DP:GQ:PL	0/1:25,19:44:99:432,0,560
chr1	26529971	26529971	T	G	RPS6KA1	exonic	synonymous SNV	NA	RPS6KA1:NM_002953:exon1:c.T51G:p.P17P	1	GME_Israel	677	119	HomozygousVariant	hom	89	0	89	1	2420.06	PASS	NA	NA	601684	Benign	NA	NA	Rosacea symptom severity[29771307;29771307];Glucose homeostasis traits[25524916];Mean corpuscular volume[27863252];Amyotrophic lateral sclerosis (sporadic)[24529757];Triglyceride levels[30108155];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.99920423791025	E	Rps6ka1	NA	NA	NA	NA	NA	0.9412	0.9539	0.9559	0.9473	0.9911	0.936701	0	0.0001153	0.947935	PASS	1	0.916	100	0.933333	14	chr1	26529971	NA	T	G	2420.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.19;AS_ReadPosRankSum=.;AS_SOR=0.715;DP=95;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.19;SOR=0.715	GT:AD:DP:GQ:PL	1/1:0,89:89:99:2434,267,0
chr1	26543119	26543119	G	A	RPS6KA1	UTR5	NA	NM_001330441:c.-43G>A	NA	0.7991	GnomAdExome_AF_eas	233	63	HeterozygousVariant	het	77	28	49	0.636363636363636	1160.64	PASS	NA	NA	601684	NA	NA	NA	Rosacea symptom severity[29771307;29771307];Glucose homeostasis traits[25524916];Mean corpuscular volume[27863252];Amyotrophic lateral sclerosis (sporadic)[24529757];Triglyceride levels[30108155];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.99920423791025	E	Rps6ka1	NA	NA	NA	NA	NA	0.7024	0.7991	0.7974	0.7197	0.7912	0.72504	0	0.176861	0		0	0.658	222	0.673913	60	chr1	26543119	NA	G	A	1160.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=15.08;AS_ReadPosRankSum=-0.3;AS_SOR=0.785;BaseQRankSum=0.07;DP=77;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=15.07;ReadPosRankSum=-0.281;SOR=0.785	GT:AD:DP:GQ:PL	0/1:28,49:77:99:1168,0,561
chr1	26553429	26553429	T	C	RPS6KA1	exonic	synonymous SNV	NA	RPS6KA1:NM_001006665:exon6:c.T534C:p.A178A,RPS6KA1:NM_001330441:exon6:c.T459C:p.A153A,RPS6KA1:NM_002953:exon7:c.T507C:p.A169A	1	GnomAdExome_AF_eas	805	142	HomozygousVariant	hom	29	0	29	1	748.06	PASS	NA	NA	601684	Benign	NA	NA	Rosacea symptom severity[29771307;29771307];Glucose homeostasis traits[25524916];Mean corpuscular volume[27863252];Amyotrophic lateral sclerosis (sporadic)[24529757];Triglyceride levels[30108155];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.99920423791025	E	Rps6ka1	NA	NA	NA	NA	NA	0.9984	1	1	0.9925	1	0.991214	0.9919	0.968454	0.998358	PASS	0	1	0	1	0	chr1	26553429	NA	T	C	748.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=25.79;AS_ReadPosRankSum=.;AS_SOR=1.255;DP=29;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=25.8;SOR=1.255	GT:AD:DP:GQ:PL	1/1:0,29:29:87:762,87,0
chr1	26557020	26557020	A	C	RPS6KA1	exonic	nonsynonymous SNV	NA	RPS6KA1:NM_001006665:exon12:c.A1031C:p.K344T,RPS6KA1:NM_001330441:exon12:c.A956C:p.K319T,RPS6KA1:NM_002953:exon13:c.A1004C:p.K335T	0.3072	GnomAdGenome_AF_asj	62	7	HeterozygousVariant	het	62	40	22	0.354838709677419	365.64	PASS	22.6	NA	601684	Benign	NA	NA	Rosacea symptom severity[29771307;29771307];Glucose homeostasis traits[25524916];Mean corpuscular volume[27863252];Amyotrophic lateral sclerosis (sporadic)[24529757];Triglyceride levels[30108155];	NA	NA	NA	NA	NA	NA	T	T	B	B	D	P	L	T	N	T	T	T	NA	D	T	T	T	NA	.;.;.;.;.;	D	D	AGC-kinase, C-terminal|AGC-kinase, C-terminal;AGC-kinase, C-terminal|AGC-kinase, C-terminal;.;.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.99920423791025	E	Rps6ka1	NA	NA	NA	NA	NA	0.2195	0.2882	0.2857	0.1737	0.3072	0.160942	0.1738	0.209952	0.195402	PASS	0.25	0.246	274	0.228873	51	chr1	26557020	NA	A	C	365.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.7;AS_FS=1.018;AS_MQ=60;AS_MQRankSum=0;AS_QD=5.9;AS_ReadPosRankSum=2.2;AS_SOR=0.799;BaseQRankSum=-1.654;DP=63;ExcessHet=3.0103;FS=1.018;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=5.9;ReadPosRankSum=2.22;SOR=0.799	GT:AD:DP:GQ:PL	0/1:40,22:62:99:373,0,936
chr1	26561101	26561101	T	C	RPS6KA1	exonic	synonymous SNV	NA	RPS6KA1:NM_001006665:exon15:c.T1425C:p.Y475Y,RPS6KA1:NM_001330441:exon15:c.T1350C:p.Y450Y,RPS6KA1:NM_002953:exon16:c.T1398C:p.Y466Y	0.7658	GnomAdExome_AF_eas	226	55	HeterozygousVariant	het	73	41	32	0.438356164383562	669.64	PASS	NA	NA	601684	Benign	NA	NA	Rosacea symptom severity[29771307;29771307];Glucose homeostasis traits[25524916];Mean corpuscular volume[27863252];Amyotrophic lateral sclerosis (sporadic)[24529757];Triglyceride levels[30108155];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.99920423791025	E	Rps6ka1	NA	NA	NA	NA	NA	0.376	0.7658	0.7604	0.3583	0.7625	0.510383	0.3306	0.367279	0.334975	PASS	0.397727	0.519	386	0.612676	64	chr1	26561101	NA	T	C	669.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.4;AS_FS=1.966;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.18;AS_ReadPosRankSum=1;AS_SOR=1.051;BaseQRankSum=0.425;DP=74;ExcessHet=3.0103;FS=1.966;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.17;ReadPosRankSum=1.05;SOR=1.051	GT:AD:DP:GQ:PL	0/1:41,32:73:99:677,0,910
chr1	26884230	26884230	T	C	GPN2	exonic	nonsynonymous SNV	NA	GPN2:NM_018066:exon4:c.A790G:p.R264G	0.9983	GnomAdExome_AF_eas	451	116	HomozygousVariant	hom	67	0	67	1	1880.06	PASS	19.3	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.567	NA	E	E	E	0.234511089122369	N	Gpn2	NA	NA	NA	NA	NA	0.7323	0.9983	0.9985	0.7412	0.9981	0.873203	0.7249	0.0224374	0.743842	PASS	0.82197	0.872	117	0.890845	21	chr1	26884230	NA	T	C	1880.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.06;AS_ReadPosRankSum=.;AS_SOR=0.723;DP=68;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.06;SOR=0.723	GT:AD:DP:GQ:PL	1/1:0,67:67:99:1894,201,0
chr1	26952030	26952030	G	A	KDF1	exonic	synonymous SNV	NA	KDF1:NM_152365:exon2:c.C351T:p.D117D	0.5	GME_Israel	54	7	HeterozygousVariant	het	136	60	76	0.558823529411765	1852.64	PASS	4.473	[MIM:617337]Ectodermal dysplasia 12, hypohidrotic/hair/tooth/nail type [dominant?];	616758	Benign	Autosomal dominant hypohidrotic ectodermal dysplasia	Disease-causing germline mutation(s) in	C-reactive protein levels or HDL-cholesterol levels (pleiotropy)[27286809];	HP:0000962;HP:0040154;HP:0032152;HP:0000006;HP:0000695;HP:0000966;HP:0008404;HP:0000322;HP:0011120;HP:0040162;HP:0007387;HP:0000966;HP:0000963;HP:0000964;HP:0001231;HP:0006482;HP:0002231;HP:0011220;HP:0006323;HP:0012471;HP:0001000;HP:0000457;HP:0000668;HP:0002047	Hyperkeratosis;Acne inversa;Keratosis pilaris;Autosomal dominant inheritance;Natal tooth;Hypohidrosis;Nail dystrophy;Short philtrum;Concave nasal ridge;Orthokeratosis;Hypoplastic sweat glands;Hypohidrosis;Thin skin;Eczema;Abnormal fingernail morphology;Abnormality of dental morphology;Sparse body hair;Prominent forehead;Premature loss of primary teeth;Thick vermilion border;Abnormality of skin pigmentation;Depressed nasal ridge;Hypodontia;Malignant hyperthermia	NA	NA	NA	NA	NA	T	NA	NA	NA	P	NA	NA	NA	T	T	T	NA	NA	T	T	T	T	.;	D	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Kdf1	digestive/alimentary phenotype; hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); respiratory system phenotype; homeostasis/metabolism phenotype; cellular phenotype; craniofacial phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); 	NA	NA	NA	NA	0.2202	0.2927	0.2926	0.1874	0.3552	0.127596	0.1905	0.217184	0.206076	PASS	0.5	0.246	266	0.242958	55	chr1	26952030	NA	G	A	1852.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.8;AS_FS=2.186;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.63;AS_ReadPosRankSum=-1.4;AS_SOR=0.506;BaseQRankSum=0.802;DP=140;ExcessHet=3.0103;FS=2.186;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.62;ReadPosRankSum=-1.331;SOR=0.506	GT:AD:DP:GQ:PL	0/1:60,76:136:99:1860,0,1314
chr1	26993865	26993865	T	C	TRNP1	exonic	nonsynonymous SNV	NA	TRNP1:NM_001013642:exon1:c.T79C:p.W27R	1	GnomAdExome_AF_eas	573	139	HomozygousVariant	hom	37	0	37	1	1141.06	PASS	15.5	NA	616824	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	D	T	T	T	T	.;	N	N	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.282681495523763	N	Trnp1	NA	NA	NA	NA	NA	0.996	1	1	0.982	1	0.982029	0.9879	0.0001153	0.987245	PASS	1	0.998	2	0.996429	1	chr1	26993865	NA	T	C	1141.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.84;AS_ReadPosRankSum=.;AS_SOR=1.121;DP=38;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.84;SOR=1.121	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:0,37:37:99:1|1:26993850_T_C:1155,111,0:26993850
chr1	26994239	26994239	G	T	TRNP1	exonic	synonymous SNV	NA	TRNP1:NM_001013642:exon1:c.G453T:p.L151L	0.1242	GnomAdGenome_AF_ami	3	0	HeterozygousVariant	het	40	20	20	0.5	467.64	PASS	NA	NA	616824	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.282681495523763	N	Trnp1	NA	NA	NA	NA	NA	0.0853	0.1158	0.1215	0.056	0.1242	0.0265575	0	0.0152262	0.049479	PASS	0.069767	0.025	23	0.015385	4	chr1	26994239	NA	G	T	467.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.7;AS_ReadPosRankSum=-0.5;AS_SOR=0.693;BaseQRankSum=-0.498;DP=43;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.69;ReadPosRankSum=-0.447;SOR=0.693	GT:AD:DP:GQ:PL	0/1:20,20:40:99:475,0,495
chr1	27012612	27012612	G	T	TENT5B	exonic	nonsynonymous SNV	NA	TENT5B:NM_052943:exon1:c.C59A:p.T20K	0.7268	GnomAdExome_AF_eas	133	33	HeterozygousVariant	het	34	16	18	0.529411764705882	424.64	PASS	13.65	NA	NA	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	T	B	B	N	P	NA	T	N	T	T	T	NA	T	T	T	T	T	.;	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Tent5b	NA	NA	NA	NA	NA	0.2788	0.7268	0.7292	0.1497	0.7213	0.335863	0	0.109397	0.192371	PASS	0.296748	0.455	266	0.442857	58	chr1	27012612	NA	G	T	424.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.4;AS_FS=1.459;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.5;AS_ReadPosRankSum=-0.5;AS_SOR=0.412;BaseQRankSum=-1.36;DP=36;ExcessHet=3.0103;FS=1.459;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.49;ReadPosRankSum=-0.501;SOR=0.412	GT:AD:DP:GQ:PL	0/1:16,18:34:99:432,0,440
chr1	27100305	27100305	T	C	SLC9A1	UTR3	NA	NM_003047:c.*2A>G	NA	1	GnomAdExome_AF_eas	686	120	HomozygousVariant	hom	61	0	61	1	2065.06	PASS	NA	[MIM:616291]Lichtenstein-Knorr syndrome [recessive?];	107310	NA	Progressive autosomal recessive ataxia-deafness syndrome	Disease-causing germline mutation(s) (loss of function) in	NA	HP:0002345;HP:0000007;HP:0001270;HP:0001272;HP:0002075;HP:0002066;HP:0003676;HP:0001310;HP:0001260;HP:0004322;HP:0000639;HP:0002070	Action tremor;Autosomal recessive inheritance;Motor delay;Cerebellar atrophy;Dysdiadochokinesis;Gait ataxia;Progressive;Dysmetria;Dysarthria;Short stature;Nystagmus;Limb ataxia	NA	NA	NA	Kidney and intestine.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;testis;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;head and neck;mammary gland;skeletal muscle;visual apparatus;spleen;liver;cartilage;endometrium;bone;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;lymph node;oesophagus;bladder;frontal lobe;colon;placenta;prostate;breast;	superior cervical ganglion;placenta;	0.387	E	N	N	N	0.904377749943655	E	Slc9a1	endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; 	NA	NA	NA	NA	0.9686	1	1	0.9711	1	0.98742	0.9699	0.00011	0.96798	PASS	0	0.986	11	0.98374	2	chr1	27100305	NA	T	C	2065.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=33.85;AS_ReadPosRankSum=.;AS_SOR=2.419;DP=63;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=33.85;SOR=2.419	GT:AD:DP:GQ:PL	1/1:0,61:61:99:2079,183,0
chr1	27100550	27100550	T	C	SLC9A1	exonic	synonymous SNV	NA	SLC9A1:NM_003047:exon12:c.A2205G:p.E735E	1	GnomAdExome_AF_eas	794	140	HomozygousVariant	hom	164	0	164	1	4935.06	PASS	NA	[MIM:616291]Lichtenstein-Knorr syndrome [recessive?];	107310	Benign	Progressive autosomal recessive ataxia-deafness syndrome	Disease-causing germline mutation(s) (loss of function) in	NA	HP:0002345;HP:0000007;HP:0001270;HP:0001272;HP:0002075;HP:0002066;HP:0003676;HP:0001310;HP:0001260;HP:0004322;HP:0000639;HP:0002070	Action tremor;Autosomal recessive inheritance;Motor delay;Cerebellar atrophy;Dysdiadochokinesis;Gait ataxia;Progressive;Dysmetria;Dysarthria;Short stature;Nystagmus;Limb ataxia	NA	NA	NA	Kidney and intestine.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;testis;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;head and neck;mammary gland;skeletal muscle;visual apparatus;spleen;liver;cartilage;endometrium;bone;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;lymph node;oesophagus;bladder;frontal lobe;colon;placenta;prostate;breast;	superior cervical ganglion;placenta;	0.387	E	N	N	N	0.904377749943655	E	Slc9a1	endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; 	NA	NA	NA	NA	0.9685	1	1	0.9728	1	0.989217	0.9713	0.951087	0.971264	PASS	0.977273	0.991	14	0.992958	2	chr1	27100550	NA	T	C	4935.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.09;AS_ReadPosRankSum=.;AS_SOR=1.026;DP=165;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.09;SOR=1.026	GT:AD:DP:GQ:PL	1/1:0,164:164:99:4949,492,0
chr1	27101227	27101227	T	C	SLC9A1	exonic	nonsynonymous SNV	NA	SLC9A1:NM_003047:exon11:c.A2086G:p.M696V	0.0144	GnomAdExome_AF_sas	0	0	HeterozygousVariant	het	51	24	27	0.529411764705882	557.64	PASS	18.35	[MIM:616291]Lichtenstein-Knorr syndrome [recessive?];	107310	Uncertain significance	Progressive autosomal recessive ataxia-deafness syndrome	Disease-causing germline mutation(s) (loss of function) in	NA	HP:0002345;HP:0000007;HP:0001270;HP:0001272;HP:0002075;HP:0002066;HP:0003676;HP:0001310;HP:0001260;HP:0004322;HP:0000639;HP:0002070	Action tremor;Autosomal recessive inheritance;Motor delay;Cerebellar atrophy;Dysdiadochokinesis;Gait ataxia;Progressive;Dysmetria;Dysarthria;Short stature;Nystagmus;Limb ataxia	not_provided	criteria_provided,_single_submitter	Benign	Kidney and intestine.;	T	T	B	B	N	D	L	T	N	T	T	T	NA	T	T	T	T	T	.;	D	N	Sodium/hydrogen exchanger, regulatory region	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;testis;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;head and neck;mammary gland;skeletal muscle;visual apparatus;spleen;liver;cartilage;endometrium;bone;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;lymph node;oesophagus;bladder;frontal lobe;colon;placenta;prostate;breast;	superior cervical ganglion;placenta;	0.387	E	N	N	N	0.904377749943655	E	Slc9a1	endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; 	NA	NA	NA	NA	0.0018	0.0144	0.0148	0.0002	0.0109	0.00479233	0	0.001824	0		0.007576	0.02	32	0.021127	6	chr1	27101227	NA	T	C	557.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.4;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.94;AS_ReadPosRankSum=-0.2;AS_SOR=0.765;BaseQRankSum=-0.394;DP=53;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.93;ReadPosRankSum=-0.179;SOR=0.765	GT:AD:DP:GQ:PL	0/1:24,27:51:99:565,0,506
chr1	27101830	27101830	T	C	SLC9A1	intronic	NA	NA	NA	0.3805	GnomAdGenome_AF_nfe	50	14	HeterozygousVariant	het	41	20	21	0.51219512195122	465.64	PASS	NA	[MIM:616291]Lichtenstein-Knorr syndrome [recessive?];	107310	NA	Progressive autosomal recessive ataxia-deafness syndrome	Disease-causing germline mutation(s) (loss of function) in	NA	HP:0002345;HP:0000007;HP:0001270;HP:0001272;HP:0002075;HP:0002066;HP:0003676;HP:0001310;HP:0001260;HP:0004322;HP:0000639;HP:0002070	Action tremor;Autosomal recessive inheritance;Motor delay;Cerebellar atrophy;Dysdiadochokinesis;Gait ataxia;Progressive;Dysmetria;Dysarthria;Short stature;Nystagmus;Limb ataxia	NA	NA	NA	Kidney and intestine.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0001	0	Medium	Medium	Medium	epididymis;skin;stomach;testis;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;head and neck;mammary gland;skeletal muscle;visual apparatus;spleen;liver;cartilage;endometrium;bone;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;lymph node;oesophagus;bladder;frontal lobe;colon;placenta;prostate;breast;	superior cervical ganglion;placenta;	0.387	E	N	N	N	0.904377749943655	E	Slc9a1	endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; 	NA	NA	NA	NA	0.3113	0.3713	0.369	0.3473	0.3805	0.277157	0.3618	0.315947	0.313629	PASS	0	0.333	186	0.297872	56	chr1	27101830	NA	T	C	465.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=1.204;AS_MQ=60;AS_MQRankSum=0;AS_QD=11.37;AS_ReadPosRankSum=-0.3;AS_SOR=0.99;BaseQRankSum=0.379;DP=45;ExcessHet=3.0103;FS=1.204;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=11.36;ReadPosRankSum=-0.248;SOR=0.99	GT:AD:DP:GQ:PL	0/1:20,21:41:99:473,0,428
chr1	27154266	27154266	A	G	SLC9A1	exonic	synonymous SNV	NA	SLC9A1:NM_003047:exon1:c.T69C:p.V23V	0.3805	GnomAdGenome_AF_fin	98	14	HeterozygousVariant	het	154	79	75	0.487012987012987	1659.64	PASS	NA	[MIM:616291]Lichtenstein-Knorr syndrome [recessive?];	107310	Benign	Progressive autosomal recessive ataxia-deafness syndrome	Disease-causing germline mutation(s) (loss of function) in	NA	HP:0002345;HP:0000007;HP:0001270;HP:0001272;HP:0002075;HP:0002066;HP:0003676;HP:0001310;HP:0001260;HP:0004322;HP:0000639;HP:0002070	Action tremor;Autosomal recessive inheritance;Motor delay;Cerebellar atrophy;Dysdiadochokinesis;Gait ataxia;Progressive;Dysmetria;Dysarthria;Short stature;Nystagmus;Limb ataxia	NA	NA	NA	Kidney and intestine.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	epididymis;skin;stomach;testis;unclassifiable (Anatomical System);choroid;larynx;kidney;uterus;retina;pancreas;head and neck;mammary gland;skeletal muscle;visual apparatus;spleen;liver;cartilage;endometrium;bone;parathyroid;brain;blood;heart;bone marrow;lung;salivary gland;ovary;thyroid;lymph node;oesophagus;bladder;frontal lobe;colon;placenta;prostate;breast;	superior cervical ganglion;placenta;	0.387	E	N	N	N	0.904377749943655	E	Slc9a1	endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; 	NA	NA	NA	NA	0.2983	0.3551	0.3532	0.3132	0.3805	0.2498	0.3268	0.0001153	0.270115	PASS	0.3	0.334	347	0.295775	56	chr1	27154266	NA	A	G	1659.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=2.857;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.78;AS_ReadPosRankSum=-0.5;AS_SOR=0.476;BaseQRankSum=-1.005;DP=163;ExcessHet=3.0103;FS=2.857;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.78;ReadPosRankSum=-0.429;SOR=0.476	GT:AD:DP:GQ:PL	0/1:79,75:154:99:1667,0,1897
chr1	27350434	27350434	G	A	SYTL1	exonic	synonymous SNV	NA	SYTL1:NM_001193308:exon10:c.G954A:p.K318K,SYTL1:NM_032872:exon10:c.G918A:p.K306K	0.4077	GnomAdGenome_AF_fin	77	13	HeterozygousVariant	het	89	37	52	0.584269662921348	1199.64	PASS	NA	NA	608042	Benign	NA	NA	Asthma[29273806];	NA	NA	NA	NA	NA	Highly expressed in bone marrow and lymphoid tissues. Detected at lower levels in cerebellum, occipital lobe, prostate, stomach, kidney, appendix, lung and trachea. Expressed in cytotoxic T-lymphocytes (CTL). {ECO:0000269|PubMed:11278853, ECO:0000269|PubMed:18266782}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	Medium	Medium	thymus;stomach;testis;unclassifiable (Anatomical System);kidney;uterus;whole body;pancreas;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;brain;blood;bone marrow;lung;thyroid;lymph node;bladder;colon;placenta;prostate;optic nerve;	NA	0.946	N	N	N	N	0.246455820134884	N	Sytl1	endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; digestive/alimentary phenotype; reproductive system phenotype; hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.3112	0.3761	0.3749	0.2959	0.4077	0.244808	0.3059	0.313088	0.26601	PASS	0.314394	0.349	256	0.31338	63	chr1	27350434	NA	G	A	1199.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.3;AS_FS=1.723;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.48;AS_ReadPosRankSum=-1;AS_SOR=0.526;BaseQRankSum=-0.268;DP=90;ExcessHet=3.0103;FS=1.723;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.48;ReadPosRankSum=-0.912;SOR=0.526	GT:AD:DP:GQ:PL	0/1:37,52:89:99:1207,0,796
chr1	27353306	27353306	A	G	SYTL1	exonic	nonsynonymous SNV	NA	SYTL1:NM_001193308:exon14:c.A1367G:p.Q456R,SYTL1:NM_032872:exon14:c.A1331G:p.Q444R	0.7054	GnomAdExome_AF_sas	330	74	HeterozygousVariant	het	77	29	48	0.623376623376623	1056.64	PASS	14.2	NA	608042	Benign	NA	NA	Asthma[29273806];	NA	NA	NA	NA	NA	Highly expressed in bone marrow and lymphoid tissues. Detected at lower levels in cerebellum, occipital lobe, prostate, stomach, kidney, appendix, lung and trachea. Expressed in cytotoxic T-lymphocytes (CTL). {ECO:0000269|PubMed:11278853, ECO:0000269|PubMed:18266782}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;	N	N	C2 domain|C2 domain|C2 domain;.;C2 domain|C2 domain|C2 domain;C2 domain|C2 domain|C2 domain	NA	NA	High	Medium	Medium	thymus;stomach;testis;unclassifiable (Anatomical System);kidney;uterus;whole body;pancreas;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;brain;blood;bone marrow;lung;thyroid;lymph node;bladder;colon;placenta;prostate;optic nerve;	NA	0.946	N	N	N	N	0.246455820134884	N	Sytl1	endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; digestive/alimentary phenotype; reproductive system phenotype; hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.5855	0.7054	0.7054	0.578	0.6992	0.482228	0.5993	0.5541	0.595238	PASS	0.663793	0.744	214	0.704225	52	chr1	27353306	NA	A	G	1056.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.9;AS_FS=0.902;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.73;AS_ReadPosRankSum=1.5;AS_SOR=0.591;BaseQRankSum=-2.855;DP=81;ExcessHet=3.0103;FS=0.902;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.72;ReadPosRankSum=1.59;SOR=0.591	GT:AD:DP:GQ:PL	0/1:29,48:77:99:1064,0,678
chr1	27353463	27353463	G	A	SYTL1	exonic	synonymous SNV	NA	SYTL1:NM_001193308:exon14:c.G1524A:p.G508G,SYTL1:NM_032872:exon14:c.G1488A:p.G496G	0.4105	GnomAdGenome_AF_fin	69	12	HeterozygousVariant	het	74	32	42	0.567567567567568	1008.64	PASS	NA	NA	608042	Benign	NA	NA	Asthma[29273806];	NA	NA	NA	NA	NA	Highly expressed in bone marrow and lymphoid tissues. Detected at lower levels in cerebellum, occipital lobe, prostate, stomach, kidney, appendix, lung and trachea. Expressed in cytotoxic T-lymphocytes (CTL). {ECO:0000269|PubMed:11278853, ECO:0000269|PubMed:18266782}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	Medium	Medium	thymus;stomach;testis;unclassifiable (Anatomical System);kidney;uterus;whole body;pancreas;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;brain;blood;bone marrow;lung;thyroid;lymph node;bladder;colon;placenta;prostate;optic nerve;	NA	0.946	N	N	N	N	0.246455820134884	N	Sytl1	endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; digestive/alimentary phenotype; reproductive system phenotype; hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.3054	0.3633	0.3624	0.2899	0.4105	0.241014	0.2946	0.284388	0.256158	PASS	0.322086	0.36	219	0.31338	65	chr1	27353463	NA	G	A	1008.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-2.1;AS_FS=0.913;AS_MQ=60;AS_MQRankSum=0;AS_QD=13.64;AS_ReadPosRankSum=-1.1;AS_SOR=0.56;BaseQRankSum=-2.042;DP=76;ExcessHet=3.0103;FS=0.913;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=13.63;ReadPosRankSum=-1.048;SOR=0.56	GT:AD:DP:GQ:PL	0/1:32,42:74:99:1016,0,807
chr1	27353801	27353801	A	G	SYTL1	exonic	synonymous SNV	NA	SYTL1:NM_001193308:exon15:c.A1638G:p.E546E,SYTL1:NM_032872:exon15:c.A1602G:p.E534E	0.7578	GnomAdGenome_AF_ami	173	32	HeterozygousVariant	het	114	59	55	0.482456140350877	1161.64	PASS	NA	NA	608042	Benign	NA	NA	Asthma[29273806];	NA	NA	NA	NA	NA	Highly expressed in bone marrow and lymphoid tissues. Detected at lower levels in cerebellum, occipital lobe, prostate, stomach, kidney, appendix, lung and trachea. Expressed in cytotoxic T-lymphocytes (CTL). {ECO:0000269|PubMed:11278853, ECO:0000269|PubMed:18266782}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	Medium	Medium	thymus;stomach;testis;unclassifiable (Anatomical System);kidney;uterus;whole body;pancreas;mammary gland;islets of Langerhans;visual apparatus;cervix;spleen;liver;endometrium;bone;germinal center;brain;blood;bone marrow;lung;thyroid;lymph node;bladder;colon;placenta;prostate;optic nerve;	NA	0.946	N	N	N	N	0.246455820134884	N	Sytl1	endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; digestive/alimentary phenotype; reproductive system phenotype; hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; skeleton phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.6116	0.7276	0.7242	0.6838	0.7578	0.546326	0.7175	0.62461	0.680624	PASS	0.75	0.532	277	0.5	78	chr1	27353801	NA	A	G	1161.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.2;AS_FS=7.123;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.19;AS_ReadPosRankSum=0.7;AS_SOR=1.101;BaseQRankSum=-0.105;DP=116;ExcessHet=3.0103;FS=7.123;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.19;ReadPosRankSum=0.74;SOR=1.101	GT:AD:DP:GQ:PL	0/1:59,55:114:99:1169,0,1290
chr1	27362142	27362142	G	A	MAP3K6	exonic	nonsynonymous SNV	NA	MAP3K6:NM_001297609:exon8:c.C1340T:p.T447I,MAP3K6:NM_004672:exon9:c.C1364T:p.T455I	0.5364	GnomAdGenome_AF_eas	109	17	HeterozygousVariant	het	114	57	57	0.5	1249.64	PASS	4.319	NA	604468	NA	Hereditary diffuse gastric cancer	Disease-causing germline mutation(s) (loss of function) in	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;	N	N	.;Domain of unknown function DUF4071;Domain of unknown function DUF4071	NA	NA	Medium	Medium	Medium	skin;myocardium;stomach;testis;pituitary gland;adrenal cortex;unclassifiable (Anatomical System);choroid;kidney;uterus;pancreas;muscle;mammary gland;islets of Langerhans;cervix;fovea centralis;iris;cartilage;bone;brain;heart;lung;ovary;macula lutea;colon;placenta;prostate;breast;optic nerve;	ciliary ganglion;skin;fetal lung;	0.849	N	N	S	N	0.976448184671964	E	Map3k6	neoplasm; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); cellular phenotype; homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.3255	0.5212	0.5225	0.2863	0.5364	0.310503	0.2818	0.325714	0.267652	PASS	0.337121	0.354	354	0.330986	60	chr1	27362142	NA	G	A	1249.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.1;AS_FS=1.503;AS_MQ=60;AS_MQRankSum=0;AS_QD=10.96;AS_ReadPosRankSum=0.1;AS_SOR=0.918;BaseQRankSum=-0.019;DP=115;ExcessHet=3.0103;FS=1.503;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.96;ReadPosRankSum=0.198;SOR=0.918	GT:AD:DP:GQ:PL	0/1:57,57:114:99:1257,0,1245
chr1	27382530	27382530	C	T	CD164L2	exonic	nonsynonymous SNV	NA	CD164L2:NM_001330448:exon2:c.G226A:p.V76M,CD164L2:NM_207397:exon2:c.G226A:p.V76M	0.9622	GnomAdGenome_AF_ami			HomozygousVariant	hom	65	0	65	1	1936.06	PASS	12.97	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;.;	NA	NA	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.728	NA	N	N	N	0.171019286646755	N	Cd164l2	NA	NA	NA	NA	NA	0	0	0	0.7634	0.9622	0	0	0.0000384	0		0					chr1	27382530	NA	C	T	1936.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.78;AS_ReadPosRankSum=.;AS_SOR=0.854;DP=65;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.79;SOR=0.854	GT:AD:DP:GQ:PL	1/1:0,65:65:99:1950,194,0
chr1	27382554	27382554	C	T	CD164L2	exonic	nonsynonymous SNV	NA	CD164L2:NM_001330448:exon2:c.G202A:p.G68R,CD164L2:NM_207397:exon2:c.G202A:p.G68R	1	GnomAdGenome_AF_ami			HomozygousVariant	hom	80	0	80	1	2317.06	PASS	1.775	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	NA	NA	NA	NA	NA	T	.;.;	NA	NA	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.728	NA	N	N	N	0.171019286646755	N	Cd164l2	NA	NA	NA	NA	NA	0	0	0	0.9814	1	0	0	0.0000384	0		0					chr1	27382554	NA	C	T	2317.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.96;AS_ReadPosRankSum=.;AS_SOR=0.693;DP=86;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.96;SOR=0.693	GT:AD:DP:GQ:PL	1/1:0,80:80:99:2331,240,0
chr1	27549313	27549313	C	T	AHDC1	exonic	nonsynonymous SNV	NA	AHDC1:NM_001029882:exon6:c.G2803A:p.A935T	1	GnomAdExome_AF_eas	800	141	HomozygousVariant	hom	154	0	154	1	4219.06	PASS	5.255	[MIM:615829]Mental retardation, autosomal dominant 25 [dominant?];	615790	Benign	AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome	Disease-causing germline mutation(s) in	Coronary artery disease[29212778];	HP:0002079;HP:0000006;HP:0001601;HP:0000582;HP:0001508;HP:0000316;HP:0000494;HP:0001290;HP:0006951;HP:0012448;HP:0025267;HP:0000369;HP:0009879;HP:0002870;HP:0000347;HP:0001249;HP:0005280;HP:0000565;HP:0001263;HP:0009909;HP:0000347;HP:0002474;HP:0002079;HP:0000565;HP:0001363;HP:0000582;HP:0002870;HP:0006951;HP:0001250;HP:0001999;HP:0000369;HP:0000365;HP:0000411;HP:0004887;HP:0001263;HP:0031936;HP:0000717;HP:0001508;HP:0001251;HP:0001252;HP:0100704;HP:0002779;HP:0025267;HP:0025573;HP:0002650;HP:0011477;HP:0000490;HP:0011968;HP:0001388;HP:0002353;HP:0000385;HP:0001249;HP:0001601;HP:0000316;HP:0009909;HP:0012448;HP:0002781;HP:0000494;HP:0005280	Hypoplasia of the corpus callosum;Autosomal dominant inheritance;Laryngomalacia;Upslanted palpebral fissure;Failure to thrive;Hypertelorism;Downslanted palpebral fissures;Generalized hypotonia;Retrocerebellar cyst;Delayed myelination;Snoring;Low-set ears;Simplified gyral pattern;Obstructive sleep apnea;Micrognathia;Intellectual disability;Depressed nasal bridge;Esotropia;Global developmental delay;Uplifted earlobe;Micrognathia;Expressive language delay;Hypoplasia of the corpus callosum;Esotropia;Craniosynostosis;Upslanted palpebral fissure;Obstructive sleep apnea;Retrocerebellar cyst;Seizure;Abnormal facial shape;Low-set ears;Hearing impairment;Protruding ear;Respiratory failure requiring assisted ventilation;Global developmental delay;Delayed ability to walk;Autism;Failure to thrive;Ataxia;Muscular hypotonia;Cerebral visual impairment;Tracheomalacia;Snoring;Mild myopia;Scoliosis;Upbeat nystagmus;Deeply set eye;Feeding difficulties;Joint laxity;EEG abnormality;Small earlobe;Intellectual disability;Laryngomalacia;Hypertelorism;Uplifted earlobe;Delayed myelination;Upper airway obstruction;Downslanted palpebral fissures;Depressed nasal bridge	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;.;.;.;	N	N	.;.;.;.;.	NA	NA	Medium	Medium	Medium	skin;stomach;testis;pituitary gland;lens;unclassifiable (Anatomical System);choroid;kidney;retina;pancreas;head and neck;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;cartilage;bone;brain;bone marrow;lung;thyroid;macula lutea;lymph node;oesophagus;bladder;colon;placenta;optic nerve;	prefrontal cortex;skeletal muscle;	0.011	NA	N	N	NA	0.52560473713625	E	Ahdc1	NA	NA	NA	NA	NA	0.9951	1	1	0.9956	1	0.998003	0.9949	0.0343476	0.994253	PASS	1	0.996	6	1	0	chr1	27549313	NA	C	T	4219.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=27.4;AS_ReadPosRankSum=.;AS_SOR=0.773;DP=162;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=27.4;SOR=0.773	GT:AD:DP:GQ:PL	1/1:0,154:154:99:4233,458,0
chr1	27549971	27549971	C	A	AHDC1	exonic	synonymous SNV	NA	AHDC1:NM_001029882:exon6:c.G2145T:p.P715P	0.9345	GnomAdExome_AF_afr	434	79	HomozygousVariant	hom	141	0	141	1	4279.06	PASS	NA	[MIM:615829]Mental retardation, autosomal dominant 25 [dominant?];	615790	Benign	AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome	Disease-causing germline mutation(s) in	Coronary artery disease[29212778];	HP:0002079;HP:0000006;HP:0001601;HP:0000582;HP:0001508;HP:0000316;HP:0000494;HP:0001290;HP:0006951;HP:0012448;HP:0025267;HP:0000369;HP:0009879;HP:0002870;HP:0000347;HP:0001249;HP:0005280;HP:0000565;HP:0001263;HP:0009909;HP:0000347;HP:0002474;HP:0002079;HP:0000565;HP:0001363;HP:0000582;HP:0002870;HP:0006951;HP:0001250;HP:0001999;HP:0000369;HP:0000365;HP:0000411;HP:0004887;HP:0001263;HP:0031936;HP:0000717;HP:0001508;HP:0001251;HP:0001252;HP:0100704;HP:0002779;HP:0025267;HP:0025573;HP:0002650;HP:0011477;HP:0000490;HP:0011968;HP:0001388;HP:0002353;HP:0000385;HP:0001249;HP:0001601;HP:0000316;HP:0009909;HP:0012448;HP:0002781;HP:0000494;HP:0005280	Hypoplasia of the corpus callosum;Autosomal dominant inheritance;Laryngomalacia;Upslanted palpebral fissure;Failure to thrive;Hypertelorism;Downslanted palpebral fissures;Generalized hypotonia;Retrocerebellar cyst;Delayed myelination;Snoring;Low-set ears;Simplified gyral pattern;Obstructive sleep apnea;Micrognathia;Intellectual disability;Depressed nasal bridge;Esotropia;Global developmental delay;Uplifted earlobe;Micrognathia;Expressive language delay;Hypoplasia of the corpus callosum;Esotropia;Craniosynostosis;Upslanted palpebral fissure;Obstructive sleep apnea;Retrocerebellar cyst;Seizure;Abnormal facial shape;Low-set ears;Hearing impairment;Protruding ear;Respiratory failure requiring assisted ventilation;Global developmental delay;Delayed ability to walk;Autism;Failure to thrive;Ataxia;Muscular hypotonia;Cerebral visual impairment;Tracheomalacia;Snoring;Mild myopia;Scoliosis;Upbeat nystagmus;Deeply set eye;Feeding difficulties;Joint laxity;EEG abnormality;Small earlobe;Intellectual disability;Laryngomalacia;Hypertelorism;Uplifted earlobe;Delayed myelination;Upper airway obstruction;Downslanted palpebral fissures;Depressed nasal bridge	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;stomach;testis;pituitary gland;lens;unclassifiable (Anatomical System);choroid;kidney;retina;pancreas;head and neck;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;cartilage;bone;brain;bone marrow;lung;thyroid;macula lutea;lymph node;oesophagus;bladder;colon;placenta;optic nerve;	prefrontal cortex;skeletal muscle;	0.011	NA	N	N	NA	0.52560473713625	E	Ahdc1	NA	NA	NA	NA	NA	0.6796	0.9345	0.9392	0.7147	0.9219	0.792931	0.7169	0.664564	0.699507	PASS	0.704678	0.734	315	0.746479	54	chr1	27549971	NA	C	A	4279.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.35;AS_ReadPosRankSum=.;AS_SOR=1.357;DP=147;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.35;SOR=1.357	GT:AD:DP:GQ:PL	1/1:0,141:141:99:4293,421,0
chr1	27551986	27552003	GGGGCCGGGTGGGAAGCA	-	AHDC1	exonic	nonframeshift deletion	NA	AHDC1:NM_001029882:exon6:c.113_130del:p.L38_P43del	0.0003	GnomAdGenome_AF_sas			WT/SomaticVariant	het	75	54	21	0.28	676.6	PASS	NA	[MIM:615829]Mental retardation, autosomal dominant 25 [dominant?];	615790	NA	AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome	Disease-causing germline mutation(s) in	Coronary artery disease[29212778];	HP:0002079;HP:0000006;HP:0001601;HP:0000582;HP:0001508;HP:0000316;HP:0000494;HP:0001290;HP:0006951;HP:0012448;HP:0025267;HP:0000369;HP:0009879;HP:0002870;HP:0000347;HP:0001249;HP:0005280;HP:0000565;HP:0001263;HP:0009909;HP:0000347;HP:0002474;HP:0002079;HP:0000565;HP:0001363;HP:0000582;HP:0002870;HP:0006951;HP:0001250;HP:0001999;HP:0000369;HP:0000365;HP:0000411;HP:0004887;HP:0001263;HP:0031936;HP:0000717;HP:0001508;HP:0001251;HP:0001252;HP:0100704;HP:0002779;HP:0025267;HP:0025573;HP:0002650;HP:0011477;HP:0000490;HP:0011968;HP:0001388;HP:0002353;HP:0000385;HP:0001249;HP:0001601;HP:0000316;HP:0009909;HP:0012448;HP:0002781;HP:0000494;HP:0005280	Hypoplasia of the corpus callosum;Autosomal dominant inheritance;Laryngomalacia;Upslanted palpebral fissure;Failure to thrive;Hypertelorism;Downslanted palpebral fissures;Generalized hypotonia;Retrocerebellar cyst;Delayed myelination;Snoring;Low-set ears;Simplified gyral pattern;Obstructive sleep apnea;Micrognathia;Intellectual disability;Depressed nasal bridge;Esotropia;Global developmental delay;Uplifted earlobe;Micrognathia;Expressive language delay;Hypoplasia of the corpus callosum;Esotropia;Craniosynostosis;Upslanted palpebral fissure;Obstructive sleep apnea;Retrocerebellar cyst;Seizure;Abnormal facial shape;Low-set ears;Hearing impairment;Protruding ear;Respiratory failure requiring assisted ventilation;Global developmental delay;Delayed ability to walk;Autism;Failure to thrive;Ataxia;Muscular hypotonia;Cerebral visual impairment;Tracheomalacia;Snoring;Mild myopia;Scoliosis;Upbeat nystagmus;Deeply set eye;Feeding difficulties;Joint laxity;EEG abnormality;Small earlobe;Intellectual disability;Laryngomalacia;Hypertelorism;Uplifted earlobe;Delayed myelination;Upper airway obstruction;Downslanted palpebral fissures;Depressed nasal bridge	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	skin;stomach;testis;pituitary gland;lens;unclassifiable (Anatomical System);choroid;kidney;retina;pancreas;head and neck;skeletal muscle;islets of Langerhans;visual apparatus;fovea centralis;cartilage;bone;brain;bone marrow;lung;thyroid;macula lutea;lymph node;oesophagus;bladder;colon;placenta;optic nerve;	prefrontal cortex;skeletal muscle;	0.011	NA	N	N	NA	0.52560473713625	E	Ahdc1	NA	NA	NA	NA	NA	0	0	0	0.000007094	0.0003	0	0	0	0		0					chr1	27551985	NA	GGGGGCCGGGTGGGAAGCA	G	676.6	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.3;AS_FS=1.442;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.03;AS_ReadPosRankSum=0.8;AS_SOR=1.132;BaseQRankSum=1.33;DP=119;ExcessHet=3.0103;FS=1.442;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.02;ReadPosRankSum=0.807;SOR=1.132	GT:AD:DP:GQ:PL	0/1:54,21:75:99:684,0,2064
chr1	27880077	27880077	T	C	THEMIS2	intronic	NA	NA	NA	0.5245	GnomAdGenome_AF_ami	22	16	HeterozygousVariant	het	67	26	41	0.611940298507463	843.64	PASS	NA	NA	617856	NA	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in different endometrial adenocarcinoma cell lines and various other cell lines apart from the prostate cell line LNCaP and the ovarian cancer cell line BG1. {ECO:0000269|PubMed:9563507}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	S	N	NA	NA	Themis2	homeostasis/metabolism phenotype; growth/size/body region phenotype; 	NA	NA	NA	NA	0.3495	0.4227	0.4194	0.2925	0.5245	0.273962	0.2956	0.333023	0.301314	PASS	0	0.302	81	0.294118	48	chr1	27880077	NA	T	C	843.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-3;AS_FS=2.236;AS_MQ=60;AS_MQRankSum=0;AS_QD=12.6;AS_ReadPosRankSum=0.4;AS_SOR=0.443;BaseQRankSum=-2.915;DP=67;ExcessHet=3.0103;FS=2.236;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=12.59;ReadPosRankSum=0.431;SOR=0.443	GT:AD:DP:GQ:PL	0/1:26,41:67:99:851,0,593
chr1	27882794	27882794	A	G	THEMIS2	exonic	synonymous SNV	NA	THEMIS2:NM_001105556:exon4:c.A1470G:p.L490L,THEMIS2:NM_001286115:exon4:c.A882G:p.L294L,THEMIS2:NM_001286113:exon5:c.A1083G:p.L361L	0.8	GME_Israel	279	63	HomozygousVariant	hom	116	0	116	1	3557.06	PASS	NA	NA	617856	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in different endometrial adenocarcinoma cell lines and various other cell lines apart from the prostate cell line LNCaP and the ovarian cancer cell line BG1. {ECO:0000269|PubMed:9563507}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	S	N	NA	NA	Themis2	homeostasis/metabolism phenotype; growth/size/body region phenotype; 	NA	NA	NA	NA	0.5958	0.7084	0.7106	0.5007	0.7973	0.472444	0.5188	0.583065	0.533662	PASS	0.8	0.682	237	0.669014	64	chr1	27882794	NA	A	G	3557.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.66;AS_ReadPosRankSum=.;AS_SOR=0.8;DP=117;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.66;SOR=0.8	GT:AD:DP:GQ:PL	1/1:0,116:116:99:3571,347,0
chr1	27882851	27882851	T	C	THEMIS2	exonic	synonymous SNV	NA	THEMIS2:NM_001105556:exon4:c.T1527C:p.V509V,THEMIS2:NM_001286115:exon4:c.T939C:p.V313V,THEMIS2:NM_001286113:exon5:c.T1140C:p.V380V	0.8	GME_Israel	281	62	HomozygousVariant	hom	133	1	132	0.992481203007519	5721.06	PASS	NA	NA	617856	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in different endometrial adenocarcinoma cell lines and various other cell lines apart from the prostate cell line LNCaP and the ovarian cancer cell line BG1. {ECO:0000269|PubMed:9563507}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	S	N	NA	NA	Themis2	homeostasis/metabolism phenotype; growth/size/body region phenotype; 	NA	NA	NA	NA	0.5967	0.7085	0.7108	0.503	0.796	0.474441	0.5247	0.582787	0.534483	PASS	0.8	0.68	236	0.665493	65	chr1	27882851	NA	T	C	5721.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-1.5;AS_FS=3.315;AS_MQ=60;AS_MQRankSum=0;AS_QD=31.19;AS_ReadPosRankSum=-0.6;AS_SOR=0.469;BaseQRankSum=-1.462;DP=133;ExcessHet=3.0103;FS=3.315;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=30.84;ReadPosRankSum=-0.525;SOR=0.469	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:1,132:133:99:1|1:27882851_T_C:5735,355,0:27882851
chr1	27882855	27882855	A	G	THEMIS2	exonic	nonsynonymous SNV	NA	THEMIS2:NM_001105556:exon4:c.A1531G:p.K511E,THEMIS2:NM_001286115:exon4:c.A943G:p.K315E,THEMIS2:NM_001286113:exon5:c.A1144G:p.K382E	0.8	GME_Israel	280	62	HomozygousVariant	hom	130	1	129	0.992307692307692	5632.06	PASS	17.68	NA	617856	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Expressed in different endometrial adenocarcinoma cell lines and various other cell lines apart from the prostate cell line LNCaP and the ovarian cancer cell line BG1. {ECO:0000269|PubMed:9563507}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	N	N	.;CABIT domain	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	S	N	NA	NA	Themis2	homeostasis/metabolism phenotype; growth/size/body region phenotype; 	NA	NA	NA	NA	0.5898	0.7078	0.7099	0.4798	0.796	0.450479	0.4808	0.57531	0.503284	PASS	0.8	0.678	236	0.665493	65	chr1	27882855	NA	A	G	5632.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=-0.9;AS_FS=3.216;AS_MQ=60;AS_MQRankSum=0;AS_QD=32.66;AS_ReadPosRankSum=-0.6;AS_SOR=0.398;BaseQRankSum=-0.899;DP=133;ExcessHet=3.0103;FS=3.216;MLEAC=2;MLEAF=1;MQ=60;MQRankSum=0;QD=28.1;ReadPosRankSum=-0.537;SOR=0.398	GT:AD:DP:GQ:PGT:PID:PL:PS	1|1:1,129:130:99:1|1:27882851_T_C:5646,346,0:27882851
chr1	27907061	27907061	-	A	RPA2	intronic	NA	NA	NA	0.2047	GnomAdExome_AF_eas	0	0	WT/SomaticVariant	het	37	27	6	0.162162162162162	41.6	QD2	NA	NA	179836	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.55	NA	N	E	E	0.984236451925573	E	Rpa2	NA	NA	NA	NA	NA	0.1426	0.2047	0.2009	0.0006	0.0032	0	0.0607	0.0001153	0		0	0.033	20	0.060284	17	chr1	27907061	NA	G	GA	41.6	QD2	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.7;AS_FS=10.683;AS_MQ=60;AS_MQRankSum=0;AS_QD=1.27;AS_ReadPosRankSum=-1.3;AS_SOR=2.251;BaseQRankSum=-0.206;DP=49;ExcessHet=3.0103;FS=12.041;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=1.26;ReadPosRankSum=-1.52;SOR=2.251	GT:AD:DP:GQ:PL	0/1:27,6:37:49:49,0,666
chr1	28228915	28228915	G	A	DNAJC8	intronic	NA	NA	NA	0.6224	GnomAdExome_AF_afr	5	8	HomozygousVariant	hom	31	0	31	1	835.06	PASS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Ubiquitous. {ECO:0000269|PubMed:27133716}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	Medium	Medium	Medium	cochlea;pharynx;cornea;stomach;testis;pineal gland;choroid;kidney;uterus;whole body;pancreas;bile duct;islets of Langerhans;visual apparatus;fovea centralis;spleen;liver;germinal center;gall bladder;heart;lung;salivary gland;synovium;thyroid;placenta;nasopharynx;optic nerve;thymus;intestine;tongue;smooth muscle;skin;myocardium;lens;unclassifiable (Anatomical System);retina;head and neck;mammary gland;cervix;cartilage;endometrium;bone;parathyroid;brain;blood;bone marrow;trabecular meshwork;ovary;macula lutea;lymph node;bladder;colon;prostate;breast;	NA	0.572	NA	N	S	E	0.965226731155893	E	Dnajc8	mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.3305	0.6224	0.6245	0.4226	0.6116	0.353435	0.4366	0.326218	0.408867	PASS	0	0.144	11	0.232283	43	chr1	28228915	NA	G	A	835.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.94;AS_ReadPosRankSum=.;AS_SOR=0.892;DP=31;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.94;SOR=0.892	GT:AD:DP:GQ:PL	1/1:0,31:31:93:849,93,0
chr1	28236165	28236165	A	G	ATP5IF1	UTR5	NA	NM_178191:c.-19A>G;NM_016311:c.-19A>G;NM_178190:c.-19A>G	NA	0.6124	GnomAdExome_AF_afr	32	13	HomozygousVariant	hom	44	0	44	1	1273.06	PASS	NA	NA	614981	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Atpif1	adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; 	atp5if1a	nucleate erythrocyte	decreased amount	abnormal	0.2869	0.6124	0.612	0.3803	0.6011	0.330272	0.4023	0.288069	0.366174	PASS	0	0.239	164	0.278169	53	chr1	28236165	NA	A	G	1273.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=28.93;AS_ReadPosRankSum=.;AS_SOR=1.508;DP=44;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=28.93;SOR=1.508	GT:AD:DP:GQ:PL	1/1:0,44:44:99:1287,132,0
chr1	28237741	28237741	A	G	ATP5IF1	UTR3	NA	NM_178191:c.*1285A>G	NA	0.6879	GnomAdExome_AF_afr	48	13	HomozygousVariant	hom	53	0	53	1	1740.06	PASS	NA	NA	614981	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Atpif1	adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; 	atp5if1a	nucleate erythrocyte	decreased amount	abnormal	0.3348	0.6879	0.6903	0.4433	0.6773	0.373802	0.4676	0.343663	0.424466	PASS	0	0.234	258	0.28169	54	chr1	28237741	NA	A	G	1740.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=32.83;AS_ReadPosRankSum=.;AS_SOR=2.259;DP=55;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=32.83;SOR=2.259	GT:AD:DP:GQ:PL	1/1:0,53:53:99:1754,159,0
chr1	28237768	28237768	A	G	ATP5IF1	exonic	nonsynonymous SNV	NA	ATP5IF1:NM_178190:exon3:c.A187G:p.R63G	0.6106	GnomAdExome_AF_afr	47	13	HomozygousVariant	hom	62	0	62	1	1830.06	PASS	0.056	NA	614981	Benign	NA	NA	NA	NA	NA	NA	NA	NA	NA	T	T	B	B	NA	P	NA	NA	N	T	T	T	NA	NA	NA	T	T	NA	.;	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N	NA	NA	Atpif1	adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; 	atp5if1a	nucleate erythrocyte	decreased amount	abnormal	0.287	0.6106	0.6109	0.3802	0.6006	0.330471	0.4027	0.292797	0.366995	PASS	0.37931	0.228	252	0.278169	53	chr1	28237768	NA	A	G	1830.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=29.52;AS_ReadPosRankSum=.;AS_SOR=2.019;DP=68;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=29.52;SOR=2.019	GT:AD:DP:GQ:PL	1/1:0,62:62:99:1844,185,0
chr1	28259865	28259865	C	G	SESN2	exonic	synonymous SNV	NA	SESN2:NM_031459:exon1:c.C18G:p.S6S	0.0755	GnomAdGenome_AF_eas	3	0	HeterozygousVariant	het	82	45	37	0.451219512195122	749.64	PASS	NA	NA	607767	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Widely expressed. {ECO:0000269|PubMed:12607115}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	alveolus;skin;myocardium;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;adrenal medulla;uterus;whole body;retina;pancreas;muscle;mammary gland;skeletal muscle;islets of Langerhans;visual apparatus;cervix;fovea centralis;iris;spleen;liver;endometrium;bone;parathyroid;brain;blood;heart;lung;cerebral cortex;ovary;synovium;macula lutea;lymph node;colon;placenta;prostate;optic nerve;medulla oblongata;	liver;	0.659	N	N	N	N	0.910728194805068	E	Sesn2	renal/urinary system phenotype; liver/biliary system phenotype; respiratory system phenotype; cellular phenotype; homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); 	NA	NA	NA	NA	0.0286	0.0419	0.0431	0.0319	0.0755	0.0341454	0.0275	0.0130787	0.049573	PASS	0	0.029	41	0.045775	13	chr1	28259865	NA	C	G	749.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.6;AS_FS=0.824;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.15;AS_ReadPosRankSum=0.7;AS_SOR=0.811;BaseQRankSum=0.624;DP=82;ExcessHet=3.0103;FS=0.824;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.14;ReadPosRankSum=0.76;SOR=0.811	GT:AD:DP:GQ:PL	0/1:45,37:82:99:757,0,944
chr1	28473868	28473868	C	A	PHACTR4	exonic	nonsynonymous SNV	NA	PHACTR4:NM_023923:exon6:c.C1168A:p.L390I,PHACTR4:NM_001048183:exon7:c.C1138A:p.L380I,PHACTR4:NM_001350158:exon8:c.C1162A:p.L388I,PHACTR4:NM_001350160:exon8:c.C1138A:p.L380I,PHACTR4:NM_001350161:exon8:c.C1090A:p.L364I,PHACTR4:NM_001350159:exon9:c.C1162A:p.L388I	0.350543	GME_NEA	21	5	HomozygousVariant	hom	144	0	144	1	4338.06	PASS	13.25	NA	608726	Benign	NA	NA	Plasma trimethylamine N-oxide levels[28439531];	NA	NA	NA	NA	NA	NA	D	T	B	B	N	P	M	T	N	T	T	T	NA	T	T	T	T	T	.;.;	D	N	.;.	NA	NA	Medium	Medium	Medium	NA	NA	0.862	E	N	N	N	0.202383211532007	N	Phactr4	cellular phenotype; vision/eye phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); pigmentation phenotype; embryo phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); 	NA	NA	NA	NA	0.2607	0.3063	0.3091	0.2847	0.3258	0.22504	0.2824	0.257772	0.298851	PASS	0.350543	0.176	163	0.169014	38	chr1	28473868	NA	C	A	4338.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=30.13;AS_ReadPosRankSum=.;AS_SOR=0.779;DP=146;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=30.13;SOR=0.779	GT:AD:DP:GQ:PL	1/1:0,144:144:99:4352,431,0
chr1	28535124	28535124	G	A	RCC1	exonic	synonymous SNV	NA	RCC1:NM_001269:exon5:c.G516A:p.V172V,RCC1:NM_001048194:exon6:c.G609A:p.V203V,RCC1:NM_001048195:exon6:c.G567A:p.V189V,RCC1:NM_001048199:exon7:c.G516A:p.V172V	0.344512	GME_TP	24	7	HomozygousVariant	hom	64	0	64	1	1683.06	PASS	NA	NA	179710	Benign	NA	NA	Night sleep phenotypes[27126917];	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.121	NA	E	E	E	0.999797735998675	E	Rcc1	NA	NA	NA	NA	NA	0.2608	0.296	0.2977	0.2812	0.3036	0.223842	0.2805	0.262202	0.296388	PASS	0.344512	0.177	160	0.176056	36	chr1	28535124	NA	G	A	1683.06	PASS	AC=2;AF=1;AN=2;AS_BaseQRankSum=.;AS_FS=0;AS_MQ=60;AS_MQRankSum=.;AS_QD=26.3;AS_ReadPosRankSum=.;AS_SOR=0.756;DP=66;ExcessHet=3.0103;FS=0;MLEAC=2;MLEAF=1;MQ=60;QD=26.3;SOR=0.756	GT:AD:DP:GQ:PL	1/1:0,64:64:99:1697,190,0
chr1	28690203	28690203	-	T	GMEB1	intronic	NA	NA	NA	0.5364	GnomAdGenome_AF_afr	4	0	HeterozygousVariant	het	19	2	9	0.473684210526316	179.02	PASS	NA	NA	604409	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	pharynx;epididymis;tongue;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;muscle;head and neck;visual apparatus;fovea centralis;spleen;liver;cartilage;endometrium;germinal center;brain;blood;heart;bone marrow;lung;salivary gland;ovary;macula lutea;bladder;colon;placenta;prostate;nasopharynx;breast;optic nerve;	cingulate cortex;trigeminal ganglion;superior cervical ganglion;skeletal muscle;	0.253	NA	N	N	K	0.884208316196335	E	Gmeb1	NA	NA	NA	NA	NA	0	0	0	0.4297	0.5364	0	0	0.0001921	0.486239	PASS	0	0.077	11	0.063063	14	chr1	28690203	NA	G	GT	179.02	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.5;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.45;AS_ReadPosRankSum=1;AS_SOR=0.293;BaseQRankSum=-0.961;DP=27;ExcessHet=3.0103;FS=2.935;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.53;ReadPosRankSum=0.466;SOR=0.191	GT:AD:DP:GQ:PL	1/0:2,9:19:46:196,46,74
chr1	28690203	28690203	-	TTTT	GMEB1	intronic	NA	NA	NA	0.0014	GnomAdGenome_AF_ami			HeterozygousVariant	het	19	2	6	0.31578947368421	179.02	PASS	NA	NA	604409	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	pharynx;epididymis;tongue;skin;stomach;testis;lens;unclassifiable (Anatomical System);choroid;kidney;uterus;whole body;retina;muscle;head and neck;visual apparatus;fovea centralis;spleen;liver;cartilage;endometrium;germinal center;brain;blood;heart;bone marrow;lung;salivary gland;ovary;macula lutea;bladder;colon;placenta;prostate;nasopharynx;breast;optic nerve;	cingulate cortex;trigeminal ganglion;superior cervical ganglion;skeletal muscle;	0.253	NA	N	N	K	0.884208316196335	E	Gmeb1	NA	NA	NA	NA	NA	0	0	0	0.0011	0.0014	0	0	0	0		0					chr1	28690203	NA	G	GTTTT	179.02	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.5;AS_FS=3.68;AS_MQ=60;AS_MQRankSum=0;AS_QD=4.5;AS_ReadPosRankSum=-0.7;AS_SOR=1.061;BaseQRankSum=-0.961;DP=27;ExcessHet=3.0103;FS=2.935;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=10.53;ReadPosRankSum=0.466;SOR=0.191	GT:AD:DP:GQ:PL	0/1:2,6:19:46:196,103,327
chr1	28744004	28744004	A	C	YTHDF2	intronic	NA	NA	NA	0.0005	GnomAdExome_AF_oth			HeterozygousVariant	het	31	14	17	0.548387096774194	483.64	PASS	NA	NA	610640	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	NA	NA	0.0668	NA	N	S	N	0.979516724741024	E	Ythdf2	cellular phenotype; reproductive system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); 	ythdf2	whole organism	increased amount	abnormal	0.0001	0.0003	0.0002	0.0002	0.0003	0	0.0002	0.000097	0		0					chr1	28744004	NA	A	C	483.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=1.4;AS_FS=0;AS_MQ=58.21;AS_MQRankSum=0;AS_QD=15.61;AS_ReadPosRankSum=0;AS_SOR=1.085;BaseQRankSum=1.49;DP=35;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=59.94;MQRankSum=0;QD=15.6;ReadPosRankSum=0.047;SOR=1.085	GT:AD:DP:GQ:PL	0/1:14,17:31:99:491,0,359
chr1	28812463	28812463	G	T	OPRD1	exonic	nonsynonymous SNV	NA	OPRD1:NM_000911:exon1:c.G80T:p.C27F	0.9995	GnomAdExome_AF_eas	748	123	HeterozygousVariant	het	46	20	26	0.565217391304348	648.64	PASS	15.16	NA	165195	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Detected in oocytes (at protein level). Detected in brain cortex, hypothalamus, hippocampus and olfactory bulb. Detected in oocytes. {ECO:0000269|PubMed:22417668, ECO:0000269|PubMed:7808419}.;	T	T	B	B	N	P	N	T	N	T	T	T	NA	D	T	T	T	T	.;.;	N	N	.;.	NA	NA	Medium	Medium	Medium	ovary;	trigeminal ganglion;	0.328	N	N	N	N	0.597584069623162	E	Oprd1	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.9098	0.9995	0.9997	0.9024	0.9987	0.944489	0.9158	0.0001153	0.884298	PASS	0.951515	0.948	68	0.929078	16	chr1	28812463	NA	G	T	648.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.1;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.11;AS_ReadPosRankSum=-0.7;AS_SOR=0.722;BaseQRankSum=-1.019;DP=49;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.1;ReadPosRankSum=-0.676;SOR=0.722	GT:AD:DP:GQ:PL	0/1:20,26:46:99:656,0,488
chr1	28863085	28863085	C	T	OPRD1	exonic	synonymous SNV	NA	OPRD1:NM_000911:exon3:c.C921T:p.G307G	0.7681	GnomAdGenome_AF_eas	430	70	HeterozygousVariant	het	91	51	40	0.43956043956044	887.64	PASS	NA	NA	165195	Benign	NA	NA	NA	NA	NA	NA	NA	NA	Detected in oocytes (at protein level). Detected in brain cortex, hypothalamus, hippocampus and olfactory bulb. Detected in oocytes. {ECO:0000269|PubMed:22417668, ECO:0000269|PubMed:7808419}.;	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium	Medium	Medium	ovary;	trigeminal ganglion;	0.328	N	N	N	N	0.597584069623162	E	Oprd1	behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; 	NA	NA	NA	NA	0.5889	0.7677	0.7663	0.503	0.7681	0.58127	0.471	0.544139	0.528736	PASS	0.617424	0.721	342	0.723404	64	chr1	28863085	NA	C	T	887.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-0.8;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=9.76;AS_ReadPosRankSum=-0.7;AS_SOR=0.752;BaseQRankSum=-0.752;DP=97;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=9.75;ReadPosRankSum=-0.644;SOR=0.752	GT:AD:DP:GQ:PL	0/1:51,40:91:99:895,0,1275
chr1	29120948	29120948	T	C	TMEM200B	exonic	nonsynonymous SNV	NA	TMEM200B:NM_001003682:exon2:c.A881G:p.Y294C,TMEM200B:NM_001171868:exon2:c.A881G:p.Y294C	0.0171	GnomAdGenome_AF_sas	1	0	HeterozygousVariant	het	150	63	87	0.58	2114.64	PASS	24.9	NA	NA	Uncertain significance	NA	NA	NA	NA	NA	NA	NA	NA	NA	D	D	P	B	U	D	N	NA	D	T	T	T	NA	D	T	T	T	T	.;.;	D	D	.;.	NA	NA	Medium	Medium	Medium	NA	NA	NA	NA	N	N	N	0.11437135981131	N	Tmem200b	NA	NA	NA	NA	NA	0.0018	0.0147	0.0151	0.0004	0.0171	0.00559105	0	0.0018564	0		0.003049	0.019	20	0.010563	3	chr1	29120948	NA	T	C	2114.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=0.3;AS_FS=0;AS_MQ=60;AS_MQRankSum=0;AS_QD=14.1;AS_ReadPosRankSum=0.4;AS_SOR=0.647;BaseQRankSum=0.365;DP=154;ExcessHet=3.0103;FS=0;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=14.1;ReadPosRankSum=0.476;SOR=0.647	GT:AD:DP:GQ:PL	0/1:63,87:150:99:2122,0,1465
chr1	29148829	29148829	C	T	SRSF4	exonic	nonsynonymous SNV	NA	SRSF4:NM_005626:exon6:c.G1066A:p.G356S	0.9211	GnomAdGenome_AF_ami	93	38	HeterozygousVariant	het	183	108	75	0.40983606557377	1592.64	PASS	15.3	NA	601940	NA	NA	NA	Schizophrenia[26531332];	NA	NA	NA	NA	NA	NA	T	T	B	B	N	P	N	T	N	T	T	T	NA	T	T	T	T	T	.;.;	D	N	.;.	NA	NA	High	High	High	NA	NA	NA	NA	N	N	N	0.53917561279198	E	Srsf4	homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); pigmentation phenotype; 	NA	NA	NA	NA	0.6504	0.7883	0.7889	0.6933	0.9211	0.495008	0.7342	0.580439	0.656814	PASS	0.72807	0.44	222	0.492958	64	chr1	29148829	NA	C	T	1592.64	PASS	AC=1;AF=0.5;AN=2;AS_BaseQRankSum=-1.5;AS_FS=4.34;AS_MQ=60;AS_MQRankSum=0;AS_QD=8.7;AS_ReadPosRankSum=-1.1;AS_SOR=0.808;BaseQRankSum=-1.5;DP=187;ExcessHet=3.0103;FS=4.34;MLEAC=1;MLEAF=0.5;MQ=60;MQRankSum=0;QD=8.7;ReadPosRankSum=-1.009;SOR=0.808	GT:AD:DP:GQ:PL	0/1:108,75:183:99:1600,0,2683
